[{"article": "Feb. 7, 2011 -- Giving your sweetie chocolate for Valentine's Day may show you care for their health as well as their heart.\nThe seeds are dried and then processed to produce cocoa powder.\nCocoa or cacao beans are not beans but the seeds of the fruit of the Theobroma cacao tree.\nDark chocolate generally has a higher percentage of cocoa content than milk chocolate.\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not exaggerate the effects of any diseases.", "answer": 1}, {"article": "We don\u2019t yet understand why patients with TP53 mutations consistently respond to decitabine, and more work is needed to understand that phenomenon.\u201d\n\nResponses to decitabine are usually short-lived, however, with remissions typically lasting for about a year.\nAML typically strikes in a person\u2019s mid-60s; the average age of people in the current study was 74.\nAmong the patients in the study, 46 percent achieved a remission with decitabine.\nIn AML, treatment involves intensive chemotherapy to try to kill the patient\u2019s leukemia cells and put the cancer into remission.\nTheir median survival was just over a year.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering. The release provides appropriate context on the disease.", "answer": 1}, {"article": "Their editorial accompanies the Marban report in the Feb. 14 advance online issue of The Lancet.\n\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\n\"These findings suggest that this therapeutic approach is feasible and has the potential to provide a treatment strategy for cardiac regeneration after [heart attack],\" write University of Hong Kong researchers Chung-Wah Siu and Hung-Fat Tse.\nThe finding, just in time for Valentine's Day, is the clearest evidence yet that literally broken hearts can heal.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired.\n", "question": "Does the story commit disease-mongering?", "explanation": "Some of the language in the story skirts close to disease mongering. It presents heart scarring as if it is the same as heart failure, using terms such as \u201cresurrects\u201d and \u201cbroken hearts.\u201d\u00a0 The word \u201ccure\u201d creeps in and is not qualified. The stem cells \u201cseem to be doing something much more amazing,\u201d the story says. As noted above, the study and this story say that there were no differences in the clinical outcomes of patients who received stem cells versus those who did not.\nNonetheless, we can\u2019t ding it for disease-mongering by the definition of that criterion.\n\u00a0", "answer": 1}, {"article": "MONDAY, Oct. 10, 2011 (HealthDay News) -- An experimental Alzheimer's disease drug, gantenerumab, may help lower levels of amyloid plaque in the brains of people with the disease, an early clinical trial indicates.\nAlzheimer's disease is the most common form of dementia.\n\"They are all extremely exciting and promising in animals,\" he said.\nThe higher dose yielded greater reductions in amyloid levels, the study showed.\nPeople who were given the 60 mg doses saw a nearly 16 percent reduction in the amount of amyloid, and those given the 200 mg doses saw a 36 percent reduction.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of Alzheimer\u2019s disease.", "answer": 1}, {"article": "The sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.\nAbout half got the combined approach and half received treatment as usual.\nOver two years, both groups showed steady improvement.\nThe team trained staff members at the selected clinics to deliver that package, and it included three elements in addition to the medication.\nThe gains for those in typical treatment were apparent to doctors, but much less obvious.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "\u201cDr.\nIn addition to exceptional cosmetic results, the technique is likely to improve clinical outcomes as evidenced by ongoing research that shows women who undergo this procedure experience less pain and a shorter recovery period.\nAfter a recovery period of approximately two months \u2014 during which the woman\u2019s chest skin heals, blood supply replenishes, and the expanders are gradually inflated to stretch the skin \u2014 the patient returns for an outpatient surgical procedure to replace the tissue expanders with permanent breast implants.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\n\u201cIt\u2019s important to listen to each woman\u2019s needs and then to decide together what is the best approach to treatment, so that in the end the cancer will be gone and the woman can move on with her life,\u201d says Dr. Wilson.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Descriptions of pain and long recovery periods are found in this release. But that seems essential to the nature of this procedure, which aims to reduce these and other problems.", "answer": 1}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to engage in disease mongering, although the story could be clearer about who is or is not a candidate for this kind of treatment.", "answer": 1}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nAs a point of reference, the U.S. Food and Drug Administration requires manufacturers who choose to put a \"gluten free\" label on food packaging to meet the same 20 parts per million of gluten standard.\nAs for Nima, Sundvor said, \"We're doing a huge amount of testing and one thing we want to be sure of before we start shipping is that we're 99.9 percent accurate.\"\n\"One of the things that we wanted to make sure we distinguish is that we don't see ourselves as a medical device,\" Sundvor told CBS News.\nIt costs $179 to pre-order a tester plus three one-time-use pods, and $47.95 for a refill pack of 12 pods; prices will increase later this month, according to the company's website.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story offers federal prevalence data for celiac disease, although as noted above, it could have made clearer that a lot of people who think they are gluten-intolerant likely are not.\u00a0The problem of misperception about dietary intolerance is real, and results in restrictive diets for no reason.", "answer": 1}, {"article": "In contrast, the risk of failure among recently recalled defibrillators has been estimated by the manufacturers at just 0.009 percent to 2.6 percent.\nTwo patients died.\nIt takes an hour or less,\" he said.\n\"Most patients return home the same day.\"\nAnd not every failure is deadly.\n", "question": "Does the story commit disease-mongering?", "explanation": "None noted.", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story commit disease-mongering?", "explanation": "The story does a good job of avoiding disease mongering, saying that fibroids often cause no symptoms and that they only rarely affect fertility or can be cancerous.", "answer": 1}, {"article": "During the last three months of 2008 \u2014 the most recent data available that allowed a comparison among robotic, open and laparoscopic surgeries \u2014 more than half of all prostate removals involved robot-assisted surgery.\nOpen and laparoscopic surgeries were still more common than robotic surgeries for kidney repairs and removals.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\nAbout five percent of the men who had open surgery needed a blood transfusion, compared to less than two percent of men who had robot-assisted surgery.\nEmphasis should be lmited on procedure, he said, as opposed to surgical skill.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play here.", "answer": 1}, {"article": "But this could take a few years to develop.\n\"This is the earliest phase, and you now have to show that it actually breaks down the gluten peptides that trigger a response in the stomach at a speed that will protect the human,\" said Dr. Joseph Murray, a professor of medicine in the division of gastroenterology and the department of immunology at the Mayo Clinic, in Rochester, Minn. \"Let's see how it goes with a whole slice of bread.\"\nIn this case, the researchers re-engineered the natural enzyme to recognize the peptide that triggers celiac disease and modified the protein in the laboratory so it would survive the acidic stomach environment.\n\"It will probably be helpful to someone who gets a low-level exposure [to glutens] by accident,\" he said.\nIf the researchers opt to make a prescription drug, the process of clinical trials and obtaining U.S. Food and Drug Administration approval could take a decade or more, he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Given\u00a0gluten\u2019s growing reputation for being toxic, even among those who have nothing to fear from it, we think the story could have done a better job differentiating celiac\u00a0disease \u2014 an\u00a0autoimmune intolerance to gluten that can have serious health consequences, including higher risk of\u00a0lymphoma\u00a0\u2014 from the garden variety\u00a0indigestion that some people attribute to eating wheat products.\u00a0 While some patients with gluten hypersensitivity and celiac disease can have extreme reactions (and this can be part of the spectrum of this condition), this is by far not the norm for the condition.\nWe\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "\u201cYou saw less foreign body response.\n\u201cOur goal is to bring that kind of biological cure across the spectrum of type 1 diabetes.\u201d\n\nThe potential of the approach has attracted interest from both small startups and large biopharmaceutical companies that are looking at stem cell-based therapies for diabetes.\nThe human beta cells survived exquisitely well.\u201d\n\nThe studies show \u201cyou can take stem cells and make a limitless supply of [human beta cells] and put them in a device and cure an entirely different species of animal,\u201d Anderson said.\n\u201cThis is really the first demonstration of the ability of these novel materials in combination with a stem-cell derived beta cell to reverse diabetes in an animal model,\u201d said Julia Greenstein, vice president of discovery research at JDRF, an organization trying to end type 1 diabetes that provided some funding for the studies.\n\u201cThe main issue with type 1 diabetes is a loss of beta cells,\u201d said ViaCyte CEO Paul Laikind, \u201cbut there\u2019s also good data out there to suggest dysfunction in other regulatory cell types.\u201d\n\nThe team behind the studies published Monday, meanwhile, is working on tests now in monkey models.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story. In fact, it does a nice job of explaining the disease and the specific problem this research is trying to address. It says, for example, \u201cIn people with type 1 diabetes, formerly known as juvenile-onset diabetes, the immune system dismantles the pancreatic cells that normally produce insulin. So researchers have long sought a way to put back\u00a0healthy insulin-producing cells, known as beta cells, into patients.\u201d", "answer": 1}, {"article": "\u201cLooking at hair tells us new things.\u201d\n\nThe research is part of the ongoing Murdoch Childrens Research Institute\u2019s Childhood to Adolescence Study following a cohort of 1,200 children in and around Melbourne and was published in the journal, Psychoneuroendocrinology.\n\u201cWe hope this can be used as one of the tools to identify children at risk,\u201d he said.\nCortisol is known as the \u201cstress hormone\u201d because it is released in response to acute stress to help the body react and cope.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\nThe tests could also be unpleasant and invasive for children, given blood tests require a needle and saliva tests require the child to fast beforehand.\n", "question": "Does the story commit disease-mongering?", "explanation": "None.", "answer": 1}, {"article": "To him, diet underpins longevity.\nAccording to Toribio-Mateas, the results confirm earlier theories that \"some hormone-like growth factors that are required during development to grow, then become promoting agents of aging after development and sexual maturity have been reached\".\nThe idea of caloric control improving your health, and therefore your lifespan, is nothing new, but researchers are now hoping to accurately determine the type of diet that could make you live longer.\nUnlike the 5-2 diet, which requires two days of low calories at any point in the week, Longo's diet involves fasting for five consecutive days, which requires much more willpower.\n\"Diet can have a remarkable effect on you,\" says Valter Longo, Professor of Gerontology at USC Davis, who has been long been researching the mechanisms behind human aging and has recently turned his attention to fasting.\n", "question": "Does the story commit disease-mongering?", "explanation": "Aging isn\u2019t a disease\u2013it\u2019s a universal fact of life that happens to all of us. While none of us can avoid aging, we can make changes to age in a more healthful way. This story\u00a0did seem to stick to that premise, and avoided statements that made aging sound like a disease.", "answer": 1}, {"article": "\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\nThere was also evidence suggesting improvement in working memory.\nFlavonoids, which are abundant in plants, are likely to be an important component in causing these effects.\nBefore and after the 12-week period, participants took a range of cognitive tests while an MRI scanner monitored their brain function and resting brain blood flow was measured.\nThe study excluded anyone who said they consumed more than five portions of fruit and vegetables per day, and all participants were told to stick to their normal diet throughout.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Dr. Oken said the new study might have shown no benefit in 18-month-olds because effects in infants might be \u201chard to measure\u201d or \u201cit may be that the benefit of DHA is not as important as when you\u2019re 4.\u201d\n\nDr. Makrides\u2019s team plans assessments at 4 and 7.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\nSeveral studies indicate that babies born prematurely receive too little DHA, and some studies have found that premature babies fed DHA after birth show better cognitive performance or visual coordination later on than preemies who aren\u2019t given DHA.\nIts effect in supplements for children and adults is being studied, as well as whether supplements offer the same benefit as DHA-rich fish, like salmon.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.\u00a0 Good quotes from chief of maternal-fetal medicine at a leading Boston hospital:\u00a0\u201cI think the market is running way out in front of the science.\u201d", "answer": 1}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\nFace the light but do not stare at the light.\nIf you choose to try light therapy, here are a few tips from experts.\nBut while bright-light treatment is helpful, he said, it is not sufficient for him.\nSome say their patients don\u2019t have the patience to sit in front of a light for 30 to 45 minutes every morning.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story does not exaggerate the consequences of seasonal depression.", "answer": 1}, {"article": "CDC To Doctors: Anti-HIV Pill No Magic Bullet Against Virus\n\nIn November, researchers revealed a encouraging finding: taking a pill can greatly reduce the risk of getting HIV.\nThat'll help avoid creating viruses resistant to the drug when patients miss doses.\nMake sure patients understand that warding off HIV isn't cheap.\nSome insurers might pay, but some might balk.\nThat doesn't tell the whole story.\n", "question": "Does the story commit disease-mongering?", "explanation": "NO disease-mongering here.", "answer": 1}, {"article": "There are substantial risks.\nThe modified virus retains the ability to infect and kill brain tumor cells, and also appears to trigger the patient's own immune system cells to attack the tumors, the researchers say.\nIn addition, the researchers are planning to try the approach on children with brain cancer, as well as other types of cancer, including melanoma and breast cancer.\nThe scientists removed one of the virus's genes to prevent it from causing polio and replaced that gene with one from a harmless virus known as a rhinovirus, which ordinarily causes the common cold.\n\"Those that have survived more than two years are in remission, and we expect them to continue to be long-term survivors.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here. The story said glioblastoma is the \u201cmost common and aggressive malignant brain tumor in adults.\u201d", "answer": 1}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story commit disease-mongering?", "explanation": "There are no obvious elements of disease mongering. The story provides simple, straight-forward descriptions of both Alzheimer\u2019s and Parkinson\u2019s disease, although more information might have been useful. ", "answer": 1}, {"article": "TUESDAY, Aug. 25, 2015 (HealthDay News) -- Needles beat pills for treating hot flashes in breast cancer survivors, according to a new trial that compared acupuncture, \"sham\" acupuncture, the medication gabapentin and a placebo pill.\nSome women undergoing natural menopause still might have that option available.\nMenopause also is linked to declining estrogen levels.\nThe women were enduring hot flashes at least twice a day.\nThe drug is typically used to treat seizures and nerve pain.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease mongering here.", "answer": 1}, {"article": "The effect of the newer-generation medications, gonadotropin-releasing hormones, is similar to bicalutamide, according to other trials.\nMore research will be needed to confirm which men benefit most from taking the drug.\nMen with medium-grade tumors and those who may not have had their entire cancer removed during surgery also survived significantly longer if they received the drug.\nIn these cases, radiation therapy is usually used.\nBut the new finding indicates it could also be a valuable add-on treatment to surgery if the cancer returns.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not disease monger, and made sure to discuss that some men won\u2019t need treatment.", "answer": 1}, {"article": "In an interview last spring with Psych Congress Network, an Internet news site for mental health professionals, Dr. Timothy Wilens, chief of child and adolescent psychiatry at Massachusetts General Hospital, said \u201cwe have enough data to say they\u2019re actually neuroprotective.\u201d The pills, he said, help \u201cnormalize\u201d the function and structure of brains in children with A.D.H.D., so that, \u201cover years, they turn out to look more like non-A.D.H.D.\nFor most people with A.D.H.D., stimulants can temporarily boost focus, motivation and self-control by increasing the availability of these chemical messengers.\nOne peer-reviewed 2013 study co-authored by Dr. Swanson suggested that the stimulants may change the brain over time so as to undermine the long-term response to the medication and even exacerbate symptoms when people aren\u2019t taking them.\nIn an email, Dr. Wilens said he had not received \u201cany personal income\u201d from the pharmaceutical industry since 2009.\nSuch a practice has been deemed unethical due to the widespread belief that the medication can help struggling children, at least in the short-term.\n", "question": "Does the story commit disease-mongering?", "explanation": "It is clear that the discussion is about the more than 6-million children in the United States who already have been diagnosed with ADHD.", "answer": 1}, {"article": "Could root canal procedures go by the wayside in the not-too-distant future?\n\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\nIt's like this material goes over and just taps it on the shoulder and says, 'Wake up, wake up,' and then it starts to repair itself.\"\nWhen dental pulp disease and injury happen, a root canal is typically performed to remove the infected tissues, explained Dr. Adam Celiz, Marie Curie Research Fellow at the University of Nottingham.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although the story does not meet the criteria for disease mongering we are a bit troubled by the suggestion that existing fillers are \u201ctoxic to cells.\u201d \u00a0The American Dental Association disagrees, \u201cDental amalgam is considered a safe, affordable and durable material that has been used to restore the teeth of more than 100 million Americans.\u201d", "answer": 1}, {"article": "Surgery isn't the answer for all older lung cancer patients, according to Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society.\nThat was seven years ago.\nI thought it was a death sentence,\" he says.\nFor years, they didn't.\nPatients with heart or other health problems may not be candidates.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering.", "answer": 1}, {"article": "\"The challenge in prostate cancer is how to look at all of these patterns within a cell, but hone in on the gene activity that suggests cancer, and not only this, what type of cancer - dangerous or manageable?\nIt is believed that success rates could be hindered as a result of treating all prostate cancers in the same way.\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\nThis is part of the normal functioning of the human body and can tell individuals apart, but the process can sometimes go wrong, resulting in various diseases.\nProfessor Norman Maitland, from the University of York's Department of Biology, said: \"Unnecessary prostate treatment has both physical consequences for patients and their families, but is also a substantial financial burden on the NHS, where each operation will cost around \u00a310,000.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The term \u201clife-threatening cancer\u201d was used very loosely. \u00a0A cancer that has spread beyond the prostate \u2014 but not throughout the body\u2013is not necessarily fatal.", "answer": 0}, {"article": "\u201cThey\u2019ve lost family members generation after generation after generation, or they\u2019ve had family members who\u2019ve suffered from chronic disease that\u2019s totally preventable.\u201d\n\nThese procedures not only help limit the passing on of diseases\u2014 they may also help couples get pregnant faster.\nExperts say the couples are not the only people who benefit from these tests.\nThese results have helped eliminate pre-term birth and hospitalizations for pre-term labor, and patients and families have better outcomes, he added.\n\u201cAll it does is allow us to choose the best embryos to transfer so that we can get the patients pregnant faster,\u201d he said.\nA diagnosis before pregnancy may sound like a designer baby, but doctors say that\u2019s not the case.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The Dana-Farber scientists say current [EGFR] inhibitors Iressa and Tarceva prevent EGFR from sending signals that are essential to keep tumor cells growing, the researchers say.\nHowever, over time, the tumor cells develop additional mutations, enabling them to grow again, even in the presence of the drugs Iressa or Tarceva.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\nThe scientists say non-small cell lung cancers that had become invulnerable to the chemotherapy drugs Iressa and Tarceva were stymied in a study by a compound designed and formulated in the Dana-Farber laboratory.\nMuch work lies ahead in determining whether the compound and related ones will prove to be effective therapies, but the researchers say their discovery demonstrates the power of screening specially designed compounds against cancers \"with certain genetic quirks.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The article presents accurate data on lung cancer mortality and NSCLC from\u00a0the American Cancer Society.", "answer": 1}, {"article": "Elizabeth Williams, from the School of Biomedical Sciences at Queensland University of Technology, tells Newsweek the two studies \u201cdescribe tantalizing complementary and consistent results in Phase 1 trials in melanoma patients using vaccines.\"\nAll participants were found to have a boosted immunity against the antigens specific to their tumors.\nFour of the six had no recurrence of the disease after 25 months.\nEight were still tumor free after 23 months.\nThey used a similar approach to Wu and her team to identify the mutations, then tested the vaccine on 13 people who were being treated for melanoma.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease mongering in this story.", "answer": 1}, {"article": "George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\n\"It is still possible that CETP inhibitors without off-target effects of torcetrapib could be viable as a therapy for cardiovascular disease,\" said an editorial published in today's edition of the New England Journal of Medicine, which concluded: \"It is possible that CETP inhibition might be better suited to certain subgroups of patients, such as those with impaired clearance of LDL cholesterol or low levels of HDL cholesterol at base line,\" the editorial said.\nThe study suggested a \"clean\" version of torcetrapib could increase so-called good cholesterol without raising blood pressure and causing adverse cardiovascular events.\n\"In any case, it is premature to announce the death of CETP inhibitors on the bases of the torcetrapib experience alone.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of heart disease, the target of the new drug. However, the story could have done more to point out that many researchers are now questioning the HDL/heart disease hypothesis.", "answer": 1}, {"article": "(Reuters) - Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury.\n\u201cIt is important to know that we do not expect patients to get up and play basketball,\u201d he said.\nMonday\u2019s announcement was the first about the therapy in more than two years.\nET, or more than twice their 25-day average trading volume.\nShares of BioTime Inc, a company that owns nearly 70 percent of Asterias, were little changed at $3.07.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the article.", "answer": 1}, {"article": "By the end, she felt \"back to normal,\" with a \"spring to my walk and some energy in it!\"\nAfter 10 weeks, the results were dramatic: Nearly two-thirds of the patients who received either type of weekly massage said their back pain was significantly improved or gone altogether.\nOnly about one-third of patients receiving the usual care experienced similar relief.\n\"We found that both types of massage were equally effective in helping people improve their function and diminish their symptoms,\" Cherkin says.\nStudy participants were randomly assigned to one of three treatments.\n", "question": "Does the story commit disease-mongering?", "explanation": "We wish the story had been more specific that those studied had low back pain of no identified cause lasting at least 3 months. But there wasn\u2019t any overt disease mongering.", "answer": 1}, {"article": "\"They still drank, but they drank less.\"\n\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nIt is one of the substances known as isoflavones found in kudzu.\nMay 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\nThe study is published in Drug and Alcohol Dependence.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering. The story pointed out that there is disagreement about what constitutes binge drinking, so it is not entirely clear who would be a candidate for treatment with this supplement.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A new study bolsters the case that daily aspirin may help protect against cancer, although the effect seems weaker than previously thought.\nRay called for trials that specifically check people for new cancers at given intervals to weed out the selection bias marring the previous research.\n\u201cNews about the cancer potential of aspirin use has been really encouraging lately,\u201d said Dr. Michael Thun of the American Cancer Society, who worked on the study.\nThe effect was strongest for gastrointestinal cancers, such as colon cancer and stomach cancer.\nOther researchers are more skeptical.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Professor Vieta was not involved in this work, it is an independent comment.\nOur result is statistically significant, but because the study wasn't specifically designed to test the effect of diet quality,\n\ninflammatory diets and BMI on drug response in general, it is necessary to see the work replicated in a larger study before any firm conclusions can be formed\".\n\"If we can confirm these results, then it's good news for people with Bipolar Disorder, as there is a great need for better treatments for the depressive phase of Bipolar Disorder\" said lead researcher Melanie Ashton of Deakin University in Australia.\nA total of 133 participants were randomly assigned to take a combination of nutraceuticals (compounds derived from foods such as vitamins or minerals that treat or prevent a disease or disorder) including the anti-inflammatory amino acid n-acetylcysteine (NAC), or NAC alone, or a placebo (a dummy pill) for 16 weeks.\n\"This is interesting work, which holds out the possibility that patients with Bipolar Disorder may benefit from a balanced diet.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering. The release provides context on what constitutes bipolar disorder.\nAccording to the National Institute of Mental Health \u201can estimated 4.4% of U.S. adults experience bipolar disorder at some time in their lives.\u201d", "answer": 1}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story. We do note, though, that there seems to be a general assumption with the piece that ADHD is a significant problem that must be treated with medication. There is considerable debate on this point, here\u2019s just one example. And the news release discusses this as well, noting:\n\u201cEvidence [for long-term benefits of medicating kids with ADHD] so far points to positive effects on some outcomes but not others.\u201d", "answer": 1}, {"article": "JACKSONVILLE, Fla. \u2014 Researchers at Mayo Clinic\u2019s campus in Florida have conducted the world\u2019s first prospective, blinded and placebo-controlled clinical study to test the benefit of using bone marrow stem cells, a regenerative medicine therapy, to reduce arthritic pain and disability in knees.\n\u201cThis is just a theory that can explain our results, so it needs further testing.\u201d\n\nAnother explanation is that merely injecting any substance into a knee offered relief from pain.\nThe findings in The American Journal of Sports Medicine include an anomalous finding \u2014 patients not only had a dramatic improvement in the knee that received stem cells, but also in their other knee, which also had painful arthritis but received only a saline control injection.\nBut, depending on how they are processed and used, stem cells can, in fact, be regulated by the U.S. Food and Drug Administration as biological products or drugs requiring rigorous safety and efficacy approval processes.\nGiven that the stem cell-treated knee was no better than the control-treated knee \u2014 both were significantly better than before the study began \u2014 the researchers say the stem cells\u2019 effectiveness remains somewhat uninterpretable.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here; this is a painful and widespread disorder. However, the severity of symptoms in this population were limited to those experiencing mild to moderate pain.", "answer": 1}, {"article": "(CNN) -- The use of mammograms has dipped since a medical task force made controversial recommendations that women in their 40s may not need to get breast cancer screenings every year, according to one of three small studies to be presented Monday.\n\"There is a real, but rather modest benefit.\nRoughly 15% of women in their 40s detect breast cancer through mammography.\n\"It might make women not want to get the test,\" she said.\nOf the 359 biopsies from screening mammography patients, 15% had cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering.", "answer": 1}, {"article": "With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence.\nProton therapy did not make a difference in all of these side effects, but had significant effects on several.\nProton therapy is just one of several new methods for treating cancer.\nLocated at the University of Maryland BioPark, the 110,000 square-foot, $200 million center is expected to treat about 2,000 patients a year.\nIt is also an important option for children with cancer and is expected to become an important option for some types of breast cancer.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "MONDAY, Nov. 2, 2015 (HealthDay News) -- Despite the stereotype that Americans are eating more unhealthful foods that leave them vulnerable to assorted diseases, a new study suggests the opposite may be true.\nFrom 1999 to 2012, the overall rating increased, from 40 to 48.\n\"Huge room exists for further improvement.\"\nThe findings paint a surprising picture of American health.\n\"The overall American diet is still poor,\" he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "None here.", "answer": 1}, {"article": "Medtronic, the largest company making only medical devices, could receive F.D.A.\nBut the procedure's seeming ease and its growing popularity have some experts worrying that too many doctors and patients, spurred on by medical device makers, may embrace it without fully understanding that it is generally as risky as surgery -- and potentially riskier in some cases.\nAnd advocates of the technology say that more recent data show that stenting success rates are climbing, now that the systems use temporarily implanted filters to catch bits of life-threatening plaque knocked loose during the procedure.\nBut some clinical studies have found lower complications for both procedures than those cited by Dr. Alberts, with some results seeming to favor stenting and others leaning toward surgery.\n\"There is too much focus on who is a high surgical risk and not enough on who is at high risk for stenting,\" Dr. Sriram S. Iyer, chief of endovascular interventions at Lenox Hill Hospital in Manhattan, said at the same Washington symposium where Dr. Hopkins spoke.\n", "question": "Does the story commit disease-mongering?", "explanation": "Provides natural history. While harboring an element of disease mongering in terms of stroke concern it also \ncontains a flavor of over-enthusiasm by physicians to intervene; mentions the element of competition among specialties for \nthis piece of the medical care pie. The framing of the story implies that the falls and \u201cunwell\u201d feeling were caused by the \npatient\u2019s carotid blockage, which may not really be the case.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story commit disease-mongering?", "explanation": "No evidence of disease mongering, though it would have helped if the story provided prevalence rates of HIV/AIDS in babies born to Ugandan women. ", "answer": 1}, {"article": "TUESDAY, March 27, 2012 (HealthDay News) -- When taken as a supplement, unroasted -- or green -- coffee-bean extract can help people shed pounds, according to a small preliminary study.\nA follow-up study involving 60 patients is now in the planning stages.\nIn one section, study participants, who were all between the ages of 22 and 26, consumed a capsule filled with 700 milligrams of green coffee extract.\nThe study was conducted in India and funded by Applied Food Sciences, the American manufacturer of two green-coffee-extract products.\nAll the patients were instructed to maintain their usual dietary habits, while the study team monitored them for weight loss over a period of nearly six months.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story was vague about the weight of the study subjects \u2013 \u201c16 overweight and obese patients.\u201d", "answer": 2}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of pancreatic cancer in the story.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - When symptom-free people have heart scans to look for clogged arteries, they can end up with overtreatment and side effects, researchers said Monday.\nPeople who got scans also had more additional tests and major heart procedures.\n\u201cWith these new imaging techniques, we are left with the dilemma of what to do with the results,\u201d he said.\nIf they get big enough, such buildups may cut the blood flow and cause a heart attack.\nBut after another 18 months, there was no such difference.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "NEW YORK (Reuters) - Johnson & Johnson\u2019s Stelara helped a significantly higher percentage of Crohn\u2019s disease sufferers than those who received a placebo, according to a study of patients who had not been helped by other commonly used drugs.\nCommon symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\nClinical remission was defined as a CDAI score down to 150.\nThose who received 1 mg/kg had a 36.6 percent response rate and the 3 mg/kg dose led to a 34.1 percent response rate.\nMany Crohn\u2019s patients require surgery when medicines no longer control symptoms.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "The report concluded that both are necessary for bone health but that as for preventing cancer, heart disease, diabetes and autoiummune disorders, the evidence was \u201cinconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements.\u201d Even so, the committee recommended that children and adults up to age 70 get 600 IU of vitamin D daily \u2014 from food and, if necessary, supplements \u2014 and that adults age 71 and older get 800 IU.\n\u201cThe indirect evidence is very strong.\n\u201cEveryone has gotten on the bandwagon.\n\u201cPeople want to have a simple story they can believe in,\u201d he says.\nPittas takes it in stride.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not succumb to mongering.", "answer": 1}, {"article": "\u2022 Among RCM alumni are composers and performers such as Sir Hubert Parry, Benjamin Britten, Gustav Holst, Sir Colin Davis, David Helfgott, Samuel Coleridge-Taylor, Lord Lloyd Webber, Dame Joan Sutherland, Sir James Galway, Ralph Vaughan Williams and Alfie Boe.\nThere is a link between high levels of inflammation and serious illness.\nInternational students constitute approximately 50% of our student body.\nWe do this where it is needed most - right at the heart of the community.\nThe choir is a family, simple as that.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "(CNN) Jet lag might be the worst part of long-distance travel, especially when it leaves you feeling tired, cranky and off-kilter for days.\nThere's still more testing to be done before the technique is available to the public.\nParticipants were able to sleep through the flashes of light without waking.\nThe treatment could benefit not only travelers but also overnight shift workers and people with constantly changing schedules, he said, but that's a long way off.\nThey then had the volunteers sleep in the lab, where some were exposed to continuous light for an hour and others were exposed to a sequence of flashes of various frequencies for an hour.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no obvious disease mongering here and jet lag is a common\u00a0problem with likely serious consequences for some professions.", "answer": 1}, {"article": "(Boston) -- To date, there are no methods that can quickly and accurately detect pathogens in blood to allow the diagnosis of systemic bloodstream infections that can lead to life-threatening sepsis.\nBiomarkers that report elevated inflammation are used clinically in the treatment of patients with sepsis; however, they fail to distinguish inflammation triggered by infectious pathogens from that induced by non-infectious causes, such as burns, traumas and surgeries.\n\"This highlights the advance this technology represents.\"\nThe diagnostic assay is built on FcMBL, a genetically engineered pathogen-binding protein previously developed by Ingber and Michael Super, a Wyss Senior Staff Scientist who co-leads the Institute's pathogen-detecting effort.\n\"Our pathogen detection technology solves both dilemmas: it quickly reports whether infectious pathogens are present in the body, even at early stages of infection before sepsis develops.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. Sepsis is a serious condition and we do need better ways to quickly diagnose it.", "answer": 1}, {"article": "The CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\n\"Now we have a nice collection of really powerful strategies that work for the population at greatest risk in the world.\n\"Taken together, these studies provide strong evidence the power of this prevention strategy.\"\nOn average, patients were followed for a year although some were followed for about three and a half years.\nHe is the iPrEx protocol chair.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in this story.", "answer": 1}, {"article": "The latest trial success follows Roche\u2019s announcement last week about a separate study in which Tecentriq mixed with chemotherapies carboplatin and Abraxane boosted progression-free survival, compared with chemotherapy alone, in first-line treatment of patients with advanced squamous non-small cell lung cancer.\nThe Basel-based company, which had previously announced Tecentriq, Avastin and chemotherapy had reduced the risk of disease progression or death, said on Monday it hopes for a quick approval from authorities for the cocktail.\nShe also said the survival benefit was observed across key subgroups, including those with varying levels of a protein called PD-L1 that can help tumors avoid detection.\n\u201cWe are pleased the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer,\u201d said Sandra Horning, Roche\u2019s chief medical officer.\n\u201cFacing biosimilar competition... we see Tecentriq sales coming timely to support Roche\u2019s profitability going forward.\u201d\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here, but no need. The mere mention of lung cancer will put many lung cancer patients, smokers, or worried well on high alert to this story. Some discussion of prevalence would have helped. What percentage of lung cancers fall into the category targeted by these treatments? How long do those people usually live?", "answer": 1}, {"article": "The device has gas sensors that detect various odorous molecules in sweat.\n5 Million Have Heart Failure in U.S.\n\nMore than 5 million Americans have heart failure, which occurs when the heart muscle loses its ability to pump enough blood throughout the body.\nAug. 30, 2011 (Paris) -- German researchers say they\u2019re a step closer to developing an electronic nose that can distinguish between people who have heart failure and those who don't.\nStill, that means that 11% of cases would have been missed and 16% of people would have been told they had a life-threatening condition when they didn't.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story explains clearly who might benefit from such a device. It says, \u201cMore than 5 million Americans have heart failure, which occurs when the heart muscle loses its ability to pump enough blood throughout the body. Fluid can back up into the lungs, leaving people short of breath.\u201d", "answer": 1}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\n\u201cIf a man has five or six, it increases his chances quite a bit.\u201d\n\nThe research is still in the early stages, so doctors aren\u2019t likely to be using the genetic markers to determine treatment any time soon.\n\u201cAnd if we can do that, then there\u2019ll be enough confidence to put it into use in the clinic.\u201d\n\nEven better, he suggested, it may one day be possible to use drugs to target the SNiPs, or the biological processes they influence, as a way to prevent damage from therapy.\nIf you see a radiation oncologist he\u2019ll say oncology.\u201d\n\nDetermining what type of treatment a man should receive is only part of the dilemma of prostate cancer.\nWhile Derweesh agreed with Rosenstein that such a technique will take time to validate, and be used to steer patients toward a particular therapy -- something he called the \"holy grail\" -- he suggested that in the nearer term, such markers might be used as a trigger to pre-emptively begin erectile rehabilitation or to take measures that might lessen the potential damage.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering. Prostate cancer is the most frequently diagnosed cancer, most men are diagnosed at an early stage and subsequently undergo active treatments\u2013which carry substantial risks for complications. \u00a0However, the article could have cited estimates for the risk of erectile dysfunction following treatments.", "answer": 1}, {"article": "Yet the ultimate goal of prevention is to save lives.\nThe amount of benefit he\u2019ll get is not much, but his risk reduction still is 25 or 30 percent.\u201d\n\nDr. Thompson knows what he will do about finasteride.\nBut the reality is that people are being operated on.\u201d\n\n\u201cWe are trying to avoid a diagnosis to avoid a prevention whose value is disputed,\u201d he said.\nThe drug, finasteride, is available as a generic for about $2.00 a day, and millions of men safely take it now to shrink their prostates, its approved use.\n\u201cFinasteride has to be recognized as the first clearly demonstrated way to prevent prostate cancer with any medication or any oral agent at all.\u201d\n\nFinasteride has had its ups and downs.\n", "question": "Does the story commit disease-mongering?", "explanation": "Having experts in the field talk about medicating all men instead of providing them with some understanding of the magnitude of the risk seems like disease mongering. And ending the piece with two of these experts (Scardino and Thompson) discussing their own possible plans for taking the drug introduces an imbalance to the piece. ", "answer": 0}, {"article": "Formula may somehow trigger the development of autoantibodies as these proteins are broken down for digestion.\nThe current study was randomized and double-blind (meaning neither the parents nor the researchers knew who was getting what), and compared regular baby formula to one that was made easier for babies to digest because the proteins were broken down (extensively hydrolyzed).\n\"The data in this study is not sufficiently strong to support recommending any changes for parents,\" said the author of an accompanying editorial, Dr. David Harlan, co-director of the Diabetes Center of Excellence at the University of Massachusetts Memorial Medical Center in Worcester.\nWEDNESDAY, Nov. 10, 2010 (HealthDay News) -- Offering your baby a special formula when weaning off breastfeeding may offer some protection against the development of the antibodies associated with type 1 diabetes, if you have a family history of the disease, new research suggests.\nAfter adjusting the data to try to account for the duration of exposure to one of the study formulas, the researchers found that the extensively hydrolyzed formula reduced the risk of having one diabetes autoantibody by 49 percent, and the risk of having two or more autoantibodies by 53 percent.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. The story carefully explains the results of the study and is conservative about the role a formula may play in the prevention of Type 1 diabetes in susceptible children. it would have been helpful to indicate the prevalence of type 1 diabetes and how much the risk is increased if you have a first degree relative with type 1, which would have provided some perspective on the meaning of the relative increased risk for developing these auto-antibodies if an infant is exposed to standard formula.", "answer": 1}, {"article": "Like a patch on faulty software, C.B.T.\nMy experience is consistent with these averages.\nMy sleep log also helped me be more objective.\nAnd as studies show, it works better than drugs.\nThe total amount of time that they were sleeping when in bed increased by nearly 10 percent.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no exaggeration of the impact of insomnia.", "answer": 1}, {"article": "It also has a very low rate of false positives - it is 98% accurate at ruling out RA.'\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\n'When we looked at results from more than 2000 patients we found that testing for antibodies that target citrullinated tenascin-C (cTNC) could diagnose RA in around 50% of cases, including some cases not identified by CCP.\nThe Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nStephen Simpson, Research Director, for Arthritis Research UK said: 'When it comes to rheumatoid arthritis, early diagnosis is key with research showing that there is often a narrow 'window of opportunity' following the onset of symptoms for effective diagnosis and control of disease through treatment.\n", "question": "Does the news release commit disease-mongering?", "explanation": "One could argue that this study and news release are pushing for the creation of a new disease \u2013 called \u201cpre-rheumatoid arthritis.\u201d But the value of classifying people with such a condition is not established, and the release doesn\u2019t explore any of the downsides of such an approach. Expanding the boundaries of disease without sufficient evidence that this is justified constitutes disease-mongering. So we\u2019ll flag the release here.", "answer": 0}, {"article": "These findings are published in FASEB BioAdvances journal.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nCo-first author Dr Mojgan Najafzadeh from the University of Bradford said: \"We feel that we've taken it as far as we can in proving that the test works with high predictability for cancer outcome, and IMSTAR are the right partners to improve it still further.\"\nHowever, in their two most recent clinical trials of the test involving over 700 blood samples from colorectal and prostate cancer patients (and further breast and lung cancer samples that were available), they were unable to distinguish those with cancer from healthy patients in 60 cases.\n\"I'm now convinced that if we used the powerful IMSTAR system to look at thousands of cells on all the slide samples in the trials, we would see a significant increase in the overall predictability beyond the original 93 per cent of the original 2014 study.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "Blood tests to detect cancer would provide a significant opportunity to find cancers at an early stage, when they can possibly (but not necessarily) be successfully treated. But, as we mentioned, the risk of overdiagnosis and overtreatment needs to be acknowledged.", "answer": 1}, {"article": "SAN DIEGO, July 14, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that a study featured on the cover of Urology demonstrates that Decipher\u00ae Prostate Cancer Classifier significantly influenced treatment recommendations following prostate surgery, reducing disagreement between urologists and radiation oncologists, and has the potential to enhance personalization of patient care.\nUsing clinical information alone, observation rather than adjuvant radiation therapy was recommended in 42% of decisions made by urologists and 23% of decisions by radiation oncologists (P < .0001).\nDecipher is covered by Medicare and multiple private insurance plans in the US.\nResearchers found that 60% of the clinically high-risk men would be reclassified as low risk based on the Decipher test and have only a 2.4% risk of metastasis at 5 years after surgery.\nDecipher was developed in partnership with the Mayo Clinic.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s nothing dramatic or overblown in this release.", "answer": 1}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "The Watchman is a catheter-delivered device that is permanently implanted in the opening of the left atrial appendage (LAA), a small appendage of tissue that projects off one of the upper chambers of the heart.\nIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\nOnce the device is in place in the opening of the LAA, a thin layer of tissue grows over it, preventing blood clots from forming in the LAA and therefore preventing stroke.\nWhen patients are in an abnormal irregular heart rhythm called atrial fibrillation, blood clots can form in the LAA, which can then circulate out through the bloodstream and cause stroke.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease mongering. A brief description of how many people are affected by the condition might have added some useful context.", "answer": 1}, {"article": "MONDAY, Dec. 17, 2012 (HealthDay News) -- For patients whose high blood pressure cannot be controlled despite taking several medications, a short burst of radio waves at the nerves around the kidneys may do the trick, a small new study says.\nAll the patients suffered from drug-resistant hypertension.\nThe treatment was effective for at least six months.\n\"We also found no ill effects on long-term health from the procedure.\"\nThe U.S. Food and Drug Administration has not yet approved its use.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering at play here.", "answer": 1}, {"article": "But it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nIn a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease-mongering.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story commit disease-mongering?", "explanation": "Basal or squamous cell cancers afflict more Americans annually than all other cancers combined, according to the story. \u00a0While generally not lethal, they require treatment, and that makes these types of cancers indeed a significant problem. What\u2019s key to remember is that this treatment really should only be considered for the face or other areas where standard excisional surgery is not feasible. The other element that the story could have emphasized is that it is recommend only for older individuals, >50.", "answer": 1}, {"article": "The University of Texas at Arlington has successfully patented in Europe an implantable medical device that attracts and kills circulating cancer cells that was invented by a faculty member.\nWhile there are drugs given to patients after surgery to prevent cancer cells from adhering to each other or other tissues, these drugs do not rid the body of cancer cells or collect them to allow an assessment of the patient\u2019s status.\n\u201cWe have made a nano-sized device that we can put under the skin using an injection needle to recruit the cancer cells into a small area where we can treat them with less overall side effects to the whole body,\u201d Tang said.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\nWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan,\u201d he added.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release explains the rationale for the device and notes that it would be \u201ccomplementary to current cancer treatments.\u201d", "answer": 1}, {"article": "(Reuters Health) \u2013 Patients who need to be rehospitalized within a month after major surgery have a lower risk of death over the next two months if they return to the hospital where they had the surgery rather than going to a different facility, according to a new study.\nMore than half the time, patients were readmitted or transferred to the hospital where they had the surgery.\nPatients readmitted at the original hospital also tended to be readmitted one to two days earlier than those who ended up at different hospitals.\nIf these patients have complications weeks later, they end up going to a local hospital, not the one where they had surgery.\nThose who returned to the original hospital were 26 percent less likely to die within three months of surgery than those admitted to a different hospital, as reported in The Lancet.\n", "question": "Does the story commit disease-mongering?", "explanation": "Disease mongering was not an issue.", "answer": 1}, {"article": "\"As the kids with cystic fibrosis are living longer and longer, a lot of these ancillary problems are become more apparent,\" said C. Michael White, director of the Evidence-based Practice Center and lead author of the study.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\nLungs are clogged with a thick mucus, which can lead to lung infections.\nIn the 1950s, children with cystic fibrosis generally died before age 8.\nCaused by defective genes, cystic fibrosis affects multiple organs.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "Information on breast cancer is available at cancer.gov.\nAll were taking the medication at least three times a week.\nWomen.\nHormone therapy and alcohol use were more prevalent among the participants than normal; both are considered risk factors for breast cancer and may have affected the results.\nAbout 1 of every 8 women in the United States will develop breast cancer at some point.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "BOSTON (Reuters) - If you\u2019re checking into the hospital for surgery, doctors may soon be swabbing your nose in an effort to prevent an infection from appearing after your operation.\nAbout 27 million surgeries are done just in the United States each year, and in as many as half a million cases, infections occur at the site of surgery.\nInfections are also a problem when doctors put tubes into the body.\n\u201cPreventing one infection will pay for thousands of these screenings,\u201d Dr. Henri Verbrugh of Erasmus, a coauthor of the study, said in a telephone interview.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\n", "question": "Does the story commit disease-mongering?", "explanation": "In general, the article does not appear to exaggerate this problem.", "answer": 1}, {"article": "As Albert, a pseudonym for an AA member in Georgia, previously told me, \u201cThere\u2019s just not a lot of widely advertised options available.\u201d AA and 12-step treatment are \u201cthe most well-known and most recommended option, so that\u2019s kind of where you tend to go.\u201d\n\nZemore\u2019s study begins to peel away at this problem.\nSo finding the right solutions for this problem is literally a matter of life or death.\nThat could affect substance use outcomes \u2014 and especially abstinence outcomes.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\nFor example, AA really emphasizes total abstinence from drinking as the solution to alcohol addiction.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story references reliable sources regarding the massive impact of alcohol use disorders and doesn\u2019t overstate their toll.", "answer": 1}, {"article": "Conservative treatment options for herniated disks range from over-the-counter pain medications to injections of corticosteroids directly into the affected area of the spine.\n\"We learned that when pulsed radiofrequency is followed by steroid injection, the result is longer lasting and more efficacious than injection only,\" Dr. Napoli said.\nThe results of the study are superior to those typically reported for usual care strategies and injections and may help a substantial number of patients with sciatic disk compression to avoid surgery, Dr. Napoli added.\n\"Pulsed radiofrequency creates a nerve modulation, significantly reducing inflammation and its associated symptoms,\" said study senior author Alessandro Napoli, M.D., Ph.D., professor of interventional radiology at Sapienza University of Rome in Italy.\n\"Given our study results, we offer pulsed radiofrequency to patients with herniated disk and sciatic nerve compression whose symptoms do not benefit from conservative therapy,\" Dr. Napoli said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering.\nChronic lower back pain is not only very common and very difficult to treat, but it\u2019s also one of the leading causes of disability and missed work days.", "answer": 1}, {"article": "No woman who had a mastectomy developed breast cancer during the three years of follow-up testing.\nShe said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\nCHICAGO (Reuters) - Women with mutations in the well-known BRCA1 or BRCA2 genes who have their breasts and ovaries removed are much more likely to survive than women who do not get preventive surgery, U.S. researchers said on Tuesday.\nAccording to the American Cancer Society and the International Agency for Research on Cancer, 1.3 million new breast cancer cases are diagnosed around the world every year and it kills 465,000 women annually, making it the leading global cancer killer of women.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nBecause the story lead clearly notes that the study involved only women with BRCA1/2 genetic mutation and it also points out that 10 to 20 percent of breast and ovarian cancers are linked to BRCA1/2 mutations, it could be argued that the story meets this criterion. But then a potentially confusing reference to \u201cwomen with a family history of cancer\u201d may lead many readers to believe the findings may be relevant to that much larger population of women. Also, at the end of the story it calls breast cancer \u201cthe leading global cancer killer of women.\u201d While technically accurate based on current statistics from the International Agency for Research on Cancer, the description obscures the fact that in developed nations (where genetic testing is available) the overwhelming majority of women who develop breast cancer are successfully treated.\nActually, this story dramatically understates the cancer risks facing women who carry BRCA1/2 mutation by confusing the lifetime risk of cancer with the relative risk compared to women who don\u2019t have the mutation. For example, the story erroneously reports that women with the mutations have a \u201c56 to 84 percent higher\u201d risk of breast cancer\u2026 when in fact that is their lifetime risk\u2026 which is several times higher than the commonly used figure of a 12 percent lifetime risk of breast cancer for women in the general population.\n", "answer": 0}, {"article": "What does that mean?\n\"People with chronic neck and/or back pain should be educated about their pain, [and] should be reassured,\" said lead researcher Anneleen Malfliet.\n\"These positive effects were found until the last follow-up measurement at one year after treatment,\" Malfliet said.\nThey should \"learn to put pain into the right perspective, should remain active or increase their activity levels gradually, and should avoid fear of moving,\" said Malfliet, of Vrije University Brussel in Belgium.\n\"They should also avoid the use of scary, unreassuring labels or diagnoses,\" and not limit movement in therapy, she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here. It is clear that current treatments for chronic low back pain offer patients limited benefits.", "answer": 1}, {"article": "They think I am crazy, even a [Defeat Autism Now doctor] we once saw,\" said a message posted by a parent on the AutismWeb.com bulletin board in March\n\nParents \"research anything they can get their hands on and there are so many things saying 'Try this or try that' that aren't necessarily safe.\nBut we wonder -- we speculate -- that it's possible if we have children living in a unique environment that has not [previously] been created scientifically that we can make a difference.\n\"We're not saying this is the full cause\" of autism and related illnesses, Dr. Faber said.\nThe 106-year-old Children's Institute (formerly called the Rehabilitation Institute) plans to fund the room through the $30 million capital campaign it launched in 2005, after buying out its Shady Avenue site from the University of Pittsburgh Medical Center.\nHis findings are complicated, but basically blood tests show 70 percent of his autistic patients have zinc deficiencies (pointing to problems with processing heavy metals), and the vast majority also have immune system problems of varying kinds.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article fails to mention that \"autism\" is a misnomer and that the correct term is \"autism spectrum disorders\".\u00a0 This disorder\u00a0ranges from the severely disabling to less severe syndromes, such as Asberger\u2019s syndrome.\u00a0 Readers should be wary about \"Hail Mary\" stories when the subject is a disorder for which no clear cure now exists, and which can be so very painful and heart-breaking for sufferers and their families.\u00a0 By stating that \"autism\" is \"skyrocketing,\" the story engages in disease mongering by using emotional terms with vague meanings. ", "answer": 0}, {"article": "THURSDAY, July 20, 2017 (HealthDay News) -- A laser treatment can reduce spots in people's vision known as \"floaters,\" a new study finds.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\n\"Floaters often arise as the vitreous -- a gel-like substance that fills the eye -- contracts and pulls away from the back of the eye,\" explained ophthalmologist Dr. Naomi Goldberg, who reviewed the new research.\nThey explained that, currently, there are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\n\"Greater confidence in these outcomes may result from larger confirmatory studies of longer duration,\" the study authors wrote.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story hints that many people don\u2019t need treatment: \u201cFloaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\u201d\nHowever, the story should have been stronger on this point\u2013visual floaters are so common that they can be considered normal and the majority of people don\u2019t do anything about them.\nThe news release, which we also reviewed, noted that \u201cmost\u201d people get used to them, in all but the most serious cases. We think the story should have been stronger on this point, too.", "answer": 0}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t engage in disease-mongering. It said migraines affect 40 million people in the U.S., and one to 2% of the population falls into the category of chronic migraines patients, defined 15 migraines per month for at least three months.", "answer": 1}, {"article": "Aug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\nHe was not involved in the research.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\nRecently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.\n\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering of lung cancer here.", "answer": 1}, {"article": "She said self-exams may not reveal tumors early enough to improve survival.\n\"Not only do the trials not find a benefit, the trials demonstrate harm in terms of increased physician visits and benign breast biopsies,\" said Dr. Nancy Baxter, a University of Toronto surgeon who reviewed the evidence on self-exams for the Canadian Task Force on Preventive Health Care.\n\"One danger of pushing breast self-exams on patients is that they may be falsely reassured by it and opt out of their mammograms,\" said Dr. Heidi Nelson, medical director of the\n\nin Portland.\n\"By the time a breast cancer is large enough to be detected by self-exam, tumor biology is the most important predictor of outcome, not finding a tumor a few months before it would have become apparent,\" she said.\nA scientific review, published in August by the\n\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies.\n", "question": "Does the story commit disease-mongering?", "explanation": "This otherwise balanced story leads with a frightening anecdote about a woman whose breast cancer was only diagnosed by breast self-exam. We do not know if her doctor also felt this lump.\u00a0 Her statement that she would not have survived if she had not been vigilant about monthly exam may or may not be true.\u00a0 A physician\u2019s quote buried in the piece notes that\u00a0 tumor biology (not size) is the most important predictor of mortality.\u00a0 Introducing this otherwise balanced story with such an unfortunate missed diagnosis detracts from the overall message that, in population studies there is no benefit to regular SBEs for low to moderate-risk women.\n\u00a0", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n\nThe story includes an estimate from the device manufacturer that about 10 percent of people with asthma might be candidates for this procedure \u2013 those who have problems controlling their asthma despite trying all standard treatments. It also specifically says that bronchial thermoplasty is not for people with mild, occasional asthma. \nHowever, the story closes with a quote saying that doctors will start using the treatment on more patients once they have more experience with it. Will that expanded use be based on evidence or anecdote? Journalists should keep an eye out for practitioners and marketing that encourage people with milder cases of asthma to have this treatment and check to see if there are new clinical trial results to justify the broader use.", "answer": 1}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "However, the researchers didn\u2019t have information on other key skin cancer risk factors like exposure to UV radiation.\n\u201cAlso, this potential cancer-protective effect should be taken into account when discussing benefits and harms of NSAID use.\u201d\n\nAlice Park is a writer at TIME.\nIn the U.S., skin cancer is the most common form of cancer diagnosed, affecting more than 2 million people each year.\n(One COX-2 inhibitor, Vioxx, was voluntarily pulled from the market by its maker in 2004 after it was linked to an increased risk of heart disease.)\nOver the study period, people who filled more than two prescriptions for aspirin, NSAIDS or COX-2 inhibitors had a 13% lower risk of melanoma and a 15% lower risk of squamous cell carcinoma than those who filled fewer prescriptions, the researchers found.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story states that basal cell carcinoma (BCC) is \u201cthe most common form of skin cancer in the U.S.\u201d While the statement is true, BCC is also the slowest-growing and least dangerous form of skin cancer.\u00a0\u00a0 Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "Importantly, the development opens up a possibility for a more selective cancer treatment as JPC11 was observed to specifically target the biochemistry of cancer cells, leaving healthy cells largely untouched - another improvement compared to existing platinum-based drugs, which can also attack non-cancerous cells.\nChemo-catalysts, especially those with immunogenic properties, might provide a breakthrough.\nProteins, enzymes and our DNA, for example - are handed.\nOur hands are near-identical, but are mirror images of each other.\n\"The 'handedness' of molecules is critical in the body.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "But even that can be helpful.\nIt remains far from clear, however, what proportion of children will benefit, how long the benefit might last and what proportion will need to continue to consume at least some milk or peanuts every day to maintain their protection.\nAlthough the approach appears to be highly effective for some children with milk and peanut allergies, the researchers conducting the studies and others caution that much more research is needed to prove and perfect the approach and that it is far from ready for widespread use.\n\"There's been a substantial uptick in the amount of research,\" said Marshall Plaut of the National Institute of Allergy and Infectious Diseases, which has more than doubled the funding for food-allergy research since 2007.\n\"There's definitely been a spike in the amount of work going on,\" said Hugh A. Sampson, a professor of pediatrics, allergy and immunology at the Mount Sinai School of Medicine in New York who leads a federally funded consortium studying food allergies.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story bordered on the edge of disease mongering because\u00a0the parental anecdotes about their children\u2019s allergies were extreme and a bit alarming.\u00a0\u00a0A comment indicating that the majority of food allergies are not life-threatening would have been a welcome addition to the story. Nonetheless we\u2019ll give the story the benefit of the doubt on this criterion.\u00a0 ", "answer": 1}, {"article": "The study had several limitations.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\nIn the new study from Denmark, taking low-dose aspirin continuously for at least five years appeared to reduce the risk of colorectal cancer by 27%, and using nonaspirin NSAIDs for at least five years appeared to reduce it by 30%.\n\u201cUnless low-dose aspirin is taken continuously, there is little protection against colorectal cancer,\u201d Dr. Soren Friis from the Danish Cancer Society Research Center in Copenhagen told Reuters Health.\nIn general, the risk of developing colorectal cancer varies with age, race, ethnicity and lifestyle.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no attempt to inflate the incidence or severity of the disease. If anything, the severity of the disease was underplayed by not mentioning death rates.", "answer": 1}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not commit disease mongering.", "answer": 1}, {"article": "And all of this ultimately improves general quality of life,\" she added.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\nThe possible explanation for the benefits of yoga seen in the study stems from physiologic data demonstrating its ability to help reduce cancer- as well as treatment- related fatigue and to strengthen pelvic floor muscles and increase blood flow.\n\"Despite these figures, we found that a structured yoga intervention in the form of twice-weekly classes is feasible for patients during a six- to nine-week course of outpatient radiotherapy for prostate cancer,\" said Vapiwala.\nThe effect of yoga was measured by participants' responses to a series of questions that assess overall quality-of-life, cancer-related fatigue, and prevalence of sexual and erectile dysfunction and urinary incontinence.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release cites American Cancer Society figures on the incidence of prostate cancer in the United States and therefore cannot be accused of disease mongering. However, a substantial proportion of men diagnosed with prostate cancer in a time of widespread use of prostate-specific antigen (PSA) testing are found to have low-risk cancers that do not likely require treatment. The best way to prevent treatment complications is to avoid unnecessary treatments.", "answer": 1}, {"article": "\"If your goal is a 30-year knee, you need to avoid high-impact sports,\" says John Wright, an orthopedic surgeon at Brigham and Women's Hospital in Boston.\nThey're also determined to stay active for many more years and not let pain or disability make them sedentary.\nEven the most fit patients face a long period of rehabilitation after surgery and may not be able to resume high-impact activities.\nThat said, some patients are determined to push the envelope, and some doctors give their blessing.\n\"I know that the technology is capable of this level of athletic function.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article discussed the expanding indications for knee and hip replacement. But there is no indication that this represents disease-mongering.\n\n \n", "answer": 1}, {"article": "Children's Health Foundation is dedicated to raising and granting funds to support Children's Hospital at London Health Sciences Centre, Thames Valley Children's Centre and Children's Health Research Institute.\nThe scientists measure a panel of metabolites - small molecules that are the products of the body's metabolism - in the blood to search for distinct patterns that indicate a concussion has occurred.\nConcussion is a major public health concern, often resulting in significant acute symptoms and in some individuals, long-term neurological dysfunction.\nIn the relatively inexpensive test, blood is drawn from an individual that may have suffered a concussion as the result of a sudden blow to the head (or from transmitted forces from a sudden blow to the body) within 72 hours of the incident.\n\"The discovery of a blood test that can aid in concussion diagnosis is very important,\" says Dr. Fraser.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Concussions are a real and growing problem, especially among those who play contact sports. There is no mongering here.", "answer": 1}, {"article": "\"The arthritis was so bad that I could barely step down without severe pain.\u201d\n\nBecause she wasn\u2019t eligible for a knee replacement she tried cortisone injections, physical therapy, medications \u2014 nothing relieved her pain.\nRecovery time is minimal, with most patients walking immediately after the procedure and resuming normal activities in a day or two.\nCoolief doesn\u2019t repair arthritis in the knee, but eases the pain, helping patients go back to activities without discomfort and fewer medications.\n\"I thought I was going to limp for the rest of my life,\" she said.\n\u201cI had inflammation, swelling, and my knee was like the size of a golf ball, McCloden told NBC News.\n", "question": "Does the story commit disease-mongering?", "explanation": "Osteoarthritis in the knee can be debilitating and the story didn\u2019t disease monger its severity or prevalence.", "answer": 1}, {"article": "Again, Merck disputes the connection.\nBut the \"absolute risk\" of these unusual fractures is still pretty low \u2014 13 fractures per year for every 10,000 people taking bisphosphonates for five years or longer.\n\"The big message really is the number of typical hip fractures is much, much larger than the number of unusual thigh fractures,\" says Dr. Gillian Hawker of St. Michael's Hospital in Ontario, an osteoporosis specialist and study author.\nStill, the accumulating evidence that there is a risk of these serious, unusual fractures associated with bisphosphonates is getting a lot of attention in the medical community.\n\"Although it is not clear if bisphosphonates are the cause, these unusual femur fractures have been predominantly reported in patients taking bisphosphonates,\" the FDA says.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story avoids being alarmist and takes pains to point out the low absolute risk of the unsual thigh fracture.\nIf anything, the story could have pointed out how devastating a typical hip fracture can be for an individual and society overall. The CDC estimates that one in four who suffer a hip fracture are dead within a year, and one in five will spend at least a year in a nursing home.", "answer": 1}, {"article": "Their conclusion?\nSo on running versus walking, it really depends on your values and preferences: \"One could choose walking instead of running as a mode of physical activity based on injury risks, since walking is less risky than running,\" he explained.\nJogging even 5 to 10 minutes per day can reduce the risk of death from all causes I also learned about some of the incredible health benefits of going fast: Even five to 10 minutes per day of jogging at around 6 miles per hour can reduce the risk of death from cardiovascular disease and other causes.\nAs this study described, \"Running produces ground reaction forces that are approximately 2.5 times body weight, while the ground reaction force during walking is in the range of 1.2 times body weight.\"\nOverall, more than half of people who run will experience some sort of injury from doing so, while the percentage of walkers who will get hurt is around 1 percent.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story avoids disease-mongering. It seems to have been targeted to audiences who already understand the health risks of inactivity, but nonetheless, a sentence or two about the danger of a sedentary lifestyle would have been of benefit.", "answer": 1}, {"article": "New medtech apps put specialist knowledge in patients' pockets\n\nDeep-learning networks have already been applied to produce algorithms capable of diagnosing diseases like melanoma and blindness caused by diabetes.\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d\n\nRead more: Can smartphones replace your GP?\nThe risk factors include the person\u2019s gender, smoking status, blood pressure and age\u2014estimated to within four years of the patient\u2019s actual age.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no outright disease-mongering here. However, the story provides no context about how many people are at risk of a heart attack. For that reason, it doesn\u2019t meet our criteria.", "answer": 0}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nWithin a year, 14.4 percent of spironolactone patients and 13.4 percent of antibiotic patients had switched to alternative treatments, suggesting each treatment was working at almost the same rate, despite the fact that tetracycline-class antibiotics are prescribed five times as frequently.\nThe prescription change is a proxy for ineffectiveness, since switching is often the result of treatment failure due to lack of efficacy, side effects, cost, or other factors.\n\"This indicates spironolactone may have a better safety profile than oral antibiotics, which is another factor that makes it such an appealing option,\" Barbieri said.\nThe study, published this month in the Journal of Drugs and Dermatology, found patients who were originally prescribed spironolactone changed to a different drug within one year at almost the same rate as those who were prescribed antibiotics.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release erroneously refers to acne as \u201cone of the most common diseases in the world.\u201d It\u2019s not a disease.\u00a0 It\u2019s a common skin condition and an annoyance for most people that have it, and can often be treated with careful cleansing and over-the-counter products.", "answer": 0}, {"article": "\u201cIf this is the case, dosage shouldn\u2019t matter.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nIn a new study from Duke University Medical Center, men who took statins for their hearts were 30% less likely to have their cancers come back after their prostates were removed than men who did not take the drugs.\nThose who took the highest doses saw their recurrence risk drop by half.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story presents the scope of the disease clearly and concisely. \"About one man in six will be diagnosed with prostate cancer during his lifetime, and one in 35 will die of the disease, according to the American Cancer Society. In the U.S. alone, roughly 190,000 new cases of prostate cancer were diagnosed last year.\" But why aren\u2019t we given any estimates of recurrence, since that\u2019s what the story is about?\u00a0", "answer": 1}, {"article": "The study of nearly 32,000 people in eight countries boosts hope that early detection by CAT scans may reduce the death toll of lung cancer, much as mammography has done for breast cancer.\nMany of these lump-shaped masses were watched with further scans to see whether they grew; others were examined with other imaging devices.\nOnly 15 percent of people with the disease survive five years from the time it is diagnosed.\nI think we have enough data to move forward and apply this to a high-risk population.\"\nLung cancer kills about 162,000 Americans a year and is the leading cause of cancer death in men and women.\n", "question": "Does the story commit disease-mongering?", "explanation": "By accurately describing the prevalence and seriousness of lung cancer, the story avoids disease mongering.", "answer": 1}, {"article": "Words such as \"expects,\" \"anticipates,\" \"intends,\" \"plans,\" \"aims,\" \"targets,\" \"believes,\" \"seeks,\" \"estimates,\" \"optimizing,\" \"potential,\" \"goal,\" \"suggests,\" \"could,\" \"would,\" \"should,\" \"may,\" \"will\" and similar expressions identify forward-looking statements.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nThis suggests the assays may provide better risk stratification than that available using PSA tests for men with actual or suspected PCA, leading to better patient management and fewer unnecessary biopsies.\nHowever, most men with elevated PSA levels referred for prostate biopsy either have no cancer or have low-grade cancer which needs monitoring but not treatment.\nThe tests are based on the technology platform of Nucleosomics\u00ae, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.\n", "question": "Does the news release commit disease-mongering?", "explanation": "It\u2019s nice to see a prostate cancer release that notes, \u201cmost men with elevated PSA levels referred for prostate biopsy either have no cancer or have low-grade cancer which needs monitoring but not treatment.\u201d", "answer": 1}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.\n\u00a0", "answer": 1}, {"article": "But experts say the findings likely don\u2019t apply in non-Asian countries, where the majority of all lung cancers are found in people who smoke \u2014 and where using computed tomography (CT) scans to screen for lung cancer in smokers has recently been a controversial topic.\nMost of the tumors found via CT scans were small, whereas those found through X-ray screening or in patients with symptoms were more often further advanced, according to the findings published in the journal Lung Cancer.\nLung cancer kills more people in the U.S. than any other cancer \u2014 over 150,000 each year.\nCT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nEast Asian countries are more likely to regularly screen non-smokers for lung cancer because biological differences seem to put Asians at a higher risk than other non-smokers, researchers explained.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of lung cancer.", "answer": 1}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story commit disease-mongering?", "explanation": "The story uses examples of health conditions in which medication adherence is known to affect outcomes. It could have been clearer that treatment for tuberculosis is temporary, whereas treatment for opioid use disorder may be more extended and thus affect retention rates.", "answer": 1}, {"article": "There is also another issue.\n\"Part of it is that this area of medicine we're practicing in is kind of a high wire act,\" said Dr. Michael Lee, an oncologist in private practice in Norfolk, Va. \"It is more comfortable to adopt things that are aggressive.\"\nThe study is ethical, said Dr. Larry Norton of Memorial Sloan-Kettering Cancer Center in New York, because the only women whose treatment will be decided at random are those in a kind of gray area, not women for whom chemotherapy would be a clear benefit or clearly unnecessary.\nAnd while some, including Dr. Winer, predict that the use of chemotherapy will almost certainly decline in the years ahead, for now most doctors are sticking with the current guidelines, waiting for expert advice from national panels on what to do.\nAnd so, Dr. Esteva said, he is left asking many women with early-stage breast cancer to decide what can seem like the undecidable: whether they want \"to take something potentially toxic when you have a 90 percent chance of being cured without it.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No evidence of disease mongering. This story discusses the idea of less treatment \u2013 not more \u2013 since it may not be as beneficial as once thought. The annual incidence of women who currently undergo chemotherapy for breast cancer is provided, as well as estimates of women who may or may not obtain a life-saving benefit from this treatment. ", "answer": 1}, {"article": "Shi said: \u201cScientists may turn the 'bad' side of a devastating pathogen\u2014Zika virus\u2014for potential cancer therapy.\u201d\n\nHowever, he cautioned any potential treatment which could emerge from the study is far from being rolled out.\nBut those injected with the combination lived to around 50 days, 20 days longer than the stem cell mice.\n\u201cWe still need to further improve the specificity of the cancer-killing ability, while retain the safety of the vaccine strain,\u201d Shi explained.\nCurrently, most people diagnosed with the condition die within two years.\nThe animals dosed only with the stem cells developed tumors.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering was noted in the story.", "answer": 1}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story commit disease-mongering?", "explanation": "The story did temper the enthusiasm for more testing and more treatment by including skeptical comments from editorial writer Hlatky. ", "answer": 1}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story commit disease-mongering?", "explanation": "Yes, the story avoids this. Cuff tears are so common, as the story says, that more than half of all adults over 60 are walking around with them.", "answer": 1}, {"article": "Dr Fabiansen , the main author of the paper appearing in PLOS Medicine today, underscores the importance of the findings:\n\n\"Previous studies of nutritional supplements have mainly looked at the effect on weight gain.\nThose with the most severe acute malnutrition have more than ten times increased mortality, and those surviving may have impaired development, compared to children without malnutrition.\nThe study was primarily funded by Danida, MSF-Denmark and MSF-Norway, and USAID via the World Food Programme.\nMore than 30% of children in the world have chronic malnutrition.\nApproximately 8% or 50 mio children globally are affected by acute malnutrition.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here. It would be pretty much impossible to engage in disease mongering about acute malnutrition.", "answer": 1}, {"article": "So his team designed a randomized controlled clinical trial to see if short-term use of a curcumin supplement could reduce inflammation in people with metabolic syndrome, a cluster of risk factors for heart disease.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\nThe study team also analyzed data from eight previous studies and confirmed that curcumin had shown a significant reduction of CRP concentrations in a total of 281 patients.\nThey found that the people who took curcumin had improved blood levels of all three biomarkers as well as reduced fasting blood sugar and hemoglobin A1c, a measure of long-term blood sugar levels.\n\u201cTwo key effects of curcumin that account for most of the therapeutic effects of this compound are its strong antioxidant and anti-inflammatory properties,\u201d said Sahebkar researcher at the Mashhad University of Medical Sciences in Iran, in an email.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story makes clear that inflammation is a risk factor for heart disease, rather than equating it to heart disease. It also does a nice job of placing inflammation in context by explaining how it is one of a number of \u201cmetabolic syndrome\u201d factors that increase risk for heart disease.", "answer": 1}, {"article": "LOS ANGELES (Embargoed Until Oct. 18, 2018 @ 10:05AM ET) -- A surgical technique called EDAS (encephaloduroarteriosynangiosis) significantly decreases the rate of stroke recurrence and death for patients with severe atherosclerosis of the brain arteries, according to findings of a Phase IIa clinical trial presented today at the World Stroke Congress in Montreal.\nDespite advances in medical care, annual rates of recurrent stroke and death are remain high, at 15 percent or more for ICAD patients, according to published research.\nAfter one year, 9.6 percent of the patients treated with the surgery experienced another ischemic stroke or died, compared with 21.2 percent of patients in a matched control group who received only intensive medical management.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nWhile this Phase IIa trial selected patients from previous studies as the control group, the Phase III study would enroll new ICAD patients for both the control and experimental groups, he explained.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease-mongering here. The release includes context on the annual rates of recurrent stroke or death for ICAD patients.", "answer": 1}, {"article": "\u201cThe dogma is strong,\u201d he said.\nIt\u2019s hard for us as surgeons and medical oncologists and radiation oncologists to accept that you don\u2019t have to remove the nodes in the armpit.\u201d\n\nDr. Grant W. Carlson, a professor of surgery at the Winship Cancer Institute at , and the author of an editorial accompanying the study, said that by routinely taking out many nodes, \u201cI have a feeling we\u2019ve been doing a lot of harm.\u201d\n\nIndeed, women in the study who had the nodes taken out were far more likely (70 percent versus 25 percent) to have complications like infections, abnormal sensations and fluid collecting in the armpit.\nThe complications \u2014 and the fact that there was no proof that removing the nodes prolonged survival \u2014 inspired Dr. Giuliano to compare women with and without axillary dissection.\n\u201cIt\u2019s a little frustrating.\u201d\n\nEventually, he said, genetic testing of breast tumors might be enough to determine the need for treatment, and eliminate the need for many node biopsies.\nIt is not known whether the findings also apply to women who do not have radiation and chemotherapy, or to those who have only part of the breast irradiated.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story is careful to explain to readers that the research findings only apply to a subset of women with breast cancer. \u201cNow, researchers report that for women who meet certain criteria \u2014 about 20 percent of patients, or 40,000 women a year in the United States \u2014 taking out cancerous nodes has no advantage. It does not change the treatment plan, improve survival or make the cancer less likely to recur. And it can cause complications like infection and lymphedema, a chronic swelling in the arm that ranges from mild to disabling.\u201d The Q&A that ran with the story provided more detail about the different types of cancers and cancer patients, noting, for example, \u201cFirst of all, 20 percent (the estimate of the study\u2019s lead author, Dr. Armando E. Giuliano) refers to 20 percent of all the newly diagnosed cases of invasive breast cancer each year. This does not include noninvasive breast cancer, or DCIS, ductal carcinoma in situ. The total is about 207,000, so 20 percent is roughly 40,000 women. That is about how many women would match those in the study, in terms of tumor status, affected lymph nodes and course of treatment.\u201d\u00a0\u00a0The story also says, \u201cThe results mean that women like those in the study will still have to have at least one lymph node removed, to look for cancer and decide whether they will need more treatment. But taking out just one or a few nodes should be enough.\u201d", "answer": 1}, {"article": "Although colon cancer is the second leading cause of cancer death for men and women in the U.S., many adults don't undergo the screenings once they reach age 50 (or earlier for those with a family history), Ahlquist told a news conference.\n\"We were pleased by the results of this first clinical study,\" he says.\nPatients must often take time off work and need transportation home from the procedure.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\nOne screening test, the colonoscopy, in which a flexible, lighted tube with a video camera is inserted to examine the colon, requires dietary restriction and preparation of the colon.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in this story", "answer": 1}, {"article": "For the study, researchers looked at data on 27,347 women ages 50 to 79 who joined two WHI trials between 1993 and 1998 and were followed through 2014.\nYounger women in the study appeared to have better survival odds with HRT.\nThey took hormones or a placebo for five to seven years and were followed for a total of 18 years altogether.\nOne trial tested estrogen alone against a placebo, or dummy pill, while the other trial tested estrogen taken in combination with progestin.\nWomen were 63 years old on average when they joined the trials and had already gone through menopause.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "(Reporting by Susan Kelly, editing by Dave Zimmerman)\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nAlthough diabetes and complications from the disease are serious and common, the story fails to note that this trial reported only changes in one measure of blood glucose control, not hard health outcomes. While the story says that, \u201cLowering A1C levels helps reduce the risk of long-term complications from diabetes such as eye, kidney and heart disease,\u201d it fails to point out that this study did not measure whether participants who used the pump and senor devices had lower rates of these diseases.", "answer": 0}, {"article": "TUESDAY, Jan. 5, 2016 (HealthDay News) -- For the sixth year in a row, a panel of health experts has named the heart-healthy DASH diet the best overall eating plan, according to U.S. News & World Report's 2016 Best Diets ranking.\nThe Mediterranean and the MIND diet tied for third place in this category.\nThe Fertility diet, which calls for the elimination of trans fats, also ranked as the best diet for diabetes, the report revealed.\nThey also considered how easy each diet was to follow, as well as safety and nutritional value.\nThe MIND diet includes some features of the DASH diet and Mediterranean diet, such as high consumption of fruits, vegetables and fish, but focuses on foods that promote brain health.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Cut It Out (Surgically)\n\nAt 32, it just didn't make sense that Daniel Sheiner was exhausted literally from the moment he woke up.\n\"I would say let's lose the weight; let's use CPAP and see a nutritionist; let's avoid the alcohol and let's see how you do.\"\n\"He had very large tonsils, but his tonsil tissue was also enlarged in the palate area and also at the back of his tongue.\"\n\"It didn't get any better over the course of the day, and I knew that was not normal,\" Sheiner says.\nAfter surgery, Sheiner says, \"it was a whole new life.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering.\u00a0 And at least the story disclosed that the patient profiled had \u201cone of the worst cases of apnea his doctors had ever seen.\u201d", "answer": 1}, {"article": "She bases this bold claim on her experience with seriously obese patients and a detailed analysis of the best studies yet done showing weight-loss surgery\u2019s ability to reverse the often devastating effects of being extremely overweight on health and quality of life.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\n\u201cThese patients have lost hundreds of pounds over and over again,\u201d Dr. Twells said.\nAnd the reason is not a lack of willpower.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. That said, the story\u00a0is weighted very heavily to endorsing weight loss surgery, making it guilty of \u201ctreatment-mongering.\u201d", "answer": 1}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering here.", "answer": 1}, {"article": "Dr. Arie Kaufman of SUNY Stony Brook demonstrated the virtual colonoscopy for CBS New York's Dr. Max Gomez.\nThis next step in virtual colonoscopy, called \"immersive colonoscopy,\" projects 3D images of the colon large enough to fill the walls of a room.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nColorectal cancer is the second leading cause of death among the combined group of men and women who have cancer, according to the National Institutes of Health.\n\"This will allow the physician to view 100 percent of the surface including lesions, which are hidden behind folds maybe seen on the side and back walls.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story calls colorectal cancer \u201cthe second leading cause of death among the combined group of men and women who have cancer.\u201d That\u2019s accurate, but we wish the story had also provided a person\u2019s\u00a0lifetime risk of developing colon cancer, which at 5% is more reassuring.", "answer": 1}, {"article": "Will it help avoid back surgeries, for example, that may or may not have great outcomes?\nThe study, \"Real-World Massage Therapy Produces Meaningful Effectiveness Signal for Primary Care Patients with Chronic Low Back Pain: Results of a Repeated Measures Cohort Study,\" was published online March 14 in the journal Pain Medicine.\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\nINDIANAPOLIS -- In the first study of its kind, researchers found real-world massage therapy to be an effective treatment for chronic low back pain.\n\"The study can give primary care providers the confidence to tell patients with chronic low back pain to try massage, if the patients can afford to do so,\" Munk said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. The release provides context on the numbers of people who experience back pain, but the 15 percent cited is a tad higher than the usual 7-10 percent cited in other research. ", "answer": 1}, {"article": "For more information about the NIDDK and its programs, see www.niddk.nih.gov.\nParticipants then ate and drank as much as they wanted from computerized vending machines.\nThe findings suggest a possible intervention for obesity, when combined with healthy eating and exercise.\nSpanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe and disabling conditions affecting Americans.\nThe four people who got the sham stimulation during both visits consumed the same number of calories from the vending machines on each visit and did not lose weight.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this release.", "answer": 1}, {"article": "TUESDAY, Dec. 27, 2011 (HealthDay News) -- A new test measuring levels of troponin I in the blood may help determine whether someone is really having a heart attack earlier than is currently possible.\nThe new test yields sensitive results in three hours.\nThe new test was more sensitive than the existing one.\nThis means that if a test result is negative, the person is not having a heart attack.\nMany people come to the emergency room with chest pain.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "\"When I woke up and saw that I wasn't all bandaged up, I said, \"Aha!\nThis technique, which Lee helped develop and has been using for about a year, represents a big advance over conventional kidney-cancer surgery, which can require a foot-long incision and, sometimes, removal of a rib so the doctor can reach the malignancy, according to experts.\nThe big chill was so localized, and the area of attack was so small, that Davis, 65, said he didn't feel anything during or after the March 30 procedure, which lasted about an hour.\nIt even represents an advance over conventional laparoscopic surgery, which requires separate incisions for devices that can grasp and sever the cancer, as well as an endoscope that provides illumination and a view of the target area, said Marvin Guiles, director of engineering at Cambridge Endo, who worked on the instruments with Lee.\nFrom that point on, the chemicals in Davis' body took over, breaking down and absorbing the deactivated tumors -- Lee calls them \"ice balls\" -- in a months-long process.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story adequately describes the prevalence and seriousness of early-stage kidney cancer. The story mentions that many of these cancers are found by accident, such as on an x-ray when looking for something else. The story could have described how it is unclear what would have happened to these tumors had they not been found this way. That is, some of them may never progress to cause a problem.", "answer": 1}, {"article": "\u201cThere is a great deal of interest in developing other uses of bimatoprost,\u201d Heather Katt, a spokeswoman for Allergan, wrote in an e-mail message, \u201cand Allergan is exploring ways to pursue that pathway through the F.D.A.\napproval process.\u201d\n\nFor those too impatient to wait, there is also the bold and fashionable solution of shaving one\u2019s head.\nAside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\n\u201cIt was a noticeable difference.\u201d\n\nBut Latisse does not appear to be a silver bullet for hair loss.\nThis may sound like a long time to wait, but \u201cit\u2019s important to remember that baldness is unlike other conditions where you can progress past the point of being helped,\u201d Dr. Bernstein said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does a great job avoiding what may be better termed fear-mongering in a case like this. Often stories about cosmetic medicine make people feel like their aging selves are inadequate. This story actually has a little fun with the idea of men being paranoid about their hair loss without minimizing the very real anxiety that hair loss causes. We did think one comment from Dr. Bernstein seemed to medicalize baldness. He said, that \u201cit\u2019s important to remember that baldness is unlike other conditions where you can progress past the point of being helped. \u2026Once we have a cure for hair loss, everyone will be able to benefit.\u201d", "answer": 1}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\nAlthough HT is the most effective treatment for managing most menopause symptoms, some women have turned to herbal medicine because they are either not candidates for HT or are concerned about the negative publicity surrounding potential side effects.\nA new study confirms that it is also effective in the management of postmenopause symptoms such as hot flashes, sleeplessness, vaginal dryness, and anxiety, without serious side effects.\nThe use of complementary and alternative medicine for the management of menopause symptoms has surged in recent years as women have attempted to identify alternatives to hormone therapy (HT).\n\"A larger, longer, randomized study is still needed to help determine its long-term benefits and side effect profile.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering of menopause symptoms here. While menopause is a normal phenomenon of aging sometimes symptoms can be severely bothersome.\nThe release provides some interesting context on the use of alternative and complementary medicine for treating menopause symptoms.", "answer": 1}, {"article": "Other expert groups have made similar statements.\nIf you are allergic to mold spores or to pollen from trees, grasses or ragweed, that means knowing when levels are high (by checking pollen.com or the National Allergy Bureau) and then taking steps such as these recommended by the American Academy of Allergy, Asthma and & Immunology:\n\u2022 Keep windows closed at home and in your car.\nIt's also important to administer the sprays correctly, so that they end up inside your nasal passages, not just your nose, where they might cause irritation, Sublett says.\nThese drugs work by fighting inflammation and they are in the \"single most effective drug class\" for treating nasal allergies, according to the American College of Allergy, Asthma & Immunology.\nAlso important to remember: While medications can be helpful, the first rule of allergy control is to avoid the substances that make you sniffle and sneeze.\n", "question": "Does the story commit disease-mongering?", "explanation": "While there was no overt disease mongering, the story suggests that anyone who has allergies needs to see an allergist, which is not accurate and might be said to constitute a sort of \u201cspecialty service mongering.\u201d In the majority of cases, the appropriate care setting is primary care. Inappropriate specialty care is a major contributor to rising health care costs.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Hormone replacement therapy may work slightly better than soy at reducing menopausal hot flashes, a new study says.\nIt\u2019s thought to have similar effects to estrogen on the brain, bones, and blood vessels, Bolanos-Diaz told Reuters Health by email.\nThat means that if women do take hormones, Bachmann told Reuters Health, it should be the lowest dose and for the shortest possible period of time.\nThey compared the average number of hot flashes in 760 women who had treatment with 770 who did not.\nThe researchers looked at 19 studies on how a treatment, either hormones or soy, compared to a placebo.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.\u00a0 The story included some interest factoids such as the average number of hot flashes per month reported by women in the studies.", "answer": 1}, {"article": "The researchers achieved similar results in work with pigs, whose heart closely resembles the structure of the human heart.\nIn essence, the new intervention -- known as \"visually guided laser-balloon catheter\" -- enables doctors to much more accurately target the so-called \"misfiring cells\" that emit the irregular electrical impulses that can cause an erratic heartbeat.\nAmong individuals over the age of 65, it is the most common \"serious\" form of heart rhythm irregularities, according to background information in a news release from the American Heart Association.\nThe findings are reported by study author Dr. Vivek Y. Reddy, a senior faculty member in medicine and cardiology at the Mount Sinai Medical Center in New York City, and colleagues in the May 26 online edition of Circulation: Arrhythmia and Electrophysiology.\nTHURSDAY, May 27, 2010 (HealthDay News) -- A new approach to treating irregular heartbeats appears to have demonstrated success in halting abnormal electrical pulses in both patients and pigs, new research indicates.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering.\u00a0 However, to say that \"about 2.2 million Americans currently live with an irregular heartbeat condition, known as atrial fibrillation\" in the same breath as describing a study of just 27 people may imply that this very small study has immediate ramifications for all 2.2 million.\u00a0 And it does not. Barely satisfactory. ", "answer": 1}, {"article": "Dr. Beth Karlan, director of gynecologic oncology at Cedars Sinai Medical Center in , said the results of the new trial would \u201cmake us all rethink the approach to treating patients with recurrent ovarian cancer.\u201d\n\nDr. Karlan, who was not involved in the study but presented a commentary on it, said CA125 testing should be done less frequently.\nThis new study does not refer to initial diagnosis of ovarian cancer, only to a relapse.\nDoctors are convinced that if the initial diagnosis can be made early, which is very difficult, the cancer can be treated by surgery.\nOther were resistant to chemotherapy and would not respond to treatment no matter when it was given.\nBut the overall median survival for the groups was the same, about months from the start of their remission.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of Ovarian Cancer.", "answer": 1}, {"article": "\"We already know that rivastigmine works to treat dementia by preventing the breakdown of acetylcholine, however our study shows for the first time that it can also improve regularity of walking, speed, and balance.\nParkinson's Disease.\nBMJ Open.\nHalf the group were given rivastigmine capsules and the other half a placebo for an eight month period.\nYou risk breaking bones and then needing an emergency hospital admission.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "See the Cartoons of the Week.\nRather than calling for all youngsters to have their cholesterol tested, which would entail considerable expense on the national level, Dr. Ralph Sacco, president of the American Heart Association (AHA), suggests looking more critically at current screening guidelines.\nThe question of how soon children should be screened for high cholesterol is becoming increasingly important in the U.S., with its rate of child obesity topping 20%.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nThe U.S. government currently recommends screening for high cholesterol in children with a family history of heart disease or high cholesterol (with at least one parent or grandparent who has suffered a premature heart event such as heart attack or stroke, or at least one parent with total cholesterol levels above 240 mg/dL).\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe lead of the story focuses on the number of children with elevated cholesterol who might be missed based on current national guidelines and does not jump to the conclusion that these children would necessarily benefit from treatment. The story also reports that less than two percent of the children tested had cholesterol levels high enough that doctors might consider drug treatment. Oddly, the lead sentence says current guidelines \u201cmay miss nearly 10% of those who have high levels of LDL, or bad cholesterol,\u201d but the researchers put the figure at closer to a third. It may be that the reporter confused the proportion of children overall who had elevated cholesterol (about 10%) with the proportion of children with elevated cholesterol who would not have been tested under current guidelines (about a third.)\n", "answer": 0}, {"article": "For more information, visit http://www.\nLeesburg, VA, March 13, 2018 - When compared to the screening population ages 50 and over, screening mammography in women ages 40-49 detects 19.3% additional cancers at the expense of an overall 1.5% increase in callbacks and 0.1% in increased biopsies, according to a study to be presented at the ARRS 2018 Annual Meeting, set for April 22-27 in Washington, DC.\nThe study results showed that there was a higher number of callbacks among women ages 40-49 compared to women ages 50-59 (17% compared with 12.5%) and to women ages 60-69 (17% compared with 10.2%).\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nWith educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2018 Annual Meeting, April 22-27, at the Marriott Wardman Park Hotel in Washington, DC.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release veers into disease mongering with this sentence:\n\u201cWhen compared to the screening population ages 50 and over, screening mammography in women ages 40-49 detects 19.3% additional cancers at the expense of an overall 1.5% increase in callbacks and 0.1% in increased biopsies\u2026.\u201d\nThis sentence makes it sound like the incidence of the disease is high in this age group. In fact, at age 40 the average woman has a 1.45 percent (or 1 in 68) chance of developing breast cancer over the next 10 years.", "answer": 0}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story commit disease-mongering?", "explanation": "This is one story that does not commit disease-mongering of toenail fungus.\u00a0 It includes a discussion of the mild end of the spectrum \u2013 in which nail fungus is \u201cmerely a cosmetic problem.\u201d", "answer": 1}, {"article": "Seven randomized trials with zinc acetate and zinc gluconate lozenges found that the duration of colds was shortened on average by 33%.\nThe 12% difference between the average effects of the two kinds of lozenges was explained purely by random variation.\nZinc lozenges appear to influence the common cold through the release of free zinc ions into the oro-pharyngeal region.\nHowever, zinc ions can bind tightly to various chemical complexes in such a way that little or no free zinc ions are released.\nHowever, gluconate binds the zinc ion more tightly than acetate does.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the news release. It provides some context about how zinc is believed to work to reduce cold symptoms.", "answer": 1}, {"article": "Chicago \u2014 Local bans on artery-clogging trans fats in restaurant foods led to fewer heart attacks and strokes in several New York counties, a new study suggests.\nAdmissions for heart attacks and strokes declined in all counties, going from more than 800 to less than 700 per 100,000 people, but the drop was steeper in counties that enacted bans.\nThey were once commonly used to make restaurant fried chicken, French fries, doughnuts and other foods and found in grocery items including cookies, crackers and margarine.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\n\u201cPolicies such as these when adapted on a nationwide level will be good for our entire population,\u201d said Creager, director of Dartmouth-Hitchcock Medical Center\u2019s heart center in Lebanon, New Hampshire.\n", "question": "Does the story commit disease-mongering?", "explanation": "Heart disease is a major killer; the story did a good job explaining what trans fats are, and why they\u2019re unhealthy.\nTrans fats, also called partially hydrogenated oils, enhance food texture and structure. They were once commonly used to make restaurant fried chicken, French fries, doughnuts and other foods and found in grocery items including cookies, crackers and margarine.\nThese fats can boost blood levels of unhealthy cholesterol, increasing risks for heart problems.", "answer": 1}, {"article": "And what about colon cancer screening for the elderly?\nThe USPSTF notes that only one-third of eligible adults in the United States are screened for colon cancer, and more need to take advantage of this effective method of prevention.\nThe panel's reticence to choose one option over another may be at odds with the preference of many doctors, who often advise colonoscopy as the \"gold standard\" test.\nFor its part, the American Cancer Society recommends colonoscopy screening once every 10 years, beginning at age 50, or one of a number of other tests at more frequent intervals.\nWEDNESDAY, June 15, 2016 (HealthDay News) -- Reiterating a recommendation last made in 2008, an influential U.S. panel of health experts is advocating that regular colon cancer screening begin at age 50 and continue until at least age 75.\n", "question": "Does the story commit disease-mongering?", "explanation": "If anything, this story more restrained than the USPSTF recommendation, which strongly urges colon cancer screening, saying that the biggest problem is that nearly one-third of eligible adults have never been screened.", "answer": 1}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story commit disease-mongering?", "explanation": "This story didn\u2019t disease monger;\u00a0allergies are certainly a common affliction.\nBut, while this isn\u2019t enough to lose the Satisfactory rating, there was what we call \u201ctreatment mongering\u201d because of the emphasis on immunotherapy for treatment. Most people won\u2019t\u00a0need this level of treatment,\u00a0and will do well with standard OTC and prescription medications.", "answer": 1}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no evidence of disease mongering.", "answer": 1}, {"article": "\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\nBecause of serious side effects, the drug -- Lemtrada (alemtuzumab) -- is approved in the United States only for patients who have failed other treatments.\nAlso, when the immune system rebuilds itself, \"a significant number of people, about 40 percent, will develop another autoimmune disease,\" Giovannoni said.\nThe new trial of more than 600 patients with relapsing-remitting MS was funded by Sanofi Genzyme and Bayer HealthCare Pharmaceuticals, the drug's makers.\nBy the study's end, nearly 28 percent of those given Lemtrada had improved by at least one point on a 10-point disability test, versus about 15 percent of those receiving interferon, the researchers found.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no obvious disease mongering. However, industry efforts to push very intense and very expensive drugs onto less-severely-affected patients should always be viewed with a healthy dose of skepticism. Do the benefits really outweigh the risks, or is this more about expanding the patient base?", "answer": 1}, {"article": "Women who ate walnuts tended to weigh less, consume more fish and exercise more than those who did not.\n\u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\n\u201cThis is the first on walnuts and diabetes.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable.\u00a0 There wasn\u2019t enough information given about Type 2 diabetes for any disease-mongering to have been committed.", "answer": 2}, {"article": "Less Fat.\u201d\n\nMeanwhile, Erchonia Medical, based in McKinney, Tex., has aggressively marketed its Zerona laser as \u201cthe first non-invasive body contouring procedure to effectively remove excess fat\u201d even though it has yet to receive F.D.A.\nNonetheless, a brochure for Zerona states patients can collectively \u201close up to 9 inches without the pain or down time of surgery.\u201d Nationwide, medical spas, chiropractors, cosmetic surgeons, plastic surgeons and dermatologists now offer Zerona for $1,700 to $3,800 for six sessions.\nPart of the reason the device has made inroads during these strapped times is that doctors don\u2019t buy it outright, but pay per use.\n(Such a delay is atypical, Ms. Riley said, adding, \u201cmost 510Ks are cleared within six months.\u201d)\n\nLast month, Dr. Robert B. Seltzer, a dermatologist in Pasadena, Calif., ran an advertisement in The Los Angeles Times for an informational seminar that called Zerona \u201cthe holy grail.\u201d In a phone interview, however, he said, \u201cI\u2019m not 100 percent convinced\u201d and planned to return his Zerona if he didn\u2019t continue seeing results in his patients.\nThe low-level laser causes \u201cfat to seep out of a cell, almost like a balloon being struck by a needle,\u201d said Ryan Maloney, medical director for Erchonia Medical.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not medicalize the fat-melting treatments; it makes clear they are elective and cosmetic. No claims are made for medical benefits of the treatments or the risks of love-handles or muffin-tops. Still, a positive statement that there are no known health benefits would have been useful.\u00a0 ", "answer": 1}, {"article": "Researchers reviewed data on all patients who have been exposed to JCV who are enrolled in TOUCH, the U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) program for natalizumab that requires manufacturers to document all uses of a medication to ensure that the benefits of a drug outweigh its risks.\nThere have been 756 PML cases reported worldwide as of January 2018, with a global incidence rate of 4.19 per 1,000 PML cases in people treated with natalizumab.\nThe new study, however, reports safety data through up to 72 months, or 6 years, when the extended dosing regimens were applied, with risk reduction for PML as high as 94 percent.\nThe new research showed that extending dosing of natalizumab from every 4 weeks to every 5 to 12 weeks significantly reduced the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection.\nSince the optimal extended dose schedule is not known, researchers chose to look at the data in multiple ways, with the primary definition looking at extended dose history in the last 18 months, the secondary definition looking at extended dose occurring at any time in the dosing history, and for tertiary definition looking primarily at how extended dose history affects PML risk.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here. Progressive multifocal leukoencephalopathy (PML) is a well-documented side effect in MS patients on long-term natalizumab therapy (as well as other treatments which cause immunosuppression). The news release mentions 756 reported PML cases worldwide as of January 2018 with a global incidence rate of about 4 per 1,000 PML cases in people treated with this monoclonal antibody therapy.", "answer": 1}, {"article": "An \"investigational new drug\" application was required by the U.S. Food and Drug Administration to test the pure synthetic (pharmaceutical-grade) resveratrol in the study.\nGUMC was one of 21 participating medical centers across the U.S.\n\nFurther studies, including analysis of frozen blood and cerebrospinal fluid taken from patients, are underway to test possible drug mechanisms.\nThe Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.\n\"A decrease in Abeta40 is seen as dementia worsens and Alzheimer's disease progresses; still, we can't conclude from this study that the effects of resveratrol treatment are beneficial,\" Turner explains.\nThe biggest risk factor for developing Alzheimer's is aging, and studies with animals found that most age-related diseases--including Alzheimer's--can be prevented or delayed by long-term caloric restriction (consuming two-thirds the normal caloric intake).\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the news release. And the news\u00a0release did a nice job bringing in a patient/family story, though it might have been helpful to describe the symptoms associated with mild Alzheimer\u2019s to place this story in context.", "answer": 1}, {"article": "Also, can we distinguish autism from other forms of developmental delay?\"\nFor one, this study was done in school-aged children, many of whom were actually teenagers, so it is impossible to know if these differences in neuroimaging would also be found in younger patients, Adesman pointed out.\nWhile the children were undergoing the fMRI, the researchers played recordings of their parents talking to them and watched for brain activity in areas of the brain responsible for hearing and understanding language.\nAlthough this study was done with school-aged children and teens, the same test can be done with children as young as 18 months, Hirsch noted.\nDr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven and Alexandra Cohen Children's Medical Center of New York in Lake Success, said that \"although the investigators did indeed find significant differences on neuroimaging between controls and autistic children, the clinical utility from a diagnostic standpoint is unclear.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story avoids disease-mongering and takes care to acknowledge that there are different shades of autism along a spectrum. \u201cFor one, it is not known whether this technique can identify autism across the entire spectrum of the disorder.\u201d", "answer": 1}, {"article": "The main reason to take a multivitamin is to correct or prevent a deficiency, \"but there may be a modest benefit in reducing the risk of cancer in older men,\" Gaziano said.\nThere also was a trend toward fewer cancer deaths among multivitamin users, but the difference was so small it could have occurred by chance alone.\nThe result is a surprise because many studies of individual vitamins have found they don't help prevent chronic diseases and some have even caused problems.\nMany of those were single vitamins in larger doses than the \"100% of daily value\" amounts that multivitamins typically contain.\nSome fads, such as the antioxidant craze over vitamins A and E and beta-carotene, backfired when studies found more health risk with those supplements, not less.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering. The story is clear that the results apply to older, relatively healthy men who don\u2019t smoke.", "answer": 1}, {"article": "And blood tests before and after breakfast confirmed nitrite levels in the body.\n\u201cThere are areas in the brain that become poorly perfused as you age, and that\u2019s believed to be associated with dementia and poor cognition.\u201d\n\nResearchers from the Translational Science Center looked at how dietary nitrates affected 14 adults aged 70 and older over a four-day period.\nPrevious studies have shown that nitrites \u2014 also found in high concentrations in celery, cabbage, and other leafy, green vegetables like spinach \u2014 widen blood vessels, but researchers say this was the first to find that nitrites also increase blood flow to the brain .\n\u201cThere have been several very high-profile studies showing that drinking beet juice can lower blood pressure, but we wanted to show that drinking beet juice also increases perfusion, or blood flow, to the brain,\u201d Daniel Kim-Shapiro, PhD, director of the Translational Science Center at Wake Forest University, says in a news release.\nMRI scans showed that after eating a high-nitrate diet, the older adults had increased blood flow to the white matter of the frontal lobes, which are the areas of the brain most commonly associated with the degeneration that leads to dementia and other cognitive conditions.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was very little discussion of the underlying problem of dementia, which appears prominently as \u201cthe problem\u201d in the headline.\nBut there was an element of disease-mongering in the framing of surrogate endpoints \u2013 test markers or images or scores such as MRI scans of brain blood flow and blood tests \u2013 as goals for \u201coverall good health.\u201d\nIndeed, there was not one word about how people felt, how they thought, how they performed \u2013 outcomes that really matter.", "answer": 0}, {"article": "Doctors say bronchial thermoplasty has given them a new weapon in the battle against severe asthma, and many patients call it life-changing.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\n\u201cI\u2019m a language therapist,\u201d she said, \u201cbut I can\u2019t even think of the word to describe how much better this has made my life.\u201d\n\nAcross the country, about 24 million people suffer from asthma.\nThere, it heats the lungs to 149 degrees Fahrenheit \u2014 cooler than a cup of coffee, but warm enough to shrink the smooth muscle in the airways, which swells during an asthma attack and restricts breathing.\nOne such patient, Alberto Gaulion, 68, a retired importer in Miami, estimated that for much of the last decade, his insurer, Blue Cross Blue Shield, spent about $50,000 a year on his medical care.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story notes that the procedure\u00a0\u201cis only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications.\u201d", "answer": 1}, {"article": "\"It's almost like giving your brain a physical.\nNoting the difficulty of managing something that can't be measured, Michael Collins, a University of Pittsburgh Medical Center, Ph.D., developed an exam, known as an 'Impact' test, to gauge attention span and memory, and help determine whether a person has a concussion.\n\"The brain, in its development, while it is actively developing, seems to be less able to take these forces and to really rebound from these forces,\" Dr. Gioia observed.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\n\"We don't want athletes to be playing while they're symptomatic,\" Dr. Gioia said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story cites data on the high incidence of concussions in young athletes. Although the CDC estimates that more than 300,000 sports-related concussions occur annually in the U.S. [http://www.cdc.gov/MMWR/preview/mmwrhtml/mm5538a1.htm], the broadcast\u2019s claim that one in five high school athletes will suffer a concussion appears to be a gross exaggeration. Without a clear definition of concussion, it is meaningless. A new report from the National Federation of State High School Association estimates that about 7.2 million students participate in high school athletics in the U.S. [http://www.nfhs.org/web/2006/09/participation_in_high_school_sports_increases_again_confirms_nf.aspx] Of these, an estimated 1.2 million\u2014or about one in five\u2014will suffer an injury of some kind. Of those that suffer an injury, a distinct minority will suffer a concussion. A 2004 study of high school athletics in North Carolina found that about 15% of high school football players suffered a concussion during one season. Other research shows that about one in five college football players has a concussion each season.\u00a0 \nThe broadcast hints at the danger of repeat concussions, but does not mention the low prevalence of the most feared and devastating outcomes, the so-called post-concussive and second-impact syndromes.\u00a0 Though there is some evidence that young athletes with two or more previous concussions have subtle but prolonged neuropsychological problems, the story fails to say whether most concussions resolve without incident or long-term effects.\n", "answer": 0}, {"article": "Scientists from the University of Gothenburg\u2019s Sahlgrenska Academy have developed a portable pocket-sized vestibular, or balance, stimulation device in a bid to improve the lives of Parkinson\u2019s sufferers.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\nThe effectiveness of oral levodopa reduces as Parkinson\u2019s disease progresses in the patient and can lead to involuntary movements, or dyskinesia.\nThere is extensive research in this field and I hope that it eventually will come up with a result.\nThe difference is that we use a particular current profile which you can stimulate the balance organs with without creating a balance disturbance.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story makes no reference to the incidence of Parkinson\u2019s, and there are no \u2018alarm statements\u2019 about the condition.", "answer": 1}, {"article": "\"The prospect of reducing the transmission of influenza and other respiratory viruses using far-UV radiation is very exciting,\" said Dr. Michael Grosso, chief medical officer at Huntington Hospital in Huntington, N.Y.\n\n\"Though hand-washing remains critically important, it does not prevent every instance of transmission,\" Grosso said.\nTwo flu experts were encouraged by the findings.\nHe noted that the technology's cost \"is not prohibitive, and it is safe.\n\"Immunization and antiviral medications are also important, but again, have limitations.\nBut this type of light can cause skin cancer and cataracts, so it's not used in public spaces.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story commit disease-mongering?", "explanation": "Cancers noted in this story are described as \u201ckillers\u201d and \u201cdeadly.\u201d Though most cancers are eventually lethal if untreated, the mortality rate of uterine cancer (and primarily endometrial cancer) is\u00a0about 18.7% of women within five years of diagnosis; for ovarian cancer, the death rate within five years of diagnosis is far higher,\u00a0around 53.5%.\nThe story didn\u2019t disease-monger, but it would have been stronger had it actually described burden of disease of the two cancers, though. For example, while ovarian cancer is more lethal, it\u2019s also more rare.", "answer": 1}, {"article": "Those conditions, sometimes called noninvasive breast cancers, are L.C.I.S.\nThe concern is that many women would have to take tamoxifen or raloxifene for a few to benefit.\nMore important, the difference between the numbers of side effects was not statistically significant, meaning that it could have occurred by chance and that the drugs could be similar or even the same.\nOn average, the participants actually had more than twice that risk, around 4 percent, meaning that 40 of 1,000 would be affected.\nBut since there is no way to predict who will actually get cancer, everyone has to be treated, meaning that 980 will be exposed to the drug's risks but will get no cancer benefit.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story accurately describes the 5-yr. risk of developing breast cancer for an average 60-64 year old woman. The story provides a link where the reader can calculate their own predicted risk.", "answer": 1}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story commit disease-mongering?", "explanation": "Given the ubiquity of heart disease in the American populace, anything that reduces atherosclerosis should be of keen interest. The danger with this piece is the hyping of early animal research, implying the findings are for readers to act upon now.", "answer": 1}, {"article": "Two studies published Tuesday lend support to controversial new cholesterol guidelines that could vastly increase the number of Americans advised to take cholesterol-lowering drugs called statins.\nOne study suggests that the new guidelines are better at identifying who is truly at risk of a heart attack and should be given statins than the older guidelines are.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering.", "answer": 1}, {"article": "For now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\nExisting treatments can cure about half of the cases.\nThe level of the virus in their bodies dropped significantly for several days.\nThe drugs now under development, like the one in the new study, could be added to the regimen, he said.\nThe study, published online April 21 in Nature, examines an experimental drug designed to combat the hepatitis C virus.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering in this story.", "answer": 1}, {"article": "His mind was filled with violent images.\n\"I think it's actually one of the biggest advances in psychiatry in a very long time,\" says Dr. Martin Teicher, an associate professor of psychiatry at Harvard Medical School and director of the Developmental Biopsychiatry Research Program at McLean Hospital.\nScientists still aren't sure why ketamine works, but there's evidence that it encourages the brain to rewire, to alter the connections between cells.\n\"I think it's having multiple effects, and that means it's probably useful for multiple different disorders,\" Teicher says.\nBut ketamine's story took a surprising turn in 2006, when researchers at the National Institutes of Health showed that an intravenous dose could relieve severe depression in a matter of hours.\n", "question": "Does the story commit disease-mongering?", "explanation": "In addition to using ketamine to treat depression, the story touts \u201cgrowing evidence it can help people with anxiety, bipolar disorder, post-traumatic stress disorder, and perhaps even obsessive-compulsive disorder.\u201d The story dangles unsubstantiated hopes in front of readers with a vast array of mental health diagnoses or concerns.", "answer": 0}, {"article": "SUNDAY, March 1, 2015 (HealthDay News) -- A procedure that delivers the anesthetic lidocaine (Xylocaine) directly to nerves in the back of the nasal cavity appears to offer significant relief to migraine sufferers, preliminary research indicates.\nThe study received no funding from private industry.\nThis was then repeated in the opposite nostril, according to the researchers.\nIn the new study, his team focused on 112 patients averaging about 45 years of age.\nThe procedure didn't help everyone, though.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article did not engage in disease mongering.", "answer": 1}, {"article": "By middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nShe enrolled in a trial, and by the third treatment session, \u201cI noticed a dramatic difference,\u201d she said.\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\n\u201cIt was receding.\u201d\n\u201cI was cute as button \u2014 and there was my double chin,\u201d she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to overplay the incidence of fat chins.", "answer": 1}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering.", "answer": 1}, {"article": "We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nWhen asthma symptoms occur, the number of white blood cells rises, and this measurement is used to define how severe the condition is.\nThe Lancet Respiratory Medicine, 2016.\nFor people with asthma, a sputum eosinophil reading will typically be around five percent, compared to people without asthma, who have readings that are lower than one percent.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to engage in disease-mongering.", "answer": 1}, {"article": "The experts once warned that Beta blockers were too dangerous to use in heart failure patients.\nThe majority of those patients are elderly women with high blood pressure.\n\"Thus, T3 treatment inhibited the major cause of stiffening of the heart in hypertension.\nWhile their high blood pressure was not affected, cardiac health improved.\nI predict the same will eventually be true for thyroid hormones in a large subpopulation of cardiac patients.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "For more information, visit http://www.\nThe current study, based on data from a nationwide flu surveillance network including 14 states, focused on pregnant women hospitalized with laboratory-confirmed flu over four recent flu seasons, from 2010 to 2014.\nFor expectant mothers hospitalized with flu, early treatment with the influenza antiviral drug oseltamivir may shorten their time in the hospital, especially in severe cases, suggests a new study published in The Journal of Infectious Diseases and available online.\nThe editors welcome major articles and brief reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses.\nAmong pregnant women with severe flu illness who were treated early -- within two days of the start of symptoms -- the median length of stay was about five days shorter compared to hospitalized pregnant women with severe flu illness who were treated later (2.2 days vs. 7.8 days).\n", "question": "Does the news release commit disease-mongering?", "explanation": "Influenza can be a serious illness during pregnancy and the release treats it accordingly so on that point we rate it satisfactory. However, the absolute rates of complications among pregnant women with influenza are missing so it\u2019s hard to gauge the true seriousness and rates of hospitalization without this context.", "answer": 1}, {"article": "The study had some limitations, the authors acknowledged.\nHowever, the risk reduction was modest and may have been due to chance, the authors said, noting that more research is warranted, especially because statins can cause adverse side effects.\n\"If you need to be on statins for your heart, it is not going to increase your risk for Parkinson's,\" Alcalay said.\nFor the study, researchers led by Dr. Xiang Gao, of Brigham and Women's Hospital and Harvard University School of Public Health in Boston, analyzed data on more than 38,000 men and almost 91,000 women enrolled in the Health Professionals Follow-up Study and the Nurses' Health Study in 1994.\n\"Right now we don't have any good evidence that there is anything we can do to reduce the risk of developing Parkinson's disease, but research is ongoing,\" added Isaacson, also an associate professor of neurology at Florida International University's Herbert Wertheim College of Medicine in Miami.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in the story. Instead, it explains how little we know about Parkinson\u2019s or potential treatments, such as statins. It says, \u201cNearly one million people in the United States have Parkinson\u2019s disease, a chronic and progressive movement disorder, and no one knows what causes it. The researchers can\u2019t say exactly how \u2014 or even if \u2014 statins reduce the risk of Parkinson\u2019s. It\u2019s thought these drugs may have potent anti-inflammatory effects, which could protect the brain.\u201d", "answer": 1}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the burden of Parkinson\u2019s or other diseases.", "answer": 1}, {"article": "\u201cThe treatment of cachexia just doesn\u2019t exist.\n\u201cThis same calcium signal also activates signaling pathways to increase skeletal muscle endurance and also skeletal muscle size.\u201d\n\nSah\u2019s research team hypothesized that low level calcium cycling induced by these natural compounds might promote improved exercise capacity and overall metabolic health associated with healthy muscle mass.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\nIn pre-clinical studies, compounds in thyme and oregano have demonstrated a greater than 37 percent increase in exercise tolerance and a 15 percent increase in muscle mass of certain body muscles.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We\u2019ll give the release the benefit of the doubt in this category.\u00a0 Cachexia often accompanies serious diseases \u2014 including cancer \u2014 and effective treatments are needed. But suggesting that an over-the-counter drug, based on commonly used spices tested only in mice,\u00a0might alleviate this challenging condition seems to be misleading readers hoping for simple answers.", "answer": 1}, {"article": "Griffith said a German study recently found that donated corneas cost about $2,500.\nAn estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\n\"We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation,\" said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.\nThe shortage means trouble for many of those whose corneas -- the clear surface at the front of the eye -- have been injured or damaged by illness.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story avoids disease mongering and actually presents a more conservative estimate of the number of people affected by corneal disorders. An estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.", "answer": 1}, {"article": "\"What a miracle that she found it on the Internet, that she doesn't have to go through what I went through,\" Marylin says.\n\"I had a guilty feeling.\nI hurt so bad, everything hurt,\" Marylin adds.\n\"Oh, it was awful.\n\"I was so happy that I was OK, that I had escaped the open heart,\" Barletta says.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering.", "answer": 1}, {"article": "It is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\n\"This is quite remarkable because there are no other vaccines that perform nearly so well for people in their 70s and their 80s.\nMany vaccines are made from a weakened form of the virus, but Shingrix is made from just a single protein--known as glycoprotein E--that comes from the outer shell of the herpes zoster virus.\n\"Our research shows that the vaccine stimulates your immune system to produce more antibodies and it generates a 24-fold increase in T cells.\nThe research, published in the Journal of Infectious Diseases, shows that Shingrix offers protection for up to four years, but Professor Cunningham believes it will last much longer.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease mongering. The news release states that most \u201cAustralian adults have been infected with the herpes zoster virus and are at risk of shingles, even if they do not remember having chicken pox. By age 85, approximately 50% of the population will develop shingles. Vaccination is the only way to protect against shingles.\u201d", "answer": 1}, {"article": "Reductions in pancreas, stomach and brain cancers were difficult to quantify because of smaller numbers of deaths.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\nThe findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.\nPrevious studies have found taking aspirin can cut the risk of developing colon or bowel cancer and suggested it does so by blocking the enzyme cyclooxygenase2 which promotes inflammation and cell division and is found in high levels in tumors.\nIn Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story highlights suggestions that everyone over 40 begin taking aspirin in order to reduce the risk of many types of cancer, while minimizing concerns about the limitations of this study and the risks associated with aspirin. The voices included in this story form a cheering section for the universal use of aspirin.", "answer": 0}, {"article": "\u2022 Available multimedia located on the right column of the release link: https:/\n\u2022 After February 26, view the manuscript and editorial online\n\u2022 For updates and new science from the Circulation journal follow @CircAHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\nMost participants were able to stay on both diets.\nAuthors said they did find two differences between the diets that may be noteworthy.\nThe association makes no representation or guarantee as to their accuracy or reliability.\nThe association has strict policies to prevent these relationships from influencing the science content.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering but the news release walks a very fine line of equating surrogate markers with actual cardiovascular disease.", "answer": 1}, {"article": "Results from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\n\"This treatment targets these small vessels that have been damaged.\nStudy participants received one of three treatments: low-dose CD34+ injections, high-dose injections, or placebo.\n\"Their activities are severely restricted by their chest pain and right now we have little to offer them.\"\nPatients were given a drug for several days to increase the number of CD34+ stem cells in the blood.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 0}, {"article": "And Maxwell stressed that their preliminary findings need to be replicated in the future.\nAlthough no one can pinpoint a reason for the link with certainty, \"essentially we think that alcohol may be having an effect by reducing the immune response, which leads to joint inflammation, and also that it may have a mild pain-killing effect,\" said Maxwell.\n\"We would wish to point out that, at the moment, that our findings are preliminary, and would not recommend that patients drink alcohol with the specific purpose of treating their arthritis,\" said Dr. James Maxwell, lead author of the study and a consultant rheumatologist at The Rotherham NHS Foundation Trust in England.\nFor this study, the authors compared 1,004 healthy participants to 873 people with rheumatoid arthritis.\nThe benefit of ethanol exposure for these rodents seemed to be due to higher levels of testosterone, the researchers wrote.\n", "question": "Does the story commit disease-mongering?", "explanation": "We felt disease-mongering in the air when the story didn\u2019t explain what degree of rheumatoid arthritis the subjects had.\u00a0 In fact, at one point the author referred to simply \"joint inflammation.\"\u00a0 Well one man\u2019s joint inflammation is not another man\u2019s rheumatoid arthritis.\u00a0 So this potentially disabling condition was treated as just one huge bucket of a diagnosis in this story, whereas it is a wide and varied spectrum of disease and impacts.\u00a0 ", "answer": 0}, {"article": "Guadecitabine works to reverse a so-called epigenetic change in cancer cells known as methylation, which may alter genetic activity in cells in a way that can block the action of tumor-suppressing genes, pushing cells to become cancerous and resistant to therapy.\nThere was one death during the study, possibly resulting from febrile neutropenia caused by the treatment.\nIt is manufactured by Astex Pharmaceuticals, a supporter of the Johns Hopkins-led study.\n\"However, it seemed that patients were responding at all levels of the drug.\"\nBy reversing this change in cancer cells, the drug restores cancer cells' vulnerability to drugs such as irinotecan.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. Cervical cancer kills hundreds of thousands of women across the world every year.", "answer": 1}, {"article": "\"All our patients considered the [treatment] to be worthwhile and beneficial, though some patients experienced side effects,\" study head Weiqiong Gu, MD, of Ruijin Hospital in Shanghai, tells WebMD.\nThe study was very small, and the procedure is not ready for widespread use.\nOne patient has gone without insulin injections for 3.5 years.\n\"We now have a unique approach with some positive findings, but it's still early.\nEight teens who took part in the study have remained insulin-free for two years, on average.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering", "answer": 1}, {"article": "That might take two or three years, he said.\nAs a practical matter, the goal of researchers is to convince federal regulators to cover the procedure under Medicare and Medicaid, which would open the door to routine use.\nThe standard scan, which looks for blood sugar usage, has gotten good results in tests with a variety of tumors including breast, prostate, colorectal and esophageal cancers, said Dr. Steven Larson of the Memorial Sloan-Kettering Cancer Center in New York.\nsaid Stevens, 48, of La Jolla, Calif. \"Your whole life is in sort of a limbo.\"\nBut researchers are exploring a new use for medical imaging that could shorten the stay in purgatory, possibly revealing within a few days whether chemo is working.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story dramatizes one patient\u2019s story in a way that overemphasizes the emotional impact not of treatment, but of having to wait for weeks or longer to learn whether a cancer treatment is working. It suggests the novel use of PET scans could \"shorten [the patient\u2019s] stay in purgatory\" by providing an answer \"possibly within days.\"\nThe writer uses loaded language to describe the patient\u2019s status, and at the end includes a vivid, dramatic quote in which the patient who did not have access to this PET scan technology compares his situation to \"having a rope tied around you and you\u2019re leaning over a canyon at about a 45-degree angle, and you don\u2019t know if someone is going to pull you back in. . . \"\u00a0\nWe have no idea whether the patient is receiving the experimental treatment. We learn later that he was diagnosed in 2005 and that with conventional treatments his cancer has remained stable.\u00a0\nThe overall effect is to magnifity the problem and overpromise a solution\u2013a nearly \"perfect\" illustration of disease-mongering.", "answer": 0}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not resort to disease mongering.\n\u00a0", "answer": 1}, {"article": "Paul J.D.\n\u201cThis new technology may also provide physicians with a safer, more controllable option for treating patients.\u201d\n\nThe team co-authored the paper, \u201cUltrasonic modulation of tissue optical properties in ex vivo porcine skin to improve transmitted transdermal laser intensity,\u201d which recently was accepted for publication by the society\u2019s journal, Lasers in Surgery and Medicine.\nIn 2016, the Office of Technology Management and Industry Relations reported that Mizzou received $14.9 million in revenue from more than 40 technology licenses.\n\u201cWe\u2019ve named the technique \u2018sonoillumination,\u2019 and we\u2019re hopeful that the procedure will be available widely in the near future.\u201d\n\nWhiteside and his team, including adviser, Heather K. Hunt, an assistant professor of bioengineering in the MU College of Engineering, tested the sonoillumination system on porcine skin tissue samples.\nThe techniques developed by the interdisciplinary team can be used by dermatologists and will reduce safety concerns in laser dermatology by improving laser transmission through surface layers of the skin.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It includes some context about how the new technology works.\nIt seems clear from the release that this device is intended to be used on the same sort of patients who currently receive laser treatments to remove tattoos or other skin markings.", "answer": 1}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story commit disease-mongering?", "explanation": "The problem here isn\u2019t egregious, but the story does refer to pancreatic cancer as one of the \u201ccommon cancers\u201d in the United States, which is not accurate. Pancreatic cancer isn\u2019t in the Top 10. The most common cancers in the U.S. are breast, cervical, colorectal, HPV-associated, lung, ovarian prostate, skin, uterine and vaginal and vulvar, according to the Centers for Disease Control.\nAs we noted in a review of an NBCNews.com article on this research, it\u2019s important to present statistics in context. That story was lauded for including an important caveat: \u201cFor perspective, over the course of a lifetime, 1.5 percent of Americans will develop pancreatic cancer.\u201d", "answer": 0}, {"article": "However, the question of whether such a strategy would prevent the onset and progression of Alzheimer's in people is challenging because treatment with a calcineurin-blocking agent suppresses the immune system.\nCalcineurin is an enzyme that regulates communication between brain cells and memory formation.\nThe participants were separated into groups by age at the time of last visit or death, gender and ethnicity.\nUsing a mouse model of Alzheimer's, the researchers earlier showed that blocking calcineurin restored memory function.\nIn Americans over 75 years, 15.3 percent of the population had dementia compared with 0.6 percent of the study subjects.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Hofer coined the term \"hidden regulators\" that pass between mother and baby.\nIt's not just that mother and baby are together, Gray says, but also that the mother is in some way \"programming the baby, the breathing, temperature and heart rate.\"\nThis was a \"serendipitous magical finding,\" says Gray, suggesting that skin-to-skin contact acted something like a \"natural incubator.\"\n\"The baby gets landed in a trusting environment,\" he says, reassuring them that life outside the womb can also be \"soft, comfortable and warm.\"\nHe found that when healthy newborns had kangaroo care, there was less facial grimacing and crying suggesting pain, compared to babies who had been swaddled and had the procedure in their bassinets, \"sort of alone.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story covers kangaroo care for a broad group of infants, both premature and full-term, that don\u2019t have diseases per se.\nStill, some stats on pre-term births would have been useful, as well as birth complications that make kangaroo care difficult or impossible for both mother and baby.", "answer": 2}, {"article": "A treatment for depression using Emotional Faces Memory Task (EFMT), a technology originally developed by two Mount Sinai researchers, resulted in a significantly greater reduction of major depressive disorder (MDD) symptoms compared to a control group, according to initial clinical results presented at the Society of Biological Psychiatry Annual Scientific Convention on May 19, 2017, in San Diego.\nThis aims to balance brain activity in these regions to work in concert with each other.\n.\nWe look forward to the development of this technology into a digital therapeutic that will be used to treat a major disease.\"\nIt's exciting to have the opportunity to test the program within a large health care system such as Mount Sinai.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "We want to help improve our patients\u2019 quality of life.\u201d\n\nThe study included 80 patients from 16 ECOG-ACRIN Cancer Research Group sites who had stage three or four HPV-positive squamous cell carcinoma of the oropharynx, and were candidates for surgery.\nPatients with good clinical response then received reduced radiation.\n\u201cYounger patients may have to deal with these side effects for decades after cancer treatment.\n\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\n\u201cToday, many younger patients are presenting with HPV-associated squamous cell carcinoma of the oropharynx,\u201d said Dr. Burtness.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t exaggerate the effects of\u00a0substance\u00a0abuse\u00a0disorders or otherwise engage in disease-mongering.", "answer": 1}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "Previous studies have found women's monthly hormone fluctuations can affect everything from food cravings and digestive problems to joint pain and a whole host of other health issues.\nThis is the time right after her period and before ovulation.\nNone of the study participants were enrolled in a smoking cessation program or were trying to quit.\nThey were asked to view photos both related and unrelated to smoking.\nWomen who want to quit smoking may find it easier if they time their efforts just right.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not commit disease mongering.", "answer": 1}, {"article": "\u201cI had terrible pangs of sadness and despondency.\nI was missing my husband so badly.\u201d\n\nEven after seeing a therapist, which helped, she suffered from nightmares and couldn\u2019t bear to hear arias from their favorite operas.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\n\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\nAfter he died in 2002, she sold the Long Island house they\u2019d loved and shared, finding it too filled with memories, and moved to their country home in upstate New York.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story correctly shows the controversy over the labeling of one sort of grief as \u201cabnormal.\u201d Professionals are still arguing over that.\nBut the story is on shakier ground when discussing the percentage of grieving people who might be affected by such \u201cabnormal\u201d grief. It references a study putting the proportion at around 7 to nine percent, then quotes an expert who says the \u201creal\u201d\u00a0figure might be closer to 10 to 15 percent. We thought the story should have provided some justification for why the bigger figure was the \u201creal\u201d one.\u00a0However, we don\u2019t think that omission is enough to affect our rating of Satisfactory.", "answer": 1}, {"article": "Each carries problems.\n\u201cOur new method is far more accurate and also allows us to identify the difference between cancerous and benign tissue in the prostate without the need for invasive surgery.\u201d\n\nThe prostate is a small gland in the male reproductive system and is normally about the shape and size of a walnut.\n\u201cWith an average of one man dying every 45 minutes from prostate cancer in the UK, the need for a more reliable test that can identify dangerous forms of the disease earlier is greater than ever.\u201d\n\nIn the past few years, a number of celebrities have revealed that they had been diagnosed with prostate cancer and have joined campaigns to raise awareness of the disease, including Michael Parkinson, Ian McKellen and most recently Stephen Fry, the comedian and former rector of Dundee University, who this year described how he had surgery to deal with a prostate tumour.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\nCurrent methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story implies that this test ought to be used in all men in the UK as a screening test for prostate cancer, which may find many false positive results. It also doesn\u2019t point out that despite its prevalence, some types of prostate cancer are very growing and may not require treatment.\u00a0Many more men die with prostate cancer than die because of prostate cancer.", "answer": 0}, {"article": "TUESDAY, Jan. 19, 2010 (HealthDay News) -- DNA testing for the human papillomavirus should replace the Pap smear as the main way to screen women for cervical cancer, according to Italian researchers.\nDNA testing for HPV, though, does have drawbacks -- namely that it is less specific, meaning it is likely to pick up more false-positives, than a Pap smear.\nThe HPV test works a step further back in the process, looking to see if women are infected with HPV.\nDuring the first phase of the study, women 35 to 60 who tested positive for HPV were given a cervical examination, called a colposcopy.\nFor their study, the Italian researchers compared HPV testing alone with HPV testing plus a Pap smear in 94,370 women aged 25 to 60 years old.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t exaggerate the prevalence or seriousnes of cervical cancer. The story appropriately mentions that the rate of the cancer has declined in the last 30 years.", "answer": 1}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "[But] Kalydeco controls CF at the basic defect, so I'm OK with the other 'c' word, control, because I'm living it and I've never felt better in my life.\"\nOne of those chemicals ultimately became a successful drug, but it had to be modified so patients could take it by mouth, and so it would last the right length of time in a patient's body.\n\"We tested over 600,000 chemicals in cells with the defective protein that causes cystic fibrosis,\" says Van Goor.\nIt was the early days of gene hunting, and the CF gene was a big prize.\n\"So it was a long time between the discovery of the gene and the discovery of Kalyedco.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering here. The story does a nice job describing the disease in a short space.", "answer": 1}, {"article": "\"Although there appear to be some benefit of an overall lower death rate in both groups, the [special panel] recommended stopping the trial,\" Nabel said.\nMany earlier studies had shown that tightly controlling blood sugar significantly reduced the risk of many complications.\nAbout half the excess deaths were from heart disease.\nThey determined that it was not.\nLetters were mailed to all participants Monday notifying them of the results so they could consult with their doctors about switching to the less intensive therapy.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "So, how does naltrexone work?\nThe analysis also found that another drug, acamprosate, is effective at helping people who have already stopped drinking to maintain abstinence, perhaps partly by easing the physical and emotional cravings experienced by heavy drinkers who quit.\nAlcohol is known to activate some of the same receptors in the brain that opioids do, and studies find that by tempering the pleasure from alcohol, naltrexone can help people drink less.\n\"The biggest problem we have in the field is that less than 10 percent of individuals with an alcohol use disorder get any treatment whatsoever,\" says George Koob, director of the National Institute on Alcohol Abuse and Alcoholism.\nPart of the challenge, researchers say, is that many drinkers don't realize that a medicine long used to help people addicted to opioids quit their drug habit can help alcoholics and other heavy drinkers cut back, too.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story may inadvertently overstate the portion of the population that is a candidate for treatment with this drug. The story says that 28% of the adult population are heavy drinkers or drink more than is recommended. It also says that heavy drinkers are not getting the help they need, implying that naltrexone might be an appropriate treatment for this group. However, naltrexone is indicated for the treatment of moderate to severe alcohol use disorder, formerly \u201calcohol dependence,\u201d and not for drinking more than is recommended or heavy drinking. So undoubtedly, the pool of drinkers who might benefit from this drug is smaller than the 28% figure cited in the story.\nThis is a close call. A careful reader will be able to tell that the drug isn\u2019t an option for more than a quarter of the adult population (as the 28% figure might suggest). Then again, we think some extra caution and qualification was needed to ensure that readers don\u2019t get the wrong idea.", "answer": 0}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story commit disease-mongering?", "explanation": "This story did not engage in overt disease mongering.", "answer": 1}, {"article": "The body mass index, or BMI, associated with the lowest risk of death has increased since the 1970s, a study finds, from 23.7, in the \"normal\" weight category, to 27, which is deemed \"overweight.\"\n\"One option certainly is over these three decades we have become much better at treating the cardiovascular risk factors that come with overweight and obesity.\"\nResearchers have long known that people who are very thin tend to have a shorter life expectancy, often because they're dealing with cancer or other serious illnesses.\nBut when they looked at the mortality rates in nonsmokers who had never had cancer or heart disease, it also became associated with a higher BMI over time.\nThat means a person who is 5-foot-8 could weigh 180 pounds and be in that epidemiological sweet spot, according to the NIH's online BMI calculator.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story noted that the number of people who are overweight or obese has been increasing in many countries in recent decades\u2013an assertion that can be backed up with data\u2013and\u00a0did not overstate the case.", "answer": 1}, {"article": "WEDNESDAY, June 1, 2016 (HealthDay News) -- If you find yourself hospitalized, you've got a one in five chance of needing a urinary catheter -- raising your risk for a urinary tract infection.\nBut there was no drop in infections or catheter use in intensive care units (ICUs), the study findings showed.\nAlthough about 20 percent of hospitalized patients get a urinary catheter, one-third of the time they aren't needed, Saint said.\nNow, researchers report that a new program shows it might be possible to reduce both catheter use and its associated infections.\nAnd I've seen patients who have gotten up in the middle of the night and they trip and fall on the tubing,\" he explained.\n", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t find any frightening language or graphic depictions of UTIs that would unnecessarily alarm a reader.", "answer": 1}, {"article": "This practice isn't totally harmless.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\nYou should be consuming 600 international units daily if you're between the ages of 1 and 70, and 800 IU each day if you're 71 or older, according to the Institute of Medicine, the health arm of the National Academcy of Sciences.\nYou should consume modest amounts in your diet, if possible (and for most people that is quite possible), or in the form of supplements if you can't get enough via food and drink.\n\"I think there's been a disconnect between the observational studies and the randomized clinical trials to date,\" Manson said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. The story clearly says that vitamin D supplements make sense if you\u2019re not getting enough vitamin D in your diet, and also notes that taking high doses of vitamin D increases the risk of adverse health outcomes.", "answer": 1}, {"article": "About the University of Louisville Physicians Group and The James Graham Brown Cancer Center:\n\nThe James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center.\nThe centers that collaborated on the study included University of Louisville, Louisville, KY; Henry Ford Hospital, Detroit, MI; Cleveland Clinic, Cleveland, OH; Piedmont Hospital, Atlanta, GA; Swedish Medical Center, Denver, CO; and Cancer Treatment Centers of America, Atlanta, GA.\n\nFrom July 2010 to October 2014, patients with radiographic Stage III LAPC were treated with IRE and monitored under a multicenter, prospective IRB-approved registry.\nAs part of the region's leading academic, research and teaching health center, the cancer center provides the latest medical advances to patients, often long before they become available in non-teaching settings.\nPancreatic cancer has one of the highest mortality rates of all cancers and is expected to climb from the fourth leading cause of cancer-related death in the U.S. to the second by 2020.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no exaggeration of pancreatic cancer here. Pancreatic cancer is uniformly fatal with or without this new treatment. At great expense it appears survival might be extended (it is not clear for how long) . Adding\u00a0the number of people who are diagnosed and/or die from the disease every year in the U.S.\u2013about 49,000 and 40,000, respectively\u2013would have made this release stronger.", "answer": 1}, {"article": "While the American Cancer Society, the American College of Physicians and other gastroenterology experts recommend virtual screening every five years, the U.S. Preventive Services Task Force, a congressionally mandated but non-federal, independent group of medical experts, concluded the evidence wasn\u2019t strong enough to justify Medicare coverage of the service.\nVirtual colonoscopy is a good option for those who can\u2019t be sedated for colonoscopy, or who simply can\u2019t tolerate the scope.\nAs its name implies, virtual colonoscopy is way to survey the colon without actually using a scope.\nThe images can be viewed as two dimensional CT scans, which display any possible abnormalities protruding from the lining of the colon.\nWhile the virtual colonoscopy does not require the sedation and insertion of a scope that colonoscopy does, it involves exposure to a small amount of radiation.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering.", "answer": 1}, {"article": "But the scientific evidence has been slim.\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nMillions of jet-lagged and sleep-deprived Americans--citing countless self-help articles--insist they do.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nDo melatonin supplements really help people sleep?\n", "question": "Does the story commit disease-mongering?", "explanation": "This article did not disease monger or make exaggerated claims for melatonin.", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story commit disease-mongering?", "explanation": "No evidence of disease mongering. Patient population needing reconstructed bladders is very targeted.", "answer": 1}, {"article": "MONDAY, July 6, 2015 (HealthDay News) -- A scan of calcium deposits inside your arteries can help doctors deduce how long you're likely to live, a new study has found.\nIf a plaque bursts, a blood clot can form on its surface, blocking blood flow and causing a heart attack, according to the U.S. National Institutes of Health.\nThe test, called a coronary calcium scan, uses a regular CT scan to look for calcium deposits in the three major arteries that carry blood away from the heart, said lead author Leslee Shaw, a professor of cardiology at Emory University in Atlanta.\n\"This is not a new test, but these results emphasize the importance of looking at this marker in addition to the traditional risk factors,\" said Dr. William Zoghbi, past president of the American College of Cardiology and head of cardiovascular imaging for Houston Methodist Hospital.\nFor more on coronary calcium scans, visit the U.S. National Institutes of Health.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story blurs the line between a risk factor and a disease. This study merely documented that people with very high CAC test scores have a higher risk of death over the next 15 years. It does not prove either that coronary artery calcium deposits caused those early deaths or that testing and treatment could extend lives, yet the story portrays high CAC scores as a health problem that demands action.\nOf course, we\u2019ve already mentioned this concern, and we might have given the benefit of the doubt here if the story had better connected the calcium deposits to the study outcomes. Instead, there are several errors in the description of what happens in heart disease that may serve to mislead or confuse readers about the impact of coronary calcium: 1) Coronary arteries carry blood to the heart muscle (they feed the muscle), not away from the heart as the story states; and 2) The problem with coronary plaque buildup isn\u2019t that it causes the\u00a0heart to \u201cwork harder to pump blood through the body\u201d as the story states; it is that narrowing in the coronary arteries deprives the heart muscle of blood, causing angina (chest pain), and \u00a03) Clots in coronary arteries don\u2019t break off and cause strokes in the brain; the rupturing of plaque leads to blockage in the coronary arteries, again depriving the heart muscle of blood (causing a \u201cheart attack\u201d or myocardial infarction).", "answer": 0}, {"article": "LOS ANGELES - The supplement Aged Garlic Extract can reverse the buildup of deadly plaque in arteries and help prevent the progression of heart disease, according to a new study scheduled for publication in the Journal of Nutrition.\nDr. Budoff also has received honoraria from Wakunaga.\nIt also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs.\nThe study involved 55 patients, aged 40 to 75 years, who had been diagnosed with metabolic syndrome.\nFunding for the study was provided by Wakunaga of America Co., Ltd., the producer of Kyolic Aged Garlic Extract.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not commit disease mongering.", "answer": 1}, {"article": "A University of Colorado Cancer Center study published today [May 3] in Oncotarget shows that combining a CPT1A inhibitors with anti-androgen therapy increases the cancer\u2019s sensitivity to the anti-androgen drug enzalutamide.\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\n\u201cWe had to find a way to block this pathway so that the cancer would not be able to burn lipid in the mitochondria to acquire energy to resist therapy,\u201d explains Schlaepfer.\nHowever, there are many steps involved in lipid metabolism and researchers have been working to break prostate cancer\u2019s ability to harness this energy source.\n\u201cThere is a critical need for improved therapies for this specific cancer type.\u201d\n\nMost cells use the energy of glucose (sugar).\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no overt disease mongering here except to say that those actual men with actual prostate cancers who read a story based on this news release may be mightily\u00a0concerned, wondering if they have the \u201cfat-eating\u201d type of prostate cancer and thus may be even more worried than they normally are.", "answer": 1}, {"article": "Natural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\nHoney is also known to have antioxidant and antimicrobial properties.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\nMore than a third of American adults use some form of complementary or alternative medicine, according to a government report.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "[Immunotherapy is showing benefits in an increasing number of cancers]\n\nZane Esposito, a 13-year-old from Plano, Tex., calls himself the \u201cT-Cell Explorer.\u201d He was diagnosed with ALL in June 2010.\nHer careworn father cried in the shower to hide his anguish.\n\u201cLeukemia is really smart,\u201d she said.\nShe has been in remission ever since.\nThe transplant made her sick and the whole family miserable.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The incidence has more than doubled in developed countries in recent decades.\nBut many other types are considered safe, especially smaller fish like sardines that are not at the top of the food chain and therefore not likely to accumulate mercury and other contaminants from eating other fish.\nThe research was paid for by the Danish government and private foundations.\nThe scientists bought fish oil from a company that makes it, but they said the company had no role in the study.\nMore than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not disease monger\u2013childhood asthma is a common and often exasperating condition that many parents grapple with.", "answer": 1}, {"article": "But there\u2019s a problem with a low-FODMAP diet.\nGluten is not a carbohydrate; it\u2019s a mix of proteins found in wheat and its close relatives (including spelt, kamut and farro), as well as in barley and rye.\nIf your gut can handle FODMAPs, foods that contain a lot of them can be very good choices \u2014 partly because the fermentation helps your gut biome and partly because the way FODMAPs are digested means you\u2019re absorbing fewer calories than indicated on a FODMAP-rich product\u2019s label.\n\u201cFollowing strictly the low-FODMAP diet is associated with changes in the microbiota that many would not equate with good health,\u201d says Gibson, who stresses that a low-FODMAP diet should be used to reduce specific symptoms, not as a way to improve health.\nIt\u2019s what gives bread its elasticity, but it also sets off the immune system of people with celiac disease, damaging the small intestine and sometimes producing painful and unpleasant symptoms.\n", "question": "Does the story commit disease-mongering?", "explanation": "We\u2019d like to rate the article satisfactory here, since it does counter widely held views about the prevalence of gluten sensitivity that are inaccurate. However, it\u2019s possible that disease-mongering of gluten sensitivity is being replaced by disease-mongering of FODMAPS. We are told that 10% of the population has a problem with foods high in FODMAPs, but we aren\u2019t provided with any validation of that statistic.", "answer": 0}, {"article": "Dec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\n\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nIt's a Trojan horse approach, where Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target.\n\"But we think these results are as good as we've ever seen is such a refractory [sick] population,\" he says.\nThe new drug, called T-DM1, combines Herceptin with a potent chemotherapy drug.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article doesn\u2019t exaggerate the burden of metastatic breast cancer or underestimate the options for patients with refractory disease. It also points out that only a subset of patients with the disease are HER2-positive; although not explicit, it\u2019s implied that only this subset would be eligible for the investigational treatment.", "answer": 1}, {"article": "But there are other theories about how fluoride works.\nIf you pay out of pocket, a varnish treatment costs from $23 to $55, compared with a filling, which ranges from $86 to $606, according to the American Dental Association.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\n\"Prevention has always been a part of the world of dentistry,\" says Richard Valachovic, president of the American Dental Education Association.\n\"Some of the stuff in our study has been known for 50 years,\" Evans says, referring to the use of fluoride treatments.\n", "question": "Does the story commit disease-mongering?", "explanation": "Cavities in adults can cause serious health problems if left untreated, and any new effective treatment or trends in this area is worthy of press coverage.\nHowever, the studies\u00a0discussed\u00a0in the story focused on a relatively small group of people with unusually high risk of tooth decay\u2013and so these results may not apply to the adult population at large, which this piece implies.\n\u00a0", "answer": 1}, {"article": "While the cause of Alzheimer's remains elusive, it is clear that maintaining a healthy blood-brain barrier is a critical preventative measure.\nFox Foundation and the Osteopathic Heritage Foundation.\n\"As osteopathic physicians, we constantly tell patients that a healthy lifestyle is the best medicine for preventing disease.\nOMED 15 is a five-day event offering clinical and research updates in 15 specialties, with an emphasis on osteopathic principles and practices.\nIn Alzheimer's, the brain begins to change years before symptoms emerge.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering of Alzheimer\u2019s disease in the release.", "answer": 1}, {"article": "Xyrem also helped reduce fatigue, stiffness, and other symptoms, she tells WebMD.\nMay 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nThe National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nMore than half of people who took Xyrem reported at least a 30% improvement in pain, says Kim Dupree Jones, PhD, of Oregon Health & Science University in Portland.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story cites an\u00a0advocacy group\u2019s estimate of prevalence\u00a0at 10 million.\u00a0We\u2019ve been unable to find a primary source for that estimate on the advocacy group\u2019s website. A more objective source,\u00a02008 published estimates,\u00a0suggested a prevalence closer to 5 million. However, given the difficulty in obtaining accurate prevalence information for this disease, we don\u2019t think there\u2019s evidence of disease-mongering.", "answer": 1}, {"article": "\u201cAnd what\u2019s happened with gonorrhea?\n\u201cGonorrhea rates have been going down in the vaccine group whereas in the non-vaccine group it\u2019s following the rest of the province.\u201d\n\nIt is not clear how long the protection \u2014 if it\u2019s real \u2014 will actually last.\nThe research, conducted in New Zealand, found that the gonorrhea rate among teens and young adults there who had received a meningitis B vaccine during an emergency campaign in the early 2000s was significantly lower than the rate seen in people of the same age who weren\u2019t vaccinated.\nBut the same component is one of several in the Bexsero vaccine, which was used in Quebec when the government decided to vaccinate against meningococcal B disease in a part of the province with a high relative rate of cases a few years ago.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story dramatizes the threat of antibiotic resistance with an unattributed statement: \u201cThe last remaining drugs to cure this sexually transmitted infection are showing signs they may only have a few more years of usefulness left.\u201d\nIt also gives a quote from a GSK spokeswoman who calls the findings \u201ca positive step in the search for a vaccine against this common and distressing disease that is increasingly resistant to antibiotic treatment.\u201d\nAs this Scientific American article explains, that actual rate of antibiotic-resistance\u2013while on the rise\u2013is still pretty small.\nIndependent sources would have been useful on this point, but we wouldn\u2019t say this rises to the level of disease mongering.", "answer": 1}, {"article": "Merck said trial results would be presented at an upcoming medical meeting.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\nPD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t engage in disease-mongering, but it also didn\u2019t include information beyond what was in Merck\u2019s news release. It only passed along the company\u2019s information that esophageal cancer is the \u201cseventh most commonly diagnosed cancer in the world.\u201d\nThe story could have reported that according to government data, 17,290 new cases of esophageal cancer are expected in the U.S. this year, comprising 1% of all new cancers and 2.6% of cancer deaths. About a fifth of patients die within five years.", "answer": 1}, {"article": "\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nOf 4,065 boys and men aged 16 to 26 from 18 countries, vaccination with an HPV vaccine that targets four types of HPV infection -- HPV-6, HPV-11, HPV-16, and HPV-18 -- protects against infection with these types of HPV and potentially the development of related external genital warts or lesions.\nHPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nThe vaccine is recommended for optional use in boys and men.\n", "question": "Does the story commit disease-mongering?", "explanation": "A thoughtful and careful discussion of the potential risk for genital warts, and the still-uNPRoven connection between the viruses and the development of penile and anal cancers in men. All of this does relate to the number of sexual partners, which the storyr explains.", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the vaccine for girls in 2008 and for boys aged 9 through 26 in 2009.\n\"It's a similar efficacy to what we've seen in females,\" said Giuliano, who is chair of cancer epidemiology and genetics at the H. Lee Moffitt Cancer Center in Tampa.\n\"Studies like this underscore the 'human' in human papillomavirus,\" said Fred Wyand, director of the HPV Resource Center at the American Social Health Association.\nHPV is almost ubiquitous in males and females, but experts note that most people will clear the virus naturally so that it does not result in any harm.\nAccording to a study presented last year by researchers at the University of Maryland, just one-third of teen girls and young women who start the three-dose series actually finish, and almost three-quarters don't start it at all.\n", "question": "Does the story commit disease-mongering?", "explanation": "Barely satisfactory because the story skated close to an edge. For example, \"HPV is the leading cause of cervical cancer in women but also has been linked to penile and OTHER malignancies.\" What other malignancies? How common are cervical and penile cancer? It would have been better if the sentence about \"most people will clear the virus naturally\" had been higher in the story.", "answer": 1}, {"article": "This test might help.\n\"There\u2019s a lot of work left to do before we get to that point, but we are pretty energized and excited at this point.\"\nThere's a lot more work to be done before these tests becomes available, including clinical trials.\nThis happens in about 9% of all deliveries and it can be seriously risky for the infant ; they can have all kinds of complications, including lung problems, brain hemorrhages, and infections.\nThey identified seven cfRNAs that seemed to be associated with premature birth, and in a test of 38 women, they found that they could predict premature birth up to two months in advance.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story describes some scary risks related to preterm deliveries, but nothing unwarranted to establish why a test for potential preterm deliveries might be important.", "answer": 1}, {"article": "The procedure is not yet recommended by professional medical societies, said Dr. Sara Brubaker, a specialist in maternal and fetal medicine at N.Y.U.\nThose from hospital ventilation vents or the like may be perceived as enemies and be attacked.\nSeven were born vaginally and 11 by elective C-section.\nThat difference, some experts believe, could influence a child\u2019s lifelong health.\nTo replace these microbes, some parents have turned to a novel procedure called vaginal microbial transfer.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article appropriately addresses the issue of increasing C-section use in U.S. and its potential repercussions.", "answer": 1}, {"article": "The participants completed the same cognitive tests each year during the four-year study, with 92 percent of the college-studies group displaying a significant increase in cognitive capacity, while the remaining 8 percent generally maintained their cognitive capacity.\nMost of the students took courses on campus, but some completed online classes.\nFor the control group, 56 percent displayed a significant increase in cognitive capacity, while 44 percent had no change.\nParticipants were reassessed annually for three years following their studies.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\n", "question": "Does the news release commit disease-mongering?", "explanation": "None detected.", "answer": 1}, {"article": "2018;59:160-172.\nThe researchers speculate that it may be due to the polyphenols (anthocyanins and other flavonoids) in Montmorency tart cherries, the varietal of tart cherries grown in the U.S. Polyphenols in plant-based foods are broken down by microbes to stimulate growth of good bacteria.\nThe individuals who ate a more plant-based diet, with higher intakes of carbohydrates and fiber, responded with an increase in Bacteroides and Bifidobacterium, presumably because of the specific combination of polysaccharides and polyphenols.\nThe researchers tested U.S.-grown Montmorency tart cherries, European tart cherries, sweet cherries, apricots and isolated polyphenols in each simulated region of the digestive tract.\nThe microbiome has been the focus of multiple studies in recent years due to its potential role in maintaining digestive health, as well as its impact on immunity, heart health, blood sugar control, weight management and even brain health.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease-mongering. It also doesn\u2019t provide any context for the type or extent of the problem the intervention (cherry consumption) is intended to help.", "answer": 2}, {"article": "And AbbeVie is in the midst of phase 3 trials for elagolix to treat uterine fibroids and endometriosis, a disorder in which the tissue that lines the inside of the uterus grows outside of it, causing pelvic pain.\nShe was diagnosed with fibroids at 19.\nDietary factors may also play a role.\nBleeding is reduced within five to six days, he says.\nFour years later, the fibroids are back.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here.\u00a0", "answer": 1}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story commit disease-mongering?", "explanation": "The story did not disease monger. But it would have been stronger if it had reminded\u00a0readers that some\u00a0men with enlarged prostates may have no symptoms or don\u2019t find them bothersome enough for a procedure.", "answer": 1}, {"article": "Nevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\nAt the start of the trial, 50% of those in the control group who did not get the therapy and 55% of those who did were assessed as severely autistic.\nAt the end of the first year, the researchers could see the children had improved, but the most dramatic development was seen at the follow-up six years later.\nThese results look promising for the many thousands of parents who want to find early interventions for their children based on solid science.\u201d\n\nThe researchers said children\u2019s communication with their parents was improved at the end of the six years.\nA new form of therapy has for the first time been shown to improve the symptoms and behaviour of autistic children, offering a potential breakthrough in care for millions of families.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering, although the article should have made clearer that the study was conducted on children with a severe form of autism and did not involve children elsewhere on the \u201cspectrum.\u201d", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering and takes a very careful approach to describing the types of patients who would be affected by this study\u2019s results. We also like the way they provided snapshots of patients who were in both arms of the study \u2014 surgery and non-surgery \u2014 at the end of the story, making it clear, as the study did, that both routes can be equally successful.", "answer": 1}, {"article": "TUESDAY, Dec. 1, 2009 (HealthDay News) -- When used with ultrasound, elastography helps distinguish between cancerous and benign breast lesions, which reduces unnecessary biopsies, U.S. researchers have found.\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\nAs part of an ongoing study, 179 women underwent breast ultrasound and elastography.\nAbout 80 percent of breast lesions that are biopsied turn out to be benign, according to the American Cancer Society.\nThey found that elastography correctly identified 98 percent of cancerous lesions and 82 percent of benign lesions, and they also determined that elastography was more accurate than ultrasound in gauging the size of the lesions.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. It accurately states that most breast lesions are benign.", "answer": 1}, {"article": "April 13, 2010 -- Steve Peterson, 62, a home remodeler in Seattle, has rock-climbed in Tasmania, hiked in the high alpine regions of Washington, and trekked across the island of Manhattan -- all while sporting a knee brace due to painful knee osteoarthritis (OA), the wear-and-tear form of the disease that affects 27 million people.\nAnd by and large, they did.\n\"It absolutely gave me almost immediate relief,\" he says.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering of knee arthritis. ", "answer": 1}, {"article": "Overall, the investigators said, adding sestamibi SPECT/CT helped identify 7 of 9 benign tumors, and conventional imaging with added sestamibi SPECT/CT outperformed conventional imaging alone, as measured by a statistical analysis that measures tradeoffs between sensitivity and specificity.\nOn this measure, a value of 0.50 indicates that a diagnostic test is no better than chance.\nThe remaining 40 were classified as a variety of other tumor types, including malignant renal cell carcinomas.\nRadiologists, who were not allowed to talk to each other or know the results of the surgeries, graded the conventional and sestamibi SPECT/CT images benign or malignant using a 5-point scale (1 = definitely benign, 5 = definitely cancerous).\nAt Johns Hopkins, multispecialty teams work together to determine the best care for patients and as partners on research innovations and quality improvement initiatives.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No evidence of disease mongering here. The release provides a good discussion of why more accurate imaging is needed for kidney tumor diagnosis.", "answer": 1}, {"article": "WEDNESDAY, Sept. 21, 2016 (HealthDay News) -- New guidelines issued by three leading cancer organizations suggest that more breast cancer patients should consider radiation therapy after a mastectomy.\nEdge was co-chair of the panel that developed the new guidelines.\nDoctors need to weigh the risks and benefits, Edge added.\nThat typically includes the surgeon, radiation physician and an oncologist.\nThe younger woman, he said, would typically be advised to get radiation.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "The second sentence of the story lumped all clots together, warning that they bring 'danger and death in the form of a stroke'.\u00a0 A stroke results from a clot that travels to the brain; not all clots that form in the body have the potential to be life threatening.", "answer": 0}, {"article": "Disease-free survival and overall survival three years after treatment were 48.3% and 55.8%, respectively.\nResearchers say surgical removal of tumors is the standard treatment for early-stage lung cancer, but some people are not candidates for surgery due to other coexisting illnesses such as emphysema and heart disease.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\nIn these situations, the lung cancer tumor is deemed inoperable and conventional radiation therapy or observation without cancer treatment is offered.\nIn the study, researchers evaluated the safety and effectiveness of SBRT in treating 55 people with early-stage but medically inoperable lung cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness of lung cancer. The story is clear that the study was in the context of early-stage lung cancer,\u00a0however it could have pointed out more clearly that\u00a0the results can\u2019t be applied to later-stage cancer patients.\u00a0", "answer": 1}, {"article": "Call 911 or your doctor for all medical emergencies.Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.\nThere was no significant association between healthy dietary patterns and risk of kidney failure.\nResponsibility for the information and views expressed therein lies entirely with the author(s).\nASN does not offer medical advice.\nASN has nearly 16,000 members representing 112 countries.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release.", "answer": 1}, {"article": "Scientists in Britain say they have developed a blood and urine test that can detect autism in children.\nStill, the best way to diagnose autism is through clinical interview and observation, which takes into account the many features of autism.\u201d\n\u2022 Note added 27 February 2018: The UK autism research charity, Autistica, provided the following comment to the Guardian: \u201cThis is a small, early-stage study which may explain one biological difference in autism.\nIt is estimated that about one in every 100 people in the UK has ASD, with more boys diagnosed with the condition than girls.\nThey said the next steps were to repeat the study with further groups of children to confirm the good diagnostic performance and to assess if the test could identify ASD at very early stages, indicate how the ASD is likely to develop further to more severe disease, and assess if treatments were working.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not disease monger and does well to provide this context: \u201cIt is estimated that about one in every 100 people in the UK has ASD, with more boys diagnosed with the condition than girls.\u201d", "answer": 1}, {"article": "So what is it about tai chi that works?\nAbout 10 million Americans have fibromyalgia, and about 75 percent to 90 percent of them are women, according to estimates from the National Fibromyalgia Association.\nThe improvements were still evident at 24 weeks, according to the research reported in the Aug. 19 issue of the New England Journal of Medicine.\nMost patients, according to background information in the article, remain in pain years after the diagnosis, are aerobically unfit, have poor muscle strength and flexibility, and need medications to control symptoms.\nDoctors will often suggest exercise, sleep hygiene techniques and medications to treat the condition, but often with limited success, said Dr. Gloria Yeh, an assistant professor of medicine at Harvard Medical School, who wrote an accompanying editorial in the journal.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story cites a questionable statistic about the scope of problem. Citing the National Fibromyalgia Association, the story says there are approximately 10 million sufferers of the condition in the U.S. It would have been more appropriate to rely on a number from an disinterested government source. (The National Institutes of Health estimates 5 million as the disease prevalence among adults over 18.) ", "answer": 0}, {"article": "Alzheimer's & dementia: The Journal of the Alzheimer's Association.\nThe American Journal of Neuroradiology (AJNR) is published monthly by the American Society of Neuroradiology (ASNR), a professional association of more than 5,000 members who specialize in diagnostic radiology of the central nervous system, brain, head and neck through the use of X-ray, MRI, CT and angiography.\nIt is estimated that as many as 3 million cases of Alzheimer's dementia worldwide can be prevented with as little as a 10% reduction in the burden of preventable lifestyle.\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease mongering and states that as many as three million cases of Alzheimer\u2019s dementia could be prevented with lifestyle changes. However, it does imply that there would be more cases prevented with the addition of brain imaging, a claim that is not supported by the release or the underlying review article.", "answer": 1}, {"article": "\u201cThe ability to activate white matter cells in the brain, as shown in this study, opens up an exciting new avenue of therapy development for myelin disorders such as multiple sclerosis,\u201d said Ursula Utz, Ph.D., program director at the NINDS.\nMyelin acts as an insulator and enables fast communication between brain cells.\nAll are approved for use in humans.\nAs a result, almost all of the animals regained the use of their hind limbs.\nWe are working tirelessly to ready a safe and effective drug for clinical use,\u201d Dr. Tesar said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering is evident.", "answer": 1}, {"article": "\u201cIf you gave this dataset to a clinician and asked him to predict the age\u201d of one of the cyclists based on his or her test results, Dr. Harridge said, \u201cit would be impossible.\u201d On paper, they all look young.\nBut even in advance of those results, said Dr. Harridge, himself almost 50 and an avid cyclist, this study shows that \u201cbeing physically active makes your body function on the inside more like a young person\u2019s.\u201d\nOlder people tend to be quite sedentary nowadays, and being sedentary affects health, making it difficult to separate the effects of not moving from those of getting older.\nOf course, this study is based on a single snapshot of an unusual group of older adults, Dr. Harridge said.\nOn almost all measures, their physical functioning remained fairly stable across the decades and was much closer to that of young adults than of people their age.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story implies that this study gives us a new way to see aging itself, but escapes the trap of making aging appear as if is a disease to be cured.", "answer": 1}, {"article": "Despite the fact that there have been no randomized controlled trials on whether metformin really can prevent cancer, researchers expressed excitement both over this animal study and previous epidemiological evidence pointing to this possibility.\nInsulin may have a relationship with cancer.\nAnd when the drug was administered by injection, the improvement seen was 73 percent.\nMice taking metformin in their drinking water had 34 percent fewer tumors than those not taking metformin.\nThe U.S. National Library of Medicine has more on metformin.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in this story. ", "answer": 1}, {"article": "The new research paper also demonstrates how the plant-based chemicals work together.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\n\"After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,\" says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin.\nThe experiment was designed, analyzed and written up with coauthors Alessia Lodi, John DiGiovanni and Achinto Saha, all of UT Austin.\nThe most promising active ingredients were then tested on model animals: ursolic acid, a waxy natural chemical found in apple peels and rosemary; curcumin, the bright yellow plant compound in turmeric; and resveratrol, a natural compound common to red grapes or berries.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in overt disease mongering. It describes prostate cancer as \u201cthe most common cancer afflicting U.S. men.\u201d That\u2019s true, if you don\u2019t count skin cancer. It\u2019s No. 2 to lung cancer when it comes to causing male deaths.", "answer": 1}, {"article": "On The Early Show Friday, Family Circle magazine Editor in Chief Linda Fears discussed everyday lessons that can make a big difference.\nIt's a tremendous challenge for parents to teach their teenagers and \"tweens\" everything they ought to know.\nTo watch the segment,\n\nFor much more on folic acid, from the federal Centers for Disease Control and Prevention, click here.\nFor more information on this subject, see these two articles on WebMD: Weight Loss: How To Read Food Labels and Cracking the Code.\nIn fact, according to a recent survey we conducted on the emotional lives of tweens and teens, kids want more time just hanging out with their parents, and more time talking about important issues.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "While this piece did not exactly engage in disease mongering, it provided information about yet another birth defect for which adequate intake of folic acid reduced the risk even though this information does not affect the long standing recommendation for folic acid intake.\u00a0 The problem is that it failed to note that the incidence of cleft palate and cleft lip are rare.\n\u00a0", "answer": 1}, {"article": "This study was supported by intramural funds from the National Cancer Institute.\n\"We are using a vaccine approach to generate an immune response to HER2, which is found at high levels on and drives the growth of several types of cancer, including breast, ovarian, lung, colorectal, and gastroesophageal cancers.\nThe final product, which is administered intradermally (between the layers of the skin), comprises patient-derived dendritic cells genetically modified with an adenovirus to produce parts of the HER2 protein.\n\"Immunotherapy marshals the exquisite specificity of the immune system to destroy cancer, and some types may have potentially fewer side effects than traditional chemotherapy,\" said Jay A. Berzofsky, MD, PhD, chief of the Vaccine Branch at the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.\n\"Our results suggest that we have a very promising vaccine for HER2-overexpressing cancers,\" continued Berzofsky.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release did not engage in disease mongering. It provides brief background on what HER2 cancer is and how it drives\u00a0the growth of different types of cancer, including breast, ovarian, lung, colorectal, and gastroesophageal.", "answer": 1}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "He reviewed the study but was not involved in it.\nTUESDAY, Feb. 22, 2011 (HealthDay News) -- In women who have had breast cancer, annual mammograms help detect second breast cancers, but they're not as effective in women who have never had the disease, new research suggests.\nIn their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nFor those who have dense breasts and are younger than 50, for example, \"we can alternate mammograms with breast MRIs,\" with one of the tests every six months, he said.\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\n", "question": "Does the story commit disease-mongering?", "explanation": "The headline of this story misleads the reader by stating that \u201cMammograms May Not Be Fool-Proof at Catching Second Cancers.\u201d\u00a0 No type of screening for breast cancer is fool-proof whether it is for an initial diagnosis or for a second breast\u00a0cancer.\u00a0 Regarding the accuracy of screening mammography for an initial breast cancer diagnosis, the Komen for the Cure website states that in women age 50 and older \u201c\u2026between six and 27 percent of breast cancers may be missed by mammography alone.\u201d\u00a0 Mammography is most effective in women 50 and older.", "answer": 0}, {"article": "Lona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern Dallas, reacted with cautious optimism to the findings.\nBut, she said, \"I would say this is certainly worthy of continuing research and exploration.\n\"This holds great promise, because currently there is no effective treatment for cancer-related malnutrition.\"\n\"But I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot,\" she added.\nAnd then with chemotherapy, there is some inflammation that's detrimental to the heart and muscle, as it can cause muscle breakdown.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.\u00a0 If anything, the story should have provided more background on nonsmall cell lung cancer.", "answer": 1}, {"article": "; Jerrold H. Levy, M.D.\n\"The biggest problem we face in preventing stroke in patients with atrial fibrillation is that almost half of patients don't take any blood thinner at all,\" Bernstein said.\nIn patients who received two 2.5-gram of idarucizumab infusions in a 15-minute period, blood tests revealed that dabigatran's blood-thinning effect was 100 percent reversed in all 18 patients with brain bleed.\nPatients on blood-thinning drugs, such as dabigatran (Pradaxa), who suffer a type of bleeding that occurs inside the skull (intracranial hemorrhage) are at high risk of complications or disability.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease mongering here.\u00a0However, we think the lack of clarity in one sentence could lead to confusion about the risks associated with brain hemorrhage: \u201cResearchers say before idarucizumab was available, patients on dabigatran who needed emergency surgery were given purified clotting factors, which carry the risk of patients\u2019 clotting systems forming dangerous blood clots.\u201d What level of risk were they talking about?", "answer": 1}, {"article": "Burke credits the regimen with giving him the cognitive edge he needs to thrive in California\u2019s Silicon Valley, where he\u2019s the co-founder of a food service that caters to athletes and fitness devotees.\n\u201cIt\u2019s the few who are getting ahead who are using supplements to do that.\u201d\n\nThe word \u201cnootropic\u201d was coined in 1972 by a Romanian scientist, Corneliu Giurgea, who combined the Greek words for \u201cmind\u201d and \u201cbending.\u201d Caffeine and nicotine can be considered mild nootropics, while prescription Ritalin, Adderall and Provigil (modafinil, a drug for treating narcolepsy) lie at the far end of the spectrum when prescribed off-label as cognitive enhancers.\n\u201cWe don\u2019t use it at all and never have.\u201d\n\nAs for newer nootropic drugs, there are unknown risks.\nBurke, who begins each morning with a Bulletproof coffee \u2014 a rich brew of caffeine with dollops of butter and coconut oil \u2014 has created a San Francisco meetup group called Peak Performance \u201cto teach all my friends in the tech space about life hacks so they can kick a--better every day.\u201d\n\nLast spring, 100 people showed up at a Peak Performance event where psychedelic psychologist James Fadiman said the key to unleashing the cognition-enhancing effects of LSD \u2014 which he listed as less anxiety, better focus, improved sleep, greater creativity \u2014 was all in the dosage.\nNgo has experimented with piracetam himself (\u201cThe first time I tried it, I thought, \u2018Wow, this is pretty strong for a supplement.\u2019 I had a little bit of reflux, heartburn, but in general it was a cognitive enhancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no outright disease-mongering here, but the preposterous quote that it is \u201cthe few who are getting ahead who are using supplements\u201d should have been challenged. That makes it sounds like \u201cnormal\u201d people are in some way deficient.", "answer": 1}, {"article": "For more on autism and diagnosis, visit the Autism Society.\nThe current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly.\nTHURSDAY, Oct. 14, 2010 (HealthDay News) -- With the aim of catching autism in children at an earlier age than currently possible, scientists are exploring the potential of using MRI scans as a screening tool.\n\"So if there's no targeted treatment to follow up on the results of this kind of scan, then it's just another expensive test for parents who are already barraged with so many tests at diagnosis,\" she said.\nFor her part, Laura Bono, the Durham, N.C.-based former chair of the National Autism Association and member of the board of directors of the autism advocacy group \"Safe Minds,\" expressed a certain amount of hesitancy about the prospects for MRI-driven diagnoses.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does a nice job steering clear of the typical suspect statistics about autism prevalence, and in characterizing autism disorders, it does a fairly good job. \"The current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly. These so-called \"hot spots\" are central to motor function, attention, facial recognition and social behavior \u2014 types of behaviors that are abnormal in people with autism.\"", "answer": 1}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nAt 14, MS-13 was his family.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nA former gang member recently recalled when he decided to join the gang.\nHere\u2019s how he got out.\n", "question": "Does the story commit disease-mongering?", "explanation": "The natural history of Parkinson\u2019s or its variability are not presented", "answer": 0}, {"article": "\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\nA person\u2019s breath contains a variety of chemical compounds, and it has long been recognized that certain illnesses can affect how the breath smells.\n\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful,\u201d he says.\nThe lung cancer device Mazzone is testing, called an \"electronic nose\" sensor, changes color based on the chemicals in the breath.\nPeople with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering.", "answer": 1}, {"article": "\"There is a fear among clinicians that if you ask questions about suicide, you are giving the patient an idea that this could be an option,\" says Espiritu, \"and if you ask about guns or pills, that you are giving them some hints on how they can carry out a plan.\"\nHer therapists never gave up.\nAll patients are questioned on every visit.\nShe could sit on her balcony, or do some drawing or painting.\nHenry Ford epidemiologist Brian Ahmedani studies the numbers.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Maybe the opioids themselves caused problems that negatively impacted function or quality of life, \u201csuch as constipation, fatigue, poor sleep, and depressed mood.\u201d It\u2019s possible that opioid dose reduction also resolved what\u2019s known as opioid-induced hyperalgesia, \u201ca paradoxical response in which patients receiving opioids become more sensitive to painful stimuli.\u201d\n\nOr, the researchers suggested, the observational studies simply showed reverse causation \u2014 \u201cthat is, patients successfully tapered opioids because pain severity decreased.\u201d\n\nThe findings do not mean that doctors can now simply yank patients off opioids and expect them to get better.\nMost of the studies analyzed were of poor quality \u2014 meaning there\u2019s a serious need for better research in this area.\nAnd doctors, especially primary care doctors who are frequently the first people patients see in the health care system, also need to be better trained to deal with chronic pain.\n\u201cWe should be cautious in interpreting the findings,\u201d Joseph Frank, lead author of the study, told me.\nIn a few cases, then, opioids will still be the best answer for some individual chronic pain patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t see any gratuitous wording about the opioid epidemic or treating painkiller addiction in this story.", "answer": 1}, {"article": "The message for patients, he added, is that heart failure can be treated, and researchers are looking for \"innovative\" ways to improve that treatment.\nThe sheet was placed on each patient's heart.\nStem cells are primitive cells that mature into the various cells that make up the body's tissues.\nAll of the patients were on standard medications, and some had heart devices implanted.\nThe condition cannot be cured, although medications and implantable devices can treat the symptoms.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. Heart failure is a widespread problem.", "answer": 1}, {"article": "Obesity-related health conditions include high blood pressure, type 2 diabetes and high cholesterol.\n\"The first few days are associated with a fair amount of nausea, and you will need some coaching to get through that,\" Roslin said.\n\"It's going to be effective for short-term weight-loss,\" Roslin said, \"but there is still an overwhelming question whether these devices provide any long-term benefit for obesity.\"\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\nWEDNESDAY, July 29, 2015 (HealthDay News) -- The U.S. Food and Drug Administration's approval of a temporary, implanted balloon device for weight loss may have many wondering how -- and how well -- it works.\n", "question": "Does the story commit disease-mongering?", "explanation": "We will give the story the benefit of the doubt on this criterion, but in so doing, will try to raise reader\u2019s awareness of a broader issue.\nDespite\u00a0the line that states the intervention isn\u2019t medically necessary, the story doesn\u2019t touch on the disease-mongering that can take place\u00a0when\u00a0messages imply that weight scales can measure health, and when people are medicalized simply on the basis of their weights.", "answer": 1}, {"article": "The research was presented in May at the International Congress on Integrative Medicine and Health in Las Vegas.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nIn coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\nOne group was instructed to do two sets of 10-minute breathing exercises, while the other group was told to read a text of their choice for 20 minutes.\nIf you have the time to learn only one technique, this is the one to try.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here. Stress is ubiquitous as are insomnia, anxiety, and depression.", "answer": 1}, {"article": "What's lacking are clinical studies.\n\"It was the most amazing and grace-filled experience to finally have that moment of having my baby be placed on my chest,\" Caminiti says.\nChanges like this can make a big difference, says Dr. William Camann, the director of obstetric anesthesiology at Brigham and Women's Hospital in Boston and one of the pioneers of the procedure in the U.S. At Brigham and Women's, their version of the family-centered cesarean is called the gentle cesarean.\nIn addition, Penn says, the mother's hands were not strapped down and the intravenous line was put in her nondominant hand so she could hold the baby.\nThe techniques are relatively easy and the main goals simple: Let moms see their babies being born if they want and put newborns immediately on the mother's chest for skin-to-skin contact.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is potential for disease-mongering in the concept of the family-centered C-section. If it ends up increasing the number of women who deliver surgically instead of vaginally, then that would represent a further unnecessary medicalization of the birth process. However, the story specifically quotes an expert who says that\u2019s not something advocates are looking for: \u201cNo one is trying to advocate for C-sections. We really don\u2019t want to increase the cesarean rate, we just want to make it better for those who have to have it.\u201d\nWhile that\u2019s a useful sentiment, we think it would have been helpful for the story to explicitly acknowledge the problem of high cesarean birth rates in the U.S. compared with other economically advanced nations.", "answer": 1}, {"article": "MONDAY, Sept. 27, 2010 (HealthDay News) -- In a head-to-head comparison of drug-coated stents -- the metal mesh tubes used to keep clogged arteries open -- the well-established model using the drug sirolimus came out on top, South Korean researchers report.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\nThe researchers found that 10.2 percent of the patients who received zotarolimus-coated stents suffered a major adverse cardiac event, compared with 8.3 percent of the patients who received sirolimus-coated stents and 14.1 percent of those with paclitaxel-coated stents.\n\"In this large-scale, practical randomized trial, the use of zotarolimus-eluting stents resulted in similar rates of major adverse cardiac events compared with sirolimus-eluting stents and in fewer major adverse cardiac events compared with paclitaxel-eluting stents at 12 months,\" the researchers concluded in their report.\nThe number of heart attacks and deaths was about the same in each group, but the rate of blood clots in the stents was significantly lower with sirolimus-eluting stents, Park's team also found.\n", "question": "Does the story commit disease-mongering?", "explanation": "We give the article a Satisfactory rating because, in this very focused and balanced review, it doesn\u2019t balloon the target population for drug-coated stents.\nThat said, we would\u2019ve liked to have seen at least some overview of who is a candidate for stents at all, bare or coated. Not everyone with a clogged artery gets stents, or, rather, should get stents based on the evidence. It\u2019s a complex topic, with different guidelines for those having heart attacks and those with stable angina, but it\u2019s also a hot topic these days due to widespread misconceptions about who gets stents and what benefits they actually have. Recent evidence, such as the COURAGE trial, suggests that for most people with stable angina, stents don\u2019t prevent heart attacks or improve survival compared to only taking medicine and leading a heart-healthy lifestyle.", "answer": 1}, {"article": "[Why it's so hard to find a mental health professional ]\n\nLam and his colleagues followed 122 patients and evaluated whether light therapy improved their mood when it was used both with and without fluoxetine, or Prozac, a commonly prescribed antidepressant.\nSome participants were instead given placebo pills and placebo devices.\nResearchers have two main theories on why light therapy works.\nBut now a study has found that light therapy also works in treating non-seasonal depression.\nOne is that it affects the biological clock in the brain.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Wednesday\u2019s study detected no safety concerns, clearing the way for Genentech and its parent company Roche to open two large-scale studies that aim to prove if the drug works.\nBut that barrier can break down with age, opening sensitive eye cells to harm from the spillover, explained Genentech immunologist Menno van Lookeren Campagne.\nAn antibody, it works by inhibiting a particular enzyme named factor D that helps power the immune pathway.\nNormally, there\u2019s a barrier that keeps such cells away from the retina.\n\u201cIt\u2019s a very, very exciting study,\u201d said Khurana, the ophthalmologist association\u2019s spokesman, who also wasn\u2019t part of the research.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the article. Macular degeneration is a debilitating and irreversible condition.", "answer": 1}, {"article": "ACOG already recommends that women who are at high risk of preeclampsia take a low-dose baby aspirin beginning between 12 and 28 weeks of pregnancy.\nThe exact cause of the disorder is unknown, but certain risk factors make it more likely to occur, including:\n\u2022 Being pregnant with more than one baby,\n\u2022 Having chronic conditions, such as type 1 or type 2 diabetes, autoimmune disease and kidney problems.\nWEDNESDAY, June 28, 2017 (HealthDay News) -- Something as simple as taking a low-dose aspirin every day may protect pregnant women from the life-threatening condition known as preeclampsia, new research suggests.\nIn those studies using smaller doses, the reduction in preeclampsia risk hovered around 10 percent, he said, but the higher dose in this latest study was linked to a 62 percent reduction in risk.\n\"Preeclampsia is one of the most serious complications of pregnancy, with a high risk of death for the mother and baby,\" said senior study author Dr. Kypros Nicolaides.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story doesn\u2019t appear to commit disease-mongering. We do think the story would have been stronger if it had discussed the prevalence of preeclampsia, which is thought to affect about 5-8% of all pregnancies, and is one of the most common cause of maternal deaths globally.", "answer": 1}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story commit disease-mongering?", "explanation": "No evidence of any disease mongering.", "answer": 1}, {"article": "The company's stock plummeted.\nAt that point, the worms do something amazing: They suppress the immune system, says P'ng Loke, an immunologist at the New York University School of Medicine.\nThe first study to finish was a big one in Europe that looked to see if pig whipworms helped with Crohn's disease.\nYou see, the worms don't shut down the immune system completely \u2014 just enough so that the immune cells won't attack the worm.\nIt's unclear why the worms haven't worked in these trials, Loke says.\n", "question": "Does the story commit disease-mongering?", "explanation": "The conditions listed are all real disorders, so the story doesn\u2019t disease monger. However,\u00a0we did want to point out that some\u00a0of the conditions listed have\u00a0effective\u00a0treatments, yet it was implied that they are untreatable.", "answer": 1}, {"article": "(CNN) -- Eating a diet rich in healthy fats and limiting dairy and meat could do more than keep your heart healthier.\nBetween 1 and 4 percent of people over the age of 65 have vascular dementia, according to the Mayo Clinic.\nParticipants were asked about their diet and then, about six years later, underwent an MRI.\n\"You've got to get in there and figure out what actually works for prevention, and not have people guessing.\"\nThose who most strongly adhered to the dietary regimen had a level of protection similar to people who did not have hypertension.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0No disease-mongering of Alzheimer\u2019s disease or vascular dementia in this story. ", "answer": 1}, {"article": "\"Although it was allowed for the participants to continue with the pharmacological [drug] treatment they were taking beforehand, when the study was finished, the patients who received individualized acupuncture were taking less medication than the group on sham acupuncture,\" Vas said.\nThe benefits were still seen after a year.\n\"Acupuncture can calm or quiet the nervous system and help slow down the pain signals to the brain.\nThe condition affects up to 5 percent of the population, Vas said.\nPatients had nine weekly treatments, each session lasting 20 minutes.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story does not appear to commit disease mongering.", "answer": 1}, {"article": "Or are these symptoms merely the consequence of the violence of the shock, of which will ultimately only leave a bump behind?\nThese results, patented by UNIGE and awarded the Prix de l'Innovation Academy in December 2017, will be marketed from 2019 by ABCDx, a start-up founded four years ago by Jean-Charles Sanchez of UNIGE and Joan Montaner of Vall d'Hebron Hospital in Barcelona, co-authors of this study.\nAs their case is not a priority, it often takes a long time for the majority of patients to return home without risk of sequelae, except for bad memories.\n\"We are currently preparing an even more effective TBIcheck, which will allow 50% of patients to be sent home, but which requires an increase in the sensitivity of the test that receives the blood.\"\n\"We wondered if it was possible to isolate certain proteins whose presence in the blood increases in the event of mild traumatic brain injury,\u00bb explains Jean-Charles Sanchez, professor at the Department of Internal Medicine of Specialties and the Biomarkers Centre of the Faculty of Medicine of the UNIGE.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release doesn\u2019t engage in disease-mongering; potential concussions are very common. It also provides useful context on the frequency of suspected traumatic brain injury in the UK.", "answer": 1}, {"article": "Women with heterogeneously dense breasts make up about 40 percent of the U.S. screening population (women ages 40-74) \u2014 approximately 25 million women in the U.S.\n\n\"Utilizing Genius\u2122 3D MAMMOGRAPHY\u2122 exams for breast cancer screening will reduce the need for subsequent unnecessary testing, and decrease the number of unnecessary breast biopsies\u2014 addressing concerns that were previously raised as limitations of conventional mammography while also reducing costs for health systems,\" said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions.\nBreast cancer screening using tomosynthesis in combination with digital mammography.\nMammographic density and risk of breast cancer by age and tumor characteristics.\nIn addition, there can be no assurance that the systems will achieve any expected level of sales or market share.\nThe latter two groups are considered dense; however, the vast majority of women whose mammograms are considered dense have heterogeneously dense breast tissue.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The report did not appear to engage in disease mongering.", "answer": 1}, {"article": "Researchers compared 136 women with rheumatoid arthritis with 544 healthy women of similar age.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\n\u201cBreast-feeding for an entire year is difficult for many women,\u201d said Dr. Mitra Pikwer, the lead author and an intern at Malmo University Hospital in Malmo, Sweden.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\nA Swedish study suggests yet another health advantage of breast-feeding, this time for the mother: it reduces the risk of rheumatoid arthritis.\n", "question": "Does the story commit disease-mongering?", "explanation": "\nThe news story does not hype or oversell rheumatoid arthritis, an often-debilitating but relatively uncommon disease. On the other hand, it also does not report the prevalence or incidence of rheumatoid arthritis, which would be helpful. Estimates of annual incidence vary; in the UK the estimated incidence is 36/100,000 of women of all ages, while in the new Swedish study the estimated incidence was double that, or 72/100,000.\n", "answer": 1}, {"article": "[4]\n\nWriting in a linked Comment, Simon Thompson and Peter Willeit from the University of Cambridge in the UK say, \"One appealing aspect of the website is the representation of an individual's estimated 5 year mortality risk as what the authors call \"Ubble age\" (the age where the average risk in the population is most similar to the estimated risk of the individual); this concept is similar to that of heart age developed for communicating cardiovascular risk.\nThe performance of the score was validated in 35810 participants enrolled at two Scottish centres which were not used to develop the score, and was found to have around 80% accuracy in men and women (table 2).\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\n\"The Ubble website allows anybody in the UK between forty and seventy years old to calculate their 'Ubble age' and their risk of dying within the next five years compared to the general population, using a simple set of a dozen or so questions,\" says study co-author Professor Erik Ingelsson from Uppsala University, Sweden.\nUsing these findings, the researchers then developed an easy-to-calculate risk score for an individual's risk of dying in the next 5 years, based on the most predictive self-reported information, including 13 questions for men and 11 for women.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We didn\u2019t see anything that implied a doomsday perspective to use of this data. The release also clearly implies this is for UK citizens and not for others. So we\u2019ll award a Satisfactory rating, although we\u2019d note again that there\u2019s an aspect of this test that could possibly lead to increased anxiety and \u201ccyberchondria,\u201d as the release puts it.", "answer": 1}, {"article": "It's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\nThose parts of the brain soon start to die.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nA stroke occurs when a clot cuts off blood flow to parts of the brain.\nMild strokes -- characterized by such symptoms as clumsiness in the hand, weakness of an extremity, some slurred speech, temporary loss of vision, and/or dizziness -- account for more than half of strokes in the U.S.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering of mild stroke.", "answer": 1}, {"article": "She's a breast surgery fellow at Massachusetts General Hospital and Brigham and Women's Hospital in Boston.\nThe researchers also found that 32 percent of the women met the groups' eligibility standards for regular screening MRIs, and 25 percent would be eligible for genetic testing, Plichta said.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\nThe finding is important because the latest guidelines on mammograms advise that most women can wait until the age of 45 or 50 to start having annual screenings.\nHowever, she noted the ASBS added a few extra conditions:\n\u2022 Women should start mammograms earlier than 45 if they have a calculated lifetime risk greater than 15 percent.\n", "question": "Does the story commit disease-mongering?", "explanation": "In the first line of the story it states that \u201c\u2026all women turning 40 should get a breast cancer risk assessment, since half of them may have risks that are high enough to warrant annual mammograms right away.\u201d This sentence alone makes it sound like this risk is in the general population instead of a finding from the study of women visiting a breast specialty clinic.\nIn addition to mammography-screening mongering, the article states that \u201cthe researchers also found that 32 percent of the women met the groups\u2019 eligibility standards for regular screening MRIs, and 25 percent would be eligible for genetic testing.\u201d There is no mention of problems associated with MRI screening or of the significant cost of this screening. Even a co-pay for an MRI can be hundreds of dollars. \u00a0Eligibility for genetic testing should be determined by a certified genetic counselor, not by a database review.", "answer": 0}, {"article": "Half ate 22 grams of freeze-dried blueberry powder (equivalent to a cup of blueberries) daily for eight weeks.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\n\u201cThere is something very special about the composition of blueberries that is responsible for their effect on blood pressure,\u201d she said.\nLevels of nitric oxide, known to be involved in relaxing and widening blood vessels, increased significantly in the blueberry eaters.\nThe others consumed an identical-looking and tasting placebo.\n", "question": "Does the story commit disease-mongering?", "explanation": "High blood pressure affects the health of millions of Americans and people around the globe. No disease mongering here.", "answer": 1}, {"article": "Nivolumab has been approved by the U.S. Food and Drug Administration for advanced melanoma, lung cancer, kidney cancer and Hodgkin lymphoma.\n\"The response rate is better than we've seen for other potential second-line treatments and nivolumab is really well-tolerated, which is important because bladder cancer patients are a fragile group after frontline treatment with platinum chemotherapy,\" said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology at MD Anderson.\nThe study found no significant difference in response rates between those with little to no PD-L1 on their tumors (26 percent) and those with greater PD-L1 expression (24 percent).\nAt a median follow up of 213 days, 33.3 percent remained on treatment, and 45.6 percent of patients survived for at least one year, which Sharma noted \"is better than anything we've seen in the past.\"\nBoth nivolumab, known as Opdivo, and ipilimumab, known as Yervoy, were developed and marketed by Bristol-Myers Squibb, which funded the clinical trial.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release might have added value by including a larger context on bladder cancer such as overall survival rates for it and how many people have to undergo treatment with one or more chemo regimens.", "answer": 1}, {"article": "PROVIDENCE, R.I. [Brown University] -- New results from a clinical trial involving more than 900 military veterans at high risk for keratinocyte carcinoma skin cancer provides evidence that using the generic skin cream fluorouacil 5 percent for two to four weeks may reduce the risk of a squamous cell carcinoma (SCC) needing surgery by 75 percent within a year.\nThe finding that less than one month's use of fluorouacil 5% (5-FU) appeared to prevent cancer for up to a year is encouraging, said lead author Dr. Martin A. Weinstock, a professor of dermatology in the Warren Alpert Medical School of Brown University and chief of dermatology at the Providence Veterans Affairs Medical Center.\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged.\nBut in the new study, 5-FU appeared to provide prolonged protection after discontinuation and could be combined with sunscreen, Weinstock said.\n\"This suggests that using the 5-FU can reduce the resources needed to treat these carcinomas,\" Weinstock said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No indication of disease mongering here. However, the release missed an important opportunity to inform readers about the nature of these typically slow-growing cancers which rarely spread. There\u2019s no context provided on what these cancers are or the burden they put on patients or the health care system.", "answer": 2}, {"article": "At 6 months, casting resulted in measures of ankle function equivalent to that with surgery.\nAmong older adults with an unstable ankle fracture, the use of a modified casting technique known as close contact casting (a molded below-knee cast with minimal padding) resulted in similar functional outcomes at 6 months compared with surgery, and with fewer wound complications and reduced intervention costs, according to a study appearing in the October 11 issue of JAMA.\n\"Close contact casting was delivered successfully for most participants, substantially reducing the number of patients requiring invasive surgical procedures at the outset and additional operations during a 6-month period,\" the authors write.\nAlthough close contact casting may be unfamiliar to some orthopedic surgeons, it can avoid surgery for older patients with ankle fractures, yet result in equivalent functional outcomes.\nKeith Willett, M.B.B.S., F.R.C.S., of the University of Oxford, United Kingdom, and colleagues randomly assigned 620 adults older than 60 years with acute, unstable ankle fracture to surgery (n = 309) or casting (n = 311).\n", "question": "Does the news release commit disease-mongering?", "explanation": "No signs of disease mongering. These fractures are actually quite common, especially in the elderly, so it would have been appropriate to discuss the high disease burden from these fractures.", "answer": 1}, {"article": "Higher grade tumors correlate with higher restricted water volume in the cancer cells\u2019 large nuclei.\n\u201cDoctors at UC San Diego and UCLA now have a non-invasive imaging method to more accurately assess the local extent of the tumor and possibly predict the grade of the tumor, which can help them more precisely and effectively determine appropriate treatment.\u201d\n\nThe current standard of care for detecting and diagnosing prostate cancer is contrast enhanced magnetic resonance imaging (MRI), which involves intravenously injecting patients with a contrast agent to highlight blood flow.\nBy doing both, the ability of imaging to accurately plot a tumor\u2019s location is increased and there is a more refined sense of the tumor\u2019s extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.\n\u201cIf by imaging we could predict the tumor grade,\u201d added Robert Reiter, MD, professor of urology at UCLA, \u201cwe may be able to spare some patients from prostate resection and monitor their cancer with imaging.\u201d\n\nCo-authors include senior author Anders M. Dale, Hyung W. Choi, Joshua M. Kuperman, Natalie M. Schenker-Ahmed, Hauke Bartsch, Robert F. Mattrey and William G. Bradley, Department of Radiology, UCSD; J. Kellogg Parsons and Michael A. Liss, Department of Urology, UCSD; Ahmed Shabaik, Department of Pathology, UCSD; Jiaoti Huang, Department of Pathology, UCLA; Daniel J. Margolis and Steven S. Raman, Department of Radiology, UCLA; Leonard S. Marks, Department of Urology, UCLA.\nWriting in the January 6, 2015 issue of the journal Prostate Cancer and Prostatic Disease, a team of scientists and physicians from the University of California, San Diego School of Medicine, with counterparts at University of California, Los Angeles, describe a novel imaging technique that measurably improves upon current prostate imaging \u2013 and may have significant implications for how patients with prostate cancer are ultimately treated.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This story does not disease monger and is actually tipped toward the idea that with this method, in some cases, nothing but watching and waiting is necessary. However, there is some \u201cmongering\u201d of the idea that MRI has a more important role in cancer management than is supported by the evidence. The release states that contrast enhanced MRI is the current \u201cstandard of care,\u201d but many prostate cancers are not imaged (other than by ultrasound during biopsy).", "answer": 1}, {"article": "\"The questions aren't predictive,\" Sekhar said.\nBlood tests for iron deficiency without anemia have been developed but they are more costly and difficult to obtain in the doctor's office compared to hemoglobin testing for anemia.\nQuestions were included on depression, poor attention and daytime sleepiness, symptoms which all have been associated with iron deficiency or iron deficiency anemia, but were not captured in the prior NHANES analyses.\nNinety-six female adolescents participated in this study, published in The Journal of Pediatrics.\nNon-government funding from Sackler Institute for Nutrition Science of the New York Academy of Sciences provided 100 percent of funding for this research project.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is probably very little harm and possibly some benefit to having lower iron stores, but the headline makes it seem like a disease.", "answer": 0}, {"article": "For more information about Pitt Public Health, visit the school's Web site at http://www.\nMore than 1,500 of those people suffered a major bleeding event while using one of the drugs.\nAbout half of those people resumed one of the two anticoagulants a few months after the bleeding, while the others did not.\nThe risk of dying from any cause or having a stroke was 23 to 34 percent higher in patients who discontinued anticoagulation therapy compared to those who resumed it.\nPeople who took dabigatran after their initial bleeding event had nearly half the risk of another major bleeding event within one year compared with those who took warfarin.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease mongering.", "answer": 1}, {"article": "In an earlier pilot study supported by Life Extension, Drs.\nIndividuals with Down syndrome have an extra full or partial copy of chromosome 21.\nAll subjects also underwent cognitive training during the 12-month trial.\nThe Journal of nutritional biochemistry.\nKey Findings: Prevalence of Down syndrome in .\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release.", "answer": 1}, {"article": "\u201cNow that you can just write a prescription, I use them in my practice a lot more.\u201d\n\nSince the Food and Drug Administration approved the first topical Nsaid in 2007, sales in the United States have soared \u2014 to more than $264 million in 2009, according to IMS Health, a health care research company.\nThe risks in the most vulnerable population \u2014 people with other illnesses, like liver disease, or those on blood thinners \u2014 are not known, because these patients are generally excluded from studies.\nStill, in one of the only head-to-head trials between topical and oral Nsaids, subjects taking the pills had a much higher rate of indigestion, diarrhea, abdominal pain, abnormal liver tests and anemia than those using the creams.\n\u201cI think many people are not aware of topical Nsaids, or there is a perception that they don\u2019t work well, or people confuse topical Nsaids with other topical drugs, like the topical salicylates or capsaicin,\u201d Dr. Chou said.\nThe main advantage of a skin cream is that it bypasses the stomach and much of the bloodstream, theoretically minimizing serious side effects.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not exaggerate the common pains these drugs are intended to treat, but the personal anecdotes and opinions highlighted at the beginning and ending of the story are unrepresentative of the typical experiences reported by participants in clinical trials and create a powerful impression that is at odds with the evidence.", "answer": 0}, {"article": "While the findings aren\u2019t likely to resolve questions over whether meditation should become a standard part of heart disease care, the results should give more doctors confidence in discussing the practice with their patients and giving them some scientifically based information that\u2019s an improvement over the advice that \u201cit can\u2019t hurt to try.\u201d\nAll of the participants continued to receive their normal medical care as well, including appropriate medication.\nThe meditating group enjoyed an average drop of 4.9 mm Hg in systolic blood pressure compared to the control group and also reported less stress and less anger.\nTranscendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nThe participants were randomly assigned to participate in either a health education class about heart-friendly diet and exercise, or to attend a transcendental meditation program.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "[On average] \"22 grams (about .78 ounces) of new heart tissue grew,\" which he says is quite remarkable considering this had never been done before and the average weight of the part of the heart that is responsible for pumping the blood through the body is about 150 grams (about 5.3 ounces).\n\"By preventing the consequences of a heart attack you may be able to prevent further down the heart failure that happens in [many of these] patients.\"\n\"This is the first instance of therapeutic regeneration,\" says Dr. Eduardo Marb\u00e1n, director of the Cedars-Sinai Heart Institute.\nNot only did this show that the procedure was safe, it also showed that the cells can help reduce scarring and even cause new heart muscle to grow.\nA total of 25 patients participated in the clinical trial, which was designed to determine if it was safe to have cells grown from one's own heart tissue injected back into the heart.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. It makes it clear that this was a study in a particular group of patients, not just any patient with heart disease. \u201cTo qualify for this clinical trial, patients had to have suffered a recent heart attack and \u201chad to have a significant amount of damage to begin with and weren\u2019t squeezing [blood into the body] as well as they should have, says Dr. Peter Johnston, one of the study authors who injected the new heart cells into patients treated at Johns Hopkins Hospital.\u201d\n\u00a0", "answer": 1}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nGetting the vaccine makes it less likely that adults will get the painful rash that can occur when the varicella zoster virus, which causes childhood chickenpox, reactivates to cause shingles.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\nJan. 11, 2011 -- The herpes zoster vaccine, better known as the shingles vaccine and recommended for adults 60 and older, cuts the risk of getting the painful disease by 55%, new research finds.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story reports that this vaccine is recommended for people 60 and older. It also includes a comment about who should not get the vaccine, \u201cincluding people with a compromised immune system and certain cancers.\u201d Our medical editor on this story thought there was an element of disease-mongering in how the story didn\u2019t emphasize that it is post-herpetic neuralgia that \u201ccan last months or even years\u201d and by not then emphasizing immediately that most people with zoster do not have this condition. But we\u2019ll give the story the benefit of the doubt on this criterion.\n", "answer": 1}, {"article": "But the mind is a powerful thing.\nand did not have celiac disease or a wheat allergy.\nThey found no difference in symptoms among the groups.\nThey were run by the same team.\nEveryone participating in the study was on a gluten-free diet.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "Of the 100,000-plus Americans waiting for a donor kidney, about one-third are \"sensitized,\" said Dr. Robert Montgomery, director of the Transplant Institute at NYU Langone in New York City.\nIngelfinger agreed.\nPatients receive one infusion of an enzyme called IdeS four to six hours before the transplant.\n\"The outcomes have been good,\" Jordan said.\nThat means antibodies started to attack the new kidney.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "Powered by a small wireless device, this circular array of nanowires mimics densely packed retinal cells to help achieve \"functional vision,\" says Gabriel A. Silva, professor of bioengineering and ophthalmology at UC San Diego.\nThese promise that patients could become more independent.\u201d\n\nWhen healthy, retinal cells transmit visual information to the brain.\nThe devices are only experimental prototypes with many years of additional research and development likely before they might be ready for commercial use.\nThe researchers were unable to determine how well the rats were able to see, if at all, but they noted that the animals\u2019 eyes continued to react to light more than six months after the implant was installed.\nThe new prosthesis is designed to be implanted onto the back wall of the eye, where it absorbs light and transforms it into an electrical signal that stimulates the still-active retinal cells to restore vision.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story\u00a0does not engage in disease mongering. The reader learns of the prevalence of age-related macular degeneration worldwide.", "answer": 1}, {"article": "Grob says work by his group and others has shown that psilocybin can help treat \u201cterminal cancer patients with overwhelming existential anxiety, an area that traditional medicine struggles with.\u201d And a study in late 2014 found that LSD permanently reduced anxiety in a small number of patients.\n1\u201d and the so-called \u201cwar on drugs\u201d began.\nStudy participants \u201cmade claims to be more sensitive, compassionate, tolerant, to have increased positive relationships, an increased need to serve others,\u201d according to Griffiths.\nAll this combined to give psychedelics a bad name at the time and led to most of them being outlawed.\nAnother chemical, called MDMA, the active ingredient in the drug Ecstasy, can help treat post-traumatic stress disorder.\n", "question": "Does the story commit disease-mongering?", "explanation": "No obvious disease mongering.", "answer": 1}, {"article": "One expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\n\"Regardless of whether or not a person has cancer, statin use should be discussed with a health care provider,\" said Eric Jacobs, strategic director of pharmacoepidemiology at the American Cancer Society.\nFRIDAY, July 8, 2016 (HealthDay News) -- Some cancer patients who take cholesterol-lowering statins may live longer than those not on these heart medications, a study from Britain suggests.\nWhile it did not prove a cause-and-effect connection, the study of nearly 1 million cancer patients found that those taking statin drugs such as Lipitor and Crestor appeared to have:\n\u2022 and a 30 percent lower risk of dying from colon cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering, though the jump to attributing this possible side benefit of statins could lead to people using statins for reasons not fully backed up by science.", "answer": 1}, {"article": "Seventy-four subjects with type 2 diabetes were randomly assigned to follow either a vegetarian diet or a conventional anti-diabetic diet.\nThe vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nThe vegetarian diet was found to be almost twice as effective in reducing body weight, resulting in an average loss of 6.2kg compared to 3.2kg for the conventional diet.\nUsing magnetic resonance imaging, Dr. Kahleov\u00e1 and colleagues then studied adipose (fat-storage) tissue in the subjects' thighs to see how the two different diets had affected subcutaneous, subfascial and intramuscular fat (that is, fat under the skin, on the surface of muscles and inside muscles).\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no evidence of disease mongering in this release. \u00a0However, the fat measures are surrogate markers, which are not necessarily indicative of long term improvement in diabetes, specifically outcomes like death, blindness, leg loss and neuropathy.", "answer": 1}, {"article": "\"The approach we used here could be applied to any number of other conditions, and may reveal new and important uses for thousands of already approved drugs, without large investments in additional clinical trials,\" Makunts said.\nFor financial and ethical reasons, ketamine has never been tested for its safety and effectiveness in treating depression in a large-scale clinical trial, but it reportedly works much more rapidly than standard antidepressants.\nBetter known as an anesthetic or as an illicit hallucinogenic drug, ketamine has also long been noted for alleviating depression.\nKetamine is relatively inexpensive and is covered by most health insurance plans if three other antidepressants fail.\nThe team is now working to separate Botox's beauty effects (which could indirectly make a person feel better emotionally) and its antidepressant effects.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here, but the release doesn\u2019t provide any context about depression. We\u2019ll rate it N/A. ", "answer": 2}, {"article": "Guss says, \u201cThe randomization, placebo control, and double-blind procedures maximized the validity of the study results.\u201d\n\nOne of the key findings was that improvements in clinical evaluation scores for anxiety and depression lasted for the remainder of the study\u2019s extended monitoring period \u2014 specifically, eight months for those who took psilocybin first.\nSerotonin imbalances have also been linked to depression.\nAll patients, who volunteered to be part of the study, were provided with tailored counseling from a psychiatrist, psychologist, nurse or social worker, and were monitored for side effects and improvements in their mental state.\nThose who initially received psilocybin took a single dose of placebo, and those who first took niacin, then received psilocybin.\nNeither patients nor researchers knew who had first received psilocybin or placebo.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "June 30, 2010 -- A drug used in Europe as emergency contraception may also treat painful uterine fibroids, researchers say.\nAs many as 80% of all women have uterine fibroids (noncancerous growths in the uterus), according to the nonprofit National Uterine Fibroids Foundation.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\nThe hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story verges on disease mongering by exaggerating the seriousness of fibroids. While it is true that up to 80% of women may have fibroids, only about 20% of women will have symptoms that are bothersome enough that they would seek treatment. Fibroids in of themselves are benign and are not problematic unless they cause symptoms and treatment should only be initiated if a woman is bothered by them. Symptoms of fibroids also most often go away after menopause. However, this story leaves the impression that all women with fibroids should be treated.", "answer": 0}, {"article": "\u201cLike most studies, it probably raises more questions than it answers.\u201d\n\nIn the U.S., kids aged 9 to 13 should get a total of 300 micrograms of folate a day from food and supplements according to the Institute of Medicine\u2019s \u201cDietary Reference Intakes.\u201d Kids 14 and older and adults are urged to get 400 micrograms a day and pregnant women should get 600 micrograms.\nMost of the population is thought to get adequate amounts for that reason.\nThose in the bottom third \u2014 less than 173 micrograms folic acid per day for girls and 227 for boys \u2014 had an average score of only 120.\nFolic acid is naturally present in green, leafy vegetables and legumes.\nThe differences remained even after the researchers accounted for gender, smoking, the mothers\u2019 education and which schools the kids went to.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "For more information about featured studies, as well as a schedule of availability for featured researchers, please visit http://www.\nThe team also reported that endoscopic sleeve gastroplasty patients customarily left the hospital on the same day of treatment, while laparoscopic sleeve gastrectomy patients stayed for about three days and laparoscopic banding patients for a day and a half.\n\"Obesity continues to be a problem in America and it is an epidemic rapidly spreading around the world,\" said Reem Z. Sharaiha, MD, MSc, assistant professor of medicine at Weill Cornell Medicine and attending physician at New York-Presbyterian/Weill Cornell Medical Center, the study's lead author.\nObesity is associated with heart disease, stroke, diabetes and some cancers, and researchers estimate that it is the second-leading cause of preventable death, after tobacco use.\n\"For years, patients seeking weight-loss interventions had limited options because they could not tolerate or did not want surgery, or it was not even an option for them,\" added Dr. Sharaiha.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It does refer to the \u201cobesity epidemic\u201d and there\u2019s some difference of opinion as to whether obesity is a disease. The\u00a0word \u201cepidemic\u201d applies (or should apply) solely to disease. But there\u2019s no question that obesity contributes to a host of health problems and is a\u00a0significant risk factor for serious diseases, which are discussed near the end of the release.", "answer": 1}, {"article": "In the first 24 hours, more than 80% of the children in the study needed pain relief at home.\n\"This result suggests that adequate pain management should be an important goal of care, even after minor outpatient surgery, and that more effective pharmacologic and nonpharmacologic strategies should be explored,\" writes Dr. Naveen Poonai, Clinician Scientist, Lawson Health Research Institute, and Associate Professor, Emergency Medicine, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, with coauthors.\nWidely available ibuprofen is a better choice for pain relief in children who have undergone minor orthopedic outpatient surgery, as it has fewer adverse effects compared with oral morphine, according to results from a clinical trial published in CMAJ (Canadian Medical Association Journal).\nThe study included 154 children aged 5 to 17 years who underwent minor orthopedic surgery, such as keyhole surgery on joints, ligament and tendon repair, suture or hardware removal at London Health Sciences Centre in London, Ontario.\n\"Morphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\" write the authors.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease mongering here. The news release clearly states that these children had minor procedures. It\u2019s a little bit confusing that one take-away provided from the study is that more study needs to be done about management of severe pain, but overall the case is stated matter-of-factly.", "answer": 1}, {"article": "The new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\nAfter 1998, that number rose to 112 per 100,000.\n\u201cRight now, it is a difficult place for the patient to be in,\u201d Wiener said.\n\u201cI think doctors should think carefully about the pretest probability of a pulmonary embolism before they order this test,\u201d Wiener told Reuters Health.\nAnd the dyes used to enhance the scan also cause kidney damage in a significant portion of people.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of pulmonary emboli.", "answer": 1}, {"article": "\u201cNot everything that is natural is safe,\u201d she said.\n\u201cWe\u2019re trying to answer the question: Does this work against bacteria, and how does it work, and is it safe to use?\u201d\n\nThe Brazilian peppertree, a shrubby tree native to South America, is an invasive species throughout the southern United States, particularly in Florida, where it\u2019s sometimes called the Florida holly or broad-leaf peppertree, and is considered a noxious weed.\nFighting bacteria with drugs designed to kill them helps fuel the problem of antibiotic resistance if stronger bacteria can survive and evolve to become \u201csuperbugs.\u201d\n\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.\nMRSA has become a serious threat to human health; in 2011, it was responsible for more than 80,000 invasive infections and more than 11,000 deaths in the United States, according to federal statistics.\nThe discovery may hold the potential for new ways to treat and prevent antimicrobial-resistant infections, an enormous global problem that was the focus of a rare high-level United Nations summit last fall.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story discusses prevalence of superbugs, which are indeed a growing public health problem. \u201cMRSA has become a serious threat to human health; in 2011, it was responsible for more than 80,000 invasive infections and more than 11,000 deaths in the United States, according to federal statistics.\u201d\nWhile that\u2019s accurate, it may overstate the danger to some extent. Many of the people who died were terminally ill and would\u00a0have died regardless of the type of infection.", "answer": 1}, {"article": "He recommends trying to incorporate barley into existing recipes, using it as a substitute for rice or even on its own -- just like oatmeal.\nSt. Michael's Hospital provides compassionate care to all who enter its doors.\nFounded in 1892, the hospital is fully affiliated with the University of Toronto.\nBarley reduced both low-density lipoprotein, or LDL, and non-high-density lipoprotein, or non-HDL, by seven per cent.\nHigh cholesterol and diabetes are major risk factors for cardiovascular disease and stroke, historically treated with medications.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No obvious disease mongering.", "answer": 1}, {"article": "\u201cI prescribe them all the time,\u201d she said.\n\u201cA 5 percent loss of weight is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\n\nPatients in Bohula\u2019s study did see improvements in hypertension and blood sugar levels with weight loss.\nThat\u2019s how we need to start looking at drugs for obesity.\u201d\n\nWhat many don\u2019t understand is that weight gain leads to changes in the brain that may not be reversible, Aronne said.\n\u201cRather than thinking about how good you\u2019ll look in that dress, you need to be thinking, \u2018I won\u2019t get diabetes now.\u2019\"\n\nBeyond that, a little patience goes a long way.\nThere are probably a few reasons for this, including cost, if not covered by insurance, and a perception that these agents are not safe in light of the history with weight loss agents.\u201d\n\nIn fact, a 2017 report that examined the medical records of 2.2 million patients found that fewer than one in 50 patients who were eligible for a diet pill prescription received one.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story accurately stated that two-thirds of Americans have obesity or overweight. It could have been clearer explaining how not everyone in this group experiences health risks, and it\u2019s not always clear why. It also could have avoided some stigmatizing language such as \u201cpacking on the pounds\u201d and \u201cfatter.\u201d", "answer": 1}, {"article": "WHAT: NIH-supported researchers are reporting additional details about a widely-publicized study that linked a systolic blood pressure target under 120 mm Hg (millimeters of mercury) with reduced cardiovascular disease and a lower risk of death.\nThe new analysis singles out adults aged 75 and older and confirms that those with high blood pressure also benefit from the lower pressure target similar to the larger group studied in the earlier research: non-diabetic adults aged 50 and older.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nIn addition to primary sponsorship by the NHLBI, SPRINT is co-sponsored by the NIH's National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke, and the National Institute on Aging.\nAbout three-fourths of the U.S. population aged 75 and older live with hypertension, a leading contributor to cardiovascular disease and death.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not appear to commit disease-mongering.", "answer": 1}, {"article": "It can be very unpleasant.\n\u201cScratching leads to swelling, cracking, weeping clear fluid, and finally, coarsening and thickening of the skin.\u201d\n\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\n\u201cThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u201d the FDA notes.\n\u201cOf the adults with uncontrolled moderate to severe atopic dermatitis in the United States, it is estimated that 300,000 are most in need of new treatment options,\u201d Regeneron said.\n", "question": "Does the story commit disease-mongering?", "explanation": "While we would have liked to see independent sources used here, the story doesn\u2019t go overboard in stating the impact of the disease, though it is pretty dramatic:\n\u201cPeople with moderate to severe atopic dermatitis cope with intense, sometimes unbearable symptoms that can impact them for most of their lives,\u201d Julie Block, president and CEO of the National Eczema Association, said in a statement provided by the company.\nIt also attempts to delineate who could benefit from this drug, quoting one of the manufacturers:\n\u201cOf the adults with uncontrolled moderate to severe atopic dermatitis in the United States, it is estimated that 300,000 are most in need of new treatment options,\u201d Regeneron said.\nIt further states, \u201cDupixent is for the hard-core cases that aren\u2019t helped by anything else.\u201d", "answer": 1}, {"article": "* Anorexia among most common psychiatric disorders in girls\n\nLONDON, March 7 (Reuters) - Scientists have for the first time reported successful use of a brain-stimulating implant to help patients with severe anorexia whose condition had not improved with other treatments.\nThey implanted electrodes into the area and connected them to a pulse generator under the skin.\nThe patients, all women, were aged between 24 and 57 and had had anorexia for between four and 37 years.\nUnder previous therapies, none had shown progress.\nThe devices were activated 10 days later and researchers measured changes in the patients\u2019 mood and anxiety to help find the correct level of stimulation.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in the story.", "answer": 1}, {"article": "+3582944 54542\n\nIntake of fermented and nonfermented dairy products and risk of incident CHD: the Kuopio Ischaemic Heart Disease Risk Factor Study Timo T. Koskinen, Heli E. K. Virtanen, Sari Voutilainen, Tomi-Pekka Tuomainen, Jaakko Mursu, Jyrki K. Virtanen.\nMilk was the most commonly used product in this category, and a very high consumption was defined as an average daily milk intake of 0.9 litres.\nWhen the study participants were divided into four groups on the basis of their consumption of fermented dairy products with less than 3.5% fat, the risk of incident coronary heart disease was 26% lower in the highest consumption group compared to the lowest consumption group.\nThe study participants were divided into groups on the basis of how much they ate different dairy products, and the researchers compared the groups with the highest and lowest consumption, while also taking various lifestyle and nutrition factors into consideration.\nFor further information, please contact:\n\nJyrki Virtanen, PhD, Adjunct Professor in Nutrition Epidemiology (principal investigator).\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering is noted in this news release. Nor does the release provide any context on the prevalence of\u00a0 coronary heart disease.", "answer": 2}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. The story mentions that only 5% of cases of endometrial cancer occur in women under 40, and is careful to emphasize that this study was performed in a \u2018select group of patients\u2019.", "answer": 1}, {"article": "He cautioned that persistent use of ibuprofen can lead to gastritis, or inflammation of the stomach lining, but said that, in comparison, \"there is very little to lose when measuring its side effects against the effects of Parkinson's,\" which can include loss of balance, stiffness, hallucinations and dementia.\nIn a six-year span, 293 were diagnosed with the disease.\nParkinson's is not considered an inflammatory disease, he said, adding: \"We might be missing something.\nTagliati called the study \"eye-opening.\"\nPeople who took three or more tablets a week showed a 40 percent lower risk than those who didn't take the common pain reliever, their study found.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of Parkinson\u2019s Disease. ", "answer": 1}, {"article": "But Gee believes reimbursing patients to play games could cut other health costs \u2014 by promoting exercise and preventing disease, for example, or even reducing the amount of expensive drugs people take.\nThey see the potential of these games to not only make money \u2014 but to save money, too.\nIn fact, the creators believe their game will be so effective it might one day reduce or replace the drugs kids take for ADHD.\n'Play This Video Game And Call Me In The Morning'\n\nI'm driving through a frozen world, where the roads are paved in ice.\nBut this kind of goal requires a totally different business model; before they can deliver their game to players, they first have to go through the Food and Drug Administration \u2014 the FDA.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t exaggerate the need for this sort of video game treatment, if it was ever offered.", "answer": 1}, {"article": "I\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\nIt needs to be carried out at an accredited centre or as part of a clinical trial.\n\u201cI couldn\u2019t dress or wash myself; I didn\u2019t even have the strength to carry my daughter.\u201d\n\nShe had needed a wheelchair before her transplant, but after the treatment she walked out of hospital.\nThese will be followed by periods where symptoms are mild or disappear altogether.\nI got my life and my independence back and the future is bright again in terms of being a mum and doing everything with Isla.\u201d\n\nTwo years after the treatment, she has had no relapses and there was no evidence of active disease on her scans.\n", "question": "Does the story commit disease-mongering?", "explanation": "Relapsing remitting multiple sclerosis is a common form of the disease for which there is currently no cure.\u00a0 So the stakes are sufficiently high.", "answer": 1}, {"article": "The population studied was relatively homogenous, and \"the [body mass] findings were not the object of the study (wheezing or asthma in children was the primary objective), growth was a secondary finding,\" Rabin explained.\n\"The use of fish oil in the latter part of the pregnancy has an impact on bone and muscle mass.\nThough these children are larger, they do not have increased rates of obesity,\" Wu added.\n\"For the past decade, the importance of fish oil and the omega-3 fatty acids have been stressed to patients,\" explained Wu, who was not involved in the study.\nHowever, the findings only showed an association and did not prove that fish oil pills caused healthier growth in children.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\"In health as elsewhere, if something looks too good to be true, it should be treated with great caution,\" says an editorial published this week in the medical journal BMJ.\nAnd some experts believe the evidence is getting thinner all the time.\n\u2022 Age matters too.\nStudies have failed to prove any difference.\nFor some people, even moderate drinking is clearly risky.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article did not engage in disease mongering.", "answer": 1}, {"article": "To find out more about the activities of EULAR, visit: http://www.\nFor further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress \n\nPress Office in Room 5B of Fiera Roma during EULAR 2015 or on: \n\nEmail: eularpressoffice@cohnwolfe.com \n\nOnsite tel: +44 (0) 7738 890 799 / +44 (0) 20 7331 5442 \n\nTwitter: @EULAR_Press \n\nYoutube: Eular Pressoffice\n\nThe European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.\nReducing the TNFi dose by two-thirds resulted in more flares (exacerbations of symptoms and signs) but these subsided when the higher dose of TNFi was restarted, and did not adversely affect subsequent progression of any disability.\nOver the course of the congress there will be some 300 oral and just under 2,000 poster abstract presentations, more than 150 sessions, 400 lectures, 40 poster tours and 350 invited speakers.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release mentions the potentially debilitating effects of RA, but does not exaggerate them. It would have been stronger if it had mentioned the prevalence of the disease and well as the prevalence of disability is in those with the disease.", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story commit disease-mongering?", "explanation": "The headline notes that this trial included only people with cardiovascular disease. The story reports that the patients were taking statins to reduce their cholesterol, but they still had high triglyceride levels or diabetes (which increases the risk of heart attacks and strokes).", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story commit disease-mongering?", "explanation": "The story does a good job on this, discussing the prevalence of prostate cancer nationally and globally, and how some men may not need treatment for it, depending on their circumstances.", "answer": 1}, {"article": "After taking into account other factors that might affect health and disease risk, like smoking, researchers found women who drank light or moderate amounts of alcohol were less likely to develop chronic diseases as they aged.\nThe women filled out questionnaires about what they ate and drank at midlife, about age 58.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\nResearchers then analyzed health status information collected after the women turned 70.\nA new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering.", "answer": 1}, {"article": "TUESDAY, March 20, 2018 (HealthDay News) -- Tiny pellets could treat arthritic knee pain, delaying the need for knee replacement surgery, a small study has found.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\nThe small pilot study -- the first U.S. clinical trial of this procedure -- involved 20 patients with moderate to severe arthritis pain.\n\"It's an outpatient procedure, and no physical therapy is required before or after this procedure,\" he said.\nMuch of the pain that comes from knee arthritis actually stems from inflammation in the lining of the knee joint, also called the synovium, Bagla said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t engage in disease-mongering. While some data on the prevalence of knee pain would have been useful, the story does provide a link to the Arthritis Foundation.", "answer": 1}, {"article": "Australian researchers have discovered that an existing medication could have promise in preventing breast cancer in women carrying a faulty BRCA1 gene.\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\n\"We therefore investigated what effect RANK inhibition had on the cancer precursor cells in BRCA1-mutant breast tissue.\"\n\"We think this strategy could delay or prevent breast cancer in women with an inherited BRCA1 gene mutation,\" Professor Lindeman said.\n\"By thoroughly dissecting how normal breast tissue develops, we have been able to pinpoint the precise cells that are the culprits in cancer formation,\" she said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This is borderline. Patients who have the BRCA1 gene mutation will not necessarily get breast cancer. However, they are at high risk of developing breast cancer. The release would have been stronger if it had given readers some numbers related to that elevated risk, rather than using vague language (i.e., \u201chigh risk of developing aggressive breast cancer\u201d). But they offered enough of a qualifier to earn a \u201csatisfactory\u201d here.", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not overplay the import or incidence or cognitive decline.", "answer": 1}, {"article": "With his colleagues, he looked back at some 40,000 such surgeries done at dozens of academic medical centers in the U.S. \u2014 roughly 14,000 open procedures and 26,000 laparoscopic ones.\nFirst, it looks only at academic medical centers.\n\u201cOverall, this study shows benefit from laparoscopy on every aspect, including cost,\u201d he told Reuters Health.\nOn average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\n\u201cIn healthy individuals, the death rate is very (small) for all groups of patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play here.", "answer": 1}, {"article": "The article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\n.\nThe article is available free on the Journal of Child and Adolescent Psychopharmacology website.\nChildren taking the delayed-release stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening, according to the study results published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.\nIts biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "These weekend warriors cram the recommended amount of exercise into one or two days, while the rest of us faithfully head to the gym multiple times a week for a half-hour hamster run on the treadmill.\nMore than 90 percent of the subjects were white.\nThe survey included questions about health history and fitness habits.\n\u201cIn theory, someone who did one bout of 150 minutes of moderate exercise is a weekend warrior,\u201d says O\u2019Donovan.\nThe coronary heart disease patients who stuck with the recommended 150 minutes a week had the lowest risk for heart attack and stroke.\n", "question": "Does the story commit disease-mongering?", "explanation": "No evidence of disease mongering here.", "answer": 1}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story commit disease-mongering?", "explanation": "Advanced stage prostate cancer is a common, life-threatening disease. The article gives an estimate, albeit from the companies behind the test, that 50,000\u00a0U.S. men with advanced prostate cancer would be candidates for the test.", "answer": 1}, {"article": "However, for a study that lasts this long, \u201cthose are acceptable numbers,\u201d noted Arber.\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\nStill, the results are \u201cvery promising,\u201d Arber told Reuters Health by e-mail, adding he is now working to identify people who could benefit from the drug without experiencing the side effects.\nColorectal cancer is the third most common cancer in men and women, and strikes 1.2 million people each year.\nAs a result, he said he suspects most people would choose to rely on regular colonoscopies to catch the disease in its early stages, rather than take a potentially risky drug for years.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story states that colorectal cancer strikes 1.2 million people each year. It probably should have specified that\u00a0this figure represents a global tally\u00a0and not the incidence in the United States. Since the story quotes an American researcher and the study appears in the American Journal of Gastroenterology, readers might assume that the statistics are also U.S. \u2013 centric.\nWith that being said, neither this nor anything else\u00a0in the story rises to the level of disease-mongering.", "answer": 1}, {"article": "If you are interested in enrolling in a clinical trial, you can find one at clinicaltrials.gov.\nThe particular kind of cells used in this research are called mesenchymal stem cells, and come from adults, not embryos.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nThe stem cells reduce the amount of scar tissue and increase the pumping strength of the heart in heart attack patients, Hare said.\nThe drug, which consists of stem cells from donor bone marrow, gets injected into the vein.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does nothing to exaggerate the prevalence or severity of the damage to the heart muscle by heart attacks. ", "answer": 1}, {"article": "\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\nOverall, both medical and non-medical approaches are key to treating the disease in the future, Aref added.\nAbout 1,700 participants were over age 40, had no other known eye diseases and had full eye examination results from the survey.\n\u201cPatients can and should be involved and take an active role in the management of their ailments,\u201d Hecht said.\nOther studies indicate that antioxidants in tea could have similar effects, he noted.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "For the study, Schneider's team randomly assigned 201 black Americans with heart disease either to a Transcendental Meditation stress-reducing program or health education class about lifestyle modification in diet and exercise.\nBoth groups increased exercise and drank less.\n\"So it's only learned live.\"\nTranscendental Meditation is not generally covered by health insurance, he said.\nOriginally from India, it is not associated with any particular religion or philosophy.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "The bar was developed over the past 10 years by a team of scientists led by Drs.\nThe power of nutrient-rich, properly formulated food-based supplements, such as the CHORI-bar, to move dysregulated metabolism in a healthy direction may help reverse obesity-associated conditions, and thereby reduce the risk of future chronic diseases.\nImproved metabolism resulting from eating the bar is also associated with a number of reports of feeling better (though this observation has not yet been formally tested), which the CHORI team predicts will help people transition to improved lifestyle habits.\nThe CHORI-bar is intended as a non-traditional means to positively impact the obesity epidemic by initiating a healthier metabolism without requiring sudden drastic behavioral changes.\nWhile poor diets contain much that is not healthy (e.g., too much salt, sugar), they also are missing or deficient in a number of important components (e.g., vitamins/minerals, omega-3 fatty acids, fiber) necessary for healthy metabolism.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Obesity is a big problem, and this press release does not overstate it. That said, the contribution that the CHORI bar might make to reducing the problem is hard to determine.", "answer": 1}, {"article": "They then measured concentrations of a hormone called the anti-Mullerian Hormone (AMH) that is produced by cells in women\u2019s ovaries.\nThe average difference between the predicted age and the women\u2019s actual age at menopause was a third of a year, and the maximum margin of error was three to four years.\nThe test, which measures levels of a hormone produced by cells in the ovaries, was able to predict the age at which women reached menopause to within an average of 4 months, according to data to be presented at the conference of the European Society of Human Reproduction and Embryology in Rome on Monday.\nThe average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\n\u201cUsing this model, we estimated mean average ages at menopause for women at different time points in their reproductive life span.\u201d\n\nTehrani said the results showed \u201ca good level of agreement\u201d between predicted and actual age at menopause for the 63 women in the group who reached menopause during the study.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. The story should have also avoided referring to women who want a career before having babies to know how long to wait. \u00a0Having a career does not preclude having a family, biological or otherwise. ", "answer": 1}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nHe said the sessions weren't that painful and his knee felt better after each one.\nHe still does the recommended exercises several times a week.\nAfter six months, both groups had similar rates of functional improvement.\nRobert Dvorkin had both treatments for injuries on each knee several years apart.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering of torn menisci.", "answer": 1}, {"article": "Whoopi Goldberg recently stepped in with a new line of medical marijuana\u2013based edibles and bath products (of questionable effectiveness) aimed at this underserved market.\n\u2014 the pain is gone.\nPrescribed one this morning in fact.\"\nThey really help some women, she added.\nBut this assumes Livia will take off enough to justify retailing.)\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not overstate the problem.", "answer": 1}, {"article": "MONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nDanish researchers analyzed data from more than 31,000 patients hospitalized with heart attack between 2000 and 2005 and divided the patients into four groups: two groups with heart failure (one that received Plavix and one that did not) and two groups without heart failure (one that received Plavix and one that did not).\nThe U.S. National Heart, Lung, and Blood Institute has more about heart failure.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0Not applicable because there was really no discussion of heart failure incidence or seriousness. ", "answer": 2}, {"article": "WEDNESDAY, April 28, 2010 (HealthDay News) -- A new drug may be the first new treatment in 25 years for a common diabetes-linked eye condition called diabetic macular edema (DME), researchers report.\n\"First and most importantly, it provides patients an improved therapy for diabetic macular edema.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nFor 25 years, laser treatment has been the standard of care for DME, the main cause of vision loss in people with diabetes.\nBut researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering. ", "answer": 1}, {"article": "We have shown that skin is a fertile land where we can grow the elements of any organ that is declining,\" said Dr. Chandan Sen, director of Ohio State's Center for Regenerative Medicine & Cell Based Therapies, who co-led the study with L. James Lee, professor of chemical and biomolecular engineering with Ohio State's College of Engineering in collaboration with Ohio State's Nanoscale Science and Engineering Center.\nThe procedure is also non-invasive.\nResearchers studied mice and pigs in these experiments.\nThe chip does not stay with you, and the reprogramming of the cell starts.\n\"The concept is very simple,\" Lee said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here.", "answer": 1}, {"article": "\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\nHe was able to get up and walk two day after his transplant.\n\u201cI feel great,\u201d says Xiao, through an interpreter.\nAbout five per cent of people on kidney waiting lists die every year.\nToronto General Hospital is a research and teaching hospital affiliated with the University of Toronto.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story commit disease-mongering?", "explanation": "The article did not commit disease mongering. It highlights the story of a desperate patient in a balanced way.", "answer": 1}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in disease mongering.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story commit disease-mongering?", "explanation": "The opposite of disease mongering, this story explains the study\u2019s questions of preventive benefit from the Plavix-aspirin combination, including one researcher\u2019s quote: \u201cYou don\u2019t use this drug for patients without coronary artery disease.\u201d ", "answer": 1}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story commit disease-mongering?", "explanation": "The story begins:\u00a0 \"Want to forget about that painful breakup? Wish you could put some troubling childhood memories out of your mind? Someday soon, it might be as easy as popping a pill.\"\u00a0 While it goes on to discuss post-traumatic disorder \u2013 a serious memory issue \u2013 the story leads by framing the memory of painful breakups as something that is a disease that should be treated.\u00a0 That\u2019s disease mongering. ", "answer": 0}, {"article": "However, they say these findings \u201craise questions that warrant investigation\u201d and call for verification in randomised studies \u201cbefore recommending a change to current practice.\u201d\n\nNotes to Editors\n\n Research: Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study\n\n Journal: The BMJ\nThere was no consistent evidence that either iron or folic acid use were associated with a reduced risk of ASD.\nMore boys are diagnosed with the condition than girls.\nIt\u2019s estimated that about 1 in every 100 people in the UK has ASD.\nHowever strengths included the relatively large population-based sample size and the advanced analytical methods used to gauge the robustness of findings.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease-mongering. Autism spectrum disorders are simply described.", "answer": 1}, {"article": "\"In these types of studies you think of things like this,\" Haber said, \"but how real it is, is something we're going to have to see.\nIt raises more questions, and many more experiments that can be done.\"\nI think just trying to work out that there is some similarity in very simple learning [processes in the brain] is important.\"\nCurrently, deep brain stimulation is used to control the tremors associated with Parkinson's, symptoms of obsessive-compulsive disorder and some other psychiatric conditions, including depression.\nDuring the video game task, participants learned their way around a virtual town with and without five-second periods of deep brain stimulation, and were tested for their ability to reach predetermined landmarks.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate who might eventually benefit from this line of research.", "answer": 1}, {"article": "But Cao doesn't think people should start taking aspirin to prevent cancer until more research is done.\nThere was a 20 percent lower risk of cancers of the gastrointestinal tract, especially in the colon and rectum, among people taking aspirin, said lead researcher Yin Cao, a postdoctoral research fellow at the Harvard School of Public Health in Boston.\nThe association of aspirin with reduced cancer risk was the same for women and men regardless of race, history of diabetes, family history of cancer, weight, smoking, regular use of other painkillers or taking multivitamins, the study authors added.\nThe data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThe benefit was no longer seen within four years of stopping it, the researchers found.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story suggests that colorectal cancer is one of the two \u201cleading causes of sickness and death in the U.S. and much of the world.\u201d However, it\u00a0never supports that statement with figures on the prevalence or incidence of these cancers, or an individual\u2019s lifetime risk. Such figures are easily obtainable from the American Cancer Society.", "answer": 0}, {"article": "[Added June 10] So Gokhale studied findings from anthropologists, such as Noelle Perez-Christiaens, who analyzed postures of indigenous populations.\nIn fact, if you look at drawings from Leonardo da Vinci \u2014 or a Gray's Anatomy book from 1901 \u2014 the spine isn't shaped like a sharp, curvy S. It's much flatter, all the way down the back.\nAnd people who are thinner probably have less curvature\" \u2014 and thus a spine shaped more like J than than an S.\n\nAmericans are also much less active than people in traditional cultures, Mummaneni says.\nIf you look at an American's spine from the side, or profile, it's shaped like the letter S. It curves at the top and then back again at the bottom.\nIt's what goes into making the J-shaped spine that matters: \"You have to use muscle strength to get your spine to look like a J shape,\" he says.\n", "question": "Does the story commit disease-mongering?", "explanation": "We looked closely at some of the story\u2019s statistics on low back pain for this criterion. The story says that \u201cmost Americans will at some point have a problem with their backs,\u201d which is true \u2014 the NIAMS data back it up. But the story also says that \u201cfor an unlucky third, treatments won\u2019t work and the problem will become chronic.\u201d The \u201cunlucky third\u201d claim links to a 2012 Gallup news release, which reported \u201can average of 31% of Americans reported having a [chronic] neck or back condition.\u201d But the numbers in the same release shed a little extra light on the subject. Specifically, the numbers show that the \u201cunlucky third\u201d would appear to refer primarily to the 36-37 percent of Americans in their mid-50s and older who self-reported having chronic pain in their back or their neck during a Gallup poll. NIAMS estimates that the number of people with chronic lower back pain is more in the 2-8 percent range. However, the \u201cunlucky third\u201d claim is supported by some data, and the story linked to it. So it gets a Satisfactory rating.", "answer": 1}, {"article": "She notes that using trastuzumab to selectively treat uterine serous carcinoma that express HER2/neu is part of a broader trend at Johns Hopkins and other cancer centers to use the tools of tailored therapy, or precision medicine, based on the molecular and genetic makeup of tumors and patients.\nFader no longer holds that role.\nAll tested positive for the HER2/neu receptor.\nCOI: Amanda Fader has reported a consulting or advisory role for Merck, which also makes HERher2- blocking drugs.\nThe researchers say this may lead to new national guidelines for treating this cancer subtype, known as uterine serous carcinoma.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "WASHINGTON (Reuters) - A urine test can help doctors better spot prostate cancer than either the current blood test or a rectal exam alone, U.S. researchers reported on Tuesday.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\nIt is a string of RNA that does not appear to have any function but that is overexpressed, or overactive, in prostate cancer.\nThe prostate is a walnut-shaped gland that produces semen and it is hard to get to.\nBiopsies are difficult and painful to do and may take a portion of healthy prostate, missing any tumors entirely.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering.", "answer": 1}, {"article": "U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\nThe study directly compared the clinical performance of a new test based on PSA, called IsoPSA, to PSA itself with patients already scheduled for prostate biopsy.\nLocated in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation.\nThe results show that if validated and adopted clinically, IsoPSA could significantly reduce the rate of unnecessary biopsies by almost 50 percent.\nPatients came for treatment from every state and 185 countries.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the news release. \u00a0It provides some useful context on the pros and cons of PSA screening.", "answer": 1}, {"article": "\"Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging,\" noted Wende Hutton, general partner at Canaan Partners and a member of Chrono's board of directors.\nThe clinical trial was a randomized, double blinded study of 24 adult males who smoked 11 or more cigarettes per day, indicating a high level of nicotine dependence.\nFor example, 75% of all smokers reach for their first cigarette within 30 minutes of waking up.\nOur goal is to solve this crisis of public health with an innovative, integrated smoking cessation solution, and the data we presented demonstrates that we are on the right path.\"\nI'm very excited to be working with a company that has the potential to solve such a serious problem.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release accurately characterizes smoking as a serious global health problem.", "answer": 1}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story commit disease-mongering?", "explanation": "The story mentions \"the estimated 15 million American men suffering from erectile dysfunction.\"\u00a0 Whose estimate is that?\u00a0 What is it based on? Is this lumping together all men who have occasional problems with erections with those who have organic disease?\u00a0 ", "answer": 0}, {"article": "He emphasizes he is not against the use of gastric band surgery, but that based on his study results, patients who opt for the procedure should know there's a good chance they will need a follow-up procedure and they may have less weight loss and more complications than those who choose other weight loss surgeries.\nThe average weight loss was below what experts consider good results.\nHis study findings, he tells WebMD, are ''a reality call.\"\nBut Himpens tells WebMD he's skeptical either would make much difference.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease-mongering.", "answer": 1}, {"article": "The games are based on the work of Japanese neuroscientist Ryuta Kawashima, M.D.\n\"Functional MRI allows you to study which brain areas are simultaneously active and gives information on the participation of certain areas with specific brain circuits,\" Dr. De Giglio said.\nThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function, the higher-level cognitive skills that help organize our lives and regulate our behavior.\nOAK BROOK, Ill. - Playing \"brain-training\" video games may help improve some cognitive abilities of people with multiple sclerosis (MS) by strengthening neural connections in an important part of their brains, according to a new study published online in the journal Radiology.\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The combination in the release of information about the incurable disease of MS, plus the appeal of video games potentially playing a therapeutic role, makes this a release that should trigger broad interest, but that does not seem to reach the level of disease-mongering.", "answer": 1}, {"article": "She worries about the small chance of benefit in light of the larger chance of finding and treating a cancer that did not need to be treated.\nWhen the study was planned, the scientists expected that screening would be even more effective than it was in studies from decades ago.\nAnd 5 to 15 of those women would be treated for cancers that, if left alone, would have grown so slowly they would never have been noticed.\nFive hundred would have biopsies.\nIn the study, which is continuing, women were followed for a maximum of 8.9 years.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story does not exaggerate the risk of breast cancer or the need to be screened for it.", "answer": 1}, {"article": "Neither treatment prompted significant side effects, the authors said.\nAnd while theorizing that the apparent success of this alternative approach may have something to do with stimulating blood flow, retinal nerve growth and visual cortex activity, the authors acknowledged that the exact mechanism by which it works remains poorly understood.\nHowever, while this approach is often successful in younger children (between the ages of 3 and 7), it is successful among only about a third of older children (between the ages of 7 and 12).\nOf those, between one third and one half have a type of lazy eye known as anisometropia, which is caused by a difference in the degree of nearsightedness or farsightedness between the two eyes.\nThe team nonetheless pointed out that their study's tracking period was relatively short, and that acupuncture is a complicated system that may lend itself to different success rates, depending on the skills of the particular acupuncturist.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story repeats statistics provided in the study regarding the worldwide prevalence of amblyopia.\u00a0These figures do not appear to overstate or exaggerate the impact of amblyopia.", "answer": 1}, {"article": "Newswise \u2014 HOUSTON \u2015 For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused by treatment with immune checkpoint inhibitors (ICIs).\nThe current data further suggests there is the potential for many molecular studies to better understand the role of the microbiome in driving ICI-colitis and immunotherapy response more broadly.\nThe first patient\u2019s colitis resolved within two weeks following a single FMT treatment; the second patient experienced a partial recovery after the first treatment, followed by complete recovery after a second FMT.\n\u201cWe have a limited amount of time to fix the problem so they can resume ICI treatment, but I feel that we\u2019ve made great progress in this area.\u201d\n\nThe researchers chose to investigate the potential for FMT as an alternative, compassionate-use therapy for patients suffering from refractory, or unresponsive, ICI-associated colitis.\n\u201cBased on these results, this should be evaluated even as a first-line therapy for ICI-associated colitis because it\u2019s safe, quick, and the effect is durable - from one treatment.\u201d\n\nImmune checkpoint inhibitors, which release a block on the immune system to attack cancer, have been successful in providing durable responses for patients with several cancer types.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t disease-monger. Inflammation of the colon is the second most common side effect of employing immune checkpoint inhibitors, according to the release.\u00a0 That makes finding a way to minimize this side effect important.", "answer": 1}, {"article": "Iron is essential to the developing brain, he said, and deficiencies during early months \u2014 perhaps linked to early clamping \u2014 could affect nerve and muscle control, making it harder for the child to later control a pen or interact comfortably with peers.\nThe benefits of those extra few minutes may last a long time.\nThen, moments after birth, that cord is severed.\nCutting the cord is a momentous event in a baby's life.\nBabies who are anemic often appear tired and pale.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "\"For all practical purposes, the programs all worked about the same,\" said Kelly D. Brownell, director of Yale University's Rudd Center for Food Policy and Obesity and creator of the Lifestyle, Exercise, Attitudes, Relationships and Nutrition (LEARN) program for weight management, one of the diets studied.\nAll the participants reported eating about 2,000 calories a day when the study began.\nReactions to the findings were mixed.\nAt first, the Atkins group lost weight faster.\nHigh levels of LDL are a major risk factor for heart disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering.", "answer": 1}, {"article": "The researchers are continuing the treatments and compiling data.\nDespite its less invasive nature, UFE has yet to be fully embraced in the medical community as a fertility-preserving treatment for women with symptomatic fibroids due to concerns that the procedure may cause inadequate blood flow to the endometrium, or lining of the uterus, and the ovaries.\nAfter an average follow-up of almost six years, 149 of the 359 women, or 41.5 percent, had become pregnant one or more times, and 131 gave birth to a total of 150 babies.\n\"Our findings show that UFE is a fertility-restoring procedure in women with uterine fibroids who wish to conceive, and pregnancy following UFE appears to be safe with low morbidity,\" Dr. Pisco said.\nHowever, myomectomy is not always possible or effective and can result in major complications including hysterectomy, according to study co-author Jo\u00e3o Martins Pisco, M.D., Ph.D., from the Department of Interventional Radiology at Saint Louis Hospital in Lisbon, Portugal.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Disease mongering is the most serious shortcoming of this release. The cited statistic that \u201cone out of every four women with fibroids has problems related to fertility\u201d inflates the causal relationship between fibroids and infertility. The more relevant statistic would be the percentage of infertile women who have fibroids.\nThe release disease mongers because it makes it sound like all women with fibroids are at high risk of infertility, and thus, should receive treatment. In reality, UFE and related procedures are generally reserved\u00a0for women with fibroids who have symptoms such as bleeding and pain.\nThe concern is that readers will infer that all women with fibroids who wish to optimize future fertility need treatment for the fibroids \u2014 regardless of whether they are causing bothersome symptoms \u2014 and that the use of UFE will be extended to treating women with fibroids but without symptoms who hope for a future pregnancy. That\u2019s a very large group indeed, since fibroids are so common.", "answer": 0}, {"article": "Both studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nFeb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nIn another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering. This story provided a few more facts than the AP story and made it clear why these findings may be hugely important for women with fibroids. It said, \u201cUterine fibroids are the most common indication for the close to 600,000 hysterectomies performed each year in the U.S. About 1 in 4 women in their childbearing years have symptoms related to fibroids, such as heavy periods and related iron deficiency, abdominal pain, and fertility problems, according to figures from the National Institutes of Health.\u201d", "answer": 1}, {"article": "For now, he suggested that people choose olive oil and other unsaturated fats over saturated fats (found largely in meat and dairy) and trans fats (found in some processed foods, like crackers, cookies and chips).\nOlive oil is one part of the Mediterranean diet that has been tied to heart benefits.\nOlive oil is a key ingredient in the so-called Mediterranean diet.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nHigh olive oil intake is also linked to a lower risk of heart attack, and a longer lifespan among heart attack survivors.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of stroke in the story.", "answer": 1}, {"article": "But investors had been anticipating a bigger effect.\nLilly is conducting a similar large study to try and prove the heart benefits of its once-weekly GLP-1 drug Trulicity.\nBecause about half of deaths in people with diabetes are caused by heart disease, reducing heart risk is considered essential to their care.\nDeaths from heart disease were 22 percent lower in the Victoza group.\nVictoza is only the second diabetes drug to show such heart benefits, after Eli Lilly (LLY.N) and Boehringer Ingelheim\u2019s pill Jardiance.\n", "question": "Does the story commit disease-mongering?", "explanation": "Type II diabetes is a major public health problem and, as the story mentions, patients frequently die of heart disease. No disease-mongering here.", "answer": 1}, {"article": "But in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nMay 23, 2011 -- Researchers in Europe say a fermented dairy product containing a specific bacterium known as a probiotic did not relieve constipation in children more than a dairy product without a probiotic.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\n", "question": "Does the story commit disease-mongering?", "explanation": "We\u2019re going to rule this one unsatisfactory.\nThe story explains that the study looked at kids \u201cwith constipation for at least two months with a defecation rate of less than three times per week.\u201d\u00a0 Is that the definition of constipation?\u00a0 If not, what is it?\nInstead, the story floats a scary statistic without giving a source \u2013 \u201cdespite intensive medical and behavioral therapy, 30% of patients who develop constipation before the age of 5 continue to have severe complaints.\u201d\nThat sounds like 30% of ALL kids <5 who get constipation even though clearly there is a spectrum of problems from milder to more frequent and bothersome \u2013 something the story never clarifies.\u00a0 That\u2019s disease-mongering. Even the published research paper listed as a possible limitation that \u201cthis study was conducted in secondary and tertiary centers, which have attracted more severely constipated children.\u201d\n The story explains that \u201cconstipation in children differs considerably from that in constipated adults with regard to its prevalence, onset, etiology, symptoms, treatment, and prognosis.\u201d\u00a0 But it doesn\u2019t clarify what the differences are.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. Instead, the story provides appropriate caveats that not everyone is a suitable candidate for eye surgery.\u00a0 Eye surgeons, ophthalmology researchers and patients interviewed elaborate on this point by providing clear information about laser eye surgery and noting some of the pros and cons.\u00a0 ", "answer": 1}, {"article": "What would that look / sound / smell like?\nProfessor Jackie Andrade, Professor in Psychology at the University of Plymouth, is one of the co-creators of FIT, and she explains: \"FIT is based on two decades of research showing that mental imagery is more strongly emotionally charged than other types of thought.\nLed by Dr Linda Solbrig from the School of Psychology, the research involved 141 participants, who were allocated either to FIT or Motivational Interviewing (MI) - a technique that sees a counsellor support someone to develop, highlight and verbalise their need or motivation for change, and their reasons for wanting to change.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nThe full study, entitled Functional Imagery Training versus Motivational Interviewing for Weight Loss: A randomised controlled trial of brief individual interventions for overweight and obesity is available to view in the International Journal of Obesity (doi: 10.1038/s41366-018-0122-1).\n", "question": "Does the news release commit disease-mongering?", "explanation": "Weight loss is not inherently good. The release refers, once, to study participants as being \u201coverweight,\u201d but it\u2019s not clear what they mean. Are these people who could stand to lose a pound or two? Or are they morbidly obese? It is possible to be both healthy and \u201coverweight,\u201d depending on how you define those terms. In the paper, they define \u201coverweight\u201d as having a body mass index (BMI) of greater than or equal to 25. Having a BMI of 25 puts you exactly on the borderline between \u201cnormal\u201d and \u201coverweight\u201d \u2014 and the BMI itself is a very incomplete means of measuring an individual\u2019s body fat and assessing health.", "answer": 0}, {"article": "But the results do merit further research.\nA preliminary study shows salsalate reduced blood sugar levels and helped with glycemic control at a variety of doses in people with type 2 diabetes.\nSalsalate contains the same active ingredient as aspirin but is associated with fewer side effects.\nHowever, it also has been shown to increase protein in the urine and its long-term safety will need further investigation.\nThe results showed those who took salsalate at each of the dosage levels experienced a beneficial decrease in blood sugar A1c levels of 0.5% or more.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable because the story didn\u2019t really give any detail about incidence or serousness of diabetes. ", "answer": 2}, {"article": "Meanwhile, another researcher suggested that exercise might help stave off nocturia.\nBut the lower doses used in this study (1.5 or 0.75 mcg) \"may help to improve the overall safety profile, particularly for geriatric patients,\" he said.\n\"Nocturia is very common in patients over 50 years old, and can cause significant problems by causing loss of sleep, and injury due to falls,\" said study lead author Dr. Jed Kaminetsky.\nThe researchers also found that those in the higher-dose spray group experienced a \"significant improvement\" in overall quality of life, compared with the untreated group.\nSUNDAY, May 8, 2016 (HealthDay News) -- Countless people -- often men with enlarged prostates -- need to visit the bathroom during the night.\n", "question": "Does the story commit disease-mongering?", "explanation": "Nocturia can impact quality of life, and increase the risk of falls among older adults, which can be devastating. So this story doesn\u2019t disease monger, but we wished it had made the point that the majority of people getting up twice a night (very mild nocturia) likely do not need to take a medication and are not suffering from terribly disturbed sleep nor have an increased risk of falling.", "answer": 1}, {"article": "\u201cBut there were other components to it -- there was oppositional defiant disorder, there were some [autism] spectrum-like behaviors, and difficulty later on socializing with other children.\u201d\n\nOppositional defiant disorder is one of the most common conditions linked to ADHD in children and is characterized by anger, tantrums, opposition to authority and, sometimes, aggressive behavior.\n\u201cWhat thinking really is is really coordinating different networks in the brain so that we can bring all of those networks together at one time,\u201d Melillo told FoxNews.com.\nShe has since gone on to complete two more cycles of Brain Balance learning and no longer takes medication to manage her condition.\nParents are a big part of the learning experience and are tasked with at-home exercises to do with their kids.\nThe spectrum of ADHD and related disorders is broad, and there is no one-size-fits-all treatment.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Fast food outlets should hand out free cholesterol-lowering statin drugs to their customers to \u201cneutralize\u201d the heart risks of eating fatty foods like burgers and fries, British scientists suggested on Thursday.\nIn the U.S., all statins are only available by prescription.\n\u201cComplimentary statin packets are prone to ... give Quarter Pounder consumers a sense of false security,\u201d he told Reuters Health by email.\n\u201cStatins don\u2019t cut out all of the unhealthy effects of a burger and fries.\nIt\u2019s better to avoid fatty food altogether.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story.", "answer": 1}, {"article": "SATURDAY, Sept. 29, 2012 (HealthDay News) -- Researchers say they've discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma.\nAmong patients receiving the combination treatment, the development of side effects such as skin rash and a less dangerous type of skin cancer called squamous cell carcinoma was similar to that typically seen in patients taking only one of the drugs.\nMelanoma is the most serious, and often deadly, form of skin cancer.\nAfter one year of treatment, 41 percent of patients receiving the full-dose combination treatment had no progression of their melanoma, compared with 9 percent of those receiving dabrafenib alone.\nThe study was scheduled for presentation Saturday at the European Society for Medical Oncology meeting in Vienna and simultaneous publication in the New England Journal of Medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story notes that the treatment applies only to patients with a specific mutation that can be targeted by the drug.", "answer": 1}, {"article": "Study author Dr. Kang Zhang, the chief of ophthalmic genetics at UC San Diego's Shiley Eye Institute, told CBS News, \"Unlike [the] current way of cataract surgery, which destroys over half of lens stem cells and requires implantation of a plastic intranet ocular lens, we devised a new surgery to make a very small opening at the side of a cataractous lens bag, remove [the] cataract inside, allow the opening to heal, and promote dormant lens stem cells to regrow an entirely new lens with vision.\"\nThe new procedure described in Nature involves making a slim incision at the side of the lens capsule, removing the entire lens, yet preserving the empty capsule bag or \"scaffold.\"\n\"I would anticipate that it may be available after several independent studies with a large number of patients,\" he said.\nA certain kind of stem cell, called endogenous stem/progenitor cells, when left intact, then begins to repopulate the damaged lens and essentially grow a new, healthy lens.\nMany children also later go on to suffer from glaucoma.\n", "question": "Does the story commit disease-mongering?", "explanation": "No, this story did not cross over into disease-mongering. It did a good job of explaining why it\u2019s important to treat congenital cataracts.", "answer": 1}, {"article": "Working with Borges's Young Women's Breast Cancer Translational Program at CU Cancer Center, young investigator Elena Shagisultanova, MD, PhD, recently earned a $1.4m competitive ASPIRE grant from Pfizer, Inc., to conduct a clinical trial exploring the use of tucatinib against so-called \"triple positive\" breast cancer - those cancers driven by both estrogen and progesterone receptors and the HER2/neu oncogene.\nThe fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against brain metastases of the disease.\nThere are women who are alive today because of this drug,\" says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women's Breast Cancer Translational Program at the University of Colorado Cancer Center.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nThe drug works by targeting the HER2 \"tyrosine kinase\" - a link in the chain of communication that allows HER2 receptors to signal the growth of the cell.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not commit disease mongering, but it also provides no information about what percentage of breast cancers are of the HER2+ variety. (According to the Mayo Clinic website, about 20% of breast cancers have the HER2+ gene mutation, which makes them more aggressive.) Thus, a na\u00efve reader might be inclined to think that the drug would benefit a larger percentage of breast cancer patients than is likely to be the case.\nWe won\u2019t give credit or dock points in this case; we\u2019ll rate it Not Applicable. ", "answer": 2}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nLooking back, the experience was even better than I was expecting, and I hope to see nanoparticle therapy advance into an option for anyone diagnosed with prostate cancer in the future.\u201d\n\nThe gold nanoparticles were invented by Naomi Halas, the head of Rice University\u2019s Laboratory for Nanophotonics.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\n\u201cThis therapy could be life-changing for men diagnosed with prostate cancer and I\u2019m honored to be among the first doctors the U.S. Food and Drug Administration approved to put it to the test,\u201d said Steven Canfield, M.D., chair of the division of urology at McGovern Medical School at UTHealth, who recognized the possibility of the nanoparticles to treat prostate cancer and helped developed the trial to test the theory.\nThe shells seek out and saturate cancerous cells, and their advanced vibrational properties are then harnessed to cause the tumorous tissue to pulse with extreme temperature when light is applied through a laser specifically designed to excite the particles.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease-mongering. Prostate cancer can be fatal for some men and this release does not exaggerate the dangers of prostate cancer, even though the release appears to downplay the concept of active surveillance which is a suitable option for many men.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "This story did not engage in disease mongering.", "answer": 1}, {"article": "Dong, an expert in vitamin D and a professor in the MCG Department of Population Health Sciences, says about 15 minutes daily in the \"young\" sun - between 10 a.m. and 2 p.m. - but before your skin starts to get pink, is the best source of vitamin D.\n\nFoods like milk, milk products like cheese and yogurt, fatty fish like mackerel and sardines, some greens like kale and collards and fortified cereals also are good sources.\nThe researchers say a vitamin D supplement is an inexpensive and safe option for most of us.\nWhile heart disease is the leading cause of death in the United States, according to the Centers for Disease Control and Prevention, blacks have higher rates of cardiovascular disease and death than whites and the disease tends to occur earlier in life.\n\"When your arteries are more stiff, you have higher pulse wave velocity, which increases your risk of cardiometabolic disease in the future,\" says Raed.\nRigid artery walls are an independent predictor of cardiovascular- related disease and death and vitamin D deficiency appears to be a contributor, says Dr. Yanbin Dong, geneticist and cardiologist at the Georgia Prevention Institute at the Medical College of Georgia at Augusta University.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not hype the dangers of vitamin D deficiency or even heart disease in general, mentioning once and low in the release that heart disease is the leading cause of death in the U.S.", "answer": 1}, {"article": "\"Oh absolutely,\" she said.\nBut this study - the most definitive so far - may encourage more doctors to consider ultrasound, which is easier and less expensive.\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\n\"This could have gone on for years before anybody found it, and it could have been a whole different story,\" she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disase mongering.\u00a0 The focus of the broadcast a review of a peer-reviewed JAMA paper showing ultrasound in addition to\u00a0 mammography may find more early-stage cancers in women with dense breast tissue.\u00a0 The story appropriately mentions the population at higher-risk, and why traditional screening methods may miss early-stage cancer in these women.", "answer": 1}, {"article": "The paper\u2019s authors, in addition to Small, are Prabha Siddarth, Dr. Zhaoping Li, Karen Miller, Linda Ercoli, Natacha Emerson, Jacqueline Martinez, Koon-Pong Wong, Jie Liu, Dr. David Merrill, Dr. Stephen Chen, Susanne Henning, Nagichettiar Satyamurthy, Sung-Cheng Huang, Dr. David Heber and Jorge Barrio, all of UCLA.\nThe amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nParticipants were randomly assigned to receive either a placebo or 90 milligrams of curcumin twice daily for 18 months.\nThat study will include some people with mild depression so the scientists can explore whether curcumin also has antidepressant effects.\nThe researchers plan to conduct a follow-up study with a larger number of people.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release.", "answer": 1}, {"article": "He was fascinated by certain powerful cells of the immune system \u2014 T cells.\nshe told her doctor.\nAllison repeated the experiment with more mice over his winter break.\nHe thought they would jump at the chance to try a new approach.\n\"I got very depressed,\" Allison says.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Researchers then narrowed their analysis to see how the urine test scores matched the men\u2019s Gleason score, which helps doctors gauge how aggressive a cancer may be.\nThe two tests together appeared to generate both sensitive and specific results.\nThose scores were then compared to the biopsy results.\nBased on the levels of PCA3 and TMPRSS2:ERG detected, the men were given numerical scores that were classified as being high, medium, or low.\n\u201cThe men in the highest group have a risk of cancer on biopsy of about 70% and those in the lowest group have a risk of cancer of about 20%,\u201d says Tomlins.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "For more information: http://www.\nWhile the medication remains the single most effective agent in the management of PD symptoms, long-term use causes its own side effects, among them abnormal involuntary movements or AIMS.\nCitation: The combination of lithium and L-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: relevance for Parkinson's disease therapy.\nBased in Novato, CA, The Buck is dedicated to extending \"Healthspan\", the healthy years of human life and does so utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases.\nHowever, this study provides additional evidence on top of prior work from Dr. Andersen's lab and others that lithium may have therapeutic potential in PD, which is a hypothesis that should be tested in clinical trials,\" he said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release notes that Parkinson\u2019s disease is diagnosed in 60,000 new people each year, a figure which is supported by the NIH. It would have been helpful to state one\u2019s lifetime risk of developing the disease, to help put this number in context.", "answer": 1}, {"article": "To me, it was monumental.\"\n\"Both guys were taking steps the first time we turned the systems on,\" said Ron Triolo, a professor of orthopaedics and biomedical engineering at Case Western Reserve and executive director of the Advanced Platform Technology (APT) Center.\n\"In both cases, there is a disconnect between the brain and muscles,\" said Stephen Selkirk, MD, a neurologist at the VA's Spinal Cord Injury Division and assistant professor of neurology at Case Western Reserve School of Medicine.\nThe pulses stimulate the nerves, which in turn stimulate the muscles in both of Bush's legs and McGlynn's left leg.\n\"I went in there and I could barely take two steps,\" said Bush, 42, who researchers believe is the world's first MS patient to \"test-drive\" an implanted FES system.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It does provide some perspective, stating that a \u201csubstantial\u201d number of people could stand to benefit from this technology. It further states:\n\u201cThe National Multiple Sclerosis Society estimates that more than 2.3 million people have the disease worldwide. Surveys have found that 93 percent suffer gait impairment within 10 years of diagnosis and 13 percent report they are unable to walk twice a week. Other research has found that 6 million to 7 million people live with stroke nationally and nearly 30 percent require assistance to walk.\u201d", "answer": 1}, {"article": "CHICAGO -- Acupuncture gets a thumbs-up for helping relieve pain from chronic headaches, backaches and arthritis in a review of more than two dozen studies -- the latest analysis of an often-studied therapy that has as many fans as critics.\nDeciding specifics is being left up to the states.\nAcupuncture's use has become more mainstream.\nSome believe its only powers are a psychological, placebo effect.\nSeveral weekly sessions are usually involved, typically costing about $60 to $100 per session.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering of diseases here.", "answer": 1}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story commit disease-mongering?", "explanation": "The story engaged in subtle disease mongering because in its discussion of the use for this new product to treat \u2018blocked blood vessels\u2019 it failed to acknowlege that in fact, national guidelines don\u2019t recommend the use of stents to treat all\u00a0blocked coronary arteries, only those through which flow is occluded 70% or more.", "answer": 0}, {"article": "A controller the size of a cellphone enables her to set her Esteem to different environments, such as \"home,\" \"restaurant\" or \"school.\"\n\"This really fills a need for adults with moderate to severe sensorineural hearing loss,\" Marzo said.\n\"When I wore a hearing aid, I turned it off when I got home because all the background noise was so agitating,\" said Merlo, 40.\nIt contains a battery that must be replaced in about seven years.\n\"There are little things that I probably heard when I was younger, before my hearing loss, but I don't remember them,\" she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not provide much information on the conditions leading to damage to the inner ear, or to nerves from the inner ear to the brain. More background and context on these disorders would have been welcome in this case.", "answer": 1}, {"article": "The study appears in the September issue of the journal PLoS Medicine.\n\"It would certainly be premature to suggest taking statins to prevent rheumatoid arthritis ,\" he tells WebMD.\nThe analysis revealed that patients who took statins for at least eight years during the decade-long study period were roughly 40% less likely to develop rheumatoid arthritis than people who did not take statins at all or who took them less persistently.\nThere is also a suggestion that statins reduce systemic inflammation and may be protective against RA and other chronic inflammatory diseases.\nThe most widely prescribed class of drugs in the world, statins such as Crestor, Lescol, Lipitor, Pravachol, and Zocor reduce cholesterol in the blood by blocking an enzyme in the liver associated with its production.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThis story does not engage in disease-mongering. At the same time, it fails to mention the prevalence or seriousness of rheumatoid arthritis. The American College of Rheumatology estimates the prevalence of RA between 2 and 10.7 per 1000 adults. While relatively uncommon, RA can be a devastating chronic illness. It would have been helpful to provide some information on prevalence in the story.", "answer": 1}, {"article": "In a study presented Tuesday at the American Chemical Society's spring national meeting in San Diego, 16 overweight young adults took, by turns, a low dose of green coffee bean extract, a high dose of the supplement, and a placebo.\nIn the meantime, he said, consuming an extract that contains both good and bad chemicals in dense concentration seems an unwise thing to do.\nIn fact, it is already available as a naturopathic medicine and antioxidant.\nWhen roasted at 475 degrees, coffee beans are sometimes described as rich and full-bodied.\nSubjects did not change their calorie intake over the course of the trial.\n", "question": "Does the story commit disease-mongering?", "explanation": "Since we weren\u2019t told anything about the weight of the people being studied, we can\u2019t make any judgment about disease-mongering.", "answer": 2}, {"article": "WASHINGTON (Reuters) - Viagra, developed to help ailing hearts long before it got a more high-profile job fighting erectile dysfunction, might help treat heart symptoms of muscular dystrophy, researchers reported on Monday.\nDuchenne muscular dystrophy affects an estimated one in 3,500 males, according to the National Institutes of Health.\nPatients with DMD lack expression of the protein dystrophin as a result of mutations in the X-linked dystrophin gene,\u201d the researchers wrote.\n\u201cDuchenne muscular dystrophy (DMD) is a progressive and fatal genetic disorder of muscle degeneration.\nMany patients die of heart failure and most patients with the condition die before age 40.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story points out that Duchenne muscular dystrophy affects about one in 3,500 males.", "answer": 1}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering.", "answer": 1}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nIn the year after a heart attack, about 12% of people have a second heart attack or stroke.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering.", "answer": 1}, {"article": "We are very interested in clarifying the best ways to prevent these infections, reducing the burden on the patients, on their infants and on the health-care system as a whole.\u201d\n\nAn estimated 1.3 million women in the U.S. delivered their babies by C-section in 2013, with surgical-site infections complicating 5 to 12 percent of those deliveries.\nNew England Journal of Medicine.\nThere are few circumstances when a single study should change our practice.\nThe average cost of treating those cesarean-related infections in the hospital is $3,500 and may be much higher for severe infections.\nFeb. 4, 2016.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease mongering here.", "answer": 1}, {"article": "Benign prostate hyperplasia, also known as enlarged prostate, is a non-cancerous condition familiar to millions of aging males.\nMeanwhile, there is no size limitation for PAE, which requires only local anesthesia and also lowers the risk of other side effects, such as blood loss and retrograde ejaculation, which occurs when semen leaks into the bladder, researchers said.\nHowever, the authors did not see as great an improvement in \"urodynamic\" results, such as improved flow rate of the urine, which would indicate how well the bladder and urethra are performing; in this area, the patients did not improve as much as those who underwent TURP surgery, they noted.\nThe treatment -- called prostatic artery embolization, or PAE -- is ready to be used in certain patients, namely those with a prostate larger than 60 cubic centimeters, \"with severe lower urinary tract symptoms and a weakened urinary stream,\" said Dr. Joao Martins Pisco, lead author of a study slated to be presented March 29 at the annual meeting of the Society of Interventional Radiology in Chicago.\nDrugs are used to treat most patients with an enlarged prostate, with only about 10 percent qualifying for surgery to remove the entire gland, said Dr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York City.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease-mongering. \u00a0It would have been helpful to know that BPH rarely causes problems that require medical attention, though it can result in symptoms that are bothersome for some men.", "answer": 1}, {"article": "The prostate study sought a better way to use PSA tests, which are troublesome because PSA can be high for many reasons besides cancer, and doctors don't know which cancers need treatment or whether screening saves lives.\nThis thing documents it,\" Brawley said.\nHPV tests cost $80 to $100 compared to $20 to $40 for Paps.\nCervical cancer is easy to prevent.\nFew of the Swedish men were treated for prostate cancer as most men are today, which can affect survival.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "THURSDAY, May 24, 2018 (HealthDay News) -- Because vertigo can have many causes, treating it can be difficult, but researchers have identified a new type that may be effectively treated with medication.\nThe researchers noticed that uncontrolled eye movements, called nystagmus, lasted longer in people with this new form of vertigo.\nThose with the new form of vertigo were also more likely to have severe motion sickness than those with other forms of the condition, the study showed.\nOthers had them two to three times a week.\nThey then moved each patient's head forward and shook it from side to side for about 15 seconds.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no pathophysiological or biological basis for\u00a0the\u00a0disease and only the vaguest of information about the disease as being defined simply by an abnormal test. The story should have provided some counter-balance to this viewpoint \u2014 is it really a new diagnosis?", "answer": 0}, {"article": "Strengthening gamma oscillations appeared to switch the microglia back into a productive state.\nDavid Reynolds, chief scientific officer at Alzheimer\u2019s Research UK, said: \u201cIt is conceivable that changing brain cell rhythms could be a future target for therapies, but researchers will need to explore how light flickering approaches could not only reduce amyloid in the visual area of the brain but in those areas more commonly affected in Alzheimer\u2019s.\u201d\n\nThe authors suggest that it may be possible to take a multi-sensory approach, using a combination of flashing lights and vibrating chairs.\nEd Mann, an associate professor of neuroscience at the University of Oxford, said: \u201cI was surprised, and it\u2019s exciting, that such a simple stimulus can target a molecular pathway and have such an effect in an hour.\u201d\n\nQuestions remain, however, about whether boosting gamma oscillations and sweeping amyloid plaques out of the visual brain region would help with memory, which is centred in the hippocampus, or broader cognitive abilities.\n\u201cIf humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so non-invasive, and it\u2019s so accessible,\u201d said Li-Huei Tsai, director of the Picower Institute for Learning and Memory at MIT, and the paper\u2019s senior author.\nThe study, in mice, found that exposure to flickering light stimulated brain waves, called gamma oscillations, that are known to be disturbed in Alzheimer\u2019s patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "The study does not engage in disease mongering. It would be hard to overstate the tragedy of Alzheimer\u2019s disease. We\u2019re a little disappointed that the article closes by conflating dementia with Alzheimer\u2019s, when it tells readers that dementia has passed heart disease as the second leading cause of death in Britain.", "answer": 1}, {"article": "Newswise \u2014 Women who need breast surgery to remove an abnormality that cannot be felt, also known as a non-palpable breast lesion, now may benefit from the convenience and comfort provided by an advanced new tissue locating technology offered at Rush University Medical Center.\nThat advantage may lead to less tissue needing to be removed and a better appearance of the breast after surgery.\nThe reflector replaces the widespread current practice of inserting a thin, hooked wire into the breast the same day as surgery.\nThe wire is placed into the breast to help guide the surgeon in removing the abnormality later that day.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering.", "answer": 1}, {"article": "Hamilton, ON August 11, 2016 - A study led by McMaster University researchers has found that, contrary to recent reports, flu nasal sprays provide similar protection against influenza as standard flu shots.\nPublished today in the scientific journal Annals of Internal Medicine, the study shows that the nose spray had a similar effect to the standard flu shot.\nOur study challenges previous studies because our results show conclusively that the vaccines show similar protection when both direct and indirect effects are taken into account.\"\nPrevious recommendations from the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) had previously called for nasal sprays, or live attenuated influenza vaccine (LAIV), not be used during the 2016-2017 flu season.\nThen, subsequently, it was no longer preferred and now not recommended at all.\n", "question": "Does the news release commit disease-mongering?", "explanation": "While media attention is routinely heightened leading up to and during flu season, this release does not appear to reach the level of disease mongering.", "answer": 1}, {"article": "The HSRx product demonstrated superior treatment performance throughout the entire clinical study.\n\"Acne is among the 10 most prevalent human infectious diseases and recent studies show it has a significant long-term psychological impact on many of the 80+% of teenagers and young adults who suffer from it,\" he added.\nAfter 48 hours, the percentage of subjects with unsightly acne-associated redness was reduced nearly three times as much with HSRx 2121 as with the competing product.\nAt 24 hours, the percentage reduction in total acne count with HSRx 2121 was 20 times greater than it was for subjects using the competing product.\n\"Acne is a universal plague,\" said Frank Parise, HSRx Group Chief Financial Officer, citing a recent NASA warning that even the International Space Station harbors germs that can cause the disease.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is a fair amount of fear mongering here. The release calls acne \u201ca universal plague\u201d, \u201cunsightly\u201d and even cites a NASA \u201cwarning\u201d about acne bacteria living on the International Space Station! (The release links, by the way, to a story in the UK Daily Mirror \u2014 not exactly a credible news source.) For the record, NASA itself never produced a \u201cwarning\u201d as stated in the release. Its scientists merely described all kinds of organisms found on the ISS which, not surprisingly, include bacteria that live on human bodies (http://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-015-0116-3).\nThe release also refers to acne as \u201camong the 10 most prevalent human infectious diseases\u201d as if it were some deadly virus or bacteria. Though bacteria does play a role in acne, it is, in fact, better known as an inflammatory condition and bacteria is but one pathophysiological mechanism responsible for it.", "answer": 0}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in the story. ", "answer": 1}, {"article": "Total hip replacement surgery is increasingly common, with more than 300,000 procedures done every year in the U.S.\n\"The people who are against the whole idea for same-day discharge for hip replacement are concerned about the very rare instances where somebody could develop a blood clot that goes to the lung, or a fracture of some sort,\" said Davidovitch.\nThere are two common surgical approaches for a total hip replacement: anterior, which involves entering surgically through the front of the hip, and posterior, or entering surgically through the side or buttocks.\nBut it's not the surgical approach alone that allows some of his patients to go home the same day -- it's a combination of what happens before, during and after surgery.\n\"While I recognize there is no place like home, should there be the need for urgent or medical care the question is will that be available to the patient when they're in the setting of their own home,\" Padgett said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the extent of hip problems or the relevance of replacement surgery to people with chronic hip pain.\nThis\u00a0does appear to target younger, healthier people, and surgery for them comes with special considerations\u2013a hip replacement has a 20 to 25 year life span, less when put into a more physically active person. So, younger people may face a second procedure at an older age. When deciding on the timing of the first procedure, this should be considered since second surgeries are more involved and higher risk.", "answer": 1}, {"article": "Soy may keep breast cancer from coming back\n\u201cThere are probably 30,000 people in the U.S. who never smoked and who have lung cancer.\u201d\n\nLung cancer kills 160,000 Americans a year.\nFor the study, Gong Yang and colleagues at Vanderbilt University Medical Center, Shanghai Cancer Institute, and the National Cancer Institute looked at data from a large study of Chinese women called the Shanghai Women\u2019s Health Study.\nThe findings, published in the Journal of Clinical Oncology, lends support to the idea that adding soy foods to the diet can help people in multiple ways, says Dr. Jyoti Patel, a lung cancer specialist at Northwestern University in Chicago, who was not involved in the study.\n\u201cAlthough the risks are probably different for American women for developing lung cancer, I do think it is a call to action for more research about how we develop lung cancer,\u201d Patel said.\n", "question": "Does the story commit disease-mongering?", "explanation": "This was a tricky call. The story calls lung cancer \u201cthe No. 1 cancer killer across the world,\u201d and gives various lung cancer statistics\u00a0describing a huge toll\u00a0in the United States. The story qualifies these statements by noting that the Chinese women in this study were overwhelmingly non-smokers, and that lung cancer in non-smokers is probably a different disease than in smokers. But it never completely\u00a0closes the loop on what this all means for\u00a0women in the USA and other Western countries who are trying to make sense of these findings.\u00a0Smoking accounts for some 87% of lung cancer deaths in the\u00a0USA, according to the American Cancer Society, and the rate of lung cancer in\u00a0nonsmoking women is much lower in the USA than it is in China. The upshot is that the findings probably have much less relevance\u00a0for women in USA than they do for Chinese women. The story should\u00a0have stated this more clearly.", "answer": 0}, {"article": "The last update, in 2005, put more emphasis on chest pushes by alternating 30 presses with two quick breaths; those \"unable or unwilling\" to do the breaths could do presses alone.\nThe CPR guidelines had been inching toward compression-only.\nBut less than a third of victims get this essential help.\nOn Sunday, he visited Goodall in the hospital where he is recovering from triple bypass surgery.\nHands-only will be added to CPR training.\n", "question": "Does the story commit disease-mongering?", "explanation": "The segment does nothing to exaggerate the frequency or severity of sudden cardiac arrest. ", "answer": 1}, {"article": "The nitrate-free beetroot juice was the basis of the placebo group.\nTo put the importance of these findings in context: The authors note that large-scale observational studies show that for every 2 mmHg increase in blood pressure, the risk of death from heart disease goes up 7 percent and the risk of stroke by 10 percent.\nCommenting on the findings, Prof. Ahluwalia says:\n\nShe says that one reason the findings are exciting is that they open up the potential for people with high blood pressure to increase dietary nitrate in a way that can be easily worked into their daily lives while still providing a positive benefit.\nAccording to the Centers for Disease Control and Prevention (CDC), high blood pressure is either the primary cause of or contributes to more than 1,000 deaths in the United States every day.\nBeetroot contains high levels of dietary nitrate (NO3), which the body converts into biologically active nitrite (NO2) and nitric oxide (NO).\n", "question": "Does the story commit disease-mongering?", "explanation": "High blood pressure is common, and lowering blood pressure may decrease future risk of stroke and heart attack. But we do question this story\u2019s suggestion that a mere 8/4 mmHg reduction could make someone\u2019s blood pressure levels \u201cnormal\u201d or that these participants\u2019 blood pressure was \u201cnot controlled\u201d at the higher level. We\u2019ll give the benefit of the doubt, but medicalizing blood pressure levels that fall slightly outside a somewhat arbitrary \u201cnormal\u201d range raises disease-mongering concerns.", "answer": 1}, {"article": "Autism has always been a tricky disorder to diagnose.\nThe images of the children in the study -- MRIs of the brain -- were taken at 12 to 29 months while their language was assessed one to two years later at 30 to 48 months.\nThe spectrum is wide and some are destined to be on the mild end and be very talkative, sometimes almost indistinguishable from those without the disorder in some settings, while others will suffer from a more severe form and have trouble being able to speak basic words.\n\"Why some toddlers with ASD get better and develop good language and others do not has been a mystery that is of the utmost importance to solve,\" Eric Courchesne, one of the study\u2019s authors and co-director of the University of California-San Diego's Autism Center, said in a statement.\nThere\u2019s no such thing as a blood test, cheek swab or other accepted biological marker so specialists must depend on parent and teacher reports, observations and play assessments.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article skirts the line when it talks about the \u201csoaring\u201d rates of autism diagnosis, which has reached 1 in 68 children. But it does provide some context to that number when it says, \u201cThe spectrum is wide and some are destined to be on the mild end and be very talkative, sometimes almost indistinguishable from those without the disorder in some settings, while others will suffer from a more severe form and have trouble being able to speak basic words.\u201d", "answer": 1}, {"article": "In their study, Singh and his colleagues identified nearly 5,000 individuals aged 50 to 80 who had been diagnosed with the cancer between 1992 and 2008, across the entire Canadian province of Manitoba.\n\u201cTherefore, it is important to study the factors associated with the diagnosis of colon cancer occurring after colonoscopy.\u201d\n\nDuring a colonoscopy, a flexible camera is passed through the colon in search of abnormal growths known as polyps and other warning signs of early tumors.\nIt is one of a few screening tests for colon cancer, the second-leading cancer killer in the U.S., according the Centers for Disease Control and Prevention.\n\u201cTo increase their chances of an early diagnosis, it is important that all individuals undergoing colonoscopy strictly follow the instructions for bowel preparation for colonoscopy,\u201d added Singh, speaking of the large amounts of special drinks consumed before the test to clean out the bowel.\nThe US Preventive Services Task Force, an independent panel of medical experts appointed by the federal government, recommends screening people aged 50 to 75 for the disease, but does not specify which test is best.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. Some mention of how often people live with polyps that don\u2019t become cancer or that, in the later stages of life, don\u2019t merit the risk of a procedure.", "answer": 1}, {"article": "We need to look at dietary patterns rather than individual nutrients or individual food components.\u201d\n\nWhether the association will change its advice about consuming linoleic acid isn\u2019t clear yet, but Ramsden says the results of the latest study \u201ccould have important implications\u201d for the way people eat if they want to stay heart-healthy.\n\u201cWhat happened is that in the 1960s all polyunsaturated fats were considered the same.\n\u201cOne of the things we learned is that we need to look at the whole picture,\u201d says Lichtenstein.\n\u201cI wouldn\u2019t necessarily say that the [current advice] is necessarily completely wrong,\u201d he says.\nThe other half were not told to change their diet in any way.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease-mongering.", "answer": 1}, {"article": "For participants with more severe vision loss (20/50 or worse), aflibercept improved vision on average nearly four lines, bevacizumab about 2.5 lines, and ranibizumab almost three lines.\nThose with mild vision loss (20/32 to 20/40) at baseline in all three treatment groups gained on average almost two lines on an eye chart.\nOne year after starting treatment, all participants had improved vision.\nOver the past few years, drugs that target VEGF have become a standard treatment for DME, providing a preferred alternative or adjunct to laser treatment.\nIn light of these positive results, \u201cit is more important than ever for patients with diabetes to be evaluated on a regular basis for eye disease and receive treatment promptly once indicated as we now have excellent success in treating patients with DME,\u201d says Dr. Aiello.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Vision problems associated with diabetes are well known. There is no disease mongering in this story.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to engage in disease mongering. ", "answer": 1}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\nEven though the study\u2019s participants were not told whether they were assigned active or placebo treatment, one limitation of the experiment is that participants often stopped placebo treatments before the recommended 20-minute course of stimulation was done, the authors note in Neurology.\nMost of them were female, and more than half of them reported experiencing what\u2019s known as aura\n\nOverall, participants had a total of 299 migraines during the study period.\nThe study involved 71 people with episodic migraines who had two to eight attacks a month and had not taken drugs to prevent the episodes for at least two months.\n\u201cWe worked on stimulation at a far away location, which makes the treatment more convenient and more discrete so people can use it even during working hours without anyone noticing,\u201d Yarnitsky added by email.\n", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t find any disagreeable or fear-stoking language. The story would have been stronger if it had also discussed the prevalence of migraine sufferers\u00a0in the general population.", "answer": 1}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story commit disease-mongering?", "explanation": "The story does avoid disease-mongering by presenting the new test as a useful and practical advancement without making any heart-wrenching claims about any of the disorders a child may inherit. In our view, this is a shortcoming. How many children are born each year with genetic diseases? That would be telling information, but the story does not provide it. We do get a different statistic \u2013 that approximately 20 percent to 30 percent of infant deaths are due to genetic diseases. This is interesting, and worth including, but it gets at only a part of the picture.", "answer": 1}, {"article": "The theoretical -- but still unproven -- advantage to this new IUD method, Poynor said, is that \"there is a lower risk of systemic side effects .\nAlthough the IUD is not yet approved to treat endometrial cancer, it is approved and widely used to treat endometriosis and abnormal uterine bleeding.\nIn background material, the researchers stated the progestin-releasing IUD should be effective in treating AEH and also early endometrial cancer, as long as those patients were evaluated with laparoscopy, ultrasound and MRI to make sure their cancer had not spread and there was no simultaneous ovarian cancer.\n(The disease progressed in one of the women with AEH and four of the women with early-stage cancer.)\nAbout 3 percent to 5 percent of women who get endometrial cancer, which affects the womb lining, are under the age of 40 and will lose their fertility if they undergo a hysterectomy.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of uterine cancer and is clear to point out that this treatment is only appropriate for a small subset of cases.", "answer": 1}, {"article": "For more information, recipes and facts about pasta, please visit http://www.\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\nThe study examined associations between pasta consumption, shortfall nutrient intakes as defined by the 2015 Dietary Guidelines (2015 DG) and diet quality in comparison to non-pasta consumption in U.S. children and adolescents (ages 2-18).\nThe association provides leadership to the industry on public policy issues, serving as its voice in Washington, D.C. NPA also forges alliances with key organizations, monitors and addresses technical issues and conducts nutrition and food safety research on behalf of the U.S. pasta industry.\nThey are:\n\n-Better overall diet quality (as measured by USDA's Healthy Eating Index-2010 scale) -Greater intake of key shortfall nutrients like dietary fiber, folate, iron, magnesium and vitamin E -No significant associations were seen with body weight, waist circumference and body mass index\n\nPasta has long been celebrated as one of America's favorite foods and is advocated by nutritionists for its good nutrition.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. While the release named some nutrients that the USDA deems are in \u201cshortfall\u201d in American diets, we would have liked the release to provide more context about what nutrient mix is considered ideal for children, which is a complicated picture.", "answer": 1}, {"article": "Related Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nPatients who had lumpectomy plus radiation had more local recurrences than the mastectomy patients but had fewer deaths.\nWhy The Research Is Interesting: Patients with DCIS are often treated with radiation after lumpectomy, although it has remained unclear whether this can reduce the risk of dying from breast cancer.\nResearchers were not intervening for purposes of the study and cannot control all the natural differences that could explain the study findings.\nEvery article is free online from the day of publication.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering. The release provides context on the prevalence of DCIS in the U.S.", "answer": 1}, {"article": "Blocking the triggers through the use of a specific kind of bile acid prevented cardiac fibrosis from occurring.\n(Edmonton, AB) Groundbreaking research from the University of Alberta and McGill University has opened the door towards the future prevention of cardiac fibrosis--a condition leading to heart failure for which there is currently no treatment.\n\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\n\"It offers hope to those who are living with heart failure,\" adds Luis Agellon, co-principal investigator and a professor at McGill University's School of Dietetics and Human Nutrition.\n\"This is something that nobody has ever seen before,\" says Marek Michalak, co-principal investigator and a distinguished professor in the Department of Biochemistry at the University of Alberta's Faculty of Medicine & Dentistry.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is little\u00a0evidence of disease mongering. The information on heart disease is on point, although the 30% one-year mortality rate is higher than the often cited\u00a0Meta-analysis Global Group in Chronic Heart Failure (MAGGIC), a 2012 study of 41,972 patients which found a 12-14% annual mortality rate.", "answer": 1}, {"article": "In the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.\nOther doctors were not so sure.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\nThey came from about three dozen countries.\nHalf were chosen at random to take the drug another five years, while the others were told to stop.\n", "question": "Does the story commit disease-mongering?", "explanation": "No evidence of disease-mongering.", "answer": 1}, {"article": "Nov. 18, 2012 -- Researchers say they've been able to use nanoparticles to stop multiple sclerosis (MS) in mice that are bred to have the disease.\nThey are made from the same material that's used to create dissolving stitches.\nThe particles are about 200 times smaller than the thickness of a human hair.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\nWe just don\u2019t know.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering here.", "answer": 1}, {"article": "Zarate and his colleagues had previously demonstrated that ketamine shots helped some patients with treatment-resistant unipolar depression, meaning they did not cycle through manic episodes.\nThe problem in bipolar illness and depression, he explains, doesn\u2019t appear to be that a person has too much or too little glutamate; instead, it\u2019s likely that the way their neurons release and take up the chemical is out of whack.\nIt\u2019s also a drug of abuse, at much higher doses than those used in Zarate\u2019s research; while patients in the current study received about 50 milligrams during a 40-minute period, a dose too low to induce anesthesia, recreational users of ketamine, known as \u201cSpecial K,\u201d may take hundreds of milligrams per week.\nIn the US, research is continuing on the drug, he added, and some physicians are likely trying the drug in their patients with bipolar illness or depression who aren\u2019t helped by standard treatments.\nThe 18 patients in the study had tried an average of seven different drugs for treating their bipolar illness, and were still severely depressed; 55 percent had failed electroconvulsive therapy (ECT), or shock treatment.\n", "question": "Does the story commit disease-mongering?", "explanation": "The press release did more disease mongering than the story. But the story does paint a scary picture, even raising the specter of suicide. \"Right now, medications available for treating either major depression or bipolar illness can take weeks, or even months, to work, notes Dr. Carlos A. Zarate Jr. of the National Institutes of Health in Bethesda, Maryland, one of the researchers on the study. And as a person waits for their medications to kick in, he added, they will continue to have difficulty working and coping with social and family life; they may even be having thoughts of suicide.\" This is a borderline case. \nWithout additional context or some actual numbers explaining how many people have severe depression that is unresponsive to existing drugs or other therapies, the effect is disease mongering.", "answer": 0}, {"article": "\"Our study is the largest and longest controlled study of growth hormone treatment for osteoporosis in postmenopausal women to date,\" said one of the study's authors, Emily Krantz, MD, of S\u00f6dra \u00c4lvsborgs Hospital in Bor\u00e5s, Sweden.\n, ahead of print.\nThe women were between the ages of 50 and 70 when they were recruited for the decade-long study.\nAfter 18 months, the women who received the placebo halted the injections.\nThe Endocrine Society is based in Washington, DC.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Ramsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nThe 458 male participants in the original study had been between the ages of 30 and 59 at enrollment, and all had a history of heart disease, with most having survived a heart attack.\nWhile omega-3 consumption was not affected, the men were also asked to lower their saturated fat intake so that it made up less than 10 percent of their diets.\nThe second group continued their routine nutritional habits, and both groups kept food diaries and underwent regular assessments during the three-year-plus study period.\n\"What to many people had at one time seemed pretty straightforward in the 1960s has turned out to form a much less black-and-white picture,\" he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of heart disease. The story is clear that the study involved middle-aged men with a history of heart disease and might not apply to other groups.", "answer": 1}, {"article": "Researchers said challenges in measuring the effectiveness of mammography screenings include increases in breast-cancer awareness and advances in treatment.\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\n\"Among women in the screening group, there was a 28 percent reduction in mortality from breast cancer during the same period.\nThe study involved women in Norway between ages 50 and 69.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the prevalence or seriousness of breast cancer.\u00a0 ", "answer": 1}, {"article": "He presented the findings here at the annual meeting of the American Academy of Dermatology.\nResearchers used a ''microfocused\" ultrasound to target the sweat glands in 14 men and women, aged 18 to 75, says Mark Nestor, MD, PhD, a dermatologist and voluntary associate professor of dermatology at the University of Miami Miller School of Medicine.\nMarch 19, 2012 (San Diego) -- Ultrasound treatment can reduce excessive sweating in the underarms by nearly 80%, according to a new study.\n\"Microfocused ultrasound appears to be effective and safe in the treatment of hyperhidrosis,\" Nestor says.\nThe sweating can occur even when the temperature is cool and the person is at rest.\n", "question": "Does the story commit disease-mongering?", "explanation": "We all sweat.\u00a0 How much is excessive?\nWhat pushes someone from the estimated 97% who are \u201cnormal sweaters\u201d (by inference in the story) into the 3% who \u201csuffer\u201d from excessive sweating (stated in the story)? Primary focal hyperhidrosis is not defined simply by \u201cexcessive sweating.\u201d\u00a0 In order for the diagnosis to be made other criteria need to be met.\u00a0 Suggesting excessive sweating is enough to put a person into the elite 1-3% of the population with the condition is a bit of over reach.\nWhere does that 3% estimate come from?\nOther estimates we found in a quick web search put the estimate at less than 1%.\nWhen does this become a problem worthy of ultrasound treatment over several months\u2019 time?", "answer": 0}, {"article": "Results from an approach dubbed metabolic enhancement for neurodegeneration are now available online in the journal Aging.\n\u201cWe think addressing multiple targets within the molecular network may be additive, or even synergistic, and that such a combinatorial approach may enhance drug candidate performance, as well.\u201d\n\nWhile encouraged by the results of the study, Bredesen admits more needs to be done.\nThe study, which comes jointly from the Buck Institute for Research on Aging and the UCLA Easton Laboratories for Neurodegenerative Disease Research is the first to objectively show that memory loss in patients can be reversed, and improvement sustained, using a complex, 36-point therapeutic personalized program that involves comprehensive changes in diet, brain stimulation, exercise, optimization of sleep, specific pharmaceuticals and vitamins, and multiple additional steps that affect brain chemistry.\n\u201cFollow up testing showed some of the patients going from abnormal to normal.\u201d\n\nOne of the more striking cases involved a 66-year old professional man whose neuropsychological testing was compatible with a diagnoses of MCI and whose PET scan showed reduced glucose utilization indicative of AD.\nBy 2050, it\u2019s estimated that 160 million people globally will have the disease, including 13 million Americans, leading to potential bankruptcy of the Medicare system.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release points out the vast and growing number of Alzheimer\u2019s cases. But it edges toward disease-mongering when it quotes a researcher suggesting the protocol can \u201ctransform the perception and reality of Alzheimer\u2019s disease from a death sentence to a preventable reversible condition.\u201d\nIt also recommends genetic testing for everyone, which clearly is not appropriate or warranted. The release states, \u201cNow we\u2019re recommending that people find out their genetic status as early as possible so they can go on prevention.\u201d", "answer": 0}, {"article": "Roslin said limiting grains and sugars reduces insulin surges, which sparks water loss, curbs hunger and can boost energy.\nBut the company said Efron is just one person and that more than 100,000 people have tried and succeeded on the plan, including the beauty director of Essence magazine, Mikki Taylor, who lost nine pounds in seven days.\nThe diets have found popularity in Hollywood, and one of the most Googled detoxes is one consisting of cayenne pepper, syrup and lemon juice, made famous by celebrities like Denise Richards and Beyonce Knowles, who reportedly lost 20 pounds for \"Dreamgirls\" using the detox.\n\"If you need to get into a dress in two weeks, you'll lose weight,\" Roslin said.\n\"When I'd come home from work, I'd be very tired and have to go take a nap for like an hour and a half,\" Rick said.\n", "question": "Does the story commit disease-mongering?", "explanation": "This segment opened with a statement that \u2018Doctor say that there are as a many as 140 unwanted chemicals in our bodies\u2019. Perfect TV lead.\u00a0 Also a perfect example of unsubstantiated fear-mongering. ", "answer": 0}, {"article": "The findings suggest that ibuprofen-acetaminophen is a reasonable alternative to opioid management of acute extremity pain due to sprain, strain, or fracture, but further research to assess longer-term effect, adverse events and dosing is warranted.\nAbout 1 in 5 patients required additional medication to control their pain.\n: Link will be live at the embargo time http://jamanetwork.\nStudy Limitations: The results apply only to pain after two hours.\nDespite the epidemic, opioid analgesics remain a first-line treatment for moderate to severe acute pain in the emergency department.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Take this test to see how well you're managing your diabetes\n\nThe researchers looked at over half a million people from 50 previous studies on the Mediterranean diet, which included people in Spain, Greece, the U.S., France, Sweden, Italy and Australia, among other countries.\nBut it's not only in the U.S.\n\n\"This is a global epidemic,\" Eckel emphasized.\n\"[The study is] one of the first studies that evaluated the role of Mediterranean diet on metabolic syndrome, and revealed a beneficial association- quite a big influence, taking into account that the Mediterranean diet is a non-pharmacological mean,\" said study author Demosthenes Panagiotakos, from the Department of Science of Dietetics-Nutrition at Harokopio University of Athens in Greece.\nFor children, the numbers are also sobering: 20 million kids under age 5 are overweight.\nThe Mediterranean diet isn't just a little extra olive oil, noted Dr. Robert Eckel, an endocrinologist and past president of the American Heart Association.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story included data from the American Heart Association about the numbers /percentage of people who met the criteria for metabolic syndrome, and its prevalence in adolescents.\u00a0 But it made an awkward and unsupported transition immediately into obesity and a \u201cglobal epidemic.\u201d\u00a0 This story \u2013 as the opening sentence stated, was about \u201ca cluster of risk factors for heart disease and diabetes.\u201d The study was about risk factors for risk factors. It did not report on end organ disease endpoints. Metabolic syndrome is not a disease.\u00a0 It\u2019s a fine point.\u00a0 It\u2019s semantics.\u00a0 But it\u2019s an important fine point about semantics.\u00a0 So we grade this unsatisfactory.", "answer": 0}, {"article": "Her report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\n\u201cThis is why we have clinical trials,\u201d she said.\nThey had the same rates of heart attack, death and heart failure.\nAbout a third of heart attack patients show up after 12 hours.\nThe median time since the heart attack was eight days.\n", "question": "Does the story commit disease-mongering?", "explanation": "No obvious elements of disease-mongering.", "answer": 1}, {"article": "Questions about the best method of performing cardiac catheterizations, one of the most common procedures in medicine and among the most profitable for hospitals -- Medicare reimburses GWU about $10,600 for an angioplasty involving one stent -- reflect some of the issues in the roiling health-care debate.\nHis groin was black and blue for two weeks.\n\"All that remained the next day was a little red dot.\nIt was removed after about eight hours and replaced by a simple bandage.\n\"These data support the efficiency and safety [of radial surgery] .\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering.", "answer": 1}, {"article": "\u2022 LPCN 1021 was well tolerated and had a favorable safety profile in the long-term management of hypogonadal patients\n\u2022 No hepatic, cardiac or drug-related serious adverse events were reported\n\u2022 The most common drug-related adverse events for LPCN 1021 and T gel 1.62 percent were acne (2.9 percent vs. 2.9 percent, respectively), headache (0.5 percent vs. 3.8 percent, respectively), weight increase (2.4 percent vs. 0 percent, respectively), hematocrit increase (1.9 percent vs. 0 percent, respectively), liver enzyme level increase (1.4 percent vs. 0 percent, respectively), fatigue (0.5 percent vs. 1.9 percent, respectively), and hypertension (0.5 percent vs. 1.9 percent, respectively)\n\u2022 Lipid parameters (i.e., cholesterol, LDL, HDL, and TG) were comparable between treatment groups at Week 52\n\u2022 Androgenic parameters including hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen (PSA) showed no significant differences in change from baseline to end of study between treatments\n\n\"Based on the results of this study, we might be closer than ever to having an oral form of therapy to treat the millions of men with hypogonadism,\" said Dr. K\u00f6hler.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nOf the 315 men, 210 were randomized to LPCN 1021 and 105 were randomized to active control.\nThe AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.\nTestosterone therapy is used to treat men with clinically diagnosed testosterone deficiency (serum T levels <300 ng/dL), also known as hypogonadism.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. However, the promotion of \u201clow T\u201d syndrome is suspect according to the FDA.", "answer": 1}, {"article": "CHICAGO, Dec. 2, 2015 /PRNewswire/ -- An analysis of clinical data from over 200 patients treated by Dr. Michael Stehling found that a new procedure that uses MR and ultrasound to guide treatment to the precise tumor location allows for faster recovery times and lower side effects in all stages of prostate cancer.\nIncontinence is one of the most common adverse side effects of current treatments for localized prostate cancer and can have a substantial impact on the quality of life.\nIRE uses strong electric fields that cause cells to die without exposing the tissue to radiation or heat.\nIRE is precision guided and reliably destroys cells within the treatment field, but important anatomical structures in and around the prostate such as nerves, the intestinal wall, the sphincter, veins and arteries are spared.\n\"The cutting edge technology of IRE makes this a reality.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not use disease mongering language.", "answer": 1}, {"article": "And the fact that there isn't ... medical treatments for obesity, including pharmaceuticals, really is a challenge, considering how big the problem is in this country.\"\nShe's gained back half of the weight she lost.\nWe're talking about medications to help those who are struggling with the health impact of obesity,\" Nadglowski says.\nWe see decreased rates of progression to diabetes.\nWhat might look like a rare problem now could turn into another public health disaster, she says.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of overweight or obesity.", "answer": 1}, {"article": "Neurontin causes sleepiness, and soy extracts can produce gastrointestinal troubles.\nNone of the drugs or extracts are approved by the Food and Drug Administration to treat hot flashes \u2014 only hormones are approved for that purpose \u2014 but doctors are free to prescribe medicines for any use they see fit, and many recommend the drugs or plant products for hot flashes, based on study findings and their patients' experiences.\n\"There's a lot of hype around trying things that we haven't proven effective and, sadly, we haven't proven they're safe,\" said Dr. Heidi D. Nelson, the first author of the journal article and an internist and professor at the Oregon Health and Science University.\n\"I wouldn't encourage the mindset of putting women on these drugs thinking they're going to be on them for life,\" he said, adding that patients should try the drugs for a few months and then try to stop.\nThough hormones cause small increases in the risks for breast cancer and heart disease, a short course may still be the best choice for women with very severe symptoms, she said, though she added that women who have had breast cancer should definitely not take hormones.\n", "question": "Does the story commit disease-mongering?", "explanation": "Does not appear to be disease mongering. In fact, the closing line addresses this issue head-on: \u201cWe hate to medicalize a natural process,\u201d Dr. Nelson said, but she added that severe symptoms should not be dismissed. \u201cWe want to take it seriously, but not everybody needs to be on prescription drugs for it.\u201d", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in the story.", "answer": 1}, {"article": "\n\u2022 Study addresses key U.S. Food and Drug Administration (FDA) requirement, keeping SHP465 on track for potential 2017 U.S. launch\n\u2022 Key secondary endpoint also met, showing higher proportion of patients were rated improved (p<0.001)\n\u2022 Data add to overall robust clinical development program for SHP465\n\nShire plc (LSE: SHP,NASDAQ: SHPG) today announces positive topline results from a four-week Phase 3, randomized, double-blind, multi-center, placebo-controlled, dose-optimization, safety and efficacy study, SHP465-305, in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD).\n\"These results represent an important step toward a new treatment option for patients with ADHD.\nThere are patents supporting Shire's overall ADHD franchise in the U.S. that extend to 2029.\nShire enables people with life-altering conditions to lead better lives.\nReaders are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release does not take part in disease mongering.", "answer": 1}, {"article": "Eteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nMr. Garabedian said Sarepta did not have the money or the manufacturing capacity to make the drug available outside of clinical trials.\n\u201cThat would be the quickest path to insolvency,\u201d he said.\n\u201cHe\u2019s no longer riding the handicap bus to school,\u201d she said.\nEteplirsen could also be the first drug to reach the market for Sarepta since it was founded 32 years ago.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here", "answer": 1}, {"article": "Shimokawa and his team had conducted previous studies showing that LIPUS improved blood vessel formation in pigs with myocardial ischemia, a condition where there is reduced blood flow to the heart.\nBut there are currently no curative treatments available for vascular dementia or Alzheimer's disease, the most common causes of dementia.\nThe first clinical trials to evaluate the effectiveness and safety of the LIPUS treatment are already underway.\nThe researchers conclude that their study, recently published in the journal Brain Stimulation, provides the first experimental evidence that whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects by enhancing specific cells related to dementia's pathology.\nThe team, led by cardiologist Hiroaki Shimokawa, found that applying low-intensity pulsed ultrasound (LIPUS) to the whole brain of the mice improved blood vessel formation and nerve cell regeneration without having obvious side effects.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It provides some context about the prevalence of dementia worldwide.", "answer": 1}, {"article": "[3] Analysis only included cases occurring 10 days after receiving the vaccine to account for the incubation period of the Ebola virus.\nWhen a new Ebola case was diagnosed, the research team traced all people who may have been in contact with that case within the previous 3 weeks, such as people who lived in the same household, were visited by the patient, or were in close contact with the patient, their clothes or linen, as well as certain \"contacts of contacts\".\nThe vaccine's manufacturer, Merck, Sharpe & Dohme, this year received Breakthrough Therapy Designation from the United States Food and Drug Administration and PRIME status from the European Medicines Agency, enabling faster regulatory review of the vaccine once it is submitted.\n[1]\n\nThe vaccine, called rVSV-ZEBOV [2], was studied in a trial involving 11,841 people in Guinea during 2015.\nIn addition to showing high efficacy among those vaccinated, the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach (so-called \"herd immunity\").\n", "question": "Does the news release commit disease-mongering?", "explanation": "Ebola is certainly a serious disease, given the high fatality rates when outbreaks occur. The news release acknowledges this but does not use sensational language or otherwise overplay the risks Ebola poses.", "answer": 1}, {"article": "\"But I didn't need to hear perfectly to be a good teacher.\u201d\n\nIt was when Priddy's hearing started a rapid decline his freshman year that he decided to visit Dr. Wayne Berryhill, a neurotologist at OU Physicians who specializes in cochlear implants.\nHer son never went blind, but his hearing steadily declined.\n\"I am most happy to hear my music,\u201d he said.\n\"I wasn't even really worried about the deafness because it was hurting so bad.\nThe implant uses those signals to stimulate hearing nerves in the inner ear and replicate the sound.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story describes a real problem\u2014deafness\u2013without overselling or exaggerating its importance.", "answer": 1}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. The story was very careful not to over-hype risks associated with giving birth, whether at home or in the hospital.", "answer": 1}, {"article": "Research reported in this article was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) award CE12-11-4667.\nThe Vanderbilt University Medical Center study led by Daniel Barocas, M.D., MPH, associate professor of Urologic Surgery, compared the side effects and outcomes of contemporary treatments for localized prostate cancer with active surveillance in order to guide men with prostate cancer in choosing the best treatment for them.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\nSurgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\nNewswise \u2014 Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released Tuesday by the Journal of the American Medical Association (JAMA).\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. Instead, the release provides some encouraging context on the use of all three therapies: \u201cThree-year survival from prostate cancer was excellent in the study at over 99 percent for patients regardless of whether they chose surgery, radiation or active surveillance.\u201d", "answer": 1}, {"article": "Some people do need supplements.\nMost recently, researchers at Johns Hopkins University tracked nearly 3,000 adults and found that those who took calcium supplements at the study outset were 22% more likely to show artery calcification 10 years later.\nCalcium-rich foods, such as milk (300 mg a cup), plain yogurt (400 mg per cup) and kale (100 mg a cup), come with added nutritional benefits.\nThe mineral found in popular supplement pills \u2014 and in dairy foods, leafy greens and many fortified foods \u2014 is unquestionably good for your bones.\nThe first is that most people don\u2019t need them, Rosen says.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. If anything, this is quite the opposite: giving readers more information in order to help them make informed decisions.", "answer": 1}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story commit disease-mongering?", "explanation": "The report does not exaggerate the risks or consequences of taking the pills. [Though see \"Quantification of Benefits of Treatment,\" below]", "answer": 1}, {"article": "The human collagen used to develop the corneas was provided by biotechnology company FibroGen Inc.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nIn a newly released study, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas.\n\u201cThis is the first time we have been able to regenerate a cornea in humans,\u201d researcher May Griffith, PhD, of the Ottawa Hospital Research Institute and the University of Ottawa tells WebMD.\nA shortage of human donor tissue coupled with the threat of graft rejection from donor corneal transplants has driven the search for other ways of treating corneal damage.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story. There are, however, some suspect numbers about how many people suffer from corneal blindness and how many receive transplants. Global numbers about conditions such as corneal blindness can be tricky, but several studies put the number at closer to 5 million, not 10 million. The declaration that \"only a small fraction ever receive transplants,\" should have been attributed.", "answer": 1}, {"article": "Researchers conducted a systematic review of existing peer-reviewed research evaluating infusion care for several conditions, including cystic fibrosis, antibiotics following orthopedic surgery and several cancers requiring infused chemotherapies.\nDespite this, clinical outcomes and quality of care have not previously been systematically evaluated.\nCare is administered by experienced infusion nurses and pharmacists, and in addition, patients receive additional disease management education and support throughout their treatment.\nThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting.\nThis unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "TUESDAY, Feb. 23, 2010 (HealthDay News) -- A popular nutritional supplement -- extract of bitter melon -- may help protect women from breast cancer, researchers say.\nThe bitter melon extract killed only the cancer cells, not the healthy breast cells.\n\"I don't believe that it will cure cancer,\" Ray said.\nThe next step is to see if the team can repeat these findings in animals, Ray said.\n\"We didn't see any death in the normal cells,\" she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable because there really wasn\u2019t any meaningful discussion of breast cancer. ", "answer": 2}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story commit disease-mongering?", "explanation": "This article accurately characterizes\u00a0Leger\u2019s congential amaurosis as an inherited disease that results in severe visual impairment in childhood and total blindness by the third or fourth decade of life.\u00a0 While the disease is rare, there is no cure.\u00a0 ", "answer": 1}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story commit disease-mongering?", "explanation": "The story appropriately frames the target population:\u00a0 \u201cis meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment. Glioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.\u201d", "answer": 1}, {"article": "What if we told you that a guy with no background in science or medicine - not even a college degree - has come up with what may be one of the most promising breakthroughs in cancer research in years?\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\nIt was the worst kind of luck that gave Kanzius the idea to use radio waves to kill cancer cells: six years ago, he was diagnosed with terminal leukemia and since then has undergone 36 rounds of toxic chemotherapy.\n\"So right from the beginning you're trying to show that radio waves could activate gas and not harm the human-anything else,\" Stahl remarked.\nHis name is John Kanzius, and as correspondent Lesley Stahl first reported last April, he's a former businessman and radio technician who built a radio wave machine that has cancer researchers so enthusiastic about its potential they're pouring money and effort into testing it out.\n", "question": "Does the story commit disease-mongering?", "explanation": "The question here is whether the story uses anecdote, emotional appeal and speculation to falsely raise hopes about a safe cure for all cancers. The answer clearly is yes. \nThe anecdotes and stories from the cancer ward (hollow\u00a0eyes of children with cancer, etc.) may distort viewers\u2019 perceptions about the problem.\u00a0 Would the technique even work for the kinds of cancers those children had? Note that the story said, \"So far the Kanzius method has only been appolied to solid, localized tumors in animals.\" \u00a0 ", "answer": 0}, {"article": "Newswise \u2014 BOSTON \u2013 November 13, 2015 \u2013 A clinical trial among more than 300 patients has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy (PDR), a complication of diabetes that can severely damage eyesight.\nEyes were assigned randomly to treatment with Lucentis or laser.\nLucentis is among several drugs that block the effects of VEGF.\nWe develop and disseminate innovative patient therapies and scientific discoveries throughout the world.\nOur mission is to prevent, treat and cure diabetes.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Dr. Eric A. Klein, chairman of the Glickman Urological and Kidney Institute at the Cleveland Clinic, said that he would like to see the findings of the new study independently confirmed, but that other studies also have suggested that the risk of cancer is low in men whose P.S.A.\nThey still have a very low individual risk of dying from prostate cancer, judging from the new data.\nDuring that time, there were 43 cases of advanced prostate cancer and 35 deaths in the group.\nscore at 50 can predict his long-term risk.\ntest shows him to be at low risk at age 50 may decide not to be retested again until the age of 60.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering.", "answer": 1}, {"article": "\u201cThey often don\u2019t appreciate the downside of screening,\u201d Dr. Brooks said, \u201cand they don\u2019t appreciate the delay in benefit.\u201d In addition, Dr. Brooks said, primary care doctors often \u201coverestimate the likelihood that early detection of prostate cancer will lead to survival benefits.\u201d\n\nAdded to that, Dr. Brooks said, is the length of time it takes to discuss the pros and cons of screening with patients.\nOften it is easier to just order the test.\nSide effects can include impotence and incontinence.\ntest indicates a possible problem.\n\u201cAnytime a practice becomes ingrained, it is difficult to eradicate,\u201d says Dr. Brooks.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in this piece.", "answer": 1}, {"article": "\u201cThis M.R.I.\n\u201cThe early data is very interesting and exciting.\u201d\n\nThe complexity of a study like this goes beyond the science.\nBut in the last five years, the number of patients who survive 2 years has increased to 25 percent, from 8 percent, largely because doctors began using a chemotherapy pill called temozolomide, or Temodar, along with radiation (Temodar is believed to seep through the blood-brain barrier).\nBut it has not been helpful with glioblastoma, because until recently there was no chemotherapy to infuse that would have much effect on those tumors.\n\u201cNobody knows.\u201d\n\nIndeed, the death of the first patient was a reminder that glioblastoma can invade other parts of the brain and the spinal fluid and that the highly localized spray of Avastin might miss deadly seeds of cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article describes glioblastoma\u2019s deadliness with facts and data rather than appeals to emotion. The language is in some places dramatic but not inappropriately so. ", "answer": 1}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\nThe direct clinical benefit of temporarily increasing tear production as a therapy for patients with dry eye disease was not assessed as part of these clinical trials.\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\n\"Interestingly, neurostimulation has been used as an approach for a wide variety of disorders for more than 30 years.\nFor the full Directions for Use, please call 1-800-678-1605.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release doesn\u2019t engage in disease mongering, but it doesn\u2019t provide any context about dry eye either.", "answer": 2}, {"article": "itself the first clear and reproducible example of cancer immunotherapy, developed at Fred Hutch ?\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nThe findings in this group of trial participants contrast with the outcomes the researchers observed in a cohort of similar patients who received transplants around the same time but did not receive engineered T cells.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release notes that the trial involved only acute myeloid leukemia (AML) patients considered at high risk of relapse. It gives readers a sense that these patients are not typical of patients with AML. The release would have been better if it had provided some sense of the proportion of AML patients who fit the description of those in this trial.", "answer": 1}, {"article": "Additionally, change in IRLSSGS score was significantly greater for the RLS device (17.22) compared to historic reports for ropinirole versus the placebo (12 versus 8.9 respectively).\nRestless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nThe RLS device was designed to put adjustable targeted pressure on two muscles in the foot known to relax symptoms of RLS, the abductor hallucis and the flexor hallucis brevis.\n\"By putting pressure on specific muscles in the feet, we are able to create a response in the brain that relaxes the muscles activated during RLS,\" said Phyllis Kuhn, MS, PhD, and the study's lead researcher.\nAdverse effects were reported by seven patients in the study.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release quotes the National Institute [sic] of Health as saying more than nine million people in the US experience moderate to severe restless leg symptoms similar to those of the participants in this trial. However, it would have been helpful for the release to also point out that the NIH says 70 to 80 percent of people with RLS have a milder form, and that people who report leg movements during sleep have different conditions, such as \u201cperiodic limb movement of sleep\u201d (PLMS).", "answer": 1}, {"article": "LONDON (Reuters) - Taking cholesterol-lowering statin drugs such as Pfizer\u2019s Lipitor and AstraZeneca\u2019s Crestor could help prevent people dying from pneumonia, according to a study by British scientists released on Tuesday.\nSeparate research published in March found that lowering cholesterol levels could help the body\u2019s immune system fight infections, a finding that appears to be supported by Tuesday\u2019s study.\nThey then matched each statin user \u2014 who was aged over 40 when first prescribed a statin between 1995 and 2006 \u2014 with up to five non-statin users for comparison.\nThese findings suggest the pills may help protect against death in patients with pneumonia.\nPrevious studies have suggested statins, which are also available as cheaper generics, may be linked to better outcomes after bacterial infection.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease-mongering in this story.", "answer": 1}, {"article": "Participants in the study familiarized themselves with the workstations during one visit.\n\u201cExercise is a good way to counteract the negative effects of sitting, but just incorporating physical activity into one part of our day may not be enough to overcome the damage caused by prolonged sitting and an otherwise sedentary lifestyle.\u201d\n\nBecause the workday is a major contributor to sedentary behavior, with more than 20 percent of workers in the U.S. reporting more than 8 hours each day, tactics that promote workstation activity have emerged in recent years, including standing desks, as well as dynamic pedal and treadmill workstations.\n\u201cWe expected to see the metabolic rate increase with each progressive stage, but instead found that metabolic rates from movement while seated were either equal to or higher than rates while standing.\u201d\n\nHorswill says the study needs to be further validated, but that the findings should be especially applicable to individuals poised to benefit from NEAT but unable to access popular standing desks because of injury, disability or discomfort.\nThe device, which is commercially available, was a movable footrest, suspended from the underside of the desk, which enabled the feet to swing, twist or teeter.\nThe findings are published in WORK, a journal affiliated with the Canadian Association of Occupational Therapists and endorsed by the International Ergonomics Association.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release fear mongers by citing a statistic based on one association study that looked at the relationship between sitting and risk of death. The study suggests that 7% of deaths from any cause were attributed to long periods of sitting down. What does it even mean that \u201cUp to 7 percent of deaths have been attributed to sitting alone.\u201d Does it mean those people died earlier than they would have otherwise? If so, how much earlier? And what sort of evidence would allow us to say with any certainty that sitting down was the cause of these deaths as opposed to the myriad other possibilities? If a statistic like this is to be used, it\u2019s meaning must be explained \u2014 otherwise it constitutes unacceptable fear-mongering.\nThe authors of that study also cautioned that \u201csedentary behavior research is still in its infancy and that more high-quality prospective studies are needed.\u201d", "answer": 0}, {"article": "\u201cNo metal may also reduce the potential of future blockages that occur with permanent metallic stents.\u201d\n\nData released in October concluded Absorb was comparable to Abbott\u2019s own Xience drug-coated metal stent in safety and effectiveness but showed a higher risk of heart attacks and blood clots.\nAbsorb will be priced at a \u201cmodest\u201d premium to Xience, he said.\n\u201cThis is a game changer,\u201d he said in an interview.\nAbsorb\u2019s appeal is that it allows the blood vessel to return to a natural state, free from a permanent metal implant.\nAbbott plans to roll out the device to about 100 hospitals in the next several months as it trains surgeons on the implant procedure before ramping up sales, said spokesman Jonathon Hamilton.\n", "question": "Does the story commit disease-mongering?", "explanation": "Permanent metal mesh stents have complications, so the search for an alternative makes sense.", "answer": 1}, {"article": "(Reuters Health) - Getting too little sleep during the week can increase some risk factors for diabetes, but sleeping late on weekends might help improve the picture, a small U.S. study suggests.\nOn another occasion, the same men were allowed to sleep 8.5 hours for four nights.\nThe volunteers were given a calorie-controlled diet to limit the potential for their food and drink choices to influence the outcomes.\nIn the real world, when people don\u2019t get enough sleep they tend to overeat, which may limit how much results from this lab experiment might happen in reality, the authors note in a report scheduled for publication in the journal Diabetes Care.\n\u201cWe don\u2019t know if people can recover if the behavior is repeated every week,\u201d Broussard added by email.\n", "question": "Does the story commit disease-mongering?", "explanation": "None here.\u00a0Insulin resistance and type 2 diabetes are important public health problems.", "answer": 1}, {"article": "\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\nIt\u2019s too soon to tell if resistant starch can help people weight.\nThere, they\u2019re fermented and turned into short-chain fatty acids, which the body burns as energy.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\nEven if you heat them up again, they retain their new resistant starches.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Overall, the study found, measures of spasticity dropped an average of three points \u2014about 30 percent \u2014 on a 24-point scale when patients smoked marijuana, but didn\u2019t change after they smoked the placebo.\n\u201cBlinding\u201d people as to whether they are on marijuana or a placebo is tough since the drug creates a \u201chigh\u201d feeling.\n\u201cBut smoking marijuana does not appear to be a long-term solution, because of the cognitive effects,\u201d he told Reuters Health.\nAnd a new clinical trial suggests they are not just blowing smoke.\nBefore and after each treatment, an independent rater assessed the patients\u2019 muscle spasticity.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of spasticity of MS.", "answer": 1}, {"article": "The drug briakinumab reduced psoriasis symptoms by at least 75 percent in nearly 82 percent of those taking it, compared to just 40 percent of those on methotrexate.\nResearch on briakinumab is continuing.\nAn ongoing three-year trial involves 248 people from the current study.\nThe disease causes patches of thick, red, inflamed skin that have silvery scales.\nThere were also two cases of cancer in people taking briakinumab and none in the methotrexate group.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of psoriasis here.", "answer": 1}, {"article": "Still, with an infection that currently has no good treatment and leads to an estimated 275 million lost work days a year in the U.S., well, what a difference a day makes.\nA typical adult has a few colds every year.\nBy comparison, a normal cold lasts about a week.\nThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\nBut not a whole lot.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering. We appreciated that this story\u00a0gave information about the financial and clinical impact of the common cold.", "answer": 1}, {"article": "The study also found other benefits.\nBut Ronald Evans, director of the institute's Gene Expression Laboratory and lead author of the new study, said in an interview that if it shows the same promise in primate studies, clinical trials on humans could begin in a couple of years.\nThe drug contributed to development of brown fat, which helps burn calories, and relieves inflammation of cells in various tissues, which is the result of chronic obesity.\n\"We can get that whole process of what a meal does without actually having the meal,\" he said.\n\"We described a new type of therapy that targets the known genetic switch in our bodies that is linked to eating and metabolic control,\" Evans said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Obesity is a serious health issue. The story mentions that this drug might be an alternative to surgery for people who are morbidly obese.", "answer": 1}, {"article": "\u201cEverything got better,\u201d says Lustig.\nBut I worry that people are going to hang everything on this when we still need to reduce consumption.\u201d\n\nLustig hopes that won\u2019t happen as more data emerges that details how sugar is altering the body in unhealthy ways outside of its caloric contribution.\n\u201cThis is causation.\u201d\n\nThe diet he provided the children isn\u2019t considered ideal from a health perspective \u2014 starches are still a considerable source of calories and can contribute to weight gain.\nAnd in studies where people reduce the amount of sugar they eat, for instance, those people end up eating fewer calories overall, so it\u2019s difficult to know whether any changes are due to the removal of sugar or to the drop in calories.\nNow, in a paper published Tuesday, he and his colleagues believe they have come up with the definitive evidence that sugar, as Lustig says, \u201cis toxic.\u201d\n\nIn most lab studies, the doses of sugar that scientists test are quite high; they want to see what the effect is quickly and, depending on the research, they may not have time to wait to study the more gradual effects that might emerge.\n", "question": "Does the story commit disease-mongering?", "explanation": "As noted, increased sugar consumption, especially in children, has long been linked to alarmingly high and growing rates of obesity, diabetes and other chronic diseases in children and adults. There is no disease mongering here, and indeed, some numbers (prevalence) would have helped the story.", "answer": 1}, {"article": "Adding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\nHemoglobin A1c levels dropped from 6.5% to a normal level of 6.1%.\nAnd during Victoza treatment, patients needed less and less insulin.\nThey can see that their unexpected and unpredictable oscillations of blood sugar are minimized.\nThis appeared to be due to reduced appetite and food intake.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering in this story.", "answer": 1}, {"article": "In an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent\nOld age is not necessarily a barrier to kidney donation.\nThe study is in the Clinical Journal of the American Society of Nephrology.\nRecipients were at most seven years older or younger than the donors.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Breast Cancer Patients Have Improved Immune And Neuroendocrine Functions Following Massage Therapy.\nIn a controlled study composed of HIV-positive adolescents, participants who received massage therapy showed enhanced immune function by the end of the 12-week study.\nThe association is directed by volunteer leadership and fosters ongoing, direct member-involvement through its 51 chapters.\nIndividuals should consult with a professional massage therapist to determine the best massage therapy approach for their specific needs.\nAMTA works to advance the profession through ethics and standards, the promotion of fair and consistent licensing of massage therapists in all states, and public education on the benefits of massage.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not commit disease mongering, although it would have been helpful to learn more about conditions that compromise patients\u2019 immune systems.", "answer": 1}, {"article": "(Reuters) - Tiny Israeli drugmaker Oramed Pharmaceuticals Inc on Wednesday said its experimental oral insulin succeeded in significantly reducing night-time blood glucose in patients with type 2 diabetes, according to initial data from a midstage trial.\nThe main attraction of an insulin pill, aside from avoiding injections, is that it comes much closer to the path of natural insulin, which is produced in the pancreas and goes directly to the liver.\nWhile insulin is typically associated with type 1 diabetes, many patients with type 2 eventually see their disease progress to the point where they need insulin.\nThe result is likely to surprise many skeptics who did not believe insulin could be delivered orally because they doubted it could survive the onslaught of digestive juices so it could have the intended effect.\n\u201cIt\u2019s been a long trip but it\u2019s finally at the point that it\u2019s beyond a doubt, the oral insulin works,\u201d Nadav Kidron, chief executive of Jerusalem-based Oramed, said in a telephone interview.\n", "question": "Does the story commit disease-mongering?", "explanation": "Type II diabetes is a known disease of the industrial world and the numbers of people are increasing while the ages at which they are diagnosed is decreasing.\u00a0 An oral insulin would aid people in controlling their blood sugar levels.", "answer": 1}, {"article": ", and receive monthly highlights by signing up at http://www.\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\nDetails: Solaiman Tarafder, Esther Chen, Yena Jun, Kristy Kao, Kun Hee Sim, Jungho Back, Francis Y. Lee, and Chang H. Lee.\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\nIt is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. Inflamed tendons make life miserable for many folks, who find that this type of injury is very slow to heal.", "answer": 1}, {"article": "For more information, visit http://www.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\nThe study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world.\nIn their study published in Computers in Biology and Medicine, researchers detected breast cancer with more than 95 percent average accuracy using an inexpensive commercial electronic nose (e-nose) that identifies unique breath patterns in women with breast cancer.\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. The release provides some statistics on breast cancer prevalence, but then makes a tentative connection between early screening and breast cancer mortality which seems unwarranted given the preliminary status of the research.", "answer": 1}, {"article": "Khalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\nThe print edition is scheduled to be published in August.\nAbout the Alzheimer's Research and Prevention Foundation\n\nThe Alzheimer's Research and Prevention Foundation is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease.\n\"Science is showing that meditation and spiritual fitness can be an important dimension in battling Alzheimer's, and Kirtan Kriya is a safe, affordable, fast, and effective way to keep the brain spiritually fit.\"\nFor more information, please visit www.alzheimersprevention.org.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Disease-mongering was not among the problems with this news release.", "answer": 1}, {"article": "March 29, 2011 -- A minimally invasive procedure that cuts off the blood supply to an enlarged prostate may help when medications fail, and it appears to provide good symptom control without sexual dysfunction, a new study shows.\n\u201cWe don\u2019t know how well these particles are localized to the prostate or if they\u2019re going to the pelvis or other parts of the body.\u201d\n\nMalizia notes that in one serious complication reported in the study, the particles appeared to migrate and kill a small part of the bladder wall.\nWe really don\u2019t know what the short- and long-term success or complication rates are,\u201d says Anthony Malizia Jr., MD, president and director of the Malizia Clinic, a nonprofit urology specialty center in Atlanta.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\nIt\u2019s the same kind of growth,\u201d says study researcher Joao Martins Pisco, MD, chief radiologist at Hospital Pulido Valente and director of interventional radiology at St. Louis Hospital, both in Lisbon, Portugal.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story provided the reader with the fact that benign hyperplasia affects 19 million American men without any additional context about the men affected. \u00a0It would have been useful, for example to explain that this was a chronic condition that becomes more common as men age; some men find their symptoms severe enough to seek treatment; others are less bothered by the condition. BPH is not likely to cause serious complications. There are men who choose to watch and wait, and who bypass treatment entirely. You\u2019d never get that notion from this story.", "answer": 0}, {"article": "Reuters - A nicotine addiction pill can help smokers quit gradually when they can\u2019t go cold turkey, a study finds, suggesting that it may be time to revisit practice guidelines that focus primarily on immediate cessation.\n\u201cIt offers compelling evidence that gradual reduction should be considered to facilitate quitting,\u201d she said.\nBy the last ten weeks of treatment, weeks 15 to 24, the group taking the pill had significantly higher abstinence rates than the group on placebo.\nTen years after quitting, the risk of lung cancer drops by half, according to the CDC.\nPeople with a history of major depressive or anxiety disorder, suicidal behavior, panic disorder, post-traumatic stress disorder, schizophrenia, or psychosis were excluded from the study, published in the American Medical Association\u2019s journal JAMA.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Dr. Vijay B. Vad, a sports medicine specialist at the Hospital for Special Surgery in Manhattan, compares the problem to a thermostat in a cool room.\nThe syndrome may follow 5 percent of all injuries, according to the Reflex Sympathetic Dystrophy Association, an advocacy group for people with chronic pain.\nStill, most patients accept this vibrating version of white noise, says Dr. Richard North, a retired neurosurgery professor at Johns Hopkins who developed several patents related to the technology, although he no longer receives royalties.\n\u201cSometimes efficacy wanes over time, but I still believe in them,\u201d said Dr. Kaufman, also an assistant professor of anesthesiology at the New Jersey Medical School.\nThe study, which was financed by the implant maker Medtronic, followed 100 patients who had undergone spinal surgery and had developed chronic pain in one or both legs.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not make clear that the study upon which the story is based concerned patients for whom an initial surgery had failed.\u00a0 The story suggests that the procedure might be an alternative to initial surgery.\u00a0 The story also mentions complex regional pain syndrome (CRPS) as an indication for use of the device.\u00a0 But the study did not address this condition.\u00a0 Radicular pain \u2013 so-called \"neuropathic pain\" in the source study is not CRPS.\u00a0 Finally, the second paragraph suggests that this is an alternative for chronic pain.\u00a0 This is too bold a message while the jury is not yet in. \u00a0 ", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.\u00a0It did make it sound like heart failure exacerbations happen rapidly, with minor changes in diet. This is not supported by the science. But this is a minor quibble.", "answer": 1}, {"article": "This determined the most effective treatment frequency.\nThe heat shock response (HSR) is activated as a response to stress in the human body, but its function decreased in those with type 2 diabetes.\nFurthermore, adding the MES+HS treatment to a DPP-4 inhibitor, which is the most often used therapeutic drug for diabetes in Japan, showed an even stronger blood glucose improvement.\n\"This device is very easy to use since it simply attaches to the abdomen, and it has a low-impact on the patient.\nDeclines in HbA1c were 0.10%, 0.36%, and 0.65% in the 2, 4, and 7 treatment-per-week groups respectively.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release provides a good description of the mechanics of Type 2 diabetes. The release might have been improved with a brief discussion of the prevalence of the disease.", "answer": 1}, {"article": "Still, he said, he was impressed.\n\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\nMoreover, they had a 48 percent reduced risk of having an elevated level of prostate-specific antigen, or P.S.A., the protein measured in a common blood test for prostate cancer.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article provides very limited information about prostate enlargement, known as benign prostatic hyperplasia or BPH. Of note, this condition is not cancerous or life-threatening. Also, the article mentions a possible benefit being lower PSA levels, noting that this is a common blood test for prostate cancer. This implies that using aspirin or other similar drugs for BPH can also reduce a man\u2019s chance of prostate cancer, for which there is no evidence. In fact, elevated PSA levels can often be due to conditions like BPH and not due to cancer; with less enlargement of the prostate, it\u2019s not unexpected to also find lower PSA levels. The broad use of the term \u201curological problems\u201d also seems to overstate what the study was about, evaluating a specific condition (BPH). ", "answer": 0}, {"article": "Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas.\nTHURSDAY, April 14, 2011 (HealthDay News) -- In the latest research to test the concept of an artificial pancreas for the management of type 1 diabetes, British researchers report that they were able to improve blood sugar control and reduce the risk of dangerous low blood sugars overnight.\nPrevious research suggests that in a 24-hour period, the average person with type 1 diabetes spends about 10 hours with blood sugar levels too high, and about an hour a day with blood sugar levels too low, according to Aaron Kowalski, assistant vice president for treatment therapies at the Juvenile Diabetes Research Foundation.\nAn analysis of pooled data showed that the overall time that plasma glucose levels were in target \"increased by a median 28 percent\" with the artificial pancreas, said the study's lead author Roman Hovorka, a principal research associate at the University of Cambridge in the United Kingdom.\nFor the eating-in portion of the randomized study, 12 of the study volunteers were assigned to consume a medium-sized meal (60 grams of carbohydrates) at 7 p.m., and then another half were placed on the artificial pancreas program during the night, while the other half maintained their standard insulin pump therapy.\n", "question": "Does the story commit disease-mongering?", "explanation": "We don\u2019t think the story intended to engage in disease-mongering, but the story is framed in such a way that the risk of renal failure following surgery is overly hyped. The second sentence of the story says, \u201cFor reasons doctors don\u2019t completely understand, this complication, which is called acute kidney injury (AKI) or acute renal failure, is on the rise, and it dramatically increases a patient\u2019s risk of dying during recovery.\u201d It isn\u2019t until later in the story that we are told, \u201cOverall, about 2% of patients experienced renal failure within two weeks of their procedures.\u201d That should ease patients\u2019 concerns a bit until later in the story it says, \u201cDepending on how researchers define it, studies have shown that it may occur in up to 40% of patients.\u201d This sort of whipsawing can turn readers off to a topic and leave them feeling scared and confused.", "answer": 0}, {"article": "Studies suggest that for more than half of depressed patients, antidepressants alone don\u2019t eliminate symptoms.\nIt\u2019s a medication that works differently than everything else.\u201d\n\nThe study was funded by a grant from the National Institutes of Mental Health, but the SAMe pills and placebo pills were provided by the dietary supplement maker Pharmavite.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nAnd about 26 percent of patients in the SAMe group experienced a complete remission of symptoms, compared to just 12 percent in the placebo group, according to a report published in The American Journal of Psychiatry.\nAs a result, doctors are looking for additional treatments to help these patients, referred to as \u201cnonresponders.\u201d\n\nModern antidepressants essentially work by building up concentrations of neurotransmitters, which amplifies their effect on the brain.\n", "question": "Does the story commit disease-mongering?", "explanation": "We liked how the story restricted the target population to nonresponders. However, we slap its wrist because it said the study was in adults with depression who failed antidepressant treatment. It was actually major depressive disorder and failure of 6 weeks adequately dosed with a specific class of SSRIs. \nFurthermore, it defines \u201cnonresponders\u201d as patients for whom \u201cantidepressants don\u2019t eliminate symptoms.\u201d Eliminate is too strong, and it produces a broader definition of nonresponder than was used in the study. The trial required subjects to have at least a 16 on a particular measurement of depression symptoms, the HAM-D. According to the story, you\u2019d think a nonresponder would be anybody for whom antidepressants didn\u2019t eliminate symptoms (i.e., those with \u201cnormal\u201d HAM-D scores). But that wasn\u2019t the case. Antidepressants may have reduced their symptoms and they could still be nonresponders.\nThe story\u2019s definition of nonresponder is broader than what most clinicians or researchers woul duse; the standard is two or more failed trials. ", "answer": 0}, {"article": "Taylor discovered that the study participants who received in-person cognitive behavioral treatment for their insomnia reported significantly greater improvements in sleep quality -- as determined by the sleep diaries and activity monitors -- than those who received the Internet therapy.\nBoth the in-person and Internet therapy had the exact same content, with the Internet lessons presented as audio recordings accompanied by visual graphics and animations.\n\"The online program can also be done from home rather than at a military behavioral health clinic, which some service members may avoid due to concerns about stigma,\" said Pruiksma, an assistant professor of psychiatry at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).\nIn a previous study of civilians with insomnia, Taylor and his research team discovered that cognitive behavioral therapy led to significant improvements in sleep efficiency, with the research subjects' use of sleep medication declining from 87.5 percent before therapy to 54 percent afterward, although the subjects weren't required to stop taking their medication.\nFor deployed military personnel, the side effects such as grogginess, slowed cognitive processing and slowed reaction time can be dangerous,\" Taylor said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No signs of disease mongering here. The release also provides some context on what chronic insomnia is and how it is a risk factor for other health conditions.", "answer": 1}, {"article": "DOI: 10.1016/j.ajog.2017.11.570.\nThese questions addressed in a new study by researchers from Charit\u00e9 - Universit\u00e4tsmedizin Berlin, the results of which have been published in the American Journal of Obstetrics and Gynecology*.\nHowever, the women who were involved during the planning stages, all of whom were affected by menstrual pain, wanted an app,\" reports the study's principal investigator, Prof. Dr. Claudia Witt of the Institute of Social Medicine, Epidemiology and Health Economics.\nSo far, research into the clinical effectiveness of apps has been limited, and only a few have been tested using randomized controlled trials,\" says Dr. Daniel Pach of the Institute of Social Medicine, Epidemiology and Health Economics.\nHowever, despite our experience with conventional clinical trials, there was a lot for us to learn - something we found both exciting and eye-opening.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "Although the vast majority of women are estimated to have mild to moderate menstrual pain, and menstruation has often been inappropriately construed as a \u201cdisease\u201d always in need of medical intervention, this release presented the issue matter-of-factly, and reasonably.", "answer": 1}, {"article": "But researchers say the preliminary findings could one day lead to diabetes treatments.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\n\u201cSurgery puts the diabetes into remission.\nMost of the research has focused on changes in gut hormones, but we have shown that a decline in specific circulating amino acids also occurs.\u201d\nWhen researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in overt disease mongering.", "answer": 1}, {"article": "Ilaris can lower the immune system\u2019s ability to fight infections.\n\u201cFor the first time, patients with TRAPS and HIDS/MKD, two painful and life altering diseases, have access to a treatment that may help improve their quality of life,\u201d said Badrul Chowdhury, M.D., Ph.D, director of the Division of Pulmonary, Allergy and Rheumatology Products in FDA\u2019s Center for Drug Evaluation and Research.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients:\n\nAll three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain.\nThe agency is also responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in fear-mongering, but neither does it tell us how prevalent and disabling these diseases are. It would have been nice to get more information about the new indications, the numbers who suffer from them and the way they may be currently treated even if there are no approved drugs.", "answer": 1}, {"article": "(Reuters) - A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.\nLarger studies are slated to begin later this year.\nSuch patients were deemed likely to benefit from treatment.\nBut patients gradually tapered off on those drugs and were no longer taking either of them after 9 weeks.\nThroughout the Phase IIa trial, half the patients also received weekly injections of dupilumab, while half received placebo injections.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story.", "answer": 1}, {"article": "\"We do need something,\" he said.\n\"We now feel pretty confident that, in many children with autism, there are alterations either in structure growth or connectivity of the brain, but we really don't understand the implications of that for core features of autism, one of which is problems with communication,\" Amaral said.\nWEDNESDAY, May 19, 2010 (HealthDay News) -- Researchers hope that a simple brain scan performed in infants and toddlers can presage the development of autism, leading to early detection and early intervention.\n\"We're focusing on this earliest time period, when the brain is still developing and still changing,\" explained study author Lisa Eyler, an assistant professor of psychiatry at the University of California, San Diego.\n\"This is probably not going to be used for wide-scale screening but it could be used for children who we have some sense that they have autism and want to gather more information,\" said David Amaral, president of the International Society for Autism Research and research director of the University of California Davis MIND Institute.\n", "question": "Does the story commit disease-mongering?", "explanation": "Unlike most autism stories, which tend to spend a lot of time talking about the exponentially larger number of kids with autism every year and the horrors that the disease brings to a family, this article was straight forward. We all know what autism is, even if we haven\u2019t lived with a family member who has that diagnosis, and here is what a group of researchers is trying to do to pin down what exactly is going on inside an autistic child\u2019s brain.", "answer": 1}, {"article": "WASHINGTON (Reuters) - Statin drugs may lower the risk of colon cancer by as much as 12 percent, U.S. researchers reported on Monday.\nStatins are not risk-free.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\nIn May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\nOverall, patients who took statins had a 12 percent lower risk of being diagnosed with colon cancer than people who did not take the drugs, they found.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable because the story really delivered no substantive background information on colon cancer.", "answer": 2}, {"article": "WASHINGTON (Reuters) - A new, longer-lasting \u201cmorning-after\u201d pill to prevent unwanted pregnancy appears to work with no unexpected side effects, U.S. health regulatory staff said in documents released on Tuesday.\nCost is also an issue.\nEasier access to the drug won approval in 2006.\nAt the meeting, an FDA panel of outside experts will decide whether to recommend the agency approve the emergency contraceptive for the U.S. market.\nHRA is not seeking to sell ella without a doctor\u2019s prescription.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story.", "answer": 1}, {"article": "Fried, a dermatologist and clinical psychologist, points out that psoriasis itself can be associated with mental health problems.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\nThe most common side effects of the drug were joint and muscle pain, headache, fatigue, diarrhea, throat pain, nausea, flu, low white blood cell count, fungal infections and reactions at the injection site.\nBy blocking the receptor from being activated, it keeps the body from receiving signals that can fuel inflammatory responses and psoriasis progression.\nThis small difference is significant, says Dr. Richard Fried, a member of the National Psoriasis Foundation medical board, since responses to drug treatments can vary dramatically from person to person.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to commit disease-mongering. However, it would have been more helpful\u00a0it had stated what percentage of patients with psoriasis\u00a0may have such severe disease, and how \u201csevere\u201d is defined.", "answer": 1}, {"article": "To date about 700 individuals have been screened in the Augusta area and Schroeder is working to expand statewide, hoping to use the state public medical school's extensive campus network that has students learning from physicians at practices and hospitals across Georgia, as a natural base.\nThe combination technology is often used to visualize other tumor types throughout the body and many patients require an injection of sugar dye, which will be taken up by the tumor but must first circulate for about an hour before the scan is done.\nThe screening of 264 high-risk individuals within a 150-mile radius of Augusta found 3 percent had lung cancer and 75 percent of those were caught early, said Dr. Carsten Schroeder, thoracic oncology surgeon at the Georgia Cancer Center and Medical College of Georgia at AU.\nThey may follow up on smaller nodules in six months, then if the nodule is stable, go back to annual reviews.\nThe area's median household income is 27 percent lower than the national average and the poverty level is 67 percent higher, according to the U.S. Census Bureau.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here, when it comes to lung cancer. However, we do have some concerns with the headline and first paragraph. More on that below in the Unjustifiable Language section.", "answer": 1}, {"article": "CHICAGO (Reuters) - The hallucinogen psilocybin \u2014 known by the street name magic mushrooms \u2014 may help ease the anxiety that often accompanies late-stage cancer, U.S. researchers said on Monday.\nEverything had to be shut down,\u201d Grob said in a telephone interview.\n\u201cIt was something of a public health crisis.\n\u201cForty to 45 years ago, the culture was going through tremendous upheaval.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Despite recent debate about how well antidepressants really work in people with only mild or moderate depression, a new analysis of drug studies suggests they may have some benefit across the board.\nAbout 9,000 participants were included.\n\u201cMore than 80 percent of the patients are not getting a significant benefit from the drug \u2014 either they\u2019re not getting better or they would get the same benefit with placebo,\u201d he told Reuters Health.\n\u201cDefinitely it doesn\u2019t look like antidepressants are placebos,\u201d he concluded.\nThe benefits were seen regardless of how severe patients\u2019 symptoms were before starting treatment.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering about depression here.", "answer": 1}, {"article": "\u201cIt was really bad,\u201d Joyce, 29, told FoxNews.com.\n\u201cBut now I don\u2019t really feel allergy symptoms anymore.\u201d\n\nTo find a prescribing doctor for Allerdent in your area or to find more information, visit Allovate.com.\n\u201cThe patients who came in were treated for the very things that they were sensitive to, and that included indoor allergens, like dustmite and pet dander, as well as outdoor allergens such as tree pollen, grass pollen, ragweed pollen,\u201d Dr. William Reisacher, an associate professor of otolaryngology and director of allergy services at Weill Cornell Medicine/New York-Presbyterian Hospital, told FoxNews.com.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story is built upon the major discomfort that allergy sufferers face and fails to offer any substantive research data backing up its claims. \u00a0It talks about \u201cmillions\u201d of sufferers, but doesn\u2019t quantify the total with any precision. It also presents a heart-tugging anecdote of a woman faced with the prospect of abandoning her two cats because of insufferable symptoms. We think the story goes too far both in its portrayal of the condition and the benefits of the potential toothpaste remedy.", "answer": 0}, {"article": "By March, Ramas could hardly walk.\n\"In the past, we would have had to wait to diagnose Parkinson's or chosen different medications to test, which might have had different side effects, and this would have delayed the timely diagnosis of Parkinson's,\" Xie said.\nA new scan to help in difficult-to-diagnose cases of Parkinson's disease or other parkinsonian syndromes is available at more than 80 U.S. hospitals, including some in the Chicago area, since receiving federal approval earlier this year.\nDuring an FDA advisory panel meeting, committee members were mostly positive about DaTscan, though one neurologist objected to the average $1,500 cost of a scan versus $150 for a month's supply of carbidopa or levodopa medications for a Parkinson's patient, according to Medscape Medical News.\nAs part of the study, recently diagnosed Parkinson's patients and healthy subjects are tested with DaTscan, and clinical and behavioral assessments are done to identify biomarkers of Parkinson's disease progression.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does a poor job describing who this should be used for. Parkinson\u2019s is a clinical diagnosis that is readily made by physicians without the need for such a test. Although the story does report prominently that the DaTscan test is intended for use in \u201cdifficult-to-diagnose cases of Parkinson\u2019s disease or other parkinsonian syndromes,\u201d it should have noted that these groups represent only about 5 percent of patients. What\u2019s more, the patient example and other sections of the story would likely lead readers to believe that the test is useful in many patients who do not fit the population for which the test was approved. Indeed, the story generally flips the intended use upside down, creating an impression that the DaTscan detects cases of Parkinson\u2019s disease that other tests and exams may miss, when actually the test is intended to help doctors rule out Parkinson\u2019s in patients who actually have some other condition. A news release from GE Healthcare says the test may help reduce the cost of care by \u201cpreventing patients from receiving misdiagnoses or inappropriate treatment.\u201d\nGE Healthcare news release:  http://md.gehealthcare.com/component/content/article/940-press-release/102-impact-of-datscan.html", "answer": 0}, {"article": "\u201cI really cannot overstate the size of this effect.\u201d\n\nThe key finding is that there is often more time than doctors realized in which brain cells can still be rescued by a procedure to remove the clot.\nThe study showed that the time window could be expanded to 16 hours.\nTraditional guidelines have set a limit of six hours after stroke symptoms begin, and said after that it would be too late to help.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nOnly about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story.", "answer": 1}, {"article": "Dr. Louis Jacques, director of the coverage and analysis group at the Centers for Medicare and Medicaid Services, said cost was not a factor and that the agency had reviewed products approved by the F.D.A.\nwere it not for its high cost.\nThat is between 3, which is intermediate confidence and 5, which is high confidence.\nSo it cannot be completely ruled out that XL184 somehow stopped bone growth without killing the cancer.\ninitially declined to approve it in 2007.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "By comparison, the only approved long-term prescription weight loss medication available on the market today, Xenical, is associated with a seven-pound weight loss when combined with diet and exercise.\nTopamax is commonly used to treat migraines and seizures.\nAccording to the manufacturer's study, the two drugs, when taken together, and at controlled-release doses, were very safe.\nTwo existing drugs, in combination, have shown significant promise in promoting weight loss, according to a new report.\nParticipants in the trial reported minor side effects such as dry mouth and constipation, however at higher doses, some participants did complain about some psychiatric side effects.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in the story.", "answer": 1}, {"article": "But such evidence often does not pan out in human studies.\nThe question is whether the rate-of-living theory is operational in mammals.\u201d\n\nPollak says that none of the most exciting possible benefits for the drug have yet been proved in randomized clinical trials of non-diabetics.\n\u201cPlain old metformin given in the same dose as we do for Type 2 diabetes doesn\u2019t seem to be a breakthrough for cancer, at least for pancreatic cancer.\u201d\n\nMany other metformin clinical trials are underway for breast, colorectal, endometrial and other cancers.\nSo much metformin is taken in the United States \u2014 some 72 million prescriptions were written for it in 2013 \u2014 that a recent study found higher trace levels of it (presumably from the urine of people taking it) in Lake Michigan than of any other drug, including caffeine.\nThe author of the study, Niteesh Choudhry, an associate professor of medicine at Harvard Medical School, also found that newly diagnosed Type 2 diabetics who start on metformin are the least likely to need an additional diabetes drug later.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no overt disease mongering. However, the picture presented is so rosy in places that one might reasonably conclude that this is something everyone should take \u2014 like a multivitamin. That suggestion borders on disease mongering.", "answer": 1}, {"article": "Holick and others say there is little or no downside to ingesting even high levels of vitamin D.\n\n\"I've been treating patients with 50,000 units of vitamin D once a week for eight weeks followed by 50,00 every other week for over a decade, and I've not seen any untoward toxicity,\" Holick says.\n\"It was believed that megadoses of vitamin E, beta-carotene, selenium, folic acid and the B vitamins would confer a large array of health benefits.\nThose who are sick may have low levels because they don't have those healthy habits.\nForty years ago, he discovered the active form of the vitamin, 1,25-dihydroxyvitamin D. He has written several popular books on the subject and has another one, The Vitamin D Solution, coming out next month.\nIn the case of beta-carotene, scientists were surprised to find that when the results of randomized trials were in, those taking the supplement actually had a higher risk of lung cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering.\u00a0 Even the suggestion that conditions from Alzheimers\u2019 \u00a0to autism down to tuberculosis could be avoided with vitamin D supplementation was countered by another perspective.", "answer": 1}, {"article": "Related: CDC study finds opioid dependency begins within a few days of initial use\n\u201cIt\u2019s an avenue that shows some promise.\u201d\n\nAlthough research on humans is not yet planned, study authors Kim Janda and Paul Bremer, chemists at the Scripps Research Institute, are encouraged about this next step.\nThe current study of the vaccine, published in the Journal of the American Chemical Society, follows eight years of laboratory research and studies in rodents that indicated the compound could neutralize heroin at different doses.\nBut in light of the growing drug abuse epidemic, for which, he says, \u201cwe have so few tools,\u201d adding a vaccine to the available treatments could help.\nAll four monkeys responded to the vaccine, but the two that were receiving it a second time had a stronger response, hinting that their immune systems were already primed with the \u201cmemory\u201d of the compound.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease mongering here. Having said that, we would have liked to have seen a comment or two on the rising abuse of heroin and other opioids.", "answer": 1}, {"article": "\u201cTraining peer counselors to do phone counseling is an effective, low-cost and non-stigmatizing way for new moms to get the help they need.\u201d\n\nParticularly for first-time mothers, postpartum depression can be hard to distinguish from the stress and fatigue that come with caring for a new infant around the clock, Letourneau said.\nWhile all of the mothers were depressed at the start of the study, at mid-point only 32 percent were at risk for depression, and this declined to 15 percent at the end.\nOn average, the women spoke more than eight times and the calls typically lasted about 38 minutes, the researchers reported in the Journal of Advanced Nursing.\nThey also had nurses available for phone consults if they had concerns about anything the moms said during their conversations.\nBy midway through the study, 37 new moms had received at least one call from a peer counsellor.\n", "question": "Does the story commit disease-mongering?", "explanation": "PPD affects large numbers of women, by many accounts, And it quotes experts affirming its seriousness and impact. No mongering here.", "answer": 1}, {"article": "For more information about the AACR, visit http://www.\nThe AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer.\nIn the dose escalation phase, the researchers determined that the maximum tolerated dose was 200 milligrams (mg) every 12 hours; the dose-limiting toxicity was grade 3 fatigue.\nAbemaciclib also penetrates the central nervous system, whereas palbociclib does not, raising the possibility that it could be used to treat primary or metastatic brain tumors, he added.\nPatnaik has received research funding from Lilly.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not exaggerate the seriousness of the cancers that were studied.", "answer": 1}, {"article": "\"The electronic nose discriminates between patients with asthma and healthy subjects and its performance is increased when combined with FENO,\" wrote the Italian team led by Dr. Paolo Montuschi of the Catholic University of the Sacred Heart in Rome.\nNone of the study volunteers had a history of smoking.\nThese VOCs produce a unique smell print for each individual and specific patterns are seen in people with asthma.\nWe also need to know if it's good for diagnosing all types of asthma.\"\nEach test is non-invasive, requiring only the use of exhaled air.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering in this story.", "answer": 1}, {"article": "But Dr. Stephen F. Sener, a professor of surgery at the Keck School of Medicine at the , wrote in an e-mail message: \u201cI\u2019ve seen enough injections of fat after mastectomies to tell you that fat necrosis is a real problem.\u201d It can result in a \u201cpalpable mass\u201d that needs to be biopsied to establish malignancy or infection, wrote Dr. Sener, the former president of the .\nBut when they can\u2019t, biopsies may be done.\nThe study, which Dr. Khouri plans to publish in a peer-reviewed journal, found that the procedure does not impede the reading of mammograms and that on average, 85 percent of transplanted fat survived to give patients natural-feeling larger breasts.\nThis kind of is a two-fer: trim fat where you don\u2019t want it and put it where you do.\nThat hasn\u2019t stopped Dr. Todd Malan, a board-certified ob-gyn in , Ariz., who is the surgeon in the ABC news clip, from anointing himself the \u201cFirst in U.S. to perform Stem Cell Enhanced Breast Augmentation!\u201d on his Web site.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story does not address how women should make a decision about breast augmentation, whether through fat grafting, implantation or other means. ", "answer": 2}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story commit disease-mongering?", "explanation": "The story inappropriately describes women with polycystic ovarian syndrome (PCO) as those \"who don\u2019t produce mature eggs and can get sick on fertility drugs.\"\u00a0 As a sweeping statement it is way off the mark and given the focus in the scientific literature about IVM is on this subfertile group, it is an exagerration.\nIn a British study that is a good example of reproductive epidemiology (Clayton RN, Clin Endocrin 1992) that systematically screened 353 women with ultrasound for PCO they found: Proven prior fertility was the same in PCO (56%) and non-PCO (64%) women and an equal proportion in each group had not yet tested their fertility. Of those women with previously proven fertility, self-perceived difficulty in conception occurred in similar proportions of women with and without PCO. Unresolved primary or secondary infertility (2.5-4%) was similar in both groups. \nThe prevalence of PCO\u00a0in the general population and in infertility treatment populations don\u2019t match \u2013 it is a biased sample that are referred \u2013\u00a0and the outcomes are not comparable. A number of trials have shown metformin and clomiphene citrate (both pills) to enhance conception in women with PCO and metabolic syndrome. These drugs do not cause ovarian hyperstimulation and thus would be general gynecology treatments used far before IVF (or IVM with IVF). \n\u00a0", "answer": 0}, {"article": "WEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\nThe study included 520 youngsters with ear infections.\nAbout three-quarters of children have ear infections in their first year of life.\nWhat's more, the children in the five-day group didn't have a lower risk of antibiotic resistance or of side effects such as diarrhea or diaper rash.\nThe study was published Dec. 21 in the New England Journal of Medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "Ear aches are a real and present concern of parents with young children.", "answer": 1}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. It correctly states the risk of broken bones in people over age 50 and the risk of death in older people who break a hip. This story will also help reduce over-treatment and over-medicating of older adults, which is common.", "answer": 1}, {"article": "And Medicare has established a registry to see how well large-scale screening works.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nAmong the 65- to 74-year-olds getting CT scans in the national trial, moreover, many had other serious health problems \u2014 heart disease, diabetes, hypertension, pulmonary disease \u2014 which probably contributed to only 55 percent surviving five years, compared with 64 percent among those under age 65.\n\u201cThe only way to prevent lung cancer or reduce your risk,\u201d Dr. Gould said, \u201cis to stop smoking.\u201d\n\u201cIf I find a teensy lung cancer in a 77-year-old with heart disease, I may not have done him any favor,\u201d Dr. Arenberg said.\n", "question": "Does the story commit disease-mongering?", "explanation": "In some ways, this story is an example of a way to avoid disease-mongering. Because any Medicare-approved procedure will, by definition, be carried out on elderly individuals, the story\u2019s reflections on \u201ccompeting mortality\u201d\u2014the tendency for older folk to be saddled with multiple chronic diseases\u2014emphasizes the importance of situating lung cancer among the elderly in a larger matrix of health issues. Lung cancer is clearly an important disease, but, as one physician/researcher noted in the story, \u201cIf I find a teensy lung cancer in a 77-year-old with heart disease, I may not have done him any favor.\u201d", "answer": 1}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story commit disease-mongering?", "explanation": "The story provides a brief description of the nature of type 2 diabetes, namely that it is more common with age and among those who are overweight, which is true. ", "answer": 1}, {"article": "Israel is director of the respiratory therapy department at Brigham and Women's Hospital in Boston.\nFor more on asthma, visit the U.S. National Heart, Lung, and Blood Institute.\n\"By blocking the signal that helps keep mast cells alive, we were hoping to reduce the number of these cells,\" Israel said.\n\"There was a small but significant improvement in the airway narrowing in these patients, which we didn't expect because we didn't think the mast cells were necessarily promoting that airway narrowing all the time,\" Israel said.\nGleevec (imatinib) reduced the \"twitchiness\" of airways, making them less likely to reflexively constrict when exposed to an allergen or asthma trigger, said senior researcher Dr. Elliot Israel.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t exaggerate the prevalence of severe asthma. It would have been useful to indicate how many people fall into this category. Some 18.4 million U.S. adults have asthma, or 7.6 percent of the adult population, and about half of those cases are uncontrolled, according to the CDC.\n\u00a0", "answer": 1}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the prevalence or severity of heart failure. \n", "answer": 1}, {"article": "THURSDAY, Feb. 24, 2011 (HealthDay News) -- Blood tests that indicate prostate-specific antigen (PSA) levels are rising rapidly over time are of little use in detecting aggressive prostate cancer and should not be done, a new study indicates.\nThe men in the study were all from the placebo arm, meaning they had not received the drug.\nMen with both high and low levels of PSA can have cancer or not have cancer.\nThe National Cancer Institute has more on the PSA test.\nAs part of the trial, all of the men agreed to have a biopsy at the end of the trial, needed or not.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "However, a pre-planned interim review of the treatment effectiveness after 200 patients were enrolled in the trial led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial, based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the studied patients.\nOnly 13.1 percent of the medication group had a similar decrease.\nThe mantra 'time is brain' still holds true.\"\nThere was no difference in mortality or other safety end-points between the two groups.\nThe trial was sponsored by Stryker Corporation, a medical technology company that manufactures the clot removal devices used in the study.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe top of the story notes that this drug is intended for use in a small subset of lung cancer patients. Deeper in the story, readers are told that roughly 4 percent of patients with advanced non-small cell lung cancer have tumors with the gene variant that may respond to this drug, and it quotes a Pfizer company source as saying that about 6,000 Americans a year develop cancer fitting this definition. It would have been helpful for this story to include some estimate of the number of lung cancer patients who may be candidates for testing to see if their tumors have the relevant gene.", "answer": 1}, {"article": "Nearly 40 percent of participants getting the drug saw all or almost all of their rash disappear.\nMost patients who got the active drug, dupilumab, instead of a placebo reported that the itching began to wane within two weeks and was gone in a few months, as their skin began to clear.\nOn Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\n\u201cI knew immediately I was on the drug\u201d and not the placebo, said Daniela Velasco, an event planner in Playa del Carmen, Mexico.\n", "question": "Does the story commit disease-mongering?", "explanation": "The estimate of the prevalence of \u201cuncontrolled, moderate-to-severe\u201d eczema used in the story seems to be in line with conservative estimates. As noted above, the story would have been better if it had told readers that eczema is far more common in children than adults, and that preliminary studies involving children are just getting underway.", "answer": 1}, {"article": "On the other hand, that analysis also found aspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d\n\nHeart disease is the leading killer worldwide and accounts for more than a third of deaths in the U.S., according to the American Heart Association.\nAbout 100,000 men and women age 45 and up took part in the studies.\n\u201cThere is not universal agreement on what is high risk,\u201d he told Reuters Health.\nEvery year, heart attacks alone kill some 400,000 Americans.\n\u201cA blanket recommendation that everybody should take an aspirin is not a good idea.\u201d\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in this story.", "answer": 1}, {"article": "Wolf notes, however, that chemoradiation often severely damages the larynx, which may cause problems with eating or swallowing years later.\nAll three must be involved to assess the patient and refer to the appropriate therapy.\nThe responders can continue with combination chemotherapy and radiation.\n\"This approach allows us to enhance quality of life for all of our patients.\nThe non-responders can be referred immediately for surgery.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The study, conducted in conjunction with the University of Washington, involved 56 men who were assigned to receive one of three types of gels: one gel containing both testosterone plus a gel containing one of two doses of the synthetic progestin; or a gel containing testosterone on its own plus a \"placebo\" gel with no progestin.\nUp to 78 percent of men receiving the drug combination in the study saw their concentrations drop to no sperm at all, versus only 23 percent of men taking testosterone alone.\nThat's apart from mild-to-moderate acne or an increase in acne, which was seen in about 21 percent of participants.\nUnfortunately, condoms and vasectomy have remained the only commercially available contraception options for men.\nOne important and unanswered question is what the long-term side effects of this regimen might be.\n", "question": "Does the story commit disease-mongering?", "explanation": "Providing alternative contraception options for men is an important issue, as the story suggests.", "answer": 1}, {"article": "UW-Madison radiology professor Weibo Cai is also a senior author on the study.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\nMeasuring less than 1 centimeter across, or about a third of the area of a U.S. penny, the tiny devices -- which are safe for use in the body and implantable via a minimally invasive procedure -- generate gentle electric pulses from the stomach's natural churning motions and deliver them to the vagus nerve, which links the brain and the stomach.\nMADISON, Wis. -- More than 700 million adults and children worldwide are obese, according to a 2017 study that called the growing number and weight-related health problems a \"rising pandemic.\"\nThat existing unit, \"Maestro,\" approved by the Food and Drug Administration in 2015, administers high-frequency zaps to the vagus nerve to shut down all communication between the brain and stomach.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The lead sentence of the release proclaims that more than 700 million adults and children worldwide have obesity. However, many people who are obese are not considered candidates for treatment with this type of weight loss device. Obesity is defined as a Body Mass Index greater than 30. The existing similar device is approved only for certain patients with a BMI greater than 35 or 40, depending on other health factors and previous treatment. In other words, the release overstates the number of people who might be candidates for receiving this experimental device, if it ever comes to market.", "answer": 0}, {"article": "At study enrollment, none had signs of dementia.\nThe participants were recruited from people already taking part in the Rush Memory and Aging Project, a study of residents of more than 40 retirement communities and senior public housing units across northern Illinois, plus older adults identified through church groups and social service agencies.\nThe study did not find a significant difference in the rate of decline in episodic memory (recollection of personal experiences), working memory (short-term memory used in mental function in the immediate present) and visuospatial ability (comprehension of relationships between objects).\n\"This study helps show that while cognitive abilities naturally decline as part of the normal aging process, there is something that we can do to mitigate this process,\" says Martha Clare Morris, ScD, a Rush nutritional epidemiologist and senior author of the paper.\nThe results were the same after researchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The opening paragraph talks about protecting against \u201cthinking problems.\u201d Readers could be excused if they translate \u201cthinking problems\u201d to mean senility or dementia. But the story quickly notes that \u201ccognitive abilities naturally decline as part of the normal aging process\u201d \u2014 and that\u2019s what we wanted to see. This study was about slowing that normal decline, not addressing specific medical conditions such as Alzheimer\u2019s disease.", "answer": 1}, {"article": "And will they change the quality of sleep in any way?\nThe appeal of orexin antagonists, said Dr. Michael Thorpy, director of the Sleep-Wake Disorders Center at Montefiore Medical Center in New York City, is that they \"target a system that's more specific for sleep.\"\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\nUslaner and his colleagues investigated a compound called DORA-22, which has the same mechanism of action as suvorexant, to see how it fared alongside not only Ambien and Lunesta but also diazepam (Valium) in rats and rhesus monkeys.\nLunesta and Ambien affect GABA receptors, which are found throughout the brain and are associated with side effects, including thinking disturbances, and deficits in attention and memory, explained Uslaner.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering is seen. While the \u201c30 million Americans\u201d figure used in the story oversimplifies the extent of insomnia, it is in the range of estimates commonly used by experts.", "answer": 1}, {"article": "\"Sixty to 80 percent [success] for something that somebody's not going to get guaranteed pain relief -- in my mind, it's not something I would go for,\" Duggal says.\nThe healing process takes place over several months after the shock-wave therapy, which Theodore does in a single treatment.\nSuddenly the room is filled with the rhythmic click-click-click of a metronome.\nDuggal is not impressed with reported success rates.\nAfter a few months, she's back to running -- but shorter distances.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not exaggerate the effects of heel pain.", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in the story.", "answer": 1}, {"article": "In investigating how BCG administration produces its beneficial effects, the research team identified a mechanism never previously seen in humans in response to treatment with any drug - a shifting of the process of glucose metabolism from oxidative phosphorylation, the most common pathway by which cells convert glucose into energy, to aerobic glycolysis, a process that involves significantly greater glucose consumption by cells.\nParticipants in the placebo group and in a comparison group of patients receiving no treatment experienced consistent HbA1c elevations over the same eight-year time period.\nMassachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School.\nNetea was not involved in the current study.\nor by emailing DiabetesTrial@partners.org.\n", "question": "Does the news release commit disease-mongering?", "explanation": "None. Type I diabetes is common and can be difficult to treat.", "answer": 1}, {"article": "The other half went to Weight Watchers meetings, had access to Weight Watchers' online materials and had two phone consultations and follow-up email contact with certified diabetes educators who told them how to modify the Weight Watchers plan to help with their diabetes.\nDiabetes is a growing problem.\n\"You do have some power and control,\" he said.\nWeight loss is seen as a good way to slow its progression.\nPromoting healthy communities is part of MUSC's mission.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "Currently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\n\"This drug inhibits the pathway that's activated in smokers.\nThe U.S. National Cancer Institute has more on lung cancer.\n\"This definitely has potential.\"\n\"We have identified a marker for an early risk of developing lung cancer.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering about lung cancer. ", "answer": 1}, {"article": "\"This study does not indicate that distance runners are any more likely to get osteoarthritis than any other person,\" Seeley said.\n\"What we now know is that for young, healthy individuals, exercise creates an anti-inflammatory environment that may be beneficial in terms of long-term joint health,\" said study lead author Robert Hyldahl, BYU assistant professor of exercise science.\nThe researchers found that the specific markers they were looking for in the extracted synovial fluid--two cytokines named GM-CSF and IL-15--decreased in concentration in the subjects after 30 minutes of running.\nRunning may also slow the process that leads to osteoarthritis\n\nWe all know that running causes a bit of inflammation and soreness, and that's just the price you pay for cardiovascular health.\nIn other words, it appears running can reduce joint inflammation.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. Osteoarthritis in the knees and other joints is a factor of aging.\u00a0 Anything that can prevent this occurrence is of benefit.", "answer": 1}, {"article": "Cardinal says older adults need to realize that exercise can greatly improve their quality of life by maximizing function as long as possible.\nPhysicians can also help.\nSemantics can help.\n\"It's the secret ingredient to successful aging in terms of quality of life.\"\nNot so.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not commit disease-mongering.", "answer": 1}, {"article": "As is often the case, there are many additional factors at play.\nThe good news, we're told, is that there are many things we can do \u2013 or not do \u2013 in our adult lives to lower our risk of developing different types of cancer.\nA cursory review of the data suggests, for example, that the number of male sexual partners is greatly underreported.\nIt's important to note, right off the bat, that this study is not purporting to establish a cause and effect relationship.\nIt has long been established that men who are uncircumcised are more prone to contracting sexually transmitted infections.\n", "question": "Does the story commit disease-mongering?", "explanation": "We\u2019ll flag this story for an overly bombastic and totally unnecessary lead sentence. Cancer is not the medical equivalent of Lord Voldemort from the Harry Potter books.", "answer": 0}, {"article": "However, the N.Y.U.\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\nThe Standardized Assessment of Concussion had performed rather miserably, correctly identifying only two of the concussed athletes, missing 10, and finding that three of the uninjured control athletes had supposedly sustained a concussion, since their scores had declined compared with their baseline (almost certainly, the study\u2019s authors believe, because these young athletes were physically tired).\nThe upshot, Dr. Galetta believes, is that parents and coaches \u201cshould absolutely consider\u201d familiarizing themselves with the King-Devick test and administering it to young athletes before the season starts, then having those baseline numbers and the test itself handy on the sidelines.\nThe most commonly recommended sideline test is the Standardized Assessment of Concussion, a multipart examination during which athletes are asked to name the date, describe how they feel, memorize and recall lists of words, and do jumping jacks and other tests of coordination.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. If anything, the story could have reinforced the seriousness of the issue of concussion among student athletes. The University of Pittsburgh\u2019s Brain Trauma Research Center, one of numerous institutions conducting concussion-related research, estimates that 300,000 sports-related concussions occur annually in the United States, and that athletes have a 19 percent chance of experiencing a concussion each season.\nThat being said, we don\u2019t want to be accused of disease-mongering ourselves, so we\u2019d add that it\u2019s not at all clear what the long-term consequences of these concussions are. \u00a0There are obviously news stories about tragic events, but how large a problem is it in terms of long-term impairment? And how does it compare to head injuries resulting from non-athletic events? While there is a lot of attention right now on head injuries \u2013 and that is a good thing if it leads to more studies \u2013 it isn\u2019t clear how serious a problem it is compared to other health risks.", "answer": 1}, {"article": "\"I wasn't interested in going as far as getting an amniocentesis because of the risk associated with that,\" she explains, \"and so when I heard about this test, that was part of the reason that I was most interested in it.\"\nThe tests are being used more and more widely.\nThey're less likely to flag a normal pregnancy as high risk.\nDoctors say the impact has been huge.\nSeveral companies now offer the test, including Sequenom and Illumina.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not commit disease mongering.", "answer": 1}, {"article": "\"Multicentric Cancer Detected at Breast MR Imaging and Not at Mammography: Important or Not?\"\n\"Patients with clinically insignificant cancers undergoing potential overtreatment versus patients who may be undertreated is at the heart of the controversy surrounding breast MRI,\" said the study's lead author Chiara Iacconi, M.D., from the Breast Unit at USL1 Massa-Carrara in Carrara, Italy.\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\n\"In general, it is accepted that radiation can likely treat invasive cancer less than 1 centimeter, but lesions larger than 1 centimeter, especially invasive carcinomas, may not be reliably treated with conservation.\"\nOAK BROOK, Ill. - Additional breast cancers found with MRI are sometimes larger and potentially more aggressive than those found on mammography, according to a study published online in the journal Radiology.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We will give the release a satisfactory rating on this criterion because it does point out that the MRI images were obtained during preoperative planning for women already diagnosed with breast cancer. However, the release would have been much better if it specifically warned that the researchers were not looking at MRI breast scans of women in the general population and that this study is not relevant to discussions about whether or not to include MRI in screening women.\nAlso, the wording of the release, in particular the final quote, could create confusion about how often MRI scans revealed \u201ca larger tumor burden.\u201d The quote refers to \u201ca quarter of patients,\u201d but it appears to refer to a quarter of patients who had tumors found through MRI (18 of 73 women), not a quarter of all 2,021 patients in the study. Writers of releases should be careful about technically-accurate language that could confuse or even mislead readers.", "answer": 1}, {"article": "Over-the-counter multivitamins typically contain 15 to 25 IU of vitamin E.\n\nThe newly-released Physicians Health Study showed an 8 percent reduction in total cancer occurrence for participants taking a multivitamin, but no benefit was seen for rates of prostate cancer, the most common cancer seen among the participants in the study.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\nThey also saw a 12 percent reduction in the risk of death from cancer, although those findings also were not statistically significant.\nExcluding prostate cancer, researchers found about a 12 percent reduction in overall cancer occurrence and said the protective effect seemed to be greater in people who had previously battled cancer.\nThe research was sponsored by the National Institutes of Health.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story points out that the participants were healthy middle-aged men. There was no disease-mongering of cancer.", "answer": 1}, {"article": "\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nWhile the new screen only looks for Down syndrome, Sullivan says that some of the other trisomy birth defects can be more easily identified on an ultrasound exam.\nFor now the test just looks for Down syndrome, but \u201ctechnology will advance to the point where noninvasive testing will encompass more of the less common genetic anomalies,\u201d she says.\n\u201cIt\u2019s not ready for prime time, but researchers are actively working on methods to increase its efficiency,\u201d he says.\n\u201cFor women who are concerned about losing a pregnancy as a result of an invasive test, this is an excellent addition to our armamentarium of screening,\u201d she says.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does avoid disease monitoring, but we wish it had included some of the data from the paper about the frequency of Down syndrome and even some of the other disorders. The LA Times blog piece managed to do this in much less space.", "answer": 1}, {"article": "The efficacy and safety analyses with tramiprosate published in JPAD reveal a therapeutic effect in patients who are carriers of APOE4 after segmenting them from the larger, non-genetically-defined study population in the Phase 3 clinical program, involving more than 2,000 AD patients in North America and Europe.\nThe rate of nausea and vomiting was also lower than with tramiprosate tablets.\nAs a result, the European study was terminated before completion, and the results were not previously published.\nALZ-801 at the dose of 265 mg provided equivalent systemic plasma exposures to tramiprosate 150 mg tablets.\nAPOE encodes for a protein called apolipoprotein E, which combines with fats to form lipoproteins that can be moved throughout the body.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "The study is presented today (4 September, 2016) at the European Respiratory Society's International Congress.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\nFindings revealed that during the weeks that infants were breastfed, those carrying the asthma risk genotypes, had a 27% decreased relative risk of developing respiratory symptoms.\nDr Gorlanova said: \"As research in this field progresses, we are understanding more and more about the gene-environment interaction for the development of asthma.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here. However, we would have liked to have seen some information in the release about the prevalence of asthma in the developed and developing world.", "answer": 1}, {"article": "San Francisco--A new study, presented today at the Society of NeuroInterventional Surgery's (SNIS) 15th Annual Meeting, found that new stroke imaging technology could decrease delays in care by up to 60 minutes, giving patients a better chance at making a full recovery.\nThe imaging allows accurate detection of hemorrhage, occlusion site, ischemic core, and tissue at risk, suggesting that baseline imaging can be performed in the angiosuite using cone beam imaging.\nThe time required to transfer a patient from their CT scan to the operating room could delay EVT by as long as 60 minutes.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\nThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. Minimizing the consequences of acute stroke is an important health topic. It would have been helpful if the release had included some context about the prevalence of stroke or how many patients might potentially be candidates for the new technology.", "answer": 2}, {"article": "THURSDAY, June 8, 2017 (HealthDay News) -- Scary pit vipers may need an image upgrade: Their venom might end up helping human heart patients, research suggests.\nReviewing the findings, he agreed that the drug under development may have merit.\nHowever, it is often at the cost of serious bleeding complications,\" he said.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\nWhen mixed with blood, the new compound prevented blood cells called platelets from clotting.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not disease monger.", "answer": 1}, {"article": "The results were published in January in Nature Medicine.\nThis is why researchers continue to look for other ways to control the virus--and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\n\"But to clearly demonstrate that these antibodies have an advantage over the pill that's currently used, we would need to test them in large numbers of people and show that they remain active for a prolonged period of time in the body.\"\n\"It has been challenging to find trial participants with high levels of the virus here in New York,\" Caskey says, \"so our collaboration with the University of Cologne has been very valuable.\"\nAlthough it has been a lifesaver for people infected with the virus, antiretroviral medications have significant drawbacks: they can cause severe side effects, and patients have to take them for life.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no overt disease mongering but the release states\u00a0that \u201cpeople who do not have HIV are at substantial risk of getting it,\u201d especially those with multiple sexual partners\u00a0or an HIV-infected partner.\nThe release didn\u2019t provide context on HIV prevalence. However, it did offer context on current\u00a0antiretroviral therapy and its drawbacks.\n\u201cToday, HIV is typically treated with antiretroviral therapy, a drug regimen that became available in the 1990s. Although it has been a lifesaver for people infected with the virus, antiretroviral medications have significant drawbacks: they can cause severe side effects, and patients have to take them for life. This is why researchers continue to look for other ways to control the virus\u2014and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\u201d", "answer": 1}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\n\"We don't want to send the message to people who have bone-on-bone, with big bone spurs and limited range of motion that they're all of a sudden going to get relief from injecting a little bit of cement into their bone,\" Hepinstall said.\n\"But there's a very narrow window of patients who are good ideal candidates for this, who basically have a real overload of their bone causing severe enough pain to warrant a surgical procedure, but also have healthy enough cartilage that doing something about the bone swelling is going to alleviate the majority of their pain,\" he stressed.\nThe procedure involves a smaller incision than joint replacement surgery, so there's less risk of infection, and a quicker recovery time that means fewer of the side effects associated with being bedridden, Vasileff said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Arthritis is a common concern for many, and this story does not distort the impact it can have on people\u2019s lives.\nOne thing to note: Arthritis is typically associated with aging, and the quote from one recipient of the bone cement procedure that he feared having a \u201ca fake hip in there at the age of 30\u201d confuses this issue, since it is rare for a young adult to have advanced arthritis that would require joint replacement surgery.", "answer": 1}, {"article": "CHICAGO (Reuters) - Exelixis Inc\u2019s cabozantinib experimental drug shrank bone malignancies from prostate cancer in 76 percent of patients, interim results from a midstage trial show.\nExcluding patients on placebo, the median survival without disease progression was 29 weeks.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\nExelixis expects to have initial results around midyear from a pivotal trial of the drug as a treatment for thyroid cancer.\nThe drug reduced by 87 percent the risk of disease progression or death.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of late-stage prostate cancer.", "answer": 1}, {"article": "This gives them a tool.\u201d\n\nNow the looming questions are how to implement risk calculators in doctors\u2019 practices \u2014 and, Owens said, whether that benefits patients\u2019 health in the real world.\nDoctors generally add their own judgment to that decision as well.\nIt also factored in what\u2019s known about different types of patients\u2019 responses to various blood pressure medications.\nIt found that the tailored approach could prevent 43 percent more heart attacks and strokes than the simpler, general recommendations used now.\nDoctors, ideally, then adapt those guidelines to individual patients\u2019 situations.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering.", "answer": 1}, {"article": "Sometimes patients get stents when they have no pain at all, just blockages.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nHeart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nMore than 500,000 heart patients worldwide have stents inserted each year to relieve chest pain, according to the researchers.\n", "question": "Does the story commit disease-mongering?", "explanation": "Heart disease is very common in our society and opening up blocked arteries is a common almost routine procedure. No disease mongering occurred in the article.", "answer": 1}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story commit disease-mongering?", "explanation": "The story\u00a0is putting forth the idea that this type of drug might be a great idea to use in everyone older than 50.\u00a0The suggestion that everyone needs a pill in the absence of any evidence, and that healthy older adults would benefit, is classic disease-mongering.", "answer": 0}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\nThey graded the severity of these calcium deposits using scans done for osteoporosis screening.\nThis makes bone density testing even more useful in screening.\"\nThe study was recently published in the Journal of Bone and Mineral Research.\n, follow us on Twitter @H_SeniorLife, like us on Facebook or read our blog.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "None of the participants had serious side effects from the MILs therapy.\nResults of the trial involving a particular type of tumor-targeting T cell, known as marrow-infiltrating lymphocytes (MILs), are described in the May 20 issue of Science Translational Medicine.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nIn nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nThe overall survival was 31.5 months for those with less than 90 percent disease reduction, but this number has not yet been reached in those with better responses.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Describing multiple myeloma as \u201cthe second most common cancer originating in the blood\u201d doesn\u2019t add much to our understanding of this disease. However, other statistics provide context regarding the scope of the problem in the United States. We\u2019ll give it a pass.", "answer": 1}, {"article": "\"PSA can identify those at low risk of prostate cancer and once you have done that, you can remove almost 50 percent of men in the age group 55 to 74 [from undergoing biopsies],\" said study senior author Monique Roobol, an epidemiologist in the department of urology at Erasmus University Medical Center in Rotterdam.\nEighty percent of men in the group had PSA levels below that threshold.\nThe National Cancer Institute has more on prostate cancer.\nIn comparison with typical laparoscopic surgery, RALP offers surgeons three-dimensional vision and such improvements as better magnification and hand tremor filtering.\nThis compares with 15.7 percent of those with scores from 2 percent to 2.9 percent developing a malignancy and 0.36 percent dying of the disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "The German analysis found only five such studies.\nThough that difference is well established among radiologists, the new study may be of assistance in the general medical community, including general cardiologists, because \"it summarizes the advantages of CT at this point in time,\" he said.\n\"For ruling out coronary artery disease, CT is more accurate than MRI,\" researchers from Humboldt University in Berlin said in a report in the Feb. 2 issue of the Annals of Internal Medicine.\n\"This article holds no surprises whatever,\" said Dr. Uwe Joseph Schoepf, a professor of radiology and cardiology at the Medical University of South Carolina.\nBut doctors do not always want to run the risks that can be associated with that technique, and the leading candidates for less invasive assessment are CT and MRI.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story doesn\u2019t exaggerate the burden of coronary artery disease, the biggest cause of deaths for humans in the developed world. \nIt\u2019s worth nothing, however, that we think the story does exaggerate the number of people who are appropriate candidates for CT scans of the heart.", "answer": 1}, {"article": "By using image processing and machine learning to teach computers how to spot signs of precancerous and cancerous cells, Asiedu hopes to remove the need for a trained physician at any point in the screening process and shift the task to midwives, community health workers and even the women themselves.\nThe colposcope is a magnified telescopic device and camera designed to allow medical professionals to look through the speculum to see the cervix, which is located three to six inches inside the vagina.\n\"Nearly everyone said they preferred it to a traditional speculum and more than 80 percent of the women who tried the device were able to get a good image.\nWhile more than 4,000 American women die of the disease each year, the mortality rate has dropped more than 50 percent in the past four decades, largely due to the advent of well-organized screening and diagnostic programs.\n\"There have been a few other attempts to come up with a better solution, but none of them have succeeded,\" said Asiedu.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this release. It provides ample context on cervical cancer incidence and tests used in its diagnosis.", "answer": 1}, {"article": "Prozac was developed by Eli Lilly and is now available in a cheaper generic form as fluoxetine.\nSignificantly greater improvements in motor function were recorded after three months in patients taking Prozac, where the average test score improved by 34.0 points, than in the placebo group, where the average improvement was 24.3 points.\nHemiplegia \u2014 paralysis to one side of the body \u2014 and hemiparesis \u2014 weakness on one side of the body \u2014 are the most common disabilities after stroke and scientists believe SSRIs might help improve movement by increasing the level of the brain chemical serotonin in the central nervous system.\nThe cost of caring for its victims, who often have motor function difficulties like paralysis or weakness on one side, puts a heavy burden on already stretched healthcare systems.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\n", "question": "Does the story commit disease-mongering?", "explanation": "This is one of the areas where this story could have been a lot clearer by explaining the study population with more detail than just \u201cpeople who just had a stroke.\u201d It was people who had the more common type of stroke, ischemic stroke, leading to a specific type of motor deficit.\nPatients enrolled in this study had profound weakness due to a stroke, and these results may be generalizable to that population. But many patients have milder and even more severe stroke symptoms. It is uncertain whether these results would apply to lesser or more severely affected patients. By not saying these results only apply to a certain subset of stroke patients, the story implies that this is a good treatment for any patient with motor weakness after a stroke. That implication would widely overstep the findings reported in this study.\nIn addition, the study itself doesn\u2019t say how many patients were screened to enroll the 118 patients. In other words, it doesn\u2019t describe how much the general population was filtered. That information would give a clue to how small this subpopulation really is out there in the real world.", "answer": 0}, {"article": "MINNEAPOLIS - People who eat vegetables, fruit and whole grains may have lower rates of depression over time, according to a preliminary study released today that will be presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles, April 21 to 27, 2018.\nParticipants were divided into three groups based on how closely they adhered to the diets.\nThe American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with over 34,000 members.\nThey were monitored for symptoms of depression such as being bothered by things that usually didn't affect them and feeling hopeless about the future.\n.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit.\nInformation on their diabetes medications was collected from electronic pharmacy records.\nThis study was funded by the National Institutes of Health.\nSakoda declares no conflicts of interest.\nOf them, 80 were nonsmokers, and 203 were current smokers.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not commit disease-mongering.", "answer": 1}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.\nWe were glad to see the article include this relevant context:\nAs many as two-thirds of people with depression aren\u2019t helped by the first antidepressants they try, leaving many to spend months after they are diagnosed without real help \u2026. [genetic testing] is meant to help avoid the painful trial-and-error process many depression patients endure in the search for the right medicine.", "answer": 1}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release commit disease-mongering?", "explanation": "OK, they got one batter out here \u2014 one Satisfactory rating. Weight loss is indeed recommended for most Americans, and as the release states, it is indeed difficult, with most diet plans failing to deliver long term benefits.", "answer": 1}, {"article": "\"The study by Schwartz and colleagues in this issue of JAMA Pediatrics adds to a growing body of evidence supporting the importance of providing drinking water access in schools.\n\"Even a small, straightforward, relatively inexpensive policy intervention was associated with a small but statistically significant drop,\" Elbel told CBS News.\nModern water dispensers may be more effective than old-fashioned water fountains since water quality and cleanliness may deter kids from using older fountains, and they're not as efficient at serving large numbers of children, experts noted in an accompanying editorial.\nWater jets also were linked with a decrease in the amount of half-pints of milk students bought, which could be a potential mechanism of weight reduction, the researchers found.\nThe large, clear, electrically cooled jugs with a push lever for fast dispensing were placed in 483 school cafeterias, about 40 percent of schools during the 2008-2009 and the 2012-2013 school years.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story.", "answer": 1}, {"article": "So far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nSumathi Reddy has details on Lunch Break.\nPhoto: AP.\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nProbiotics are widely used to aid digestion and help restore gut bacterial balance after antibiotics.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "Largely due to its anti-inflammatory and anti-bacterial properties, the herb thyme -- which is found with other herbs in the produce section of most food stores -- may well earn itself a place in the skin care section of your local drug store.\n\"The problem with treatments containing benzoyl peroxide is the side effects they are associated with,\" namely a burning sensation and skin irritation.\n\"Herbal preparations are less harsh on the skin due to their anti-inflammatory properties, while our results suggest they can be just as, if not more, effective than chemical treatments,\" she says.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\n", "question": "Does the story commit disease-mongering?", "explanation": "There wasn\u2019t any meaningful discussion of acne \u2013 so this is not applicable.", "answer": 2}, {"article": "Today\u2019s action supports the FDA\u2019s Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging\u2014an effort to ensure that each patient is getting the right imaging exam, at the right time, with the right radiation dose,\u201d said FDA Commissioner Scott Gottlieb, M.D.\nThe Brain Trauma Indicator was able to predict the presence of intracranial lesions on a CT scan 97.5 percent of the time and those who did not have intracranial lesions on a CT scan 99.6 percent of the time.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\nBeing able to predict if patients have a low probability of intracranial lesions can help health care professionals in their management of patients and the decision to perform a CT scan.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no outward disease-mongering but the information about deaths from TBI seemed a bit over-the-top since the population targeted by this test have potential mild TBI which would be unlikely to kill.", "answer": 1}, {"article": "and AIDS.\nThe virus is transmitted by blood, so most people who have hepatitis C either have injected illegal drugs or received blood transfusions or blood products before the early 1990s.\nSome 2.7 million to 3.9 million Americans are estimated to have hepatitis C, and 12,000 die from it each year, according to a recent report by the Institute of Medicine.\nThe standard therapy of interferon and ribavirin was given for either 24 weeks or 48 weeks, depending on how the patients were faring after four weeks and 12 weeks.\nOf those who got 12 weeks of telaprevir, 75 percent had a sustained viral response, meaning the virus was not detectable in their blood 24 weeks after completing treatment.\n", "question": "Does the story commit disease-mongering?", "explanation": "The description of the scope of the disease is fairly standard and well sourced. \"Some 2.7 million to 3.9 million Americans are estimated to have hepatitis C, and 12,000 die from it each year, according to a recent report by the Institute of Medicine. The disease can cause cirrhosis, which is a scarring of the liver, as well as liver cancer. The virus is transmitted by blood, so most people who have hepatitis C either have injected illegal drugs or received blood transfusions or blood products before the early 1990s.\" We wish we\u2019d seen a source on the idea that most recent Hep C patients have injected illegal drugs.", "answer": 1}, {"article": "TUESDAY, March 29, 2011 (HealthDay News) -- If you're looking to lose those extra pounds, you should probably add reducing stress and getting the right amount of sleep to the list, say researchers from Kaiser Permanente's Center for Health Research in Portland.\nThese factors may also have a biological impact, he added.\nAnd the extra calories mostly came from saturated fat, which can spell trouble for waistlines.\nThose in the second phase of the trial continued their diet and exercise program.\nDuring this part of the trial, the participants lost an average of almost 14 pounds.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "The end point also shifts the paradigm from palliation to cure,\" remarked Dr. Scher.\nHowever, none achieved the primary end point of undetectable PSA with testosterone recovery at 20 months after initiation of therapy with ADT alone, although one patient had a PSA of Of the 15 patients with bone metastases, 14 (93%) reached an undetectable PSA when ADT, surgery, and radiation were used.\nThe results suggest that some men who have previously been considered incurable can possibly be cured; investigators also establish a new paradigm for testing various drug combinations in conjunction with local treatment of the prostate to determine which is the best approach (ie, has the highest undetectable disease rate).\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\nUltimately, four (27%) achieved the proposed end point, a PSA of 150 ng/dL at 20 months after the start of ADT, which remained undetectable in two patients for 27 and 46 months, respectively.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release focuses on the fact that metastatic prostate cancer has been considered incurable. That\u2019s true. And it\u2019s true that metastatic prostate cancer is often fatal. But it\u2019s also true that patients with metastatic prostate cancer can live with the disease for 5, 10 or 15 years \u2014 or longer.\nWhile the release doesn\u2019t disease monger per se, it does \u201ctreatment monger\u201d by over-hyping the benefit of the tested treatment approach and implying in several instances that this is a cure for metastatic prostate cancer. This small pilot study didn\u2019t show that.", "answer": 1}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering. The story offered some perspective on the impact of the the disease: \u201cAn estimated 5.7 million Americans live with Alzheimer\u2019s, a figure expected to rise as the population ages, the Alzheimer\u2019s Association says.\u201d", "answer": 1}, {"article": "Ankle replacement has been around for three decades, but it has been slow to catch on.\n\u201cBut I can\u2019t tell you how many patients come in, and I mention this option they don\u2019t even know exists.\u201d (Dr. Radnay, who says he has performed more than 100 ankle replacements using an Inbone device from Wright Medical Group of Arlington, Tenn., is now a paid consultant to the company, helping to gather data on long-term success rates.)\nThe procedure usually relieves pain, but the patient loses mobility in the ankle, leading to changes in gait and, ultimately, additional wear and tear and arthritic pain in other parts of the ankle.\nStill, Dr. Deland said, \u201cwe\u2019re getting fewer and fewer failures.\u201d\n\nThe new models require that less bone be removed, so the bone to which the device is affixed is stronger.\nAn estimated 50,000 people a year experience end-stage ankle arthritis, in which the ankle cartilage has worn away completely, causing painful bone-on-bone contact and some level of disability.\n", "question": "Does the story commit disease-mongering?", "explanation": "Borderline.\u00a0 The numbers fly fast and furious \u2013 \"Each year about two million Americans visit the doctor for ankle pain from arthritis or fracture. An estimated 50,000 people a year experience end-stage ankle arthritis.\"\u00a0 In framing the ankle as \"fast becoming a candidate\" for joint replacement, there is a whiff of disease-mongering in the air.\u00a0 Given the sourcing on the story \u2013 all experts with potential conflicts of interest \u2013 we\u2019re going to give this one a thumbs down. ", "answer": 0}, {"article": "P-Cure continues to develop advanced patient-centric solutions with a focus on adaptive therapy and real time motion management.\nP-Cure (P-Cure, Ltd.), a leading provider of Patient-Centric solutions for proton therapy, has received U.S. Food and Drug Administration (FDA) approval for its patented upright imaging solution.\nThe P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nIt may also deliver less collateral radiation to sensitive organs while enabling greater accuracy in proton beam delivery,\u201d said Michael Marash, Ph.D., founder and CEO of P-Cure.\nWith P-Cure, oncologists can develop a compact, gantry-less proton center for significantly less capital and operating costs, essentially making proton therapy more widely available and attainable.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release. It just plainly states that \u201cAdult and pediatric patients who will initially benefit from this clinical breakthrough will be those treated for cancers of the lung, breast, chest, the head and neck, and lower torso.\u201d\nWe\u2019d like to point out, though, that the release implies that there is an abundance of demand for this type of therapy (whether evidence-based or not) and the only limit is the supply.", "answer": 1}, {"article": "At two years following definitive SBRT for lung cancer among elderly patients, survival rates were 73 percent for cancer specific survival (CSS) and 57 percent for overall survival (OS).\nABOUT ASTROThe American Society for Radiation Oncology (ASTRO) is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies.\nThis high degree of precision makes SBRT particularly effective at sparing surrounding healthy tissue, which is important for tumor sites near essential organs, such as the heart and lungs.\nWhile the primary treatment for early stage lung cancer is surgical removal of the tumor, some patients may not be able to tolerate surgery due to health status, advanced age or other factors.\nAs the world\u2019s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer.\n", "question": "Does the news release commit disease-mongering?", "explanation": "It should be clear to readers that this study applies only to elderly patients with early stage lung cancer who are not able to undergo surgery.", "answer": 1}, {"article": "Swedish Study Finds Surgery For Prostate Cancer Better Than Waiting\n\nFor men diagnosed with prostate cancer, uncertainty about what to do remains a big problem, despite years of research on the options.\nResults are some years off.\n\"Active surveillance means observing the patient in a proactive way, with regularly scheduled biopsies,\" he adds.\nFar from it.\nBut don't leap to any conclusions.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease mongering.", "answer": 1}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story commit disease-mongering?", "explanation": "This story did not engage in disease mongering.", "answer": 1}, {"article": "Evivo has commenced rigorous clinical trials with the prototype to demonstrate the results from infant stool samples.\nThe liquid will remain pink if a sample has low levels of acetate and lactate, indicating that Bifidobacterium is missing and that key nutrients from breast milk, human milk oligosaccharides (HMO), are being wasted.\nPoint-of-Care Diagnostic Expert Turns Focus to the Infant Gut\n\nThe development of the prototype is led by Dr. Bethany Henrick, Ph.D., Director of Immunology and Diagnostics for Evivo.\nThe generational loss of this good bacteria in the infant gut allows for potentially harmful bacteria such as E. Coli and Clostridia to thrive, which are linked to higher risk of short- and long-term health issues such as colic, eczema, allergies, diabetes, and obesity.\nIdentifying a Disappearing, Yet Critical Piece of Gut Health\n\nDr. Henrick's previously published findings, which are the basis for the Evivo test, show an inverse correlation between rising infant fecal pH, reduced acetate and lactate, and lower levels of beneficial Bifidobacterium, proving that the infant gut microbiome has been rapidly changing over the last three generations.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release doesn\u2019t have any scary or over-the-top wording, but it does warn parents that not treating the microbiome in infants may lead to future health problems for their child. And that suggestion is not based on research showing a causal relationship. This appears to be a product looking for a disease that does not exist, or at the very least, a condition that is poorly understood.", "answer": 0}, {"article": "This clinical trial was funded by Merck.\nThe findings indicate that if uninfected populations are vaccinated with Gardasil 9, approximately 90 per cent of all cervical cancers worldwide could be prevented.\nPublished in the New England Journal of Medicine, the study found that, among uninfected women, Gardasil 9 was 97 per cent effective at preventing high-grade cervical, vulvar and vaginal disease caused by HPV 31, 33, 45, 52 and 58, and was equally effective as the current Gardasil vaccine in preventing diseases caused by HPV 6, 11, 16 and 18.\nA pivotal international clinical trial compared the safety and efficacy of the new vaccine, Gardasil 9, with the current vaccine, Gardasil, in more than 14,200 women aged between 16 and 26 years old.\nOur focus for prevention must be on girls aged 12-13, as the current UK vaccine programme is doing, but the vaccine may also be appropriate for women 25-45 as part of a screening appointment.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t exaggerate the burden of HPV infection or cervical cancer. In fact, we think the release could have done more to create urgency around the need to vaccinate.", "answer": 1}, {"article": "The results were just published online by the medical journal The Lancet.\nIt works by keeping the body from breaking down clots.\nA study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nSome 14.5 percent of patients who got the drug were dead within a month of being injured compared with 16 percent of those who got the dummy medicine.\nA 25-year-old medicine that costs less than $10 a treatment could save tens of thousands of people seriously injured in accidents or by violence.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering in this story.", "answer": 1}, {"article": "Related: De Niro says 'find the truth on vaccines'.\nThe scans showed that 70 percent of high-risk toddlers diagnosed with autism at age 2 had an elevated amount of cerebrospinal fluid around their brains at 6 and 12 months, compared to toddlers who were not diagnosed with autism.\nIt may be possible to predict autism in infants as young as 6 months who have older siblings with the disorder, according to a new study by a national network of researchers.\nIt may also be a mechanism in the development of autism, and it opens up new possibilities for research, she said.\nRelated: See the special bond between a boy with autism and a deaf shelter dog\n\nThe study results are \u201cvery exciting,\u201d said Dr. Adriania Di Martino, a professor of child and adolescent psychiatry at NYU Medical School.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this article, and it does a good job of establishing how prevalent autism is in the general population, and the rate of diagnosis\u00a0between siblings.", "answer": 1}, {"article": "\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nThe experimental treatment that may be closest to market is also one of the simplest.\nThe company has identified the peanut proteins that trigger allergic reaction and is filling little capsules with the stuff.\nResearchers at Stanford University are building on the concept of desensitization.\nTwo types of immune cells \u2014 called mast cells and basophils \u2014 are the biggest culprits behind allergic reactions.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering: the prevalence of allergies is high and, according to some sources, rising rapidly in the developing world as well as in the U.S.", "answer": 1}, {"article": "Type 2 diabetes is caused by the body\u2019s in ability to break down sugars from the diet.\nThe current study takes that work a step further and shows that it\u2019s possible to actually reverse the disease in people who have been diagnosed.\nMost importantly, 46% of the people in the diet group went into remission with their diabetes, compared to just 4% in the control group.\nBut excess fat in the pancreas and liver can start to shut down these insulin-producing cells, leading to spikes in blood sugar levels.\nMORE: Antibiotics Are Linked To Type-2 Diabetes\n\n\u201cPeople newly diagnosed with diabetes for the first time can look at this and know it isn\u2019t necessarily for life,\u201d says Taylor.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering about diabetes here. The story would have been stronger if it had discussed that remission is not the same as a cure\u2013the disease can recur if the behavior change isn\u2019t maintained.", "answer": 1}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story commit disease-mongering?", "explanation": "Not even one comment about how \"dull and wrinkled skin\" is not a disease that must be treated. ", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story commit disease-mongering?", "explanation": "We\u2019ll flag the story for casually throwing around the term\u00a0\u201cgluten sensitivity,\u201d which the story says can produce\u00a0\u201csymptoms such as stomach aches, joint pain, fatigue and headaches.\u201d\u00a0These are generalized complaints that are unlikely to be caused by gluten, and we think this description will help feed the public\u2019s (largely unfounded) fear that gluten is a harmful substance that should be avoided. While some researchers now believe\u00a0that certain\u00a0people do experience adverse effects from gluten that are not a result\u00a0of celiac disease (i.e. \u201cgluten sensitivity\u201d), the number of people affected is most certainly tiny compared to the number of people who think they are sensitive to gluten.\u00a0The story makes gluten sensitivity sound like a garden variety ailment, when in fact it\u2019s an uncommon and poorly understood phenomenon\u2013if it even exists at all.", "answer": 0}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\nIn some cases, studies have found that people who use products like nicotine patches and gums are more likely to relapse than their counterparts who go cold turkey.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\nAmong 787 adults who had quit smoking within the previous two years, nearly a third reported having returned to using cigarettes, according to a study published online Monday by the journal Tobacco Control.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "CHICAGO (Reuters) - A new analysis of evidence used by a U.S. advisory panel to roll back breast cancer screening guidelines suggests it may have ignored evidence that more frequent mammograms save more lives, U.S. researchers said on Tuesday.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\nWhen they were issued, the task force\u2019s guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, kicking off a fury of protest among breast cancer experts and advocacy groups who argued the recommendation of fewer screenings would confuse women and result in more deaths from breast cancer.\nMany groups, including the American Cancer Society, have stuck by their long-standing recommendations of a yearly breast exam for women starting at age 40, stressing that the breast X-rays have been proven to save lives by spotting tumors early, when they are most easily treated.\nIn the new analysis, the team found that annual mammograms starting at age 40 save 65,000 more women from breast cancer than mammograms done every other year in women 50 and older.\n", "question": "Does the story commit disease-mongering?", "explanation": "While the article does not exaggerate the incidence of breast cancer, it does state that \u201cannual mammograms save 65,000 more women from breast cancer.\u201d\u00a0 This could\u00a0lead women to believe that mammography prevents breast cancer when its purpose is to detect breast cancer. Incorrect and misleading. .", "answer": 0}, {"article": "To learn more about NAMS, visit http://www.\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nCLEVELAND, Ohio (November 28, 2016)--It's somewhat of a little-known adverse effect of having breast cancer, but studies suggest that approximately 30% to 40% of women with breast cancer report persistent hot flashes.\nThe study showed electro-acupuncture to be comparable to, if not better than, gabapentin in helping to reduce hot flash severity and frequency and improving overall sleep quality (including falling asleep faster and fewer sleep disruptions).\nAlthough it is not exactly understood how acupuncture affects sleep, it has been shown to affect a number of neurotransmitters associated with sleep, such as serotonin and melatonin.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release steps over the line in suggesting that hot flashes \u2014 a normal part of menopause for some women and especially for breast cancer survivors \u2014 is like a disease unto itself that always requires medical treatment.\u00a0 According to Johns Hopkins University, about 75 percent of all women going through menopause experience hot flashes, the most common symptom of menopause. Many are able to manage their symptoms through simple, inexpensive lifestyle changes.\u00a0\u00a0", "answer": 0}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "?\nAcupuncture involves the use of hair-thin disposable metallic needles inserted into various parts of the body; treatments are supposed to be painless and are designed to correct energy imbalances.\nAcupuncture No Better Than Placebo for Hot Flashes\n\nThe search for a benign, effective alternative treatment for hot flashes -- which has included the use of soy products, Chinese herbs and hypnosis -- has hit another roadblock.\nBeginning in 2002, WHI researchers reported that estrogen was beneficial in reducing hot flashes, but that the hormone, routinely prescribed to middle-aged women for years, also raised the risk of cancer, heart disease, stroke, dementia and other ailments.\nExperts in women's health say they are one of the most common ailments for which women use alternative medicine and that interest in non-hormonal treatments has increased as a result of the WHI findings.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does a commendable, well-balanced job of explaining that hot flashes can vary widely in both how severe and how bothersome they are. ", "answer": 1}, {"article": "As a result of the review, the team say their study highlights the need for randomised trials to establish the evidence needed to support low-dose aspirin as an effective additional treatment of cancer.\nThat's why we specifically looked at the available evidence of bleeding and we wrote to all authors asking for further data.\nThe study was the longest of its kind to probe the influence of environmental factors in chronic disease.\nAs a result, we set out to conduct a systematic search of all the scientific literature.\"\nIn no study was serious or life-threatening bleeding reported.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "We didn\u2019t see any evidence of stoking fears about disease; the language is grounded and straightforward.", "answer": 1}, {"article": "Kappelmann, N et al.\nIn other words, regardless of whether a drug successfully treated rheumatoid arthritis, for example, it would still help improve a patient's depressive symptoms.\nThis approach is starting to show success in treating cancers, and it's possible that in future we would use anti-inflammatory drugs in psychiatry for certain patients with depression.\"\nThe team of researchers carried out a meta-analysis of these clinical trials and found that the drugs led to an improvement in the severity of depressive symptoms independently of improvements in physical illness.\nDr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. Untreatable depression is a mental disease that impacts quality of life as well as physical health.", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\n\"The nerve root is a sensitive structure that when pinched becomes inflamed and causes pain,\" said lead investigator Alessandro Napoli M.D., Ph.D., an interventional radiologist at Sapienza University of Rome.\nThe single-center prospective study included 80 patients experiencing at least three months of low back pain due to a herniated disk that had not responded to conservative treatments including exercise and medication.\nMost back pain is short-term, but about 20 percent of people affected by acute low back pain go on to develop chronic low back pain lasting a year or more.\nA compressed and herniated disk, in which the rubbery cushion between vertebrae impinges on and irritates nearby nerves, is a major cause of low back pain that can radiate to the legs.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release overstates the severity of the problem of low back pain, and it doesn\u2019t need to. Pain is a very real problem in the United States and around the world. But stating that \u201cLow back pain is an extremely common problem that affects at least 80 percent of the population at some point in their lifetime\u201d is emphasizing something that may be intermittent or even acute for a few years and making it seem like it is constant. The actual prevalence of low back pain globally is about 8,500 cases for every 100,000 people, according to the University of Washington\u2019s Institute for Health Metrics and Evaluation.\nSo, while it may technically be true that 80 percent of us will \u201cat some point\u201d experience low back pain, we feel like providing the actual prevalence of low back pain would be a more realistic context.\nFurther, this study focuses on those with back and leg pain due to a disc herniation. Disc herniations only represent a small fraction of patients with low back pain. Moreover, these patients had symptoms for more than 3 months. Most patients (around 75 percent) with a disc herniation improve over time without invasive treatment. So the actual population studied here is a fraction of the low back pain population that is mentioned in the title and the start of this piece.", "answer": 0}, {"article": "Armstrong thinks that a diet rich in folate might be important for brain functioning throughout life.\n\"We know that, in young children, folate deficiencies are associated with poorer neurocognitive function and neurocognitive development,\" he noted.\n\"These results provide new information that points to the importance of keeping a closer watch on folate status in childhood and adolescence.\n\"It's too early to say that everyone should start taking folate,\" he stressed.\nTo find out whether folate might do some good, a team led by Dr. Torbjorn K. Nilsson, from the department of laboratory medicine at Orebro University Hospital in Sweden, collected data on folic acid levels in 386 teens aged 15 years.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although the study reported on examined the association between folic acid intake and composite school group score, this story strayed awkwardly into a litany of all sorts of problems associated with low folic acid intake:\u00a0 heart disease, brain development and function, poorer neurocognitive function and neurocognitive development, autism, spina bifida, dementia, and Alzheimer\u2019s disease. But such a laundry list, with no discussion of the strength of the evidence, seems alarmist.\n", "answer": 0}, {"article": "MILAN (Reuters) - An established targeted therapy for bowel cancer may also help women with an aggressive form of breast cancer, a mid-stage clinical study revealed on Monday, opening up a potential new market for the medicine.\nNo question,\u201d he said.\nSales last year were $1.7 billion.\n\u201cThis study clearly opens the field ...\n\u201cWe are very excited by these results,\u201d lead researcher Jose Baselga of the Massachusetts General Hospital Cancer Center in Boston told the European Society for Medical Oncology (ESMO) \u2014 Europe\u2019s biggest cancer meeting.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "It found that bariatric surgery:\n\u2022 produced a mean weight loss of more than 100 pounds\n\nCHARLOTTESVILLE, Va., Oct. 1, 2015 - A study evaluating the effects of bariatric surgery on obese women most at risk for cancer has found that the weight-loss surgery slashed participants' weight by a third and eliminated precancerous uterine growths in those that had them.\nThe study looked at the effects of bariatric surgery in a relatively short timeframe, one to three years after surgery.\nWomen are considered obese at a BMI of 30 and morbidly obese at 40 (which is typically about 100 pounds over a woman's ideal body weight), yet almost a third of women presenting for bariatric surgery did not identify themselves as obese.\nAnd exercise does seem to be protective -- even if you don't lose all the weight, it absolutely has beneficial effects,\" she said.\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease mongering and, in fact, provides a nice explanation of what it means to be obese and how some women did not perceive themselves that way.", "answer": 1}, {"article": "But as for whether they\u2019ll help a client prepare for an important presentation?\nIt\u2019s very relaxed, not like a spa.\nBut like a private club.\nStill, the trend seems to be going strong.\nThey\u2019re part of a huge \u2014 and wildly popular \u2014 supplement industry which goes largely unregulated.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Researchers suggested that a combination of this talk therapy and medication might be especially effective.\nBefore the trial, one 40-year-old, who said he had fears starting at age 10 that he was going to die in his sleep, rated his certainty that he was suffering from a serious illness as an 8 on a scale of 1 to 10.\nThe study found that hypochondriacs who got cognitive behavior therapy, which encourages people to challenge the validity of their disabling beliefs, also improved -- as much as those given the drug.\nAccording to the standard manual of mental disorders, hypochondriasis is a potentially serious condition that can prompt people to go doctor shopping, abuse sick time at work and become complete invalids.\nResearchers from Columbia University in New York and Hebrew University of Jerusalem followed nearly 39,000 Israeli men whose children were born between 1964 and 1976, and it found that 712 of the fathers had been diagnosed with prostate cancer by 2005.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not include information on the prevalence of hypochondriasis in the population, and didn't differentiate between cases that might fit the definition of \"potentially serious\" and others.\u00a0 Yet it highlighted one study participant (without telling how many were in the trial) \"who said he had fears starting at age 10 that he was going to die in his sleep.\"\u00a0 Is that a common, representative example?\u00a0 Or is it an extreme? \u00a0 \nOn the other hand, the opening line \u2013 \"a real pill for your unreal illness\"\u00a0 \u2013 insults people who do have this condition.", "answer": 0}, {"article": "For pain, they were randomly assigned to take acetaminophen along with a non-opioid \u2014 ibuprofen \u2014 or with one of three commonly prescribed opioids: oxycodone, hydrocodone or codeine.\nAdults with arm or leg pain caused by a sprain, strain or fracture.\nMight non-opioid painkillers work just as well as these addictive drugs?\nData on pain came from the participants' ratings; no information on side effects was collected.\nWho may be affected?\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "MONDAY, March 23, 2015 (HealthDay News) -- Vitamin D supplements may slow or prevent low-grade prostate cancer from progressing, a small new study suggests.\n\"In greater than 60 percent of those taking it, vitamin D actually made the cancer better,\" said Hollis.\nFor more about prostate cancer, visit the American Cancer Society.\nIt's also found in fortified dairy products and fatty fish.\nDoctors often recommend a \"watch and wait\" period for men with low-grade, or less aggressive, prostate tumors.\n", "question": "Does the story commit disease-mongering?", "explanation": "No evidence of disease mongering.", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story commit disease-mongering?", "explanation": "This story including many laundry lists of symptoms ranging from the commonplace (sluggish) to scary (irreversible neurological problems) without appropriate context as to the incidence of the more serious problems or bothering to discuss that many of the problems described commonly result from problems other than vitamin B12 deficiency.", "answer": 0}, {"article": "\"Is it possible with cosmetic use?\n\"This is a new pathway, and we need to think about the implications of this,\" says Edgar Salazar-Grueso, chief medical officer of Solstice Neurosciences, which makes Myobloc.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nThe reason countless lab animals have given their lives during the testing of experimental drugs is to allow manufacturers and regulators to see that a compound might be toxic, even deadly, before millions of people use it.\nWith the new evidence that Botox can spread to the brain in ways that preclinical tests failed to turn up, it's enough to bring back those Botox-erased frown lines.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story is an example of disease mongering. \u00a0It is perhaps unnerving to learn that the injection of botulinum toxin into muscle may not be as completely localized, at least in rats, as had been previously thought. \u00a0\u00a0Implying, however, that the adverse events and deaths are somehow related to the evidence presented in this study is incorrect and misleading. \u00a0While it makes the story more compelling to the average reader, it is factually incorrect and an unfortunate example of fear mongering.\nThough the story included an estimate of the number of adverse events (1,437) that have been reported following the use of this product, in order to understand whether adverse events are frequent or not, it is necessary to know the total number of treatments with this product. \u00a0", "answer": 0}, {"article": "The study was funded by the Veterans Health Administration's Health Services Research and Development Service\nThe newly published study did show that one in five veterans randomly assigned to ImPAT or the comparison approach did not actually attend any sessions - likely because of delays in getting the sessions going.\nThe sharp rise in opioid addiction in recent years - often among people who started taking the painkillers as treatment for acute or chronic pain -- has made the search for effective non-drug pain treatment options even more urgent, Ilgen notes.\nBut a new study shows the potential for patients to break out of that cycle through a non-drug approach that combines behavioral therapy and social support to help them manage their pain.\nIn the meantime, he notes, people struggling with addiction who want to seek relief from pain should explore the full range of treatment options that have been shown to work in non-addicted patients, including physical therapy, exercise and psychotherapy as well as antidepressant medications.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release does a good job of explaining why non-pharmaceutical interventions are needed to help patients with chronic pain who suffer from addiction.", "answer": 1}, {"article": "\u201cIf you\u2019re a busy surgeon, you have a volume to maintain,\u201d Bollinger says, \u201cand it\u2019s hard to go from doing three a day to one during the learning period.\u201d\n\nChristopher Chen, a surgeon who uses the anterior approach at Alta Bates Summit, adds that most doctors \u201cstill use the posterior approach because it\u2019s the one they were taught.\u201d And, he says, the majority of younger surgeons learn the older approach because established surgeons are typically the ones who staff the residency training programs and demonstrate the method they know best.\nI was home in three days, and a week later, [I] walked one or two blocks without pain or a cane.\nUnger performed both surgeries.\n\u201cAfter the first, I needed pain medicine when I came home from the hospital.\nAlso, he says, they work in a \u201cvery high-stress, high-liability environment.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story.", "answer": 1}, {"article": "\"Although there was no significant difference in either physician visits or antibiotic use, as might be expected over only a 6-month follow-up period, our findings concerning consultations are important in the longer term, given antibiotic use increases the risk of antimicrobial resistance.\"\nSteam inhalation did not appear to alleviate symptoms of sinusitis.\nMore than 25 million people in the United States and about 2.5 million Canadians suffer from chronic rhinosinusitis, or sinus infection, and experience compromised quality of life.\nTo alleviate symptoms, steam inhalation and nasal irrigation are widely suggested as an alternative to common treatment with antibiotics, which are often not effective and contribute to antibiotic resistance.\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "\u201cYou can say, \u2018O.K., let\u2019s dismiss the observational studies because they have all these problems.\u2019 \u201d But, he said, despite the virtues of a randomized controlled clinical trial, such a study \u201cwill never ever be done.\u201d It would be impossible to keep people on a low-sodium diet for years with so much sodium added to prepared foods.\nDr. Alderman said that he once was an unpaid consultant for the Salt Institute but that he now did no consulting for it or for the food industry and did not receive any support or take any money from industry groups.\nBut that study, others say, will never happen.\n\u201cIt\u2019s a problematic study,\u201d Dr. Sacks said.\nDr. Briss adds that it would not be prudent to defer public health actions while researchers wait for results of a clinical trial that might not even be feasible.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\nJournal of Child and Adolescent Psychopharmacology.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\n2016.\nMindfulness-based therapies for mood disorders is one such example with promising evidence,\" said Cotton, adding the university is both studying and implenting these therapies.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Sanofi said this was mainly due to neutropenia, a blood disorder people can get from chemotherapy treatment, and its complications.\nThe French drugmaker said on Thursday that the combination of the treatments led to an improved median overall survival of 15.1 months against 12.7 months in patients who took a chemotherapy of mitoxantrone with prednisone/prednisolone.\n\u201cThe development of cabazitaxel is one of many investigational compounds we hope to present to the cancer community in the months and years to come,\u201d Debasish Roychowdhury, Sanofi\u2019s oncology senior vice president, said.\nCabazitaxel won priority review from the U.S. Food and Drug Administration (FDA), meaning the health regulator will take about six months instead of the usual 10 months to assess if a drug is efficient and safe to be marketed.\nFiling for approval in the EU has been completed.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story engaged in disease mongering of a sort in that it failed to mention that this drug is being investigated for advanced prostate cancer, meaning metastatic disease, not for early-stage prostate cancer.\u00a0 Not all prostate cancers are equal and certainly not all become advanced or deadly. ", "answer": 0}, {"article": "While the value of CT scans for screening remains the focus of debate, no one questions the value of the tests for allowing doctors to quickly diagnose a wide variety of health problems, including head injuries, heart problems, cancer, appendicitis, fractures and gallstones.\nYounger people face more risk than older people because they have more time for a cancer to develop.\nThe individual risk varies depending on the age of the patient and the type of scan.\nChildren are especially vulnerable because their rapidly developing bodies are at least four times as sensitive to the damaging effects of radiation.\nYou can't get that kind of information any other way.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of cancer, or the risk from radiation exposure.", "answer": 1}, {"article": "The compound WAY-316606 could therefore be used to treat baldness, without patients suffering the same side effects as they would on CsA.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\nThe scientists were then able to identify that WAY-316606, a compound used to treat osteoporosis, has a similar effect on how SFRP1 is expressed.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\nThey found that CsA changed how the follicles expressed a protein called SFRP1, which stunts the development and growth of hair follicles and other tissues in the body.\n", "question": "Does the story commit disease-mongering?", "explanation": "We take issue with the use of the word \u201ccure\u201d because it implies that hair loss is a lethal or seriously disabling medical disease that needs to be remedied. While hair loss can be distressing, it is not a disease.", "answer": 0}, {"article": "They concluded that five different types of prostate cancer were found based on 100 genes.\n\"These findings could lead to more optimized diagnostic testing on all aspects of the prostate cancer diagnosis process and brings full circle the coming approach to cancer being an individual disease based very much on the patient's individual genetic profile,\" said Dr. Samadi.\nFor men with a family history of the disease, contact Dr. Samadi to learn more about your risk factors and to get a baseline PSA blood test.\nThis may mean that each type of the disease needs its own approach to screening, diagnosis, treatment and even recurrence,\" noted Dr. Samadi.\nPrior research had shown six of the genes were linked to prostate cancer, however researchers noted in the published study that it turns out the other 94 genes had not been associated with prostate cancer until now.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The statistics provided about prostate cancer are close to what the American Cancer Society and the Centers for Disease Control and Prevention have published on their websites.\u00a0However, the headline for the release \u2014 \u201cAre you at risk?\u201d \u2014 seems to be blatantly exploiting the results of a preliminary research study to create worry. In addition, men with a family history of prostate cancer should do more than consult Dr. Samadi for a baseline PSA test as suggested by the news release \u2014 they should engage in shared decision-making with their provider about their options.", "answer": 0}, {"article": "\"Observing this, we asked ourselves if it was possible to pharmacologically induce immune quiescence with medication that was better assured of reaching the point of infection,\" said Ho.\nThe implant is composed of a hollow tube and two pliable arms to hold it in place.\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\nThe implants were tested in an animal model and the team observed a significant reduction in T cell activation, meaning that the vaginal tract was demonstrating an immune quiescent state.\nWhen the T cells stay resting, it's referred to as being immune quiescent.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering. Prevention of HIV transmission is a global public health priority.", "answer": 1}, {"article": "This press release contains forward-looking statements.\nMRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology.\nIn comparison, those patients receiving lower doses via non-adaptive treatments experienced 15.8 percent grade 3 or higher toxicities.\nStatements in this press release that are not purely historical are forward-looking statements.\nOne sample received a higher biologically effective dose (maxBED10 >90), primarily enabled by MRIdian MR-guided on-table adaptive radiotherapy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "With five-year survival rates of 1 to 14%, it would be hard to engage in disease mongering about pancreatic cancer.", "answer": 1}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering.", "answer": 1}, {"article": "Nature publishes broad review articles, called Primers, that cover global aspects of various diseases and describe all aspects from epidemiology, disease mechanisms, diagnosis, screening and prevention, management and quality of life.\nWith its patented Site Specific Targeting (SST\u00ae) technology, pioneered by IM HealthScience\u00ae, IBgard\u00ae capsules release Ultramen\u00ae, an ultra-purified peppermint oil, quickly and reliably to the small intestine, where its actions help manage IBS.\nIn a meta-analysis by Dr. Enck, entitled \"Therapy Options in Irritable Bowel Syndrome,\"3 published in The European Journal of Gastroenterology & Hepatology, Dr. Enck and the authors concluded that the highest efficacy in the management of IBS is currently found in peppermint oil.\nThe data showed that IBgard\u00ae demonstrated a statistically significant reduction in the Total IBS Symptom Score (TISS) in as early as 24 hours and at four weeks.\n\"IBS considerably affects quality of life and places an enormous burden on patients, physicians and the health-care system,\" said Brooks D. Cash, M.D., A.G.A.F., F.A.C.G., F.A.C.P., F.A.S.G.E., Professor of Medicine in the Gastroenterology Division at the University of South Alabama in Mobile, Ala. \"The results of these studies add to the growing body of medical evidence supporting the utility of IBgard\u00ae, a novel formulation of peppermint oil, in improving the symptoms, patient satisfaction and quality of life of patients with IBS.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release states that \u201cone in six Americans experience Irritable Bowel Syndrome (IBS).\u201d That estimate is about twice as high as the range cited in the Nature article (between 5-10 percent or 1-in-20 to 1-in-10). The release does say that only doctors can diagnose IBS and that IBgard should be used only under medical supervision, even though this product and other brands of peppermint oil capsules are available without a prescription.\nThe estimate of prevalence is inflated, but it is true that IBS should be diagnosed by a medical professional.\u00a0 Other more serious conditions such as inflammatory bowel disease (ulcerative colitis and Crohn\u2019s) can mimic IBS symptoms.", "answer": 0}, {"article": "Responding to the research, Yale Child Study Center director Fred Volkmar told WebMD: \u201cThe question remains, \u2018Is fluoxetine better than risperidone for this symptom?\u2019 It would be interesting to see studies comparing these two drugs head to head.\u201d\n\nHollander has previously received funding from pharmaceutical companies, but the current study was paid for by a grant from the Food and Drug Administration\u2019s \u201corphan\u201d drug program.\nIt is not known if the differences between these studies are due to differences between the medications or other factors.\nThe antidepressant Prozac may alleviate repetitive behavior and obsessive-compulsive symptoms in adults with autism, reducing these defining symptoms of the disorder, according to new research.\nA previous, larger study of a similar medication, Celexa (citalopram), in autistic children did not find a reduction in repetitive behaviors, but the drug did reduce irritability and was superior to placebo among children who had the highest levels of irritability.\n\u201cIt takes the edge off,\u201d Hollander explains, noting that the findings were statistically significant and clinically meaningful.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering but it could have provided a little more detail about the differences between Asperger\u2019s syndrome and other forms of autism.\n\u00a0\n\u00a0", "answer": 1}, {"article": "That study was funded by the device\u2019s manufacturer, Neuronetics, a company based in Malvern, Pa.\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\nThere\u2019s a huge range in my clinical experience.\u201d Carpenter, a physician, says research has not found any safety issues for patients returning for additional treatments, but cost is a factor.\nThe procedure, which is more widely used than rTMS, requires two to three treatments a week for three to four weeks and is effective for many patients.\nThe costs of ECT \u2014 typically about $3,300 for four weeks of thrice-weekly treatments, according to AHRQ data \u2014 are covered by most private insurers as well as by Medicare and Medicaid.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story specifies that rTMS should only be considered for patients who do not respond to or who can\u2019t tolerate medication.\nIdeally, we\u2019d like to see the story spell out the proportion with treatment resistant depression and define more carefully so that a reader would have a better sense of how many patients affected (and if they have depression, is this story applicable to them).", "answer": 1}, {"article": "Research has shown that giving statins to patients who already have Alzheimer's does not seem to help.\nThey were about half as likely to develop either early signs of trouble thinking or full-blown dementia.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nBut today's study looked at people before any hint of dementia.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\n", "question": "Does the story commit disease-mongering?", "explanation": "The segment does nothing to exaggerate the risk or consequences of Alzheimer\u2019s disease. ", "answer": 1}, {"article": "Van Hemelrijck and colleagues studied more than 30,000 men in Sweden with prostate cancer who got hormone therapy between 1997 and 2006, for about three years.\n\"For the vast majority of men, the benefits of hormone therapy are absolutely clear: it can halt the disease or stop it for years,\" she said.\n\"It makes a lot of sense and could one day change treatment guidelines.\"\nMore than 670,000 men are diagnosed with prostate cancer globally every year, making it the second-most common cancer in men, after lung cancer.\nExperts said the findings could make doctors think twice before prescribing the standard hormone treatment to men with prostate cancer, particularly if they are at risk of heart disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nPlenty of caveats.\u00a0 There was no overt disease-mongering of prostate cancer nor of heart disease.\u00a0 ", "answer": 1}, {"article": "Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto, Anna-Mari Heikkinen, Jari Tiihonen, Hilkka Soininen, Sirpa Hartikainen, Anna-Maija Tolppanen.\nThe largest study comprised approximately 230,000 Finnish women and the follow-up time in different studies was up to 20 years.\nThe protective effect of hormonal therapy may depend on the health status of neurons at baseline and may be lost if therapy starts years after menopause,\" Dr Imtiaz concludes.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nThe newest results were published recently in Neurology and Maturitas and the earlier results in the Journal of Alzheimer's disease.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release. The release also provides some context concerning how Alzheimer\u2019s disproportionately affects women. ", "answer": 1}, {"article": "TUESDAY, Feb. 28, 2012 (HealthDay News) -- Menstrual cramps are the bane of many women, but new research suggests that a form of vitamin D may one day be added to the meager list of pain relievers for the sometimes disabling condition.\nThe Italian study participants all had blood levels of vitamin D measuring in the lowest 25 percent of normal at the study's outset, although the researchers didn't report the womens' blood levels afterward.\nIn the study, 40 Italian women were split into two groups: one receiving a single oral dose of 300,000 IUs of vitamin D3 and the other getting a placebo five days before the expected start of their menstrual periods.\nA small study in Italy found that a single, high dose of cholecalciferol -- also known as vitamin D3 -- was linked to a marked reduction in menstrual cramps, with the largest benefits observed in women reporting the most pain at the beginning of the study.\n\"It was a very well-done study, but my comment is, it was one study.\n", "question": "Does the story commit disease-mongering?", "explanation": "The lead in to the story hinges on disease-mongering with its \u201cbane of many women\u201d description, but we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "While some studies have shown promise, he says, \u201cthe quality of the evidence is not strong.\u201d That\u2019s why Briggs and his colleagues are starting a study looking at dry needling in \u201crunner\u2019s knee,\u201d the condition that has plagued Pierce.\nAcupuncturists beg to differ.\nInstead, needles are placed directly in problem areas.\nWill insurers pay for this?\nDo all physical therapists offer this?\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this piece.", "answer": 1}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nThe diagnosed incidence is estimated to be one in 68 children and effective interventions remain limited.\nThere is currently no medical treatment for these problems.\nThis is the first time a medical treatment has shown this type of benefit for children with autism and findings reinforce outcomes from a longer sustained program of research by this team.\nOverall, the nasal spray was well tolerated and the most common adverse events were thirst, urination and constipation.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease-mongering.", "answer": 1}, {"article": "Just one center in the north of the country offers proton therapy for certain types of eye tumors.\n\"I have a number of letters from parents of young kids saying if it had not been for this treatment we would have lost our kid,\" he said.\nAt the moment, fewer than 1% of cancer patients are treated with proton therapy, but Jongen is hopeful that smaller and cheaper machines will be the game changer.\n\"It would be much less expensive making it more possible for a hospital to afford it -- a smaller system can already treat a relatively large number of patients per year.\"\n\"In this space we accelerate the protons and we give them a higher and higher velocity until they reach two thirds of the speed of light -- that's 200,000 km per second and this acceleration takes place in the shape of a spiral,\" he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "A story such as this one, that makes only broad, sweeping claims about cancer \u2013 in general \u2013 never provided enough information about any one disease or condition to even warrant a satisfactory or unsatisfactory grade. \u00a0This can only be ruled as Not Applicable.", "answer": 2}, {"article": "Thanks to members Drs.\nUsing a network meta-analysis we are able to compare the multiple studies done on viscosupplementation and have found that people are more likely to show clinical improvement with viscosupplementation over placebo (saline) and intra-articular steroids.\nWith this knowledge, the American Medical Society for Sports Medicine (AMSSM) has released a new scientific statement that provides guidance for physicians and healthcare professionals who provide care for those patients with knee osteoarthritis.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\nThe AMSSM hopes that this information can assist healthcare professionals as they provide care for patients with osteoarthritis.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The statistics provided are fairly consistent to what is given out by the NIH and Centers for Disease Control and Prevention so we see no disease mongering here.", "answer": 1}, {"article": ", and receive monthly highlights by signing up at http://www.\n\"The biological mechanism of labor initiation remains unknown, and a large percentage of preterm pregnancies do not respond well to current medications,\" said Ronghua Zhuge, Ph.D., associate professor within the University of Massachusetts Medical School's Department of Microbiology and Physiological Systems in Worcester, Massachusetts.\n\"The bitter taste receptors that we have found on uterine muscle could be one more piece of the puzzle to understand the onset of labor, both at term and preterm, and develop new therapeutics for preterm labor.\"\nThis could be good news for those trying to prevent preterm labor: New research published online in The FASEB Journal suggests that exposing bitter taste receptors in the uterus to certain substances can stop many unwanted contractions that occur during premature labor.\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release. Premature birth resulting in complications or death are a known problem around the world.\nWe do think the release relies on exaggerations that should have been avoided:\n\u201cBitter taste receptors may hold the key to managing preterm labor\u201d\n\u201cThis could be good news for those trying to prevent preterm labor: New research published online in The FASEB Journal suggests that exposing bitter taste receptors in the uterus to certain substances can stop many unwanted contractions that occur during premature labor.\u201d", "answer": 1}, {"article": "\"This is hugely promising and very significant research,\" he tells WebMD.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nFor decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story veers toward the sensational in its anecdotal reporting on what nighttime hypoglycemia is like. Overall, though,\u00a0it didn\u2019t\u00a0exaggerate the impact of type 1 diabetes and appropriately focused on hypoglycemia as an important risk that a new glucose management system could help address. \u00a0", "answer": 1}, {"article": "Denver, CO. (February 17, 2016) - U.S. children are not consuming enough vegetables, resulting in an inadequate intake of key nutrients, including potassium and dietary fiber, which are important for growth, development and overall health.\nNutrient Density and the Cost of Vegetables from Elementary School Lunches.\nIn fact, a study of elementary school students demonstrated that students are not consuming the majority of vegetables offered to them in school lunches.\nThe journal supplement features seven papers authored by leading nutrition scientists that explore the state of the science pertaining to vegetable consumption in children.\nBased in Denver, Colorado, the USPB represents more than 2,500 potato growers and handlers across the country.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease mongering.", "answer": 1}, {"article": "The results are chronicled in Robison\u2019s new book, \u201cSwitched On: A Memoir of Brain Change and Emotional Awakening.\u201d\n\nIn a moving, often harrowing narrative reminiscent of \u201cAwakenings\u201d and other popular works by the late neurologist and writer Oliver Sacks, Robison writes of the transformations these sessions helped unlock, the welcome ones \u2014 and the not so welcome.\nRather, it may be best used to alleviate certain symptoms associated with spectrum disorder, including depression.\n\u201cPerhaps I was hearing music pure and true, without the distorting lens of autism.\u201d\n\nOther striking changes in perception and mood soon followed.\nIt didn\u2019t occur to me that most of the news out there, most of the emotion, is, if not bad, at least not all good.\n\u201cAnd what I wrote about in the book isn\u2019t 10 percent of what they\u2019re doing now.\u201d\n\n\u201cSwitched On\u201d ends in 2013.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering. There are no well proven, effective treatments for autism spectrum disorder.", "answer": 1}, {"article": "Thousands of breast cancer patients at risk of developing aggressive secondary tumours could benefit from a potential new genetic test.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\nBut if successful, it could be incorporated into the routine testing of breast cancer patients to see if they could benefit from bisphosphonate treatments such as zoledronic acid.\nA study led by researchers at the University of Sheffield has shown women with breast cancer who lack a key genetic marker are more likely to respond to a treatment that can prevent the disease spreading to their bones.\nWomen who do not carry the gene - approximately 80 per cent of women with breast cancer - were found to benefit from the bone strengthening treatment.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering and as the study co-author, Professor Roger Gomis, observed the current study could help clinicians \u201c\u2026 avoid unnecessary treatment of patients who would not benefit or could be harmed by the treatment.\u201d", "answer": 1}, {"article": "Surinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\nIt attacks and breaks down a naturally-occurring protein in the body which normally prevents cancer cells from spreading.\nHe said this was \u201ca difficult but not impossible task\u201d and one that would be made easier by the better understanding of the biological processes gained in this early research.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\nIn tests in the laboratory, the UEA team found that by blocking WWP2, levels of the natural inhibitor protein were boosted and the cancer cells remained dormant.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release commit disease-mongering?", "explanation": "No obvious disease mongering is evident here.", "answer": 1}, {"article": "(That\u2019s a high dose; a 3 oz.\nThese are questions Kwong and others hope to answer with more studies.\nfor more on that).\nThe 4g is a high dose; previous studies in which people were given 1g of fish oil were more inconsistent.\nNormally after a heart attack, part of the heart is starved of oxygen, and that portion never recovers.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering.", "answer": 1}, {"article": "There\u2019s no reason why women should be caught unaware in the late stages of a pre-eclampsia\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\nThere is currently no test to predict which women will develop pre-eclampsia, which is marked by high blood pressure and high protein levels in urine.\n\u201cA high caliber predictive test would allow women who are identified at high-risk for pre-eclampsia to seek obstetric care by specialists and to be monitored more vigilantly,\u201d Eleni Tsigas, executive director of the Pre-eclampsia Foundation, said in a statement.\n\u201cIf we can bring the rates of maternal deaths in undeveloped countries down to the rates in developed countries, by being able to determine which women are at the greatest risk for developing pre-eclampsia, then it has that potential to save thousands of lives,\u201d Baker said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is little evidence of disease mongering in the article. Preeclampsia is a serious and potentially lethal condition for both mother and child, and that is made clear.\u00a0", "answer": 1}, {"article": "Patients treated with a placebo saw a 1 percent increase in LDL cholesterol.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nThe Phase II trial found that after 12 weeks, patients treated with a low dose of AMG145 had a 43 percent reduction in LDL, while those given a higher dose had a drop of 55 percent.\nLOS ANGELES (Reuters) - Amgen Inc\u2019s experimental drug AMG145 reduced levels of bad cholesterol by as much as 55 percent in combination with statin drugs in patients genetically predisposed to high cholesterol, according to data from a midstage trial presented on Monday.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although this story meets a minimum standard by reporting that the trial looked only at people with a genetic mutation that causes high cholesterol and heart disease, and that this mutation affects about one person in 500, it should have been more clear that the results of this trial may have no relevance to the 99.8% of people who do not carry this mutation.", "answer": 1}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "She noted that glitazones -- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance -- have all shown initial promise in clinical trials before worrisome side effects began to surface in users (due to concerns around heart risks, Avandia remains on the U.S. market but under limited distribution).\nDr. Minisha Sood, endocrinologist at Lenox Hill Hospital in New York City stressed that, \"given the rising global incidence of type 2 diabetes, the medical community is eagerly awaiting the development of novel agents to add to our existing armamentarium of anti-diabetic agents.\"\nThe new drug, called TAK-875, is a pill designed to enhance the secretion of insulin in response to such changes, which means that it has no effect on insulin secretion when blood sugar levels are normal -- potentially reducing the risk for hypoglycemia.\nThe trial, led by Dr. Charles Burant of the University of Michigan Medical School, included 426 patients with type 2 diabetes who were not getting adequate blood sugar control through diet, exercise or treatment with the first-line diabetes drug metformin.\nShe said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering and instead offers a brief and accurate description of the disease. It says, \u201cType 2 diabetes is the more prevalent form of the disease, accounting for about 90 percent of cases. Often tied to obesity, type 2 diabetes involves a gradual decline in how insulin responds to changes in blood sugar (glucose).\u201d", "answer": 1}, {"article": "However, radiation therapy and surgery have a negative impact on quality of life.\nThe number of prostate cancer diagnoses dropped by more than 12% (1363 cases) in the month after the USPSTF draft guideline was issued and the number continued to drop, resulting in an overall decline of 28% in incident prostate cancer diagnoses in the year after the draft guideline was issued.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,.\nHowever, the study also identified a drop of 28.1% in diagnoses of intermediate risk disease and 23.1% in high risk prostate cancer one year after the draft guideline, which could result in missing important opportunities to spare men with higher risk cancers from progressive disease and cancer death.\n\"Our study was designed to assess the impact of the USPSTF recommendation on screening practices among urologists and primary care providers and the incidence of prostate cancer,\" explained lead investigator Daniel A. Barocas, MD, MPH, of the Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We think there\u2019s some fear-mongering going on related to the downside of following USPSTF guidance. Specifically the headline, which states that \u201cmore men are at risk of prostate cancer\u201d due to following these guidelines. While it\u2019s true that fewer men are being diagnosed with cancer, the idea that more men are \u201cat risk\u201d of aggressive cancer isn\u2019t addressed by the study at all and may not be true.\u00a0The study actually found that the rate of non-localized cancer did not increase during the study. The headline seems very one-sided considering that the study also shows a steep drop in the diagnosis of low-risk cancers, something which has clear and tangible benefits.", "answer": 0}, {"article": "Timothy Hardy, Mujdat Zeybel, Christopher P. Day, Christian Dipper, Steven Masson, Stuart McPherson, Elsbeth Henderson, Dina Tiniakos, Steve White, Jeremy French, Derek A. Mann, Quentin M. Anstee and Jelena Mann.\nCirrhosis - the most severe stage, occurring after years of inflammation, where the liver shrinks and becomes scarred and lumpy; this damage is permanent and can lead to liver failure (where the liver stops working properly) and liver cancer\n\nIt can take years for fibrosis or cirrhosis to develop and the presence of this scarring predicts those people with the worse prognosis.\nNon-alcoholic steatohepatitis (NASH) - a more serious form of NAFLD, where the liver has become inflamed; this is estimated to affect up to 5% of the UK population \n\n3.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nSenior author Dr Jelena Mann of Newcastle University's Institute for Cellular Medicine added: \"This is the first time that a DNA methylation 'signature' from the blood has been shown to match the severity of a liver disease.\n", "question": "Does the news release commit disease-mongering?", "explanation": "As noted above, NAFLD is both fairly common and \u2014 for most patients \u2014 is not cause for undue alarm. In a small number of patients, it can progress to more serious conditions. That is not clear from the release. Readers who know little about NAFLD could be forgiven for thinking that NAFLD is likely to progress to cirrhosis and liver failure. A little bit of extra context would have been good here; for example, noting that approximately 5 percent of patients with NAFLD are likely to deal with long-term liver failure. Is NAFLD something that should be taken seriously? Absolutely. But it needs to be discussed responsibly.", "answer": 0}, {"article": "To address this gap, researchers conducted a randomized controlled trial including 352 healthy infants from 3 pediatric outpatient clinics, including 7 physician practices, who received scheduled vaccinations in their first year of life.\n\"However, there are gaps in knowledge about what is the best way to alleviate pain during vaccination.\"\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\nThe infants were randomized to 1 of 4 groups: placebo control; video instruction to parents on how to soothe their baby; video plus oral sugar solution; and video, oral sugar solution and lidocaine applied to the skin.\n\"Vaccinations cause acute distress for both infants and their parents, contributing to vaccination avoidance,\" states Dr. Anna Taddio, a pharmacist and senior associate scientist at The Hospital for Sick Children (SickKids) and professor, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We didn\u2019t see anything that would cause a reader distress or blow the problem of vaccine injection pain out of proportion.", "answer": 1}, {"article": "Larsson and her colleagues combed through research databases spanning the last 45 years to find studies that tracked how much magnesium people took and how many of them had a stroke over time.\nOther experts said the results were consistent with dietary recommendations.\n\"It's again the diet per se, not any one individual component of the diet.\"\nThose are things that have low sodium, high potassium and high magnesium,\u201d said Larry Goldstein, director of the stroke center at the Duke University Medical Center in Durham, North Carolina.\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "About 10 percent of the students had an abnormal EKG.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\n\"It's pretty much while they're in training or while they're on the field performing, because that's when the adrenalin is flowing,\" and that's when they're calling on the heart for peak performance.\nThe American Heart Association suggests that athletes who are identified as at risk for heart problems as a result of a family history or physical exam be referred for further cardiovascular examination, which could include an electrocardiogram.\nAccording to Zipes, \"The adrenalin that is released when you're participating [in sports] can stimulate this abnormally thick heart muscle and cause a fatal heart rhythm problem, that is a very rapid heartbeat with no effective contraction, no blood being ejected to the brain and other organs.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\nThe story correctly notes in the second paragraph that sudden death in student athletes is rare, but it later states that 10% of students screened in a recent study had abnormal EKGs. This is problematic, because the story does not then indicate how many of those individuals with an abnormality needed to be treated.\u00a0 In reality not all EKG abnormalities require either treatment or alterations in exercise.\u00a0 The 10% number in the story followed by a single anecdote makes it appear that the risks are larger than most data would suggest.", "answer": 0}, {"article": "For more information, go to UHhospitals.org.\nA new investigational delivery method for localized vaginal estrogen therapy that utilizes an applicator free softgel to alleviate moderate-to-severe vaginal pain during intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), received high rates of patient satisfaction among post-menopausal women, according to post-trial survey results published in the journal Menopause.\n\"These survey results show that something as simple as a change to a more elegant delivery system that is easier to use and not messy might empower more post-menopausal women to seek prescription treatment for VVA, and perhaps help them stay with the application guidelines for longer,\" said study first author Sheryl Kingsberg, PhD, Division Chief, OB/GYN Behavioral Medicine, UH Cleveland Medical Center; Professor of Obstetrics and Gynecology and Psychiatry, Case Western Reserve University School of Medicine; and first author of the survey analysis.\nThe majority of women taking either TX004HR or placebo (85.4 - 92.1 percent) found the product easy to use.\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release states that \u201c50 to 70 percent of post-menopausal women\u201d suffer from vaginal dryness and discomfort or painful intercourse. Another reliable source put the prevalence of vulvovaginal atrophy (VVA) at about half of postmenopausal women, although not all of them experience painful intercourse. Nonetheless, most sources suggest this condition may affect 32 million women in the United States. Given that other research shows that more than 90% of those who experience these symptoms find them troubling, it seems reasonable to conclude that it is a legitimate problem, despite being a normal development as women age.", "answer": 1}, {"article": "This is often not enough to make a meaningful improvement.\nThe tests also measured activities of daily living affected by neglect, such as dialing numbers on a phone, reading a menu, and sorting coins.\nThis condition often occurs after a stroke on the right side of the brain and is typically treated with a combination of physical therapy and brain retraining or mental tasks using a pen and paper or computer.\nDuring transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nResearcher Giacomo Koch, MD, PhD, of the Santa Lucia Foundation in Rome, Italy, and colleagues point out that the changes could be the combined effects of the mental tasks and the TMS.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t exaggerate the challenges faced by individuals who\u2019ve had a stroke, but it would have been helpful to know how many stroke sufferers experience the \u201cneglect\u201d symptoms discussed in the story. The Reuters piece helpfully explains that about half of stroke sufferers experience these symptoms.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Taking multivitamins may help women without cardiovascular disease to ward off a heart attack, new research shows.\nThey usually smoke less, are more physically active and have a healthier diet,\u201d the researcher wrote.\nTaking vitamins for 10 or more years cut risk by 41 percent.\nThe women ranged in age from 49 to 83 at the study\u2019s outset, and about 60 percent in each group used some type of dietary supplement.\nAmong the women who initially had no heart disease and did not take any dietary supplements, 3.4 percent had heart attacks, compared to 2.6 percent of the women who took multivitamins plus other supplements; this translated to a 27 percent lower heart attack risk with vitamins.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering.", "answer": 1}, {"article": "Both types are thought to be beneficial.\nThe MRIs showed higher white matter hyperintensity volume, tiny lesions in the brain, raising the risk for death, stroke and dementia for the low omega-3 fatty acids group.\nPeople with diets short on omega-3 fatty acids \u2013 the kind found in fish oil \u2013 were more likely to experience accelerated brain aging, a new study found.\nThe typical American diet doesn't contain enough of either.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no outright disease mongering, but the headline\u2019s suggestion that your brain may \u201csuffer\u201d without sufficient DHA comes close.\n\u00a0", "answer": 1}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here regarding the brain cancer glioblastoma.", "answer": 1}, {"article": "A week later, under no medication, participants returned to repeat the experiment.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nTo treat such diseases, we already have clinically approved drugs that block these enzymes, including the antibiotic doxycycline, so we wanted to see if they could help to prevent fear memories from forming in the brain.\n\"We have demonstrated a proof-of-principle for an entirely new treatment strategy for PTSD,\" explains Professor Bach.\n\"When we talk about reducing fear memory, we are not talking about deleting the memory of what actually happened,\" explains lead author Professor Dominik Bach (UCL Wellcome Centre for Neuroimaging, Max Planck UCL Centre for Computational Psychiatry and Ageing Research and University of Zurich Division of Clinical Psychiatry Research).\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It provides some context about what PTSD is and what causes it.\nSome context about the rate of PTSD in certain populations (e.g. combat veterans, terrorist attack survivors, children of war) and methods currently used to prevent or treat the condition might also have been helpful to include.", "answer": 1}, {"article": "TUESDAY, Aug. 2, 2011 (HealthDay News) -- There's still no cure for the common cold, but there may be a way to shorten its misery: A new study suggests that higher doses of zinc lozenges in certain formulations may cut the length of colds by more than 40 percent.\n\"I would tell my patients we still don't have a cure [for the common cold], and we don't know if zinc works.\"\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\n\"When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds.\"\nAllowing the lozenge to dissolve instead of swallowing it seemed to provide a therapeutic effect.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story says there\u2019s no \u201ccure\u201d for the common cold \u201cbut there may be a way to shorten its misery.\u201d\u00a0 Yet it doesn\u2019t discuss the fact that most colds for most people are self-limiting and of short duration.\u00a0 And what is the average duration of this \u201cmisery\u201d?", "answer": 0}, {"article": "Tamoxifen, a generic drug, is already approved for reducing the risk of breast cancer.\n\"Although media coverage of the early release of data from the STAR trial suggests a clear 'winner' in raloxifene, the data from clinical endpoints and patient-reported symptoms suggest a less clear conclusion,\" Dr. William J. Gradishar and David Cella of Northwestern University wrote in an editorial in the medical journal.\nSo, in response to the cancer institute's announcement two months ago, some experts quickly declared that raloxifene was not clearly superior, leaving women in a quandary.\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "There are no elements of disease mongering noted. However, the article missed an opportunity to provide some context by failing to mention that out of nearly 20,000 women in the trial, about 4 per 1000 women each year (a total of 331 over 4 years) developed breast cancer. If compared with the number of women who experienced side effects, this information would have helped readers understand better how many women would need to take preventive medication in order for some to get the benefits. The comment on patient advocates\u2019 questioning does provide balance in the article.", "answer": 1}, {"article": "In the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\n\"It's a pessimistic trade-off, the weight gain and other side effects for what looks like a modest delay in the acute psychotic episode,\" said Dr. Steven Hyman, a professor of neurobiology at Harvard.\n\"Unfortunately, the study's numbers are so small that it cannot be decisive on the key issue, which is whether it's prudent to treat people early when there are uncertainties about the diagnosis and given the effect of stigma and adverse effects,\" said Dr. William Carpenter, director of the Psychiatric Research Center at the University of Maryland, who was not involved in the study.\nBut by then, more than two-thirds of the young people in both groups had dropped out, making it difficult to interpret differences between them.\n\"The positive result was only marginally significant, and the negative result was clear,\" said Dr. Thomas McGlashan, a professor of psychiatry at Yale and the study's lead author.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story discusses the prevalence of schizophrenia as 3 million in the U.S. According to the National Institute of Mental Health, this number is closer to 2 million. (http://www.nimh.nih.gov/publicat/schizoph.cfm) ", "answer": 0}, {"article": "Nevertheless, accumulating evidence has her urging patients to get their calcium from their diet, rather than reflexively telling them to take 1,200 milligrams of calcium a day.\nA recent meta-analysis done by the same group of researchers found a 27 to 31 percent increased risk of heart attacks in women taking calcium without vitamin D.\n\nMany older women take calcium supplements with or without vitamin D to keep their bones strong, especially since that has long been standard medical advice.\n\"The cautious way forward seems to be to encourage people to obtain their calcium from the diet, rather than from supplements, since food calcium has not been shown to carry this increased risk of heart disease,\" Reid added.\nAnd in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\n\"There is a lack of consensus at the present time as to what recommendations should be regarding the use of calcium supplements,\" said study senior author Dr. Ian Reid, who fully expected that the new results will have a \"significant impact on recommendations.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering and, in fact, takes a very cautious approach to the topic. This could have been a story that attempted to grab readers\u2019 attentions by striking a fear-inducing note. Instead, it says repeatedly that the scientific consensus is still forming and that there may not be any dramatic clinical practice changes as a result of this latest study.\n", "answer": 1}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story commit disease-mongering?", "explanation": "The story mentioned in passing that type 2 diabetes was the most common form of diabetes and that diabetes increased the risk of \u2018everything from heart attacks to kidney failure\u2019. \u00a0As there was no context provided for this claim about what the magnitude of this increase was or how long an individual would need to have type 2 diabetes before being at increased risk, this statement could be considered disease mongering.\nThe statement that this medication could \u2018radically reduce these risks\u2019 does not appear to grounded in data at this point in time.\u00a0", "answer": 0}, {"article": "As this Lancet study points out, because annual flu shots were recommended for the elderly since the 1960s, it has been unethical to conduct high-quality randomized controlled trials where you give only one group the shot in order to compare it with another group that didn't get the vaccine.\nIn a year when the WHO guesses badly, you need to vaccinate 100 people to prevent one flu case.\nIn February, the World Health Organization offers a prediction \u2014 based on surveillance and laboratory and clinical studies \u2014 and then each country uses that prediction to approve vaccines in its jurisdiction.\nThat seems to be the same conclusion that other studies have drawn \u2014 the flu vaccine is modestly helpful, and doesn't hurt.\nThe potential for error here can dramatically alter the effectiveness of the flu shot in a given season.\n", "question": "Does the story commit disease-mongering?", "explanation": "The annual influenza outbreaks offer the possibility for disease-mongering but we feel that\u2019s not the case with this story.", "answer": 1}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease-mongering in this story, but it could have cited what percentage\u00a0of asthma patients have severe symptoms that are not adequately controlled", "answer": 1}, {"article": "The FASEB Journal, June 2018.\n\"This is the first study to demonstrate positive vascular effects of mango intake in humans,\" said lead researcher Robert Hackman, with the UC Davis Department of Nutrition.\nBOSTON (June 11, 2018) -- A new study conducted at the University of California, Davis found that two cups of mangos a day had beneficial effects on systolic blood pressure among healthy postmenopausal women.\nIn the study, 24 healthy postmenopausal women consumed 330 grams (2 cups) of mango daily for 14 days.\nMangos contain a mix of polyphenols, including mangiferin, quercetin, gallotannins, and gallic acid, that have been the focus of previous investigations exploring the potential health-protecting properties of mangos.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release states that \u201ctwo cups of mangos a day had beneficial effects on systolic blood pressure among healthy postmenopausal women.\u201d However, if the women had healthy blood pressure levels already (as the release indicates), they didn\u2019t need to lower their systolic blood pressure. Treating blood pressure as something that is inherently bad is misleading. High blood pressure can be dangerous. So can low blood pressure. It\u2019s maintaining a healthy blood pressure that is important.", "answer": 0}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story commit disease-mongering?", "explanation": "There are no obvious elements of disease mongering. ", "answer": 1}, {"article": "While nivolumab is approved for treating metastatic NSCLC, for example, that indication calls for using it if the disease continues to progress either during or after chemotherapy.\nIn three papers presented at the American Association for Cancer Research annual meeting, and published simultaneously in the , lung cancer experts found innovative ways to weaken lung tumors to improve people\u2019s chances of surviving the disease.\nFor example, newer targeted therapy drugs home in on specific genetic mutations that are responsible for driving a person\u2019s cancer.\nAfter nearly a year, the lung cancer in people taking the immunotherapy was 42% less likely to have progressed than among people getting chemotherapy.\nThe results are even more encouraging for people with early stage lung cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering, but it also doesn\u2019t say how many people get lung cancer and might benefit from these drugs.", "answer": 2}, {"article": "Federal grants helped pay for the work.\nNew research calls into question what\u2019s in those IV bags that nearly every hospitalized patient gets.\nChemotherapy is administered to a cancer patient via intravenous drip in Durham, N.C. IVs are one of the most common things in health care.\nIV fluids have been in the news since Hurricane Maria hit Puerto Rico last fall, shutting down electricity to three plants owned by Baxter International, one of the biggest makers of these fluids.\nKellum had no role in the two studies, which were discussed Tuesday at a critical care conference in San Antonio and published by the New England Journal of Medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here, though the study could have done more to stress that the thousands of lives saved is only if the changes are replicated nationally.", "answer": 1}, {"article": "Thus, we foresee an exciting, long term relationship that will benefit cancer patients and cancer research.\u201d\n\nIn December 2007, Hitachi was the first company in the U.S. to clear FDA Premarket Notification Special 510(k) for the \u201cPROBEAT\u201d system with its spot scanning irradiation technology.\nProtons from a hydrogen atom are extracted and accelerated up to 70% the speed of light.\nIts energy is concentrated directly on the tumor while avoiding radiation dose to the surrounding healthy tissues.\nIn most cases, patients can continue with their normal daily activities while undergoing treatment.\nProton Beam Therapy (PBT) is an advanced type of cancer radiotherapy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease-mongering.", "answer": 1}, {"article": "Occasionally DBS is a last-resort treatment for obsessive-compulsive disorder (OCD).\nTrouble is, the moderation wore off in a few days, and the DBS also interfered with the animals' social behavior.\nAs reported in the PNAS paper, the characteristic anticipatory signal appeared when he expected to make $5 but not for smaller sums, suggesting some level of specificity.\nSince food isn't allowed in the operating room, the researchers monitored the patient's brain as he anticipated payoffs in a computerized money-making task.\nThe results point to a real-time biomarker for impulsive behavior, says Dennis Turner, a Duke University neurosurgeon who was not involved in the study but wrote an October review about ongoing research on a range of potential brain stimulation biomarkers.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here, though given the broad speculation about what this device might be used for, there does seem to be the potential for this intervention to be used in less than absolutely medically necessary ways.", "answer": 1}, {"article": "Safety, tolerability and response were assessed every eight weeks for the first six months and every 12 weeks thereafter.\nDr. Mehnert, who is also a medical oncologist in the Melanoma and Soft Tissue Oncology Program at Rutgers Cancer Institute, shares more about the research:\n\nQ: How was the study structured?A: At the time our abstract was submitted, 22 patients with a diagnosis of advanced or metastatic papillary or follicular thyroid cancer who failed prior standard therapy were accrued from multiple international sites.\nNewswise \u2014 New Brunswick, N.J. \u2013 June 2, 2016 \u2013 According to the American Cancer Society, the chance of being diagnosed with thyroid cancer has risen rapidly in the United States in recent years.\nQ: How are immunotherapy drugs changing the landscape of cancer treatment?A: Although many patients treated do not respond, when immunotherapy does induce responses in patients with advanced cancers, these responses may be very long lasting in terms of disease control.\nThe clinical benefit of pembrolizumab in advanced thyroid cancer will be further studied in a follow-up phase II clinical trial that is now ongoing to try to discover biomarkers which predict response to treatment with pembrolizumab.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering. However,\u00a0 the release notes: \u201c\u2026the\u00a0chance of being diagnosed with thyroid cancer has risen rapidly in the United States in recent years. This appears to be due to increased use of technology to detect thyroid nodules that may not otherwise been found previously.\u201d \u00a0But, no absolute numbers are provided. How many people are diagnosed? \u00a0How has the rate changed in the last ten years? \u00a0What are the implications of improved detection? \u00a0Although there is no outright disease mongering, the reader is left with an incomplete picture of the relative risks of the disease.", "answer": 1}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story commit disease-mongering?", "explanation": "We are always on the lookout for disease mongering in stories like this one, in which a medical condition that affects quality of life could misleadingly be treated as if it was a life-threatening illness. This story handles the issue well, treating an enlarged prostate and its related symptoms in a matter-of-fact way \u2014 neither downplaying nor sensationalizing the symptoms associated with an enlarged prostate.", "answer": 1}, {"article": "\"Future studies should examine which people or patients may need to limit their intake of saturated fat,\" assistant professor Simon Nitter Dankel points out, who led the study together with the director of the laboratory clinics, professor Gunnar Mellgren, at Haukeland university hospital in Bergen, Norway.\nTotal energy intake was within the normal range.\nIt may even be healthy,\" says Ottar Nyg\u00e5rd.\nRather, the \"good\" cholesterol increased only on the very-high-fat diet.\nBoth groups had similar intakes of energy, proteins, polyunsaturated fatty acids, the food types were the same and varied mainly in quantity, and intake of added sugar was minimized.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease mongering.", "answer": 1}, {"article": "MONDAY, March 19, 2012 (HealthDay News) -- New research finds that a minimally invasive surgical procedure to treat hernias results in less chronic pain and a faster recovery when compared to a traditional approach.\nIt can be done under local anesthesia.\nAlmost all the patients were men, and their average age was around 55.\nRecurrences decreased to 0.5 percent and 4 percent, respectively, if the procedures were performed by experienced surgeons.\nIt was developed in the 1990s, Brunt said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering.", "answer": 1}, {"article": "In an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\nThere is no cure for this disease and existing treatments just help alleviate some of the symptoms.\nKonstan says that only about 4% of the people with the disease have this specific mutation.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\n\u201cIt really is a major milestone in the treatment of cystic fibrosis,\u201d he says.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story reports that this drug works on a gene mutation seen in only 4 percent of patients with cystic fibrosis.", "answer": 1}, {"article": "Doctors from the University of Cambridge and the University of Li\u00e8ge in Belgium collaborated on the research.\nDr. Nicholas Schiff, a neuroscientist at Weill Cornell Medical College in New York, said that the study provided \u201cknock-down, drag-out\u201d evidence for mental awareness, but that it was not clear \u201cwhether we\u2019ll see this in one out of 100 vegetative patients, or one out of 1,000, or ever again.\u201d\n\nIn a more recent exam, more than 11 months after her injury, the patient exhibited a sign of responsiveness: she tracked with her eyes a small mirror, as it was moved slowly to her right, and could fixate on objects for more than five seconds, said Dr. Steven Laureys, a neurologist at the University of Li\u00e8ge and an author of the study.\nThe journal that published the new paper, Science, promoted the finding in a news release, but added a \u201cspecial note\u201d citing the Schiavo case and warning that the finding \u201cshould not be used to generalize about all other patients in a vegetative state, particularly since each case may involve a different type of injury.\u201d\n\nThe brain researchers, led by Adrian Owen at the Medical Research Council Cognition and Brain Sciences Unit in Cambridge, England, performed scans on the patient\u2019s brain five months after her accident.\nThe imaging techniques used in the new study could help identify which patients are most likely to emerge \u2014 once the tests are studied in larger numbers of unconscious people, said Dr. Joseph Fins, chief of the medical ethics division of New York Presbyterian Hospital-Weill Cornell Medical Center.\nThe chances that an unresponsive, brain-damaged patient will eventually emerge depend on the type of injury suffered, and on the length of time he or she has been unresponsive.\n", "question": "Does the story commit disease-mongering?", "explanation": "By accurately describing the woman\u2019s mental state, the story avoids disease mongering. The article also accurately states that the observed finding was in a single patient. It is unclear how common it would be when applied more broadly to patients with severe cognitive impairment.", "answer": 1}, {"article": "# # #\nThe new treatment, called HF10\u2122 therapy, uses proprietary high frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz.\nTHE AMERICAN SOCIETY OF ANESTHESIOLOGISTS\n\n\n\nFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\nMore than 1.5 billion people worldwide suffer from chronic pain, with lower back pain being the most frequent condition affecting 23 to 26 percent of the population.\nGiven the prevalence of chronic pain, high frequency SCS is an exciting advance for our patients.\u201d\n\n\n\nSCS is an increasingly common therapy that delivers electric pulses to the spinal cord, through a small device implanted under the skin, for difficult to treat chronic pain in the trunk and limbs.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release succumbs to exaggeration, noting that \u201cMore than 1.5 billion people worldwide suffer from chronic pain, with lower back pain being the most frequent condition affecting 23 to 26 percent of the population.\u201d The release should\u2019ve kept the discussion limited to back and leg pain and the specific kind of patients who would be candidates for this device \u2014 not every person in the world who suffers from chronic pain. By throwing out such numbers, the release takes on a promotional tone \u2014 as if its purpose is to increase\u00a0interest in the procedure from anyone with chronic back pain.", "answer": 0}, {"article": "When it comes to the most popular type of osteoporosis treatment, bisphosphonates, the question is not so much about how much to take, but whether there are harmful consequences from long-term use.\nHowever, the most extensive study on the calcium question, done by the Women\u2019s Health Initiative as a randomized controlled trial, was inconclusive.\nThe task force offers no advice for women younger than 60 or for men of any age, though men account for at least 20 percent of US patients with osteoporosis.\nIn a statement, the FDA said it is reviewing the data and is considering changing the labeling on bisphosphonates.\nBut in September, a different group of scientists used the same database and concluded in an article in the British Medical Journal that bisphosphonates appeared to double the risk of esophageal cancer after about 5 years of use.\n", "question": "Does the story commit disease-mongering?", "explanation": " \nThe article did not engage in overt disease-mongering. However, it would have been useful if the article could have addressed the potential for disease-mongering among patients with osteopenia.\n ", "answer": 1}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story commit disease-mongering?", "explanation": "No mongering detected, but the article could arguably have used a bit of it, at least to note the increasing public health threat of diabetes and obesity in the young.\nThen again,\u00a0the uncertainty about long-term benefits for these procedures is concerning given marketing that targets adolescents.", "answer": 1}, {"article": "First published on June 22, 2006 at 12:00 am\nCompared to placebo, the medication stimulated growth hormone secretion and was associated with an increase in lean muscle mass, improved balance as demonstrated by heel-to-toe walking, and a better ability to climb stairs.\nBut Dr. George Merriam, a professor of medicine at the University of Washington, cautioned that much more study is needed to determine whether the medication should become widely available to help counteract the effects of aging.\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\nThe study he led randomly assigned 395 men and women ages 65 to 84 with mild functional limitations to receive either sugar pills or various oral doses of the growth hormone stimulator capromorelin, an investigational medication developed by Pfizer Global Research and Development.\n", "question": "Does the story commit disease-mongering?", "explanation": "While the story notes that diet and exercise are preferred methods of prevention for staying healthy and functional as we age, the story focuses on the notion that normal physical decline involved with aging needs to be counteracted with a pill, such as growth hormone. The natural decline in growth hormones may actually be protective. Also, the term \u2018anti-aging\u2019 is a misnomer, as there is no proven medical intervention to stop or reverse the process of aging. The comparison of prescription eye-glasses to improve eyesight in older adults with taking growth hormone to increase muscle mass and improve physical functioning is unfounded. Eyeglasses are an intervention to improve a manifestion of aging, i.e. reduced eyesight, and glasses pose few (if any) risks to physical health. Growth hormone may pose serious risks to the endocrine system, and possibly the cardiovascular system, and long-term use may increase the risk of some cancers in older adults. ", "answer": 0}, {"article": "Doctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\n\u201cFewer women are having just one breast removed.\u201d\n\nYounger women, white women and women with a previous cancer diagnosis were more likely to opt for a contralateral prophylactic mastectomy, the study found, as were women who had lobular histology, meaning the cancer started in the lobules or milk-making glands of the breast.\nThough all women with breast cancer are at risk of developing a second cancer in the uninvolved breast, the risk is slightly greater with lobular histology, Dr. Tuttle said, and white women may be more likely to carry genetic mutations associated with an increased risk of developing cancer in the contralateral breast.\nBut our job is to make sure they have all the accurate information.\u201d\n\nThe study used data from cancer surveillance registries covering about a quarter of the United States to identify 152,755 patients whose cancer was diagnosed in one breast from 1998 to 2003.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. The story reports SEER data on the increase in bilateral mastectomy in women diagnosed with breast cancer in one breast. ", "answer": 1}, {"article": "TUESDAY, Nov. 23, 2010 (HealthDay News) -- Implantable devices designed to control heart rhythm and efficiency while preventing sudden death among heart failure patients are as effective at ensuring patient survival in real-world situations as they are in controlled study environments, new research suggests.\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\n\"These are very basic facts, concerning simply who lived and died,\" he noted.\nFor more on implantable devices, visit the American Heart Association.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering, but it also fails to adequately describe the target population for these devices. Another barely satisfactory score.", "answer": 1}, {"article": "So far, while Diamond has noted an immune response in patients given the combination treatment in clinical trials, he has not seen a clinical benefit.\nI think the prognosis is going to be good now.\u201d\n\nThe most frequent mutation across all cancers occurs in a gene called p53, which contributes to cells becoming oncogenic when they produce a mutant form of the p53 protein (p53 gene mutations are present in about 50% of malignancies).\n\u201cEven the marks where it was climbing up my neck are all gone.\u201dFurther study needed\n\nWhat Diamond is hoping for now is funding for a full clinical trial so that he can test the combination in advanced triple-negative breast cancer patients who test positive for p53.\nBut we\u2019ve got to get these patients in.\u201d\n\nFollowing the success in Young, the formula has recently been given to two other triple negative breast cancer patients at City of Hope.\nIt was of tremendous magnitude in the last [blood] draw.\u201d\n\nThe next step will be to take bone and CT scans to see if the cancer is disappearing internally as well as externally, which Young will receive in a couple of weeks.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It\u00a0focuses on late-stage cancer which for many people leaves few options for treatment. This is considered a terminal, non-curable disease. While patients are living longer with a diagnosis of metastatic disease, they are not at this point being cured of it.\nIt\u2019s important to inform patients when there are\u00a0newer experimental therapies and highlighting a good initial clinical response is very important. But it needs to be done in the larger context of metastatic breast cancer.\u00a0This release\u00a0should be\u00a0called out for \u201cmiracle mongering.\u201d \u00a0Referring to someone as a \u201cmiracle patient\u201d might convey to a lay person or average patient that the patient in the story has been cured. Cutaneous lesion regression is certainly a good sign, but systemic imaging and long-term follow-up is needed before the term \u201ccure\u201d can be used. In addition, the\u00a0release did not discuss that there are several subtypes of triple-negative breast cancer. It might not be expected that all cases of advanced triple-negative breast cancer would respond to this therapy.", "answer": 1}, {"article": "\"In this particular activation mechanism, the cells develop a subtle mutation within the functional part of the HER2 gene that activates the enzyme,\" said Ellis, professor and director of the Lester and Sue Smith Breast Center, part of the National Cancer Institute-designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine.\nWith this information in hand, the researchers took the next step.\nNeratinib was well tolerated by most patients.\"\nFurthermore, these tumor cells were sensitive to an experimental drug, neratinib.\nNotably, the blood test was sensitive enough that we could use it as a tool to determine eligibility for the clinical trial.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release did not appear to commit disease mongering.", "answer": 1}, {"article": "This can be made from their own vessels.\nThe vessels failed in three of the patients, which experts said was not surprising in patients so seriously ill. One other patient withdrew from the study and another died of unrelated causes.\nIn this most recent study, published Friday in the medical journal Lancet, scientists reported on the new blood vessels in those same patients and 4 others.\n\"This technology is very, very promising,\" said Vladimir Mironov of the Medical University of South Carolina, who co-wrote an accompanying commentary in the Lancet that praised the study as \"a revolutionary milestone.\"\nIn 2007, the scientists published preliminary findings for another 4 patients in the New England Journal of Medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story does not address the extent of the diseases which might be treated if this type of tissue-engineered graft is eventually approved for clinical use.\u00a0 \nThe story explains that if the experimental grafts are shown to work, they would be used as an alternative to existing therapy. However, the story does broaden the potential applications to patient with \"circulatory problems.\" As the story pointed out, the study included only patients with advanced kidney disease whose natural blood vessels had been damaged by repeated access for dialysis therapy.", "answer": 2}, {"article": "Though bothersome, B.P.H.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\n\u201cThere is a big difference between having the symptoms and being bothered by the symptoms,\u201d said Dr. Kevin T. McVary, professor of urology at the Feinberg School of Medicine at Northwestern University.\nBut for patients who have trouble getting back to sleep, \u201cthere are many effective options, and patients almost always end up with less bothersome symptoms once they choose to do something,\u201d he said.\n\u201cMy father used to be up 10 times a night and said it wasn\u2019t a problem for him,\u201d said Dr. Franklin C. Lowe, professor of urology at Columbia University College of Physicians and Surgeons.\n", "question": "Does the story commit disease-mongering?", "explanation": "While there was clear that benign prostate hyperplasia was not life threatening and did mention that there is a difference between symptoms and being bothered by symptoms, the story was strongly suggestive that postponing active treatment could have dire consequences without backing this up with information about how commonly serious problems develop.\nAdditionally, the discussion of disrupted sleep was rather specious. Treatments rarely completely eliminate symptoms so the problem of getting back to sleep will still be present.\u00a0 The comment that \"many doctors are now urging men to become proactive\" is difficult to interpret.\u00a0 What data support this statement, how many doctors are there, and who are they?\u00a0 Professional guidelines remain relatively conservative, recognizing that the truly bad outcomes are still relatively uncommon.\u00a0", "answer": 0}, {"article": "Former smokers who had accumulated 30 pack-years were included only if they had stopped smoking within the previous 15 years.\nThe day the government announced the study results, Westside Medical Imaging of Beverly Hills, Calif., issued a press release saying that the study \u201cshould once and for all settle the controversy\u201d about whether CT lung scans save lives.\n\u201cThere are people who, with good conscience and their take of the data, say it\u2019s not ready for prime time, and there are people who look at the same data and they come to other conclusions,\u201d Dr. Lepor said.\nWe know from our own anecdotes that we have saved a lot of lives.\u201d\n\nDr. Lepor said that he had just met a woman who had smoked for 50 years and was concerned about her risk.\n\u201cThe aggregate harms to all the people\u2019s lives who are not saved have to be taken into account,\u201d Dr. Bach said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Good job here as well.\u00a0 The quote from Dr. Otis Brawley of the American Cancer Society was key:\u00a0 \u201cTo take a trial that involves people at high risk for lung cancer and to extrapolate it and say it\u2019s good for people with intermediate or low risk is not appropriate.\u201d\n", "answer": 1}, {"article": "Also known as extended-release naltrexone, the medication won Food and Drug Administration approval for alcohol dependence in 2006 and in 2010 to prevent relapse in post-detox opioid users.\nA year after treatment stopped, there had been no overdoses in the Vivitrol group and seven overdoses, including three deaths, in the other group.\nIn some programs, prisoners get an injection before release, then follow-up shots from any clinic.\nPrison systems in Illinois, Vermont, Wyoming and Wisconsin are trying the drug on a small scale.\nNot so for criminal justice officials, who may be too trusting, Kolodny said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Opioid addiction is a major problem in American society and especially among the incarcerated, who are likely to relapse once released from prison.", "answer": 1}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\nTwenty-one patients resumed regular diets the day after surgery.\nPatient age ranged from 43 to 80 years.\nSurgeries lasted from three to seven hours.\nExperts from nine leading U.S. medical centers report here on their combined experience of 32 cases since 2008.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no evidence of disease mongering in the release.", "answer": 1}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story commit disease-mongering?", "explanation": "Though the story hedges a bit with its language, it still essentially acknowledges the existence of a condition termed \u201ctext neck,\u201d with symptoms including neck pain and headaches, that is caused by poor posture. However, as careful readers will figure out, other parts of the story make such a diagnosis highly problematic. As one expert (a co-author on the Physical Therapy paper) states: \u201cCan you say to the whole population: If you improve your posture you reduce your risk of neck pain? We haven\u2019t the evidence to say that.\u201d And \u201ctext neck\u201d itself is a term that has been copyrighted by the inventor of the Text Neck Indicator app. The term is not new to this story, but there\u2019s no evidence that such a thing exists. Even with some of the qualifying language (e.g., \u201csome scientists say\u2026\u201d), the story goes a little too far in discussing a condition that hasn\u2019t been proven.", "answer": 0}, {"article": "Psoriasis is an immune-mediated disease that causes itchy, dry and red skin.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\n\"For patients, the concept that psoriasis is 'just something you live with' is no longer appropriate,\" he said.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\n\"Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients,\" said first author Kenneth Gordon, MD, professor in Dermatology.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Psoriasis is a serious health condition, but this release takes it a bit too far. For example, in the fourth paragraph, the release states that psoriasis \u201calso increases a patient\u2019s risk for depression, heart disease and diabetes, among other conditions.\u201d It would have been more accurate to say that it has been associated with, or is linked to, these other conditions. While psoriasis is correlated with an increased risk of multiple adverse health outcomes, it is not known to be the cause of any of them. In most, if not all, cases we know very little about the relationship between psoriasis and those health outcomes. The release also quotes the study\u2019s lead author as saying that \u201cthe concept that psoriasis is \u2018just something you live with\u2019 is no longer appropriate.\u201d But that source is also cited as saying that about half of all patients with psoriasis do not get any treatment. Whether that is by choice, or because the patients don\u2019t have access to treatments or can\u2019t afford the newer, very expensive drugs, it\u2019s clear that many patients with psoriasis do live with the condition. Those dealing with psoriasis already know the value of treatment, they don\u2019t need their condition written about in a way that may stir additional concern.", "answer": 0}, {"article": "This study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\n\"We hope to confirm these results in a larger prospective randomized trial that is underway now at Yale during the 2015-2016 flu season.\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\n\"Using an approved flu vaccine in a novel dosing schedule yielded promising results for a group patients at high risk for infection,\" Branagan said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release accurately points out the higher risk of contracting flu among patients with multiple myeloma and other cancers of the immune system without unnecessary fear-mongering.", "answer": 1}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story commit disease-mongering?", "explanation": "The story does not imply that Botox treatments for wrinkles treats any disease, and it doesn\u2019t make the procedure appear necessary.\u00a0 ", "answer": 1}, {"article": "THURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\n\"This is a very expensive drug,\" he said.\n\"And insurance will be an issue.\nFor more on gout, visit the U.S. National Library of Medicine.\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering of gout in the story.", "answer": 1}, {"article": "Nov. 28, 2011 (Chicago) -- Researchers are using high-energy waves similar to those used to make microwave popcorn to destroy inoperable lung tumors.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nBut more patients have to be followed for far longer to see if they stay in remission, they say.\nAn electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\n", "question": "Does the story commit disease-mongering?", "explanation": "We have a problem in this category.\u00a0 The story lists the total numbers of patients in the US living with lung cancer, when in fact the therapy is only being tested/applicable to patients with inoperable lung tumors. This greatly overestimates the number of people for whom this therapy might be applicable.\u00a0 It would have been possible to provide an estimate of the number of inoperable tumors.", "answer": 0}, {"article": "A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab.\nMetastatic SCCA, a cancer often associated with human papillomavirus (HPV) infection, is normally treated with chemotherapy, although no trials have established a standard of care.\n\"There have been no standardized treatment options for metastatic SCCA patients,\" said Van Morris, M.D., assistant professor of Gastrointestinal Medical Oncology.\n\"This the first formal clinical trial completed with patients with previously treated metastatic SCCA,\" said Morris.\nOf note, patients who scored as responders had higher frequency of CD8 T-cells and PD-L1 CD45 immune cells in pre-treatment samples.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. In fact, the news release mentions right off the bat that this form of cancer is \u201crare.\u201d The news release also highlights the fact that squamous cell cancer (SCCA) is \u201con the increase,\u201d but it would have been helpful to provide details that might help readers understand why cases are increasing and at what rate.", "answer": 1}, {"article": "LOS ANGELES -- Researchers have demonstrated for the first time that the progression of Type-1 diabetes can be halted -- and possibly reversed -- by a stem cell transplant that preserves the body's diminishing ability to make insulin, according to a study published today.\nThe idea is to wipe out the faulty immune system and replace it .\nIt was funded by the Brazilian Ministry of Health and other sources.\nIn the interim, they were given antibiotics to protect against infections.\nThe treatment had no effect on one patient, whose disease had already progressed too far, doctors decided.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not overembellish the nature of the condition or its burden.\u00a0 ", "answer": 1}, {"article": "2013: New guidelines could have far more Americans taking statin drugs for cholesterol\nIn an opinion piece Sunday, Redberg and Mitchell Katz, deputy editor of JAMA Internal Medicine, advised everyone to take \u201ca step back\u201d and ask \u201cwhy this debate is so contentious.\u201d They suggest that the estimates of the benefits of statins may be inflated, that the drugs as an intervention are \u201cweak,\u201d and that the reports of adverse events are incomplete.\nLast month, National Institutes of Health Director Francis Collins wrote in the journal Lancet that \u201cit\u2019s a force for good.\u201d But Rita Redberg, a cardiologist at the University of California at San Francisco and editor of JAMA Internal Medicine, and others have been vocal about their belief that the drugs are overprescribed and that the side effects \u2014 which range from muscle pain and cataracts to possibly an increased risk for diabetes in women \u2014 should be taken more seriously.\nAnother important difference between the groups is that the task force withheld a recommendation about starting statins in adults who are 76 and older, saying that \u201cthe current evidence is insufficient to assess the balance of benefits and harms.\u201d In a commentary accompanying the recommendations, Philip Greenland and Robert Bonow note that there is \u201cuncertainty and hesitation\u201d in the guidelines regarding older people but said it appears that it is not necessary to stop taking statins at age 76 if you are already on them.\nThe new guidelines, published in the Journal of the American Medical Association, suggests that people ages 40 to 75 who have one or more risk factors \u2014 such as high cholesterol, high blood pressure, diabetes or smoking that put them at a 10 percent or greater risk of having a heart attack or stroke in the next 10 years \u2014 should be on statins.\n", "question": "Does the story commit disease-mongering?", "explanation": "This is a tough call, but the most widely-read part of the story\u2013the headline\u2013does cross the line by suggesting everyone over 40\u00a0with some level of cardiovascular risk (which means MOST of us) should consider taking a statin. Some have written extensively of the problems of creating diseases out of risk factors, such as high blood pressure, high cholesterol or low bone density, and have fairly criticized the widespread dissemination of this type of population-wide, drug-industry funded disease mongering.", "answer": 0}, {"article": "\"Unless you can be sure your biopsy has hit the most aggressive part that's in the prostate, you can't be sure\" how accurate your risk estimate is, explained Dr. Eric Klein, chief of urology at the Cleveland Clinic, who led early development of the Oncotype prostate cancer test.\nHe said a gene test may have made him more comfortable with that decision.\nIn any category of risk it added independent information compared to the standard criteria we use today,\" Carroll said.\n\"You can shop for a toaster\" better than for prostate treatment, he said.\n\"I will die from something other than prostate cancer, I guarantee you.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering of prostate cancer in the story.", "answer": 1}, {"article": "But a P.P.I.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nSmoking and alcohol can loosen tension of the upper esophageal sphincter and cause symptoms of reflux like hoarseness, postnasal drip and shortness of breath by irritating the mouth, larynx and trachea, Dr. Aviv reports.\nOne characteristic often associated with acid reflux \u2014 being overweight, especially with abdominal obesity \u2014 largely explains why the condition has become so common in Western countries.\nAccordingly, the 28-day \u201chealing\u201d diet he suggests consists almost entirely of natural, unprocessed foods, especially lean protein foods like light-meat poultry, fish, egg whites and low-fat dairy, beans (combined with whole grains), and nonacidic vegetables and fruits.\n", "question": "Does the story commit disease-mongering?", "explanation": "As we mentioned in the summary, the story conflates occasional heartburn (known as acid reflux and other names) with gastroesophageal reflux disease (GERD), which is a persistent and long-lasting form of acid reflux. These are two different things.\nFor example, the story says\u00a0\u201cAcid reflux is a serious disorder that can and must be treated to prevent symptoms and stave off potentially life-threatening consequences.\u201d\nThat is scary language \u2014 and doesn\u2019t\u00a0apply to someone who only gets heartburn once a year after having too many beers and chili dogs.\nSecond, the story states that proton pump inhibitors (PPIs) \u2014 a class of drugs used to treat acid reflux and GERD \u2014 \u201care now linked to a growing number of complications, ranging in seriousness from nutrient deficiencies, joint pain and infections to bone fractures, heart attacks and dementia.\u201d\nFortunately, the story does note that \u201cevidence from most of the risks identified thus far is lacking\u201d \u2014 but that caveat may not resonate with readers scared to see a common drug linked to, for example, dementia. More\u00a0detail on the risks\u2013using absolute numbers\u2013would have helped readers better understand the drawbacks.", "answer": 0}, {"article": "Photo/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\nBut when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nA next-generation visor from eSight can improve vision for many legally blind people.\nLeaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\n", "question": "Does the story commit disease-mongering?", "explanation": "There didn\u2019t appear to be overt disease-mongering, although the condition in question was not adequately defined for reader comprehension.", "answer": 1}, {"article": "The guidelines state that from ages 40 to 74, screening will reduce the odds of dying from breast cancer, with women 40 to 49 benefiting the least and those 60 to 69 benefiting the most.\nHe noted that breast cancer deaths have decreased since mammography came into widespread use in the 1980s, though some of the decline, he said, was also due to better treatments.\nAmong those 40 to 49 who had regular screening, for every 1,000 women tested, 121.2 had a false positive.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\n\u201cThe science supports mammography as an important tool in the fight against breast cancer,\u201d said Dr. Michael LeFevre, a former chairman of the task force and a professor of medicine at the University of Missouri.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. The story says nothing that isn\u2019t backed up by the numbers.", "answer": 1}, {"article": "In an editorial that accompanies the JAMA study, they write that the discrepancy \u201cmay be attributable to changes in diagnosis and surveillance but also may reflect a concurrent real increase in the risk of ASDs attributable to as-yet undescribed risk factors and exposures.\u201d They also note that data from the National Health Examination and Nutrition Survey published in 2009 show that the typical American consumes only 150 mcg of folic acid per day even with mandatory fortification.\nThe study also looked at folic acid use later in pregnancy but found no correlation between that and the chances of a child developing an autism spectrum disorder.\nAfter the researchers controlled for factors like these, they calculated that taking the supplements was associated with a 39% lower risk of having a child with autistic disorder.\nThose who did were more likely to have attended college, to be nonsmokers, to be first-time mothers and to have planned their pregnancies.\nMothers who took folic acid supplements around the time they became pregnant were less likely to have children with an autism spectrum disorder, a new study has found.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story mentions the puzzlement about why rates of autism appear to be rising in the US, thus giving readers a sense of how much remains unknown about potential causes or responses.", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe group, led by NIH\u2019s National Institute of Allergy and Infectious Diseases (NIAID), tested 60 cerebral spinal fluid samples, including 12 from people with Parkinson\u2019s disease, 17 from people with dementia with Lewy bodies, and 31 controls, including 16 of whom had Alzheimer\u2019s disease.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe group conducted the tests using Real-Time Quaking-Induced Conversion (RT-QuIC), an assay developed and refined over the past decade at NIAID\u2019s Rocky Mountain Laboratories.\nThe NIAID group continues to adapt the RT-QuIC assay to detect additional types of neurological diseases with greater accuracy using the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no evidence of disease-mongering. The release says Parkinson\u2019s disease affects \u201cup to 1 million people in the United States, with 60,000 new cases diagnosed each year. Lewy body dementia affects an estimated 1.4 million people in the United States, according to the Lewy Body Dementia Association.\u201d", "answer": 1}, {"article": "But a new study suggests an existing medication may help.\nFor example, the drugs may raise the risk for problems with short-term memory, reasoning and confusion, and may also hike the risk for dementia among older patients, studies indicate.\n\"Because of this, we can take advantage of the 'side effect' and decrease involuntary sweating associated with hot flashes, and decrease the hot flashes as well,\" he explained.\nFRIDAY, Dec. 7, 2018 (HealthDay News) -- Hot flashes, a common curse in menopause, can be especially bothersome after breast cancer.\nAnd oxybutynin doesn't interfere with the metabolism of tamoxifen, Leon-Ferre said, calling that an important consideration for breast cancer survivors.\n", "question": "Does the story commit disease-mongering?", "explanation": "It\u2019s indisputable that many women going through menopause experience hot flashes and that side effects of many breast cancer treatments include hot flashes, in some cases because the treatment puts a woman into immediate menopause. They result from fluctuations in women\u2019s hormones.", "answer": 1}, {"article": "The differences over when to start regular screening reflect the growing concern that the benefits of mammograms may have been oversold, and that they don't outweigh the anxiety and potential harm caused by over-diagnosis and false positives from the tests.\nWomen should trust that process, she said.\nwas among the lawmakers who pushed for the language to be included.\nCongress has sided with proponents of earlier screening.\n\"This means making sure that cost is not a deterrent to care,\" she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The artificial nutrition is infused directly into the bloodstream.\n\"We found that the current practice of feeding children in an early stage does not contribute to their recovery\", says lead author Professor Greet Van den Berghe from KU Leuven / University Hospitals Leuven.\n\"On the contrary, the children who had built up a nutritional deficiency after receiving little to no feedings had fewer infections, less organ failure, and a quicker recovery than children who had been fed through the IV.\nTherefore, the method that is applied worldwide is to artificially feed these children during the first days of their stay in intensive care.\nThe effect was present in everyone, regardless of the type of disease, the children's age, or the hospital in which they were staying.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t give us any sense of how many children may be assigned to the ICU, or how many might benefit from a change in nutrition protocol. So while it doesn\u2019t disease-monger, we\u2019re hesitant to give the release credit here. We\u2019ll call it Not Applicable.", "answer": 2}, {"article": "\u201cHowever,\u201d the researcher said, \u201cthere is a lack of clinical studies of the effect of vitamin D supplementation for preventing respiratory infections.\u201d\n\nFor the current study, Laaksi\u2019s team randomly assigned 164 male military recruits to take either 400 international units (IU) of vitamin D or inactive placebo pills every day for six months \u2014 from October to March, covering the months when people\u2019s vitamin D stores typically decline and when respiratory infections typically peak.\nExcessive vitamin D in the blood can also raise blood pressure or trigger heart rhythm abnormalities.\nStill, the extent of the benefit was not clear.\nSome researchers believe that people need more vitamin D than is currently recommended, and that intakes above 2,000 IU per day are safe.\nThe findings, Laaksi said, offer \u201csome evidence\u201d of a benefit from vitamin D against respiratory infections.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThis story does not exaggerate the effects of common winter colds.", "answer": 1}, {"article": "And the study had one particularly unexpected outcome.\nThe devices also showed that resting heart rate spiked shortly before ovulation began, according to the Berlin company, which presented data from the small, preliminary study at the European Society of Human Reproduction and Embryology's annual meeting this month.\nBut Don't Think Of This As Birth Control Even though Clue\u2019s marketing director happened to find out she was pregnant from her Fitbit, the point of the study was to demonstrate that it's possible to use Fitbit as a conception tool, not as a pregnancy test, H\u00f6gqvist Tabor said.\nThe advantage of a passive sensor is \"these things are done kind of autonomously so you don't need to do much except check when the resting heart rate starts coming up,\" Clue's head of scientific research, Dr. Vedrana H\u00f6gqvist Tabor, told BuzzFeed News.\nHow an Activity Tracker Caught an Unexpected Pregnancy Fitness trackers, by nature of being worn around the clock, have the potential to capture unexpected insights about how your body works \u2014 and simplify laborious acts like manually figuring out your fertile days.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story says that getting pregnant can be \u201ctricky,\u201d and it can be. But it doesn\u2019t make it clear that the vast majority of women are able to conceive without this device. In fact, the story doesn\u2019t really give any sense as to how common or uncommon it is to have difficulty conceiving. Without that context, the story may perhaps contribute to women unnecessarily seeking out and purchasing the device for a problem they don\u2019t have. We suppose that there is not much harm in that, but it could cost.", "answer": 0}, {"article": "TUESDAY, Dec. 29, 2009 (HealthDay News) -- Many older adults consume ginkgo biloba, hoping to keep their minds sharp, but a new study finds that the herbal product doesn't stave off cognitive decline.\nAlso, the age of the subjects is quite advanced, at an average of 79 years at the beginning of the trial.\nThese results remained the same regardless of sex, age, race or education, the researchers noted.\nThe American Botanical council took issue with the findings, however.\nHowever, ginkgo was safe and no serious side effects were noted, DeKosky added.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0There was no exaggeration of the problem of cognitive decline. ", "answer": 1}, {"article": "The study was recently published in the journal Spine.\nThe analyses indicated that SMT -- which involves manual manipulation of the spine and surrounding muscles -- has only a short-term impact on pain relief, although it eases pain faster than other treatments.\nMore than 6,000 patients were included in the compilation of results, which the study authors said were sparse in data indicating participants' overall recovery, quality of life and ability to return to work.\n\"With low back pain, there are many reasons people don't get better,\" added Perle, also a professor of clinical sciences in the College of Chiropractic at the University of Bridgeport in Connecticut.\n\"In short, no single therapy is better than another, although some individuals are likely to have more success with one therapy than another,\" said study author Sidney Rubinstein, a research fellow at VU University Medical Center in Amsterdam.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no evidence of disease mongering in this article. This article was refreshingly free of the overheated rhetoric about the \u201cagonies\u201d of chronic low back pain\u2014and the need for novel treatment breakthroughs\u2014 that often permeate media features. Instead it took a sober, matter-of-fact approach.\n\n \n", "answer": 1}, {"article": "Dr. Lazova is currently the Director of Dermatopathology at California Skin Institute in San Jose, California.\n\u201cThis test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\n\nThe finding suggests that IMS analysis, based on proteomic signatures, may improve both diagnosis and prediction of outcomes for patients with ambiguous moles, the researchers said.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\n\u200b\u200b\u200b\u200bCalifornia Skin Institute \u2014 A recently developed test for assessing suspicious moles for melanoma is more accurate than standard analyses, according to Dr. Rossitza Lazova, a former Yale investigator.\nIn this study, mass spectrometry correlated better than the gold standard of histologic examination to determine if an atypical mole was in fact benign or a melanoma.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release correctly states that melanoma \u201cis one of the most common forms of cancer and the most serious type of skin cancer.\u201d According to the National Cancer Institute, 76,380 cases are expected in the U.S. this year, with 10,130 deaths. The news release could have helped readers understand the significance of this test better by giving readers an idea of how many people have moles that are difficult to diagnose.", "answer": 1}, {"article": "(Reuters Health) - The experimental orphan drug teprotumumab significantly reduces the eye bulging associated with Graves\u2019 disease, according to results of a small trial.\nRiver Vision Development Corporation licensed the drug from Roche.\nIt is an autoimmune disorder, in which the immune system attacks the thyroid gland.\nSmith said FDA approval could come sometime in 2018.\nAmong those who completed therapy, the rates were 79 percent and 22 percent, respectively.\n", "question": "Does the story commit disease-mongering?", "explanation": "No apparent disease mongering here.", "answer": 1}, {"article": "\u2022 Delayed surgery with long-course (25x2 Gy) radiotherapy followed by surgery after 4-8 weeks.\n\"Back then we showed that preoperative radiotherapy reduces the risk of local recurrence by over 50 per cent for patients with rectal cancer,\" says principal investigator Anna Martling, senior consultant surgeon and professor at Karolinska Institutet's Department of Molecular Medicine and Surgery.\n\"The results can now be immediately put to clinical use to the considerable benefit of the patients.\"\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\nIt also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease mongering. It says rectal cancer affects 2,000 men and women in Sweden per year.", "answer": 1}, {"article": "The average age of the participants was 11.\n\"This receptor has several effects, but one of them may be to modulate the calcium inside and outside the neuron, which is very much related to the excitability of nerve cells,\" he explained.\n\"This was a very, very treatment-resistant group, and the response was very promising,\" Devinsky said.\n\"We know that our placebo rates can be as high as 30 percent, and sometimes higher,\" said Dr. Amy Brooks-Kayal, American Epilepsy Society president, who wasn't involved in the studies.\nA second study from the University of California, San Francisco, explored the long-term effectiveness of cannabidiol for children with epilepsy, by adding the marijuana-derived oil to the regular drug regimen of about 25 kids for one year.\n", "question": "Does the story commit disease-mongering?", "explanation": "Children whose epileptic seizures are not controlled by current drugs have few options. This is a real problem. There was no disease (or pot) mongering.", "answer": 1}, {"article": "For more information about Red Journal, visit www.redjournal.org.\n\u201cWe found that patients generally can resume normal activities the following day with typical side effects.\u201d\n\nThe study, which appeared in the Red Journal\u2019s January 2017 issue, presented the results of a nonrandomized, prospective clinical trial of 58 patients with low- or intermediate-risk (non-metastatic) prostate cancer, with a median follow-up period of 2.9 years.\nWithin the six months following HDR therapy, seven patients (12.1%) experienced grade 2 urinary side effects, most commonly frequency/urgency (6.9%).\nToxicity rates were extremely low, with essentially no major complications encountered in this initial group of 58 patients.\u201d\n\nWhile findings highlight the potential tolerability of a single fraction of HDR brachytherapy for localized prostate cancer, the article also emphasizes the need for additional follow-up to compare long-term cancer control rates with conventional treatment approaches, which generally administer larger cumulative doses than the 19 Gy dose used in this trial.\nThe study is available online in the International Journal of Radiation Oncology \u25cf Biology \u25cf Physics, the flagship journal of the American Society for Radiation Oncology (ASTRO).\n", "question": "Does the news release commit disease-mongering?", "explanation": "Promoting brachytherapy radiation for treatment of low-risk men is a form of disease-mongering, particularly since there is no mention of the surveillance option. The American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) guidelines recommend that men with low-risk cancers be offered active surveillance.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story commit disease-mongering?", "explanation": "The story provides no background on hepatitis C, so this criterion is not applicable. \u00a0 ", "answer": 2}, {"article": "Newswise \u2014 Baltimore, Md.\nThe combined School and Medical System (\u201cUniversity of Maryland Medicine\u201d) has a total budget of $5 billion and an economic impact of nearly $15 billion on the state and local community.\nIt is a highly effective treatment for a wide range of localized tumors such as those found in the brain, base of the skull, head and neck area, eye tumors, tumors of the esophagus, lung, prostate, liver, breast, spinal cord, as well as gastrointestinal malignancies.\n\u201cEarly research suggests that adding thermal therapy to proton-beam therapy may be associated with an even greater benefit than when combined with standard radiation therapy, and we are excited to be at the forefront of making this combination therapy available to cancer patients,\u201d says Dr. Vujaskovic, an internationally recognized expert in hyperthermic oncology.\nMPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.\n", "question": "Does the news release commit disease-mongering?", "explanation": "While the release doesn\u2019t engage in disease mongering, it includes\u00a0almost no information about the cancers that would be targeted.\u00a0 That would have been useful context to include.", "answer": 2}, {"article": "\u201cIn contrast, if CPR is not initiated before the arrival of the emergency medical services, only 1 in 30 people survive a cardiac arrest.\u201d\n\nFor the current study, researchers looked at 30-day survival for patients who had cardiac arrests outside of a hospital between 2005 and 2011.\nCardiac arrest may occur with no warning and is often fatal.\n\u201cWe know from previous research that 1 in 8 people survive after a cardiac arrest if a bystander initiates CPR before the arrival of the emergency medical services,\u201d Rajan said by email.\nFor ambulance arrival times up to ten minutes, 6.7 percent in the CPR group and 2.2 percent of the other patients survived.\nWhen ambulances took up to 10 minutes to arrive, bystander CPR was associated with tripled survival odds, the study also found.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story.", "answer": 1}, {"article": "WASHINGTON -- Bacteria live on everyone\u2019s skin, and new research shows some friendly germs produce natural antibiotics that ward off their disease-causing cousins.\n\u201cIt does open a window for a potential new treatment.\u201d\n\nHealthy skin harbors a different mix of bacteria than skin damaged by disorders such as atopic dermatitis, the most common form of eczema.\nBut those good bugs are rare in the skin of people with atopic dermatitis, Gallo said.\n\u201cIt\u2019s boosting the body\u2019s overall immune defenses,\u201d said Dr. Richard Gallo, dermatology chairman at the University of California, San Diego, who is leading the work.\n\u201cIt\u2019s a really important paper,\u201d said Dr. Emma Guttman-Yassky of the Icahn School of Medicine at Mount Sinai Hospital in New York, who wasn\u2019t involved with the new research.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t disease monger.\nBut, it\u00a0would have been helpful to know how many people might benefit from a cream like this. For example, what percent of people with eczema develop staph infections? Would it be used to treat other active staph infections in people who don\u2019t have an underlying skin disorder? Other types of infections?", "answer": 1}, {"article": "Experts are still divided as to whether raising HDL levels will actually result in any meaningful improvements in clinical outcomes.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\n\"There are a lot of people in the prevention/lipid field that are simultaneously excited and leery,\" said Dr. Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.\n\"We have 94 percent confidence that this drug doesn't have the harmful effect that torcetrapib had, but we didn't prove a reduction in events,\" said Brigham and Women's Cannon.\nAlthough the trial was primarily designed to look at safety, researchers scheduled to present the finding Wednesday at the American Heart Association's annual meeting in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and cut LDL, HDL's evil twin, almost in half.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although this story doesn\u2019t give details about the type of patient included in this trial and the only specific reference is not quite accurate; it does not engage in disease-mongering. The story says that this trial included patients with coronary heart disease, but according to the article on the trial in the New England Journal of Medicine the participants also included people who were considered to have a greater than 20 percent chance of a cardiovascular event (heart attack, stroke, etc.) within 10 years according to standard risk models. While the story erred in describing the trial participants, the error portrays the story as relevant to a narrower, rather than a broader, definition of eligible patients. So we\u2019ll say that it doesn\u2019t oversell the potential population that might be offered this sort of drug.", "answer": 1}, {"article": "The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.\nSiliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies.\n\"Patients and their health care providers should discuss the benefits and risks of Siliq before considering treatment.\"\nPsoriasis is an autoimmune disorder that occurs more commonly in patients with a family history of the disease, and most often begins in people between the ages of 15 and 35.\nMore patients treated with Siliq compared to placebo had skin that was clear or almost clear, as assessed by scoring of the extent, nature and severity of psoriatic changes of the skin.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release. It provides some good, concise context on the skin condition and its symptoms.", "answer": 1}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story commit disease-mongering?", "explanation": "There was no obvious disease-mongering in the article. Chronic back pain is a common, vexing problem.\n\n\n\n ", "answer": 1}, {"article": "A Marine veteran who ran the New York City Marathon the year he turned 40, Carver has scheduled a similar procedure on his left knee in May, early enough \u201cto be ready for golf season.\u201d\n\nFor those who are still working at physically demanding jobs, there are other considerations.\nWhile physical activity obviously plays a role in joint deterioration, genetics may be the biggest factor in determining who needs a replacement and when, he said.\nKnee replacements increased at an even faster clip in the same period, from 274,467 to 680,886.\n\u201cThey\u2019re aging, they\u2019ve had some injuries, and they want to continue to be active into their 60s, 70s, and 80s.\nThe surgical surge has created an expanding brigade of bionic baby boomers whose artificial parts are accompanied by sky-high expectations \u2014 something doctors struggle to manage.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story ignored a body of evidence showing many patients who receive joint replacements don\u2019t get much benefit, including a recent report that found one in four joint replacements in Australia weren\u2019t needed.", "answer": 0}, {"article": "London, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\n\"With this type of vaccine, you would at least be able to start using the vaccine as soon as you knew a new pandemic was starting.\nYou could stockpile the vaccine and wouldn't have this wait to make a new pandemic-specific vaccine,\" she said.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nNormally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $800 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.\nSurvival rates and the incidence and type of tumor recurrence all were similar to what has been reported for photon radiotherapy.\nAll had previous surgery to remove as much of the tumor as possible, and all received chemotherapy before, during or after proton therapy.\nStudy participants were tested for hearing, a variety of cognitive functions, levels of important hormones and height and weight at the outset of the study and at several follow-up visits for up to eight years.\n\"At experienced centers, proton therapy has a proven track record of treatment success and safety.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release.", "answer": 1}, {"article": "\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\nIt occurs when the small central portion of the retina, known as the macula, deteriorates.\nThe retina is the light-sensing nerve tissue at the back of the eye.\nIn this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.\nWhen animal models with macular degeneration were injected with induced neural progenitor stem cells, which derive from the more commonly known induced pluripotent stem cells, healthy cells began to migrate around the retina and formed a protective layer.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease-mongering of the serious problem of macular degeneration in the news release.", "answer": 1}, {"article": "\"They attached, but they were not getting enough food.\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\nThe results are published in the current issue of Fertility & Sterility, the international journal of the American Society for Reproductive Medicine.\nFor women who suffer multiple pregnancy losses in the first four to six weeks of gestation, the hormone progesterone could offer hope for a successful birth, according to a new study by Yale School of Medicine researchers and their colleagues at University of Illinois at Chicago.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no obvious disease mongering here. The release does provide some context about miscarriages, stating that it \u201caffects 30,000 women each year in the United States. About 25% of all women who become pregnant have a first-trimester loss.\u201d", "answer": 1}, {"article": "Visual analog pain scores at 6 weeks after the injections improved by a mean 3.8 points or 61.47 percent in patients who had the PRP injections compared to the autologous blood group, a mean 2.5 points or 41.6 percent improvement.\nAnalogous blood injections, in which the patient\u2019s own blood is taken and then injected into a specific area of the body, is used to help harness the healing power of blood to treat the degeneration of tendons.\nThanasas added that further studies are needed to see how and when the PRP therapy is most effective, adding that he and his colleagues are about to start trials of PRP therapy in which different concentrations of white blood cells are used to see how this affects the regeneration of tendons.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story nicely avoids disease mongering and, right in the lead, explains that this treatment would work best in patients \u201cwhere other treatment methods have failed\u201d.", "answer": 1}, {"article": "Associate Professor Michael Buckland is Head of the Molecular Neuropathology at the University of Sydney and Head of the Department of Neuropathology at Royal Prince Alfred Hospital.\nGiven exosomes can cross the blood-brain barrier, it is likely that some of the circulating exosomes in MS patients come from affected central nervous system cells or the associated inflammatory milieu.\n\"This, in turn may lead to fewer relapses and a slower loss of brain volume, resulting in slowing or potentially halting progression of the disease for the person living with MS.\nThe research team assessed the utility of microRNAs (miRNA) in serum (blood) exosomes as biomarkers of MS disease.\nUsing next generation sequencing and integrative bioinformatics they found that serum exosome micro-RNA profiles not only distinguish MS from healthy controls, but also distinguish relapsing-remitting MS (RRMS) from progressive MS with high accuracy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. MS is a chronic disease with serious, disabling consequences for the nervous system.", "answer": 1}, {"article": "Dr. Christina Luedke of Children\u2019s Hospital Boston said she carefully screens teenagers and their families before prescribing a pump.\n\u201cWithout appropriate glucose monitoring, the pumps can increase the risk of getting sick more quickly compared to injections,\u201d Luedke said.\nIn the FDA study, appearing in the May issue of the journal Pediatrics, the reports of adverse events and deaths in adolescents using the pumps occurred from 1996 to 2005.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nThe pumps are used for those with Type 1 diabetes, which accounts for about 5 to 10 percent of all diabetes cases and used to be called \u201cjuvenile diabetes.\u201d The more common form is Type 2, which is often linked to obesity and more often affects adults.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article accurately summarizes\u00a0the\u00a0prevalence of adverse events related to insulin pump usage in adolescents and presents this information without sensationalism.\u00a0\u00a0The brief amount of background information\u00a0on Type 1 diabetes was useful\u00a0for context.", "answer": 1}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story commit disease-mongering?", "explanation": "The story does not overstate the risk of skin cancer. By focusing on sunburn, rather than skin cancer, the story avoids disease mongering.", "answer": 1}, {"article": "May 4, 2010 (New York) -- An experimental weight loss/blood pressure pill may pack a one-two punch against hunger and high blood pressure, one of the main health consequences of obesity, according to new research presented at the American Society of Hypertension\u2019s 25th annual meeting in New York.\nThe new analysis of three separate studies included more than 4,500 people.\nThe higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\nData on this drug are slated to be reviewed this summer by an FDA advisory panel.\nOparil is a consultant for Qnexa manufacturer Vivus.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering.", "answer": 1}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in the story.", "answer": 1}, {"article": "Two clinical trials examined by Khandaker focused on another drug blocking the action of a different cytokine, and both studies showed it improved symptoms of depression.\nLooking to the future\n\n\"Evidence at this point suggests that cytokine antagonists -- which are much more specific in their anti-inflammatory effects than drugs like aspirin -- show modest antidepressant effects in individuals with depression and increased inflammation,\" said Raison, who did not participate in in Khandaker's research.\nThe findings also suggest that \"anti-inflammatory drugs may be helpful in treating patients with depression who are chronically inflamed.\"\n\"The findings suggest that inflammation may contribute to the pathogenesis of depression,\" Khandaker said.\nAnti-cytokine drugs \"dampen down inflammation by blocking the actions of specific inflammatory cytokines ... with 'surgical precision' and are now routinely used for treating patients who respond inadequately to standard treatments for inflammatory conditions such as rheumatoid arthritis, psoriasis and Crohn's disease both in the US and Europe,\" explained Dr. Golam Khandaker, a clinical lecturer in Cambridge's department of psychiatry and lead author of the new study.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here, as depression is a serious illness.\nThe story would have been stronger if it had included information on the prevalence of serious depression, and the makeup of the subset of people who might benefit from the new drugs.\nAlso, making the connection between inflammation (a vaguely defined and far-reaching phenomenon) and depression could inspire some unfounded concerns among readers that they or their family members are at risk for the latter.", "answer": 1}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "[2] This number is expected to double every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050.\nThe primary outcome parameter was selected to assess the effect on cognitive function (a broad measure of thinking) during 24 months intake of Fortasyn Connect compared with a control product.\nSince its establishment, evidence has been accumulated to support the hypothesis that certain nutritional molecules are beneficial in reducing disease progression in Alzheimer's.\nTobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\n\u2022 Academy of Sciences of the - Institute of Physiology\n\nFor further information on the European LipiDiDiet study and consortium, visit: http://www.lipididiet.eu\n\u2022 A Clinical Trial investigating the effects of Fortasyn Connect (Souvenaid) in Prodromal Alzheimer's Disease: Results of the LipiDiDiet study H. Soininen, , M. Kivipelto, T. Hartmann for the LipiDiDiet study group (2016), presentation held at 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy,\n\u2022 The World Alzheimer Report 2015: 'The Global Impact of Dementia'.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release liberally applies hype on a narrowly focused area called \u201cearly dementia\u201d and focuses on the purported benefits of this drink for this phase of mental disorder. It is important to note that not all people with mild cognitive impairment (what the release calls early dementia) go on to develop full blown symptoms of Alzheimer\u2019s.", "answer": 0}, {"article": "Probiotic organisms are non-pathogenic bacteria that, when present in the gut flora, are known to improve the overall health of the host.\nThe results showed that the group receiving the probiotic supplement, on average, didn't return to the hospital as quickly and required less in-patient treatment time compared to the placebo group.\nThere is also mounting evidence linking imbalances in the microbial species that make up the gut microbiome to a number of health problems including allergies, autoimmune disorders, and psychiatric mood disorders.\nThis connection, named the \"gut-brain axis\" (GBA), allows for crosstalk between the endocrine, immune, and autonomic nervous systems.\nOverall, these results indicate that changes in intestinal inflammation can alter the trajectory of psychiatric mood disorders and that modulating the intestinal microbiota may be a new avenue of treatment for patients suffering from these diseases.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It provides context on the prevalence of bipolar disorder in the US.", "answer": 1}, {"article": "He is also founder of Durin Technologies Inc., the company that is developing the test.\n''This is a simple test that has high accuracy and can be run from a single drop of blood,\" says Robert Nagele, PhD, a professor of medicine at the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.\nAn estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nAug. 3, 2011 -- A new blood test for Alzheimer's disease is 96% accurate at identifying the disease and can perhaps detect it even before symptoms such as memory loss appear, says the test's developer.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story does not exaggerate the extent or severity of Alzheimer\u2019s Disease. However, it might have been helpful to include some description of the sort of individual who might consider using this sort of test. \n\n\nStories like this need to be clear that since there is no meaningful treatment currently available for Alzheimer\u2019s disease, many individuals may not want to be burdened with the prospect of impending dementia when there is no known way to do anything about it. The story would have been better if rather than focusing on individuals and the fearful prospect of Alzheimer\u2019s, it had given more attention to the most likely near-term use for Alzheimer\u2019s tests: as aids to researchers studying potential treatments in controlled trials.\n", "answer": 1}, {"article": "This study was presented at a medical conference.\nIt appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nIt blocks an enzyme crucial to the production of male hormones, which spur the growth and spread of advanced prostate cancers.\nOct. 12, 2010 -- Even when medical or surgical castration fails, a potent drug extends survival by four months in patients with metastatic prostate cancer.\nBut there's more hope than that from the study of some 1,200 men with late-stage cancer at 147 medical centers in 13 nations.\n", "question": "Does the story commit disease-mongering?", "explanation": "In a 264-word story, no space was given to any meaningful discussion of the condition itself, so we rule this Not Applicable in this case. ", "answer": 2}, {"article": "Walnuts, that is.\nAnd a study of men attending a fertility clinic, published in May by the journal Human Reproduction, found that high intake of omega-3 fats was linked to more normal sperm size and shape, while high intake of saturated fats was related to lower sperm concentration.\nThe researcher looked at sperm concentration, vitality, ability to move, shape and size, and chromosome abnormalities, all thought to be related to fertility.\nEating 2.5 ounces of walnuts a day -- a little more than half a cup -- for 12 weeks improved sperm quality in healthy young men, researchers report.\nAnimal and human studies have shown that omega-3 fats and other polyunsaturated fatty acids \u201cplay critical roles in sperm maturation and membrane function,\u201d Robbins\u2019 team writes.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of male fertility problems \u2013 if you can get past the lead line that suggests that any man aspiring to fatherhood should think about eating nuts to improve sperm quality.", "answer": 1}, {"article": "Sha says it\u2019s not clear what might be found in plasma from young people that might help the symptoms of Alzheimer\u2019s.\nWhole plasma must be matched to blood type.\nThen they swapped the two sides.\nResearchers trying to answer the question say they found the treatments are at least safe.\nAnd they got a tiny hint that they just may help.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t disease-monger.", "answer": 1}, {"article": "\u2022 Available multimedia including photos and an audio interview are on the right column of the release link - https:/\n\u2022 Story on previous JAHA study (June 21, 2018): Breastfeeding may reduce a mother's heart attack and stroke risk\n\u2022 For updates and new science from JAHA, follow @JAHA_AHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\nAdditional research should consider the degree to which breastfeeding might alter racial/ethnic differences in stroke risk,\" Jacobson said.\nAt the time of recruitment, the average age was 63.7 years and the follow-up period was 12.6 years.\nThis is among the first studies to examine breastfeeding and a possible relationship to stroke risk for mothers, as well as how such a relationship might vary by ethnicity.\nBecause the study was observational, it couldn't establish a cause-and-effect relationship between breastfeeding and lower stroke risk, meaning that it is possible some other characteristic that distinguishes between women who breastfeed and those who don't is the factor changing the stroke risk.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release offers context on the incidence of U.S. stroke mortality rates.", "answer": 1}, {"article": "That led some experts to suggest that weight loss and exercise should be the next frontier for cancer prevention research.\nThe average age was 53 when the study began.\nAll the women had been successfully treated for early-stage breast cancer.\nResearchers noted that none of the breast cancer survivors lost weight on either diet.\nThe study appears in today's Journal of the American Medical Association.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering. ", "answer": 1}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story commit disease-mongering?", "explanation": "Migraines are a common cause of headaches, and can be tough to treat.\nHowever, we did want to note that the family anecdote in the story is an extreme case, and not necessarily representative of what most people with migraines experience.", "answer": 1}, {"article": "DALLAS, Oct. 20, 2015 -- Botox -- known for reducing facial wrinkles -- may also prevent irregular heart rhythms when injected into fat surrounding the heart after bypass surgery, according to research in the American Heart Association journal Circulation: Arrhythmia and Electrophysiology.\nAtrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\n\"About a third of all patients undergoing bypass surgery will develop atrial fibrillation, putting them at higher risk for cardiovascular complications,\" said Jonathan S. Steinberg, M.D., senior study author and Adjunct Professor of Medicine at the University of Rochester and Director of the Arrhythmia Institute in the Valley Health System in Ridgewood, New Jersey.\nBut complications from the bypass surgery were similar in both groups, including time in intensive care and on a breathing machine, and infection rate.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Atrial fibrillation post coronary artery bypass grafting (CABG) can dramatically impact the patient\u2019s quality of life as well as potentially increase morbidity.\u00a0The story does not over state the impact and provides statistics concerning its prevalence.", "answer": 1}, {"article": "CHICAGO \u2013 Initial findings from a randomized phase III clinical trial show that patients with advanced squamous non-small-cell lung cancer (NSCLC) benefit more from initial treatment with PD-L1 targeted immunotherapy atezolizumab (Tecentriq\u00ae) and chemotherapy than from chemotherapy alone -- 29% had a reduced risk of disease worsening or death compared with those who received chemotherapy alone.\nThe researchers will explore tumor PD-L1 expression and other molecular markers, such as tumor mutational burden (TMB), that may predict whether a patient will benefit from this treatment regimen.\nAt 12 months, cancer had not worsened in twice as many patients who received atezolizumab plus chemotherapy compared to those who only received chemotherapy.\nNext Steps\n\n More research is needed to determine which patients benefit the most from the addition of immunotherapy to standard chemotherapy.\nASCO Perspective\n\n\u201cThis is one more example of how immunotherapy is making steady gains against a number of cancers.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release explains that squamous non-small cell lung cancer accounts for 25-30% of all non-small cell lung cancers and accurately portrays the poor prognosis of this cancer.", "answer": 1}, {"article": "\"More than 30 years since the discovery of the antidepressant effects of sleep deprivation, we still do not have an effective grasp on precisely how effective the treatment is and how to achieve the best clinical results,\" said study senior author Philip Gehrman, PhD, an associate professor of Psychiatry and member of the Penn Sleep Center, who also treats patients at the Cpl.\nMichael J. Crescenz VA Medical Center.\nMichael J. Crescenz VA Medical Center.\n\"Our analysis precisely reports how effective sleep deprivation is and in which populations it should be administered.\"\nAlthough total sleep deprivation or partial sleep deprivation can produce clinical improvement in depression symptoms within 24 hours, antidepressants are the most common treatment for depression.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "The 80% by 2018 campaign from the National Colorectal Cancer Roundtable, for example, which aims to increase the rate of screening, emphasizes a suite of options.\nAnd colonoscopies are well-reimbursed for the physicians who perform them.\nIt\u2019s expensive, running upward of $1,000.\nThere\u2019s a small but real risk of harm, such as a perforation.\nNo one is arguing colonoscopy is a bad test.\n", "question": "Does the story commit disease-mongering?", "explanation": "Colon cancer is the second-leading form of cancer-related death in the country; the story does not disease monger.", "answer": 1}, {"article": "He was not part of the study.\nThe first showdown pitting 3-D, heart-imaging exams against older stress tests atop treadmills or stationary bikes found that among 10,003 heart patients, their rates of eventually having serious heart events were the same \u2014 no matter which method doctors used to check their tickers, researchers said.\nIn both test groups, only about 3 percent of the people had heart attacks, suffered \"major\" complications, needed hospitalization for chest pain or died during two years of tracking, researchers found.\nIt is a real testament to how far we\u2019ve come in the treatment of patients with suspected coronary disease,\" said Dr. Steven Nissen, department chair of cardiovascular medicine at the Cleveland Clinic.\nResults of the federally funded trial \u2014 Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) \u2014 were presented at the American College of Cardiology\u2019s 64th Annual Scientific Session in San Diego.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story had competing impulses. On the one hand, the story mediates against disease-mongering by indicating that the low incidence of later heart problems among the participants suggests the value of \u201cwatchful waiting\u201d rather than treatment.\u00a0 On the other, the anecdotal story at the end of the text heads in the opposite direction, suggesting that stress tests miss vital diagnostic information. But we don\u2019t think anything in the story rises to the level of disease mongering.", "answer": 1}, {"article": "\"Beta- blocker drugs compete with stress hormones and bind to the same target receptors [on a cellular level], but unlike stress hormones, do not activate cancer cells,\" said Dr. Des Powe, a senior healthcare research scientist at Queen's Medical Centre, Nottingham University Hospital NHS Trust, in Nottingham, England.\nPowe said he plans to do another study to validate the results.\n\"I think this study is interesting, but very far from being conclusive,\" said Chung.\nOther experts called the results interesting, but preliminary.\nTo learn more about inflammation and cancer, visit the U.S. National Cancer Institute.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not exaggerate the seriousness or prevalence of breast cancer. ", "answer": 1}, {"article": "THURSDAY, June 28, 2012 (HealthDay News) -- A new drug for type 2 diabetes causes significantly less weight gain and may carry lower risks for hypoglycemia (low blood sugar), heart attack and stroke than standard medications, a new study indicates.\nThey added more research is needed to confirm their findings.\nNone of the patients had responded to metformin alone.\nThe patients on linagliptin also had fewer heart attacks and strokes compared to those being treated with glimepiride.\nPatients with type 2 diabetes may stop responding to metformin over time.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story.", "answer": 1}, {"article": "So when the government advisory panel \u2014 the U.S. Preventive Services Task Force \u2014 recommends against routine PSA testing, it\u2019s making a judgment call.\nThat\u2019s what experts can\u2019t agree about.\nOn the first issue, there is still some uncertainty.\nThe rate of new diagnoses of all cancer types combined has been falling consistently in recent years.\nMany doctors do have very strong opinions, though.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "A limitation of the study was its small sample size and short follow-up period.\nEMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 20, 2017\n\nThe commentary, \u201cYAG Laser Vitreolysis\u2014Is It as Clear as It Seems?,\u201d by Jennifer I. Lim, M.D., of the University of Illinois at Chicago; and Editor, JAMA Ophthalmology, also is available at the For The Media website.\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\nThree management options exist for floaters: patient education and observation; surgery; and the laser procedure, YAG vitreolysis, of which there are limited published studies on its effectiveness for treating floaters.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Cases of eye floaters that need medical intervention occur, but as the release notes, \u201cmost patients grow accustomed to them.\u201d Most people adapt to their floaters or the floaters settle at the bottom of the eye \u2014 out of the line of sight \u2014 without treatment. The release doesn\u2019t note that laser treatments would be relevant in those few serious cases, thus setting the stage for over-use in the majority of cases that would not require treatment.", "answer": 1}, {"article": "Growing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\nHowever, few foods naturally contain the vitamin.\nMS is a nervous system disease that attacks the material, called myelin, that covers nerve fibers.\nThe disease most often strikes adults after age 20, but it can develop in children.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not exaggerate the prevalence or seriousness of MS. ", "answer": 1}, {"article": "\u201c[PRP] works, and the results have been amazing,\u2019\u2019 says John Ferrell, the sports medicine physician who treated me.\nWe will be able to treat ailments noninvasively, and at an earlier stage.\u2019\u2019\n\nThe procedure involves collecting several ounces of blood from a patient\u2019s arm, spinning the blood in a centrifuge to concentrate the platelets and injecting the concentrated platelets into the injury site to stimulate healing.\nBy performing several tests to assess my strength and range of motion, Ferrell discovered that my left shoulder \u2014 the site of the tear \u2014 was considerably weaker than my right.\nThe researchers call the results \u201cclinically relevant,\u2019\u2019 despite the study\u2019s small size, and say the next step should be a larger, controlled clinical trial.\nCortisone injections and physical therapy didn\u2019t help, so I decided to try something else: platelet-rich plasma, a therapy that uses the body\u2019s natural healing properties to mend injuries.\n", "question": "Does the story commit disease-mongering?", "explanation": "When it comes to shoulder injuries like rotator cuff tears, the story does not disease monger.\nHowever, the author\u2019s claim that a vaccination injection resulted in the shoulder tear was an unusual claim, and one that we\u2019re dubious of.", "answer": 1}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering but it would have been nice for the author to have provided some estimates concerning the size of the problem.\u00a0 Although psoriasis is a relatively common ailment, moderate to severe forms requiring systemic treatment are much less common.\u00a0 The article suggest the standard treatment is systemic ignoring the use of topical products for less severe forms of the disease.", "answer": 2}, {"article": "\u201cThe journal knew it.\u201d\n\n\u201cThe question for the journal, given that the authors worked for the company, is, \u2018Do we publish something like that?\u2019\u201d\n\nJohnston said there was an ongoing debate about whether or not scientists who review studies should know about potential industry interests.\nThe question then becomes what, if anything, to do when there is a conflict of interest.\n\u201cScientifically there are no data there,\u201d he said about one of the company\u2019s experiments.\nWhile some people will want to see and feel an impact, he said, for many the clinical claim alone suffices.\nWhile there had been some concerns about the methods, \u201con balance there was enough interest to publish it,\u201d she told Reuters Health.\n", "question": "Does the story commit disease-mongering?", "explanation": "The opposite of disease mongering, pointing out how \"branding personal care products with clinical claims is a very common strategy.\"\u00a0 ", "answer": 1}, {"article": "\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\n\"There haven't been breakthrough treatments for heart failure for a long time,\" she said.\n\"You don't see any sustained effect,\" he added.\nThe most common side effects were headache and nausea directly after receiving the drug.\nThe improvement lasted 90 days, with the maximum increase in heart function reached in 28 days, the researchers found.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t commit disease mongering.", "answer": 1}, {"article": "\"While ENDS may have the potential to benefit established adult smokers ... [they] should not be used by youth and adult non-tobacco users because of the harmful effects of nicotine and other risk exposures,\" says Tim McAfee, director the Office on Smoking and Health at the U.S. Centers for Disease Control and Prevention.\n\"The intent of big tobacco is to sell their product,\" concludes Peruga.\n\"For every 10% increase in tax you have 4% reduction in tobacco consumption,\" says Peruga.\n\"Exposure to nicotine can harm adolescent brain development.\"\nThat craving is caused by smoking tobacco but is now being increasingly satisfied by e-cigarettes and the trend to \"vape\" instead of smoke.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "\"My wrist has gotten a lot stronger.\nIt uses stem cells in the damaged areas in hopes of restoring function and movement.\nI'm able to grasp around a lot other things,\" he said.\n\"I remember just hitting the ground,\" said Mason.\nBut it's hard to know what would have happened without them.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the frequency or severity of this condition.", "answer": 1}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story commit disease-mongering?", "explanation": "We liked that, when discussing osteopenia, the story included a quote from an expert that osteopenia \u201cisn\u2019t a disease. It merely tells us that bone density is in the lower part of normal range. There are an awful lot of people who fall into that category who may never get osteoporosis.\u201d Hurray for paragraphs like this one, which help readers understand what a potentially scary medical term actually means and tells them not to panic.", "answer": 1}, {"article": "Arterburn and Simon's coauthors are GHRI Senior Investigator Denise M. Boudreau, PhD, Research Project Management Director Emily O. Westbrook , Programmer Analyst Mary Kay Theis, and Andy Bogart; Tamar Sofer, PhD, a biostatistician at the UW School of Public Health and post-doctoral research fellow at Harvard University; and Sebastien Haneuse, PhD, an associate professor of biostatistics at the Harvard T.H.\n\"We found that bupropion is the only antidepressant that tends to be linked to weight loss over two years,\" Dr. Arterburn said.\nBut in some cases, an overweight or obese patient has reasons why bupropion is not for them--like a history of seizure disorder--and it would be better for them to choose a different treatment option.\nAfter two years, nonsmokers lost an average of 2.4 pounds on bupropion--compared with gaining an average of 4.6 pounds on fluoxetine (Prozac).\nBut many people take antidepressants--the most commonly prescribed medications in the United States--for longer than a year.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. Nor does it give us any context about the prevalence of depression which might have been warranted here.", "answer": 1}, {"article": "The ChemMedChem study is available at http://dx.\nBecause of the widespread resistance of bacteria to antibiotics on the market, there is an urgent need for the development of new antimicrobials.\nMRSA infection is caused by a type of Staphylococcus bacteria that has become resistant to many antibiotics used to treat ordinary staph infections, according to the Mayo Clinic.\nCommunity-acquired MRSA often begins as a skin boil and is spread by skin-to-skin contact.\nHe co-led the study with Phang C. Tai, Regents' Professor of Biology at Georgia State, who is an expert on the functions of SecA in bacteria.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release relates to the public\u2019s concern over antibiotic-resistant infections like those caused by MRSA but it doesn\u2019t reach the level of disease-mongering.", "answer": 1}, {"article": "\"We show that patients taking anticoagulant [blood thinning] medication had better outcomes with regards to prostate cancer death and that this benefit was most prominent in patients who had high-risk disease,\" said study lead author Dr. Kevin Choe, a radiation oncologist with the University of Texas Southwestern Medical School in Dallas.\nIn looking at the records of more than 5,000 men with prostate cancer, 2,000 of whom were taking aspirin or another blood-thinning drug, researchers presenting at the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego report that the risk of dying from the cancer was reduced by more than half.\nOf the blood thinners used in the study, aspirin was the one which seemed to account for most of the benefit, the researchers said\n\nThere has already been some evidence that cancer and the body's coagulation system might be linked in some way.\nA second study, conducted in the United States, Canada and Great Britain and also being presented at ASTRO, suggests that a combination of hormone therapy plus radiation may be the best treatment for men who have locally advanced prostate cancer with a high risk of returning.\nThe chances of the cancer spreading to the bone were reduced while PSA (prostate-specific antigen) blood levels -- thought to be a marker for cancer's advance -- were also better controlled.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story was clear that this study involved only men who had been diagnosed with prostate cancer and that it was in those with the highest-risk tumors where the differences were most apparent between those who were on anticoagulants and those who weren\u2019t. It would have been a good idea for this and the competing WebMD story to state how many men are diagnosed each year with prostate cancer and how few actually die of the disease; most men diagnosed with prostate cancer are not destined to die of their prostate cancer.", "answer": 1}, {"article": "Sleep-specific quality of life was examined with the Functional Outcomes of Sleep Questionnaire (FOSQ), which assesses the effect of sleep disorders and excessive daytime sleepiness on activities of daily living such as productivity and intimacy.\nParticipants had a mean age of 56 years, and about 54 percent were men.\nScores before and after up to one year of PAP therapy were compared.\n\"This information will guide clinicians in terms of expected quality of life outcomes with sleep apnea treatment.\"\n\"We noted consistent improvement in global and sleep-specific quality-of-life measures after PAP therapy.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering in this news release.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Botox injections may provide some relief from arm tremors caused by multiple sclerosis, according to a small study published Monday.\nLarger studies, of more-diverse groups of MS patients, are needed, he said.\nBotulinum toxin type A is sold under different brands, but it\u2019s best known by the Allergan brand-name Botox.\nTheir ability to write and draw a straight line had also improved by week six, and the benefits were still there at week 12.\n\u201cSo practitioners will have to be up to speed,\u201d LaRocca said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play here.", "answer": 1}, {"article": "Men who received the combination of surgery and radiotherapy had higher rates of erectile dysfunction (28 percent vs 20 percent) and higher rates of urinary incontinence (49 percent vs 19 percent).\nA comparison of 2 of the most common combination therapies for locally advanced prostate cancer show the more aggressive option is linked with a higher rate of survival\n\n(Philadelphia) - High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies.\nIn the largest population-based retrospective study to date, Dr. Lu-Yao and colleagues examined the records of 13,856 men in the Medicare-SEER registry diagnosed with locally advanced prostate cancer -- cancer growth that had not yet metastasized to distant sites in the body.\nSeveral large clinical trials are nearing completion that should validate these retrospective findings of the benefits of primary radical prostatectomy followed by additional therapies such as adjuvant radiation,\" said Leonard Gomella, Chair of the Department of Urology at Jefferson (Philadelphia University + Thomas Jefferson University), who was not involved in this research.\n\"However, the proportion of men undergoing prostatectomy plus radiation therapy decreased significantly over time and there were trade-offs for the survival advantages,\" said Dr. Lu-Yao.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release did not exaggerate the prevalence of prostate cancer, but it also did not provide data on how common prostate cancer is. In addition, readers may not realize that this finding applies only to some patients with prostate cancer \u2014 those with more aggressive appearing disease that falls short of metastatic disease. Most prostate cancer is lower risk. Stating this and providing some context would have helped, but we\u2019ll give the benefit of the doubt here.", "answer": 1}, {"article": "TUESDAY, Oct. 16, 2018 (HealthDay News) -- Stimulating a specific set of nerves that are nestled along the spine may deliver relief to those who suffer from chronic back pain and cut the need for opioid painkillers, new research suggests.\nThe therapy, which targets the root ganglion nerves, is more effective than other spine stimulation procedures because it places tiny leads precisely at the area where pain originates, unlike other devices that provide more generalized stimulation, the researchers said.\nThe dorsal root ganglions are nerve cells, on both sides of each of the spine's vertebra, and are the gateway to pain between nerves in different parts of the body, spinal cord and brain.\nAlso, the procedure isn't covered by all insurance companies, so out-of-pocket costs to patients can be very high.\n\"The results of this study are very significant,\" said Dr. Kiran Patel, director of neurosurgical pain at Lenox Hill Hospital in New York City.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t exaggerate the incidence of chronic back pain, though some numbers would have been helpful.\nLow back pain is a common problem \u2013 almost everyone will have it at some point. However, only a small number, 7-12%, go on to develop chronic, disabling pain. That said, this still represents millions of adults in the US, and is well known to be a contributor to the opioid epidemic of physician prescribing for chronic musculoskeletal pain.", "answer": 0}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story commit disease-mongering?", "explanation": "The first sentence\u00a0 where the story states that \"\u2026.there\u2019s nothing as important as making sure that every last bit of disease has been removed\", along with the threat of \"spreading malignancies\" is disease mongering. One might reasonably argue that there is nothing more important than leaving sufficient intact brain or other tissue undisturbed. ", "answer": 0}, {"article": "Peramivir is given intravenously, making it usable by hospitalized patients who are too ill to take two approved flu drugs that work against the virus in similar ways \u2014 Tamiflu by Roche, which is typically given as a pill, or Relenza from GlaxoSmithKline, which is inhaled.\nThe government has the right to buy up to 30,000 more treatment courses at the same price.\nThe government is paying an average of only $450 a course for those other drugs \u2014 only one-fifth of what it is paying for peramivir.\nWhile some clinical trials showed the drug had an effect in resolving flu symptoms, others did not show statistically significant differences between peramivir and either a placebo or Tamiflu.\nYet the company gets to keep as profit anything it makes from selling the drug to the federal government or to other governments.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story points out that the experimental drug is being offered only to patients who are already in the hospital and aren\u2019t being helped by approved drugs.", "answer": 1}, {"article": "\u201cThe results of the DRCR Network\u2019s comparison of Eylea, Avastin, and Lucentis will help doctors and their patients with diabetic macular edema choose the most appropriate therapy,\u201d said John A.\nThe other half had 20/50 or worse vision.\nThe need for laser treatment varied among the three treatment groups.\nThe macula is the area of the retina used when looking straight ahead.\nSubsequently, injections were resumed if DME worsened.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease mongering.", "answer": 1}, {"article": "Llanos cautioned that the study looked only at a mother's own breast milk, not donor milk, which can be used when the biological mother doesn't have enough of her own breast milk.\nThe studies included more than 2,200 preterm infants, comparing how often babies had been fed human milk or formula, and whether or not they developed ROP.\nThe greater incidence of ROP is likely due to the increasing survival rate of very preterm babies in developed countries, according to Chen.\n\"Human milk feeding potentially plays a strong role in protecting very preterm newborns from any-stage ROP and severe ROP,\" the international team of study authors wrote.\nAnd the risk of severe ROP seemed to be reduced by 90 percent, the researchers added.\n", "question": "Does the story commit disease-mongering?", "explanation": "We paused to take a second look at the statement that ROP \u201chas become a leading cause of childhood blindness in recent time.\u201d\nThat sounds scary, but the story qualifies things nicely when it notes, \u201cThe greater incidence of ROP is likely due to the increasing survival rate of very preterm babies in developed countries.\u201d That\u2019s good context because it explains that the condition is actually a consequence of a positive trend in health care.", "answer": 1}, {"article": "By year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\nWhile mortality in the hospital was 0.3 percent, some 21 percent of patients had to be admitted to the hospital again for one reason or another within a year of their operations.\nFinally, surgery isn't without risk.\nThe cost of the surgery was about $30,000, which exceeds the savings observed directly.\nThe ultimate savings case requires some extrapolation, though.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not exaggerate the prevalence or consequences of obesity or diabetes.", "answer": 1}, {"article": "The California Walnut Commission (CWC) prohibits discrimination in all programs and activities on the basis of race, color, national origin, age, disability, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or part of an individual's income is derived from any public assistance programs.\nThis new paper prospectively examined the association between the dietary habits of the participants and subsequent impairment in physical function.\nBetween 1992 and 2008, the women were asked questions about their physical function, including their ability to perform basic activities of daily living.\n\"These results add to the large body of evidence that outline the many benefits of a healthy diet for women.\nAdditionally, participants were not assigned to eat walnuts or other foods, and were just asked about their dietary choices.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not exaggerate the problem of decline in physical function with age.", "answer": 1}, {"article": "[11]\n\nEVZIO (naloxone HCl injection) Auto-injector is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.\nAdditionally, there are nearly two times the number of prescription opioid-related deaths as compared to heroin-related deaths.1 On average, 3,300 children five years old and younger are admitted to emergency departments each year due to accidental opioid exposure.\n\"By empowering more patients to have access to this potentially life-saving medicine, we believe that EVZIO will help reduce the burden of opioid overdose in the United States.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\nOn average, 79 people die from opioids, including prescription opioid analgesics and heroin, everyday in the United States; most occur outside of medical settings, such as in a home.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release quotes an official in Baltimore stating,\u201dwe believe that naloxone should be a part of everyone\u2019s medicine cabinet and everyone\u2019s first aid kit.\u201d While this initially seemed like a stretch to us, the breadth of the opioid overdose crisis in some regions of the country makes it a reasonable proposal.", "answer": 1}, {"article": "The most effective screening tests currently available are based on a single biomarker called prostate specific antigen (PSA).\nThe results, published in the Public Library of Science (PLoS) ONE journal, showed that MSMB is found at significantly lower levels in the urine of men diagnosed with prostate cancer than those without the disease.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\nScientists from the Cancer Research UK Cambridge Research Institute and the Institute of Cancer Research (ICR) said the protein, called microseminoprotein-beta or MSMB, is found at reduced levels in men diagnosed with the disease and are also lower in men with more aggressive forms of the cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did engage in a bit of disease mongering with the number of men diagnosed world wide with the disease and reporting that prostate cancer was the second most common cancer cause of death among American men without indicating that in the U.S., the lifetime risk of dying from prostate cancer is 3% . \u00a0Most problematic was the statement that \"In Britain, around 35,000 men are diagnosed with it and some 10,000 die from the disease.\" But no time frame was given \u2013 no way to give such estimates.\u00a0 ", "answer": 0}, {"article": "LONDON (Reuters) - British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.\nIt also had the potential to identify targets on the tumor that could be used to inform treatment strategies, he said.\nThe test was nearly twice as successful in eliminating false-positives than current tests, he said.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nAngle founder and chief executive Andrew Newland said the study had demonstrated the ability to correctly detect cancer, and importantly correctly detect the absence of cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "Ovarian cancer diagnosis is a difficult challenge.", "answer": 1}, {"article": "\u201cModels are models,\u201d Lin said.\nThe finding that assigned-to-screening men were no more likely to avoid death from prostate cancer might therefore have been because their screening behavior wasn\u2019t different enough from the \u201cunscreened\u201d (but in fact partly screened) men\u2019s, not because PSA screening doesn\u2019t save lives.\nAmong other drawbacks, the tests lead to overdiagnosis (meaning a biopsy finds malignant cells but they are so innocuous they would never harm, let alone kill, the man) as well as incontinence and impotence from treatment (including of harmless cancers).\nAs a result, when researchers counted deaths in each group, it wasn\u2019t a clean comparison: Rather than comparing screened to unscreened men, they were comparing assigned-to-screening men to not-assigned-to-screening men.\nIn April, however, the task force proposed instead that men aged 55 to 69 discuss PSA\u2019s pros and cons with their doctor and then decide what to do, factoring in that if 1,000 men get regular PSA screening for a decade it will save about one life.\n", "question": "Does the story commit disease-mongering?", "explanation": "There are no signs of the common type of disease mongering we sometimes encounter in commentary about PSA testing, where some will take data from one age cohort as proof to suggest that other age cohorts (ie: younger men) would also benefit from PSA testing.", "answer": 1}, {"article": "Loyola's department of urology is ranked 39th in the country by U.S. News and World Report.\nBut apart from the RAZOR trial, there have been no prospective, randomized multicenter trials to assess how robotic surgery compares to open surgery in cancer survival.\nThree main techniques are used to replace the bladder: construct a new bladder (neobladder) from the patient's intestine; place a pouch inside the body to act as an artificial bladder; or place a bag outside the body to collect urine.\n\"It is important to conduct these trials before widespread adoption of technology, as has been the case with robotic prostatectomy (removal of the prostate),\" he said.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not exaggerate the prevalence of bladder cancer. It does not push treatment on those who are unlikely to benefit.\nThe release could be interpreted as promoting a newer more expensive form of therapy that doesn\u2019t provide any advantages over the standard therapy.", "answer": 1}, {"article": "Nov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\n\"More fish, more brain, less Alzheimer's,\" he tells WebMD.\nRaji presented the findings here at the annual meeting of the Radiological Society of North America.\nSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer's disease.\nAnd people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of Alzheimer\u2019s disease.\n ", "answer": 1}, {"article": "\u201cIf we feel like we have a safe method of getting drugs in there,\u201d he said, \u201cit will open up a whole new slew of clinical trials.\u201d\n\nMainprize said the patient, a \u201cremarkable woman,\u201d was chosen to go first, because of the status and large size of her tumor, because it was an area of the brain that the ultrasound machinery could easily reach, and because of her willingness to help the research.\nBut it\u2019s just one of many.\n\u201cI want to be a normal housewife \u2026 a normal grandma.\u201d\nOn Friday, as scheduled, Hall had brain surgery to remove her tumor.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\n", "question": "Does the story commit disease-mongering?", "explanation": "None detected.", "answer": 1}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nTheir findings are based on the women's T-score, which is a measure of bone density.\nResearchers say the 10-year interval is OK because the women\u2019s risk of developing the brittle bone disease osteoporosis in that time is low.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\nThat was longer than we expected, and it's great news for this group of women.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in this story.", "answer": 1}, {"article": "What if you could lose weight and reduce your risk of life-threatening disease without any changes in what you eat -- other than a five-day special diet once every few months?\nThe diet, which was designed to mimic the results of a water-only fast, allowed for participants to consume between 750 and 1,100 calories per day.\nThe researchers also noted that participants considered \"at risk\" because they had risk factors such as high IGF-1, cholesterol, blood pressure or blood sugar levels, made significant progress toward better health.\nThe research team found that the beneficial effects -- from weight loss, smaller waistlines and lower glucose, blood pressure and IGF-1 levels -- were sustained.\nThe next step for researchers is a large, FDA phase III clinical trial to test the FMD on patients diagnosed with age-related diseases or at high risk for them.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering, but there is also no\u00a0context provided on how fasting fits into current diet and nutrition recommendations, or which segment of the population might benefit from such a diet.", "answer": 0}, {"article": "Although the study looked at patients taking warfarin (Coumadin), newer drugs -- including rivaroxaban (Xarelto) and apixaban (Eliquis) -- should reduce the risk of dementia even more, Bunch said.\nAtrial fibrillation is a common heart abnormality that affects nearly 3 million American adults.\nIt causes the heart to beat abnormally or quiver.\nLee is a professor of medicine and director of the electrophysiology laboratories and clinics at UCSF.\nIn high-risk patients, a delay increased the risk 136 percent, the researchers reported.\n", "question": "Does the story commit disease-mongering?", "explanation": "Stroke and dementia are a serious problem in developing countries with aging populations.", "answer": 1}, {"article": "Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education.\nThe investigators found that Enclomiphene citrate restored blood testosterone levels to normal after 16 weeks while maintaining sperm concentrations, whereas Androgel restored blood testosterone levels but caused marked reductions in sperm concentrations by suppressing the function of the testes.\nWhile testosterone replacement therapy can boost men's energy levels, sex drive, and mood, the treatment can fool the body into thinking that it is producing enough testosterone, so that it in turn starts making less of its own.\nThis can result in a significant decrease in sperm count--leading to infertility--because the body needs its own testosterone to produce sperm.\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This is a tough call.\u00a0 It\u2019s difficult to assign either a Satisfactory or Unsatisfactory grade to this criterion because the news release actually provides no meaningful discussion of the underlying condition that may lead a man to seek treatment. \u00a0In such cases, we usually assign a Not Applicable score.", "answer": 2}, {"article": "For more information, visit http://www.\nResults of the human study showed that imaging was effective for the evaluation of metastatic prostate cancer, and subsequent therapy resulted in a drop in prostate-specific antigen levels from 38.0 to 4.6 nanograms per milliliter.\nDiagnostic imaging was followed by a therapy-grade radionuclide, lutetium-177, which delivers a more powerful dose of radiation that penetrates and destroys the cells and tissues of tumors when combined with PSMA-617.\nThe current clinical methods are not sensitive enough for detecting disease beyond the prostate, but we are convinced that this novel theranostic radiotracer represents a significant step forward that could have a major impact on the future of prostate cancer care.\"\nApproximately one out of seven men will be diagnosed with prostate cancer in their lifetime, according to 2015 statistics from the American Cancer Society.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here.\u00a0 Prostate cancer is a reality and as more men are living longer, prostate cancer diagnoses increase.", "answer": 1}, {"article": "For further information, please visit www.nucleix.com.\nThe reason for the high mortality rate is that currently most cases are detected when the patient becomes symptomatic, which is usually at late stages of the disease.\nThe results will be presented in a poster presentation titled Lung EpiCheck \u2122 - Results of the Training and Test Sets of a Methylation-Based Blood Test for Early Detection of Lung Cancer at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, to take place on September 22-26, 2018 in Toronto, Canada.\n\"We are very excited to present the best published clinically validated results of a blood test for the early detection of lung cancer,\" said Opher Shapira, PhD, CEO of Nucleix.\nIn the US, low-dose CT is available for screening of individuals 55-79 years old who smoked at least 1 pack a day for 30 years, which represent less than half of the lung cancer population.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease-mongering. Lung cancer is widely understood to be a potentially devastating disease. The release provides some context on the prevalence of lung cancer worldwide.\nThere is some concern that\u00a0people at very low risk might be encouraged to ask for the test based on the positive report on this preliminary test.", "answer": 1}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in the piece. Alzheimer\u2019s is a disease for which there is no cure or effective treatment. The patients studied in this piece had moderate to severe disease\u2013meaning that their living were significantly impacted by the memory disorder.", "answer": 1}, {"article": "MONDAY, June 6, 2011 (HealthDay News) -- There's too little evidence to say definitively whether treating early, localized prostate cancer with radiation is a better option than \"watchful waiting,\" new research finds.\nThe National Cancer Institute has more on prostate cancer.\nThere was also \"moderate strength evidence\" that a higher external beam radiation was more effective than a lower dose.\n\"Some of the distinctions being made are not really supported by the evidence.\"\nMen and their doctors need to consider what the tumor looks like under the microscope, which can help gauge how aggressive it may be.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of prostate cancer.", "answer": 1}, {"article": "In March of this year, based upon earlier studies utilizing the test, Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, issued a draft local coverage determination (LCD) for the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nIt is estimated that 50,000 patients a year may be eligible for and benefit from the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nThe PROPHECY study investigated the AR-V7 test in patients receiving ARSi therapy and demonstrated that patients who tested positive had worse survival by all measures and had no clinical benefit from ARSi therapy.\nThe paper is entitled, \"Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.\"\n\"During the treatment of metastatic prostate cancer, physicians will now be able to use AR-V7 status to determine when a patient's cancer has become resistant to androgen receptor directed therapy and will respond better to chemotherapy, enabling the patient to live longer.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease-mongering here. The release states that about 50,000 men a year in the U.S. will face treatment decisions for which a test like this might prove useful.", "answer": 1}, {"article": "Lauren Pestikas sits as she receives an infusion of the drug ketamine during a 45-minute session at an outpatient clinic in Chicago on July 25, 2018.\n(AP Photo/Teresa Crawford)\n\nCHICAGO (AP) \u2014 It was launched decades ago as an anesthetic for animals and people, became a potent battlefield pain reliever in Vietnam and morphed into the trippy club drug Special K.\n\nNow the chameleon drug ketamine is finding new life as an unapproved treatment for depression and suicidal behavior.\nIts potential effects on depression were discovered in animal experiments in the late 1980s and early 1990s showing that glutamate, a brain chemical messenger, might play a role in depression, and that drugs including ketamine that target the glutamate pathway might work as antidepressants.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nExactly how ketamine works is unclear, but one idea is that by elevating glutamate levels, ketamine helps nerve cells re-establish connections that were disabled by depression, said ketamine expert Dr. Carlos Zarate, chief of experimental therapies at the National Institute of Mental Health.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t engage in disease-mongering.\nIt stated the drug could provide \u201cshort-term help for patients who have not benefited from antidepressants. That amounts to about one-third of the roughly 300 million people with depression worldwide.\u201d", "answer": 1}, {"article": "She told ABC's \"Good Morning America\" today she always hoped for a medical miracle.\n\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\n\"It will succeed not only for me, but also for other people with visual problems so that they can have a hope for their future,\" said Manuela.\nFor the first time, researchers have shown that gene therapy can be used to improve vision for blind children and young adults.\nThe area treated is tiny, just three by three millimeters \u2014 about the size of Franklin Delano Roosevelt's cheek on a dime.\n", "question": "Does the story commit disease-mongering?", "explanation": "While the story does state that these experimental subjects all had a rare form of blindness, it is not stated clearly that this procedure\u00a0is not a more generalizable treatment for many kinds of congenital blindness. Nonethless we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Colic occurs during the first three months of an infant's life in which an otherwise healthy child cries and cannot be comforted for three hours or more every day.\nThe findings were published online today in Pediatrics.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\nColic affects up to 28% of infants and has no known cause or cure.\nAll the infants were diagnosed with colic, born full-term at a healthy gestational weight, had no history of gastrointestinal disorders, were breastfed, not formula fed, and did not receive any other probiotic supplements during the week prior to the study.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not exaggerate the effects of infant colic.", "answer": 1}, {"article": "The test isn't ready for prime time, however, and it's not foolproof: a study found that it misses some premature births and incorrectly predicts others.\nIn the new study, the researchers examined blood samples from 80 women who went on to have normal births and 80 who had premature births.\nThe closer to the preterm birth, the more likely you are to have significant changes in the physiology of the woman that is observed in the blood.\"\nThey tried to find signs in the blood that indicate what kind of birth the women would have.\nThe test may cost $150 to $250, Graves said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story gave estimates of how many births are premature, so did not commit overt disease-mongering.", "answer": 1}, {"article": "TUESDAY, Nov. 2, 2010 (HealthDay News) -- MRI images can serve as a \"surrogate clock\" to pinpoint stroke onset in patients whose symptoms began during sleep, increasing the number of patients eligible for highly effective clot-busting therapy, according to a new study.\nare managed as urgently as those with known stroke onset time,\" she said.\nis that they get there too late,\" he said.\nReview the warning signs of stroke at the American Stroke Association.\n\"Really pinpointing the time of onset is so crucial for us.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0No disease mongering about stroke in this story.  ", "answer": 1}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story commit disease-mongering?", "explanation": "The article did not engage in explicit disease-mongering. Chronic migraines are painful, disabling and potentially debilitating.\nHowever, the article over-emphasizes the views of authors who have relationships with the developer of Botox. Careful reading of the study suggests that the study subjects had a special and severe type of migraine\u2014and may not be representative of the larger population with chronic migraines. The results of the study may not apply to many individuals with chronic migraines.\nOn the plus side, the story was careful to emphasize that the treatment may not be beneficial for those with less frequent and less severe migraines.", "answer": 1}, {"article": "TUESDAY, March 8, 2011 (HealthDay News) -- Acupuncture may help reduce the severity of hot flashes and other symptoms of menopause, according to a small study.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nThe beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering.\u00a0 Although the story made no attempt to explain how troublesome the study subjects\u2019 symptoms were before the intervention.", "answer": 1}, {"article": "While the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nWhereas in Parkinson's disease and essential tremor, the target for the electrodes are nodes within the motor circuits, the Alzheimer's study targeted the fornix, which is part of the memory pathway.\n\"The first phase of this study was designed to evaluate the 90-day postoperative safety of this particular surgical method.\nAdverse effects such as headache and infection occurred in 11.9% (5 of 42) of the patients in this study, consistent with rates reported in other DBS trials.\nHowever, its use is being researched for a number of conditions, including epilepsy, depression and bipolar disorder.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here. Alzheimer\u2019s disease is increasing in prevalence among a population that is living longer than ever before. The impact of the disease on the patients, their families and societies is enormous.", "answer": 1}, {"article": "One recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nBut what about Alzheimer\u2019s?\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nAnother study in 2003 in The European Journal of Clinical Pharmacology found a similarly beneficial effect for aspirin and other nonsteroidal anti-inflammatory drugs.\nRegular aspirin use may lower the risk of Alzheimer\u2019s.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease mongering in this story.", "answer": 1}, {"article": "\"There is a growing sense that VE [vasogenic edema] or ARIA [amyloid-related imaging abnormalities] is a manageable side effect and may actually be a sign that the drug is clearing amyloid from the brain and the blood vessels,\" said Salloway.\nThese imaging abnormalities may indicate inflammation of the brain caused by water retention.\nSome of the participants were followed for four years or more.\nThe edema was symptomless in most cases, he said.\nBut no problems were seen with lower doses.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease-mongering.", "answer": 1}, {"article": "(\u201cEnjoyed\u201d?\nBut in the human studies, it wasn\u2019t always clear whether active mothers who have active children simply raised their kids to exercise a lot or whether there might have been a genetic predisposition to physical activity.\nIf expectant mothers know that exercise is not only good for them but also may offer lifelong benefits for their babies, I think they will be more motivated to get moving.\u201d\nThe offspring of those mothers turned out to be about 50 percent more physically active than those born to mothers that hadn\u2019t had the exercise wheel option.\nPregnancy experts, including those at the American College of Obstetricians and Gynecologists, recommend that most pregnant women get 30 minutes of exercise a day.\n", "question": "Does the story commit disease-mongering?", "explanation": "In some ways, this story is not about disease but about wellbeing.\nThe unfortunately thing here is that a small mouse study is now circulating the internet on a number of news sites, possibly impacting the decisions pregnant women make, when this research isn\u2019t at all conclusive about what humans should or shouldn\u2019t do during pregnancy.", "answer": 2}, {"article": "Another took part in an exercise program.\n\"People need to begin to push themselves in the face of their fatigue, because if you don't, you become deconditioned and you get caught in a cycle which ... makes fatigue worse,\" says Barsky.\nNearly three decades have passed since the debate began about a series of symptoms that have come to be known as chronic fatigue syndrome.\nAnd, like most professionals who treat patients, Bateman eagerly awaits the day when science can finally pinpoint its cause.\nWhen symptoms abate and they feel better, they may go all out, exercising, doing errands and socializing.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story is quite careful to avoid disease-mongering. At the top of the story, it quickly takes readers through the last three decades of work around chronic fatigue and attempts to describe what it feels like for the typical patient. Actually, the story says \u201csome patients,\u201d but we\u2019ll give it a pass here.", "answer": 1}, {"article": "Dr. Bried, who implanted Mr. Mueller\u2019s hip last year, said he was concerned that squeaking might be \u201ca harbinger of something similar.\u201d\n\nMr. Mueller said Dr. Bried had told him to consider getting the hip replaced \u201csooner rather than later.\u201d\n\nStryker says such fears are overblown.\n\u201cThere is no evidence that the wear associated with squeaking would lead systems to fail,\u201d said Dr. James A. D\u2019Antonio, an orthopedic surgeon outside Pittsburgh, who was a chief investigator on the clinical trials that led to regulatory approval for Stryker\u2019s Trident.\nWhile there have been no reported cases of serious mishaps, some surgeons fear that the ceramic material might shatter at some point, leaving a patient with so many inflammatory shards in the hip that a doctor could never find them all.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\nLast fall, the Food and Drug Administration issued a warning to Stryker, saying it had failed to take the steps needed to prevent squeaking and other problems.\n", "question": "Does the story commit disease-mongering?", "explanation": "The first mention of the prevalence of squeaking in ceramic hip implants appears to cite the highest known estimate\u20147% of ceramic implants in one study of 143 patients. Only later do readers discover that other studies suggest the prevalence of the problem may be much smaller, from 3% (in a study of 1500 people) to less than 1%. This is not disease mongering, but it could cause some people to fear ceramic hip implants more than may be justified. In addition, the Times article says no squeaking occurred in patients with metal and plastic implants. But a recent 2007 review in the Journal of Bone & Joint Surgery (JBJS) reported that squeaking in similar implants made out of metal and plastic occurred in 4% of patients. (JBJS 2007;89:1874-85) If the JBJS review is accurate, the news story would be misleading. Unfortunately, the JBJS failed to support its own contention with a complete reference.", "answer": 1}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story commit disease-mongering?", "explanation": "The story is careful and measured in both specifics and overall tone.", "answer": 1}, {"article": "As author, Dr Antonello Bonci (Scientific Director, National Institute on Drug Abuse, and Adjunct Professor, John Hopkins University, Baltimore) said:\n\n\"Despite the fact that more than 20 million people worldwide suffer from cocaine use disorders2, there are no effective neurobiological treatments for patients with this devastating condition\".\nIt is important that this is taken forward to a larger trial.\nCocaine use is widespread in the Western World.\n\"This study represents a creative approach to a disorder that is notoriously difficult to treat in the real world.\nThere is no effective drug treatment for cocaine addiction, with behavioural therapies being the main element of any treatment regime.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release does not promote disease mongering.", "answer": 1}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story commit disease-mongering?", "explanation": "This article article does not pander to popular fad diets. Obesity is a significant health problem that has reached epidemic proportions among all segment of the\u00a0population.\u00a0\u00a0Current dietary guidelines do not appear to be helping Americans maintain a healthy body weight.\u00a0 ", "answer": 1}, {"article": "Jill adds: \"Anal cancer is on the increase and those of us who have been through what at times was gruelling radiotherapy regimen, welcome this study and the impact it will have on the treatment plans of patients in the future.\"\nResearch is urgently needed to improve detection and treatment and to save lives.\nOur research team has done a wonderful job highlighting an important and as yet unrecognised issue in the staging of cases of anal cancer.\nAnal cancer is a rare form of cancer, but cases have increased dramatically in recent years.\nFortunately my treatment has been successful and seven years on my own late effects are manageable but will only get worse.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering; anal cancer is a serous disorder.", "answer": 1}, {"article": "Cholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\n\u201cThis is hugely significant.\nThey then interfered with production of the molecule and found it slowed the cancer cells\u2019 growth by between 30% and 50%.\nThe scientists grew cancer cells in the lab in the absence of oestrogen and found they produced an alternative fuel, in the form of the cholesterol molecule.\nDelyth Morgan, chief executive at Breast Cancer Now, which funded the research, said: \u201cThis is a really crucial discovery.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "Those studies are expected to launch later this year, including two at Penn.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\nThe study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\nThe study evaluated 25 patients with pleural mesothelioma, all of whom were over the age of 18 and had either already been treated with chemotherapy or were unable to receive it.\n\"There have been a lot of studies looking at different drugs, but researchers have not seen positive results,\" said the study's lead author Evan Alley, MD, PhD, chief of Hematology and Medical Oncology at Penn Presbyterian Hospital.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There release doesn\u2019t engage in disease mongering. It provides ample context on what malignant pleural mesothelioma is and how often it occurs, as well as current treatment strategies.", "answer": 1}, {"article": "\"Women should be informed that the benefit is smaller than expected, and there should be a balanced discussion on the benefit and the possible harms of screening, such as overdiagnosis, false-negative and -positive tests and psychological distress,\" said the study's lead author, Dr. Mette Kalager, an epidemiologist with the Cancer Registry of Norway in Oslo and a visiting scientist at the Harvard School of Public Health in Boston.\n\"It's clearly muddying the waters,\" he said.\nThe difference in the rate of death from breast cancer among women in the screening group versus the control group was 28 percent.\nThey both said that the time frame was insufficient to assess the effect of screening.\n\"Our observed 10 percent reduction in death from breast cancer is much lower than previously thought,\" Kalager said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story.", "answer": 1}, {"article": "WEDNESDAY, Nov. 30, 2011 (HealthDay News) -- Eating baked or broiled fish as little as once a week may boost brain health and lower the risk for mild cognitive impairment and Alzheimer's disease, new brain scan research suggests.\n\"They had larger brain cells in areas of the brain responsible for memory and learning.\n\"We're talking about just a half serving a day,\" he said.\n\"Like maybe people who eat fish exercise more, or eat less total calories.\n\"And that would be a very small lifestyle change that can affect disease risk a long time down the line.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of Alzheimer\u2019s disease.\n ", "answer": 1}, {"article": "For more information about ColonaryConcepts, LLC, please visit http://www.\n\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\n\"The ECP approach allows patients to eat solid food bars and drink palatable low-volume beverages, a patient-friendly design that participants in the study clearly favored over conventional preps,\" comments Dr. Siegel.\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "Colon cancer is an important public health issue. But the release may overstates things when it says, \u201cApproximately 40% of those who ought to have a colonoscopy avoid the procedure\u2026\u201d We\u2019re uncomfortable painting with a broad brush regarding who \u201cought\u201d to be screened for colon cancer. Screening is a personal choice based on an evaluation of benefits and harms.", "answer": 1}, {"article": "GALVESTON, Texas -Researchers from The University of Texas Medical Branch at Galveston found that testosterone replacement therapy may slow disease progression of chronic obstructive pulmonary disease.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\nLow testosterone is common in men with COPD and may worsen their condition.\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\nThe paper is currently available in Chronic Respiratory Disease.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here. The release provides context on how many people could be affected globally by COPD.", "answer": 1}, {"article": "\"These are exciting results.\nThough too early to call it a cure, the procedure has enabled the young people, who have Type I diabetes, to live insulin-free so far, some for as long as three years.\nDr. Lainie Ross, a medical ethicist at the University of Chicago, said the researchers should have studied adults first before exposing young teens to the potential harms of stem cell transplant, which include infertility and late-onset cancers.\nThe study was approved by ethics committees in Brazil, he said, adding that he personally believes it was appropriate to do the research in children as well as adults, as long as the Brazilian ethics panels approved.\n\"It's the first time in the history of Type 1 diabetes where people have gone with no treatment whatsoever ... no medications at all, with normal blood sugars,\" said study co-author Dr. Richard Burt of Northwestern University's medical school in Chicago.\n", "question": "Does the story commit disease-mongering?", "explanation": "The\u00a0story points out the\u00a0estimated number\u00a0of people with this type of diabetes (type 1) and contrasts that with how many people have type 2 (significantly more),\u00a0giving viewers a sense that this treatment may not help the majority of people with diabetes.\u00a0 \u00a0 ", "answer": 1}, {"article": "WEDNESDAY, April 4, 2012 (HealthDay News) -- Regularly consumption of food and drink rich in substances called flavonoids, such as berries, apples, tea and red wine, can lower a man's risk of developing Parkinson's disease by 40 percent, new research suggests.\n\"Berries could be a neuroprotective agent.\nPeople can include berries in their regular diet.\n\"For total flavonoids, the beneficial result was only in men.\nAnthocyanins are a type of flavonoid plentiful in such berries as strawberries and blueberries.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "MIT scientists find evidence that Alzheimer\u2019s \u2018lost memories\u2019 may one day be recoverable\n\n\u2019Siri, I want to commit suicide\u2019 and other statements likely to yield unhelpful responses from your phone\n\nRoots of Napoleon complex may be justified: Study finds short men get short of end stick in life.\nThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \"adverse event,\" most often an increase in pain due to yoga.\n\"These findings suggest that MBSR may be an effective treatment option for patients with chronic low back pain,\" the authors wrote.\nIn an editorial, Madhav Goyal and Jennifer A. Haythornthwaite of the Johns Hopkins University School of Medicine said that the mechanisms for why meditation might work on back pain is still a mystery but that this question is merely \"academic\" for many clinicians and their patients who need immediate relief.\nThe study looks at adults with chronic low back pain, one of the leading cause of disabilities in the United States and one reason why more and more people are addicted to painkillers.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. However, we did want to point out that the story \u201cfear mongers\u201d in a sense, by stating back pain is \u201cone reason why more and more people are addicted to painkillers.\u201d\nThe story insinuates that these other treatment methods\u2013especially meditation\u2013could help with that. And maybe they could. But the study itself says \u201cNo overall differences in treatment effects were observed for\u2026self-reported use of medications for back pain.\u201d So why the mention\u00a0of painkiller addiction?", "answer": 1}, {"article": "Erenumab, a laboratory-made antibody that blocks a neural brain pathway called CGRP, is the first drug in 20 years proven to prevent migraine attacks.\n\u201cThe results of Strive represent a real transition for migraine patients from poorly understood, re-purposed treatments, to a specific migraine-designed therapy.\u201d\n\nSimon Evans, chief executive of the charity Migraine Action, said: \u201cMigraine is too often trivialised as just a headache when, in reality, it can be a debilitating, chronic condition that can destroy lives.\nThe research revealed that by months four to six, at least a 50% reduction in mean migraine days per month was achieved for just over 43% of patients injected under the skin with 70-mg of erenumab each month, while half of patients injected with the higher dose of 140-mg had such results.\nThe condition is linked to depression and sick days caused by migraine are estimated to cost the UK economy more than \u00a32bn per year.\nAmgen and Novartis, the codevelopers of erenumab, funded the trial, while Amgen also supplied the drug and conducted the data analyses.\n", "question": "Does the story commit disease-mongering?", "explanation": "A quote by an outside expert highlights the debilitating pain that many migraine sufferers experience, plus the real-world ramifications of that pain. Statistics are provided to give an estimate of how common migraines are, but we think it\u2019s always best practice to provide a source for such statistics, and none was provided by The Guardian.", "answer": 1}, {"article": "\"The easier it is to detect CF, the earlier it can be diagnosed, and the better people's chances are at living a longer, healthier life\", says Joanna Valsamis, Chief Healthcare, Research and Advocacy Officer at Cystic Fibrosis Canada.\nTesting for these biomarkers could be done in cases in which the chloride sweat test result is unclear, say researchers.\nIn Canada, one in every 3,600 children are diagnosed with CF.\nThe research was funded in part by Cystic Fibrosis Canada.\nThe test is commonly used in universal newborn disease-screening programs and measures the concentrations of salt.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The only small concern they found was that patients taking resveratrol lost about two pounds during the one-year study, and weight loss is already a problem with Alzheimer's, Turner said.\nA music legend fights Alzheimer's disease on his unforgettable farewell tour.\nA large, phase 3 clinical trial getting at these issues could start in as soon as a year, Turner said.\nOne glass of red wine a day could help those with mild Alzheimer's, \"but no more than that,\" Turner said.\nIn comparison, the control group gained about 1 pound.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Investigators in the Netherlands report the results of a three-year follow-up of a randomized controlled trial that compared three noninvasive treatments that included imiquimod and fluorouracil cream.\n\"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams,\" explained lead investigator Marieke Roozeboom of the Department of Dermatology, Maastricht University Medical Center in the Netherlands.\n\"Based on our findings, both imiquimod and fluorouracil are effective noninvasive treatments in most primary, low-risk superficial BCC, but the data provide no definite evidence for superiority of imiquimod to fluorouracil,\" commented Dr. Roozeboom.\nWhile most types of BCC require surgery, superficial BCC can be treated topically with noninvasive treatments such as PDT, imiquimod cream, fluorouracil cream, cryosurgery or electrodessication and curettage.\nA total of 601 patients with a superficial BCC participated in this study: 202 patients were treated with methylaminolevulinate photodynamic therapy (MAL-PDT), 198 with imiquimod cream, and 201 with fluorouracil cream.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release tells us that \u201cmore than 80% of all skin cancers are BCC, arising from the basal cells (i.e., small, round cells found in the lower layer of the epidermis),\u201d that more than 2 million cases occur each year in the United States, and that outcomes are excellent. It also tells us that a person\u2019s lifetime risk of developing a BCC before age 85 is one in five.\nIt would have been more complete had it said where it got those figures.", "answer": 1}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world's most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\nUnderstanding how these proteins can clump together could point researchers in new directions and help them find other possible drugs that could potentially treat Parkinson's.\nThis type of therapy increases levels of dopamine, a natural chemical in the body that sends signals to other nerve cells and can significantly decrease in cases of Parkinson's.\nFox and St. Mary's Foundations, funded the study.\n\"Proteins are constantly moving and changing shape,\" said Lapidus, a professor in the Department of Physics and Astronomy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "The study of Amgen\u2019s evolocumab involved 4,465 patients with various degrees of risk, two-thirds of whom were randomly chosen to get the drug in addition to the medication they were already taking.\nBut merely looking at cholesterol levels can be misleading.\nBy a measure known as the hazard ratio, the risk of cardiovascular events was reduced by 53 percent.\nIn many cases such big reductions were achieved even though the patients were already taking statins.\n\u201cManaged care pharmacy, indeed the health care system, has never seen a challenge like this to our resilience in absorbing costs,\u201d they wrote in the Health Affairs blog.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering.", "answer": 1}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story commit disease-mongering?", "explanation": "The section describing premature ejaculation does a better than average job attempting to define the scope of the problem while describing the limitations of the research that has been done in this area. One line could be a model for other journalists to learn from: \"Surveys have suggested that as many as 20% to 30% of men may suffer from premature ejaculation, though these figures are often drawn from broadly worded survey questions and may overstate the number of men with significant problems.\"\u00a0", "answer": 1}, {"article": "But previous studies suggest more than 50 percent of these biopsies are unnecessary and can result in pain, worry, infertility and higher health care costs.\nThe new study builds on the Johns Hopkins team's previously published work, in which investigators identified three genes associated with cervical cancer or abnormal-looking cells known to become cancerous: FKBP6, INTS1 and ZNF516.\nUsing methylation as a value to diagnose malignancy, the three genes together showed a 90 percent sensitivity, meaning that their presence was able to predict a true positive cancer sample this percentage of the time.\nThe next step, the researchers report, was to verify that the four-gene test worked using freely circulating DNA from blood and urine, rather than DNA taken directly from cervical tissue.\nThe new urine test, they say, is different because it analyzes not only multiple sources of human cellular DNA altered by precancerous changes, but also DNA from HPV that is sexually transmitted and causes virtually all cases of the disease.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Disease-mongering is not a feature of this release. The focus of the release is on a new, presumably cheaper test for cervical cancer, a major killer in less developed countries. The release also puts the problem of cervical cancer screening in global context.", "answer": 1}, {"article": "\"The interesting thing about the Safety Planning Intervention is that it is a relatively brief intervention and can be used in a lot of different [health care] settings,\" says Brian Ahmedani, director of behavioral health research at the Henry Ford Health System in Detroit, who wasn't involved in the new study.\nFor example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\nThe next step is for the patient \u2014 with help from the clinician \u2014 to come up with a set of coping strategies to help get through moments of intense suicidal ideation.\nThis is the first large-scale study of the Safety Planning Intervention, which Stanley and her group developed in 2008 and which has been adopted at hospitals and clinics around the country.\nIf people contemplating suicide can distract themselves with something they enjoy doing, they can bypass that narrow window during which suicidal thoughts can overpower them, notes Stanley.\n", "question": "Does the story commit disease-mongering?", "explanation": "Suicide is the 10th leading cause of death in the United States overall and suicide rates have increased by more than 30% in half of U.S. states since 1999. Suicide rates are especially high among middle-aged men and veterans. This story doesn\u2019t inflate the prevalence.", "answer": 1}, {"article": "\"This drug has had, in this trial, the highest efficacy we have ever seen with any biologic in psoriasis before,\" says study researcher Kristian Reich, MD.\n\"We in dermatology have never spoken about remission before.\n\"We had amazing responses,\" Reich says.\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\nThose same results were achieved by about 10% to 20% of 163 patients in the methotrexate group.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of psoriasis here.", "answer": 1}, {"article": "All were treated with medicines that improve chest pain and heart and artery health such as aspirin, cholesterol-lowering statins, nitrates, ACE inhibitors, beta-blockers and calcium channel blockers.\nTo the surprise of the researchers, both groups fared about the same: approximately 19 percent had a heart attack or died within seven years, adds LaPook.\nBut most angioplasties are done on a non-emergency basis, to relieve chest pain caused by clogged arteries crimping the heart's blood supply.\nAbout 1.2 million angioplasties are done in the United States each year.\nIf that does not help, they can consider angioplasty or bypass surgery, which unlike angioplasty, does save lives, prevents heart attacks and gives lasting relief of chest pain.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of heart disease. Furthermore, the story clearly states that this study was done on patients at low risk, that is, those with stable heart disease.", "answer": 1}, {"article": "Based on the overall results, Devinsky believes CBD should be evaluated for epilepsy types beyond Dravet syndrome, which is caused by a genetic mutation and affects about one in 20,000 to 40,000 children in the United States.\nOn the need for more scientific research, all these experts agree.\nConsidered a spectrum disorder, different epilepsy syndromes are defined by clusters of symptoms or features and treated accordingly.\n\"If future clinical trials confirm these promising results, then appropriate regulation will enable the drug to be safely used for medical purposes,\" he said.\nShe was not involved in the new study.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the piece and it goes into a lot of detail to explain the specific condition.", "answer": 1}, {"article": "Among the children born during the study, Pan and his colleagues found no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth.\nThis research was supported by Gilead Sciences.\nIn addition, infants should receive hepatitis B vaccine and immune globulin.\nThe information entered on this page will not be used to send unsolicited email, and will not be sold to a third party.\nBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release does not commit disease mongering.", "answer": 1}, {"article": "The study was part of the ongoing Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) project, through which Mukherjee and study co-author Geoffrey Manley, MD, PhD, vice chairman of neurological surgery at UCSF and chief of neurosurgery at Zuckerberg San Francisco General Hospital, along with collaborators from many other research institutions are leading studies and gathering common data across research sites to more quickly advance TBI research.\nAlthough effective drug treatments for mTBI await discovery, rest and counseling are known to be helpful for patients, Mukherjee said.\nThe study revealed telltale patterns of brain activity that, six months later, were associated with worse performance on behavioral and cognitive tests and were different from patterns seen in healthy control subjects.\nIn the new study, the researchers focused on well-known networks of activity that are observed when the brain is in a resting state.\nPreviously there has not been a way to predict whose symptoms will fade or persist following mTBI.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release.", "answer": 1}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story commit disease-mongering?", "explanation": "The story tells readers that lung cancer is\u00a0the leading cause of death from cancer\u00a0in the U.S.\u00a0 The story does also describes the burden of lung cancer, providing estimates of 5-year survival without screening (estimates from the general population who were diagnosed as a result of symptoms).\u00a0 No obvious embellishments or overstatements.\u00a0\u00a0\u00a0 ", "answer": 1}, {"article": "Founder and Chairman: Dr. Scott Morehouse, scott@clearpop.com\nDue to increasing concern about antibiotic overuse and its links to obesity, celiac disease, and Superbugs, the American Academy of Pediatrics now recommends against the use of antibiotics to treat routine ear infections in children over 2.\n\"Eardrops don't work,\" says Dr. Scott Morehouse, founder of ClearPop, \"because the Eustachian tube, where the pain occurs, is connected to the mouth, not the outer ear.\"\nSince 2013, the American Academy of Pediatrics endorses a wait-and-see approach, seeking to let more earaches heal on their own without antibiotics.\nIn light of this, Morehouse developed a lollipop with a patented shape optimized to pull congestion out of the middle ear and into the mouth.\n", "question": "Does the news release commit disease-mongering?", "explanation": "As readers of this site know, we are reluctant to give this distinction, but in this case we feel it was warranted. Instead of just acknowledging that earaches are a bother and \u2014 as we note above \u2014 could potentially be signs of more serious illness, the release stokes fears, saying:\n\u201cDue to increasing concern about antibiotic overuse and its links to obesity, celiac disease, and Superbugs, the American Academy of Pediatrics now recommends against the use of antibiotics to treat routine ear infections in children over 2.\u201d\nThe question is: Do you need to run and buy a product for a problem that likely will go away? Antibiotic or no antibiotic, the release seems to be trying to scare people into buying the product.\nIn addition, the release propagates the idea that antibiotics would work for ear infections but that doctors are just \u201creluctant to prescribe\u201d them. This is a problematic idea that could lead\u00a0to mistrust and pressure to prescribe in the pediatrician\u2019s office.", "answer": 0}, {"article": "TUESDAY, Jan. 17, 2012 (HealthDay News) -- Combining two drugs that target an aggressive type of breast cancer known as HER2-positive appears to work better than using either drug alone, researchers report.\nThe study is well done and important, said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.\nThe two drugs, he said, \"affect the same pathway but do it in a different way.\"\nIn HER2-positive breast cancer, test results are positive for a protein called human epidermal growth factor receptor 2, which promotes cancer cell growth.\nIn the study, 154 women got Tykerb, 149 Herceptin and the other 152 both drugs.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering at play here. It may have been useful to note that 20-25% of all breast cancers are HER-2 positive.", "answer": 1}, {"article": "For the current study, she and her colleagues sent out questionnaires to a representative sample of about 600 office-based doctors and hospital departments around the country.\n\u201cOften a provider just does the HPV test\u201d without telling the patient.\nFirst, they might not know about the guidelines.\nThey asked doctors and staff what tests they used for cervical cancer screening and presented them with three patient scenarios.\nIf both tests are normal, those guidelines call for a three-year wait before the next screening.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering at play here.", "answer": 1}, {"article": "The surgery she's upset about may be archaic - but it's very common.\nAbout 600,000 of them are done every year in this country.\nLiterally, no pain.\"\nAnd right away, she wanted to go home.\nHysterectomy is the surgical removal of the uterus.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "\u201cIt\u2019s really recommended to replace white rice with the same amount of brown rice or other whole grains.\u201d\n\nThe researchers who did the study analyzed rice consumption among 39,765 men and 57,463 women who participated in the Health Professionals Follow-up Study and the Nurses\u2019 Health Study I and II; participants in the three groups ranged in age from 26 to 87.\nMany food studies simply lump brown and white rice together.\nA serving is half a cup of cooked rice.\nDuring the course of the studies, more than 10,000 participants developed Type 2 diabetes.\nSuch food studies can be unreliable, since they rely on self-reported surveys.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering about Type II diabetes.", "answer": 1}, {"article": "In the study, published in the Annals of Internal Medicine, researchers reviewed 83 studies on the two methods.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\n\"Based on currently available evidence, it appears reasonable to substitute core needle biopsy procedures for open surgical biopsy given the comparable sensitivity and lower complication rates,\" write researcher Wendy Bruening, PhD, of the ECRI Institute Evidence-Based Practices Center in Plymouth Meeting, Pa., and colleagues.\nThey say additional studies are needed to find out what factors affect the accuracy of core-needle breast biopsy.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.\u00a0 The story discusses recent analysis that women may be able to avoid surgical biopsies in lieu of core needle biospies for diagnosis of breast cancer.\u00a0 The story appropriately\u00a0notes that many women who undergo a biopsy following an abnormal mammogram do not have breast cancer.", "answer": 1}, {"article": "\"The hope for neurofeedback is that after training ends, the benefits that resulted from training will persist -- that in some sense there's been more enduring change in the child's ability to focus and attend and to regulate their behavior,\" he says.\nIn particular, it measures rhythmic patterns known as theta and beta waves.\nI'd hear bird song and beautiful flowers would bloom,\" she says.\nHe wasn't doing his homework.\nHe was being very difficult with his little brother.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering in this story.", "answer": 1}, {"article": "Many smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nLetters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nThe trial enrolled people ages 55 to 74 who were or had been very heavy smokers and gave them one scan a year for three years.\nNor is it clear if the study results are applicable to all smokers.\nSome previous studies have suggested that the earlier detection helps, while other research concluded it may do more harm than good by spotting too many benign growths.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story clearly states that this trial only involved people who are or were \u201cvery heavy smokers\u201d and that it is not clear that the results are applicable to other smokers.", "answer": 1}, {"article": "Colic is usually defined as excessive and inconsolable crying for at least three hours a day for more than three days a week over more than three weeks.\nA study of probiotics, which are reputed to help digestion, found that 95 percent of infants given L. reuteria probiotics seemed to reduce their average crying time compared to 7 percent of babies given simethicone, which is marketed to relieve gas under the brand names Mylicon and PediaCare Infants' Gas Relief.\n\"This is pertinent given that simethicone is considered the best available and most commonly prescribed treatment for colic, although it previously has been shown to be no more effective than the placebo,\" according to the authors.\nThis implies the improvement may \"have more to do with the therapeutic effect of touch than the actual therapy itself,\" Dr. Edzard Ernst, of the department of complementary medicine at Peninsula Medical School, Universities of Exeter and Plymouth, in the United Kingdom, and colleagues wrote in the report.\n\"It's reasonable for parents to consider those kinds of interventions for which there is some suggestion of benefit but no known risks,\" said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Steven and Alexandra Cohen Children's Medical Center of New York.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering and, in fact, goes further by making it clear that colic is transitional, even if it feels like it will never end. \u201cIn the United States, between 5 and 19 percent of infants are estimated to have colic, according to background information in the article. Because pediatricians can\u2019t offer parents much help with it \u2014 for the most part, babies grow out of colic in time \u2014 desperate parents often turn to alternative or complementary treatments, according to the study.\u201d", "answer": 1}, {"article": "Overall, there is relatively little research on hyperbaric treatment for brain injury, in part because pressurized oxygen can't be patented, which limits its potential profitability.\nKnown as post-concussion syndrome (PCS), this phenomenon is difficult to treat.\n\"These patients don't have enough oxygen to heal the injured parts of their brains,\" said Shai Efrati, a researcher and physician at Tel Aviv University in Israel and a leading hyperbaric scientist.\n\"People want to believe that hyperbaric can fix [brain injuries], and it can't,\" said David Cifu, a researcher at Virginia Commonwealth University in Richmond, who has spent much of his career treating veterans with brain injuries.\nIn 2013, about 2.8 million TBI-related emergency department visits, hospitalizations and deaths occurred in the United States, according to the Centers for Disease Control and Prevention.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story. Mild traumatic brain injury (mTBI) and post-concussion syndrome (PCS) are both widely accepted and researched medical conditions.", "answer": 1}, {"article": "The latest advances in Alzheimer\u2019s disease involve people who don\u2019t appear to show any signs of cognitive decline yet.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\nAt the annual Alzheimer\u2019s Association International Conference, researchers say they have found a series of substances in saliva that can distinguish between people who experience normal aging, those with mild cognitive dementia (MCI, which in some cases can lead to Alzheimer\u2019s and in other cases not), and Alzheimer\u2019s disease.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t engage in disease mongering, but there\u2019s really not enough context about the disease or its impact to justify a Satisfactory rating. We\u2019ll call it Not Applicable.", "answer": 2}, {"article": "URBANA, Ill. - Nearly every American who has become a parent in the last decade has heard the slogan, \"breast milk is best,\" and has likely been encouraged to offer breast milk to newborns.\nThe work was supported by Mead Johnson Nutrition.\n\"There are so many ways we can alter the composition of the microbiota and they can have very strong benefits.\nIf they spent more time with the new toy, that was an indication that the piglet recognized it as new and preferred it.\n\"We can actually change the way piglets learn and remember by influencing bacteria in the colon.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no obvious disease-mongering here.", "answer": 1}, {"article": "Kalluri and his colleagues examined serum samples from 190 patients with pancreatic cancer, 32 patients with breast cancer and 100 healthy volunteers.\n\u201cIt kills people and it kills them quickly.\u201d\n\nA screening test could have a huge effect, said Dr. Timothy Donahue, an associate professor of surgery and molecular and medical pharmacology and chief of pancreas and gastrointestinal surgery at the University of California, Los Angeles.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\nBut, by good fortune, the protein turns up in exosomes only when there is cancer, so its presence could be an early, and testable, marker for the disease.\n\u201cUsing this test we were 100 percent accurate at identifying all cancer patients.\u201d\n\nIn 2015 48,960 Americans will be diagnosed with pancreatic cancer, according to estimates by the National Cancer Institute.\n", "question": "Does the story commit disease-mongering?", "explanation": "We wish more stories took the time to explain to readers how common or rare a condition is. This story gets high marks for pausing to say, \u201cFor perspective, over the course of a lifetime, 1.5 percent of Americans will develop pancreatic cancer.\u201d", "answer": 1}, {"article": "After reviewing the data, the committee concluded that the evidence for the benefits of high levels of vitamin D was \u201cinconsistent and/or conflicting and did not demonstrate causality.\u201d\n\nEvidence also suggests that high levels of vitamin D can increase the risks for fractures and the overall death rate and can raise the risk for other diseases.\n\u201cWe thought that probably higher is better,\u201d he said.\nThe two nutrients work together for bone health.\nSales rose 82 percent from 2008 to 2009, reaching $430 million.\nVitamin D is more complicated, the group said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "Qi Sun of the Harvard School of Public Health and his colleagues analyzed data collected from 13.984 female nurses participating in the Nurses\u2019 Health Study, an ongoing study examining a variety of health issues.\nThat was after accounting for other factors, such as smoking.\nThose who drank between one-third and 1 drink per day five to seven days a week were almost 50 percent more likely to be in good health when they got older compared with those who did not imbibe.\nGood overall health was defined as having no major chronic diseases, such as heart disease or diabetes, as well as having no significant decline in their thinking or physical abilities.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering.", "answer": 1}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nIt is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime.\nAccording to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.\n\"Psoriasis and psoriatic arthritis are chronic inflammatory conditions that can be quite uncomfortable and often painful for patients, so any treatment that might reduce symptoms may improve quality of life,\" says lead study author Soumya Reddy, MD, an assistant professor of medicine in the division of rheumatology at NYU Langone, and co-director of NYU Langone's Psoriatic Arthritis Center.\nResults were even more pronounced in those with severe disease activity, with scores falling from 7.7 before surgery to 5.7 after for patients with severe psoriasis, and from 8.2 to 4.8 after surgery for patients with severe psoriatic arthritis.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No evidence of disease mongering here. The story cites accurate numbers for psoriasis in the United States.\nAs a caution, we\u2019d like to add that anytime bariatric surgery is mentioned as a treatment option, it should be stressed that it is a procedure of last resort, only offered to those who are severely obese, have additional health problems such as cardiovascular disease, and for whom other, safer weight-loss options have not worked.", "answer": 1}, {"article": "Although many guidelines rely on self-reports, Hennekens and his collaborators from Baylor College of Medicine and Meharry Medical College, used the Surveillance, Epidemiology, and End Results (SEER) program file linked to the Medicare administrative claims file, which allowed them to identify screening mammography use from 1995 to 2009 from 64,384 non-Hispanic women (4,886 black and 59,498 white).\nIn a new study published in the American Journal of Medicine, Charles H. Hennekens, M.D., senior author and first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, indicates that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\nFrom 1995 to 2005, according to Science Watch, Hennekens was the third most widely cited medical researcher in the world and five of the top 20 were his former fellows and/or trainees.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\nThe University is placing special focus on the rapid development of critical areas that form the basis of its strategic plan: Healthy aging, biotech, coastal and marine issues, neuroscience, regenerative medicine, informatics, lifespan and the environment.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The liberal use of statistics such as \u201c1 in 8 women\u201d will be affected and \u201c1 in 25\u201d without qualification earns this release a Not Satisfactory. The release opens with a long list of stats but doesn\u2019t explain for an already worried public that some breast cancers are not deadly. There\u2019s a long-running debate among medical experts that one of the most frequently diagnosed breast cancers \u2014 carcinoma in situ (CIS) \u2014 shouldn\u2019t necessarily be termed \u201ccancer\u201d because it\u2019s more of precancerous abnormality rather than a definite cancer precursor.\nIn addition, the first paragraph of the release ends by pointing out that 41% of breast cancer deaths in 2010 occurred in women between ages 65 to 84 but fails to add the important information that many, if not most of those women who died were diagnosed years, if not decades, before ages 65-84. \u00a0The release leaves the reader with the impression that 41% of breast cancer deaths in 2010 occurred in women\u00a0diagnosed between ages 65-84.", "answer": 0}, {"article": "Results from two phase III boceprevir trials are published in the New England Journal of Medicine.\nThe Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story does not engage in disease-mongering, but it would have been helpful had it indicated what percentage of the 3.2 million Americans living with chronic hepatitis C have the genotype 1 infection, for which these new drugs are indicated.\n ", "answer": 1}, {"article": "Commenting on the Nature Medicine study, he tells Newsweek the paper is \u201cvery interesting on a number of levels.\u201d\n\n\u201cFirst of all there\u2019s clearly growing interest in the potential therapeutic role of cannabinoids and in this particular case THC on various human conditions,\u201d he says.\n\u201cThis paper is addressing a possible role for that compound in memory and cognition, which is relevant to disorders such as Alzheimer\u2019s and other dementias.\u201d\n\nHe said that while it is important to remember the study was carried out on mouse models, the differences in the effect of the drug on younger animals versus older animals tells us a lot about our understanding of the differences between old and young brains.\n(The study\u2019s authors noted that this was in \u201cgood agreement with the known detrimental effects of THC on cognition in young animals and humans.\u201d\n\nNext, they created a task where mice had to locate a specific object.\nThus, chronic, low-dose treatment with THC or cannabis extracts could be a potential strategy to slow down or even to reverse cognitive decline in the elderly.\u201d\n\nZameel Cader, associate professor in clinical neurosciences at Oxford University, is involved in the institution\u2019s $13 million cannabis research project.\nIn the U.K., Oxford University recently launched a \u00a310 million ($13 million) program to \u201cidentify new medical therapies through research into the molecular, cellular and systems mechanisms of cannabinoids.\u201d Meanwhile, the U.S. Food and Drug Administration has now approved several medications derived from THC.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here. Learning and memory deficits are a looming epidemic in an aging population, and rates of Alzheimer\u2019s disease are increasing. People have reason to worry. But, is there \u201ctreatment mongering\u201d in this article? We\u00a0think not. From the headline to the last graph, the article emphasizes the pre-clinical nature of the research.", "answer": 1}, {"article": "Researchers studied 78 children who were scheduled for the operation, and a control group of 27 children having other surgery.\nAlthough the surgery has become less common with antibiotics, more than 400,000 children under 15 have their tonsils, adenoids or both removed every year, according to estimates by the Metropolitan Insurance Company.\nCompared with the control group, the children scheduled for adenotonsillectomy were more likely to be hyperactive by their parents' estimates and more likely to experience behavior problems and sleepiness at school.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\nThe rest have the operation to relieve breathing difficulty or nighttime sleep apnea, a serious disorder in which the sleeping child briefly stops breathing during the night.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story leads the reader to believe that adenotonsillectomy could be used for all children with ADHD, a very large population given recent trends in diagnosis and treatment. However, this story is really about a research study that looked at children who were scheduled for adenotonsillectomy and found a high proportion of them had sleep disturbance and ADHD, a much narrower population, and the cause and effect is not clear.", "answer": 0}, {"article": "\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nThe group eating the most chocolate got the most benefit, reducing stroke intake by 20%.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nLarsson isn't sure why.\nThe new Swedish study echoes previous research in men and women.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t exaggerate the effects of strokes.", "answer": 1}, {"article": "\"Guidelines changed based on this study,\" Jolly noted.\n\"These findings will likely have important implications for clinical practice,\" Fonarow said.\n\"This is an unexpected finding, and we want to confirm this in other studies,\" Jolly said.\nAmong all the patients, 6.9 percent who had clots removed, and 7 percent of those who didn't, died, had another heart attack or developed heart failure in the 180 days after the procedure.\n\"As a routine therapy, clot removal is not beneficial and could have some significant downsides,\" he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in this story.\u00a0 Heart attacks occur and need to be treated, and this story presents a view on what the best treatment might be.", "answer": 1}, {"article": "For those who have resolved to get fit in the New Year, O\u2019Donovan recommends to start with moderate exercise, such as brisk walking, and then to set realistic, incremental goals to boost confidence without running the risk of setbacks due to injury.\nNearly 9,000 of the study participants died in the period.\nThere are doing a large proportion of vigorous exercise and that makes you fitter than moderate exercise,\u201d said O\u2019Donovan.\n\u201cWe find a clear benefit.\n\u201cA middle aged or older person should do as much as 12 weeks of moderate exercise before introducing vigorous exercise,\u201d he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No evidence of disease mongering here.", "answer": 1}, {"article": "For example, a poor test grade or bad performance evaluation might lead to feelings of \"I'm not good enough,\" but the lessons encourage more positive thinking about \"how many exams have you passed, to put this failure in a more accurate light,\" Guille said.\nShe said she became very depressed but had little time to seek help.\nIt often involves 80-hour weeks and overnight hospital shifts dealing with multiple medical crises.\nAn earlier study of 740 interns found that suicidal thoughts increased almost four-fold during the first three months of residency, said Dr. Constance Guille of the Medical University of South Carolina in Charleston.\nThe training also encourages seeking out activities or thoughts that bring pleasure, especially when feeling down.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story provides some useful insight into the realities of medical training and in the risk of suicide especially in the early internship months.There does not seem to be any evidence of disease mongering.", "answer": 1}, {"article": "In this study, researchers randomly assigned half of 263 healthy Swedish full-term newborns to have their cords clamped more than three minutes after birth.\nThe other half were clamped less than 10 seconds after birth.\nIt is unclear whether the practice could harm infants' health.\nJaundice is treated with blue light therapy and rarely has serious complications.\nWhen separated by sex, only the boys showed statistically significant improvement.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "He reviewed the findings for WebMD.\n\"There certainly seems to be a benefit to using the laser,\" says American Academy of Ophthalmology (AAO) spokesman James Salz, MD, clinical professor of ophthalmology at the University of Southern California in Los Angeles.\n\"The idea is that all the surgeon will have to do is remove the pieces with a vacuum,\" says researcher Mark Packer, MD, of Oregon Health and Sciences University in Portland.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease-mongering. However, one might quibble with the fact that the story did not discuss the track\u00a0record for traditional cataract surgery, which according to NIH is one of the\u00a0most common, safe, and effective types of surgery performed in the U.S. How important is it for us,\u00a0given escalating healthcare\u00a0costs,\u00a0to have a pricier\u00a0alternative to a treatment that is already quite successful?", "answer": 1}, {"article": "The change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\n\"More testing is not always more intelligent testing.\"\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\nThese recommendations are sound,\" she said.\nBut in this case, if anything, we're taking money out of our own pockets.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does nothing to exaggerate the prevalence or severity of cervical cancer. ", "answer": 1}, {"article": "(Reuters) - Johnson & Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.\nThe patient had no prior history of high blood pressure or cirrhosis, the drugmaker said.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\nStelara, which brought in sales of $1.34 billion in the second quarter of 2018, is also being tested in autoimmune disease lupus.\nCurrent treatments include Pfizer Inc\u2019s Xelijanz, an oral treatment for adults patients with moderate-to-severe UC, and Merck & Co\u2019s Renflexis.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The researchers, led by Dr. Gabriele Di Lorenzo of the University of Palermo, describe the benefits as \u201cmodest.\u201d\n\nIn an email, Di Lorenzo told Reuters Health that the findings suggest that sublingual immunotherapy is \u201chighly effective in many, but not in all patients.\u201d He said that more work is needed to identify which patients might be most likely to benefit.\nThe most common side effects include itchiness and irritation in the mouth, ears and eyes, swelling of the mouth or tongue, headache and gastrointestinal problems like stomach pain and heartburn.\nIn theory, that could pay off if long-term use of allergy medications was cut, but that has yet to be shown.\nA study published earlier this year \u2014 and not included in the current analysis \u2014 found that during that post-treatment year, Grazax patients had one-quarter fewer hay fever symptoms than those who had been given a placebo for comparison.\nAllergy shots may be used for hay fever when antihistamines and other allergy medications do not control a person\u2019s symptoms adequately, or for people who want to reduce their reliance on medication.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n \nGiven the number of allergy sufferers in the U.S., the story could have easily engaged in disease mongering, but that was not the case. \n", "answer": 1}, {"article": "LONDON (Reuters) - Scientists have developed an eye implant that allowed three blind patients to see shapes and objects within days of treatment in a trial and say the device could become routine for some kinds of blindness in five years.\n\u201cTo go from being completely blind for many years, to being able to read a few letters and see shapes is an amazing step.\u201d\n\nRetinitis pigmentosa in a genetic eye condition that leads to blindness and affects about 1 in 4,000 people worldwide.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\nHe was cautious about possible wider applications, but said that if it was developed further, the device may someday be used to help people with severe cases of age-related macular degeneration, the leading cause of blindness in older people.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story engages in disease mongering\u00a0by throwing in some sketchy numbers about the frequency of the disease.\u00a0It says the device \u201ccould eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\u201d Later it says, \u201cRetinitis pigmentosa in a genetic eye condition that leads to blindness and affects about 1 in 4,000 people worldwide.\u201d By our math, 200,000 out of 6.8 billion people worldwide means that 1 out of every 34,500 people is affected. And if we\u2019re just talking about adults, that number drops to 1 out of every 22,105 people, a far cry from 1 out of every 4,000. If it were truly one out of every 4,000 people worldwide, that would mean that 1.1 million people have the disease.", "answer": 0}, {"article": "Even so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats.\nI was meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d\n\nThe fat issue is complicated by the types of fatty acids found in coconut, versus other saturated fats.\nIt\u2019s simple all the way around.\u201d\n\nOne tablespoon of coconut oil contains 120 calories and 14 grams of fat, 12.5 grams of which is saturated.\n\u201cIt\u2019s trickling down to the mass market.\u201d\n\nThe company is growing so quickly, he said, it had to hunt for coconuts from outside of Brazil, where it previously harvested most of its fruit.\n\u201cA lot of rehydrating beverages have additives, whereas the coconut water \u2014 it\u2019s super clean.\u201d\n\nCoconut oil and milk, though, are receiving mixed reviews.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story portrays average consumers as somehow suffering from deficiencies which need a \u201ccoconut cure.\u201d\u00a0 It quoted a publisher of a trade publication saying, \u201cIn the past couple of years a couple of brands have figured out the right angle \u2014 electrolytes and hydration.\u201d\u00a0 But there was no discussion of whether electrolytes and hydration are issues that the average American needs to worry about \u2013 and \u201ctreat\u201d \u2013 regularly.", "answer": 0}, {"article": "Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.\nNone of the participants had glaucoma when they entered the study.\nGlaucoma is a leading cause of blindness.\nThe disease involves damage to the optic nerve, which relays images from the retina to the brain.\nCompared with the group as a whole, those people who were diagnosed with the eye disease during the following decade were older, had higher blood pressure, and were more likely to be female.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of glaucoma in the story.", "answer": 1}, {"article": "So why weren't they all cured?\n\"This study really underscores the fact that children who have other issues with sleep should be looked at for bedwetting because anything that depresses sleep at night can lead to bedwetting,\" said AUA spokesman Dr. Anthony Atala, a urologist at Wake Forest University in Winston-Salem, N.C.\n\n\"If a child has bedwetting, pay close attention to their sleep patterns, and observe them while they are asleep and you can see whether they are breathing at a regular pace, and if not, seek additional help,\" Atala said.\n\"There are several potential causes of bedwetting, and sleep apnea is clearly one of them,\" said Dr. Lane S. Palmer, chief of pediatric urology at the Cohen Children's Medical Center in New Hyde Park, N.Y.\n\n\"There are secondary positive effects of this tonsil- or adenoid-removing surgery, but I don't know that I would jump to have my child's tonsils or adenoids out as a primary treatment for bedwetting,\" he said.\nThe findings were to be presented Monday at the annual meeting of the American Urological Association (AUA), in Washington, D.C. Research presented at medical meetings should be viewed as preliminary until it has been published in a peer-reviewed medical journal.\n\"About 5 to 7 million children are bedwetters, and the causes fall into three main groups: bladder issues, sleep-related problems and the kidneys,\" he explained.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. It takes great pains to explain to readers that surgery may not be the solution for their child\u2019s sleeping problems and their child\u2019s bedwetting problems. It also is very clear about the potential audience for this surgery, beginning with the headline, which says, \u201cTonsil removal may cure bed wetting in some children with sleep apnea. Children with sleep apnea are a small subgroup, and that group is made even smaller by including only those children who wet the bed. Then, this headline and the story, go even further to make it clear that not all of those children will be cured. We would have liked to have seen a few additional pieces of information about the other effects of sleep apnea in children, such as daytime sleepiness and difficulty in school. Most parents would not consider surgery to solve something like bedwetting, which in the majority of children will resolve on its own. ", "answer": 1}, {"article": "Studies have been inconclusive, but doctors and patients have voted with their feet in favor of the less-invasive procedure \u2014 clearing clogged arteries and propping them open with tiny scaffolds called stents.\nThat can call into question the ultimate relevance of the findings.\nU.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nThey had blockages in either two or three coronary arteries but did not require emergency procedures.\nSo the new data may be the best that doctors and patients in this situation can expect for the foreseeable future.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not engage in disease mongering.", "answer": 1}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story commit disease-mongering?", "explanation": "Atopic dermatitis, although not lethal, afflicts millions of Americans and carries with it a high social cost.", "answer": 1}, {"article": "Why are so few women being treated?\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\n\u201cThe management of menopause has been relatively similar in the UK, the USA and in Australia.\u201d\n\nUp to half of women in menopause experience so-called vasomotor symptoms, such as hot flashes and night sweats.\n(Reuters Health) - Many women with severe menopausal symptoms are not being treated for them even though safe, effective remedies are available, a study from Australia suggests.\nBut after the initial findings of the Women\u2019s Health Initiative study showed that HRT can increase the risk of breast cancer, stroke and other serious problems, many women stopped using it.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story\u2019s characterization of how many women are suffering from menopausal symptoms seems reasonable. But it does seem a bit skewed toward discussion of women with severe, long-lasting symptoms and doesn\u2019t acknowledge that women may also have milder, transient symptoms that don\u2019t require treatment.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in this story.", "answer": 1}, {"article": "The protective effect for hip fractures disappeared.\nIn the new analysis, researchers analyzed data collected from 7,645 women who were in the part of the study examining the effects of taking estrogen alone an average of 10.7 years, after the study was halted because of the evidence the drugs were harming women.\nThere\u2019s some good news and some bad news for women who took estrogen to help them get through menopause until the health risks of taking the hormone were discovered.\nA new analysis of the landmark Women\u2019s Health Initiative, the federal study that discovered the health risks, indicates that women who stopped using estrogen after the dangers were uncovered are no longer at increased risk for strokes and blood clots about 10 years after they stopped.\nFor years, women took estrogen or a combination of estrogen and progestin to help alleviate hot flashes and other symptoms of menopause, and in the belief that the drugs had a host of health benefits, including protecting their hearts.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n\nThis short story avoids mongering, although our medical editor on this review thought the tone hypes the dangers of estrogen when the data show that the risks, though real, are small in absolute terms.", "answer": 1}, {"article": "\"Might this be a good application to help that person recover or prevent this decay from advancing?\n\"An alternative could simply be brushing better in a certain location and not drinking Coca-Cola all day long,\" says Mark Wolff, a professor of dentistry at New York University who specializes in cariology, or the study of tooth decay.\nBut the third is a decay that is not so advanced, and Dr. Jin-Ho Phark, her dentist, is going to use a treatment he's testing that involves no drilling -- \"which is nice because many patients don't like the sound of the drill, and the feeling or the pain that might be associated with it,\" Phark says.\nHowever, some dentists argue that any time before a cavity actually forms, tooth decay can be stopped -- and even reversed -- by the patients themselves, using, for example, fluoride toothpaste.\n\"We aim to treat these intermediate lesions -- not the very early ones, but the intermediate ones -- where usually, as a dentist, you are not sure whether you should make a filling or not,\" Paris says.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe premise of this story is that the featured product is an alternative to drilling and filling a cavity. However, this product and others like it are not intended as an alternative to fillings at all, they are used to seal pits that might (or might not) grow into cavities if the patient doesn\u2019t take better care of his or her teeth. In other words, the story misrepresents the health issue that the product is meant to address.", "answer": 0}, {"article": "Bochner and his colleagues Drs.\nIf the results are favorable, the next step would be to get funding to actually test whether taking a BTK inhibitor will improve the ability of food-allergic adults to eat foods they're allergic to.\nCurrently, the study is being expanded to adults with food allergy to see if their skin test and basophil activation test responses show a similar reduction with just a few doses of ibrutinib and how long such benefits might last.\nIn this recent study, Bochner and his team performed traditional allergy skin tests and the basophil activation test, a related allergy test using blood cells, on cancer patients before they had taken ibrutinib and again after one week and after one to two months of taking it.\nWhile the study was small - only two patients qualified out of about 35 that were screened for allergies - the implications are much larger for later phases of this study.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We rarely see overt disease mongering in the news releases and stories we review. This is a notable exception. The release notes in the opening paragraph: \u201cThe promising data from this pilot study could have greater implications for adults with food allergies,\u201d tantalizing legions of people with allergies to peanuts and other foods. Some news stories jumped on that connection. But the study did not include any people with food allergies, just one patient with a cat dander reaction and one patient with a ragweed reaction.", "answer": 0}, {"article": "Pancreatic cancer is currently very difficult to detect while it is still resectable.\nIn the future, the screening method could be used to screen people who are at a higher risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients and patients with chronic inflammation of the pancreas.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\n\"Our test can detect pancreatic cancer with 96% accuracy at stage I and II, while there is still the possibility of successful surgical intervention.\nThere is currently no cure and few treatment options for advanced pancreatic cancer, which is the late stage when pancreatic cancer is usually diagnosed\", explains Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This news release does not disease monger. It does quite well in establishing that an early detection method for pancreatic cancer is sorely needed since early clinical diagnosis is notoriously difficult with this very lethal cancer.", "answer": 1}, {"article": "And it needs to be strong enough and elastic enough that it actually affects the recoil of the skin.\u201d\n\nThat, he said, \u201cis the challenge I put to them.\u201d\n\nDr. Robert Langer, a biomedical engineer who is a professor at M.I.T.\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\n\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\n\u201cWhen we move skin, it doesn\u2019t snap back to what it used to be.\u201d\n\nWhat if there was a way to restore the elastic nature of skin?\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\n", "question": "Does the story commit disease-mongering?", "explanation": "Given the tone of the piece\u2013lots of medical language and interviews with researchers\u2013and that it appeared in the Times\u2019 Health section, we feel this story disease-mongers a normal life event (aging). For example, it refers to under-eye bags as \u201ca condition\u00a0that plagues so many middle-aged and older people.\u201d \u00a0Are under-eye bags really a \u201ccondition\u201d in need of treatment?", "answer": 0}, {"article": "Using alcohol with phentermine may result in an adverse drug reaction.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nIt has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.\nThe possible role of phentermine has not been established, therefore the possibility of an association between heart valve disease and the use of phentermine alone cannot be ruled out.\nLosing five to 10 percent of total body weight is likely to produce health benefits, such as improvements in blood pressure, blood cholesterol, and blood sugars.3\n\nSome side effects of phentermine that have been reported include pulmonary hypertension, valvular heart disease, palpitations, increased heart rate or blood pressure, insomnia, restlessness, dry mouth, diarrhea, constipation and changes in sexual drive.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The drug Lomaira is designed to treat persons who are obese or overweight and therefore plays on the interests of a large portion of the population who are concerned about their weight. While it does not seem to cross the line into the realm of disease-mongering, it does get about as close as possible without stepping over.", "answer": 1}, {"article": "Moreover, the test's rapid turnaround and relatively low cost, especially compared to next-generation DNA sequencing, provide a potential opportunity for universal monitoring of more patients than is currently done,\" explained lead investigator Hanlee P. Ji, MD, Associate Professor in the Department of Medicine at Stanford University and Senior Associate Director of the Stanford Genome Technology Center.\nThe report describes the use of the test to analyze samples from six patients.\nIn one patient, the assay was able to show the presence of three different mutations.\n\"For monitoring patient tumors, only a handful of blood tests are available which are limited to only several types of cancers.\nThe three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release.", "answer": 1}, {"article": "\"In 2012, scientists took that particular frog and wanted to know why is it, why do these frogs keep milk fresh?\nIf there is a similarity, it may explain why H1 viruses are vulnerable to urumin's wrath.\n\"They thought that they would be more targeted to membranes, but the data looks like they target the H1 protein specifically and that data looks pretty firm.\"\n\"I need to come up with a strategy to deliver it systemically as well; maybe an injectable, which goes in the bloodstream and kills influenza viruses,\" Jacob mused.\n\"So, we tested it against viruses that came from the 1930s until the current ones, and it kills all of the H1s.\n", "question": "Does the story commit disease-mongering?", "explanation": "Flu viruses are ubiquitous and often dangerous. Seeking another line of defense to accompany vaccination and other drugs makes sense.", "answer": 1}, {"article": "WASHINGTON--A new dietary review of 49 observational and controlled studies finds plant-based vegetarian diets, especially vegan diets, are associated with lower levels of total cholesterol, including lower levels of HDL and LDL cholesterol, compared to omnivorous diets.\nThe meta-analysis appears as an online advance in Nutrition Reviews.\nHis former hometown of Roseburg, Ore., is now a Blue Zones community.\nWithin the first month of making the dietary change, he effortlessly lost 10 pounds.\n\"To make any form of health care work and to truly power economic mobility, we have to get healthy,\" says Levin.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no evidence of disease mongering.", "answer": 1}, {"article": "What is the effect of Topical Curcumin Gel for treating burns and scalds?\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nThe process goes through a sequence of acute and chronic inflammatory events, during which there is redness, swelling, pain and then healing, often with scarring in the case of burns and scalds of the skin.\nIn this report, use of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\nThe sequence is started by the release of phosphorylase kinase about 5 mins after injury, which activates over 200 genes that are involved in wound healing.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the news release. The release provides some context on the medicinal uses of\u00a0 curcumin throughout history.", "answer": 1}, {"article": "That's a potentially life-saving development.\nThe skin patch \u2014 intended to desensitize patients to peanuts by exposing them to tiny amounts of the allergen \u2014 may be particularly appealing to children who are too frightened to try oral or under-the-tongue therapy.\nWith this you just slap a little patch on their backs.\u201d\n\nAlthough some volunteers experienced redness and itchiness at the site of the patch, there were no serious side effects.\nIt means that \u201cthey are not going to have to worry about traces of peanut in a package that came from a plant where peanuts were used or minor contamination of food in a restaurant,\u201d said the study\u2019s lead author, Dr. Hugh Sampson, a professor of pediatrics at the Icahn School of Medicine and director of the Jaffe Food Allergy Institute at Mount Sinai.\n\u201cAnd the patch may be a way of doing this that is safer.\u201d\n\nThe patch study's results are promising, although researchers need to continue following the participants for another year, Sampson said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although the story paints a rather scary picture of the risks to individuals with food allergies in a world where otherwise benign food products can easily be contaminated, the data presented back up the scenario. The world IS scary place for folks with food allergies.", "answer": 1}, {"article": "SUNDAY, Jan. 17, 2010 (HealthDay News) -- Giving a vaccine through a scratch on the skin (scarification) triggers a stronger immune response than injected vaccines, say U.S. researchers, who also found that scarification requires 100 times less vaccine to prompt an immune response.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\nAfter all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nIn a series of tests, the Brigham and Women's Hospital researchers also found that the memory of T-cells -- the cells that mount an immune response against invading viruses -- may be more important than the antibodies generated by injected vaccines.\n\"The lessons we are learning from these studies of vaccination by scarification could help us develop new and more powerful vaccines for influenza, HIV, malaria and other infectious diseases,\" Kupper explained.\n", "question": "Does the story commit disease-mongering?", "explanation": "There really wasn\u2019t any meaningful discussion of the diseases for which the vaccines might be given, so we rule this criterion Not Applicable. ", "answer": 2}, {"article": "Richard Neal, professor of primary care oncology at the University of Leeds who was not involved in the research, welcomed the study.\nBut it remained unclear whether the condition could signal an increased risk of all cancers, and how it ties in with factors such as age and sex.\nWithin a year of the blood test, the team found that cancer was more common among those who had thrombocytosis: 11.6% of men and 6.2% of women were found to have cancer compared to 4.1% of men and 2.2% of women without a raised platelet count.\nFor comparison, among women aged between 50 and 59 who have discovered a breast lump, the proportion who are found to have breast cancer is 8.5%.\nOf the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here. They didn\u2019t try to overplay thrombocytosis as a cancer predictor.", "answer": 1}, {"article": "ZURICH (Reuters) - Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine\u2019s limited benefits.\n\u201cWe are not hopeful here.\u201d\nCanakinumab is already approved as Ilaris for rare autoimmune conditions.\nThere was no significant difference in the rate of deaths from all causes between the placebo group and those on canakinumab.\nIlaris now costs about $200,000 per patient annually for treating rare immune conditions and brings in some $400 million in yearly sales for the Swiss company, though its price is likely to be slashed should it win approval in the heart setting.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story commit disease-mongering?", "explanation": "This story does not engage in disease-mongering. \u00a0", "answer": 1}, {"article": "But Riddle soon heard that certain compounds in cannabis\u2014cannabinoids\u2014have been shown to induce cancer cell death.\nI said, \u2018He\u2019s dying.\n\u201cAt this point, they kept telling us we have to keep going.\n\u201cI\u2019m done with this shit,\u201d she remembers saying.\nInitially, her hope was that the drug would lessen the side effects.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 2}, {"article": "But some pain experts defend the value of the diagnostic tests.\nDoing away with a painkilling injections, or nerve blocks, as a test to determine the root cause of the back pain didn't hurt patients who went on to have their pain treated by zapping nerves with electrodes.\nPatients don't care much about the finer points of diagnostic accuracy.\nBecause the diagnosis of pain can be imprecise, doctors often order multiple tests before treatment.\nOf about 150 patients, the group that got radiofrequency treatment immediately had more people who felt better.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0No disease-mongering.\u00a0 The story was about pinpointing causes of low back pain \u2013 a condition as broad as the ocean. ", "answer": 1}, {"article": "MEMPHIS, Tenn., Oct. 26, 2015 /PRNewswire/ -- Imagine.\n\"For women with certain types of breast cancer, cryoablation is showing promise as an alternative to surgery, particularly for patients over age 65,\" says Susan K. Boolbol, MD, Chief of the Appel-Venet Comprehensive Breast Service, Mount Sinai Beth Israel, who is participating in the trial.\nDeveloped by IceCure Medical (Caesarea, Israel/Memphis, TN), specifically for breast applications, the IceSense3 Cryoablation System\u2122, has a long history of successful treatment of benign breast fibroadenomas.\nIts effectiveness in breast cancer has been proven in a number of smaller studies, including a recent American College of Surgeons Oncology Group (ACOSOG) trial and extensive long-term ongoing, unpublished studies in Japan.\nAs a market leader in cryoablation treatment of breast disease, IceCure will utilize its resources to provide clinical and technological support to sites in the cancer trial.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s some strong language describing the pain and lengthy recovery of surgery, and the suffering that many women experience following surgery. But that\u2019s not disease-mongering per se \u2014 it\u2019s more of a way for the release to pump up the advantages of the new approach.", "answer": 1}, {"article": "\"It was a very aggressive cancer and we needed to start treatment right away,\" said Chris Mullin, Brian's father.\nOne tagged with antibody, the cancer can be more easily recognized and attacked by the body's own white blood cells.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\nBut then his doctor offered an additional step: an experimental treatment called immunotherapy, in which antibodies that target the cancer are injected into the bloodstream and attach to the tumor cell.\nAfter two years, 46 percent receiving standard treatment alone were free of tumor recurrence versus 66 percent of those like Brian who also received the antibody.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no overt disease-mongering about neuroblastoma.\u00a0 But a simple line about the very low incidence of this tumor would have added helpful perspective.", "answer": 1}, {"article": "MONDAY, March 21, 2011 (HealthDay News) -- While the majority of morbidly obese patients who undergo gastric banding say they are generally satisfied years later, almost 40 percent are saddled with major complications, while about half have to have their bands removed, a small, new Belgian study reveals.\n\"So bands are easy to sell and very heavily marketed,\" he added.\nIt's just not as good as bypass.\"\nOne in six of the patients ended up deciding to have a gastric bypass procedure, and all of these patients demonstrated good outcomes following their subsequent surgery.\n\"Some groups have very good results, with 60 to 70 percent weight loss.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease-mongering.", "answer": 1}, {"article": "\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAccording to Arbelo, 91 percent of patients choose to have ablation to relieve symptoms, while 66 percent do so to improve their quality of life.\nBut the procedure can have complications, which should be considered carefully by doctors and patients, said Arbelo, a senior specialist in the Cardiovascular Institute at the Hospital Clinic of Barcelona in Spain.\n\"Further trials are needed to evaluate the benefits and risks of catheter ablation and its potential role as first-line therapy,\" he suggested.\n\"Catheter ablation is a valid alternative for the management of atrial fibrillation with a satisfactory success rate,\" said study lead researcher Dr. Elena Arbelo.\n", "question": "Does the story commit disease-mongering?", "explanation": "This was a tough call. The story does some things well here: It gives us the prevalence of atrial fibrillation, and explains that this procedure is for people who don\u2019t experience improvement with medications.\nBut it could have gone a step further, and explained that most people with atrial fibrillation have no symptoms, or the symptoms are well controlled with medication\u2013so catheter ablations are really only considered for a minority of this patient population.\nSince it does make that distinction to a degree (that the procedure is reserved for people who can\u2019t control symptoms via medication) we\u2019re rating it satisfactory.", "answer": 1}, {"article": "TUESDAY, July 24, 2018 (HealthDay News) -- The active ingredient in pot that gets you high can calm agitation in people with advanced Alzheimer's disease, a small new study suggests.\nDuring the clinical trial, 39 patients with moderate to severe Alzheimer's disease received nabilone for six weeks to treat their clinically significant agitation, followed by six weeks with an inactive placebo.\nAnd for every nine to 25 people helped, one will die.\nHowever, many study patients suffered from sedation due to the drug, noted Keith Fargo, director of scientific programs and outreach at the Alzheimer's Association.\nFor example, only one person out of five to 14 treated with antipsychotics actually experiences a decrease in agitation, Lanctot said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does an admirable job of not only explaining how common agitation is in Alzheimer\u2019s, but also why it\u2019s so difficult to treat.", "answer": 1}, {"article": "This was a phase 2 trial.\n\"This is a new book.\nThe U.S. National Cancer Institute has more on breast cancer.\n\"Both excitement and caution are appropriate in interpreting the trial,\" she wrote.\n\"Some clear drawbacks should be noted.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "\"Without sensory feedback, somebody would have to actually have to look at the prosthetic, look at the cup, start to close the hand, (and) visually see the cup is starting to deform,\" he says.\nAnd there's no good way to control them without implanting electrodes in the brain.\nFor several years now, people have been able to control robotic arms using thoughts alone.\nThen they waited for the brain to heal, as it adjusted to the presence of the electrodes.\nBut he also describes many of the sensations coming from his robotic hand as \"natural.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "As Ben-Gurion University of the Negev (BGU) looks ahead to turning 50 in 2020, AABGU imagines a future that goes beyond the walls of academia.\nAll patients received a prescription after consulting with a doctor who prescribed treatment.\nHe is also the head of the Clinical Research Center and Research Authority at Soroka.\nMore than 60 percent were prescribed medical cannabis due to the pain, particularly pain associated with cancer.\nVisit vision.aabgu.org to learn more.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering in this news release.", "answer": 1}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story commit disease-mongering?", "explanation": "Did not engage in overt disease mongering.", "answer": 1}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story commit disease-mongering?", "explanation": "We observed no evidence of fear-mongering language in the story.", "answer": 1}, {"article": "To learn more, visit stjude.org or follow St. Jude at @stjuderesearch\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\nIndeed, the comparison of gut bacteria in normal and AIM2-deficient mice showed a different 'microbial landscape' in the two types of mice.\n'We have only scratched the surface of the role of AIM2 in controlling stem cell proliferation and the maintenance of a healthy gut microbiota,' Kanneganti said.\nBoosting the activity of a protective gene and giving patients 'good' gut bacteria could help prevent or slow progression of colorectal cancer, St. Jude Children's Research Hospital scientists have found\n\nMemphis, Tenn., JUNE 19 -- Scientists at St. Jude Children's Research Hospital have discovered how an immune system protein, called AIM2 (Absent in Melanoma 2), plays a role in determining the aggressiveness of colon cancer.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Colorectal cancer is a serious problem and more effective treatments are needed. The release did a fine job of explaining that AIM2 mutations were often associated with colorectal cancers, while still distinguishing those mutations from the cancer itself.", "answer": 1}, {"article": "Tumor cells make PD-L1 turn on PD-1 when immune cells approach.\n\"I suspect the findings were significant enough that this will be a practice-changing finding,\" Dr. Pasi Janne, lung cancer specialist at Harvard Medical School and the Dana-Farber Cancer Institute, told NBC News.\nLung cancer is the top cancer killer in the U.S. It\u2019s diagnosed in more than 220,000 people a year and it killed nearly 160,000 people last year, according to the National Cancer Institute.\nRelated: Keytruda Keeps Some Patients Alive For Three Years\n\n\"Immunotherapy is a whole new way of treating cancer, including lung cancer,\" said Janne, who was not involved in the study.\nThe drug, Keytruda, is the same drug that former president Jimmy Carter says helped stall advanced melanoma that had spread to his brain.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story. Instead it says accurately that \u201cLung cancer is the top cancer killer in the U.S. It\u2019s diagnosed in more than 220,000 people a year and it killed nearly 160,000 people last year, according to the National Cancer Institute.\u201d", "answer": 1}, {"article": "\"Cardiovascular disease is the number one cause of death in the U.S., and while statins are very effective, a good proportion of people are not meeting their goals, and in this setting the shot could be a valuable addition,\" he said.\nThere were also decreases seen in levels of total cholesterol and apo-B (tiny fat particles in the blood that also increase the risk for heart disease).\n\"It is the early days, but the data look strong.\nAn LDL of less than 100 mg/dL of blood is considered optimal.\nThe study included 54 men and two women aged 18 to 45 who did not have elevated cholesterol levels.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease-mongering in this story. However, several points deserve consideration:", "answer": 1}, {"article": "Jordan says the new findings will quickly change care for some patients.\nBreast cancer survivors have mixed reactions to the results.\nGray noted that tamoxifen has risks.\nSome switch to an AI, although these drugs can also cause problems, such as joint pain and osteoporosis.\nIn the U.K., tamoxifen costs only $5 a month.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease-mongering.", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story commit disease-mongering?", "explanation": "\nHip and knee osteoarthritis afflict millions of Americans, and this story fairly represents their predicament.", "answer": 1}, {"article": "For now, says Weiner, there is \"no consensus\" on which patients should get the costly new PET scans that use Amyvid, and large insurers such as Medicare and Medicaid have not made decisions about coverage for such tests.\nWeiner conducted much of the research leading to Amyvid's approval.\nNo one wants to hear that he or she has Alzheimer's disease.\nThis is a way of getting closer to an answer,\" said Weiner.\nMany patients experiencing cognitive lapses may also be reassured if the test fails to reveal amyloid plaques, he added.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "The study evaluated the performance of one such questionnaire--the Pain Self Efficacy Questionnaire (PSEQ)--in migraine surgery patients.\nPlastic and Reconstructive Surgery\u00ae is published by Wolters Kluwer.\nhas been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon.\nRepresenting more than 7,000 physician members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery.\nThe study included 90 patients who underwent migraine surgery, performed by Dr. Austen, between 2013 and 2015.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "People who completed 11 or more speed training sessions were at 48 percent less risk for developing dementia over the 10 years of the study, Edwards said.\nThe preliminary findings, presented at the Alzheimer\u2019s Association International Conference in Toronto, are the first to show that any kind of intervention could delay the development of dementia in normal, healthy adults.\n\u201cThis may even be clinically relevant.\u201d\n\nIn 2014, a group of nearly 70 neuroscientists and cognitive psychologists led by researchers at Stanford University\u2019s Center on Longevity and the Berlin Max Planck Institute for Human Development signed a letter saying there was \u201clittle evidence\u201d of such results from brain games.\nTo date, cognitive psychologists and neuroscientists have largely rejected evidence that computer-based cognitive-training software or \u201cbrain games\u201d have any effect on cognitive function.\nShe found that the group that did speed training showed 33 percent less risk of dementia relative to the control group, while the memory and the reasoning interventions offered no such benefit.\n", "question": "Does the story commit disease-mongering?", "explanation": "People at risk for Alzheimer\u2019s may benefit from brain games if the preliminary results presented hold up to further scrutiny. While the article acknowledges this, it does not commit any disease-mongering regarding Alzheimer\u2019s or other cognitive disorders.", "answer": 1}, {"article": "There were also big improvements in their parenting style.\nThe international research project into the impact of depression on pregnant mothers and their babies, led by Professor Sonia Bhalotra from the Institute for Social and Economic Research at the University of Essex, could have major implications for public policy.\nThe study, one of the largest randomised control trials to be held in the developing world, followed women diagnosed with depression mid-pregnancy in 40 communities in rural Pakistan.\nThe NHS website explains that it is \u201cbased on the concept that your thoughts, feelings, physical sensations and actions are interconnected, and that negative thoughts and feelings can trap you in a vicious cycle\u201d.\nThe study found that women who had least social support such as those who were not living with or near their mother or mother-in-law, benefited most from the therapy intervention, both in the short and long term.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering. We were also pleased that the story talked about multiple impacts on patients with this diagnosis, including their financial health.\nHere is what the\u00a0researcher said about the patients who responded to treatment: \u201cTheir mental health has improved, their financial situation and their empowerment over their lives, and undoubtedly the way they interact with their children.\u201d", "answer": 1}, {"article": "Other New York counties took similar actions after New York City\u2019s measure was enacted.\n(Reuters Health) - - People were less likely to go to the hospital with heart attacks or strokes after several counties in New York State restricted the use of trans fats, according to a new study.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nBrandt and colleagues write that in 2015, the U.S. Food and Drug Administration (FDA) removed manufactured trans fats from its list of safe food additives.\nFor the new study, the researchers compared data on people hospitalized between 2002 and 2013 for heart attacks or strokes in counties that did or didn\u2019t restrict trans fats.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story\u00a0deals with a serious health issue, and it did a good job describing what trans fats are and why they\u2019re unhealthy.\nTrans fats raise bad cholesterol, lower good cholesterol and ultimately increase the risk of heart attacks and strokes. They\u2019re found naturally in some foods but are often manufactured and added to processed foods to improve taste and texture.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A large waistline more than doubles the risk that people in their 40s will develop precancerous cells in the colon, according to Korean researchers.\nThat number was the same in younger people who had large waistlines, and even lower in those with metabolic syndrome, a combination of risk factors including belly fat, high blood pressure and high blood sugar.\n\u201cThe idea that you\u2019re tailoring screening to age and some combination of risk factors is entirely reasonable,\u201d said Robert Smith, the director of cancer screening at the American Cancer Society.\nThe chances of finding abnormal cells during a screening test were just as good in younger men with too much belly fat as in slimmer men over 50.\n\u201cYou want to make sure that the advantages are going to outweigh the harms,\u201d said the American Cancer Society\u2019s Smith.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of polyps or colon cancer. The story clearly states that most polyps do not develop into cancer.", "answer": 1}, {"article": "Sixty percent of the people who considered pets to be a part of their social networks placed them in the central, most important circle \u2014 the same place many people put close family and social workers.\nThey give affection without needing to understand the disorder.\n\"The routine these pets provide is really important for people,\" says Brooks.\nHaving a pet that was well taken care of was a source of pride for them.\n20 percent placed pets in the second circle.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\"It's a lot shorter, and it's obviously convenient,\u201d said Dr. Doug Kelly, a radiation oncologist with Cancer Treatment Centers.\nAlthough long-term data are unavailable, results have been positive.\nThe procedure requires a hospital stay, at the end of which the needles and pellets are removed.\nIn the multiple-catheter method, a doctor places 10 to 20 \"needles\u201d about one centimeter apart around the tumor cavity, and a machine inserts the radioactive pellet.\nIn the balloon-catheter method, also known as Mammosite, a doctor inflates a balloon in the tumor cavity, and a catheter delivers the radioactive pellet.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not exaggerate the consequences of the cancer itself or of either treatment. ", "answer": 1}, {"article": "There is help available.\nIt\u2019s no longer that you need to stay away from hormone replacement therapy, it\u2019s that you need to use it wisely.\u201d\n\nThat wisdom comes from a careful medical assessment and ongoing surveillance of blood pressure, blood work, breast changes, side effects and effectiveness.\nIt\u2019s a process, but hormone replacement therapy is helping women have a better life in an era when they live longer.\u201d\n\nJohnson, Firouzbakht and other experts will tell you that hormone therapy protects against heart disease, a much more common killer of women than breast cancer, as well as against dementia, colon cancer, osteoporosis and other health issues.\nIt\u2019s an unfortunate thing that that\u2019s out there,\u201d Firouzbakht says, \u201cbecause women also need to know: You don\u2019t have to suffer, you don\u2019t have to have incontinence or vaginal prolapse or hot flashes.\nThe doctors emphasized not just the medical benefits, but that the treatment can enable and boost a woman\u2019s overall day-to-day existence, too.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article presents several examples of disease mongering language as applied to menopause:\n\u201d It\u2019s not a death sentence or a dependence\u2026\u201d\n\u201d You don\u2019t have to suffer..\u201d\n\u201d treatment can enable and boost a woman\u2019s overall day-to-day existence\u201d\n\u201d Too many women have been taught to accept suffering in this stage of life\u201d", "answer": 0}, {"article": "There are clear philosophical differences.\n\u201cBeyond adding an element of suspense, this strategy allowed us to come to unbiased conclusions.\u201d\n\nAfter Lockwood found that recent studies suggest that elective inductions at 39 weeks decrease Caesarean delivery rates and might reduce the rate of infant and maternal complications, what was supposed to be a debate proceeded as a discussion in support of induction.\nShe said the induction recommendation \u201creinforces a century-old, pre-feminist American obstetric view that birth is pathological and the doctor\u2019s job is to extract the fetus from the incubator \u2014 like in the \u201950s, when every baby was pulled out of its shackled, unconscious mother by episiotomy.\u201d\n\nConsumer groups such as hers, she said, have been calling on ACOG to evolve toward care that is more centered on women.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\nThe question was presented in May at the yearly ACOG meeting in Washington: \u201cWhy not induce everyone at 39 weeks?\u201d Two doctors had been asked to debate: Errol Norwitz, chairman of obstetrics and gynecology at Tufts University School of Medicine, and Charles Lockwood, dean of the Morsani College of Medicine at the University of South Florida.\n", "question": "Does the story commit disease-mongering?", "explanation": "This rating is a close call, because the underlying premise of the story is that some experts think that, after 39 weeks, normal pregnancy should be considered a problem requiring treatment. Such a position would shift the overwhelming majority of expectant mothers from \u201cnormal\u201d to \u201cat risk.\u201d\nNevertheless, we will rate the story Satisfactory on this criterion because it includes several vocal opponents of any change in the prevailing definition of the healthy length of pregnancy.", "answer": 1}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\nThe findings were presented at the American Academy of Neurology meeting.\nThat compares with a 15-point decline in patients who initially received placebo and switched to IVIG, says Norman Relkin, MD, of Cornell Weill College of Medicine in New York City.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering of Alzheimer\u2019s Disease.", "answer": 1}, {"article": "Dec. 2, 2011 (Chicago) -- An experimental approach in which penile nerve tissue is frozen to knock out overactive nerves helped men with premature ejaculation last three times longer.\n\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nThey lasted an average of 110 seconds before ejaculation, or nearly two minutes, over the three months they were followed, compared with 36 seconds before treatment.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story\u2019s estimate of PE prevalence (20% to 38%) is\u00a0in line with the figures reported in a 2006 review of the literature.\u00a0 We wish such stories would cite prevalence sources \u2013 as we just did.\nWe also think the story could have mentioned that there is considerable uncertainty about these numbers due to the fact that there is no standard definition of PE.\u00a0We think that estimates at the higher\u00a0end of this range are likely overstating the scope of the problem. In one study that reported a\u00a032.5% overall prevalence of PE,\u00a0for example, about half of participants said that their\u00a0PE symptoms caused them little or no distress. And if you\u2019re including men who suffer no distress in your population of PE \u201csufferers,\u201d that smacks of medicalizing people who are exhibiting a normal range of behavior. In other words, disease-mongering.", "answer": 0}, {"article": "LONDON (Reuters) - Men who have a certain genetic variations that put them at higher risk of prostate cancer may benefit from regular screening for the disease, a study by British scientists found Friday.\nProstate cancer is the second most common cancer in men worldwide and kills 254,000 men a year.\nIt aims to screen 1,700 men for five years, but results from the first 300 men were published in the British Journal of Urology International.\nThe ICR-led study is aiming to find out whether screening men who have genetic variants that increase their prostate cancer risk could lead to earlier diagnosis.\nGenetic factors that increase prostate cancer risk include inheritable variations in genes known as BRCA1 and BRCA2.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exagerate the seriousness or prevalence of prostate cancer.", "answer": 1}, {"article": "The fact that this uncertainty is occurring so long after the 1998 approval of Herceptin \u2014 the paragon of \u201cpersonalized medicine\u201d \u2014 suggests that it will not be so easy to tailor other drugs to patients based on gene or protein tests.\nThey are now classified as negative but might still derive some benefit from the drug.\nBut scientists have now gone back and retested those preserved tumor samples and found that as many as 20 percent of them were actually Her2-negative.\nOn the other hand, he said, many women who are Her2-positive do not benefit from Herceptin.\nBut two studies discussed at the oncology meeting found that patients who were considered Her2-negative even using both tests benefited from Herceptin.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering, although there are elements of drug-mongering.\u00a0 See \"Benefits\" below. ", "answer": 1}, {"article": "\"In conclusion, gemcitabine did not result in improved overall survival compared with fluorouracil plus folinic acid in patients with [surgically removed] pancreatic cancer,\" the authors concluded in their report.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\nThe pool of nearly 1,100 patients that the researchers focused on were part of the large European Study Group for Pancreatic Cancer trial that took place across 159 pancreatic cancer centers located in Europe, Canada, Australasia and Japan.\nThe finding, reported in the Sept. 8 issue of the Journal of the American Medical Association, stems from work conducted by Dr. John P. Neoptolemos, of the Cancer Research U.K. Liverpool Cancer Trials Unit at the University of Liverpool in England, and colleagues.\nDr. Michael Choti, a professor of surgery and oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, described the study as \"important,\" but he does not believe it will alter the current approach to post-surgical chemotherapy.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. Instead, it nicely draws boundaries on the target population for this treatment by saying that only a minority of patients with pancreatic cancer are candidates for surgery.", "answer": 1}, {"article": "The paper \"Real-time imaging of the resection bed using a handheld probe to reduce incidence of microscopic positive margins in cancer surgery\" is available online at http://cancerres.\nIn the clinical study, surgeons treated patients according to the standard surgical procedure, but OCT data were collected from the margin of the tumor cavity and the margin of the removed tissue mass during surgery so that the results could be compared later.\nCancer cells and normal tissue scatter light differently because they have different microstructural and molecular features, Boppart said, so OCT gives physicians a way to quantitatively measure the cellular feature of a tumor.\nThe pathologist will process, section and stain the tissue, then examine the thin sections on microscope slides.\nThey also found that the way that OCT spotted cancer in the removed tissue was closely correlated with the results from the postoperative pathology reports, which often came days later.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here, but instead a quite clear explanation of why assessing margins is important in the surgical treatment of cancer.", "answer": 1}, {"article": "Ultimately, a candidate molecule called ICEC0942 suppressed tumour growth in a wide range of cancer types in lab tests.\nProfessor Charles Coombes, from the Department of Surgery & Cancer, said: \"Treatment-resistant tumours represent a significant threat for patients, as once a cancer stops responding to treatments there is increasingly little clinicians can do.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nThe discovery of the drug was spurred by an initial meeting between Professor Anthony Barrett, from the Department of Chemistry, and oncologist Professor Charles Coombes from the Department of Surgery & Cancer.\nDr Iain Foulkes, Cancer Research UK's executive director of research and innovation, said: \"It's exciting to see how Cancer Research UK's partnerships with both academia and industry are bringing urgently needed new tests and treatments to patients.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release offers this quote:\nProfessor Charles Coombes, from the Department of Surgery & Cancer, said: \u201cTreatment-resistant tumours represent a significant threat for patients, as once a cancer stops responding to treatments there is increasingly little clinicians can do.\nBut there\u2019s no data on how frequent treatment-resistant cancers occur.", "answer": 0}, {"article": "It is sort of a window into the lung.\u201d\n\nCigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nThey put these on a gene chip or microarray to see which genes were active in the cells.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\nThese were patients with precancerous lesions in their lungs called dysplasia.\n\u201cTogether it gives us the story of the importance of this pathway,\u201d Bild added.\n", "question": "Does the story commit disease-mongering?", "explanation": "      This story did not exaggerate the seriousness or prevalence of lung cancer in smokers.  \n ", "answer": 1}, {"article": "\u201cWe can\u2019t yet say that this study means that DHEA is a viable alternative to HRT, but ... we should be looking to do larger studies to confirm these initial results.\u201d\n\nDHEA, or dehydroepiandrosterone, is a natural steroid hormone mostly made in the adrenal glands and has a variety of therapeutic uses.\nWhat we need to do now is to look at a larger study, to confirm that these initial results are valid,\u201d she added.\nBut they stressed that the trial was small, so far larger studies are needed to confirm the results.\nOver a year, 12 women took vitamin D and calcium, 12 took DHEA, 12 took standard HRT and 12 took a synthetic steroid called tibolone which is used to alleviate menopausal symptoms.\nAfter 12 months, all the women on hormone replacements had improvements in menopausal symptoms, but those taking vitamin D and calcium did not show any significant improvement.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.\n\u00a0", "answer": 1}, {"article": "\"The reason we talk about it so much is in the 1960s and 70s, researchers discovered people living there had lower blood pressure problems, cholesterol problems so they started to analyze the diet,\" Dr. Senay told The Early Show co-anchor Julie Chen.\nFor more further information, you can see the studies here and here.\nAs far as alcohol goes, they consume red wine in moderation.\nThey are the first studies to examine the association between the Mediterranean Diet and neurological diseases \u2013 specifically Alzheimer's.\n\"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to engage in disease mongering and mentions that the study does not provide definitive data for a nutritional means of preventing Alzheimer\u2019s. ", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering\u2013a smoking habit is unhealthy and harmful, and efforts to improve quit rates are important to study.", "answer": 1}, {"article": "European regulatory bodies recommend pharmaceutical-grade chondroitin sulfate as well as pharmaceutical-grade glucosamine sulfate as first-line treatments for osteoarthritis, Reginster said by email, because of the side effects associated with celecoxib and other non-steroidal inflammatory drugs (NSAIDs) including stomach ulcers, bleeding, liver and kidney problems.\nSOURCE: bit.ly/2rcPLh0 Annals of the Rheumatic Diseases, online May 22, 2017.\n\u201cI tell them about the mixed results of chondroitin in the literature.\n\u201cI tell my patients, \u2018buyer beware,\u2019\u201d Shepard said in an email.\n\u201cIf you are going to stay on an NSAID for a prolonged period then you need regular follow up with your doctor,\u201d Shepard cautioned.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story\u00a0does not engage in fear-mongering.", "answer": 1}, {"article": "An estimated 10 percent of the world's population suffers from the condition.\nFor more information on IBS and the new blood test for the disorder, watch this video:\n\nFirst Ever Blood Test for IBS\n\nCedars-Sinai has entered into an exclusive license agreement with Commonwealth Laboratories for several patent applications covering the blood tests, developed by Pimentel to detect both anti-CdtB and anti-vinculin antibodies in the diagnosis of irritable bowel syndrome and inflammatory bowel disease.\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\nThe blood tests identified the two antibodies associated with IBS -- anti-Cdtb and anti-vinculin -- with greater than 90 percent certainty.\nThe disorder, nearly impossible to diagnose until now, is characterized by a cluster of confounding symptoms that include chronic bloating, abdominal pain, gas, and bouts of relentless diarrhea, constipation, or both.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release says IBS affects \u201cnearly 40 million people\u201d in the U.S., and \u201can estimated 10 percent of the world\u2019s population.\u201d But this isn\u2019t a test for IBS \u2014 it\u2019s a test for those with the diarrhea predominant version. It\u2019s not clear how many people we\u2019re talking about, but according to this study, less than half of the people with IBS meet the criteria for the diarrhea-predominant version. The release exaggerates the potential impact of the test in a way that promotes a commercial interest, so we\u2019ll flag it for disease mongering.", "answer": 0}, {"article": "Megan L. Kavanaugh, a senior research scientist at the Guttmacher Institute, which studies reproductive health, said in an interview that \u201call new insurance plans obtained through the act\u2019s exchanges fully cover all contraceptive methods without any co-payments or other out-of-pocket costs.\u201d Title X family planning clinics and Planned Parenthood clinics are more likely than other sources to offer LARC methods, she said.\nFully 43 percent of these pregnancies follow incorrect or inconsistent uses of contraception.\nWith both implants and IUDs, fertility returns quickly as soon as the devices are removed.\n\u25a0 Compared with other reversible methods, they are more effective and have higher rates of continued use and user satisfaction.\nThe copper IUD does not contain hormones.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in this story.", "answer": 1}, {"article": "But for now this category is useful only to researchers.\nAnd it's also because there are no treatments that can prevent, slow or stop early signs of Alzheimer's.\n\"It's in the fine print, but it definitely says in multiple places that the biomarkers are for research purposes.\"\nWell, the biomarker tests and PET scans aren't yet accurate enough to reliably diagnose Alzheimer's, and haven't been approved by the Food and Drug Administration.\nThe guidelines say, for instance, that newly developed \"biomarker\" tests, such as assays for proteins in spinal fluid, and some specialized brain scans can be used for early diagnosis of Alzheimer's.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story reports that about 5 millions Americans have Alzheimer\u2019s disease. It doesn\u2019t exaggerate to whom this news is relevant.", "answer": 1}, {"article": "Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity.\nThe researchers analyzed patients' answers before treatment and at each follow-up appointment, and found that patients reported an improved quality of life and lower rates of depression after radiosurgery.\nAccording to the new study, radiosurgery, which is normally a second line treatment to be used following the medication, helps improve quality of life and reduce depression in patients with TN.\nWhile this can reduce the pain, it makes patients drowsy and tired, and they report feeling drunk.\nInternational Journal of Radiation Oncology * Biology * Physics (IJROBP), known in the field as the \"Red Journal,\" is the official journal of the American Society for Radiation Oncology (ASTRO).\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no obvious disease mongering here.The statement that the pain is a 15 on a 0-10 scale borders comes close. The release provides helpful context on what trigeminal neuralgia is and the problems with some current treatments.", "answer": 1}, {"article": "The findings offer important guidance to the growing number of women who face planned C-sections -- one in three babies in the United States, estimates the National Center for Health Statistics.\nAll of the women had previously had C-sections.\nOf those, more than 13,000 had elective C-sections.\n\"This happens to me every day,\" Lavin said.\n\"I think it points to a role for the baby in the initiation of labor and the baby's readiness to make the transition.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "Doctors currently diagnose colds and flus through a patchwork of testing, observation and process of elimination.\nThe new test, called the xTAG respiratory panel, approved earlier this year by the U.S. Food and Drug Administration, is the most comprehensive FDA-approved virus-panel to date.\nThe downside is that the test is expensive, about $300 to $400, but is covered by most insurers.\nFor example, the FDA-submitted data say it detects RSV, a common cause of infant pneumonia, 100% of the time, while giving false positives 2% of the time.\nIt tests for a dozen viruses, including several types of influenza, two types of respiratory syncytial virus, or RSV, three types of parainfluenza, adenovirus and even rhinovirus, which causes the common cold.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article is topical\u00a0because the winter flu season is arriving.\u00a0 However,\u00a0clarification of the type of patient and situation where this test would be most beneficial was missing.\u00a0 This test would be beneficial for\u00a0children seen in emergency rooms or hospitalized with acute respiratory\u00a0illnesses,\u00a0where making the correct diagnosis as rapidly as possible is essential.\u00a0 The test is generally not needed for most children in\u00a0the primary care setting who\u00a0present with symptoms of a short-term flu.\u00a0 In these cases, good physician judgement will determine whether an acute illness is viral in most instances, precluding the need for antibiotics.\u00a0 Although the example of influenza treatment (as a \u2018missed opportunity\u2019) was given, this treatment would only decrease symptoms by 1-2 days, which would not be significant for\u00a0most healthy children.\u00a0 ", "answer": 1}, {"article": "Dr. Jae Jung, a dermatologist at City of Hope cancer center in Duarte, California, agreed.\n\"It's safe, it's almost obscenely inexpensive, and it's already widely commercially available,\" Dr. Diona Damian, the senior author of the study and a professor of dermatology at the University of Sydney, told HealthDay.\nIt doesn't involve any high-priced new pharmaceuticals -- the key may be an over-the-counter vitamin supplement that costs less than $10 a month.\nThe two most common forms of the disease, basal cell carcinoma and squamous cell carcinoma, can usually be treated successfully.\nFor the study, researchers in Australia looked at nearly 400 people who had had at least two non-melanoma skin cancers.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article hashes out key statistics with skin cancer in general, basal and squamous cell skin cancers (which are described as readily treatable), and melanomas (which are more deadly). As noted above, we think the discussion will leave readers confused as to what kind of cancers were prevented in this study. But since we\u2019ve already docked points elsewhere, we\u2019ll rule the story Satisfactory here.", "answer": 1}, {"article": "Drugs ranged from more than one third more effective than a placebo to more than twice as effective.\n\u201cAlthough antidepressants are of proven benefit\u2014as this study shows,\u201d she said, \u201cno doctor wants their patients to become reliant on medication.\u201d\n\nCarmine Pariante, a professor at the UK\u2019s Institute of Psychiatry, Psychology and Neuroscience and spokesperson for the Royal College of Psychiatrists, said the study \"finally puts to bed the controversy on antidepressants.\"\nThe results add up to a complex treatment picture for what authors called \u201cone of the most common, burdensome, and costly psychiatric disorders worldwide in adults.\u201d\n\nAntidepressants do not improve symptoms in about 40 percent of people, study author Andrea Cipriani of Oxford University told a press briefing.\nShe said in a statement: \u201cTaking antidepressants is frequently portrayed as a negative thing or something done only when other therapies are not available or have failed, but this in itself can add to the unfortunate stigma that sometimes exists around people with mental health conditions.\u201d\n\nBut she also urged caution.\nRead more: Trump Health Exam: President Still Taking Hair Loss Drug Even After Research Revealed Link to Erectile Dysfunction and Depression\n\nIn the U.S., the National Institute of Mental Health estimates 16.2 million adults experienced at least one major depressive episode in 2016.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story gives readers clear numbers on the widespread problem of depression and the estimates of people with depression who go untreated. That\u2019s laudable.\nHowever, the assertion that \u201cmany more\u201d people should be taking antidepressants constitutes a form of disease-mongering in our view because it\u2019s unsupported by evidence and could lead some people to seek out drugs they might not benefit from.", "answer": 0}, {"article": "These infant siblings were compared with 33 infants with no known family history of autism.\nOverall, the biggest differences in brain activity were seen at 9 months \u2013 which is much earlier than when a child typically shows behavioral problems associated with autism.\nBut he says by using an electroencephalogram and new, sophisticated computer programs to analyze the EEGs, he and his co-authors were able to correctly identify with 80% accuracy, which babies were at higher risk for autism and which were not.\nPaterson says that if the results out of Boston can be confirmed, \"It's very exciting because finding an early sign for autism is really the holy grail.\"\nScientists have known for quite some time now that the earlier a child with autism gets therapy, the easier it is to improve language and behavioral skills.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did a better job than the HealthDay story to avoid disease-mongering. It\u00a0accurately stated the prevalence of autism spectrum disorders and the much higher risk seen in siblings.\u00a0We felt the overall tone of the story was still too anxiety-provoking, though, and it ended on a curious note with a fundraising plea from a researcher.", "answer": 1}, {"article": "[3]\n\nWriting in a linked Comment, Professor Avan Aihie Sayer from the University of Southampton, Southampton, UK, and Professor Thomas Kirkwood from Newcastle University, Newcastle upon Tyne, UK discuss whether grip strength could be a new biomarker of ageing, writing that, \"This is not a new idea, but findings from PURE add support.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nThe findings show that every 5kg decline in grip strength [2] was associated with a 16% increased risk of death from any cause; a 17% greater risk of cardiovascular death; a 17% higher risk of non-cardiovascular mortality; and more modest increases in the risk of having a heart attack (7%) or a stroke (9%).\nThe current study followed 139691 adults aged between 35 and 70 years living in 17 countries from The Prospective Urban-Rural Epidemiology (PURE) study for an average (median) of four years.\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The outcomes highlighted in the release, including overall death rates and cardiovascular disease, are indeed important, as is evidence on ways of improving clinical practice. But we\u2019re\u00a0troubled by the\u00a0introduction of the concept of hand grip strength being a \u201cnew biomarker of aging\u201d \u2014 as if aging were some type of disease that we need better tools to diagnose and/or monitor. We\u2019ll rule it Satisfactory with some reservations.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "The story mentioned the hypothesis that increased folic acid consumption may be responsible for the increased incidence of colorectal cancer; it described this as an increase of 4-6 colorectal cancers per 100,000 people or an additional 15,000 new cases per year.\nThe story also mentioned several positive associations that have been observed with increased folate levels.", "answer": 1}, {"article": "Many practitioners and patients have turned to diet as a possible treatment, but many of the dietary recommendations have not been backed by clinical trials.The study, the largest of its kind, measured the degree of relief from low FODMAP, a frequently recommended diet, which stands for Fermentable Oligo-Di-Monosaccharides and Polyols.\nAnd unfortunately there is no cure.\nThere was also more improvement of other bothersome symptoms compared to the control group: bloating, diarrhea and stool urgency.\nOver a six-week process, registered dietitians educated and monitored the progress of more than 90 IBS patients.\n\u201cLow-FODMAP is not a new treatment, but we are now convinced that it really works,\u201d she says.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no evidence of disease mongering.", "answer": 1}, {"article": "D'Amico, chief of the Department of Plastic Surgery at Englewood Hospital and Medical Center in Englewood, N.J.\nAs bariatric surgery has grown more common (some 144,000 such procedures were performed in the United States in 2004, more than double the number in 2002), D'Amico says, patients seeking body contouring have \"started to show up in plastic surgeons' offices in large numbers.\"\nThe skin, she says, \"has been irreparably damaged by the stretch [and it] doesn't shrink down like the rest of the body does.\nBut there's a catch often not understood by those who undergo the procedure: Once they lose the weight the surgery helps them lose, there may be more surgery to come -- surgery that is costlier and riskier and that requires a longer recovery time than the original operation.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article presents body contouring after weight loss surgery as something inevitable. It turns excess skin into a disease that must be treated. While there are individuals for whom excess skin can develop into a situation that is of health concern, this is not always the case. Further, excess skin does not just occur after bariatric surgery but can be a consequence of loss of large amounts of weight even without a bariatric procedure. ", "answer": 0}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story commit disease-mongering?", "explanation": "To the reporter\u2019s credit, no disease mongering.", "answer": 1}, {"article": "That's according to a study just published in the journal CANCER.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nIt includes criteria like whether the doctor can feel a nodule through rectal examination, and whether a tumor is detected through a test called trans-rectal ultrasound.\nThe new study discrediting the test, coupled with persistent questions about how useful prostate screening is for most men anyway, add up to a whole lot of discussion points patients should take to their doctors.\n\"I use all those parameters to tell a patient what his chances of a good outcome are,\" Andriole says.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was an imbalance in the story in that it only discussed the perils of failing to treat prostate cancer aggressively enough because of a treatment course based on clinical staging.\u00a0 But the flip side is equally important and the story did not mention the pitfalls of treating a prostate cancer that was not destined to be problematic.\nSo, in effect, the story only focused on the aggressive prostate cancers but didn\u2019t remind readers that most prostate cancers are not.", "answer": 0}, {"article": "\"Results lend support to current national initiatives from the National Academies, White House, and bipartisan legislation requesting that the U.S. Food and Drug Administration create a new regulatory classification for hearing devices meeting appropriate specifications to be available over the counter,\" the authors write.\nThe researchers found that the change in accuracy in speech understanding from unaided to aided varied by device.\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\nA comparison between less-expensive, over-the-counter hearing assistance devices and a conventional hearing aid found that some of these devices were associated with improvements in hearing similar to the hearing aid, according to a study published by JAMA.\nA limitation of the study was the modest number of participants.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We didn\u2019t see anything alarming or overblown.", "answer": 1}, {"article": "Yet the study suggests the opposite has happened.\nThe drugs are benzodiazepines, which are widely known by their brand names Xanax and Valium and commonly prescribed to help treat anxiety.\nThe study found that among all opioid users, concurrent use of benzodiazepines more than doubled the risk of an emergency room or inpatient visit for a drug overdose.\nGiven that the opioid epidemic has quickly turned into the deadliest drug crisis in US history, it\u2019s important \u2014 and potentially lifesaving \u2014 for doctors and policymakers to at least consider the study\u2019s findings.\nThere\u2019s another type of prescription drugs, besides opioid painkillers, that\u2019s involved in thousands of drug overdose deaths in the US every year.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does some editorializing but accurately depicts the magnitude of the problem when it states that the opioid epidemic is the \u201cdeadliest drug crisis in U.S. history.\u201d", "answer": 1}, {"article": "And functional electrical stimulation is using low levels of electricity in order to activate nerves and muscles in order to restore movement,\" explains Dr. Hunter Peckham, director of the Cleveland F.E.S.\nis functional electrical stimulation.\n\"I had these two implanted electrodes here.\n\"Electrodes are implanted in the body.\n\"This is a multi-channel implantable device,\" Peckham explains.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story commit disease-mongering?", "explanation": "This story does not engage in disease-mongering. ", "answer": 1}, {"article": "For the work, a cohort of 541 9- to 11-year-olds in China, 54 percent boys and 46 percent girls, completed a questionnaire about how often they consumed fish in the past month, with options ranging from \"never\" to \"at least once per week.\"\n\"This area of research is not well-developed.\nChildren are sensitive to smell.\nThose whose meals sometimes included fish scored 3.3 points higher.\n\"Children should be introduced to it early on.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no evidence of disease mongering here.", "answer": 1}, {"article": "If all goes well, a genetic treatment for hemophilia B \u201ccould be available for widespread use in a couple of years.\u201d\n\nIn a trial in 2006, a patient injected with a corrective gene produced his own Factor IX but only for 10 weeks.\nThe designer of that treatment, Dr. Katherine A.\n\u201cWe are pretty close to the sweet spot,\u201d he said.\nDr. Nathwani and his team reported that they treated the patients by infusing the delivery virus into their veins.\nThe virus homes in on the cells of the liver, and the gene it carries then churns out correct copies of Factor IX.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering of hemophilia B.", "answer": 1}, {"article": "\"Our results demonstrate that [Opdivo] is more effective in treating patients with stage III and IV melanoma, cutting the risk of relapse by a third,\" lead researcher Dr. Jeffrey Weber, professor of medicine at NYU School of Medicine, said in a university news release.\n\"Results like this will change how we practice medicine.\nPatients were treated at 130 medical centers across 25 countries.\nIn some patients, the drugs are used in combination.\nThe U.S. National Cancer Institute has more on melanoma.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "For this case-control study, researchers recruited 5,307 colonoscopy patients, 60 percent of them men, at two Tennessee hospitals over a seven-year period ending in April 2010.\nAfter controlling for age, race, body mass index, smoking and other factors, the researchers found that women in the highest fifth for omega-3 consumption \u2014 those who consumed three or more servings of fish a week \u2014 were 33 percent less likely than women in the lowest fifth to have adenomatous polyps, a type likely to become cancerous.\nAll patients were interviewed about diet, health habits and medical history.\nThey found 2,141 people with polyps, leaving 3,166 polyp-free controls.\nThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable.\u00a0 In 223 words, there really wasn\u2019t much meaningful background given at all about colon polyps.", "answer": 2}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story commit disease-mongering?", "explanation": "The story repeats the commonly cited CDC statistics on people who are obese and overweight. It does not engage in disease-mongering.", "answer": 1}, {"article": "Campbell is one of only 14 people in the United States participating in an FDA-approved study of an artificial retina -- a microchip implanted in the eye to stimulate damaged cells.\nThe shape is communicated to the brain -- the idea being that Campbell might one day perceive some semblance of a shape of that tree.\n\"This is really the first step toward a really bionic eye,\" said Aries Arditi, a senior fellow in vision science at Lighthouse International, a nonprofit advocacy group for the blind and one of the study sites for the artificial retina.\n\"Being able to repair, in some way, a function that has been lost is a very exciting thing,\" Del Priore said.\n\"We can now take someone who is totally blind and turn them into someone with very, very poor vision,\" said Arditi, who trains Campbell weekly on how to nurture her vision.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the prevalence or impact of retinitis pigmentosa. The first few paragraphs use overly emotional language. But the condition is real, blindness is disabling and the story ultimately portrays the condition accurately. ", "answer": 1}, {"article": "Chinese manufacturers gave the first hint a week ago that one dose could be enough.\nThe dose question has an important ramification: It means people will have to line up for influenza vaccinations twice this year instead of three times \u2013 once for the regular winter flu shot and a second time to be inoculated against swine flu, what doctors call the 2009 H1N1 strain.\nThe winter flu vaccine is widely available now, and U.S. health authorities urged people to get it out of the way now before swine flu shots start arriving in mid-October.\nDespite all the headlines about swine flu, which has become the main influenza strain circulating in the world, doctors do expect some garden-variety flu to hit this fall too \u2013 the kind that every year kills 36,000 Americans and hospitalizes 200,000.\nCSL, which is one U.S. vaccine supplier, found the same side effects in its study that people experience with regular flu vaccine, which is no surprise since this shot is merely a recipe change from the annual standby.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n \nThe story reports that the seasonal flu \u201cevery year kills 36,000 Americans and hospitalizes 200,000\u201d and that H1N1 swine flu is already causing outbreaks in schools. As a result of reporting these disconnected facts, without also reporting anything about what is known about the severity of swine flu, readers may get the impression that there will be widespread swine flu deaths at schools, perhaps even concluding that if swine is likely to hit more people than seasonal flu, that the death toll could be higher than the 36,000 figure mentioned.\n Although there is a great deal of uncertainty about how many people will be hospitalized or die following swine flu infection, the story should have mentioned something about the outcomes seen so far.", "answer": 0}, {"article": "Lange said the findings should help make the process of diagnosing autism more scientific because it would rely on a test rather than a subjective assessment.\nThe test, which uses conventional magnetic resonance imaging or MRI machines, detected 94 percent of individuals with a high-functioning form of autism, they reported on Thursday.\nThey found that the brain circuitry is significantly different in those with autism compared to people with normal brain function, specifically in areas of the brain that are engaged in language and social and emotional functioning.\n\u201cThese results are the best yet in the search for a biological basis in terms of being able to distinguish those with and without the disease,\u201d said Nicholas Lange of Harvard Medical School, who directs the Neurostatistics Laboratory at McLean Hospital in Belmont, Massachusetts.\nAutism disorders are diagnosed in one in 110 children in the United States and affect four times as many boys as girls.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease-mongering. Like the CNN story, the story correctly notes that 1 in 110 children in the US potentially has an autism spectrum disorder according to the CDC.", "answer": 1}, {"article": "Before Starting A Statin, Talk It Over With Your Doctor\n\nA study published Monday is pushing back against the notion that up to 40 percent of Americans should be taking statin drugs to reduce the risk of heart disease.\n\"The elderly do not benefit as much as previous studies might have thought,\" he says.\n\"One size doesn't fit it all,\" he concludes.\n\"In our approach we very explicitly considered the harms.\"\n\"That's a very important message.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering here.", "answer": 1}, {"article": "NEW ORLEANS \u2014 Eighty-year-olds with clogged arteries or leaky heart valves used to be sent home with a pat on the arm from their doctors and pills to ease their symptoms.\nThis improved dramatically as the study went on, from 85 percent in the early years to 98 percent by its end.\nThat led more doctors to operate on older patients for everything from bum knees to bad backs.\nOverall, 90 percent survived their surgery to leave the hospital.\nTreatment guidelines by the heart association and other groups do not have age cutoffs for such operations.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "But Miller says the experiment also seemed to show they were beginning to repair the patients\u2019 immune systems.\n\u201cThere is nothing rare or exotic or strange here,\u201d said NIBIB\u2019s Heetderks.\nThe particles are easy to produce, he said.\nHowever, it was hideously expensive.\n\u201cIt cost probably about a million dollars to treat 10 patients using live cells,\u201d he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story.", "answer": 1}, {"article": "For the new analysis - the first of its kind - the research team looked at dietary data from 160,191 women and assigned inflammation scores based on 32 food components that the women reported consuming in the three months prior to their enrollment.\nThis was despite the fact that they started off with lower bone density overall.\nEnrollment ran from 1993 to 1998.\nFracture data was collected for the entire study group.\n\"This suggests that as women age, healthy diets are impacting their bones,\" Orchard said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release.", "answer": 1}, {"article": "Representative Rosa DeLauro, Democrat of Connecticut, said that the new guidelines would have no effect on federal policy and that \u201cRepublicans are using these new recommendations as a distraction.\u201d\n\n\u201cMaking such arguments, especially at this critical point in the debate, merely clouds the very simple issue that our health reform bill would increase access to care for millions of women across the country,\u201d she said.\nIt is by no means clear that doctors or patients will follow the new guidelines.\nOnly some people who are exposed to it develop cancer; in most, the immune system fights off the virus.\nIf cancer does develop, it can take 10 to 20 years after exposure to the virus.\ninfection or having an organ transplant or other condition that would lead to a suppressed immune system.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does nothing to exaggerate the prevalence or severity of cervical cancer. ", "answer": 1}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\nExcitement is spreading as oncologists learn about the findings.\nA manmade virus-like vector is used to transfer special molecules to the T cells.\nThe treatment uses a form of white blood cells called T cells harvested from each patient.\n\"Within three weeks, the tumors had been blown away, in a way that was much more violent than we ever expected,\"June says in a news release.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "In January, Bayer announced that the U.S. Food and Drug Administration (FDA) had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\nPreviously, no treatment was available for these patients.\"\nIn this trial, regorafenib was well-tolerated with manageable adverse events, according to the paper in Lancet.\nTwo patients treated with regorafenib had their tumor shrink to an undetectable level, according to the study.\nDr. Llovet was a member of the clinical trial's steering committee, and Charissa Chang, MD, Assistant Professor of Medicine and Liver Diseases at the Icahn School of Medicine, was principal investigator of the Mount Sinai testing site.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "This decrease was largely confined to women with hormone receptor-negative tumors and women who were not treated with anti-estrogen therapy such as tamoxifen (which blocks the effects of estrogen).\nA free abstract of this article will be available via the Cancer News Room upon online publication.\nIn contrast to some previous research, high levels of isoflavone intake were not associated with greater mortality among women receiving hormonal therapy.\nNOTE: The information contained in this release is protected by copyright.\nFor more than 200 years, we have delivered consistent performance to our stakeholders.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release also provides useful context.", "answer": 1}, {"article": "Page has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nAll participants passed safety tests including liver and kidney health checks.\nThe study was funded by the National Institutes for Health.\nThis article has been updated to include more information on DMAU.\nThey found testosterone and two hormones needed for the production of sperm were notably suppressed in men who took the highest dose of DMAU.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Lozano acknowledges that retrieving childhood memories, which he says has occurred in about one-third of his patents \u2014 requires lofty voltages that he would be uncomfortable sending patients home on.\nGlucose is our brains' primary fuel.\nWith increasing voltages, his memories became more vivid, including remembering their clothes.\nMore intriguing for now were comparisons of glucose utilization.\nLike in Lozano's study no serious side effects were seen.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "By accurately describing the seriousness and prevalence of lung cancer, the story avoids disease mongering. However, the story verges on \"treatment mongering\"\u00a0by compared lung cancer screening to the \"many cures\" from\u00a0prostate cancer screening, which has\u00a0not been shown to save lives. Furthermore, the story inappropriately highlights a patient with a cough, a symptom of lung cancer, who went on to die of the disease.\u00a0First, it is\u00a0not clear if doing the CT scan in this patient would have prolonged his life and second, this example highlights the use of CT for diagnosing lung cancer, not screening for lung cancer in people who do not have symptoms. These are very different concepts.", "answer": 1}, {"article": "\"What we found is that kids get home from school around 4 p.m.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\n\"We'd like to think it's preventable, but from where I sit right now, there hasn't been a lot shown to be very effective on a large scale.\"\nThe 12-week study was conducted by researchers at the University of Houston Department of Health and Human Performance (HHP), Baylor College of Medicine and Texas Woman's University.\nHispanic middle school children, at high risk for being overweight or obese, reduced their Body Mass Index (BMI) when they adhered to a nutrition intervention that included a snack of peanuts, compared to those children who did not.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering, but the quotes from the lead researcher used in the release made a lot of assumptions about the study population\u2019s lack of supervision, \u201cstructure\u201d at home, inactivity and eating habits without providing supporting evidence.", "answer": 1}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in the story.\nIf anything, the story missed a chance to explain that according to the CDC, almost half a million emergency department visits for concussions and other traumatic brain injuries are made annually by children aged 0 to 14 years.", "answer": 1}, {"article": "Newswise \u2014 Omega-3 fatty acids may lower the risk of breast cancer in postmenopausal obese women, according to researchers.\nSome epidemiological data supports the idea that omega-3s protect against breast cancer, but the findings have been inconsistent.\nThe researchers plan to test the effect of DHA alone in obese subjects, potentially in combination with weight loss, in a future trial.\nAlthough Lovaza contains both of the fatty acids DHA -- 375 milligrams -- and EPA -- 465 milligrams, only DHA blood levels were associated with breast density reduction.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease-mongering.", "answer": 1}, {"article": "COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.\nPatients in this trial were not selected by PD-L1 expression but the study did find that those with higher PD-L1 had a higher response.\nThese showed progression-free survival was 4.2 months with Opdivo and 5.9 months with chemotherapy, although the difference was not statistically significant.\nKeytruda, as a sole agent, was targeted only at patients with high PD-L1, making them more receptive to immunotherapy.\nThe second trial, mixing Keytruda with chemotherapy, was much smaller but was notable because it was the first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not disease monger. Non-small cell lung cancer is an often lethal disease.", "answer": 1}, {"article": "Since amniocentesis carries a small risk of spontaneous miscarriage \u2014 Patsalis put it at around one or two percent \u2014 scientists have been looking for new less invasive ways to test for Down\u2019s and other potential genetic problems.\nIt involves taking a small amount of blood from the mother when she is between the 11th and 13th week of her pregnancy and detecting extra copies chromosome 21 in the fetus by analyzing the maternal blood.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nPatsalis\u2019 method takes advantage of differences in the DNA methylation patterns \u2014 which are important to control levels of genes \u2014 between mother and fetus.\n\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "I would be in my 60s when I had to do this again, and who wants to have surgery unnecessarily when you are 60 something?\"\nAs many as half of patients will need to have additional surgeries or have the implants removed in the first decade.\nHer doctor immediately recommended removing them, which she did.\nFor years afterward she felt ill, suffered multiple bouts of pneumonia, had trouble breathing and pain in her chest.\nDoctors reassured her it wasn't her implants.\n", "question": "Does the story commit disease-mongering?", "explanation": "It would be difficult to oversell the caveats in this story; the article presented dramatic, significant concerns.\n", "answer": 1}, {"article": "The research was published online Wednesday in the journal Cancer and is to be presented at the American Society of Clinical Oncology's annual Breast Cancer Symposium, which starts Friday in National Harbor, Md.\nThe findings will no doubt do little to quell a controversy that has existed since the 1980s over the value of mammography screenings for women in their 40s.\nThat recommendation met with outrage from breast cancer specialists, while other organizations, including the American Cancer Society, continued to recommend annual mammograms for women in their 40s.\nThe benefits were greater in women aged 45 to 49, vs. those aged 40 to 44, the researchers said.\nIn all, more than 1 million women were involved in the study and the follow-up period was a lengthy 16 years.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story does provide the NNT (number needed to treat)\u00a0 to place mortality risk in context here: i.e. screening 1,250 women five times over a 10-year period would save one life. ", "answer": 1}, {"article": "In 2014, a review[2] suggested that there is probable efficacy (a level A recommendation) for short-term rTMS treatment of neuropathic pain, including central post-stroke pain, but did not speak to long-term efficacy.\nPain relief was sustained in six patients who continued treatment for one year.\nData were collected for eight years, ending in 2014.\nIn this second phase, the 18 patients underwent 12 weekly rTMS sessions.\nOf 18 patients in the open-label series, 11 patients achieved satisfactory-to-excellent pain relief.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No obvious mongering here. \u00a0Post-stroke pain is serious.", "answer": 1}, {"article": "\u2022 Surgery should be followed by intraperitoneal, or localized, chemotherapy delivered to the abdomen.\n\"For decades, women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced-stage ovarian cancer, but there are many survivors as well,\" said Dr. Narod, senior scientist at Women's College Research Institute.\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\nUp to half of women with advanced-stage ovarian cancer might be cured, compared to the current 20 per cent survival rate, argues Dr. Steven Narod, senior scientist at Women's College Research Institute, who calls for a new standard of treatment for women with late-stage ovarian cancer.\nBased on an analysis of existing evidence, published in an opinion article in the Nature Reviews Clinical Oncology journal on January 20, Dr. Narod argues that to achieve a cure, rather than simply delay progression or reoccurrence of the disease, women should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release takes a balanced tone when discussing late-stage ovarian cancer. However, we always like to see some broader context of where a disease falls in terms of incidence, survival rates, etc.", "answer": 1}, {"article": "TUESDAY, Oct. 6, 2015 (HealthDay News) -- Cancer patients who have ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study finds.\nAverage age of the first transplant was 33.\nIn six cases, it was more than eight years.\n\"It remains to be seen which method is better.\"\nThirty-two of the women attempted pregnancy.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "LOS ANGELES (EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT ) - Cardiac stem cell infusions could someday help reverse the aging process in the human heart, making older ones behave younger, according to a new study from the Cedars-Sinai Heart Institute.\nCedars-Sinai and Marb\u00e1n have financial interests in Capricor.\n\"Now we find that these specialized stem cells could turn out to reverse problems associated with aging of the heart.\"\n\"They secrete tiny vesicles that are chock-full of signaling molecules such as RNA and proteins.\n\"The way the cells work to reverse aging is fascinating,\" Marb\u00e1n said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease mongering here.", "answer": 1}, {"article": "Newswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nThe first statistically significant reduction in depression severity with brexanolone injection relative to placebo was observed as early as 24 hours after dosing.\nA unique dose group of brexanolone 60 \u00b5g/kg/hr in one of the studies was not included in the integrated efficacy analysis, but was included in integrated analyses of safety.\nA New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation.\nThe reduction of symptoms in the patients receiving brexanolone injection was maintained throughout the last study visit at Day 30.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering. The release explains how common postpartum depression is worldwide.", "answer": 1}, {"article": "The investigators found that in the vaccinated group, 86 percent of patients showed a significant response, compared with 27 percent of those in the \"control\" group who did not get the injection.\n\"Whether it actually has an increase in survival remains to be seen,\" he said.\nStill, the study remains very preliminary, he cautioned.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\nPhase 3 studies are needed before the vaccine could be approved.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of HER2-positive breast cancers.", "answer": 1}, {"article": "In the study, published in the Proceedings of the National Academy of Sciences, researchers examined the effects of POPG on RSV infection in human lung cells in the lab and in mice infected with the virus.\nThere is no vaccine or easy, effective treatment for RSV.\nThey found that inoculating human lung cells with POPG before exposure to RSV prevented infection with the virus as well as the cell death and inflammation normally associated with RSV infection.\nThe findings also suggest that POPG\u2019s role in the lungs may be to help the lungs tolerate the daily barrage of inhaled irritants.\nApplying POPG to the cells after RSV infection also inhibited the spread of the virus to neighboring healthy cells.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story gives appropriate background about respiratory syncytial virus (RSV) infection. ", "answer": 1}, {"article": "In the current analysis of treatment between 6 and 24 hours after symptoms were observed, or after the person was last seen to be well, researchers found:\n\u2022 each 1-hour delay reduces the chance of recovery with minimal or no disability by 11 percent; and\n\u2022 treatment remains beneficial through 24 hours, with patients who had their clots removed being 35.5 percent more likely to have minimal or no disability 90 days later, but the overall effect of treatment declines with time.\nFollow us on Facebook and Twitter.\nThe association has strict policies to prevent these relationships from influencing the science content.\nTo learn more or to get involved, call 1-888-4STROKE or visit StrokeAssociation.org.\n.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Along with Hernandez, CTE has been diagnosed in San Diego Charger and Hall of Famer Junior Seau, as well as the Philadelphia Eagles' Kevin Turner and the Oakland Raiders' Ken Stabler, to name a few.\nThese are critical next steps,\" she said.\nNew research released Tuesday may make that possible.\nAn early step in the right direction\n\nMcKee also cautioned that this is still early research.\nIt is believed to result from repeated trauma to the head, which causes a buildup of the abnormal protein tau which clumps in the brain.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "So, how best to reach these targets?\n\"This is a really important study ... [suggesting] that the more fiber you eat during your high school years, the lower your risk is in developing breast cancer,\" says Kimberly Blackwell, a breast cancer specialist at the Duke Cancer Center.\nGiven the known benefits of high-fiber diets and the growing evidence that fiber may play a role in preventing disease, the government's Dietary Guidelines for Americans also say most people need to consume more.\nThe researchers found that women who consumed high levels of fiber (28 grams per day, on average) had a 24 percent lower risk of developing breast cancer before menopause, compared with women who ate low levels of fiber (14 grams per day, on average).\nFor instance, high-fiber diets may reduce the risk of breast cancer by improving insulin sensitivity, since fiber can slow down the absorption of sugars and help keep blood sugar levels more stable.\n", "question": "Does the story commit disease-mongering?", "explanation": "In its second paragraph, the story says \u201c\u2026if you\u2019re skimping on fiber, the health stakes are high, especially if you\u2019re a teenage girl.\u201d That\u2019s scary language. This study is an interesting one, and possibly an important one, but it is also just one study addressing one risk factor for one disease. Granted, breast cancer is a scary disease. But the language here appears to be unduly alarming about the consequences of not eating a fiber-rich diet as a teenager.\u00a0Also, since the absolute risk reduction is 0.2 percentage point there is no cause for alarm here.", "answer": 0}, {"article": "\"This is [similar] to the effect that we and others have shown for [cholesterol-lowering] statins,\" he said, noting that \"bisphosphonates and statins share the same metabolic pathway.\"\nThese drugs work by increasing bone thickness, thereby reducing the risk of fractures, the researchers said.\nIn prior studies, bisphosphonates have already been shown to be associated with a reduced odds for breast cancer.\nFor more information on colon cancer, visit the American Cancer Society.\nFortunately, there are other proven ways to help lower risk of colorectal cancer, he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Neither story engaged in disease-mongering.", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering or suggest that women should opt for mammograms at centers that have the new CAD technology. ", "answer": 1}, {"article": ".\nThe only drug currently approved for Huntington's is tetrabenazine, which treats only involuntary movements and can cause serious side effects.\nThe participants took either pridopidine (45 milligrams once daily or 45 mg twice daily) or a placebo for 26 weeks.\nAnd, though the compound is apparently well tolerated without significant side effects, the benefit is modest and limited to the motor symptoms of the disease and it is unknown how long the improvement observed could last,\" he added.\n\"There has been a great deal of attention for this drug, as it is one of the few molecules that in preliminary studies was found to have some efficacy in Huntington's disease,\" said Dr. Alessandro Di Rocco, professor in the department of neurology and chief of the division of movement disorders at NYU Langone Medical Center in New York City.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is not any disease mongering, but the article does not provide much background information on Huntington\u2019s disease, regarding its epidemiology, risk factors and treatments. However, the story does mention dopamine and its role in movement and coordination.", "answer": 1}, {"article": "Another conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.\nThe study also challenges concerns about neurotoxicity and a recent hypothesis that patients must experience hallucinations during ketamine infusion in order to have an anti-depressant benefit.\nThe study, \"Practical application of the neuroregenerative properties of ketamine: real world treatment experience,\" addresses key points in the controversy surrounding the use of intravenous ketamine for the treatment of depression.\nEvidence points to the regeneration of brain cells as a critical mechanism for the relief of depression, as published in peer-reviewed journal Neural Regeneration Research, February 2016 issue.\nKetamine infusion therapy, the controversial treatment for depression, has been resisted by many physicians due to concerns about short-lived benefits, risks of addiction, and the lack of large scale studies.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t define depression or give any sense of its prevalence or impact. So while it doesn\u2019t disease-monger, we\u2019re hesitant to give the release credit here. We\u2019ll call it Not Applicable.", "answer": 2}, {"article": "March 20, 2011 -- Elevated levels of a group of five amino acids may predict the development of diabetes years before any noticeable symptoms occur, according to a new study.\nFor example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "Others have such high cholesterol that taking statins alone is not enough.\n\"It seems that the group that takes them, compared to the group that doesn't, has half the rate of cardiovascular events and mortality as those that don't,\" Dr. Seth S. Martin of the Johns Hopkins School of Medicine told CBS News.\nThese new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nBut some patients can't tolerate the side effects, which can include headache, difficulty sleeping, muscle aches, diarrhea, constipation and nausea or vomiting.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering, although the story\u2019s suggestion that 1 in 6 Americans \u201clives\u201d with high cholesterol \u2014 as if that were a disease in and of itself \u2014 gets close to the line.", "answer": 1}, {"article": "But he also emphasized the structured nature of the program tested in his study.\nIn general, \"mindfulness\" practices encourage people to focus their attention on the present moment, instead of the past or future, and to take an objective look at their thoughts and emotions.\n\"It'll be interesting to see whether people can learn mindfulness techniques, then see durable effects,\" he said.\nIt asked a range of questions -- including whether the person had problems falling asleep or staying asleep, had difficulty breathing at night, or felt drowsy during the day.\nBy the end of the study, the mindfulness group was showing a significant improvement -- shaving about three points, on average, from their scores on the sleep-problem scale.\n", "question": "Does the story commit disease-mongering?", "explanation": "It\u2019s common to see stories about sleep spun out of control \u2014 i.e. losing sleep can kill you/ruin your life/make you sick/etc. It was nice to see this trope avoided.", "answer": 1}, {"article": "AIDS researchers have rejected the approach on any kind of scale for patients with HIV.\n\u201cIt\u2019s not practical and it can kill people,\u201d said Dr. Robert Gallo of the Institute of Human Virology at the University of Maryland, who helped discover the human immunodeficiency virus that causes AIDS.\nNearly four years after the transplant, the patient is free of the virus and it does not appear to be hiding anywhere in his body, Thomas Schneider of Berlin Charite hospital and colleagues said.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\nWASHINGTON (Reuters) - German researchers who used a bone marrow transplant to treat a cancer patient with the AIDS virus, have declared him cured of the virus \u2014 a stunning claim in a field where the word \u201ccure\u201d is barely whispered.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.\u00a0The story does point out the staggering number of people worldwide (33 million) infected with the AIDS virus.\u00a0We would have liked to have seen some mention of the number of people who more closely resemble this patient, having both HIV infection and a type of leukemia that might be treated with a bone marrow transplant.", "answer": 1}, {"article": "The hospital recently received the green light from federal authorities to start the first ever human trial of DBS for stroke, and plans to announce Tuesday that it will perform the procedure as soon as an initial patient is identified.\nDepending on how the first procedure goes, the hospital will enroll more people into its trial.\nAbout 87% of all strokes are this type.\nDBS has never been used on humans as a way to regain a function.\n\u201cWhen we are treating stroke, we are really trying to make movement come back.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering of stroke in the story.", "answer": 1}, {"article": "\"But the [overall] rate of invasive breast cancer diagnosis was no different with or without CAD,\" Fenton said.\n\"It has the potential risk of a false-positive mammogram.\nAnd the technology makes mammograms more expensive.\nThe CAD software looks for areas that may indicate cancer so the radiologist can then look more closely at the mammogram.\nSo is the new computer technology worth it?\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "\"Our concern is there are so many CT scans being done right now that we should really be starting to think: Do we need to all of these CT scans?\"\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\nThe dose depends on the type of machine and the person - obese people require more radiation than slim ones - and the risk accumulates over a lifetime.\n\"The CT scan is a wonderful tool for examining internal organs, organs that are below the depth of where a poking finger or a listening stethoscope can hear, and yet don't show up on routine X-rays,\" Dr. Michael Brant-Zawadzki, a clinical professor of radiology at Stanford University tells CBS News.\nA previous study by the same scientists in 2001 led the federal Food and Drug Administration to recommend ways to limit scans and risks in children.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story reported that the article it discussed estimated that the percentage of cancer caused by CT scans will increase from 0.4% to 2.0%.\u00a0 It did not, however explain that the content was extrapolated from epidemiological data and estimation of radiation doses.\nIt would have been useful to provide a framework to understand the relative significance of the reported on\u00a0increase in number of cancers.\u00a0 How does it compare, for example to the numbers of cancers due to cigarette smoking?", "answer": 1}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t exaggerate the seriousness or prevalence of partum depression.", "answer": 1}, {"article": "This data is clinically significant.\n\"The sTMS may be a great option for these patients and allow doctors to better meet their unique needs.\"\nThe eNeura SpringTMS Post-Market Observational U.S. Study of Migraine study, also known as ESPOUSE, instructed participants to self-administer four pulses with the device in the morning and four pulses at night over three months to prevent and treat migraine attacks as needed.\n\"Our study demonstrated that the four pulses emitted from this device twice daily reduce the frequency of headache days by about three days per month, and 46 percent of patients had at least 50 percent or less migraine attacks per month on the treatment protocol.\nMigraine symptoms, which can be debilitating for many people, are the sixth leading cause of disability, according to the World Health Organization.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering.\nThe news release clearly establishes that migraine headaches are the \u201csixth leading cause of disability, according to the World Health Organization.\u201d", "answer": 1}, {"article": "Another method involves a specially designed treadmill tank.\n\u201cI personally prescribe it for knee issues and low back issues.\u201d\n\nHydrotherapy uses a water-friendly treadmill that can be placed in a pool.\nIt\u2019s also an easy-on-the joints form of exercise for seniors and others who suffer from arthritis, and a recent study shows it can speed recovery from stroke faster than using a traditional treadmill.\n\u201cThe study proposes a different, very innovative approach\u201d to rehabilitation after stroke, said Dr. Gisele Wolf-Klein, director of geriatric education at Northwell Health in Great Neck, New York.\n\u201cIt\u2019s a very pleasant way of achieving exactly what you\u2019re trying to do \u2013 allowing a cardio-respiratory response,\u201d Wolfe-Klein told CBS News.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. Though, the story implies that this form of therapy can be used for just about any condition where treadmill or bike treatment is indicated. So not disease mongering, but possibly treatment mongering.", "answer": 1}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story commit disease-mongering?", "explanation": "No over-the-top language to describe Alzheimer\u2019s disease or other dementia conditions.", "answer": 1}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "It is an oral, small-molecule drug that is different from current biologic therapies, such as infliximab [Remicade], adalimumab [Humira], golimumab [Simponi] and vedolizumab [Entyvio],\" Friedman said.\nOnly 11 percent of patients on placebo saw a remission.\nSymptoms include diarrhea with blood or pus and abdominal discomfort, according to CCF.\n\"There is still a substantial unmet need for new treatments for patients with ulcerative colitis,\" said study lead author Dr. William Sandborn.\nForty percent of those taking a 10-mg dose of the drug had remission at a year.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. The story accurately describes the prevalence and symptoms of ulcerative colitis.", "answer": 1}, {"article": "CHICAGO (Reuters) - A study in rats and monkeys suggests an experimental Merck & Co sleep drug may help induce sleep without causing the memory loss and attention problems sometimes seen in the commonly used drugs Ambien and Lunesta, company researchers said on Wednesday.\nLevels of this compound rise during the day and fall at night.\nThe most common side effects from Suvorexant have been headache and sleepiness.\nFor this study, the team wanted to find out what would happen if someone is awakened on this drug and has a very high level of it in their system.\nIn the study, rats given GABA blockers were less likely to recall the objects than those given DORA-22.\n", "question": "Does the story commit disease-mongering?", "explanation": "The medical literature contains a wide range of insomnia estimates. The 10% figure used in the story matches many estimates.", "answer": 1}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story commit disease-mongering?", "explanation": "We think that statements such as, \u201cAnd one major study suggests that even people with minimal risk factors in their late 50s and early 60s should have the test\u201d and \u201cBut genetic factors can also contribute to elevated CRP in people without traditional risk factors\u201d would leave many readers with the impression that just about everyone needs to have the test performed.\nFor the record, the US Preventive Services Task Force states: \u201cThe U.S. Preventive Services Task Force (USPSTF) concludes that the evidence is insufficient to assess the balance of benefits and harms of using the nontraditional risk factors (including\u00a0high-sensitivity C-reactive protein \u2013 hs-CRP) \u2026to screen asymptomatic men and women with no history of CHD to prevent CHD events.\u201d ", "answer": 0}, {"article": "For those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\nThe women ranged in age from 49 to 83 years.\nOver the next decade, there were 1,549 strokes, and the more chocolate women ate, the lower their risk.\nNearly 800,000 Americans suffer a stroke every year, with about a sixth of them dying of it and many more left disabled.\nSOURCE: bit.ly/qhsaZ0 Journal of the American College of Cardiology, October 10, 2011.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering.", "answer": 1}, {"article": "Patients were randomised to receive the combination of anti-TNF\u03b1 and anti-IFN?\nFlorence, Italy - 9 July 2016: Immunotherapy reduces cardiovascular risk in patients with rheumatoid arthritis, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2016 by Professor Aida Babaeva, head of the Department of Internal Medicine, Volgograd State Medical University, Volgograd, Russia.1 The combination of two extra-low dose anticytokine drugs reduced rheumatoid arthritis disease activity and cardiovascular events.\nFor example, rheumatoid arthritis is associated with dysfunction of the blood vessel lining (called endothelium), which leads to lipid accumulation in the artery wall, plaque formation and atherosclerosis.\nShe concluded: \"We do not think that all patients with rheumatoid arthritis should be treated with this combination.\nIn patients with highly active disease, the standard biologics are better at preventing severe complications such as progressive joint destruction and/or systemic manifestations (vasculitis, uveitis, involvement of internal organs).\n", "question": "Does the news release commit disease-mongering?", "explanation": "No obvious disease mongering here. We would caution that whenever a drug study encourages physicians to prescribe the drug more often, particularly in patients with mild disease, it could be construed by some observers as disease mongering.", "answer": 1}, {"article": "Scientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\nMoreover, the scientists \u2013 together with colleagues in Barcelona and from the CIMBA* consortium mapping more than 23,000 women \u2013 showed that genetic variants in the RANK gene are associated with a higher risk of developing breast cancer in women who carry BRCA1 and also BRCA2 mutations.\nIn 2010, Josef Penninger, the scientific director of IMBA in Vienna and his team have shown that sex hormones can trigger breast cancer (Schramek et al., Nature) through proteins called RANKL and its receptor RANK, which are key factors in bone metabolism.\nUntil now, prophylactic surgery is the only procedure which significantly reduces the breast cancer risk, but which is also often associated with postoperative complications.\nBased on our discovery, the already approved drug Denosumab or other future drugs that will block RANKL/RANK, could be used for breast cancer prevention in BRCA mutation carriers,\" explains Verena Sigl.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t exaggerate (or sugar coat) the risk of breast cancer. And yet it does seem to \u201cdrug monger\u201d a bit by pressing the idea that denosumab could be a preventive \u201cfor everyone\u201d even though the research is clearly limited to mice and cell cultures with the BRAC1 or BRAC2 gene.", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story commit disease-mongering?", "explanation": "The text makes it clear that internet-based therapies may be more valuable for individuals with mild to moderate depression than for persons with severe depression, who would be more likely to seek face-to-face therapy regimens.\nBut, in a word of caution, does that encourage people to overdiagnose themselves? That\u2019s something to consider.", "answer": 1}, {"article": "The development of olaparib, which is now owned by AstraZeneca, was underpinned by scientific research carried out with funding from Cancer Research UK at The Institute of Cancer Research (ICR) and the University of Cambridge, and clinical trials led by the ICR and The Royal Marsden, and other institutions in the UK and overseas.\nIt is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.\nIt provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease.\nMost of these men, who all had terminal prostate cancer with limited treatment options, had disease control lasting much longer than expected in this group of patients.\nA total of \u00a362 million is being provided over five years, to support pioneering research work, and is being shared out over eight different cancer themes.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The subset of men in this study were dying of prostate cancer. There was no disease mongering about their condition.", "answer": 1}, {"article": "Without limiting the generality of the foregoing, words such as \"may\", \"will\", \"to\", \"plan\", \"expect\", \"believe\", \"anticipate\", \"intend\", \"could\", \"would\", \"estimate\", or \"continue\", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.\nThe healed tear could not be penetrated by the probe.\nThe patient experienced very little downtime and was able to resume normal activities in less than 1 week.\nDuring the 12-month follow-up period, the patient reported a reduction in pain and an improvement in knee function.\nThe arthroscopic images showing resolution were also consistent with quality of life improvements for the patient, including a reduction in pain and resumption of normal activities.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering apparent here. The release provides some context regarding the incidence of torn meniscus.", "answer": 1}, {"article": "\"Oh, definitely.\nThe hope is that if PRP can get an elite athlete like Bornstein up and running, it can help the baby boom generation and their creaky joints get back in the game.\n\"I knew something was wrong, and I knew that I was going to have to take some time to heal,\" Bornstein says.\nHe would be out of action for six to 10 weeks, CBS News medical correspondent Dr. Jon LaPook reports.\nThe hope is that the same technology that allowed Bornstein to get back on the field so quickly can now be used to treat injuries in weekend warriors as well.\n", "question": "Does the story commit disease-mongering?", "explanation": "The anchor lead-in \u2013 the \"hook\" for the story \u2013 commits egregious disease-mongering.\u00a0 It says \"Every year, Americans make 15 milion visits to doctors because of knee pain and recovering from surgery can take months.\"\u00a0 Then, without qualification, it connects that number to the story by saying \"But a new, non-surgical treatment could get you up and running in record time.\"\u00a0 The clear implication is that this very preliminary approach could be answer for the 15 million visits per year.\u00a0 That number begs explanation and qualification, which was not provided. \u00a0 \n\u00a0\n\u00a0", "answer": 0}, {"article": "\"You don\u2019t want to go screening people for hallmark (cancer) mutations unless you absolutely know that when you find it, that there is a tumor there and that it is a tumor that needs to be treated,\" said Wyndham, who was not involved in the study.\nCancer screening is still often a tricky issue.\n2 killer overall in the United States.\nSeveral different liquid biopsies are already on the market, used to help track whether cancer treatments are working.\nAnd then it will have to be shown that using the test allows doctors to intervene sooner and help people.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "The study was supported by the National Institutes of Health (grants F32 GM114948 and CA041101).\nThe new study shows that scientists can make a third modification\u2014which interferes with a bacterium\u2019s cell wall in a new way\u2014with promising results.\nThe next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps.\nCombined with the previous modifications, this alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.\nThis suggests bacteria already have a hard time overcoming vancomycin\u2019s original \u201cmechanism of action,\u201d which works by disrupting how bacteria form cell walls.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release provides some useful context about vancomycin\u2019s 60-year run as an antibiotic. ", "answer": 1}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story commit disease-mongering?", "explanation": "The story does nothing to exaggerate the risks or emotional aspects of elective c-sections. ", "answer": 1}, {"article": "PITTSBURGH, June 2, 2016 - Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute (UPCI) professor revealed.\nNearly 42 percent of the women who received surgery lived to five years after diagnosis, compared with less than 25 percent of the women who did not receive surgery.\n\"Our thinking is similar to how you might approach a battle against two enemies,\" said Dr. Soran.\nAt about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts who received standard therapy alone.\nDr. Soran began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this release.", "answer": 1}, {"article": "Though the system is in the prototyping stage, it could eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes and helping health centers with fewer resources offer easy, cheap testing.\nInfertility affects up to 12 percent of the male population worldwide.\nHis team\u2019s new approach aims to change that with a simple and inexpensive at-home test option.\nThe testing kit also includes a tiny weight scale that connects wirelessly to the testing app and measures the total number of sperm swimming in the sample.\nThe researchers tested the device on 350 clinical semen specimens in Massachusetts, including both trained and untrained users in their trial.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s\u00a0no mongering\u00a0or\u00a0scary language here, and the story discusses the global prevalence of male infertility.", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story commit disease-mongering?", "explanation": "It did not disease monger.", "answer": 1}, {"article": "Rosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nOnly children who really had ear infections were included in the trials.\nHe, too, has been eagerly awaiting the results of these 2 studies.\nIn treatment outcomes for pain, there was no difference, he notes.\n\"Parents and doctors need to understand what the benefits and what the downside of treatments are.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering in this story.", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story commit disease-mongering?", "explanation": "Does not appear to overtly disease monger.", "answer": 1}, {"article": "Some Wall Street analysts are betting that products like Absorb will allow companies to raise prices and boost revenue.\nAmid these concerns, Abbott and others began developing dissolving stents that would slowly melt away like stitches, presumably reducing complications.\nHospitals often bill $30,000 for stenting procedures, which includes the costs of the stent, medical staff and other equipment and services.\nCurrently-available stents are permanent, mesh-wire tubes that hold open arteries after a procedure used to clear fatty plaque.\nExperts describe Abbott's device as an important step in finding a better approach to treating the leading cause of death in the U.S.\n\n\"This is presumably a better technology going forward, at least that's the theory, but it will take years to prove,\" said Dr. George Vetrovec, professor emeritus at Virginia Commonwealth University.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. Permanent mesh stents have complications, so the search for an alternative is useful.", "answer": 1}, {"article": "Without such interactions, language and social skills do not develop.\n\"The [brains of] children who received the ESDM looked virtually identical to typical 4-year-olds,\" Dawson says.\nThe treatment, dubbed Early Start Denver Model or ESDM, offers a child 20 hours a week of one-on-one treatment with a trained therapist.\nAs measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\n\"We jump-started and improved the responses of children's brains to social information,\" says Dawson, professor of psychiatry at the University of North Carolina and chief science officer at Autism Speaks.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story receives kudos on this count. There are very few stories about autism that do not spend time trying to alarm parents about the rising number of cases. There is more fear and mistrust around autism than most childhood disorders, in part because of the constant drumbeat that the numbers are on the rise and that your child could be next. More reporters should take the straight forward approach that WebMD has taken here.\n\u00a0", "answer": 1}, {"article": "The game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\n\u201cThis proof-of-concept study...demonstrates that the memory game can help where drugs have so far failed.\nThere is increasing evidence that computer-assisted training can help people with schizophrenia overcome some of their symptoms, with better outcomes in their daily lives.\nSchizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\nImportantly, the patients also said they enjoyed the game and were motivated to play it across the eight hours of cognitive training.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Beaumont's Radiation Oncology department is ranked among the nation's best for advanced technology, innovative treatment and research.\nI felt that gave me the best chance of success.\nThere was photon therapy available in San Francisco, but, in my research, I found out the photon beams don't stop at the tumor and have a greater possibility of affecting surrounding organs, too.\nIt is the only operational proton therapy center in Michigan.\nLike a pencil, the beam uses back and forth motions to target the treatment area \u2013 the shape, size and depth.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release provides useful background on the prevalence of sacral chordoma.", "answer": 1}, {"article": "Current treatments target the immune cells involved in the disease and none are specific for FLS.\n\"Although these results are promising, much more research needs to be conducted before we can use scorpion venom components to treat rheumatoid arthritis,\" Beeton said.\n\"Here, we investigated whether this venom component, called iberiotoxin, would be able to specifically block the FLS potassium channel and reduce the severity of the rheumatoid arthritis in rat models of the disease.\"\n\"We think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\"\nIn addition, treatment with iberiotoxin did not induce side effects, such as tremors and incontinence, observed when treating with another channel blocker called paxilline.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease-mongering but the news release cuts corners when offering context about the\u00a0 impact of rheumatoid arthritis. It mentions \u201c1.3 million people with rheumatoid arthritis,\u201d but doesn\u2019t say where that number comes from or whether it\u2019s a U.S. or worldwide figure.", "answer": 1}, {"article": "For more information, visit http://www.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\nDuring the study period, 58.4 percent of patients underwent laparoscopic procedures and 41.6 percent had open anti-reflux operations performed through a long abdominal incision.\nCHICAGO (January 26, 2017): Patients with gastroesophageal reflux disease, known as GERD, who undergo laparoscopic anti-reflux operations compared with traditional \"open\" operations suffer fewer postoperative complications, experience faster recovery, and incur lower health care costs, according to study results published online as an \"article in press\" on the Journal of the American College of Surgeons website, ahead of print publication.\n\"Surprisingly, in 2003, 12 years after the first laparoscopic anti-reflux operation was reported, only 25 percent of all the anti-reflux operations were performed laparoscopically in the U.S.,\" Dr. Schlottmann said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. The release also provided useful context on the prevalence of GERD and further specified that smaller group of patients, from the many heartburn suffers, might be candidates for the surgery. Well done.", "answer": 1}, {"article": "For more information about our products and organization, visit http://www.\nFebruary 28, 2017 - For infants with congenital malformations of the ear, a treatment system called EarWell can gently reshape the ear--avoiding the pain and cost of later surgery, reports a study in the March issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\n\"While we can operate on ears later in the patient's life, waiting not only increases the surgery's difficulty and expense, but may expose the child to teasing, bullying, and loss of self-esteem,\" comments Editor-in-Chief Rod J. Rohrich, MD, in a featured video on the Plastic and Reconstructive Surgery website.\n\"The opportunity for early treatment can be hampered by a failure to convince pediatricians that the majority of misshapen newborn ears do not self-correct,\" Dr. Byrd and coauthors write.\nThe official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues\n\nThe American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This is a close one. The release begins by stating that EarWell can help infants \u201cavoid the pain and cost of later surgery.\u201d That\u2019s problematic, given that people aren\u2019t required to undergo a later surgery \u2014 it\u2019s purely elective. However, the release later makes clear that these treatment options are designed to address issues related to \u201cteasing, bullying and loss of self-esteem\u201d that could stem from ear deformity or malformation. And those are very real concerns that parents do take into consideration. That makes it a bit of a toss-up. What tipped it into the disease mongering camp was the section heading that states \u201cNonsurgical Treatment Avoids Later Consequences of Infant Ear Malformations.\u201d What could this mean? Hearing loss? Higher rates of ear infections? Something worse? Eight paragraphs later, the release mentions the \u201cteasing, bullying and loss of self-esteem\u201d as noted above. Those are important things for parents to consider, but they are certainly not a foregone conclusion. And scaremongering language in the section heading, and the huge gap between the section heading and the description of the \u201cconsequences\u201d go too far.", "answer": 0}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering about esophageal cancer in the story.", "answer": 1}, {"article": "The work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\nMS patients differ markedly from each other regarding which disability affects them the most.\nGene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.\nThey compared gene expression changes between regions that correspond to different disabilities.\nThey hypothesized that while inflammation causes loss of myelin and synapses, it is the decrease in cholesterol synthesis gene expression in astrocytes that explains why lesions do not repair in MS.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering, and we thought the story did a good job of explaining the mysteries that still surround sleep\u2019s relationship to mood. While sleep deprivation seems to create a temporary lifting of depression, it is also true that insomnia is a frequent symptom of depression. The story includes contradictions that remain to be resolved for researchers.", "answer": 1}, {"article": "The U.S. National Institute of Neurological Disorders and Stroke has more about autism.\nThe use of EEG-based testing may help diagnose autism in children and may improve early detection in infants, leading to more effective treatments and coping strategies, the researchers said.\nShe said the findings are important because, \"they help us understand why individuals with autism have difficulty with complex behaviors, such as social interaction and language.\nIn the new study, Dr. Frank Duffy and Dr. Heidelise Als compared EEG measurements of nearly 1,000 children with and without autism.\n\"What was unique about this study is the very large number of children studied,\" Dawson noted.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering, and we were glad to see that Dr. Dawson\u2019s comments focused on the new study and not on the broader question of the number of children with autism spectrum disorders.", "answer": 1}, {"article": "\"In addition, it is unknown whether bevacizumab [Avastin] increases survival when added to cisplatin-based chemotherapy in patients with advanced non-squamous non-small-cell lung cancer,\" Pirker said.\n\"Today we have a new option to treat non-squamous lung cancer, incorporating Avastin in chemotherapy regimens and in maintenance therapy,\" said lead researcher Dr. Lucio Crino, director of medical oncology at S. Maria della Misericordia Hospital in Perugia, Italy.\nThe report, which is funded by the maker of Avastin, F Hoffman-La Roche Ltd., is published in the July 20 issue of The Lancet Oncology.\n\"The practical implication is the possibility to incorporate Avastin with any chemotherapy regimen in the frontline therapy of metastatic non-squamous lung cancer,\" he added.\nThe researchers reported few clinically significant adverse events, meaning that most were no greater than what one would expect in the general population.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in disease mongering though it did include an estimate for the number of people who die from advanced non-squamous non-small cell lung cancer per year.\u00a0\u00a0The story should have been clear from the beginning that the study reported on the use of Avastin as a potential addition to treatment for\u00a0metastatic\u00a0non-squamous non-small cell lung cancer.", "answer": 1}, {"article": "Jaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nThe studies also looked at whether an alternative would be better tolerated or more effective, yet still safe.\u201d\n\nThe study consisted of 217 adults who had active, non-infectious intermediate or posterior uveitis, or panuveitis.\n\u201cThe hope is that by delaying or eliminating recurrences, the symptoms will be minimized or eliminated.\u201d\n\nThe researchers found that median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group.\nIn addition to Jaffe, co-authors include Andrew D. Dick, Antoine P. Br\u00e9zin, Quan Dong Nguyen, Jennifer E. Thorne, Philippe Kestelyn, Talin Barisani-Asenbauer, Pablo Franco, Arnd Heiligenhaus, David Scales, David S. Chu, Anne Camez, Nisha V. Kwatra, Alexandra P. Song, Martina Kron, Samir Tari, and Eric B. Suhler.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We couldn\u2019t find anything that would scare a reader. In fact, the release perhaps went a little too far to the other end of the spectrum and didn\u2019t mention the word \u201cblindness\u201d once, which is a possible outcome of uveitis if left untreated. ", "answer": 1}, {"article": "NEW YORK (Reuters Health) \u2014 Could one hour be all you need to quit smoking, without cravings or side effects?\n\u201cYou do not have those side effects of suicidal thoughts and feelings of paranoia that are reported for the drugs,\u201d he said.\nThe lack of any drugs involved in laser therapy \u201cwould be the beauty of this,\u201d he said.\nThe clinic uses low-level lasers - similar to those sometimes used to treat arthritis-related pain - to target specific acupuncture points on the body related to addiction, metabolism and stress, and claims that most patients can quit smoking after one session.\nIn that session, the laser is pointed at spots on the face, hands and wrist, with the aim of relieving withdrawal symptoms and preventing cravings.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not disease-monger smoking, although it could have spent a little more time with the health effects and societal costs of smoking.", "answer": 1}, {"article": "But, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nOther dietary intake and genetic propensities probably account for the rest.\nDr. Schaefer pointed out that the kind of fish consumed is important.\nEating fish is not a guarantee of having high levels of DHA.\nHigh intakes of fish oil can cause excessive bleeding in some people.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not appear to disease monger.\u00a0 ", "answer": 1}, {"article": "Microsoft stresses that Emma Watch is not a cure for the disease, which afflicts 10 million people.\nWatson erupts in tears as she calls her mother to say this is the first time she's been able to write her name in ages.\nEmma Watch remains a prototype, Microsoft says, but the developers are working with a neuroscience research team to undertake trials with a small group of Parkinson's sufferers.\n\"Once these symptoms can be identified and measured, it\u2019s possible to develop technology and devices that help humans manage their symptoms.\nThe video showed Lawton trying to draw a square with her shaky right hand, and then again, wearing Emma.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no scary language in this story,\u00a0and we\u2019re told about 10 million people have the disease.", "answer": 1}, {"article": "In recent years, doctors have started to focus on inflammation \u2014 the same process that makes cuts red and painful \u2014 as an important contributor to a heart attack.\nAnd smoking increases inflammation.\nSome will get more inflammation-lowering drugs.\n\u201cThis outcome is more than we hoped for.\nSome will get other agents that we haven\u2019t considered yet.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "Researchers here quantified the detection of cervical precancer and cancer by cotesting compared with HPV testing alone at Kaiser Permanente, where 1,208,710 women have undergone triennial cervical cotesting since 2003.\nHPV testing is more sensitive than the Pap test for detecting precancer.\nKaiser Permanente has now screened over a million women by cotesting.\nThis remains the most extensive experience of HPV testing incorporated into routine screening in the world.\nThe Pap test can also find noncancerous conditions, such as infections and inflammation.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "The drug, known chemically as denosumab, is widely considered to be Amgen\u2019s most important future growth driver and the FDA decision comes nearly two months ahead of the agency\u2019s expected action date of July 25.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\n\u201cMost of us certainly expected this drug to be approved,\u201d said Cowen and Co analyst Eric Schmidt, adding it was \u201ca surprise that it happened before\u201d July 25.\nHe estimates U.S. annual peak sales of $750 million to $1 billion in osteoporosis.\n\u201cIt\u2019s also superior to Zometa in its ability to delay subsequent events,\u201d Perlmutter said.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the \"success stories\" of modern cancer treatment.\nThis was a large-scale study involving pediatric cancer centers across the country.\nSteroids as a class of drugs are one of the most effective medications in the treatment of ALL.\nBut up to 20 percent of patients with a high risk of relapse are not cured.\nThe outcomes are getting better and better.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release doesn\u2019t demonstrate disease-mongering.", "answer": 1}, {"article": "The new drug is no miracle cure and it is not approved for young children, who are one of the most vulnerable groups, so the C.D.C.\nThe new antiviral, generically known as baloxavir marboxil but sold under the brand name Xofluza, is a single dose treatment.\nFlu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nThe first new flu drug in 20 years won approval Wednesday from the Food and Drug Administration.\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. In fact, the story provides good context on the risks posed by influenza.", "answer": 1}, {"article": "While there are more than 100,000 health-related apps on the market, the evidence to date is lacking as to whether many of those apps are safe or effective, according to Zubin Eapen, a cardiologist and assistant professor of medicine at Duke University School of Medicine.\nThat means more access across more sectors of a population.\n\"Heaps of them replied to us,\" she says.\nGlobally, cardiovascular disease is the leading cause of death.\n\"Everybody owns a mobile phone these days.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story commit disease-mongering?", "explanation": "The second graph defines the potentail impact of an advance in colon screening using plain language.\u00a0\"Colonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become full-blown cancer.\" It would have been helfpul to see how many people are diagnosed with colon cancer every year and how many die as a result. At about 100,000 new cases a year, colon cancer certainly has an impact, but what slice of those cases were detected through colonoscopy?", "answer": 1}, {"article": "Propping open clogged arteries with a tiny wire-mesh tube called a stent is no better at reducing the risk of heart attack or death in patients with stable heart disease than treatment with medications, according to a large new study that challenges routine use of a procedure that rapidly became standard medical practice.\n\"We do too many of these procedures.\"\n\"I think we're getting a midcourse correction.\"\nEnd of discussion,\" Boden said.\n\"There was no significant difference,\" Boden said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No obvious disease-mongering. ", "answer": 1}, {"article": "Newswise \u2014 Anew gastric balloon that can be swallowed like a pill and then filledwhile in the stomach, helped patients lose more than 37 percent oftheir excess weight over four months, according to new researchpresented here at ObesityWeek 2015, the largest international eventfocused on the basic science, clinical application and prevention andtreatment of obesity.\nThe FDA also approved threeweight-loss drugs since 2012.\niv The risk of death is about 0.1 percent v and the overall likelihood of major complications is about 4percent.\nSimilar to othergastric balloons, the most common adverse events reported were nauseaand vomiting.\n\u201cFor many struggling with theirweight, procedureless gastric balloon devices may serve as atreatment option that bridges the gap between weight-loss drugs andsurgery.\u201d\n\nTheU.S.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering.", "answer": 1}, {"article": "WASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\nThis approach saves many more lives than screening started at a later age or with less frequent exams.\nWe want them to know that mammography can detect cancer early \u2014 when it's most treatable and can be treated less invasively \u2014 which not only saves lives but helps preserve quality of life.\"\nThe ACR and SBI believe women 40 and older should have access to mammograms and that Medicare and private insurers should be required to cover them for these exams.\nIn 2015, according to the National Cancer Institute, 231,840 women will be diagnosed with the disease and 40,290 will die from it.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There are no gratuitous descriptions or inflammatory language in the release, and it encourages readers to discuss the issue with their doctors.", "answer": 1}, {"article": "Neither Hologic nor Rovers had input into the research design, analysis or interpretation of results.\nThe home self-collection test indicated that 12.4 percent of women were infected with high-risk HPV, the self-collection tests used in the clinic found 15.5 of the women had high-risk HPV infection, and the clinician-collected test identified 11.4 percent of the women had high-risk HPV infection.\nIn the journal Obstetrics & Gynecology, researchers published the results of mailing at-home, HPV self-collection kits to 193 low-income women in North Carolina who were overdue for screening according to national guidelines.\nThe researchers compared the results from self- and clinician-samples - which were tested for high-risk HPV strains that are linked to cervical cancer - to the Pap results and the results of cervical biopsies collected during colposcopy, which is a secondary diagnostic test that confirms the presence of cervical pre-cancerous lesions among women with abnormal Pap smear results.\n\"There are a lot of different barriers that cause women to be underscreened,\" said the study's first author Andrea Des Marais, MPH, project manager with the UNC Gillings School of Global Public Health.\n", "question": "Does the news release commit disease-mongering?", "explanation": "HPV \u2014 particularly certain strains of HPV \u2014 can significantly increase risk for cervical cancer. There\u2019s no doubt about that. However, not all women who contract HPV will get cervical cancer. There\u2019s no doubt about that either. In fact, the CDC notes that 80 percent of women have contracted HPV by the time they are 50, yet the National Cancer Institute estimates that less than one percent of women will contract cervical cancer in their lifetime. It can be difficult to highlight the importance of HPV screening without edging into \u201cdisease mongering\u201d territory. This release walks up to the line, but doesn\u2019t cross it.", "answer": 1}, {"article": "However, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\nIf the disease worsens despite all available medicinal and interventional therapies, the only options are heart transplant or a pumping assist device.\nWith advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\nThey are then injected directly into the patient\u2019s heart.\nAfter one year, the Vericel treatment led to a 37 percent reduction versus placebo in a composite of adverse events, including death, heart-related hospitalizations and unplanned clinic visits related to heart failure.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article accurately expresses the severity of advanced heart failure without making the condition seem hopeless.", "answer": 1}, {"article": "Rydapt should not be used in patients with hypersensitivity to midostaurin or other ingredients in Rydapt.\nIf the FLT3 mutation is detected in blood or bone marrow samples using the LeukoStrat CDx FLT3 Mutation Assay, the patient may be eligible for treatment with Rydapt in combination with chemotherapy.\nCommon side effects of Rydapt in patients with AML include low levels of white blood cells with fever (febrile neutropenia), nausea, inflammation of the mucous membranes (mucositis), vomiting, headache, spots on the skin due to bleeding (petechiae), musculoskeletal pain, nosebleeds (epistaxis), device-related infection, high blood sugar (hyperglycemia) and upper respiratory tract infection.\n\u201cRydapt is the first targeted therapy to treat patients with AML, in combination with chemotherapy,\u201d said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA\u2019s Center for Drug Evaluation and Research and director of the FDA\u2019s Oncology Center of Excellence.\nThe U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no evidence of disease mongering here. AML is a life-threatening condition and new agents that can prolong life are clearly needed. There\u2019s plenty of context about the disease and how the drug works: \u201cRydapt is a kinase inhibitor that works by blocking several enzymes that promote cell growth. If the FLT3 mutation is detected in blood or bone marrow samples using the LeukoStrat CDx FLT3 Mutation Assay, the patient may be eligible for treatment with Rydapt in combination with chemotherapy.\u201d", "answer": 1}, {"article": "Both groups lost about four pounds over the six months.\n\"The question one had to address was how does this play out with people in the real world,\" Jenkins said in a telephone interview.\nResearchers in Canada have shown that a special cholesterol-lowering diet works well \u2013 even with only two nutritional counseling sessions over six months.\nA control group advised to eat a vegetarian, low-saturated diet but not with the cholesterol-lowering foods a saw a slight dip in total cholesterol, from 249 to 246, and in LDL, from 167 to 161.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story tripped our disease-mongering detector by failing to discuss or even mention why someone would care about their cholesterol levels. High LDL cholesterol is not a disease, it is a heart disease risk factor. The LA Times, by comparison, reported: \u201cCleveland Clinic\u2019s Nissen stressed that researchers did not directly measure rates of coronary heart disease \u2014 just LDL cholesterol \u2014 so the health effects of the portfolio diet are not yet clear.\u201d\nThe CNN post makes it sound like lowering cholesterol is an end in and of itself. That\u2019s the kind of mindset that leads to more medical treatment instead of better medical treatment.", "answer": 0}, {"article": "Current mammography testing works well for detecting breast cancer in women over 50 with results of up to 95% accuracy.\nThe most effective screening tool for detecting breast cancer is mammography and for women of all ages to remain breast aware, reporting any changes to their [doctor].\u201d\nThe patented real-time radiofrequency scanner uses computer tomography and works by using the same technology as a mobile phone, but with only a tiny fraction of its power.\nThe scanner is based on radiofrequency technology, which is able to quickly show malignant and benign tumors when linked to a computer.\nWu says in a news release: \u201cThe system we have is portable and as soon as you lie down you can get a scan -- it\u2019s real-time.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article cites statistics about mammography and breast cancer in younger women from the press release.\u00a0They are within the range of key data in this field.\n(As an aside, the article says the stats are from the research team. We can\u2019t say whether the writer of the press release actually compiled them.)", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nFibronectin is associated with high-risk breast cancer with poor prognosis.\nThey will then pursue human trials with this approach.\n\u201cThe primary tumor sends signals to distant tissue and organs to prepare the soil for metastasis,\u201d Lu said.\nTheir testing showed that the agent is readily cleared from the body and has a low level of retention in tissues.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering with respect to breast cancer itself.", "answer": 1}, {"article": "Provenge is the first so-called therapeutic cancer vaccine \u2013 meaning it works by training the patient\u2019s immune system to attack the tumor \u2013 to win F.D.A.\nSome analysts have assumed that Medicare will pay for Provenge when used for the patients specified in the drug\u2019s label \u2013 those with advanced prostate cancer that is resistant to hormone-deprivation therapy but who are experiencing no or minimal symptoms.\nThe Medicare review might be more designed to limit off-label use of the expensive drug, such as for patients who already have symptoms.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nWith expensive medicines there is already a sort of dual approval system, especially with private insurance companies.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story reports that Provenge treatment is approved only for patients with \u201cadvanced prostate cancer that is resistant to hormone-deprivation therapy but who are experiencing no or minimal symptoms.\u201d", "answer": 1}, {"article": "The best results came from patients with the BRCA mutation: Their tumors didn\u2019t start to grow again for 21 months, on average, compared to 5.5 months for a control group that just received a placebo.\nPARP inhibitors work by stopping this repair.\nIt\u2019s being used to treat ovarian cancer in women who have already undergone chemotherapy.\nThe hope is that they\u2019ll keep cancer at bay once it\u2019s been attacked by chemo.\nThe PARP inhibitor talazoparib.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story commit disease-mongering?", "explanation": "We\u2019ll rate this satisfactory for a lack of any obvious disease mongering. But as noted above under \u201cHarms,\u201d there is a presumption in this story that increased access to imaging can only be a good thing. The story doesn\u2019t entertain the possibility that these scans will turn up meaningless \u2014 but potentially worrisome \u2014 findings that could cause anxiety for patients and lead to overtreatment.", "answer": 1}, {"article": "Led by John Weeks (johnweeks-integrator.com), the Co-founder and past Executive Director of the Academic Collaborative for Integrative Health, JACM publishes controlled trials, observational studies, scientific reviews and leading commentary intended to help medical organizations and governmental organizations optimize the use of integrative products, practices, and practitioners in patient care and in delivery and payment strategies.\nComplete tables of content and a sample issue may be viewed on the JACM website.\nThe article is available free on the JACM website until July 19, 2017.\nIts biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide.\nThe researchers measured the effects of the intervention on factors such as the children's behavior, ability to pay attention, sleep, and aspects of parenting stress.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.  ", "answer": 1}, {"article": "DOI: 10.4172/2155-6105.1000290 \n\nhttp://www.\nThe on-line survey of 941 respondents assessed subjective changes in respiratory symptoms in smokers who switched to vaping for at least two months.\nThis is because smoking increases susceptibility to respiratory infections and stopping smoking can be expected to have a positive effect.\nThese new findings from human vapers show that this is not the case.\nThe researchers say that it is not surprising that the survey respondents noticed improvements in their respiratory health.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not exaggerate the severity or extent of nicotine addiction.", "answer": 1}, {"article": "MONDAY, June 29, 2015 (HealthDay News) -- A device that grabs and drags a blood clot out through the blood vessels should be used to treat certain stroke victims, according to new guidelines issued by the American Heart Association.\n\"The outcomes were uniformly positive in all of the trials,\" he said.\nA lot of this at this point depends on logistics and manpower.\n\"It's really, really good evidence.\"\nAs with other stroke treatments, time is of the essence.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in this story.", "answer": 1}, {"article": "The U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer.\nKeytruda thereby met its main goal of the study.\nThose whose tumors expressed PD-L1, but not at high levels, did not show such a statistically significant benefit in progression-free survival.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\u201cShortly after that he told me I could relax and that I did a good job and they had retrieved the clot and just to relax and I immediately started trying to move my arm.\u201d\n\n\u201cA patient will come in, they can't speak, they can't move half their body,\u201d says neurosurgeon Dr. J Mocco, of Mt.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\n\u201cThe earlier that patients with acute ischemic stroke get to a hospital offering the appropriate treatment, the higher the likelihood is of a good outcome,\u201d said the study\u2019s lead author, Dr. Mayank Goyal of the Hotchkiss Brain Institute at the University of Calgary.\nThe intravenous drug is very effective for smaller clots, but it often fails to break up larger clots and is usually most effective when given within 4.5 hours after the first symptoms.\nRoughly 795,000 people suffer a stroke every year in the United States, and it\u2019s the fifth highest cause of death and a leading cause of adult disability, according to the American Heart Association.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no overt disease mongering in the story. However, we\u2019d note that with a procedure such as this, there will be a temptation\u00a0to use this device more often and this could lead to \u201cindication creep\u201d where more patients who don\u2019t quite meet the very strict standards of the study are\u00a0offered the therapy. This could lead to poorer results than are obtained here. The story could have commented on this.", "answer": 1}, {"article": "For more information, visit http://www.\nThe Journal of Medical Entomology is published by the Entomological Society of America, the largest organization in the world serving the professional and scientific needs of entomologists and people in related disciplines.\nIn order to test the effectiveness of the device, Christopher Bibbs and Rui-De Xue of the Anastasia Mosquito Control District in Florida studied how the device performed against hungry Aedes aegypti mosquitoes.\n\"Just look at all the bug zappers, repellent bracelets, sonic bug repellents, and other zany creations that wax and wane in popularity.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Because this release was distributed at a time when we\u2019re seeing very dramatic and almost panicked news stories and press releases about the Zika virus it points to a form of disease mongering. The device and study seem to prey on the public fear about any exposure to the A. Egypti mosquito, the carrier of Zika and other viruses.", "answer": 0}, {"article": "\"The idea is to get a point-of-care test that could be used on the field, to help the coaches, the trainers and the athletic directors, make a decision then and there about whether the child should go back to play,\" said Papa.\nThe team then tested blood serum from the same patients, which was taken less than 6 hours after their injuries.\nWhen there's an injury to the brain cells, the GFAP are released.\nThese proteins are found in glial cells, which surround neurons in the brain.\nCT scans can provide a more definitive profile of the injury, \"however, they are expensive and are associated with radiation exposure,\" said Papa.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Imperial Health Charity (formerly Imperial College Healthcare Charity) raises funds for five London hospitals within Imperial College Healthcare NHS Trust: Charing Cross, Hammersmith, Queen Charlotte's & Chelsea, St Mary's and Western Eye hospitals.\nIt invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market.\nNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nWe were the first English university established after Oxford and Cambridge, the first to open up university education to those previously excluded from it, and the first to provide systematic teaching of law, architecture and medicine.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here. The release provides context on the prevalence of glaucoma and what causes the condition.", "answer": 1}, {"article": "Monday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\nThe main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.\nThe new-generation hepatitis C regimens use a two- to three-drug combination \u2013 a nucleotide analog inhibitor or \u201cnuke\u201d and a NS5A inhibitor in Gilead\u2019s case \u2013 to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.\nLaunched in October, its sales touched $2.11 billion in the quarter ended Dec. 31.\nAchillion, one of the few companies developing hepatitis C therapies independently, plans to begin a mid-stage study this year to evaluate its proprietary doublet.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story seems to accept the commonly held premise that all with hepatitis C face doom if they are not treated. There was nothing about the natural history of the disease, or the fact that most people infected with this \u201cliver-destroying virus\u201d never develop symptomatic liver disease. The story does not raise the possibility of mass overtreatment of people with hepatitis C.", "answer": 0}, {"article": "DOI: 10.5435/JAAOS-D-17-00318\n\"This is the first comprehensive mixed-comparison analysis comparing best-evidence scientific research and excluding lower quality studies that can bias the outcomes,\" said lead author and orthopaedic surgeon David Jevsevar, MD, MBA.\n\"Using a statistical ranking technique, we worked to provide evidence regarding which of the most common NSAIDs are most likely to decrease pain and improve function, and we attempted to fill in the gaps in evidence for more inconclusive treatments such as HA, PRP, and corticosteroids.\"\nAccording to a network meta-analysis research article published in the May 1, 2018 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the nonsteroidal anti-inflammatory drug (NSAID) naproxen was ranked most effective in individual knee OA treatment for improving both pain and function, and is considered a relatively safe and low-cost treatment method.\nAlthough the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release leads off with the statement that an \u201cestimated 45 percent of people are at risk of developing knee osteoarthritis (OA) in their lifetime.\u201d The journal article also leads with this statistic. However, the \u201c45 percent\u201d figure comes from a study of people living in one county in rural North Carolina. Another recent study estimates a far lower lifetime risk of about 14 percent. The authors of the latter report addressed the discrepancy, writing that the North Carolina study looked at an older population with different sex, race and weight distributions than the US population as a whole\u2026 and it noted that people without knee problems might have been less likely to stay in touch with researchers, which could lead to a higher estimate of lifetime risk.", "answer": 0}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story commit disease-mongering?", "explanation": "The article does not exaggerate the risks or severity of community acquired pneumonia. By emphasizing MRSA as a cause, however, it does engage in disease-mongering. MRSA is an extremely rare cause of CAP. \nIt also would have been useful to report the percentage of cases of CAP caused by bacteria resistant to Biaxin. Given the fact that Biaxin\u2019s success rate in treatment is around 95 percent, fears of CAP being resistant to it may be premature or exaggerated. ", "answer": 0}, {"article": "Study Limitations: Imbalances caused by matching groups of obese patients for comparison based on age, sex, body mass index and diagnoses of diabetes.\nBecause researchers are not intervening for purposes of the study they cannot control for all the natural differences that could explain study findings.\nLink will be live at the embargo time http://jamanetwork.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease-mongering in this news release.", "answer": 1}, {"article": "Learn more at www.cdc.gov/DrugOverdose.\nHaving trained EMS staff to administer naloxone in rural areas will save lives.\u201d\n\nTo reduce opioid overdose deaths, particularly in rural areas, CDC recommends expanding training on the administration of naloxone to all emergency service staff, and helping basic EMS personnel meet the advanced certification requirements.\n\u201cNaloxone is non-addictive, and expanding training on how to administer the drug can help basic emergency medical service staff reverse an opioid overdose and save more lives.\u201d\n\nNational Emergency Medicine Service Information System data for 2012 were reviewed to better understand factors associated with naloxone administration, including demographic data, 911 call information, and details about the scene of an injury or illness as reported by EMS staff.\nThe use of naloxone by rural EMS staff, however, was only 22.5 percent higher when compared with urban EMS naloxone use.\nThe findings indicate naloxone was most likely to be administered to women, people between the ages of 20 and 29, and people living in suburban areas.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. The release\u00a0says that, \u201cIn 2013, more than 16,000 deaths in the United States involved prescription opioids, and more than 8,000 others were related to heroin.\u201d Not to split hairs, but the study data being reported on were from 2012, and it would have be even more useful to supply data on 2012 deaths for comparison. Put in context with all \u00a02.61 million deaths that occurred in the U.S. in 2012, deaths involving prescription opioids and heroin do not amount to a significant total. They are, however, preventable, and so it\u2019s a worthy goal to reduce them.", "answer": 1}, {"article": "At the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\nIn addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.\n\"This drug has minor effects on normal cells other than neutrophils (white blood cells),\" said the study's senior author, Peter J. O'Dwyer, MD, a professor of Hematology/Oncology at Penn and director of the Developmental Therapeutics Program at the ACC.\n\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nAlso, combining palbociclib with other anti-cancer agents is feasible, and early results in myeloma and some solid tumors have led to more definitive studies.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.\nIn fact, we wish the release had given some attention to the prevalence of the specific tumors studied as well as the types of tumors the drug is intended to target.", "answer": 1}, {"article": "This story has been updated with additional information.\nThe early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nIn cases of severe depression, that equilibrium gets out of whack, and Sage\u2019s drug is meant to restore it, modulating those GABA receptors to allow NMDA to do its job.\nThere\u2019s a natural push and pull between neurotransmitters called NMDA receptors and the GABA receptors that regulate their flow in the brain.\nThe data could represent a \u201cparadigm shift in how the disease is thought about,\u201d CEO Jeff Jonas said in a conference call.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not disease monger. However, because milder symptoms of the \u201cbaby blues\u201d are common in pregnant women and new mothers, the story should have been clearer about distinguishing the features of a \u201cMajor Depressive Episode\u201d like those experienced by the women in this trial from the more common blues that readers are likely to be familiar with.", "answer": 1}, {"article": "Migraines are throbbing, one-sided headaches that can be accompanied by nausea as well as sensitivity to light, sound, smell, and movement.\nAccording to one recent survey by the Centers for Disease Control and Prevention, about 10 percent of men and 20 percent of women in the U.S. reported having had a migraine in the last three months.\nRight now, the only available preventive treatments are accidental discoveries: A number of people prescribed medications for depression, high blood pressure and epilepsy discovered migraine relief, too.\n\"There's a big hole to fill, both in prevention and acute therapies,\" says Alexander Mauskop, director of the New York Headache Center in New York City.\nIn women of childbearing age, who are the ones most prone to frequent migraines, \"you can imagine that might have effects on fertility or placental function.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. The story reports federal data that about 10 percent of men and 20 percent of women in the U.S. reported having a migraine in the last three months, and as many as 2 percent of Americans have at least 15 migraine days every month. \u201cThe toll such pain can take on health, morale, and productivity is substantial,\u201d it says.", "answer": 1}, {"article": "TUESDAY, June 5, 2012 (HealthDay News) -- A simple blood test may help gauge prognosis and tailor treatments for women who have been diagnosed with early stage breast cancer.\n\"Not every cancer cell becomes a metastatic cancer cell.\nThe U.S. National Cancer Institute has more on breast cancer.\nOne area for study is how well these circulating cells predict recurrence and death in patients who have already had chemotherapy.\n\"The cells also need to have a propensity to grow elsewhere,\" she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Accessed October 2013 from http://www.hcup-us.ahrq.gov/reports/statbriefs/sb23.jsp [5] Flum, D. R., et al.\n\u201cThe balloon and other technologies may help to fill the therapeutic gaps between diet and exercise and medical therapy, and medical therapy and surgery, where the gaps are quite large.\u201d\n\nPeople with obesity and severe obesity have higher rates of heart disease, diabetes, some cancers, arthritis, sleep apnea, high blood pressure and dozens of other diseases and conditions.\n\u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d\n\nThe Obalon 6-Month Balloon System, a swallowable, gas-filled intragastric balloon for weight loss in adults with obesity for whom diet and exercise has failed, was approved in September by the U.S. Food and Drug Administration (FDA).\n\u201cThe significant weight loss achieved with the Obalon 6-Month Balloon System is maintained at 12 months,\u201d said Aurora Pryor, MD, study co-author and Chief Bariatric, Foregut and Advanced GI Surgery, Stony Brook University.\n[3] The risk of death is about 0.1 percent[4] and the overall likelihood of major complications is about 4 percent.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease mongering. Instead, it notes that the Obalon device was tested on people with a BMI of 30 or higher. Also, a quote talks about the device being offered to people \u201cwho otherwise would not seek treatment or not have as good a result with diet and exercise alone.\u201d", "answer": 1}, {"article": "\u201cOver the next couple of years, we will find out what it means.\u201d\n\nOn Oct. 23, 2008, Avid and two other companies, and , that are developing fluorine 18-based dyes for amyloid scans, got a pointed question from an advisory committee to the F.D.A.\n\u201cSomething bad happens, and now something good happens.\u201d\n\nLate last year, Avid saw the initial results of its hospice study \u2014 data from the first six patients.\nOther tests are being studied \u2014 ones that look for amyloid in cerebrospinal fluid that bathes the brain; scans that look for shrinkage of the brain in areas needed for memory and reasoning; PET scans that look for uptake of glucose, a cellular fuel, to show areas where the brain was active and where it was not.\nAnd with such a high rate of misdiagnosis, some who are mistakenly told that they have Alzheimer\u2019s are not treated for conditions, like depression or low levels of thyroid hormone or drug side effects and interactions, that are causing their memory problems.\nThe type of scans used in this study, PET scans, are expensive and patients have to go to a scanning center, get injected with a radioactive dye, wait for the dye to reach their brain and then have a scan.\n", "question": "Does the story commit disease-mongering?", "explanation": "Some of the best parts of the story have to do with the confusion and lack of hard data about Alzheimer\u2019s. This quote is typical:\u00a0\"Even at the best medical centers, doctors often are wrong. Twenty percent of people with dementia \u2014 a loss of memory and intellectual functions \u2014 who received a diagnosis of Alzheimer\u2019s, did not have it.\" More stories should try to explain how hard it is to diagnose some of these disorders.", "answer": 1}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease mongering. It talks about how hair loss is a common side effect of chemotherapy and how minimizing side effects is considered important to overall treatment.", "answer": 1}, {"article": "As part of a longer term project funded by F. Hoffman-La Roche, the team previously tested a collection of approximately 550 potential tracer molecules and identified six promising tracers, eventually narrowing them down to three to be made and tested as candidate Tau PET radiopharmaceuticals.\nAn additional six older healthy controls were recruited for full-body scanning.\nThe third part of the study examined six older controls undergoing whole-body scanning.\nSusan Resnick and Madhav Thambisetty are employees of the NIH, National Institute on Aging.\nIt was published in the December 2018 issue of the journal.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "STOCKHOLM (Reuters) - Giving patients with a history of heart attacks a margarine enriched with omega-3 oils in addition to standard drugs appears to make no difference to their chances of having a repeat attack.\nThe finding raised questions about the benefits of omega-3, which has been shown in previous studies to make for healthier hearts.\n\u201cWe found the cardiovascular mortality rate in the study population was only half that expected, probably because of their excellent treatment,\u201d he said.\nThe margarines used in the study were developed for the researchers by food and consumer goods giant Unilever.\nDiabetes patients also showed a possible benefit.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering.", "answer": 1}, {"article": "Wine rounds out the list of of 10 \"brain healthy\" food groups that help protect against Alzheimer's: green leafy vegetables, other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil and wine.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nThe study, published in the journal Alzheimer's & Dementia, looked at more than 900 people between the ages of 58 and 98 who filled out food questionnaires and underwent repeated neurological testing.\nA new study by researchers at Rush University Medical Center in Chicago shows a diet plan they developed -- appropriately called the MIND diet -- may reduce the risk of developing Alzheimer's disease by as much as 53 percent.\nBut the MIND diet helped slow the rate of cognitive decline and protect against Alzheimer's regardless of other risk factors.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story.\u00a0 The prevalence of Alzheimer\u2019s Disease is increasing and if dietary changes can prevent or delay the disease, they should be considered.", "answer": 1}, {"article": "Feb. 17, 2011 (Orlando, Fla.) -- Taking a pomegranate pill a day may help slow the progression of prostate cancer, preliminary research suggests.\nHowever, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nIn 2009, other researchers reported that pomegranate juice may also prevent prostate cancer from getting worse.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\n", "question": "Does the story commit disease-mongering?", "explanation": "What is disease-mongering here is that this story came from the same conference where this week researchers were talking about active surveillance and how \u201cWe\u2019re identifying men who are not likely to need even a pill,\u201d\u00a0 yet this story never mentioned that not all early stage prostate cancers are the same but reported on questionable evidence for still another pill that men might take.\n  \n\u00a0", "answer": 0}, {"article": "(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nBased on the most recent estimates, about 7.8 million Americans have some form of excessive sweating including palms, feet, underarms or head, and about half of this population suffer from the underarm form, said Dermira spokeswoman Erica Jefferson, in an interview ahead of the data readout.\nFor instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\nWhile the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\nThe first line of defense are anti-perspirants.\n", "question": "Does the story commit disease-mongering?", "explanation": "We\u2019re told in the story that about 3.9 million Americans suffer from excessive underarm sweating. But based on what analysis? What\u2019s the source for that figure, and is it trustworthy?", "answer": 0}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to engage in disease mongering.", "answer": 1}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering of breast cancer.", "answer": 1}, {"article": "The depth of anesthesia was monitored using bispectral index (BIS) technology, which processes electroencephalogram signals to measure drug-induced unconsciousness.\nOnly the third and fourth groups received dexamethasone.\nPatients who failed to achieve a cutoff score were excluded.\nPre-operative assessment included a battery of tests to measure mental and cognitive status.\nThe impairment may be temporary or permanent and incapacitating.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease mongering.", "answer": 1}, {"article": "Thourani V, Jensen H, Babaliaros V, Kodali S, Rajeswaran J, Ehrlinger J, Blackstone E, Suri R, Don C, Aldea G, Williams M, Makkar R, Svensson L, McCabe J, Dean L, Kapadia S, Cohen D, Pichard A, Szeto W, Herrmann H, Devireddy C, Leshnower B, Ailawadi G, Maniar H, Hahn R, Leon M, Mack M. Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial.\n\"Historically, extreme elderly patients can be at a very high risk for open surgery,\" said Dr. Thourani.\nTA-TAVR is an alternative for patients who are medically ineligible for TF-TAVR secondary to severe peripheral vascular disease.\nMajor complications, such as bleeding or vascular issues, occurred in 35% of TF-TAVR patients and 32% of TA-TAVR patients, and more than 80% of patients were discharged home after the procedure.\n.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Still, the big questions surrounding sauna bathing\u2019s safety have always centered on its occupant\u2019s (and her heart\u2019s) ability to withstand the heat.\nUsing electromagnetic radiation, infrared lamps warm your body directly.\nSo what to think of infrared saunas?\nAsk your doctor first.\n\u201cAs infrared heat penetrates more deeply than warmed air, users develop a more vigorous sweat at a lower temperature than they would in traditional saunas,\u201d says Dr. Richard Beever, a clinical assistant professor of family medicine at the University of British Columbia.\n", "question": "Does the story commit disease-mongering?", "explanation": "No obvious disease mongering", "answer": 1}, {"article": "On a low-glycemic index diet, you would avoid highly processed carbs such as white bread, white rice, many snack foods, prepared breakfast cereals, sugary desserts and sugary beverages, she says.\nExperts had different responses to the findings.\nThe dieters were admitted to the hospital four times for medical and metabolic testing.\nAdherence is the major key for weight loss and maintenance.\nThe diets had the same number of calories, but the fat, protein and carbohydrate content varied.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "THURSDAY, Dec. 9, 2010 (HealthDay News) -- The bone drug zoledronic acid (Zometa), considered a potentially promising weapon against breast cancer recurrence, has flopped in a new study involving more than 3,360 patients.\nAfter five years, about 400 women in each group either died or had recurrences.\nIn one previous study, the use of the drug was linked with a 32 percent improvement in survival and lowered recurrence in younger women with breast cancer.\n\"The younger patients are getting no benefit,\" Coleman said.\nThe focus was on disease-free survival.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no hint of disease-mongering in this article. ", "answer": 1}, {"article": "At the start, about 12% said they didn\u2019t exercise, and the rest said they exercised anywhere from \u201cup to 30 minutes\u201d to \u201cmore than 4 hours\u201d a week.\nNo relationship was observed between exercise and later anxiety, but the researchers did find a link between exercise and later depression.\nFor people who worked out more, no additional benefits were observed.\nOver the next decade, about 7% of people in the study developed depression, and about 9% developed anxiety.\nThat exercise doesn\u2019t have to be intense, either, they say.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "By MARILYNN MARCHIONE\n\n The Associated Press\n\n Monday, February 28, 2011; 9:39 PM \n\n\n\n-- In a bold new approach ultimately aimed at trying to cure AIDS, scientists used genetic engineering in six patients to develop blood cells that are resistant to HIV, the virus that causes the disease.\nHe treated his first patient with it in July 2009.\n\"My results are excellent,\" he said.\n\"I may not live long enough to see the cure, but I always hoped for a chance.\"\nThree others received about 5 billion.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "But there\u2019s one big stumbling block for both of them, a problem that has dogged medical genetics for decades: Data for non-white populations is sorely lacking.\nIt\u2019s possible that might change, with time and effort.\nAsia and South America are also relatively underserved.\nFace2Gene is meant to be more like a search engine for diseases \u2014 a means to an end.\nThey\u2019re both trained on databases of photographs doctors take of their patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this piece.", "answer": 1}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story commit disease-mongering?", "explanation": "The story accurately describes the prevalence of cardiac arrest and its consequences. If anything, the article is guilty of \u201ctreatment mongering,\u201d implying that bystander CPR would dramatically impact the survival of cardiac arrest sufferers, if only more people would get with the drill and learn it. Not so.", "answer": 1}, {"article": "Newswise \u2014 Lap band surgery has significant benefits for severely obese teenagers and, despite its controversial nature, should still be considered as a first option to manage obesity during adolescence, a new study has found.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\n\u201cIt is also important that teenagers undergoing this surgery have access to an experienced surgeon as part of a multidisciplinary paediatric team of doctors and Health professionals to ensure there is long-term regular follow-up.\u201d\n\nPaediatric surgeon Mr Sanjeev Khurana, who did all the lap band surgeries between 2009 and 2013, says lap band surgery is a reversible surgical procedure that can be safely used in teens with severe obesity.\n\u201cAlthough gastric banding has been controversial and is currently less used in adults with severe obesity, lap band surgery is one of the most studied surgeries for obesity management, has a high safety record and can be a temporary option to manage severe obesity during adolescence,\u201d says Mr Khurana, who is also a Senior Lecturer in the University of Adelaide\u2019s Discipline of Paediatrics.\n\u201cWe are talking about a group of adolescents with severe obesity and significant health and psychological problems related to their increased weight \u2013 this is not for everyone,\u201d says corresponding author and Paediatric Endocrinologist Dr Alexia Pe\u00f1a, who is a Senior Lecturer with the University of Adelaide\u2019s Robinson Research Institute.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The text makes clear that this strategy would be relevant only for severely obese teenagers and then goes on to define that term. But the definition (body mass index over 40/kg/m2 or over 35 kg/m2) will be difficult for the average reader to understand.", "answer": 1}, {"article": "The scientists recognize, too, that it's still unknown if classic psychedelics concretely led to a drop in psychological distress and suicidality; perhaps those who participated in the study and had reported using psychedelics in the past had personalities that made them less susceptible to distress and suicidality in the first place.\nIn 2011, individuals with advanced-stage cancer were given single doses of psilocybin and were found to have reduced long-term incidences of depression and anxiety.\nThe National Alliance on Mental Illness estimates that 30,000 people in the U.S. die from suicide each year, and worldwide that number is 1 million.\nOnly two population studies to date, this one included, specifically address the relationship between mental illness and psychedelics.\nParticipants answered pre-recorded questions about their individual use of classic psychedelics, and the data was collected in person.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article cites figures for the incidence of suicide and doesn\u2019t engage in disease mongering.", "answer": 1}, {"article": "In fiscal year 2014, Penn Medicine provided $771 million to benefit our community.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\n\"There are approximately 90 million post-menopausal women living in the US alone, and with the average age of onset occurring at 52, the great majority of those women will live in the postmenopausal state for at least one-third of their lives.\nPHILADELPHIA - According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving - often referred to as executive functions - related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\n", "question": "Does the news release commit disease-mongering?", "explanation": "As noted in above in this review, we\u2019re concerned that this release engages in disease mongering. Fresh off of an approval of this drug for binge-eating disorder, study co-funder Shire appears to be looking to menopausal women as a new market and possibly pathologizing such women inappropriately. Are these women truly impaired enough to require drug treatment? The release says that reports of cognitive impairment are \u201cwidespread\u201d in menopausal women. But to truly establish such a need, the release should have provided more context as to the degree of impairment and the number of women with severe impairment, and how long this lasts. The idea that this research is addressing \u201ca\u00a0major public health goal\u201d needs more high-quality evidence to be accepted. In the study itself, the authors acknowledge that \u201cthe true prevalence and severity of mid-life onset\u00a0of executive function difficulties among women experiencing a natural menopause\u00a0are not known.\u201d", "answer": 0}, {"article": "\"'Promising' is the perfect way to describe our findings,\" said study lead author Dr. David Woodrum, an interventional radiologist at the Mayo Clinic in Rochester, Minn. \"But whether or not this minimally invasive approach would ultimately become a primary method of treatment in the future will depend on the long-term results of this trial, which is still under way.\nNone of the patients was deemed eligible for standard surgical interventions.\nThe procedure is performed by an interventional radiologist on patients coping with metastasized lung tumors, the researchers noted.\nTypically, patients were able to return home the following day.\nHowever, some patients developed new tumors in that time period, the researchers noted.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no sign of disease mongering about lung cancer.", "answer": 1}, {"article": "The study was temporarily halted in 2008 because of concerns over ethics and patient safety.\nIn a statement after the study was presented, Antman, a cardiologist at Boston's Brigham and Women's Hospital and professor of medicine at Harvard Medical School, added, \"Intriguing as the results are, they are unexpected and should not be interpreted as an indication to adopt chelation therapy into clinical practice.\"\n\"A definitive answer on chelation therapy will take much additional research,\" Gervasio Lamas, chief of the Columbia University division of cardiology at Mount Sinai Medical Center in Miami Beach, Fla., said in a statement.\nIn response to such concerns, researchers revised their consent forms \u2014 the documents that explain a study's risks and benefits to patients \u2014 which had failed to mention the risk of death in chelation therapy.\nEven more concerning, that benefit passed the bar for statistical significance \u2014 the standard for judging whether a result is real or a fluke \u2014 by only 0.001.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story gets a satisfactory score for this criterion.\nYou could\u00a0argue that the study\u00a0wandered into fear-mongering territory in its discussion of chelation. There\u2019s no doubt that chelation can be a very\u00a0dangerous procedure in the wrong hands, but the primary result here seems to be that it was safely administered in the context of the study. It\u2019s not until the last sentence\u2013and after chelation is repeatedly characterized as dangerous and possibly deadly \u2014 that the story makes this point.\nThen again, this study seems so riddled with problems that it\u2019s hard to know what to make of the results.\u00a0We\u2019ll give the benefit of the doubt here, as there\u2019s certainly no reason to recommend chelation, and still plenty of reason to be worried about it.", "answer": 1}, {"article": "The company believes the total \"population in the US, Europe and select additional markets in the Americas and Asia/Pacific is up to approximately 6,000 individuals\" who have the mutation targeted by Luxturna, explained Monique da Silva, a spokeswoman for Spark Therapeutics.\nHowever, the normal gene delivered by the treatment is able to function within the retinal cells and correct vision problems.\nThis third version of the gene does not remove or replace the two mutated genes causing the disease, which remain inside the cells.\nThe mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.\nLuxturna is a liquid that is injected directly into the eye with a microscopic needle during a surgical procedure.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story made it clear that this is a very rare genetic disease that leads to blindness.", "answer": 1}, {"article": "The robot-surgeon team might not have outperformed the surgeon alone because the procedure was a relatively simple one.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nRather, surgeons move electronic instruments that are linked to the movement of other instruments inside the body, while they watch a three-dimensional image of what\u2019s going on inside.\nBecause the robot lets the surgeon get a better picture of the inside of the body, the authors had expected that surgeries using the robot would go more smoothly than those without it.\nWith the surgeon alone, \u201cthe incision is smaller (and) the manipulations are more controlled,\u201d Dr. Ceana Nezhat, an author on the study and the chair of Obstetrics & Gynecology at Northside Hospital in Atlanta, told Reuters Health.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story could provide a source for the 5 million figure used to calculate how many women suffer from the condition, but, as far as we can tell, it doesn\u2019t make the condition sound worse than it is.", "answer": 1}, {"article": ".\nThe experimental drug stimulates the 5-HT2C serotonin receptor, which is located in the hypothalamus, an area of the brain associated with regulation of food intake and metabolism.\nBut one of the two components of that drug made by Wyeth, fenfluramine, also hit a second target in the heart, which was linked to heart valve problems.\nThat is the same receptor in the brain targeted by the weight loss drug Fen-phen, which was popular in the 1990s.\nThe company plans to announce results of the first Phase 3 clinical trial of the drug at the end of March, Chief Executive Jack Lief said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although most of the story did not engage in disease mongering,\u00a0 the statement by the study\u2019s lead author indicating that the results would \u2018provide reason for optimism for the millions of Americans struggling with the obesity epidemic\u2019 could be argued to fall into this category. \u00a0It is both hyperbole to conclude that the results of one study provides optimism for millions as well as disease mongering to describe people who are obese as struggling with the obesity epidemic. That statement should have been challenged.\u00a0 \n", "answer": 1}, {"article": "(Reuters) - Shares of Evofem Biosciences Inc jumped as much as 38 percent on Monday after its birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.\nAn estimated 16.5 million women in the United States do not use any method of contraception, according to the company, on fear of side effects, leaving them highly susceptible to unwanted pregnancies and sexually transmitted diseases.\nThe rate stands at about 91 percent for oral pills and intrauterine devices, according to brokerage Roth Capital Partners.\nCondoms, the most common non-hormonal method of contraception, have an efficacy rate of 82 percent.\nOppenheimer analyst Leland Gershell said he expects Amphora, the company\u2019s lead product, to bring in sales of up to $415 million by 2032.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no disease mongering in the story.", "answer": 1}, {"article": "The study, which was conducted by researchers from Leuphana University in Lueneburg, Germany, recruited 406 people with subthreshold depression, which is defined as having some symptoms of depression but not enough to be diagnosed with major depressive disorder.\nParticipants also could repeat the online sessions as often as they liked.\nAt the next session, participants reflect on their experiences.\nIt's also not clear if this kind of program could be scaled up.\nIt was published Tuesday in JAMA, the journal of the American Medical Association.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\u201cIt\u2019s gut-wrenching.\n(A 2015 review of the evidence on the optimal diet to promote fertility \u2014 and the utility of supplements \u2014 found the data \u201cconflicting.\u201d)\n\nThey also plan to have Smith get infusions of intralipids \u2014 a cocktail of soy bean oil, egg yolks, and other fatty acids \u2014 during her third round of IVF, which she\u2019s embarking on now.\nPetrozza said he worries that women might wrongly interpret a long litany of genetic risks to mean that their hopes to start a family are \u201cdoomed.\u201d He also said he sees the test as \u201cvery costly for what it\u2019s trying to do \u2014 and not really giving, at least at this point, what I would consider meaningful information.\u201d\n\nThe Fertilome test was eight years in the making.\nAnd on a Tuesday evening earlier this summer, the company partnered with a women\u2019s group to host a conversation about \u201cproactive steps you can take today to reach your future family building goals.\u201d Appetizers, wine, and beer were served \u2014 and, in a gesture to the crowd full of women with pregnancy on their minds, non-alcoholic beverages were on the menu, too.\n\u201cNobody knows what\u2019s going on, and you can\u2019t fix the problem.\u201d\n\nSo when Eyvazzadeh suggested that she take the Fertilome test, Smith jumped at the possibility of finally getting answers.\n", "question": "Does the story commit disease-mongering?", "explanation": "Inability to conceive haunts many women, and genetics clearly plays some kind of role in the problem. But scientists are far from sure about the nature and extent of that role. Genetic testing may well evolve into an effective component of a diagnostic effort. But this company\u2019s recent efforts to market this unproven test directly to women, even those who have not yet tried to get pregnant, strays into disease mongering on the part of the company itself. The STAT story explores that new development thoroughly.", "answer": 1}, {"article": "But there are still hurdles to clear.\nBut the companies\u2019 fortunes are intertwined, he said, and \u201cthe class only wins if headache care in America improves.\u201d\n\nAiming to prevent migraines before they start\n\nThere\u2019s plenty of room for improvement.\nIt\u2019s by no means a cure for migraines, but it should be enough to merit Food and Drug Administration approvals if the companies can replicate those results in larger trials, according to Eric Schmidt, a securities analyst at Cowen and Co.\n\nEach treatment is now in late-stage development, targeting the roughly 38 percent of migraine sufferers who, like Novak, have at least four headache days per month.\n\u201cI felt like my life was being stolen from me.\u201d\n\nCollectively, Americans miss about 113 million workdays each year because of migraine.\n\u201cThat\u2019s a perfect combination of things that make people feel able to dismiss it.\u201d\n\nNovak, a professor of photography at New York University\u2019s Tisch School of the Arts, spent years trying to hide her migraines because of the stigma attached to the condition.\n", "question": "Does the story commit disease-mongering?", "explanation": "This was a close call, but\u00a0we did feel the quote \u201cIt\u2019s like you\u2019re possessed\u201d and similar strong statements crossed a line. Yes, migraines can be debilitating, but there are many effective treatments for most migraine sufferers. This story made it sound like the tortures of the damned and that none of the standard treatments helps. Although that is true for some people, it is unlikely to be true for a majority of\u00a0migraine sufferers. Some attempt to acknowledge that there are effective treatments for many people would have helped balance this out.", "answer": 0}, {"article": "\"Our research could help develop policies that make the service more accessible to low-income women,\" added senior author Nazeem Muhajarine, a professor in community health and epidemiology at the University of Saskatchewan and McRae's supervisor while she conducted the research.\nMidwifery is not available in all parts of the country.\n\"But more vulnerable women might not be as aware of the services available to them, so expanding midwifery to make it available for all women is important.\"\nCompared to those who received care from an OB, low-income women receiving midwifery care had a 41 per cent reduction in odds for small-for-gestational age birth, the researchers found.\n\"Waitlists for midwives can be quite long, so women who are educated and health-conscious typically access midwives early on in their pregnancies,\" said McRae.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease-mongering.", "answer": 1}, {"article": "And the results, just published by The Cochrane Library, are likely to disappoint people who swear by vitamin C.\n\nAccording to their analysis, daily vitamin C basically had no effect on the incidence of the common cold in the general population, except for very specific groups of people, all of them small groups.\nPreventing colds just isn't one of them.\nIt makes us look toward other methods, aside from vitamin C, Senay concluded.\nIf you suffer an injury, vitamin C is a vital part of the healing process.\nFor adult males, the recommended amount is 90 milligrams per day.\n", "question": "Does the story commit disease-mongering?", "explanation": "The report does not exaggerate the risks of the common cold. ", "answer": 1}, {"article": "And yet, a new study published in JAMA Internal Medicine has found something that may seem counterintuitive: More breast cancer screening didn't actually save lives.\nThe authors of the newest study don't advocate no screening.\nAnd not all mass screening programs are bad.\nFor women under 50 and over 75 \u2014 who aren't at a high risk of breast cancer \u2014 the benefits of mass screening are less clear.\nIf mass mammography screening for breast cancer worked well, fewer women would die from the disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article did not engage in disease mongering.", "answer": 1}, {"article": "Nine rode exercise bikes in a gym to compare the sweat patches\u2019 performance with the decidedly lower-tech method of sweat-testing used today \u2014 taping on absorbent pads and carting the resulting wet samples to a laboratory.\nBy simply looking at a color change, \u201csuch a patch allows people to now have an opportunity to understand their health and how it changes depending on activities.\u201d\n\nIt\u2019s a growing field: Other research groups around the country, including some of Bao\u2019s colleagues, are pursuing wearable biosensors.\nFor simple fitness purposes, it could give an early warning that it\u2019s time to replenish electrolytes before someone starts to feel dehydrated.\n\u201cSweat has biochemical components within it that tell us a lot about physiological health,\u201d said John A. Rogers, who directs Northwestern University\u2019s Center for Bio-Integrated Electronics and led the new research.\nTogether, those measurements can indicate such things as hydration levels or electrolyte loss.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.\nHowever, it does\u00a0suggest electrolytes are a concern for athletes engaged in a relatively short bout of exercise. In turn, this notion fuels the sports drink industry which in turn markets to the general public\u00a0and contributes to the consumption of excess calories and sugar.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story commit disease-mongering?", "explanation": "The story does a satisfactory job of explaining that hernia surgery is a common procedure and\nthat this study challenges the conventional wisdom that all hernias should be fixed.", "answer": 1}, {"article": "FRIDAY, Nov. 4, 2016 (HealthDay News) -- Obese patients who swallowed balloon capsules that helped them eat less lost an average of 15 pounds, roughly two times more weight than patients who just dieted and exercised, researchers report.\n\"As time goes on, weight loss will be about lifestyle changes,\" he said.\n\"If they are able to stick to their newfound lifestyle with their diet and exercise program, they could maintain their weight loss,\" she said.\n\"It may make it easier to become motivated,\" he said.\nAs many as three balloons were placed over three months, and all of the balloons were removed after six months.\n", "question": "Does the story commit disease-mongering?", "explanation": "The researcher quoted in the story notes that this device could be an option for people who are leery of surgery. Independent sources quoted in the story predict a small role for such devices.", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc\u2019s treatment for a side effect caused by a commonly prescribed Parkinson\u2019s drug, sending the shares of the drugmaker soaring in after-market trading.\nThe long-acting therapy is taken once-daily at bedtime.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nThe company said the drug is expected to be available in the fourth quarter, and formally launched in January 2018.\nThe main ingredient of Gocovri, amantadine, has been available in the market as an antiviral drug for several decades.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering.", "answer": 1}, {"article": "\u201cThis is still investigational and requires more research.\n(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nThe medical device maker said it completed an initial feasibility study of 30 men, average age of 60, who suffered from erectile dysfunction (ED).\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\nInitial findings showed two-thirds of men who underwent the 1- to 2-hour procedure improved by at least 4 points on the 30-point Internal Index of Erectile Dysfunction scale, he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "We think there\u2019s an element of disease-mongering at play here.\nNo source was cited for the estimates of 30 million US men and 300 million worldwide with erectile dysfunction. For example, it took us just seconds to find one citation:\nSecond, the story could have noted that erectile dysfunction comes in many forms \u2013 some as the result of illness, some from treatment of another problem.\u00a0 And many of these baseline problems \u2013 such as cardiovascular disease and diabetes \u2013 are preventable.\u00a0 And the estimates take into account ALL degrees of erectile dysfunction \u2013 not all equate to a total inability to achieve an erection.\nThird, the vascular causes might not be safely amenable to stenting. We don\u2019t know the inclusion/exclusion criteria for the study.\nSo, even in a business story, the \u201cmarket\u201d of \u201ca real unmet clinical need\u201d for a surgical procedure may have been inflated in this story.", "answer": 0}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story commit disease-mongering?", "explanation": "The numbers are there \u2013 but disconnected \u2013 in the story.\nIn one place we learn that there are \u201c36 million hapless Americans who suffer from migraines.\u201d\nIn another we learn that the FDA approved Botox for chronic migraines that afflict \u201c3 percent of migraineurs.\u201d\nIn another place, a neurologist says the approach may be \u201chelpful to a subgroup of migraineurs.\u201d\nWe wish the story had made it clear \u2013 in one place \u2013 that not all migraines are the same and not all might be candidates for an approach like this.\n\u00a0", "answer": 1}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story commit disease-mongering?", "explanation": "The story does an excellent job of questioning whether the \"disorder\" the patch is designed to treat should be considered a medical condition.", "answer": 1}, {"article": "Previous reports22,23 of the overall randomized clinical trial found locoregional control and survival advantages associated with the addition of cetuximab to radiotherapy.\nThe duration of locoregional control was defined as the absence of locoregional disease progression at the scheduled follow-up visits and was determined through a masked review of the investigator-generated data by an independent committee of experts.\nThe Kaplan-Meier method was also used to estimate the rate of preservation of larynx.24 Patients who underwent no surgery or lesser operations were censored at death or date of last contact.\nIn a recent trial from France, 269 patients were queried about the treatment choices they might make if they faced the diagnosis of advanced laryngeal cancer.30 Only 29% stated that they would not consider options with a lower chance of cure if told that the best option, with respect to survival, was total laryngectomy.\nHistorically, locoregionally advanced squamous cell cancers of the larynx or hypopharynx have been treated with surgical resection, usually involving laryngectomy with or without postoperative radiotherapy.1 Although laryngectomy is an effective treatment, investigators have sought therapeutic strategies that result in voice preservation.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release might have mentioned that layyngeal cancer is partly preventable with the human papillomavirus (HPV) vaccine.", "answer": 1}, {"article": "Down the road, the \"fantasy\" is that asymptomatic people will be able to get a biomarker test to determine whether they'll one day get Alzheimer's, but that's not possible right now, he adds.\nThe results from the study suggest that beta-amyloid is a much earlier predictor of Alzheimer's disease than tau, which supports the hypothesis that beta-amyloid accumulation in the brain occurs first in the course of the disease.\nSome of the participants, who were originally found to be stable with mild cognitive impairment after about five years, went on to develop Alzheimer's disease during the longer follow-up.\nGenerally, about 30% to 60% of patients with mild cognitive impairment show evidence of underlying symptoms of Alzheimer's, so not everyone with this condition is a good candidate for an Alzheimer's trial.\nThe current thinking is that interventions will be most effective when given to a patient as early as possible, Brickman said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in the story.\u00a0 In fact, it explained that \u201cnot everyone with this condition is a good candidate for an Alzheimer\u2019s trial.\u201d", "answer": 1}, {"article": "TUESDAY, Aug. 11, 2015 (HealthDay News) -- Colonoscopy can save lives, but experts agree that testing rates remain too low.\nThe study found that patients classified under the scoring system as low-risk did, in fact, have far fewer advanced abnormal growths that might develop into cancer, compared to patients classified as high-risk.\nFor now, he said, the data from this study is not strong enough to spur any changes in current screening recommendations.\nThe system might also make colon cancer screening more efficient and boost the number of people who get checked for the disease, said a team led by Dr. Thomas Imperiale of Indiana University Medical Center, in Indianapolis.\nHe believes that the scoring system \"was only modestly able to separate people within the risk groups.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not hype the incidence or seriousness of the disease. The prevalence statistics cited are consistent with these National Cancer Institute figures.", "answer": 1}, {"article": "The primary efficacy endpoint \u2013 change from baseline to day 28 in MADRS total score \u2013 was assessed among patients who received \u22651 dose of (nasal spray and oral) study medication by mixed-effects model using repeated measures using a one-sided significance level of 0.025.\nUpdate on partial response in depression.\nWe bring together the best minds and pursue the most promising science.\n\u2022 National Institute of Mental Health.\n\u2022 Johnson & Johnson Press Release.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Systolic blood pressure \u2014 the top number on a blood pressure reading \u2014 fell by almost six points on average in the placebo group over the 12-week study, but by just over one point in the treatment group.\nNeither the researchers nor the participants knew who was receiving the seaweed supplement.\nQuestions remain about the safety of the fiber supplement over the long term.\nIn terms of calories, flavor and appearance, the placebo and treatment drink were identical.\nJust looking at the effect of the supplement on people who finished the treatment can bias the findings, she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "\"We think that if you have an active sex life it's probably an indicator of a healthy lifestyle, especially in the oldest quartile--those 70 to 80 years old,\" Andersson said.\nIn addition to a decreased mortality, men using PDE5 inhibitors or alprostadil were 40 percent less likely to be hospitalized for heart failure compared to those not taking any erectile dysfunction drugs.\nThe meeting runs March 17-19.\nThe research is based on a Swedish national database of health records that includes all hospitals in Sweden.\nIt is possible that using erectile dysfunction drugs simply indicates a more active sex life, which could itself contribute to, or be a marker of, a heart-healthy lifestyle overall.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering. The release provides some context about the condition.", "answer": 1}, {"article": "Scientists are inching closer to a drug that may protect peanut allergy sufferers from potentially life-threatening complications that can occur due to accidental consumption.\nIn addition, the symptoms caused by the 100-fold higher dose at the end of the study were milder than the symptoms on the lower dose at the beginning of the study.\u201d\n\nEXPERTS: CHILDREN AT RISK OF LEAD POISONING IN CHATTANOOGA\n\nWith FDA approval this drug would mark the first treatment available by prescription for peanut allergies.\nWhile the drug is not being hailed as a cure for peanut allergy, it has proven successful in building up patients\u2019 tolerance to peanuts over time, lessening the potential for life-threatening complications.\n\u201cWe\u2019re excited about the potential to help children and adolescents with peanut allergy protect themselves against accidentally eating a food with peanut in it,\u201d said allergist Stephen Tilles, MD, ACAAI former president, study co-author and consulting advisor for Aimmune Therapeutics, according to EurekAlert.\n\u201cThis is not a quick fix, and it doesn\u2019t mean people with peanut allergy will be able to eat peanuts whenever they want,\u201d Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author, said, according to EurekAlert.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story appropriately characterizes peanut allergy as a \u201cpotentially life-threatening\u201d condition, with peanut ingestion. There\u2019s no data on how many people might benefit from this drug, however.", "answer": 1}, {"article": "They\u2019re also studying the cost difference.\n\u201cThe prevalence of this disruptive condition is common and increases with age, from 17 percent of women older than 45 years to 27 percent older than 75 years in the United States,\u201d they wrote.\nAnd, according to the National Institutes of Health, between 25 percent and 45 percent of all women have some degree of urinary incontinence.\n\u201cForty-six percent in the onabotulinumtoxinA (Botox) group and 26 percent in the sacral neuromodulation group had at least a 75 percent reduction in the number of episodes of urgency incontinence,\u201d they added.\nBut both groups of women reported equal satisfaction, and more women in the Botox group got urinary tract infections \u2013 35 percent versus 11 percent in the surgery group.\n", "question": "Does the story commit disease-mongering?", "explanation": "We don\u2019t see any language that would unnecessarily frighten a reader. The condition is real, uncomfortable, and carries\u00a0significant impact on people\u2019s daily lives.", "answer": 1}, {"article": "The other groups showed no significant change.\nThe study, published Monday in The Proceedings of the National Academy of Sciences, appears to be the first to link calorie-restricted diets with improved memory in people.\nEating fewer calories may lead to better memory, a new study says.\nMembers of a second group kept their calories the same but were instructed to increase the unsaturated fat (healthy fat) they ate by 20 percent.\nThe study was small, involving 50 men and women ages 50 to 72 who ranged from normal weight to overweight.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the severity or incidence of memory loss in older adults. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "No obvious elements of disease-mongering. ", "answer": 1}, {"article": "MONDAY, June 19, 2017 (HealthDay News) -- Acupuncture is a safe and effective alternative to pain medications for some emergency room patients, a new study reports.\nThe study was published June 18 in the Medical Journal of Australia.\nBut he noted that more research is needed because some patients remained in pain no matter what treatment they received.\nThe U.S. National Institutes of Health has more on acupuncture.\nThe study participants were seen at four Australian emergency departments for acute low back pain, migraines or ankle sprains.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to be disease-mongering.", "answer": 1}, {"article": "Treatment typically involves the use of inhaled steroids and bronchodilators to open airways and make breathing easier.\nIt is often marked by a chronic cough and shortness of breath.\nCOPD is the umbrella term for chronic lung diseases, including chronic bronchitis and emphysema.\nIn a new study of 68 people with COPD, some got acupuncture, along with their daily medication, for three months.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering. The story appropriately details COPD, as well as its symptoms and treatment.", "answer": 1}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story commit disease-mongering?", "explanation": "The figure cited without sourcing by the reporter \u2014 340,000 hip replacements performed annually in the U.S. \u2014 is slightly above the figure cited by the Centers for Disease Control and Prevention, but not enough to justify a claim of disease mongering.", "answer": 1}, {"article": "It shows that palliative care and cancer care aren\u2019t mutually exclusive.\u201d\n\nDr. Atul Gawande, a Harvard Medical School surgeon and writer who just published a long article in The New Yorker about hospitalized patients\u2019 suffering before death, called the study \u201camazing.\u201d\n\n\u201cThe field was crying out for a randomized trial,\u201d he added.\n\u201cWe thought it made sense to start them at the time of diagnosis.\n\u201cBut it\u2019s piecemeal,\u201d she said.\nLegislators eventually removed the provisions.\nIt includes the options any oncologist addresses: surgery, chemotherapy and radiation and their side effects.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nThe finding \u201cis not generalizable to other patients,\u201d he said.\n\u201cWe don\u2019t really know where we are,\u201d Guallar told Reuters Health.\nTheir results are published in Annals of Internal Medicine.\nTaking the highest dose of selenium was not linked to decreases in total cholesterol \u2014 but it was the only dose associated with an increase in HDL (\u201cgood\u201d) cholesterol.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in this story.", "answer": 1}, {"article": "In traditional transplants, hair follicles are taken from an area that runs an inch or two above the ears and temples to the back of the head.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\nIf you take that hair and use it in the hairline, it can end up looking harsh and pluggy, because the hair is too thick.\u201d\n\nDr. Umar was inspired to develop the procedure in part from personal experience.\nThe condition, also called androgenic alopecia, typically begins at the hairline and eventually creates a horseshoe-shaped pattern of hair around the ears.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story engages in the worst kind of disease-mongering by overstating the potential benefits of the unproven procedure and by attempting to turn one of the most naturally occurring phenomena of aging into a medical condition that requires treatment. The story says, \u201cThe procedure has the potential to restore the hairlines of millions of men with male pattern baldness, the most common cause of hair loss and often an enormous source of stress.\u201d Then it goes on to use the term that hair transplant surgeons love to use to market their techniques, \u201cThe condition, also called androgenic alopecia, typically begins at the hairline and eventually creates a horseshoe-shaped pattern of hair around the ears. It stems from a sensitivity \u2014 largely genetic \u2014 to the effects of hormones on hair follicles.\u201d Yes. It\u2019s genetic. It\u2019s called being born with an X and Y chromosome. Given this description, roughly 50% of the world\u2019s population may be potential victims of this genetic problem.", "answer": 0}, {"article": "\u201cOnce again pregnant women are being told it\u2019s O.K.\n\u201cAccording to NOAA\u2019s own statistics, per capita consumption of seafood has risen from 14.8 pounds in 2001 to 16.6 pounds in 2004.\u201d\n\nJane Houlihan, the research director of the Environmental Working Group, another advocacy group, said, \u201cThe Harvard study reads like an advertisement for the seafood industry.\u201d\n\nBoth studies reinforce advice from the Food and Drug Administration and the Environmental Protection Agency in 2004, to eat about six ounces of fish a week, preferably high in omega-3\u2019s, with a caveat for women of childbearing age and children under 12 not to eat swordfish, shark, tile fish or king mackerel and to limit their intake of albacore (white meat) tuna to six ounces a week to avoid mercury.\nDr. Malden C. Nesheim, chairman of the institute\u2019s committee and a provost emeritus at Cornell, said, \u201cWe are quite cautious because the studies we looked at are not controlled for all the variables, and we can\u2019t distinguish between the effects from omega-3\u2019s or replacement of other foods in the diet.\u201d\n\nThe National Oceanic & Atmospheric Administration had requested the institute\u2019s report because it said consumers were confused about how much and what kind of fish they should eat.\nDr. Mozaffarian agreed that, because the evidence is based on observational studies and clinical trial data, it is not definitive, but he added, \u201cIt\u2019s the best evidence we have.\u201d As for the study\u2019s finding that total mortality could be cut by 17 percent, he said, \u201cWhile one can argue over the precise size of benefits, even if the benefit is only one-half or one-quarter as large, it still greatly outweighs the risk.\u201d\n\nThe report from the Institute of Medicine tells the government that much more research is needed.\n\u201cFortunately, Environmental Defense and Monterey Bay Aquarium, who specialize in both health and environmental fish issues, provide advisory cards for choosing fish, and no one can manage this without one.\u201d\n\nThe Environmental Defense list is at oceansalive.org and the Monterey Bay Aquarium\u2019s is at mbayaq.org/cr/seafoodwatch.asp.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article will disappoint fishmongers and disease mongers alike. It carefully mutes the hope and hype surrounding both the purported benefits of dietary fish consumption (reductions in coronary death and death from all causes) as well as the risks (contamination by mercury, PCBs, and dioxins).\u00a0  ", "answer": 1}, {"article": "\u201cWhat\u2019s really important to say is that bipolar disorder is very difficult to treat, the burden is enormous, and these medications help keep people free of mood and anxiety symptoms and allow them to function,\u201d said Andrew A. Nierenberg, medical director of the bipolar clinic and research program at Massachusetts General Hospital.\nThese medications are primarily used to help epileptics control seizures and to calm the surges in energy and mood that, along with bouts of depression, characterize bipolar disorder.\nThe increased risks, while double in relative terms, are small.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\nTaken together, the risk of suicidal thoughts and behavior was 0.43 percent for those on drug therapy and 0.22 percent for those given placebos.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.\u00a0\u00a0 The story would have been improved by giving info on how often these medications are prescribed AND/OR how common the illnesses are. ", "answer": 1}, {"article": "Byrd said it is more common in men than in women.\nIn the past 10 to 15 years, doctors have discovered one specific cause of hip pain: a tear in the acetabular labrum, a condition in which the cartilage that lines the hip socket is damaged.\nThis is a marked uptick from a decade ago, when Ochiai said the single course in hip arthroscopy was nearly canceled due to lack of interest.\n\"The big difference is that with the knee, most of the things we're doing arthroscopically evolved from things we were doing in open surgery,\" Byrd said.\nWith the hip, however, doctors using arthroscopes discovered a host of conditions, including labrum tears and FAI, that had not been recognized.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n \nHip pain can be very uncomfortable and occasionally disabling. The story does not over hype the problem or medicalize a normal human variation. Although it suggests that labral tears \u201ccan lead to osteoarthritis,\u201d it doesn\u2019t provide a complete picture of the natural history: do the symptoms ever go away on their own, even if the pathology doesn\u2019t? In addition, there is no mention of how common the problem is and how many of these procedures are now being performed. ", "answer": 1}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt found that 52% of low-FODMAP patients and 41% of patients on a less-restrictive diet reported \u201cadequate relief.\u201d The difference was not statistically significant, says study co-author William Chey, a professor of gastroenterology.\n\u201cOur goal is for them to be on the most varied, nutritious diet possible.\u201d\n\nThe trickiest part is avoiding onions and garlic, the dietitians say.\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\nThe diet is aimed primarily at people with irritable bowel syndrome, a common condition in which abdominal pain and irregular bowel habits \u2014 with diarrhea, constipation or both \u2014 can wax and wane for years.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did a good job explaining what irritable bowel syndrome is, and notes that it is \u201ccommon.\u201d While we wish more had been said about the prevalence, this is enough to rate satisfactory.", "answer": 1}, {"article": "So mystery and grief hung heavy when he collapsed from a cardiac arrest Jan. 6 inside the Teutonia M??\nThe heart quits pumping blood, leaving vital organs depleted of oxygen -- a situation that can cause significant damage to the brain, kidneys and other organs, or death if quick emergency action is not taken.\n\"We believe the people who do go home have fewer neurological problems that impair the quality of life,\" Dr. Callaway said.\n\"My goal is to get back to a normal life,\" he said, noting he hates cold weather and is surprised he withstood hypothermic therapy.\nA heart attack can prompt cardiac arrest -- a situation in which the heart rhythm goes chaotic, making it quiver rather than beat, Dr. Granato said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The numbers in this story don't square up as describe.\u00a0 The story estimates that the number of people who are killed by acute cardiac arrest in this country is 250,000 per year. But the most recent estimate from the CDC (http://www.cdc.gov/nchs/) is that this is the cause of death for 171,00 people per year.\nThe story engages in treatment mongering by claiming that this treatment could save \"tens of thousands\" of lives each year.\u00a0 However, using the data in the story, (250,000 cases of cardiac arrest; out of 100 cardiac arrests, 7-8 that undergo hypothermia walk out of the hospital as compared to one or two fewer in those who don't undergo hypothermia) hypothermia has the potential for an additional 500 people to walk out of the hospital.\u00a0 This is 500 more happy outcomes but not \"tens of thousands\".", "answer": 0}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "He'd read about advances in targeted therapies \u2014 drugs that go after cancer cells at the molecular level.\nOur series is produced with member station WNYC, and with Ken Burns Presents: Cancer: The Emperor of All Maladies, which will air on PBS starting March 30.\nBut in the meantime, patients like Anselmo are grateful to have time they wouldn't have had otherwise.\n\"We took a disease where nothing really works for any length of time and we've given her a year of life, and hopefully much more, where she's been much better,\" Hyman, her oncologist, says.\nCalled a basket trial, the study is designed to include people whose tumors have the same kind of genetic fingerprint regardless of where in the body the tumors are found.\n", "question": "Does the story commit disease-mongering?", "explanation": "The opening quote from the patient profiled in this story is dramatic:\u201d\u2018Oh my God, you\u2019re history.\u2019 It\u2019s like a death sentence.\u201d \u00a0Given the poor survival statistics associated with this type of cancer, that type of reaction is certainly understandable. But if a story is going to lead with an alarming statement like that, we\u2019d also expect it to provide some backing in the form of dispassionate, evidence-based figures about survival. Otherwise it\u2019s not clear whether patients typically have weeks or years to live following a diagnosis.", "answer": 0}, {"article": "What if, her team began to think, it could come up with a blood test for schizophrenia?\n\u201cAs the development costs of a test are very high, there is a risk that the test will not be commercially viable.\u201d For severe mental illnesses like schizophrenia, it\u2019s also the case that even if a test made it through development and hit the market, it may not be successfully integrated into psychiatric practice.\nThe test, says Bahn, can accurately predict whether someone will \u201cdevelop schizophrenia over the next two years.\u201d\n\nBahn\u2019s finding is one of several recent advancements toward a comprehensive system of biological mental health diagnostic tools.\nIt took a few years to find the right \u2018formula\u2019 of meds.\u201d While the doctors recommended some medication that helped, it was a matter of trial and error, since Orlando still doesn\u2019t have a concrete diagnosis today.\nShe recalled her boyfriend at the time searching the web for her diagnosis and saying: \u201cOh God, no.\u201d After that, she kept quiet about her diagnosis, worried it would drive friends away.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this piece, and we give it high marks for how it approaches the topic of mental health. It is trying to bring readers into the very real problem of accurately diagnosing these disorders. In that way, it is a very welcome piece of reporting.\nHowever, we did want to note that saying a delayed diagnosis may come \u201ctoo late\u201d is somewhat hyperbolic\u2013it implies that there is a limited period in which prevention or effective treatment is possible, and after that, it\u2019s no longer possible. This is not always the case.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "By not\u00a0exaggerating the seriousness of wet AMD, the story avoids disease mongering. The story should have provided some sense of the prevalence of wet AMD, which is relatively rare compared to the more common dry AMD.", "answer": 1}, {"article": "This is really about patient care.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\nThe researchers estimated that shifting standard practice by 30 percent to the wrist approach, along with same-day discharge, could save the United States $300 million per year.\nDespite the fact that all of these patients were capable of leaving the hospital the same day as their procedures, only about 5 percent of these patients actually were discharged without having stayed overnight.\nBut with advances we have in technology and equipment, those challenges are rapidly decreasing.\u201d\n\nThis work was supported by a grant from Vita Solutions, a subsidiary of The Medicines Company, for whom Amin has provided consultation; and by the National Institutes of Health (NIH), grant numbers UL1TR000448, KL2TR000450, TL1TR000449 and 1KM1CA156708-01.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It provides strong context on what coronary angioplasty is, how many are performed annually, average costs and projects cost savings.", "answer": 1}, {"article": "\"Time is brain in acute stroke after vascular collaterals fail, and faster treatment yields better outcomes,\" said May Nour, M.D., Ph.D., lead researcher, interventional neurologist and director of UCLA's Mobile Stroke Rescue Program.\nThe study was funded by the Arline and Henry Gluck Foundation.\nThe association has strict policies to prevent these relationships from influencing the science content.\n\"Treatment then needs to happen as quickly as possible, and a mobile stroke unit may allow that to happen.\"\nAuthor disclosures are on the abstract.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release.", "answer": 1}, {"article": "For more information, visit http://www.\nFounded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology.\n\"This is a well-designed trial that demonstrates how a prebiotic could potentially help combat one of the most prevalent and costly conditions afflicting children in the developed world -- overnutrition -- by targeting the gut microbiome,\" said Geoffrey A. Preidis, MD, PhD, a member of the AGA Center for Gut Microbiome Research and Education scientific advisory board.\nPrebiotics reduce body fat in children who are overweight or obese by altering their gut microbiota, according to new research published in Gastroenterology, the official journal of the American Gastroenterological Association (AGA).\nGastroenterology, the official journal of the AGA Institute, is the most prominent scientific journal in the specialty and is in the top 1 percent of indexed medical journals internationally.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here; childhood obesity is widespread and a real threat to public health. The release would have benefited from inclusion of a note about the role of healthy diets, exercise and parent/child education in preventing childhood obesity as well as a caution that supplements may not be an antidote to poor adherence to a healthy lifestyle. ", "answer": 1}, {"article": "Doctors used the self-learning computer to detect changes in brain scans too subtle for humans to see.\nDr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nBritish AI expert Prof Noel Sharkey, from the University of Sheffield, said of the findings: \"This is exactly the sort of task that deep learning is cut out for - finding high-level patterns in data.\n\"This study highlights the potential of machine learning to assist with the early detection of diseases like Alzheimer's, but the findings will need to be confirmed in much larger groups of people before we can properly assess the power of this approach.\"\n\"Although the sample sizes and test sets were relatively small, the results are so promising that a much larger study would be worthwhile.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not disease monger.\nHowever, we found this sentence problematic and think it\u2019s worth noting:\nEarly detection of Alzheimer\u2019s could open the door to new ways of slowing down or even halting the progression of the disease\nAlthough the tone is speculative, it still erroneously suggests that early detection could result in slowing or stopping Alzheimer\u2019s. At this time there is no treatment \u2014 regardless of the timing of the diagnosis \u2014 that can significantly slow or definitively stop this progressive neurologic disease.", "answer": 1}, {"article": "MONDAY, Aug. 1, 2011 (HealthDay News) -- When women take a supplement of the omega 3 fatty acid DHA during pregnancy, their babies have fewer cold symptoms and shorter illnesses, new research indicates.\nThe babies were assessed at 1, 3 and 6 months of age, and the mothers completed questionnaires about their babies' health.\nThe treatment group received 400 milligrams of DHA each day, beginning when they were between 18 and 22 weeks pregnant.\nTreatment continued at least until the birth of the baby.\nAnd, at 6 months, the babies whose mothers had DHA had shorter duration of fever, runny nose and breathing problems.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "Reavill says he may be proudest of his intention to hire disabled veterans in southern Illinois, a hard-hit region economically.\nIt remains to be seen whether that saved time will result in saved lives.\nIt can be inserted in a nonsterile environment such as an emergency room.\n\"You get an objective number and it becomes less art, less gestalt and more evidence-based.\"\nThe catheter is inserted into the arm and travels to the heart within 20 to 30 seconds via the bloodstream.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable.\u00a0 There wasn\u2019t really any specific discussion of any condition.", "answer": 2}, {"article": "Hartmann said doctors could take pressure off women by performing lumpectomies first to eliminate their cancer tumors.\n\u201cIf I didn\u2019t do as much as possible to eliminate the cancer, I would feel like I was almost waiting for the other shoe to drop.\u201d\n\nWomen removing a single cancerous breast have a 1 percent chance per year of suffering cancer in the other breast.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\n\u201cI\u2019m worried about the women who are on the fence and make a very quick decision before really considering the other options or the fact that it is an irreversible procedure,\u201d said Dr. Todd Tuttle, the U\u2019s chief of surgical oncology and lead author of the study in the Journal of Clinical Oncology.\nThe rising use of magnetic resonance imaging, MRI, is likely contributing to the increase in double mastectomies, said Dr. Joseph Leach, a medical oncologist with Park Nicollet Health Services.\n", "question": "Does the story commit disease-mongering?", "explanation": "The reporter does nothing to exaggerate the risks of cancer spreading from one breast to the other. In fact, the reporter does a good job making clear that the risk is lower than many patients think. ", "answer": 1}, {"article": "Franks says thalidomide can help an additional 75% of patients achieve remission.\nIn more recent years it has been brought back to the market to treat a number of serious conditions, but its use is monitored closely to ensure that it is not taken by women who are pregnant or who might become pregnant.\nThe researchers note that the study dose was \u201cgenerally well-tolerated.\u201d No new nerve symptoms were reported.\nThe majority of the patients (60%) had the most common subtype of lupus-related skin disease, known as discoid lupus erythematosus, which is characterized by red, scaly patches that can scar.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article did not commit disease mongering. But it actually didn\u2019t provide enough background on lupus skin conditions to even be judged on this criterion.\nIt could have mentioned that this is an uncommon skin condition and that it is addressing the uncommon individual with this condition that doesn\u2019t respond to standard medications. That would have driven home point that the medication in question would be used very rarely.", "answer": 2}, {"article": "CBS News correspondent Kelly Wallace reports Kate Miller's 15-year-old son Cody killed himself just 17 days after starting the drug.\nMichelis said, \"They should not stop taking their medication unless they are experiencing a major change in their moods.\"\nShe's now writing letters to every patient who takes Singulair, urging them not to over-react.\nHis mom now believes that Singulair cost him his life.\nFDA said it is also reviewing reports of side effects with those drugs.\n", "question": "Does the story commit disease-mongering?", "explanation": "By emphasizing one tragic story about a teenager who took the drug and committed suicide, the segment exaggerates the likelihood that the two are linked.\u00a0 ", "answer": 0}, {"article": "The Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\nNobody looks forward to having a cavity drilled and filled by a dentist.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Bishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\nIt usually happens when people grip things too hard or too long.\nAnd the FlexBar makes it simple to do this kind of stretch.\nAnd he didn't want to give it all up due to a \"spot of pain\" in his elbow.\nThe exercises enable the muscle to lengthen and contract simultaneously.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not overstate the consequences of tennis elbow, which can cause\u00a0debilitating pain that\u00a0interferes with work and activities.", "answer": 1}, {"article": "Parents get frustrated with the FDA recommendations not to use cold medicines in kids under the age of 4 because they are left with few options.\nIn the study, funded by an unrestricted research grant from Procter & Gamble, makers of Vicks, researchers took 138 children between the ages of 2 and 11, with symptoms like cough, congestion, runny nose and restless sleep that lasted seven days or more.\n\"I have found that when used properly it can be a good option for parents who want to relieve some cold symptoms in their children.\nThat night, 30 minutes before bedtime, Vicks or petroleum jelly was rubbed onto the child's chest and neck.\nBut as with any product, parents need to read the instructions carefully and keep medicines out of the reach of children.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story accurately describes the children in the study as having \u201csymptoms like cough, congestion, runny nose and restless sleep that lasted seven days or more.\u201d", "answer": 1}, {"article": "Still, some researchers not involved in the study said the topic required more work.\nThe smoking rate has declined substantially since the 1960s, but the pace of decline has slowed in recent years and health experts are trying to figure out how to get more smokers to quit.\n\u201cThe approach taken here is a very reasonable one that appears to have been successful,\u201d said Gary A. Giovino, a professor of health behavior at the State University of New York at Buffalo.\nIf such studies were funded by the government, which sustains a lot of academic research, taxpayers would bear the burden for what the company would eventually profit from, he said.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the health effects of smoking, although one could argue that it engages in mild \u201ctreatment mongering\u201d of smoking cessation via the headline and a very enthusiastic quote that stretch the potential benefits of the drug.", "answer": 1}, {"article": "Moffitt researchers compared the overall survival and the time to diagnosis of a second tumor, if any, of 250,195 breast cancer patients who received either neoadjuvant or adjuvant radiation therapy.\nThe majority of patients who have early stage breast cancer have surgery to remove their tumor or a complete mastectomy.\nThis was true for patients who underwent both partial and complete mastectomies.\nThey included female patients in the analysis who were diagnosed between 1973 and 2011 with early-stage breast cancer.\n6 cancer hospital in the nation and has been listed in U.S. News & World Report as one of the \"Best Hospitals\" for cancer care since 1999.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering noted.", "answer": 1}, {"article": "But after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\n\u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\n\nLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\nLONDON (Reuters) - Exposure to bright light can raise testosterone levels and lead to greater sexual satisfaction in men with low sexual desire, according to the results of a small scientific trial.\nAfter taking baseline readings, they divided the men into two groups and gave one regular treatment with a bright light box, while the control, or placebo, group was treated with a light box adapted to give out significantly less light.\nScientists at the University of Siena in Italy found that regular, early-morning use of a light box \u2013 similar to those used to combat Seasonal Affective Disorder or SAD - helped men increase testosterone and improved their sex lives.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story says low sexual desire \u201ccan affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\u201d Still, it\u2019s unclear how many of these cases might be related to seasonal affects. Aging, medications, sleep problems, mental disorders and many other factors can affect libido.", "answer": 1}, {"article": "\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\nThere was also an 18% reduced risk of dying from any cause over the 20-year period.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\n\u201cThe role of cholesterol in causing heart disease has been disputed by some, but this paper provides yet more evidence of the link, and the benefits of statins to prevent heart disease.\u201d\nThe 20-year project examined data from 2,560 men taking part in a randomised clinical trial to test the effects of statins versus a placebo.\n", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t see any unwarranted language, though the potential is high for overtreatment when using a drug in healthy people.", "answer": 1}, {"article": "CHICAGO (Reuters) - The common diabetes drug metformin may hold promise as a way to keep smokers from developing lung cancer, U.S. researchers said on Wednesday.\nTobacco kills one-third to one-half of those who smoke.\nThey treated the mice with metformin either orally or with an injection.\nMetformin has been shown to switch on an enzyme that blocks mTOR \u2014 a protein that helps tobacco-induced lung tumors grow.\nMice that got the drug orally had 40 to 50 percent fewer tumors, while those injected with the drug had 72 percent fewer tumors.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering of disease and death from use of tobacco products. ", "answer": 1}, {"article": "Chicago (CNN) -- For the first time, patients with the deadliest form of skin cancer have two new treatment options that prolong survival, according to new research presented at a cancer conference in Chicago on Sunday.\nPatients with and without the BRAF mutation were eligible to participate.\n\"I've been doing this for 25 years, and we've not had drugs that extended survival.\nThis is very unusual in the world of drug development, he said.\nNearly 90% benefited from this new targeted drug, Schuchter said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of melanoma.", "answer": 1}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nSome of these fragments eventually turn up in blood and even in saliva.\nIn most cases, concussion symptoms last only a few days.\nThe team did an experiment that involved 50 concussion patients between the ages of 7 and 18.\nIn contrast, a concussion survey commonly used by doctors was right less than 70 percent of the time.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness of concussions.", "answer": 1}, {"article": "This data satisfies both pre-specified criteria for non-inferiority and superiority of Flublok over the traditional egg-based quadrivalent inactivated vaccine.\nVaccination with Flublok may not protect all individuals.\nHeadache, fatigue or muscle ache may occur.\nFlublok Quadrivalent is FDA approved for adults 18 and older.\nThe most common side effect from Flublok is pain at the site of injection.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "NEW ORLEANS (Reuters) - Abbott Laboratories Inc\u2019s experimental Absorb heart stent, designed to dissolve and thereby restore the blood vessel\u2019s natural flexibility, has proven safe and effective a year after being implanted in patients, researchers said.\n\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\n\u201cThat would be one compassionate use of it, a very serious application.\nHe said Absorb and stents like it will likely be the next generation of stents and ultimately improve outcomes for patients.\nAbbott said 6.9 percent of patients suffered major cardiac events \u2014 including heart attacks \u2014 over a 12-month period, which the device maker described as a low rate.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering.", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "But Shapiro stressed that making healthy changes to what you eat can only do so much.\n\"Apples really are an amazing fruit for many reasons,\" said Shapiro, who is a clinical nutritionist who counsels cardiac patients at Montefiore Medical Center in New York City.\n\"The pulp of an apple gets to be a very viscous gel-like substance that grabs cholesterol and pulls it out of the body.\n\"I never expected apple consumption to reduce bad cholesterol to this extent while increasing HDL cholesterol or good cholesterol by about 4 percent,\" Bahram Arjmandi, chair of the department of nutrition, food and exercise sciences at Florida State University in Tallahassee, said in a statement.\nMany foods can have an effect on cholesterol levels, according to the U.S. Centers for Disease Control and Prevention.\n", "question": "Does the story commit disease-mongering?", "explanation": "We\u2019re going to take a hard line on this \u2013 and we admit we hold the bar high, but we think it\u2019s for important reasons.\nThe story only discusses changes in cholesterol scores \u2013 and actually doesn\u2019t do a very good job of that because it only provides relative risk changes, not the absolute score changes.\u00a0 (14% of what?\u00a0 23% of what?\u00a0 4% of what?)\u00a0 But the bigger point is that there was no discussion of what difference these changes actually makes on peoples\u2019 cardiovascular heatlh.\u00a0 Yet the story was headlined, \u201cAn apple a day may help keep heart disease away.\u201d\u00a0 Where was that shown?\u00a0 The first sentence said \u201ceating apples\u2026may be good for your cardiovascular health.\u201d\u00a0 Where was the evidence that these lower scores actually equate to improved outcomes?\nChanges in cholesterol scores are changes in risk factors \u2013 not necessarily changes in the disease itself or in individual outcomes.\u00a0 The story could have said that in just an additional line.", "answer": 0}, {"article": "\u201cWe would hope that it would work just as well ... there is no reason why not.\u201d\n\nThe ability to base a diagnosis on an objective biological test, rather than having to rely on personality traits, should mean patients get treatment more quickly, he added.\nCognitive behavioral therapy and educational treatment can be highly effective for some patients and the impact of a more certain prognosis would be especially beneficial for children.\nExperts not involved in the research applauded the research but cautioned further study was still needed.\nThe next goal is to test it in children.\nAutism spectrum disorders are diagnosed in one percent of the population in Britain and the United States, and the condition affects four times as many boys as girls.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t exaggerate the prevalence or impact of autism.", "answer": 1}, {"article": "\"I think [the results] are very encouraging,\" Bruce Lanser, a pediatric allergist who directs the Pediatric Food Allergy Program at National Jewish Health in Denver, told us.\n\"If the symptoms were treated with just Benadryl or another antihistamine, they were considered mild or moderate.\nAs we've reported, people sometimes misinterpret the symptoms of a condition such as lactose intolerance for a food allergy.\n\"And the last thing I want to miss is the opportunity to get a food into a kid's diet.\"\n\"All they can tell us is how likely you are to react when you eat the food.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering is present in the story. Severe food allergies can be life threatening, but the story focuses on the daily experience of children who live with them.", "answer": 1}, {"article": "Has he had any use of prescription painkillers since he started the study?\n\"They make you feel great; I'm not going to lie, you take a couple pills, you feel relaxed, you don't feel nervous, you have the weight of the world off your shoulders,\" said one young man named Brian who would not letreveal his identity.\nSuboxone works by taking the place of the opioids in the receptor - not only shutting off withdrawal symptoms but also blocking the effects of any new drugs.\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\n\"When you're taking Suboxone, you're not high, you're not in withdrawal, you're at work, you're dealing with your loved ones, you're having regular interactions...you're going about your life,\" Gourevitch said.\n", "question": "Does the story commit disease-mongering?", "explanation": "In the interview with Brian, the segment explores the psychological impact of painkiller addiction. But it does not exaggerate the risks or severity of the condition.\nStill, it is worth pointing out that the segment fails to state that many patients taking medicines for pain may be physically dependent on them, but do not \"abuse\" the medicine to get \"high\" and on balance benefit from its use.\u00a0 The news piece concerns only people abusing these painkillers, so it may imply that any use of these medications is problematic. This is not true. ", "answer": 1}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. It was good to see the story discuss the concerns around over-use of stents.", "answer": 1}, {"article": "But scientists also realized it could have other uses.\nAnd the population that could be most benefited by this could be post-menopausal women.\u201d\n\nCommenting on the research, Tim Speckor, Professor of Genetic Epidemiology at King\u2019s College London, U.K., says: \u201cIt\u2019s a nice mouse study that seems to work\u2014whether it works in humans is another matter.\u201d\nIt\u2019s a fairly dramatic effect.\u201d Mice also showed increased oxygen consumption, higher levels of physical activity and more heat production in beige fat (which dissipates energy around the body).\nAs a result, they started considering it as a potential treatment for osteoporosis, particularly in post-menopausal women\u2014a period when women lose bone mass fairly quickly.\nIn trials on mice, the antibody was found to increase bone mass and reduce adipose tissue (fat)\u2014and while human studies are some way off, the findings could lead to new treatments for weight loss and osteoporosis.\n", "question": "Does the story commit disease-mongering?", "explanation": "Obesity is a disease, according to many major medical groups including the Centers for Disease Control and Prevention, the World Health Organization, the American Medical Association, among others. But what we take issue here with is how the Newsweek headline wildly and irresponsibly speculates that this research might be an \u201cobesity cure.\u201d At this point, the research is far too preliminary to be linked with the word \u201ccure\u201d (which is one of our 8 words you shouldn\u2019t use in medical news.)", "answer": 0}, {"article": "Dubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\nWhen it reaches the area of the heart that causes abnormal rhythms, the tissue is ablated, or destroyed.\nComplications related to the atrial fibrillation itself were also monitored.\nCryoablation is an alternative that is growing in popularity.\nDuring the follow-up period, 97 percent of patients who got the procedure and 92 percent of the drug therapy patients did not suffer heart attack, stroke or death.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease-mongering of atrial fibrillation. ", "answer": 1}, {"article": "The study entitled \"A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial\" is available online and will be presented at the American Society for Nutrition Annual Conference, Nutrition 2018 held in Boston this June.\nThe study was funded by the National Pecan Shellers Association.\nCalorie levels, as well as protein, carbohydrate, and total fat, were kept the same.\nObesity is a risk factor for T2D, and both obesity and T2D increase CVD risk.\nBoth the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here, and we were glad the story pointed out that\u00a0there are no adverse physical health effects from lice.", "answer": 1}, {"article": "The U.S. Preventive Services Task Force (USPSTF) says there is no proof that the benefits of routine mammogram screening outweigh the risks for average-risk women in their 40s.\nBrawley says.\n\"If all those women were screened in their 40s, only 8,500 would die.\"\nThese women will suffer the harms of early screening.\n\"They get more breast -conserving surgery and less chemotherapy .\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "So, is kiwi the new \"wonder\" fruit?\nThe new study may just \"put kiwis on the map,\" he said.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThey are rich in lutein, a potent antioxidant, and this may be what is responsible for their blood pressure-lowering powers, said researchers who were led by Mette Svendsen of Oslo University Hospital in Norway.\n\"There is biological plausibility, but I would not go and grab three kiwis a day,\" said Dr. Nehal Mehta, a preventive cardiologist at the Hospital of the University of Pennsylvania in Philadelphia.\n", "question": "Does the story commit disease-mongering?", "explanation": "We\u2019re going to rule this one unsatisfactory because this was a study of pre-hypertension \u2013 a set of blood pressure readings that not all are convinced merits treatment.\u00a0 The story should have made that distinction.", "answer": 0}, {"article": "SUNDAY, March 21, 2010 (HealthDay News) -- For the first time in humans, scientists have successfully used a gene-manipulation therapy to enter tumor cells and block the production of toxic proteins that are causing cancer, researchers report.\n\"This is one step away from getting into the actual DNA.\"\n\"This is something we've been waiting to see,\" he continued.\n\"This will run its course.\nThe experiment proceeded just as planned, as biopsies later showed.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable because no diseases were discussed in any detail. ", "answer": 2}, {"article": "Still, the authors say the study strengthens the growing body of evidence that spicy food may have protective health properties that can lead to a longer life.\nParticipants were followed for an average of 18.9 years.\nThe authors suggest further research should investigate the benefits of other spices and the effects of certain chili pepper subtypes.\nhad lower HDL-cholesterol, lower income, and less education,\u201d in comparison to participants who did not consume red chili peppers.\nThe research is observational, so no cause and effect relationship can be established.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t engage in disease mongering.", "answer": 1}, {"article": "SSIs are the most common hospital-acquired infection and the leading cause of hospital readmission following an operation.1,2,3 Due to the prevalence off SSIs, the WiSOR research team decided to see if postoperative wound monitoring could be effectively achieved by having patients upload photos through the WoundCare app and answer a few brief questions to gather information not easily captured through images.\nForty vascular surgery patients were enrolled in the study.\nGeneral and vascular surgery readmissions: a systematic review.\nJournal of the American College of Surgeons.\nAssessing the relative burden of hospital-acquired infections in a network of community hospitals.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease mongering.", "answer": 1}, {"article": "But many others are tough calls.\nMore than 70,000 people in the U.S. will be diagnosed with melanoma this year, and 16 percent are diagnosed only after the disease has spread to other parts of the body, according to estimates from the National Institutes of Health.\n\"There is no such thing as 100 percent certainty in medicine,\" said Dr. George Elias, a melanoma expert at Georgetown's Lombardi Comprehensive Cancer Center who had no ties to the company or the device.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\nThe device is approved only for dermatologists and only for use on growths that don't have obvious signs of cancer but still have one or two worrisome traits.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story both gives the broader context about melanoma while taking care to pinpoint the appropriate patient population. It says in the second paragraph, \u201cThe device is approved only for dermatologists and only for use on growths that don\u2019t have obvious signs of cancer but still have one or two worrisome traits.\u201d It also says, \u201cNearly all patients diagnosed with early-stage melanoma can be treated and cured, but 85 percent of patients with late-stage melanoma die from it within five years.\u201d The story could have more clearly stated that while many are diagnosed with melanoma only a small number actually will die from it. The late stage cases are a small fraction of the total.", "answer": 1}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. The story is quite balanced in the description of this relatively new cosmetic and reconstructive technique that is being used by some cosmetic and plastic surgeons. ", "answer": 1}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering.\nHowever, it\u2019s potentially alarmist to suggest to readers that the presence of elevated levels of Abeta42 inevitably leads to the development of Alzheimer\u2019s disease.", "answer": 1}, {"article": "\u201cI hope insurance companies will look at this and realize that early detection and surgery, if appropriate, will ultimately save them money in the long term.\u201d\n\nSOURCE: bit.ly/2gVClQv The New England Journal of Medicine, online October 25, 2017.\nBehavior and quality of life also improved.\n\u201cThe child may not be able to ambulate by his- or herself.\nThe surgery \u201chad a transforming effect on how they get along in life,\u201d Dr. Tripathi said.\n\u201cThe results are impressive,\u201d he told Reuters Health by phone.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering.", "answer": 1}, {"article": "Australian researchers have completed the world's first randomised control trial (RCT) assessing the efficacy and safety of ketamine as a treatment for depression in elderly patients.\nResearchers monitored for mood and other side-effects after each treatment session.\n\"Elderly patients with severe depression face additional barriers when seeking treatment for the condition.\nMany medications may cause more side effects or have lower efficacy as the brain ages,\" said co-author Dr Duncan George from UNSW Sydney.\nRepeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "It's a \"close call,\" says H. Gilbert Welch, MD, MPH, of the Dartmouth Institute in Lebanon, N.H.\n\n\"This is a test that women who want it should be able to have,\" Welch tells WebMD.\nHow many lives?\n\"Because we don't know which cancers these are, all cancers are treated.\n\"Some will benefit in a very large way.\n\"The vast majority will turn out not to have cancer, but all of them will worry.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "Dr. Evangelia Charmandari, associate professor pediatric and adolescent endocrinology at at the Medical School of the National and Kapodistrian University of Athens and lead author of the study, said: \"These findings suggest that simple vitamin D supplementation may reduce the risk of overweight and obese children developing serious heart and metabolic complications in later life.\u201d\n\nThe findings are set to be presented at the 57th Annual European Society for Pediatric Endocrinology Meeting, and have therefore not yet been reviewed.\nVitamin D is most commonly associated with the development and maintenance of strong bones as the body needs it to absorb calcium.\nChildren who took vitamin D had a significantly lower BMI, the researchers found.\nThey also had lower body fat, as well as healthier cholesterol levels.\nTaking vitamin D could help overweight and obese children lose weight, scientists believe.\n", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t see any sensationalized or disturbing language in this story.", "answer": 1}, {"article": "\u201cIt is not clear that it is the specific early introduction of an allergenic food that renders immunological protection, rather than the accompanying increased diversity in the diet that occurs as a by-product,\u201d writes Dr. Matthew Greenhawt, an allergy and immunology specialist at Children\u2019s Hospital Colorado, in the accompanying editorial.\nExactly why is a question researchers are still exploring.\nWhen babies eat certain foods early in life\u2014the kinds so many end up allergic to, like eggs and peanuts\u2014they\u2019re less likely to develop allergies to those foods later on, finds a new analysis published in the ( ).\nMore research is necessary to figure out the ideal amounts of these allergens, the optimum times of introduction and the reasons behind the link.\nEarly introduction of another common allergen, fish, was also linked to less allergy\u2014possibly due to the anti-inflammatory effects of omega-3s\u2014though evidence for this link wasn\u2019t as certain.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "\u201cThe findings published today substantially increase our optimism for the potential for the development of a Zika vaccine for humans.\u201d\n\nBeyond that, \u201cthis is a promising [vaccine] candidate that can be easily produced in large quantities,\u201d said coauthor, Col. Nelson Michael, an Army doctor who specializes in flaviviruses, such as Zika and dengue.\nThen the monkeys were exposed to active forms of the virus.\nMonkeys that got a sham vaccine developed no antibodies.\nRight now, just one of those three vaccines will be progressing to clinical trials.\nAll three of the vaccines were found to be safe and protected the monkeys against infection with the virus, according to the report published in Science.\n", "question": "Does the story commit disease-mongering?", "explanation": "It does not disease monger.", "answer": 1}, {"article": "\"This study suggests an intriguing link between patients taking L-DOPA and a lower incidence and delayed onset of AMD,\" said Paul A. Sieving, M.D., Ph.D., director of the National Eye Institute.\nIn those people who got L-DOPA before being diagnosed with AMD, their AMD diagnosis occurred eight years later than those without L-DOPA.\nThese provocative results were then confirmed in a much larger data set of 87 million patients where similar results were observed and the study expanded to include prevention and delay of \"wet\" AMD, the most devastating form of the disease.\nIn all the groups examined, data suggests L-DOPA may prevent or delay AMD.\nThe next step in this research is to perform a clinical trial to determine the ability of this drug to prevent AMD.\n", "question": "Does the news release commit disease-mongering?", "explanation": "While it describes the prevalence of AMD, the release doesn\u2019t commit disease mongering.", "answer": 1}, {"article": "Cao hopes her study will continue to broaden the body of research to include cancer-related deaths overall.\nStudies have showed an increased risk of both when taking a daily aspirin, but the benefit does outweigh the risk for most other people.\n(CNN) An aspirin a day may keep the doctor away.\nNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding.\nMen's risk of dying from lung cancer was also lower.\n", "question": "Does the story commit disease-mongering?", "explanation": "Cancer is a major cause of death in the U.S., and this story doesn\u2019t disease monger.", "answer": 1}, {"article": "The editorial raises the possibility that the effect of confounding factors such as socioeconomic status and physical activity could be substantial.\nThis means that a single 200-calorie sugary drink may be OK for a person who typically consumes a 2,000 calorie-per-day diet.\nHe says the bigger point is this: \"Whether poor diet is causing 1,000 cardiovascular and diabetes deaths per day, or 500, it remains among the leading causes of preventable suffering.\"\nIf you love foods that are associated with cardiovascular risks, you don't have to give them up entirely.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although the premise that poor diet\u00a0is causing between 500 and 1,000 cardiovascular and diabetes deaths per day is presented with too much certainty, this doesn\u2019t constitute disease-mongering.", "answer": 1}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story commit disease-mongering?", "explanation": "The story reports that the new drug approval may apply to about 4 percent of advanced cancers, but it highlights a description of affected patients that is simply not accurate. The story states the FDA approved pembrolizumab \u201cfor treatment of solid tumors in any organ so long as the malignancy bears a specific genetic signature.\u201d But what the FDA announcement states is that the approval is limited to \u201cpatients with solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options and patients with colorectal cancer that has progressed following treatment with certain chemotherapy drugs.\u201d\nIn other words, patients who have already tried standard treatments without success.\nThere is a reference lower down in the story to \u201cthe treatment of patients with metastatic cancers that have failed all other treatments,\u201d but there is no clear linkage to the important limitation in what the FDA approved.", "answer": 0}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story commit disease-mongering?", "explanation": "This story does not engage in disease-mongering.\u00a0 It clearly states that medullablastoma and advanced basel cell carcinoma are rare forms\u00a0of cancer, a percentage of which involve the pathway targeted by the new drug.\u00a0 ", "answer": 1}, {"article": "On the heels of this advice, a new meta-analysis (considered the best evidence and an unbiased overview of the body of knowledge on a specific topic), published in the Journal of Clinical Lipidology, adds to the growing body of research that supports the use of avocados in lieu of solid fats (and foods that have higher saturated fat content) to significantly change lipid profiles.\nCardiovascular disease is responsible for one out of every four deaths; it is the number 1 killer of American women and men, and it is a leading cause of disability.\nHowever, the optimal amount of avocado and frequency of use needs further evaluation along with the nutritional similarities and differences between other different MUFA sources.\nTo view the abstract or the published article, visit http://www.lipidjournal.com/article/S1933-2874(15)00427-4/abstract.\nIn 2010, HAB established a nutrition research program to increase awareness and improve understanding of the unique benefits of avocados to human health.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease mongering. Heart disease is clearly important and that is not overstated.", "answer": 1}, {"article": "Doctors numbed the lower half of O'Brien's body.\nThe new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\nThe day of the surgery, Berger has his patients conquer what amounts to a knee-bending obstacle course before they're able to leave \u2014 walking up and down a hallway and up and down a flight of stairs.\n\"I'll be chipping and putting in three weeks \u2014 maybe four,\" joked O'Brien from the operating table.\n\"But over time it's just checking off one more activity that I can't do.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "Blanket categorization of recovery from knee replacement surgery as long and painful is an example of disease mongering. People are different and so is their recovery from such surgery. ", "answer": 0}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story commit disease-mongering?", "explanation": "Cold and flu season is a recurring phenomenon, and the public\u2019s concern over possible contagion is the primary motivation for the purchase of such devices. But while there\u2019s a danger of wandering into disease-mongering territory with this topic, we don\u2019t think the story crosses the line. The language in the story is pretty straightforward \u2014 there are no \u201cscary\u201d anecdotes and no dramatic language referring to colds or flu. For example the story says that \u201cIn cold and flu season, pathogens spread\u2026\u201d \u2014 it doesn\u2019t refer to the \u201cscourge of flu season\u201d or use similar purple prose. And these are not uncommon health problems. We\u2019ve seen more than 100,000 confirmed flu diagnoses so far in the 2014-15 flu season, so it\u2019s a reasonable subject to write about.", "answer": 1}, {"article": "MORE: How Better Habits Can Make Your Day\n\u201cMen don\u2019t say, \u2018Let me go to the urologist and give a semen sample.\u2019\u201d That reluctance has created a $440 million-a-year market for male fertility tests in the U.S., Lopez says.\n\u201cThis at-home test was created to meet the needs of couples who are considering and just planning on starting a family, those currently having trouble conceiving,\u201d says Herr, and \u201ceven those men who are just curious about their sperm count.\u201d\n\nWould-be virile men \u201cjust curious\u201d about their sperm count?\nWhile it\u2019s just as likely that infertility is related to the male half of the couple, only 20% of men in duos struggling to make a baby get a sperm-count analysis early on or at all, according to data from SpermCheck Fertility, which earlier this month announced the availability of its at-home screening test for men.\nMORE: The Sperm Bike: Cycling to Drum Up Sperm Donations\n\nIt relies on scrutiny of a particular protein found only in the head of mature sperm; the protein was discovered by John Herr, director of the Center of Cell Biology at the University of Virginia and the chairman of SpermCheck.\n", "question": "Does the story commit disease-mongering?", "explanation": "One definition of disease-mongering includes the attempt to expand the market for diagnoses \u2013 and for products that address those diagnoses.\nThis story allows the chairman of SpermCheck to say. \u201cThis at-home test was created to meet the needs of couples who are considering and just planning on starting a family, those currently having trouble conceiving\u201d and \u201ceven those men who are just curious about their sperm count.\u201d\nThis plants the seed of expanding the market for the test to \u201cthe curious\u201d\u00a0 \u2013 a potentially unlimited market.\u00a0 Nice \u2013 if you\u2019re a company chairman.\u00a0 Less than independent vetting \u2013 if you\u2019re in journalism.", "answer": 0}, {"article": "\"Dislocation is a common reason for a total hip replacement to fail, and when it happens, sufferers can experience significant pain and require another surgery to fix the problem,\" explains lead study author Jonathan Vigdorchik, MD, an assistant professor of orthopedic surgery at NYU School of Medicine and associate fellowship director of the Division of Adult Reconstructive Surgery at NYU Langone Orthopedic Hospital.\nThe researchers reported only one dislocation in this high-risk group (or 0.5 percent of high-risk patients), compared with 3.1 percent in the previous group not assessed with the risk assessment and treatment algorithm.\nMore than 310,000 hip replacements are performed in the United States each year, and an estimated 2.5 million Americans are currently living with hip replacements.\nHowever, no guidelines currently exist to aid clinicians in deciding when to use these more flexible implants, which are often more expensive than conventional implants, may not be medically necessary, and may carry added risks if implanted unnecessarily.\nOther technologies including laser-guidance, computer navigation, and robotic surgical devices are used for the especially high-risk and complex cases identified through the algorithm in order to ensure the best possible outcome free of complications.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering. The release states that dislocations occur in about 1% of patients following hip replacement.", "answer": 1}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. The story lists the estimated prevalence of bipolar disorder in the U.S. ", "answer": 1}, {"article": "Here's the scientific proof.\n\"Therefore, continued data collection and longer follow-ups are needed.\"\nYour office thermostat is set for men's comfort.\nThe participants fell into four groups: those with no use or low use of marijuana, early chronic users, those who only smoked during their teens and those who began using it later and continued using the drug.\nThe researchers found no links to physical or mental health issues -- including depression, psychotic symptoms or asthma -- in any group, even those with very high use.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable in this case. \u00a0There was not a single disease or condition explored in any detail.", "answer": 2}, {"article": "Carmichael and Segura collaborated on the study.\n\"This study indicated that new brain tissue can be regenerated in what was previously just an inactive brain scar after stroke.\"\nIn addition to Carmichael and Segura, other authors of the paper are Lina Nih and Shiva Gojgini, both of UCLA.\nThe results suggest that such an approach may someday be a new therapy for stroke in people, said Dr. Tatiana Segura, a former Professor of Chemical and Biomolecular Engineering at UCLA who is now a professor at Duke University.\nThe study was supported by funds from the National Institutes of Health.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease mongering here. The release also adds context by stating how many Americans are living with the outcomes of stroke.", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story commit disease-mongering?", "explanation": "The story stated that MS is \u201camong the most common causes of neurological disability in young adults,\u201d but numbers would have helped.\nAccording to the FDA, 2-5% of people with MS get symptoms before age 18 and its estimated that 8,000 to 10,000 children and adolescents in the U.S. have MS.", "answer": 1}, {"article": "Boutot and Bertone-Johnson suggest that more prospective studies of their findings are warranted, including studies that compare soy-based and non-soy vegetable proteins.\n\"A better understanding of how dietary vegetable protein intake is associated with ovarian aging may identify ways for women to modify their risk of early onset menopause and associated health conditions,\" write first author and then-graduate student Maegan Boutot, with her advisor, professor Elizabeth Bertone-Johnson.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\nBoutot, Bertone-Johnson and colleagues in the School of Public Health and Health Sciences at UMass Amherst, with others, evaluated the relationship between diet and risk of early menopause among members of the Nurses' Health Study II (NHS2), an ongoing prospective study of 116,000 women aged 25-42 when they entered it in 1989.\nEarly menopause, the cessation of ovarian function before age 45, affects about 10 percent of women and is associated with higher risk of cardiovascular disease, osteoporosis and early cognitive decline, the authors note.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release doesn\u2019t disease monger. It does state that early menopause, defined as the cessation of ovarian function before age 45, affects about 10 percent of women and is associated with higher risk of cardiovascular disease, osteoporosis and early cognitive decline as well as cutting short fertility. The study itself cites prevalence figures ranging from 5 to 10 percent. The news release could have included that range instead of going with the higher estimate.", "answer": 1}, {"article": "Our research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nResearchers observed that memory loss was fully reversed to the levels seen in mice without Alzheimer\u2019s.\nThe research was conducted when mice had developed memory problems.\nFirst group was given mefenamic acid dose and the other group was given placebo for one month through a mini-pump implanted under the skin.\n\u201cThere is experimental evidence now to strongly suggest that inflammation in the brain makes Alzheimer\u2019s disease worse.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story.", "answer": 1}, {"article": "March 4, 2010 -- A new urine test may reduce unnecessary biopsies for prostate cancer.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nAt a news briefing held in advance of the 2010 Genitourinary Cancers Symposium, researchers presented results of the largest study to date of the PCA3 test.\n\"More often than not, the damage is due to benign (noncancerous) conditions such as enlarged prostate\" -- a condition called benign prostatic hyperplasia or BPH, Groskopf tells WebMD.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\n", "question": "Does the story commit disease-mongering?", "explanation": "While the\u00a0story mentions that men with higher PCA3 scores are more likely to have aggressive cancers, there are no data reported to support the claim. A major problem was that the story failed to provide any information to the effect that not all prostate cancers are likely to cause harm. Without including this counterpoint, the story does, indeed, disease monger about prostate cancer.", "answer": 0}, {"article": "Moderate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nThe team recruited 45 healthy participants aged 21-70 years who were either obese or overweight.\nBut guacamole is typically eaten with corn chips, which are high in calories and sodium.\nAlso, most people do not really know how to incorporate them in their diet except for making guacamole.\nIt is known that monounsaturated fats can help lower levels of bad cholesterol, reducing the risk of heart attack and stroke.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not resort to disease mongering to make its case.", "answer": 1}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story commit disease-mongering?", "explanation": "Chemoprevention is for a small number of women and tamoxifen should only be offered to women with a 5-year projected risk for breast cancer of 1.6% in order to reduce their risk. The side bar is helpful, providing a clearer understanding of who might be at higher risk. Also, this medication is for women with estrogen-receptor positive breast cancer. This article does a good job of explaining that this drug is only for postmenopausal women with a greater chance of malignancy and the benefit of the drug must be weighed against the health risks for each woman.", "answer": 1}, {"article": "Such shared and informed decision making might enhance treatment adherence which is one of the main challenges of treating major depressive disorder,\" said Gerald Gartlehner, M.D., associate director of the RTI-UNC Evidence-based Practice Center, who was the principal investigator of the evidence review, which was also published today by AHRQ.\nThey found that symptom improvement and rate of remission were similar between the two options, whether used alone or in combination with each other.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\nRTI-UNC Evidence-based Practice Center is a collaboration between RTI and the five health professions schools and the Cecil G. Sheps Center for Health Services Research at UNC.\n\"Our findings indicate that both options should be considered effective initial treatment strategies.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t use fear mongering language. Perhaps it even under-stressed the ill effects of major depression.", "answer": 1}, {"article": "\u2022 They tested the effects of head repositioning by having an experienced surgeon reposition test subjects' heads six to seven times.\nBladders filled with coffee grounds were built into the robot's gripper.\nAmong the materials that his predecessor had left behind was a latex bald cap.\nIt was the way the reflective markers were attached to the patient's head that was at fault.\n\"That sparked the idea of caps in general,\" Wellborn recalled.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Is a drug really needed for what seems like a trivial use?\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\n\u201cIt is reversing the epinephrine.\u201d\n\nThe label for the hypertension drug phentolamine contains warnings about heart attacks and occlusion of blood flow to the brain.\nOraVerse does the opposite, dilating the blood vessels and speeding up blood flow so the anesthetic can be carried away.\n\u201cWe aren\u2019t reversing the local anesthesia,\u201d said Dr. Paul A. Moore, chairman of anesthesiology at the University of Pittsburgh School of Dental Medicine, who is an adviser to Novalar.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article implictly accepts the drug-maker\u2019s premise that lingering numbness after dental anesthesia is a condition that requires treatment. One could easily find medical sources who disagree.\u00a0 But the Times didn\u2019t \u2013 or at least they didn\u2019t quote them.\u00a0 ", "answer": 0}, {"article": "But stimulating the vagus nerve requires surgery to implant a device near the collarbone.\n\"For me it's extremely effective,\" says Jennifer Rees, 49, who lives in the Los Angeles area and has been using the nerve stimulator for six years.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\n\"For me, all it involved was putting two gel pads above my eyebrows, one on each eyebrow,\" she says.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\n", "question": "Does the story commit disease-mongering?", "explanation": "One of our reviewers thought that the the story bordered on disease-mongering by presenting epilepsy, in essence, as a disease where people have been painted into a corner and desperately need a way out and that he best way out is this one device.\nBut, in the end, the doorway into the story\u2019s discussion of epilepsy is appropriate \u2013 \u201cAbout 3 million Americans have epilepsy, and for about one-third of them, drugs alone do not control their seizure.\u201d", "answer": 1}, {"article": "The test, developed by researchers at the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS foundation trust, picks out men suitable for treatment with olaparib, part of a revolutionary class of drugs called \u201cPARP-inhibitors\u201d, which stops damaged cells from repairing themselves.\nSome patients respond to olaparib for years but in others the treatment can fail early or the cancer can evolve resistance.\nThe researchers collected blood samples from 49 men at the Royal Marsden with advanced prostate cancer enrolled in the phase II clinical trial of olaparib.\nHe said: \u201cBlood tests for cancer promise to be truly revolutionary.\nThirdly, they used the test to monitor a patient\u2019s blood throughout treatment to quickly pick up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article did not overhype the risks of prostate cancer.\n\u00a0", "answer": 1}, {"article": "The ability to control the tightness is presumably part of the reason that patients who opt for banding lose less weight, at least initially, than gastric bypass patients -- an average of 50 to 65 percent of their excess weight in the first three years.\nNot enough time has elapsed since the advent of second operations to get a long-term assessment.\nHe regained 45 pounds by the time he decided to go for banding.\nAfter a gastric bypass, there's often scarring that causes organs to adhere to one another.\nI did it many, many times.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "The distorted valve functions poorly, its flaps swinging apart.\nIn the new trial, 614 patients with severe heart failure in the United States and Canada were randomly assigned to receive a MitraClip along with standard medical treatment or to continue with standard care alone.\nIn the new study, a device called the MitraClip was used to repair the mitral valve by clipping its two flaps together in the middle.\n(The clip is made by Abbott, which funded the study; outside experts reviewed the trial data.)\nThe leaky mitral valve makes the heart enlarge even more, as it tries to compensate, and heart failure worsens.\n", "question": "Does the story commit disease-mongering?", "explanation": "The lead states that \u201calmost two million Americans have heart failure, and for them even mundane tasks can be extraordinarily difficult.\u201d\nLater, we\u2019re told the number who might ultimately be treated will be less than the number who could be treated.\nThe story did not fully capture the fact that only a limited number of patients might actually benefit from this technology. In other coverage, the lead investigator was quoted saying that 10% of all patients with heart failure are similar to those in this trial.", "answer": 1}, {"article": "They used functional magnetic resonance imaging (fMRI) to study this phenomenon.\nThis was another small study -- 20 dyslexic volunteers and 21 participants without the condition -- testing how people identify shapes, navigate a virtual environment, and do other tasks involving spatial reasoning.\n\"If they can create projects -- instead of drawing a picture of a room, if they can make a model of a room -- they will generally do it pretty much to scale because they can visualize things very clearly,\" she said.\nCelebrities including Whoopi Goldberg, Cher and Henry Winkler (the \"Fonz\") have made their dyslexia publicly known, and great artists such as Pablo Picasso are said to have had it.\nThe most important intervention is a direct, explicit teaching of phonics, or how symbols correspond with sounds, Branstetter said.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story refers to estimates that between 5 percent and 20 percent of the population has dyslexia. Unlike the Reuters story we also reviewed, this story provides a useful definition of dyslexia as \u201ca condition that, broadly speaking, hinders a person\u2019s ability to interpret language.\u201d", "answer": 1}, {"article": "\"Studies comparing stage of disease with outcome following surgery suggest that death rates frompancreatic cancer would be reduced if the disease were diagnosed at an earlier stage,\" said Dr. Raghu Kalluri, chair of cancer biology at M.D.\nPatients usually have no symptoms until the cancer has spread.\nThe study was published in the June 24 issue of the journal Nature.\nAnderson Cancer Center.\nLevels of the protein were markedly lower after surgical removal of a patient's tumors.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not promote disease mongering.", "answer": 1}, {"article": "So far, Freedman noted, the only hot-flash treatment that has consistently worked in studies is hormone replacement therapy (HRT).\nThose findings appear in a separate report in the journal Menopause.\nThey increase levels of the brain chemical serotonin, which may have a role in regulating body heat.\nTheir exact cause is unknown, but hormonal regulation of body temperature is thought to be involved.\nBut no one knows if altering serotonin levels actually does affect women\u2019s hot flashes.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article did not commit disease mongering of hot flashes.", "answer": 1}, {"article": "The problem is that over the years the stomach stretches, and when that happens, Watson says, \"Patients are able to eat more at one sitting and they feel hungrier more often.\"\nIf the stomach pouch has stretched, new sutures are put in place to once again reduce the size of the stomach.\nAt the same time, hormonal changes that reduce the appetite and take effect immediately after the surgery begin to decline.\nAfter the surgery, Watson says, patients report feeling fuller and less hungry and they ultimately gain greater control over what they are eating.\n\"It was the first time in my life that I've ever lost a lot of weight and was able to maintain it.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "Given the high incidence of obesity in the United States, exaggerating the seriousness of the problem is unnecessary. No disease mongering here.", "answer": 1}, {"article": "Antibodies \"are easily accessible in the blood, so it provides a fantastic test to identify an early-stage cancer,\" said project lead Professor Mel Ziman, leader of the university's Melanoma Research Group on Monday.\nSurgery to remove the growth is the most common form of treatment.\n\"We're in the wrong place with the wrong skin color.\nOver three years, the research team identified a combination of 10 types of antibodies that best signal the presence of a melanoma.\n\"In order for it to be valued by clinicians we would need to get to 90% accuracy in detection,\" she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The study was conducted in Australia, where melanoma is very prevalent. \u00a0The story provides statistics without hyperbole.", "answer": 1}, {"article": "For every one point increase in processed foods consumption, they lost 1.67 points in IQ.\nConversely, every one point increase in healthy eating translated into a 1.2 point increase in IQ, the researchers found.\nThe key seemed to be the diet at age 3, since diet at 4 and 7 seemed to have no effect on IQ, the research team noted.\n\"This can have a series of deleterious effects, including decreased cognitive ability, poor behavior and social skills,\" she said.\nWhen a child's diet consists primarily of high-calorie foods that are low in the nutrients they need (such as healthy fats, vitamins and minerals), their brains don't get the compounds necessary to develop and function properly, Heller said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The over-the-top headline crossed the line into fear mongering. The findings were not strong enough to\u00a0warrant this kind of bold warning.", "answer": 0}, {"article": "MONDAY, Dec. 6, 2010 (HealthDay News) -- Long-term use of a daily low-dose aspirin dramatically cuts the risk of dying from a wide array of cancers, a new investigation reveals.\nThe patients (some of whom had been given a low-dose aspirin regimen, while others were not) were tracked for up to 20 years after.\nThe protective impact of low-dose aspirin on stomach and colorectal cancer death was not seen until 10 years out, and for prostate cancer, the benefits first appeared 15 years down the road.\nThe authors determined that while the studies were still underway, overall cancer death risk plummeted by 21 percent among those taking low-dose aspirin.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not exaggerate the impact of cancer and it accurately described the possible relevance of this study to a large segment of the population.", "answer": 1}, {"article": "Jan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\nThe findings are published in TheJournal of the American Medical Association.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\n", "question": "Does the story commit disease-mongering?", "explanation": "Menopause has been the subject of considerable disease mongering over the years \u2014 see here for some examples.\u00a0This story, though, confines the discussion to women whose symptoms are severe enough to disrupt their lives and quality of life. That seems to be a fair basis\u00a0upon which to\u00a0identify women who might be candidates for some kind of medical treatment of\u00a0menopause symptoms. The story could have\u00a0provided data on how many women suffer from moderate to severe hot flash symptoms, to give a better\u00a0idea of how widespread the problem is.", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story commit disease-mongering?", "explanation": "This story did not engage in overt disease mongering. ", "answer": 1}, {"article": "April 9, 2012 -- Taking soy to relieve hot flashes has received mixed reviews over the years.\nTwo co-authors, not including Melby, have ties to the soy industry.\n\"I personally think foods [containing soy] are better.\"\n\"What this study shows is that ingesting soy isoflavones will help you,\" she says.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering, but, then again, there wasn\u2019t much information about hot flashes at all in the story.", "answer": 2}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in disease-mongering.", "answer": 1}, {"article": "THIS STUDY randomly assigned 60 adults with mild cognitive impairment or mild to moderate Alzheimer\u2019s disease to be given, via nasal spray, 20- or 40-milligram doses of insulin detemir (Levemir), a man-made insulin that is longer acting than natural insulin, or a placebo daily for three weeks.\nSome research has suggested a link between lower levels of insulin in cerebrospinal fluid and the formation of plaques often found in the brain tissue of people with Alzheimer\u2019s.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering here. And the story does a good job explaining the connection between Alzheimer\u2019s and memory loss.", "answer": 1}, {"article": "The research, supported by the European Research Council and titled Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells, is published by PNAS.\nOur new compounds work by attacking the energy balance in cancer cells\u201d.\nBy stopping this switch of energy source, the drug causes the cancer cell to die.\nThe new drug works by forcing cancer cells to use their mitochondria, the \u2018power house\u2019 of a cell, to generate the energy necessary to function.\n\u201cIt is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells\u201d.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story commit disease-mongering?", "explanation": "The story provided an estimate of the number of individuals with fibromyalgia, and included the doubts of some about the existence of this condition. \n\u00a0", "answer": 1}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\n(CNN) -- Most heart attacks strike with no warning, but doctors now have a clearer picture than ever before of who is most likely to have one, says Dr. Arthur Agatston, a Miami cardiologist and author of the best-selling South Beach diet books.\n\"Do you put this 50-year-old who has this family history on a statin medication with potential expense (and) side effects for the next four decades of his life, or do you further refine how far at risk he is?\"\n\"There is a large group in the middle called intermediate risk, which may be as much as 50% of the population,\" said Dr. Erin Michos, a cardiologist at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University\n\nA good candidate for a coronary calcium scan, she says, would be a 50-year-old man with slightly elevated cholesterol and a father who had a heart attack.\nOne large federally funded study found the coronary calcium score a better predictor of coronary events like a heart attack than the traditional Framingham Risk Score, which considers age, cigarette smoking, blood pressure, total cholesterol and HDL, the \"good\" cholesterol.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story exemplifies disease-mongering by highlighting threats of terrible consequences and wildly exaggerating the number of people likely to benefit from these scans. With statements like, \u201cunless you do imaging, you are really playing Russian roulette with your life\u201d and \u201cAgatson thinks that the coronary artery calcium scan should be routinely scheduled at age 50\u2026\u201d provide the uninitiated reader with the impression that everyone needs one of these tests.\u00a0 While the comments of Dr. Michos modify the unabashed enthusiasm, the overall tenor is over the edge.", "answer": 0}, {"article": "The first problem we solved was: how do we make the hand move electronically?\n\"His main interest was to create a shocking response from onlookers by pulling it off in the grocery store,\" Falardeau wrote on CNN iReport .\n\"We quickly found out this is much less about fitting in and feeling normal, and much more about expressing yourself,\" Petresky said.\n(CNN) By the time Cynthia Falardeau read about Alex Pring, a little boy who got a battery-powered robotic arm last summer, she had made peace with her son Wyatt's limb difference.\nThe UCF project started when Albert Manero, an engineering doctoral student, heard a story on the radio about one of the inventors of the 3-D printed hand.\n", "question": "Does the story commit disease-mongering?", "explanation": "We will give the story a passing mark on this criterion, because it obviously applies only to people who do not have two arms. However, while the story did mention that 3D printers might be able to help provide prosthetic arms to people around the world who do not have access to conventional prosthetic arms, the story would have been better if it provided some explanation of why the patients it profiled would choose a 3D printed arm over any of the other prosthetic arms currently available.", "answer": 1}, {"article": "The only once-and-be-done-with-it option for women has been tubal ligation (\"tying the tubes\") -- surgery that renders a woman sterile.\nUntil then, the patient must use another form of birth control.\nEven the IUD can't stay in place for more than 10 years.\nThere is the risk of infection or a puncture of the vagina or uterus while inserting the hysteroscope.\nWhat's New The Pill.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to engage in disease mongering.", "answer": 1}, {"article": "This randomised trial (phase 2a) recruited 28 patients with Dupuytren's disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand.\nThere is currently no NICE approved treatment for early disease and typically people are told to return to their GP once their fingers become so bent that their hand function is impaired.\n\"This brings new hope to people who suffer from this disabling condition, who currently have to wait for their situation to be deteriorate, watching their hand lose function until it is bad enough for surgery.\n\"We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren's disease,\" said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here. It\u2019s mentioned Depuytren\u2019s disease affects about 4% of the population.\n(This percentage is much higher in parts of Northern Europe.)", "answer": 1}, {"article": "A medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nSymptoms range from mild stomach or skin reactions to a constriction of the airways.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nAn estimated 12 million Americans suffer from food allergies, including about 2.2 million children.\nBecause even a minor exposure can set off a reaction, many people at risk strictly avoid foods that contain an allergen or were prepared in places where nuts or other allergens might have been used.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering about the seriousness or incidence of these food allergies. ", "answer": 1}, {"article": "For the study, Lumeng's team collected data on more than 43,700 Michigan preschool-age children between 2005 and 2013.\nIn their first year in Head Start, obese and overweight kids lost weight faster than two comparison groups of children who weren't in the program, researchers found.\nBecause obesity in childhood tends to continue into adulthood, experts worry that these children are at risk of future health problems.\nThe daily routine might translate into less TV time and more regular sleep schedules, she said.\nAlmost one-quarter of preschool-aged children in the United States are overweight or obese, and obesity rates within Head Start populations are higher than national estimates, the study authors noted.\n", "question": "Does the story commit disease-mongering?", "explanation": "The reporter does not exaggerate the burden of obesity in children, especially those who are impoverished.", "answer": 1}, {"article": "Awair is the first smart air quality device that monitors, analyzes and provides feedback to improve the air you breathe.\nDry air can also exacerbate some illnesses and can be a problem as well.\u201d\n\nDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves, but these aren\u2019t the worst culprits, Lahita said.\nWhile breathing fresh, clean air can boost productivity, sleep and overall health, not everyone can live in the great outdoors and it\u2019s difficult to know just how clean the indoor air in your home or office is.\nAs soon as you see other colored (amber and red) dots show up on top of the green dots, your environment is getting off the healthy ranges whether it being temperature, humidity, CO2, VOCs, and dust,\u201d Ronald Ro, the CEO and co-founder of Bitfinder Inc., the makers of Awair, told FoxNews.com.\nIt analyzes the data in real-time and gives an Awair score on a 0 to 100 color-coded scale, 0 being the worst air quality.\n", "question": "Does the story commit disease-mongering?", "explanation": "Disease mongering is when a potential problem is exaggerated, or when a story describes a risk factor as if it\u2019s a disease. And this story is guilty on both counts. For example, among the litany of possible air quality problems in a home, the story states \u201cDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves.\u201d The story goes on to say \u201c\u2026but these aren\u2019t the worst culprits\u201d \u2014 yikes! In fact, the story tells readers, \u201cEvery room in your house could be susceptive to some form of an air pollutant.\u201d Unfortunately, the story doesn\u2019t tell readers why they should be worried about any of these things. Even when mentioning carbon monoxide poisoning, the story doesn\u2019t explain why carbon monoxide poisoning is dangerous or how dangerous it is. In fact, the only air quality issue for which the story articulates any specific health risk is dry air, when the story tells readers that low humidity can make asthma worse or exacerbate nasal infections in some people.", "answer": 0}, {"article": "COLUMBUS, Ohio - Results from an international, randomized study show that an implanted nerve stimulator significantly improves symptoms in those with central sleep apnea, without causing serious side effects.\nThe study was funded by Respicardia.\nOnly eight (11 percent) of those in the control group achieved the same reduction.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nDuring the first six months of evaluation, 68 devices were activated for treatment, while 73 were left inactive as the control group.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Fleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nNot a huge dent, but a significant one.\nNor is it for women who have other conditions that raise their risk of preterm birth, such as high blood pressure or infection.\nThe drug is not for women whose prior premature births were of twins or other multiple births, or who are carrying more than one fetus in their current pregnancy.\nIn 1956, the FDA approved 17-HP for the treatment of certain cancers and other hormonal disorders, under the brand name Delalutin.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of prematurity or its consequences.", "answer": 1}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nThere were only a few complications related to the SIJ implant procedure.\nThe group serves customers in over 170 countries, and employs over 19,000 people worldwide.\nThe company is headquartered in Alphen aan den Rijn, the Netherlands.\nWolters Kluwer is a global leader in professional information services.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease mongering.", "answer": 1}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story commit disease-mongering?", "explanation": "A late diagnosis of ovarian cancer is way too common, and the outcome is grim.\nAt the same time, the anecdotes seem to highlight the sad aspect of the disease without necessarily providing a relevant case in which the tests described would have helped (any more than a basic blood test would have).", "answer": 1}, {"article": "(Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co\u2019s diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker\u2019s biggest product.\nIt was undertaken after heart safety concerns were raised over other diabetes medicines.\n\u201cFor the heart failure concern raised by other agents in the class there is no difference (with placebo),\u201d he added.\nPancreatic cancers, also uncommon, were numerically fewer with Januvia, 9 versus 14.\nAcute pancreatitis, a concern with some diabetes drugs, was uncommon but higher with Januvia, 23 versus 12.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in this piece.", "answer": 1}, {"article": "The reviewed studies included the use of cannabis extracts delta9-tetrahydrocannabinol, or THC, and cannabidiol, or CBD, in people with MS.\n\n\"We found evidence that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms,\" Lakhan says in a news release.\nHowever, side effects also were seen in people in placebo groups.\nInvoluntary muscle spasms (spasticity) are common symptoms of MS.\nThe researchers say that many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\nBut subjective assessment of relief of spasticity suggested significant improvement after treatment, they write.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no exaggeration of the muscle spasm symptoms of MS. ", "answer": 1}, {"article": "Here is how I would think about asking the question instead: What is the easiest way to reduce my chance of death?\nThe optimal speed is between 5 and 7 mph, and if you do 25 minutes about three times a week, you\u2019re all set.\nThe ideal measure would combine the length of time spent exercising with the amount of energy expended \u2014 basically, we want to figure out a way to credit people who walk at half the speed for twice as long the same amount as those who walk faster for less time.\nBut since the people in the studies are of different ages, researchers can\u2019t just look to see whether they have, say, a 2 percentage point lower risk of death in a given year, since that lower risk would mean a lot more for someone who is 30 than for someone who is 90.\nWhat is a bit surprising about this chart is that running faster or farther doesn\u2019t seem to reduce death rates any more than running slowly and, in fact, in both cases is slightly worse.\n", "question": "Does the story commit disease-mongering?", "explanation": "Death is the only health endpoint discussed here, and as the story accurately points out, \u201cultimately everyone dies.\u201d We\u2019ll rule this Satisfactory.", "answer": 1}, {"article": "\"Success begets success,\" Dombrowski said.\nBefore the FDA action, pain-relieving patches were available in the United States only by prescription, said Dr. John Dombrowski, director of the Washington Pain Center in Washington, D.C. Their active ingredients include such medications as lidocaine, capsaicin and non-steroidal anti-inflammatory drugs, or NSAIDs.\nThe active ingredients in Salonpas are methyl salicylate and menthol, common components of pain-relieving gels and creams, such as Bengay.\n\"Salonpas is the Western world catching up with Asia,\" said Dr. Rick Rosenquist, a professor of anesthesia and director of pain medicine at the University of Iowa Carver College of Medicine and chairman of the American Society of Anesthesiologists' committee on pain medicine.\nFor instance, some analgesics are likely to cause an upset stomach unless they're taken with food.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story may lead the reader to think minor aches deserve treatment with a medication when, in fact, they might not benefit from any medication. The story does not exaggerate the numbers of people suffering from the condition under discussion, but, perhaps worse, it ignores the question completely. Not only do we have no idea how prevalent the problem is, there is no delineation of what type of \u201cache\u201d this nostrum treats. It it good for a minor bruise? What about torn ligaments? Stress fractures? Metastases? When it is left to the reader\u2019s imagination to select the disease, there is disease-mongering. This is exactly what vague advertisements for drugs hope to achieve. They plant the seed in the patient\u2019s mind that there might be help for whatever problem they have.", "answer": 0}, {"article": "They were also able to detect 100 percent of people with memory impairments who would progress to Alzheimer\u2019s disease within five years.\n\u201cThe unexpected presence of the Alzheimer\u2019s disease signature in more than one-third of cognitively normal subjects suggests that Alzheimer\u2019s disease pathology is active and detectable earlier than has heretofore been envisioned,\u201d Geert De Meyer of Ghent University in Belgium and colleagues wrote.\nCurrently, only an autopsy can confirm that a person has Alzheimer\u2019s, a fatal and incurable deterioration of the brain that affects more than 26 million people globally.\nIn the study, De Meyer and colleagues analyzed spinal fluid from 114 adults with normal brain function, 200 who had mild cognitive impairment \u2014 a precursor to dementia \u2014 and 102 who had Alzheimer\u2019s.\nCHICAGO (Reuters) - Measuring certain proteins in spinal fluid can accurately diagnose Alzheimer\u2019s and predict which patients with memory problems will develop the fatal brain-wasting disease, Belgian researchers said on Monday.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nWithout attribution, this story states that 26 million people worldwide have Alzheimer\u2019s Disease. By contrast, the World Health Organization puts the global figure at 18 million people. The Alzheimer\u2019s Association says that 5 million American\u2019s have the disease. Some caution should be used when considering estimates by advocacy organizations. The Alzheimer\u2019s Association estimates that the number of cases will increase by more than 50 percent over the next two decades, but it should be noted that two decades ago the group estimated the disease affected more than 4 million Americans.\n\u00a0\nReference:\nALZHEIMER\u2019S DISEASE : The Brain Killer\nhttp://www.searo.who.int/en/Section1174/Section1199/Section1567/Section1823_8066.htm\n ", "answer": 0}, {"article": "The agency, he added, remains concerned about \u201cthe proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims.\u201d\n\nIn April, an advisory committee unanimously recommended approval of the drug for the two types of epilepsy.\nGottlieb noted that the action was \u201cnot an approval of marijuana or all of its components\u201d but rather of one specific CBD medication for a particular use.\nThe FDA previously cleared medications containing synthetic versions of THC for nausea for patients getting chemotherapy and for other uses, but it had not approved any drug derived from the plant itself.\nThe drug contains only trace amounts of the psychoactive element THC and does not induce euphoria.\nThe drug is the first treatment approved for Dravet syndrome.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "\u201cOur study shows that there may be some relationship between dietary factors and things like egg quality so one idea may be recommending supplementation with omega 3s to improve fertility.\u201d\n\nExactly how the healthy omega 3 fatty acids are helping the ovary to produce better quality eggs isn\u2019t clear yet.\n\u201cBased on this study, it looks very encouraging that omega 3s can potentially improve fertility,\u201d says Skaznik-Wikiel.\n\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\n\u201cWe hope in the future to have more answers to be able to say firmly that yes, omega 3 fatty acids are the way to go [for women hoping to get pregnant,]\u201d she says.\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s not enough context on the scope of the problem to determine if there was disease-mongering.\u00a0", "answer": 2}, {"article": "Scheduled biopsies were performed two and four years after they entered the trial.\n\"We now have two studies showing that two different drugs in this category can reduce the overall risk of prostate cancer,\" American Cancer Society Director of Prostate and Colorectal Cancers Durado Brooks, MD, tells WebMD.\nWhile the studies suggest a role for Avodart and Proscar in the prevention of prostate cancer, experts tell WebMD that important questions remain about using the drugs for this purpose.\n\"We know from experience that many of these men are likely to have microscopic prostate tumors that were missed by their original biopsy,\" he says in a news release.\nStudy researcher Gerald L. Andriole, MD, says a significant proportion of men screened for prostate cancer fall into this clinically ambiguous category of having elevated PSAs and negative biopsies.\n", "question": "Does the story commit disease-mongering?", "explanation": "Several times the story mentions that it is unknown if preventing these cancers would result in preventing deaths from those cancers. The story could have been more explicit about the fact that prostate cancer is slow growing and most men with prostate cancer die from other things. Thus, preventing low-risk cancers may not, in fact, save lives.", "answer": 1}, {"article": "The California Walnut Commission (CWC) prohibits discrimination in all programs and activities on the basis of race, color, national origin, age, disability, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or part of an individual's income is derived from any public assistance programs.\nAICR 2007.\nResearchers conducted the randomized study with two groups of mice.\nCWC is an equal opportunity employer and provider.\nWorld cancer research fund/american institute for cancer research.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Dr. Ellen Marmur, the chief of the division of dermatologic and cosmetic surgery at Mount Sinai Medical Center in Manhattan, did say Algenist could fairly claim that alguronic acid offers protection against ultraviolet damage to cells, and that she might use the product as \u201ca nice sun protection on top of S.P.F.\nIn Japan, \u201cfood and health care companies have found cosmetic applications for their ingredients, so they are creating skin care brands.\u201d\n\nFor example, Frutarom, a flavor-ingredient house based in Israel, makes Alguard, a purified polysaccharide shield from a red microalgae that it says protects skin from daily assaults and reduces roughness as well as the look of fine lines.\nBut Dr. McDaniel, who does research into using plant-derived products to lengthen the life of cells, says he thinks the comparative data must be viewed with caution because the studies that yielded it are \u201cchallenging to do accurately, hard to interpret and not necessarily predictive of final products.\u201d\n\nSoon, consumers will judge whether Algenist products are a breakthrough.\nThe patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\n\u201cWe want to give it a lot of visibility all at the same time.\u201d But Mr. Burke knows that marketing has its limits.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story, like so many stories about aging, treats the natural biological process of getting older as something that can and should be fought, stopped or altered. By setting up these products as being able to \u201cprotect middle-aged faces from environmental assault,\u201d among other phrases used in the story, it gives credence to the marketing claims and contributes to a pervasive sense that people must protect themselves somehow against aging lest they be damaged.", "answer": 0}, {"article": "Blitz said debate should be aired publicly, and he is not rattled by opposition to plans for a regional approach.\nIt's the most common cause of sudden cardiac arrest.\nEven those who do are often neurologically impaired.\nBut the national average is about 4 percent.\nColumbus handles about 500 cardiac arrests a year.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story cited cardiac arrest statistics. \u00a0", "answer": 1}, {"article": "The average age of people in both groups was 73.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\n\"Right now it's hard to say whether an older person with normal cognition or mild cognitive impairment is likely to develop dementia,\" said lead author Cyrus A. Raji, MD, PhD, an assistant professor of radiology at Washington University's Mallinckrodt Institute of Radiology.\n\"We could tell that the individuals who went on to develop dementia have these differences on diffusion MRI, compared with scans of cognitively normal people whose memory and thinking skills remained intact,\" Raji said.\nIn a small study, MRI brain scans predicted with 89 percent accuracy who would go on to develop dementia within three years, according to research at Washington University School of Medicine in St. Louis and the University of California San Francisco.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease-mongering. The release said Alzheimer\u2019s affects 5.5 million Americans, according to the National Institutes of Health (NIH).", "answer": 1}, {"article": "See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.\nAccording to the National Institutes of Health, approximately 30 million men in the United States suffer from Erectile Dysfunction2, of which 9 million do not respond to pharmacological treatments such as Viagra, Levitra and Cialis.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\nThe goal of this procedure is to regenerate blood vessels and smooth muscle, parts of the penis that are not functioning properly in this patient population.\nIntracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial.Eur Urol Focus.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release mentioned that there are about 30 million men in the United States affected by ED, and backed it up with statistics from the National Institutes of Health. No disease mongering here.\nThe population for this potential treatment are those men with erectile dysfunction who do not have an adequate response to standard medicines. This is still a very large group and the one published study focused on men with erectile dysfunction after treatment for prostate cancer.", "answer": 1}, {"article": "But there are still a lot of unanswered questions about immune therapy.\nIn some patients, just removing the brake is enough to allow the person's immune system to fight and contain the cancer.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\nThe new trial looked at a type of lung cancer called squamous cell non-small cell lung cancer, which accounts for about 20%-30% of lung cancers.\n\"We as a lung cancer community are incredibly excited about the activity of immunotherapy in various aspects of the disease,\" said Pasi Janne, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute in Boston.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story points out that lung cancer is a scary disease \u2014 and it is. No disease mongering here.", "answer": 1}, {"article": "\"We tested acupuncture as a standalone treatment, and the results are very positive,\" said study author Rachel Manber, a professor at the Stanford University School of Medicine Sleep Medicine Center in Redwood City, Calif.\nAll were between 12 and 30 weeks of gestation.\nThe treatments lasted an average of 25 minutes.\nMany women are cautious about using medications during pregnancy, reports the study.\nAs many as 20 percent of women may experience depression during pregnancy, according to the March of Dimes.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of partum depression.", "answer": 1}, {"article": "The review identified a handful of drugs that \u201care probably effective and should be considered for migraine prevention.\u201d These include the antidepressants amitriptyline (Elavil, Endep or Vanatrip) and venlafaxine (Effexor); the beta blockers atenolol (Senormin or Tenormin) and nadolol (Corgard); and for menstrual migraines, naratriptan (Amerge) and zolmitriptan (Zomig).\nIt can cause throbbing pain in the head.\nIn addition, an herbal remedy derived from a family of plants called Petasites or butterbur was found to be effective, according to the review.\nThey were developed in conjunction with the American Headache Society.\nActually, odds are you wouldn\u2019t.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "The findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nThe participants were followed for 20-22 years and filled out questionnaires about the foods they ate.\nThe cause of the disease is unknown, and the risk of developing it increases with age.\nNor is it clear why the results differed for men and women.\nThis was an observational study and therefore can\u2019t establish cause and effect.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease-mongering about Parkinson\u2019s disease in the story.", "answer": 1}, {"article": "But then a few years later she started noticing something interesting.\nThe greatest hope for a so-called \"female Viagra\" was a drug called flibanserin, but it was nixed by a panel of Food and Drug Administration experts on Friday, who said the drug didn't seem to really help women with sexual dysfunction.\n\"There hasn't been much action in this area, and that certainly has to come up when a company is thinking about dumping money into researching a drug for female sexual dysfunction,\" says Phyllis Greenberger, president of the Society for Women's Health Research, which received money from Boehringer Ingelheim, the company that makes flibanserin.\nThis was the second time a so-called \"female Viagra\" failed to make it on the market; in 2004, an FDA panel said no to Intrinsa, a testosterone patch meant to hormonally help women with a lack of desire for sex.\nIn 2008, a survey of more than 30,000 U.S. women in the journal Obstetrics & Gynecology found that nearly 40 percent reported that they'd had a sexual problem at some point in their lives, most often a lack of desire.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article passes along a claim that has been repeated ad nauseum in the run-up to the FDA\u2019s decision about flibanserin: \"nearly 40 percent\" of women say they have\u00a0sexual problems, usually a lack of desire. However, the story neglected to mention some important details about this statistic:\nExaggerating the prevalence of a disorder and pathologizing minor or transient changes in function are the hallmarks of disease-mongering.", "answer": 0}, {"article": "The research, published online in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, studied participants in the Baltimore Experience Corps, a program that brings retired people into public schools to serve as mentors to young children, working with teachers to help them learn to read in understaffed school libraries.\nThey share their knowledge and know they are doing good in the world.\nThey took MRI scans of their brains at enrollment and then again after 12 and 24 months.\nThey engage in problem solving and they socialize in ways they wouldn't have if they stayed at home.\nThe control arm of the study, those not involved in Experience Corps, exhibited age-related shrinkage in brain volumes.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease-mongering in this report on cognitive decline.", "answer": 1}, {"article": "LaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\n\u201cBut what we have here is solid evidence that light physical activity reduces a woman\u2019s risk of dying over the next three to four years\u2014and we see the benefits are substantial and independent of moderate-to-vigorous physical activity.\u201d\n\nThe study could not show a cause-and-effect relationship between activity level and risk of death, only an association.\n\u201cIt\u2019s not one size fits all.\u201d\n\nBut national guidelines still recommend that adults over age 65 follow the same guidelines as younger people: to get at least 150 minutes of moderate-to-vigorous physical activity per week.\nBut the link was present in all types of women in the study, including those of all races and ethnicities, women who were obese and those who were not, women with high and low functional abilities and women older and younger than 80.\nAnd recent analyses, compiled from studies in which adults self-reported their levels of physical activity, have suggested that older adults have to log moderate-to-vigorous exercise in order to reduce their risk of early death.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s really no disease mongering here, though there is one note we\u2019d like to make that falls under this heading as well as anywhere. The story tells readers that increased physical activity is \u201clinked to a lower risk of death.\u201d Reader, we have bad news\u2026death is inevitable. It would be more accurate to note that physical activity reduced the relative risk of dying during a given timeframe (in this case, the three-year period of observation).", "answer": 1}, {"article": "Cowen & Co estimates that use of DNA blood tests for cancer screening will exceed $10 billion a year by the end of the decade.\nBut the move by Pathway, a privately owned maker of genetic tests ranging from cancer risk and heart health to drug response, underscores a growing debate over how much genetic information should be made available to healthy people if it is not yet clear how it can improve their health.\nThe test represents a first in the rapidly developing field of \u201cliquid biopsies,\u201d which use gene sequencing technology to screen blood samples for trace amounts of DNA associated with different cancers.\n\u201cWe do expect to detect cancer DNA when the tumors are small - much sooner than stage three or four,\u201d Plante said.\nThe company is focusing on mutations that are relatively well-understood, and for which there are specific treatments, said Chief Executive Jim Plante.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in this story. Quite the opposite. It turned a light onto this growing industry and questioned whether tests of biomarkers would actually lead to better clinical outcomes.", "answer": 1}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nHalf of them received traditional acupuncture treatment.\nLevels of estrogen and other hormones were measured before the study and after the first and last acupuncture sessions in both those receiving real and sham treatments.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering.", "answer": 1}, {"article": "A limitation of the study is that the evidence on acetaminophen was mainly for acute low back pain, but as the University of Leeds's Philip Conaghan explained, \"There is very little long-term data [on chronic back pain], and if a drug doesn't work in the acute problem, it seems unlikely to work in the chronic phase \u2014 though back pain may be even more complex than osteoarthritis pain.\"\nThis may help to explain the popularity of drugs like Tylenol for kids.\nAspirin also interferes with blood coagulation for days after taking it.\nIt turns out this is another fascinating problem area for pain researchers.\nRead more about Dear Julia here.\n", "question": "Does the story commit disease-mongering?", "explanation": "There are no examples of disease mongering in the story.", "answer": 1}, {"article": "Hare was not involved in the study.\n\"This is a groundbreaking study of extreme importance,\" Joshua Hare, MD, director of the University of Miami's Interdisciplinary Stem Cell Institute, tells WebMD via email.\n\"The reported benefits are of an unexpected magnitude,\" writes Gerd Heusch, MD, PhD, chair of the Institute of Pathophysiology at the University of Essen, Germany, in an editorial in the Nov. 14 online issue of The Lancet.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\nThe breakthrough comes just as researchers were becoming discouraged by studies in which bone-marrow stem cells failed to heal damaged hearts.\n", "question": "Does the story commit disease-mongering?", "explanation": "By the definition of this criterion, the story does not commit disease-mongering about heart failure after heart attack. So we\u2019ll give it a satisfactory score on this criterion. \nMany times, though, our reviewers wish to comment on what they consider to be treatment mongering. And that was the case this time as well. The story sets a tone of urgency and awe early in the story that carries through the rest of the story, culminating in the idea that people are somehow missing out on a \u201cbreakthrough\u201d \u2013 a term used twice in the story. \u201c\n\n\n\nThe only downside of this early success is that the ongoing study already has enrolled all 20 of the patients who will be treated. The experimental treatment simply will not be available to other patients in the near future.\u201d Readers with heart disease worried that they may have missed their chance to find a cure are told \u201cto maintain close contact with their doctors\u201d. This creates a panic mentality that does not serve patients or stem cell science.\n", "answer": 1}, {"article": "\"We found that, in general, African-American breast cancer patients exhibit increased likelihood for tumor recurrence, particularly to regional and distant sites, after receiving any combination of adjuvant therapy (treatment following surgery) compared to European-American breast cancer patients.\nThe researchers also found that among early stage patients (noninvasive or minimally invasive breast cancer), African-Americans displayed higher tumor recurrence than European-American patients.\nRecurrent breast cancer has hindered the successful management of this disease for decades and is one of the primary factors for the racial disparity in prognosis and outcomes.\nWhen breast cancer recurs, it is more challenging to treat regional and distant tumors than local tumors (in the breast), Wright explained.\nDifferences in recurrence rates and patterns between the races following various forms of treatment have not been thoroughly investigated.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release did not disease monger; breast cancer is indeed more deadly among African American women.", "answer": 1}, {"article": "WEDNESDAY, Aug. 31, 2016 (HealthDay News) -- Weight-loss surgery helps people drop a significant amount of weight, and now a new study confirms that much of the weight appears to stay off for at least 10 years.\nTo learn more about bariatric surgery procedures, visit the American Society for Metabolic and Bariatric Surgery.\nAfter four years, those who had gastric bypass lost nearly 28 percent of their starting weight.\nIn addition, women who undergo bariatric surgery are typically in their 30s through their 50s, he said.\nWhile other research has found that weight-loss surgery is the most effective treatment for obese patients, there is less data on long-lasting effects.\n", "question": "Does the story commit disease-mongering?", "explanation": "Morbid obesity is a major and growing health issue with frustratingly few treatment options.", "answer": 1}, {"article": "Over the 18-year period, the number of breast cancers diagnosed at very early stages increased 66 percent, while the number of more advanced cancers (stage 3) decreased by 66 percent.\n\"The findings make sense,\" she said.\nThey found that cancers can be detected earlier by mammogram.\n\"That's where the money is,\" Malmgren said.\n\"They are concentrating on the harms.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Tensions ran so high at one point that two prostate cancer specialists, who had urged the F.D.A.\nBased on those results, an advisory panel to the F.D.A., meeting in March 2007, voted 13 to 4 that there was \"substantial evidence\" that the drug worked and 17-0 that the drug was safe.\nThe only approved treatment for them now is the chemotherapy drug Taxotere, from Sanofi-Aventis, which extended median survival by about three months in trials.\n\"Since that delay, we have lost a lot of good men,\" Ted Girgus of Bellingham, Wash., who has advanced prostate cancer, said Tuesday, calling the F.D.A.\nThe F.D.A.\u2019s decision two years ago ignited an outcry from some prostate cancer patients and from investors in Dendreon, who said the agency was being unreasonable and denying patients a treatment that might work.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story quotes the drug maker\u2019s chief executive estimating that 100,000 American men per year are diagnosed with cancer that has spread beyond the prostate gland and is not benefitting from other therapies. \nThe reporter should not have depended on this self-interested source. \nOther news stories, quoting a variety of independent sources, estimated the number of affected men at 40,000 to 60,000 per year.\u00a0 \nIn addition, the reporter allows a source with dual conflicts of interest\u2013he is a patient who could benefit from the treatment and a stockholder in the company that makes the drug\u2013to make emotional appeals for approval.\nHe says many men have been \"lost\" since the FDA\u2019s failure to approve the drug, and that he and other patients are \"looking into the abyss\" and just \"want a chance\" to live. ", "answer": 0}, {"article": "MONDAY, June 27, 2011 (HealthDay News) -- Brilinta, an experimental anti-clotting medication currently awaiting U.S. Food and Drug Administration approval, performed better than the industry standard, Plavix, when used in tandem with low-dose aspirin, a new study finds.\nThe data and conclusions of the research should be viewed as preliminary until published in a peer-reviewed journal.\nHowever, patients who took Brilinta with higher doses of aspirin (more than 300 milligrams) had worse outcomes than those who took Plavix plus high-dose aspirin, the investigators reported.\n\"Physicians choosing to use ticagrelor in countries where it is approved and available should consider using a low-dose of maintenance aspirin with the drug.\"\n\"A higher aspirin dose (325 mg versus 81 mg) increases the risk of bleeding without increasing the efficacy of the drug.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The population is pretty well specified in the article as those with acute coronary syndromes, and it explains that the FDA is considering an indication for these patients who are undergoing angioplasty or stenting.", "answer": 1}, {"article": "Did I feel guilty for potentially contributing to the development of a superbug?\nThe studies also noted that the use of antibiotics must be weighed against the risk of antimicrobial resistance, to which prescriptions for childhood maladies such as ear infections are thought to contribute mightily, and against antibiotics' side effects, which can include diarrhea and eczema.\nBoth of the studies, in contrast to earlier research on which the \"watchful waiting\" approach has been based, are considered well-designed, even if they are on the small side.\nOne of the studies noted that while antibiotics -- specifically, amoxicillin paired with clavulanate -- shortened the duration of symptoms, half the children on placebo eventually got better without the aid of those drugs.\nCurrent practice guidelines for treating kids' mild middle-ear infections -- or acute otitis media -- call for watchful waiting, to be followed by antibiotics only if symptoms worsen or don't cease.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although the blog\u2019s unjustified dismissal of watchful waiting verges on disease-mongering by making ear infections sound worse then they are, this is an issue we\u2019ll deal with elsewhere in the review. The blog didn\u2019t otherwise exaggerate the impact of ear infections.", "answer": 1}, {"article": "(Reuters) - A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.\nIt works by taking the brakes off the immune system to more efficiently attack cancer.\nThat compared with 1 percent overall response rate and no complete responses for Yervoy alone.\nThere were no complete responses with Yervoy alone.\nPatients were also more likely to stop taking the combination of drugs.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "MONDAY, May 16, 2011 (HealthDay News) -- A daily dose of the antioxidant selenium doesn't appear to elevate \"bad\" cholesterol levels, and may in fact prompt a very modest boost in \"good\" cholesterol, a new British study reveals.\nThe finding comes from a six-month examination of the impact of various dosages of the supplement on the cholesterol levels of healthy people in England.\nFor six months, some participants were assigned to take daily selenium yeast supplements in either low, intermediate or high doses, while others were given a dummy pill for the duration.\nNone of the patients experienced any serious side effects as a result of selenium supplementation.\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t exaggerate the prevalence of selenium deficiency or otherwise try to scare people into taking supplements.", "answer": 1}, {"article": "In addition, the non-invasive nature of the device and its relatively large surface area make this technology a potential candidate for delivering multiple ocular drugs at once, further reducing the burden of self-administration on patients.\nNo surgery is required.\nThey were also supplied artificial tears.\nNearly 3 million people in the United States have the condition.\nThe ring became dislodged in 15 patients but was replaced each time, allowing therapy to continue.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Line Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\nCataracts are the leading cause of blindness in the world, and are often related to aging.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nSo the researchers use infrared light, delivered by an extremely fast-pulse laser.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering of cataracts. ", "answer": 1}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\nIt now has only five employees and a business of collecting a roughly 11 to 12 percent royalty on sales of Xiaflex.\nIt already was selling a gel for men with low testosterone and had learned from urologists about the need for better treatments for bent penises.\nUnfortunately, she had sold most of her holdings years earlier for a relative pittance.\nFinally, in the early 1990s, two professors of orthopedics at the nearby State University of New York at Stony Brook suggested using the drug for Dupuytren\u2019s.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no exaggeration of the prevalence or consequences of Dupuytren\u2019s contracture.", "answer": 1}, {"article": "Overall, the studies involved nearly a million participants.\nResearchers say the number of people with type 2 diabetes is expected to increase by 65% by 2025, reaching an estimated 380 million people worldwide.\nThe results showed that people who drink more coffee, whether it\u2019s regular or decaffeinated, or tea appear to have a lower risk of developing type 2 diabetes.\n\u201cDespite considerable research attention, the role of specific dietary and lifestyle factors remains uncertain, although obesity and physical inactivity have consistently been reported to raise the risk of diabetes mellitus,\u201d write researcher Rachel Huxley, DPhil, of the George Institute for International Health, University of Sydney, Australia, and colleagues in the Archives of Internal Medicine.\nThe study also showed that people who drank more than three to four cups of decaffeinated coffee per day had about a one-third lower risk of developing type 2 diabetes than those who didn\u2019t drink any.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story gives no source for the projection that \"Researchers say the number of people with type 2 diabetes is expected to increase by 65% by 2025, reaching an estimated 380 million people worldwide.\"", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story commit disease-mongering?", "explanation": "There is only a benefit to special rehydration in sustained vigorous exercise, not the usual 15 minutes on the treadmill. The author recommends rehydration with a commercial sports drink for \u201celite athletes\u201d without defining the term. Most physical exercise does not require special, commercially-marketed products. By focusing on the studies in which the subjects are competitive cyclists perfoming 80 kilometer time-trials, or on subjects losing 2.5% of their weight (equivalent to a 160 pound person losing 4 pounds), the story crosses the line into disease mongering. In the setting of an obesity epidemic, there may be more harm than benefit in the widespread consumption of calorie-rich beverages when, in most situations, water would suffice. The truth is that except at the extremes, our kidneys do a miraculous job of keeping our electrolytes in precise and normal concentrations without a need for commercial concoctions. ", "answer": 0}, {"article": "INTERVIEW FOOTAGE WITH PROFESSOR ALICE STANTON, The Royal College of Surgeons in Ireland CAN BE DOWNLOADED VIA: https://vimeo.com/241661898\n\nNOTES TO EDITOR:\n\nDEVENISH\n\nDevenish delivers sustainable and innovative nutritional products and solutions for the feed industry, the food industry and for human health.\nThe study showed that consuming omega-3 enriched chicken and eggs resulted in a halving of the number of subjects with such a high-risk omega-3 Index.\nThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\nA low omega-3 Index (<4%) indicates a heightened risk of heart and brain disease.\n\"International guidelines recommend eating oily fish at least once per week, however, many people do not eat fish at all and less than 20% of the world's population have optimal omega-3 PUFA levels.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t disease monger.\nHowever, we think the release steps over the line into \u201ctreatment mongering\u201d without evidence.", "answer": 1}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story commit disease-mongering?", "explanation": "We wish some of the skepticism expressed in the body of this piece had made it to the top. Instead, readers are drawn in with scary statements along with exaggerations of the test\u2019s capabilities. The headline states the tests \u201ccheck for signs of early aging,\u201d as if aging were a disease, and that companies claim the tests \u201ccan signal disease risk and a need to take corrective measures.\u201d The first paragraph continues the alarming tone, stating that \u201cyour cells might be aging faster than you are.\u201d", "answer": 0}, {"article": "\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\nExperts agreed that the findings held promise, but much more research will be needed.\nThey found that the saliva of people with Alzheimer's had different levels of certain substances compared to the saliva of healthy people or those with mild cognitive impairment.\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\n\"It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer's risk will be maintained in a large multicenter study.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "Fear of Alzheimer\u2019s is real and pervasive, but this story didn\u2019t get into disease-mongering territory.", "answer": 1}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story commit disease-mongering?", "explanation": "It\u2019s arguable that this story contributes to concentrating on appearance rather than health, and may get people with a normal BMI worrying about whether they are \u201cskinny fat\u201d \u2014 without offering any evidence that this is a real problem. However, since we didn\u2019t see any egregious exaggerations of the obesity problem, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "But she said it\u2019s more convenient and less time-consuming to administer.\nThe 10-minute, non\u00adinvasive examination can detect subtle lapses in the brain\u2019s perceptual ability that may signal the early stages of mental decline caused by dementia.\nThe test, which has been around since 1975, offers only a broad indication of cognitive abilities and fails to pick up borderline problems, she said.\n[Scientists are cautiously optimistic about progress toward finding treatments for Alzheimer\u2019s disease]\n\n\u201cLook, there is a late-life tsunami of late-life cognitive decline coming at us, and health-care providers are standing on the beach,\u201d said Charles J. Duffy, a neurology professor at the University of Rochester Medical Center who founded the company.\nThe federal government\u2019s approval to market the device comes as Alzheimer\u2019s researchers everywhere step up the pursuit for easier and more inexpensive ways to identify dementia in its earliest stages.\n", "question": "Does the story commit disease-mongering?", "explanation": "Dementia is a serious public health problem and as the population ages it will become a larger issue.\u00a0 The story does a good job in providing some useful context.\u00a0 However we think that the construct of a, \u201c\u2026late-life tsunami of late life cognitive decline coming at us\u2026\u201d and \u201c\u2026Dementia is the gorilla in the corner of the room in every primary care visit with every older adult..\u201d don\u2019t add much in the way of information and suggest that the problem is nearly universal after a given age. Such descriptions are particularly problematic when applied to a cognitive disease that is the source of worry for many and is often conflated with normal behaviors. The company source says doctors haven\u2019t been provided with tools to assess dementia, yet several other tools are mentioned in the piece, including the one that is used as the gold standard comparison for his new test.", "answer": 0}, {"article": "Still, a psychological evaluation may make sense for IBS patients because it\u2019s possible their symptoms might be a byproduct of untreated depression, said Dr. Agnieszka Kulak-Bejda, a psychiatry researcher at the Medical University of Bia\u0142ystok in Poland who wasn\u2019t involved in the study.\nRates of \u201cno relief\u201d were highest with placebo treatments.\nPeople were 34 percent less likely to have no relief from antidepressants and 31 percent less likely to get no relief from psychotherapy, the study found.\nPeople with IBS typically suffer from chronic abdominal pain, gas, diarrhea and constipation.\nA family of medicines known as tricyclic antidepressants were more effective at relieving global symptoms of IBS, the analysis found.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "SAN DIEGO -- Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective.\nAnd cancer patients may experience low platelet counts and be at risk for a clotting disorder called 'heparin-induced thrombocytopenia.'\"\n\"Nearly 1 in 5 patients with cancer will develop a clot in the veins, referred to as either a deep vein thrombosis or pulmonary embolism,\" says Dr. McBane.\nThe drug was associated with fewer major bleeding events and fewer recurrent blood clots, compared to low-molecular- weight heparin.\nWhile twice-daily injections of low-molecular-weight heparin has been the traditional treatment of choice for cancer patients who suffer a venous clot, Dr. McBane notes that there are numerous limitations to this therapy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release briefly notes how many cancer patients are affected by blood clots (1-in-5) which is useful context.", "answer": 1}, {"article": "In the latest look at various treatments, the Cochrane group evaluated studies that examined both pharmaceutical and alternative techniques, including acupuncture, acupressure (a noninvasive variation of acupuncture), ginger, vitamin B-6 and conventional anti-vomiting drugs.\nAuthors of the review found some evidence that ginger, vitamin B-6 and anti-vomiting drugs relieved nausea.\nThe studies in the review comprised more than 4,000 women who were up to 20 weeks pregnant.\nUnfortunately, medicines to relieve morning sickness have a checkered history.\nTake ginger.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story didn\u2019t exaggerate the effects of morning sickness.", "answer": 1}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering.", "answer": 1}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story commit disease-mongering?", "explanation": "In general, the story does not exaggerate spinal stenosis, though it may be a stretch to characterize the problem as \u201ccommon.\u201d (It exists in about 3% of people who visit a doctor with back pain, and is a common cause of\u00a0 back surgery in the elderly.) And while it is true that spinal stenosis can cause \u201cdebilitating pain,\u201d the condition can often be less dire as well. Although people who received nonoperative care in this SPORT study did not do as well as those who received surgery, some 40% of all enrolled patients still preferred to manage their problem without surgery at the two-year mark and, on average, showed modest improvement.", "answer": 1}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. ", "answer": 1}, {"article": "\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\nAlpha-carotene is part of a group of antioxidants known as carotenoids, which also includes beta-carotene and lycopene.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nNot applicable, mainly because the story really didn\u2019t give any background on any specific health problem or disease.\n", "answer": 2}, {"article": "How often, for example, does HPV testing lead to biopsies, versus Pap testing?\nUsually, the immune system clears the infection, but persistent infection with certain strains of HPV leads to cervical cancer in some women.\nIn the so-called liquid-based version, the cells are placed in special preservative liquid designed to make the specimen easier to \u201cread\u201d; those same cells can also be used for HPV testing (unlike the cells collected with conventional Pap tests).\nYou\u2019re trying to make a tradeoff between sensitivity and specificity.\u201d\n\nSince cervical cancer screening is repeated over time, what\u2019s needed is evidence of the longer-term effects of different tests, according to Whitlock.\nBut there are still questions about the effects of HPV screening, and \u201cmore complete evidence\u201d is needed before it becomes widely used, Whitlock and her colleagues write.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does a good job of describing the rapid drop in cervical cancer rates after introduction of the traditional Pap screening test. The story is careful to point out the not all HPV infections are dangerous, by noting that the immune system usually clears them on its own.", "answer": 1}, {"article": "CAM2038 is also being developed for treatment of chronic pain.\nCAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\n\"This study provides clinical proof of concept that CAM2038 will be an effective treatment for opioid use disorder,\" said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals, \"The current opioid crisis demands innovation, and CAM2038's novel technology is now one step closer to providing physicians and patients with a different approach to treating this deadly chronic disease.\"\nThe ability of CAM2038 to produce a long-lasting and robust blockade of hydromorphone-induced Drug Liking is especially encouraging,\" said Sandra D. Comer, Ph.D, Professor of Neurobiology, Columbia University.\nAbout CAM2038\n\nThe investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid use disorder are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t overstate the impact of opioid overdose. On the other hand, it would have been nice to include some context on the incidence of opioid addiction which this drug is designed to treat.", "answer": 1}, {"article": "Naomi Wolf, author of \"Misconceptions: Truth, Lies, and the Unexpected on the Journey to Motherhood,\" blames insurance companies and hospitals, who she says deny women information about their choices.\nBut the image that viewers may find most shocking is that of a baby being cut out of a woman's abdomen via Caesarean.\nThe epidural can then retard contractions and lead to more drugs, fetal stress and the doctor's recommendation of a Caesarean.\n\"We all have this idea that normal birth is a woman lying in a hospital bed screaming,\" says Block.\nThere are many births in the documentary film \"The Business of Being Born,\" including a scene of former talk-show host Ricki Lake giving birth naked in her tub.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story is clear that there are clear indications for which Caesarean birth\u00a0is appropriate but that the overuse of the elective procedure is concerning.", "answer": 1}, {"article": "\"Currently, the standard practice in North America is to prescribe medication to patients with stable coronary artery disease and avoid PCI,\" said Dr. Peter J\u00fcni, Director of the Applied Health Research Centre (AHRC) at the Li Ka Shing Knowledge Institute of St. Michael's Hospital, who is a senior author on the study.\nWhile the FAME 2 trial showed that PCI reduced urgent hospital admissions and revascularizations and likely reduced heart attacks, it did not provide evidence for a difference between PCI and medication alone in the prevention of deaths.\nThe medication used in the FAME 2 trial consisted of a combination of aspirin, cholesterol-lowering and blood pressure-lowering drugs as required by current treatment guidelines.\nThe World Health Organization reports that every year, 17.7 million people die from cardiovascular diseases, which is an estimated 31 per cent of all deaths worldwide.\nIn situations where the heart's arteries narrow less suddenly and do not cause a heart attack but induce chest pain during exercise - a condition known as stable coronary artery disease - it has remained unclear whether PCI in addition to medication was better than medication alone in preventing future heart attacks.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering. The release appropriately calls attention to the grave toll of heart disease around the world.", "answer": 1}, {"article": "\u201cNow it\u2019s, like, \u2018When do we get this here?\nTeichner asked Brad and Amy Price, \u201cYou keep using the word \u2018miracle.\u2019 In what way is all of this a miracle?\u201d\n\n\u201cOur son\u2019s still with us, and Cecilia as well,\u201d they replied.\nTeichner asked, \u201cDo you believe that gene therapy is finally coming into its own?\u201d\n\nThe MLD trial, she thinks, demonstrates what\u2019s possible -- offering promise to the 30 million Americans who suffer from some 7,000 rare diseases.\nAmy recalled: \u201cShe\u2019s sitting on the bed in her tutu and her colorful sweater, and they\u2019re telling me she\u2019s gonna die.\u201d\n\nMany children with the disorder are dead by the age of 6.\nThe genetic legacy each of us inherits is a powerful force -- and in a few extreme cases, it can be deadly.\n", "question": "Does the story commit disease-mongering?", "explanation": "MLD is referred to as a \u201crare, nightmare disease.\u201d We feel this is not disease mongering considering that\u00a0MLD is currently untreatable and usually kills children before they reach five years old.", "answer": 1}, {"article": "Observational studies, which include all people with a condition, can never conclusively prove cause and effect, Keating acknowledged, because \"the thing we can't account for is whether people who are on a treatment are different from those who aren't.\"\nAlbertsen wrote an accompanying editorial in the journal.\nThe U.S. National Cancer Institute has more on prostate cancer.\n\"One third of men over 65 who don't have surgery or radiation get this therapy,\" she said.\n\"We are beginning to realize that there can be significant problems in terms of cardiovascular risk.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease mongering about prostate cancer.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Monitoring high-risk pregnancies with ultrasound tests may help prevent some fetal and newborn deaths, a new research review finds.\nHowever, with Doppler an established technique for monitoring high-risk pregnancies, Alfirevic said it is very unlikely that any future studies will test Doppler against no Doppler \u2014 as most studies in this review did.\nThere have been concerns that abnormal findings on Doppler ultrasound may prompt doctors to sometimes unnecessarily intervene \u2014 by, for instance, performing a cesarean section.\nIn some cases, early delivery may be the best course, but it is unclear whether other options \u2014 such as bed rest or tighter blood pressure control in a woman with high blood pressure \u2014 are effective.\n\u201cThere is no evidence to suggest that it should be done in low-risk women,\u201d Alfirevic said.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story clearly states that the evidence on the use of Doppler ultrasound applies only to high-risk pregnancies and that there is no evidence the examinations should be done in low-risk pregnancies.", "answer": 1}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nDuring these operative procedures, surgeons seek to relieve pressure on these nerves or to disconnect the nerves in order to prevent them from triggering future headaches.\nThe technique is a new use of an approach that many surgeons are already familiar with: the Gillies incision, used for surgical repair of cheekbone fractures.\nMost recently, a study in Plastic & Reconstructive Surgery reported similar results whether the nerve is decompressed or disconnected.\nHe describes his initial experience with the new approach in 19 patients.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the news release. On the contrary, it\u2019s quite balanced in its tone.", "answer": 1}, {"article": "MS is an autoimmune neurodegenerative disorder that affects nearly 2.5 million people worldwide.\nThat myelin increases the speed of neural transmission is one of the most well-established concepts in neurobiology, and combined with the clear evidence from Chan's preclinical research showing that clemastine fumarate promotes myelin formation, myelin regeneration is the only plausible explanation for the VEP results, the authors said.\nIn light of previous laboratory studies of the antihistamine compound at UCSF, the researchers said, the drug most likely exerted its effect by repairing damage MS had inflicted on myelin, an insulating membrane that speeds transmission of electrical signals in the nervous system.\nTo enhance the power of their study, the researchers used a \"crossover\" design: they divided the patient population in two and gave the drug, blinded to both participant and researcher, to one group, and a placebo to the other for 90 days; then they switched between the two groups, giving a placebo to the first group and the drug to the other for the next 60 days.\nThe effect persisted in the group that had switched to placebo, suggesting that durable repair of myelin had been induced by the drug.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release. It gives readers a primer on what myelin is and how its progressive degeneration leads to MS. One clever clarification was to point out the differences between myelin and rubber insulation around wires.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "\"If you have your choice, you want to get poked with a needle or you want to try this?\n\"In vaccines, what's really hard is that there's a very, very high volume, and you're competing with a needle and syringe, which is tremendously low cost,\" Anquetil says.\nAnd the same vaccine continues to be recommended and used in European Union markets, AstraZeneca says.\nThe vaccine's effectiveness was just 3 percent, so low that \"no protective benefit could be measured\" for children ages 2 to 17, the CDC said in a statement.\n\"To create the jet, you have to instantaneously create 100 times more pressure than you've got in the tire of a car,\" he says.\n", "question": "Does the story commit disease-mongering?", "explanation": "The headline \u201cBeyond the Nasty Needle\u201d seems over the top.\u00a0Still, it\u2019s true that some people are pathologically afraid of needles, and the rest of the headline and article don\u2019t approach the issue that dramatically.", "answer": 1}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nWhatever the case, the energy drink boom has come full circle in Asia, the region where it started.\n\u201cI don\u2019t believe that it is misleading,\u201d said Ms. Lutz, who added that the advertising division of the Council of Better Business Bureaus had approved the \u201cNo Crash Later\u201d claim.\nAmong them: bringing out Lipovitan Junior, a caffeine-free version for children.\nAsked whether consumers mistakenly believe that the shot does not produce a caffeine-related crash, Ms. Lutz said that the use of the special mark and its explanation were clear.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Chinese researchers found those who ate the most of the healthy plant components were 11 percent less likely to develop breast cancer than women who ate the least.\nWhile earlier research has yielded mixed conclusions on the link between cancer and fiber, it would make scientific sense: According to the Chinese researchers, people who eat high-fiber diets have lower levels of estrogen, which is a risk factor for breast tumors.\nStill, it\u2019s impossible to rule out that big fiber eaters had healthier habits overall that would cut their risk, Jia-Yi Dong of Soochow University in Suzhou and his colleagues write in the American Journal of Clinical Nutrition.\nThe guidelines recommend that women eat 25 grams of fiber per day and men eat 38 grams, while the average Americans gets just 15 grams a day.\nThe results \u201ccan identify associations but cannot tell us what will happen if people change their behavior,\u201d said John Pierce, a cancer research at the University of California, San Diego, who was not involved in the work.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering of breast cancer in the story.\u00a0 In fact, it includes an important little line of context: \u201cAbout one in eight American women get breast cancer at some point, with less than a quarter of them dying from it.\u201d", "answer": 1}, {"article": "July 30, 2012 -- If it weren't for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\nThat kind of prostate cancer -- metastatic prostate cancer, in which the cancer spreads to the bone or other parts of the body -- is rapidly fatal, usually within two years or less.\nStudies looking back at cancer trends in a population are very unreliable when it comes to showing what caused those trends.\nIt finds that in the three years before widespread PSA testing (1983-1985), men getting their first diagnosis of prostate cancer were three times more likely to learn they had very late-stage cancer than men diagnosed in the most recent three years for which data is available (2006-2008).\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering and did a good job explaining that prostate cancers are not all the same. \u201cThat kind of prostate cancer \u2014 metastatic prostate cancer, in which the cancer spreads to the bone or other parts of the body \u2014 is rapidly fatal, usually within two years or less.\u201d", "answer": 1}, {"article": "To be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nEven a baby aspirin might be enough.\nThey range from pancreatic cancer to the type of lung cancer that strikes nonsmokers.\nIn the United States, a baby aspirin weighs in at 81 milligrams.\nThe biggest is stomach bleeding, although it also raises the risk of brain hemorrhage.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "SIR Annual Scientific Meeting, March 17-22, 2018.\nThis abstract can be found at sirmeeting.org\n\nThe Society of Interventional Radiology is a nonprofit, professional medical society representing more than 7,500 practicing interventional radiology physicians, trainees, students, scientists and clinical associates, dedicated to improving patient care through the limitless potential of image-guided therapies.\n\"Advanced stage liver tumors, including ones that have spread from other locations, have limited treatment options because the patients can be in poor health; further, the complex structure of the organ can make it difficult to target with standard approaches,\" said Steven S. Raman, M.D., professor of radiology, surgery and urology at the David Geffen School of Medicine, University of California, Los Angeles, and lead author of the study.\nLOS ANGELES (March 21, 2018)--Advanced stage liver tumors may be safely treated through image-guided injections of an immunotherapy approved for melanoma, according to a study presented today at the Society of Interventional Radiology's Annual Scientific Meeting.\n\"This is an exciting way to look to the future, but patients living with advanced liver cancer should understand that this treatment will not be available for several years, except through clinical trials.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. However, the news release didn\u2019t add any context about the scope and impact of liver cancer.\nThe American Cancer Society estimates there will be 42,220 new cases of liver cancer diagnosed in 2018, and about 30,200 deaths.", "answer": 1}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.\nHowever, the story should have been more cautious about claims of benefit for conditions ranging far beyond the scope of the research at hand, which focused on mental health problems among people with advanced cancer.", "answer": 1}, {"article": "For them, a combination of two existing CFTR modulators can ease breathing problems -- but the overall effects are only \"modest,\" Rowe said.\nThen there's the 30 percent of CF patients who carry only one copy of F508del, plus another defect known as a \"minimal-function\" mutation.\n\"This is not a cure for cystic fibrosis,\" stressed Dr. Steven Rowe, who led one of the trials.\nNow the questions are whether the improved lung function can be sustained, and whether the drugs prevent symptom exacerbations and other complications, wrote Dr. Fernando Holguin, of the University of Colorado, Aurora.\nMost side effects in the four-week trials were \"mild to moderate,\" the researchers said, and included cough, headache and increased sputum.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t engage in disease-mongering. It said more than 30,000 people have cystic fibrosis in the U.S., and most have the genetic mutations targeted by these compounds. We also appreciated the genetic descriptions.", "answer": 1}, {"article": "The data will help the system make even better recommendations and provide more personalized treatment.\nThe preliminary study did not include a control arm, so it's possible that some people who enrolled in the trial would have improved anyway, partly because they may have been motivated to try something new, Mohr said.\nThe IntelliCare algorithm recommends new apps each week to keep the experience fresh, provide new opportunities for learning skills and avoid user boredom.\n\"These are designed to help the millions of people who want support but can't get to a therapist's office.\"\nThe apps offer exercises to de-stress, reduce self-criticism and worrying, methods to help your life feel more meaningful, mantras to highlight your strengths, strategies for a good night's sleep and more.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t go overboard describing the prevalence of depression in our society. It reasonably states, \u201cMore than 20 percent of Americans have significant symptoms of depression or anxiety each year, but only around 20 percent of people with a mental health problem get adequate treatment.\u201d", "answer": 1}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world\u2019s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\n\u201cIt might not be people smoking marijuana,\u201d Kaminski said.\nWith antiretroviral therapy \u2013 a standard form of treatment that includes a cocktail of drugs to ward off the virus \u2013 these cells have a better chance of staying intact.\nYet, even with this therapy, certain white blood cells can still be overly stimulated and eventually become inflammatory.\n\u201cThe patients who didn\u2019t smoke marijuana had a very high level of inflammatory cells compared to those who did use,\u201d Kaminski said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the piece.", "answer": 1}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nAs many as 20 percent of American adults have some symptoms of irritable bowel syndrome, according to the National Institutes of Health.\nIf the drug succeeds in a second Phase 3 trial, with results expected by the end of the year, Ironwood plans to file for regulatory approval next year.\n\u201cThe exciting thing about the data on linaclotide is that it improves both of those symptoms,\u201d he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Irritable bowel syndrome is a controversial diagnosis.\u00a0\u00a0Some view it as a minor problem that has been\u00a0medicalized\u00a0by the drug industry to\u00a0sell new medicines. However,\u00a0there are clear criteria for\u00a0identifying the condition, and it is now a generally\u00a0accepted\u00a0diagnosis.\u00a0 The story captures some of this uncertainty when it says the condition is\u00a0\"poorly understood and somewhat vaguely defined.\"\u00a0We don\u2019t think this\u00a0story is\u00a0an example of disease-mongering.", "answer": 1}, {"article": "TUESDAY, Nov. 27, 2018 (HealthDay News) --What if a simple zap to the spine could relieve the debilitating lower back and leg pain brought on by a herniated disk?\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\n\"Without inflammation the pain fades, and the body starts a self-healing process that allows for complete resolution of the disk herniation in a large proportion of patients.\"\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\n", "question": "Does the story commit disease-mongering?", "explanation": "Back pain is common, and this story does not disease monger. It gives a concise description of what disk herniation of the lower back is.", "answer": 1}, {"article": "In the nearly year and a half since having the surgery, her condition has improved substantially, she said.\nThe results come at time when a growing number of people are reaching their late 50s and early 60s, when they are most likely to be diagnosed with the disease, which affects between 500,000 and 1.5 million Americans.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\n\"This (the JAMA study) is the largest, most complete and thorough analysis of deep brain stimulation to date,\" Hiner said.\nThe six-month study, which involved 255 people, found that those who underwent surgery had 4.6 more hours each day of good control of their symptoms than those who got the best drug therapy.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story begins and ends with an anecdote illustrating what appears to be a \"dramatic\" improvement. But that outcome is based on self-reports rather than a medical assessment. Still, it falls short of disease mongering. \nThe reporting of the patient\u2019s story did not reflect whether she had side effects. Given the fact that the study shows the risk of serious side effects is about 4 times higher with the surgery, we wish this angle had been reported. ", "answer": 1}, {"article": "Boston, MA-- The investigational drug abaloparatide-SC (subcutaneous) may help increase bone mineral density in postmenopausal women with osteoporosis and reduce their risk of vertebral and nonvertebral fractures, new industry-sponsored research suggests.\nOsteoporosis was defined broadly, using both BMD criteria as well as recent history of nonvertebral fracture and confirmed prevalent vertebral fracture on x-ray.\nFollow us on Twitter at @TheEndoSociety and @EndoMedia.\nThe Society, which is celebrating its centennial in 2016, has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries.\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Statements about the potential value of the drug are reasonable and cautious and there\u2019s no disease mongering here.", "answer": 1}, {"article": "J&J also said Cosentyx demonstrated quicker effectiveness than Tremfya during the study.\nWith $2.1 billion in sales in 2017, Cosentyx has become one of the top revenue earners for Novartis and is expected to make up for falling revenue from its blood cancer treatment, Gleevec, whose patent expired two years ago.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\n\u201cThese results imply that Cosentyx remains a good option for moderate-to-severe psoriasis patients that want to achieve more rapid skin clearance,\u201d brokerage Jefferies wrote in a note following the results.\nTremfya, first approved in July 2017 as a plaque psoriasis treatment in the United States, is also being tested as a for psoriatic arthritis and Crohn\u2019s disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.\nThe story does well to inform readers that plaque psoriasis is fairly common, affecting about 7.5 million Americans.", "answer": 1}, {"article": "Saturated fats can remain a part of a healthy diet, in limited amounts \u2013 but there are two easy ways to help:\n\u2022 Saturated fats should make up 10 percent of total caloric intake daily.\nA new study suggests the answer may be no.\nFollow her on Twitter @drfernstrom.\nAll that is known is the participants had a normal cholesterol levels and normal blood pressure.\nWhether statins have additional properties to reduce risk, in addition to lowering serum cholesterol remain under study.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story commit disease-mongering?", "explanation": "Although the story accurately reports statistics on the number of people who have strokes, it confuses readers by referring to \u201cscreening\u201d (which is testing people who don\u2019t have symptoms) with the testing the reporter underwent to diagnose the cause of specific symptoms. After noting that a U.S. task force (the US Preventive Services Task Force) recommends against screening people without symptoms, the story says, \u201cMy experience, along with some evidence from screening of thousands of individuals, raises questions about the task force\u2019s conclusions.\u201d\nSince his experience was with diagnostic testing, it is not relevant to a discussion of screening tests.", "answer": 0}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease-mongering. However, the story could have made it more clear that BRCA-associated tumors account for only a small percentage \u2014 5% to 10% \u2014 of all breast cancers.", "answer": 1}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nIn the study, patients who received monthly gantenerumab injections showed reductions in such brain plaques.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\nThe study is published in the online edition of Archives of Neurology.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play here.", "answer": 1}, {"article": "EMBARGOED FOR RELEASE: 11 A.M. (ET) TUESDAY, AUGUST 16, 2016\n\nMedia Advisory: To contact Paul D. Miller, M.D., call 303-925-4514 or email millerccbr@aol.com.\nThe trial was conducted at 28 sites in 10 countries.\n: This study was funded by Radius Health.\nOverall, there were no differences in serious adverse events between the treatment groups.\nBone mineral density (BMD) increases were greater with abaloparatide than placebo.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release.", "answer": 1}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story commit disease-mongering?", "explanation": "No elements of disease mongering. Article clearly states that estrogen therapy is an option for treating severe menopause symptoms; it does not overstate the number of women entering menopause nor does it imply that they all will experience severe symptoms that warrant treatment.", "answer": 1}, {"article": "Beyond walking, weight lifting and other resistance training may improve bone mineral density in the lower back, and maintain bone density in the hips.\n\"It's the cyclic loading and unloading of weight, not simple compression, that keeps bones strong,\" he added.\nWalking has not been shown to restore bone that is already lost to osteoporosis, but it can help preserve the bone density that a person has, said Dr. Carol Hartigan, a spine specialist at New England Baptist Hospital.\n\"Anything that makes bone bear weight is good for bone quality,\" said Dr. Kirkham Wood, head of orthopedic spine surgery at Massachusetts General Hospital.\nIf you already have osteoporosis, check with your doctor before embarking on a weight lifting program because if you try to lift too much weight too soon, you could fracture a bone.\n", "question": "Does the story commit disease-mongering?", "explanation": "The entire paragraph indicating the number of people with osteoporosis and in addition, the number at risk because they have low bone density is an example of disease mongering. \u00a0\nOsteoporosis and its precursor, osteopenia are both asymptomatic and not a disease, per se. The issue is rather fragility fractures, which are a major cause of morbidity and mortality among the elderly. \u00a0However the story did not even mention the role of age in the picture.\u00a0", "answer": 0}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story commit disease-mongering?", "explanation": "The focus of this story was the opposite of disease-mongering.", "answer": 1}, {"article": "\"The trend is away from traditional soda pop [toward] products claiming to provide magical health benefits,\" Silverglade says.\n\"Once I learned they were really just cleverly marketed sugar waters, I stopped.\"\nBut that doesn't mean the claims are invented -- most are based in research.\nA 2007 study found that research on health drinks that was funded entirely by beverage companies was between four and eight times more likely to find a favorable result than research with no industry support.\n\"These days it's possible for a food company to pay just about anybody to conduct a study,\" says Silverglade.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t exaggerate any of the conditions POM supposedly prevents or treats.", "answer": 1}, {"article": "The findings were published today in the Journal of Bone and Mineral Research.\n\"The development of osteoporosis drugs by pharmaceutical companies has focused heavily on blocking CatK in recent years,\" said Dieter Br\u00f6mme, a professor in the faculty of dentistry and a Canada Research Chair in Proteases and Disease.\nUsing a compound derived from red sage, UBC researchers have found a way to selectively block an enzyme called Cathepsin K (CatK), which plays a major role in the breakdown of collagen in bones during osteoporosis.\n\"CatK is a multifunctional enzyme with important roles in other parts of the body and we think completely blocking it is what causes unexpected side effects in other drugs,\" said Preety Panwar, a research associate in the Br\u00f6mme lab.\nMost drugs in development have been so called active site-directed inhibitors, which act like master keys and lock the entire enzyme, blocking both its disease-relevant functions such as collagen degradation and its other normal functions.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release states that osteoporosis \u201cis a global health problem that will affect one out of three women and one out of five men worldwide.\u201d We don\u2019t know where these numbers came from and they appear to be on the high side. On the other hand, osteoporosis is common. One study put osteoporosis prevalence in nine industrialized countries at 9 to 38 percent of women and 1 to 8 percent of men ages 50 and over. In these countries, osteoporosis was found to affect up to 49 million people.", "answer": 1}, {"article": "THURSDAY, Oct. 12, 2017 (HealthDay News) -- Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.\nThis is an important part of breast health,\" she said.\nIts effectiveness depends on the size of a breast tumor and the density of breast tissue.\nNot all women with breast cancer experience the same warning signs of the disease.\n\u2022 Mammogram: An X-ray of the breast used to examine breast changes.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article does not disease-monger.", "answer": 1}, {"article": "Give these a click:\n\nPersonalized cancer vaccines have already helped treat three patients\n\nSmartwatches might cause cancer, says article based on \u2018expert\u2019 who pushes holistic breast cancer treatments\n\nSun damage keeps happening even after you go inside, new study says\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nA modified version of the Herpes Simplex 1 virus (known for causing cold sores and some cases of genital herpes) called T-Vec has successfully been used to treat melanoma in a phase III clinical trial.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nSo in addition to the destructive power of the T-VEC cells themselves, the therapy summons the immune system right to where it's needed -- the tumor.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article could have more quickly pointed out that this treatment is for only one cause of skin cancer, melanoma, and for those with very advanced/metastatic disease. Reading just the title and first paragraph may lead the reader to believe this is a more generic treatment for all skin cancers \u2014 most of which are locally growing and do not put one at any risk for distant spread or death. But the story does not\u00a0disease monger. Melanoma is a cancer that is difficult to treat, especially in its late stages, and the scope of the problem is not exaggerated.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "Although the primary focus could be characterized as excessive hype about a treatment, the references to avian flu and cancer amounted to disease mongering, especially when it falls under the subheadline of \"Almost Everyone Needs More of the Sunshine Vitamin.\"\u00a0 ", "answer": 0}, {"article": "However, Richmond says patients considering viscosupplementation should discuss this as a treatment option with their doctor.\n\"This is not a first line treatment, but it's a reasonable treatment in those people who have been appropriately screened.\"\nDr. John Richmond disagrees.\nHyaluronic acid is a lubricating fluid that is naturally found in the knee, but degenerates over time in people with osteoarthritis.\n\"This needs to remain one of those limited treatment options and should be used appropriately by the physician giving it.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of knee osteoarthritis.", "answer": 1}, {"article": "\u2022 The study compared the results of RCTs, which explore interventions under strict clinical conditions, to those of prospective cohort studies that are observational, and followed larger populations for longer periods of time.\n\u2022 Be appropriately powered to detect an effect in current clinical conditions.\nAn accompanying editorial in Mayo Clinic Proceedings also acknowledges the importance of the study.\nCurrent RCTs have varying durations, different baseline CHD status for study participants, and utilize several methods for patient selection and randomization.\n\u2022 Extensively detail how subjects are diagnosed to create uniform diagnostic criteria.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. But there\u2019s also no context about the prevalence of coronary heart disease.", "answer": 2}, {"article": "His father\u2019s eventful medical history included a serious stroke and coronary bypass surgery.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\n\u201cHe said, \u2018I don\u2019t want to spend my time doing this,\u2019 \u201d recalled his son, Dr. Gerald A. Hladik.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\n", "question": "Does the story commit disease-mongering?", "explanation": "If anything, this article is protective against disease-mongering. It questions the idea that everyone with a particular disease should get treatment, regardless of other factors.", "answer": 1}, {"article": "\"The treatment I received on the trial changed my life.\n\"The fact that the treatment was performed so successfully by non-specialist centres in various health systems is really remarkable,\" says Professor Emberton, who is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.\nThe research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group.\nThe chances of cancer progressing to a more dangerous stage were three times lower for patients on VTP, and the treatment doubled the average time to progression from 14 months to 28 months.\nHe says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release contains an inflammatory quote from a patient who signed up for the trial because, he said, \u201cSome men prefer to delay treatment, but I couldn\u2019t live with the fear of the cancer spreading until it either couldn\u2019t be treated or needed a treatment that would stop me living a normal life.\u201d \u00a0That\u2019s one man\u2019s take, certainly not representative of all men \u2014 and it exaggerates the risk of small prostate cancers.\nQuotes from the investigator are also questionable. Active surveillance is described as monitoring and treating only \u201cwhen\u201d the cancer becomes more severe. The correct phrasing would be \u201cif and when\u201d the cancer progresses, because many of these cancers will not progress. \u00a0Moreover, we are not still \u201ccommonly\u201d removing or irradiating the whole prostate\u2013studies have shown a marked increase in the uptake of active surveillance.", "answer": 0}, {"article": "PROVIDENCE, R.I. [Brown University] -- To the tantalizing delight of chocolate lovers everywhere, a number of recent studies employing various methods have suggested that compounds in cocoa called flavanols could benefit cardiovascular health.\nLiu noted some limitations in the trials.\nThose with lower doses of flavanols only saw a significant HDL benefit.\nIn all, 1,139 volunteers were involved in these trials.\nThose consuming higher doses saw some of the insulin resistance benefits and a drop in triglycerides, but not a significant increase in HDL.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this release.", "answer": 1}, {"article": "Up until June 1, LabCorp of America had a product on the market.\nThat's why the American Cancer Society, which estimates there will be about 108,000 new cases of colon cancer and 40,700 new cases of rectal cancer this year, added the stool DNA test to its screening guidelines this spring.\n\"Our idea was that if you had an inexpensive test that was easy to use and wasn't invasive, you could reach a lot of people and prevent deaths from happening every day of the year,\" Markowitz said.\nThat test, which looks at two different DNA markers (instead of the one marker used by PreGen-Plus), is the one with which Markowitz is more familiar.\nFear of doctors, the prospect of being poked and prodded in strange places, a lack of insurance to cover the costly test -- or a combination of all three -- are to blame for as many as half of the over-50 crowd putting off or avoiding the screening test altogether.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story\u2019s first several paragraphs are designed to alarm readers (some 150,000 people will be newly diagnosed with colon or rectal cancer this year) and prod them to action (if you are over age 50, get screening to detect and, presumably, cure early cancer). Although any life lost prematurely to colorectal cancer is a terrible misfortune, the chances that it will happen to the average reader are quite small. About 2% of those over age 50 will die of colorectal cancer during the next 30 years if they don\u2019t receive screening, and less than 1% if they do. To our eye, the story is teaching fear when it should reassure. It is problematic that the only reasons given for NOT having a colonoscopy are: \"fear of doctors, the prospect of being poked and prodded in strange places, lack of insurance to cover the costly test\"; another perfectly sane reason is that a person made a well-informed decision against colorectal cancer screening. The story does not even consider that many patients are making a choice here.", "answer": 0}, {"article": "If it gets to that point, then clearly things will change.\u201d\n\nStroke is the fourth-leading cause of death in the United States.\nThe other half of the patients got standard treatment, which didn\u2019t include the procedure.\nIf it did, the doctors went after it with an endovascular procedure.\nThey also got CAT or MRI scans to see whether they had a large or small amount of brain tissue still alive and salvageable.\n\u201cWe did this study with the strong expectation that we would find a positive benefit.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering noted in the story.", "answer": 1}, {"article": "\"What we wanted to find out was: 'Would cooling the surface of the brain of insomnia patients result in lower metabolism and improved sleep?\nThe most effective treatment is cognitive behavior therapy, which involves changes such as avoiding cigarettes, alcohol and caffeine before bed, and getting plenty of bright light in the morning but turning off the TV, computer and dimming the lights during a wind-down period, among other techniques for improving \"sleep hygiene.\"\nPrevious research has shown that the brains of people with insomnia are \"hyperaroused\" and have a higher brain metabolism in the frontal lobes, which helps explain why they have trouble drifting off to sleep and staying asleep, said study co-author Dr. Daniel Buysse, a professor of psychiatry and clinical and translational science at University of Pittsburgh School of Medicine.\n\"The theoretical concept is correct, in that we do know from many previous studies that as the body core temperature cools, our sleep improves, and with warming of the core temperature, we have more restless sleep,\" Kohler said.\nWhile wearing the cooling cap, it took insomnia patients an average of 13 minutes to fall asleep and they spent 89 percent of their time in bed actually sleeping, about the same as controls who didn't have insomnia (the latter group averaged 16 minutes to fall asleep and 89 percent of the time in bed sleeping) .\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of insomnia. Although how the 12 patients with insomnia compare to the \u201ctypical\u201d patient with insomnia is hard to know from what was presented. Presumably people have insomnia for different reasons. Did they somehow identify a group that would be more likely to respond to this treatment? Specifically what were the criteria for participating? So while not \u201cdisease mongering\u201d, it is unclear if these results are applicable to the average person with insomnia.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to engage in diseae mongering.", "answer": 1}, {"article": "Newswise \u2014 SEATTLE (March 24, 2017) \u2013 The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nHis team foundational work on the role of immune cells in MCC paved the way for immunotherapy trials in the disease, including one he leads of another immunotherapy drug with a similar mechanism of action (Merck\u2019s Keytruda), whose results were published last year and changed the field overnight.\nA rare and aggressive form of skin cancer, MCC, is 35 times less common than melanoma, but on average, it is about three times more likely to be deadly.\nHe is a consultant for EMD Serono Inc. and receives funding from Bristol-Myers Squibb to perform biomarker studies in MCC clinical trials.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no overt disease mongering in the release. It provides some context on MCC and how often it occurs in relation to melanoma, the most common form of skin cancer. However, the comment that MCC is \u201c35 times less common than melanoma, but on average, it is about three times more likely to be deadly,\u201d is difficult to interpret.", "answer": 1}, {"article": "For the next 13 years, Gao would work for Wilson, engineering new and better viruses for the therapies, called \u201cviral vectors.\u201d These molecular FedEx trucks can be loaded with healthy versions of genes and deliver them to the correct location in the body.\nIt smells like caffeine and money.\nIn other words, use genes as medicine.\nThe last barrier is financial but not impossible to overcome.\nOne of those trials enrolled a teenager named Jesse Gelsinger.\n", "question": "Does the story commit disease-mongering?", "explanation": "The diseases discussed here are relentless and ultimately lethal.", "answer": 1}, {"article": "\"The CMA test alone has triple the detection rate of karyotyping or fragile X,\" said co-senior author Bai-Lin Wu, director of the Genetics Diagnostic Laboratory at Children's Hospital Boston.\nStill, there is much geneticists can't tell parents.\nThe U.S. National Institute of Neurological Disorders and Stroke has more on autism.\nThe study appeared online March 15 and will be published in the April print issue of Pediatrics.\nOf that, CMA alone can detect 7 percent of those.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not exaggerate the prevalence or seriousness of autism. ", "answer": 1}, {"article": "SILVER SPRING, Md., May 18, 2016 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma.\nThis trial measured the percentage of patients who experienced complete or partial shrinkage of their tumors (objective response rate).\nThis is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.\nThe FDA granted the Tecentriq application breakthrough therapy designation, priority review status and accelerated approval for this indication.\nThe Ventana PD-L1 (SP142) assay companion diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "But a 2012 Cochrane review of randomized clinical trials found there's no evidence that removing wisdom teeth will prevent or reduce crowding of other teeth down the line.\nSo the question comes down to which side of the fence medical professionals fall on, and what works best for their patients.\nEach year, five million people have wisdom teeth removed, but it's up in the air whether all of those surgeries were necessary.\nThey're thought to crowd out other teeth or cause tooth decay, which is why many dentists and oral surgeons think it's better to just nip those problems in the bud and take them out as a preventative measure.\nMany dental professionals stick with a watch and wait approach with wisdom teeth to avoid surgery if possible.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t exaggerate the possible harms of preventative wisdom tooth extraction or of the wait and see approach.", "answer": 1}, {"article": "Trials of medications for treating mental illness typically don\u2019t include people younger than 18, Amminger noted, while starting minors on these medications is \u201calways very difficult, and always quite controversial.\u201d\n\nBut if future research bears out the current findings, he added, fish oil promises to offer a safe way to help prevent psychosis in at-risk people, and could also potentially be used to prevent or delay the onset of chronic depression, bipolar illness, and substance abuse disorder \u2014 all of which are far more common than psychotic illness.\n\u201cFor young people they don\u2019t want to commit themselves to a treatment which they might need to take for the next five to ten years,\u201d he said.\nFurthermore, only about a third of people at high risk for psychotic disorders will go on to develop full-fledged mental illness in a given year.\nThey are also key to the proper function of two brain chemical signaling systems, dopamine and serotonin, which have been implicated in schizophrenia.\nPeople taking fish oil also showed significant reductions in their psychotic symptoms and improvements in function, while they were at no greater risk of adverse effects than people taking placebo capsules.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering on the condition of psychotic illness in at-risk adolescents and young adults.\n", "answer": 1}, {"article": "The falls were lower in those given smaller doses rather than higher monthly doses of vitamin D.\n\nThe clinical trial, the first to examine vitamin D's impact on respiratory infections in nursing home residents, looked at 107 patients with an average age of 84 over a 12 month period.\nThose with higher doses saw ARIs cut nearly in half.\n\"This is a potentially life-saving discovery,\" Ginde said.\nAll are from the University of Colorado Anschutz Medical Campus.\nThey also had over double the incidence of falls, the study said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the release.", "answer": 1}, {"article": "But there are dangers to this approach.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\n\u201cIt was not known that inflammation was a common feature of different types of epilepsy.\u201d\n\nNormal brain function is regulated by the glial cells, which protect neurons and induce an inflammatory response if the brain is injured.\n\u201cOver time, both of them may feed off each other.\u201d\n\nAbout 50 million people worldwide, including more than 2.7 million people in the United States, are struggling with epilepsy in some form.\nRefractory epilepsy, its intractable form, and the medications with which doctors attempt to treat it can cause lifelong problems with learning, memory and behavior.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. It provides some good information about epilepsy in clear terms. It says, \u201cAbout 50 million people worldwide, including more than 2.7 million people in the United States, are struggling with epilepsy in some form. Half of all patients are children. Epilepsy can result from brain injury, but in most cases the cause is unknown and may be genetic. Refractory epilepsy, its intractable form, and the medications with which doctors attempt to treat it can cause lifelong problems with learning, memory and behavior.\u201d", "answer": 1}, {"article": "Even so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nHowever, the impact of the probiotics varied greatly from study to study, researcher found.\nThe review confirms the findings of another review in 2004, which also showed that probiotics had some effect against diarrhea.\n\"Surprising thing was it didn't really matter what type of probiotic was used or in which setting,\" Allen says.\n\"The conclusions we can draw [now] are much stronger,\" Allen says.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "Chavarro and colleagues studied 926 men who had prostate cancer that hadn\u2019t spread.\n\u201cOur findings with Western diet and prostate cancer-specific mortality, however, were surprising, in part because there are very little data regarding how diet after diagnosis may impact disease prognosis.\u201d\n\nThe findings could be important for many men.\n\u201cOur results suggest that the same dietary recommendations that are made to the general population primarily for the prevention of cardiovascular disease may also decrease the risk of dying from prostate cancer among men initially diagnosed with nonmetastatic disease (cancer that has not spread),\u201d said Dr. Jorge Chavarro of Brigham and Women\u2019s Hospital and Harvard Medical School, who led the study.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\nThey were more than 2.5 times as likely to die of their prostate cancer than patients eating the healthiest diet and they were more than one and a half times as likely to have died of anything over the 10 years, Chavarro\u2019s team reports in the journal Cancer Prevention Research.\n", "question": "Does the story commit disease-mongering?", "explanation": "The fear-mongering headline of this story was out of step with the strength of the findings. We\u2019d note that journalists often have no control over the headlines of their stories, but it\u2019s a problem that can\u2019t be overlooked here.", "answer": 0}, {"article": "Molina\u2019s study was recently published by the journal Lancet Infectious Diseases.\nThe authors noted, however, that the study length was short and they can\u2019t tell if the strategy would work as well over the long term.\n\u201cBut if you can select a group with a high incidence rate of syphilis or chlamydia, and you want to try to reduce the rate of syphilis quite quickly in this group of people, you may think that this strategy could be used for a couple of months.\u201d\n\nRates of syphilis in particular have risen steadily in recent years; the rate in 2015-2016 \u2014 8.7 cases per 100,000 people \u2014 was the highest since 1993, the Centers for Disease Control and Prevention reported.\nThe rate of infection increased in every age group over the age of 15, in both men and women, and in all ethnic groups.\nThere was, however, a 70 percent reduction in chlamydia infections and cases of syphilis decreased by 73 percent.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story includes several comments from the researchers and others warning that this sort of strategy should be considered only for short-term use in special circumstances. However, that message follows a headline and lead that imply a more general relevance.", "answer": 1}, {"article": "Moscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\n\u201cDevelopment of effective antiviral drugs and vaccines for human parainfluenza virus has lagged far behind influenza, despite the recognized impact of these diseases in children\u201d and adults, \u201cparticularly the elderly, immunocompromised and patients with underlying airway disease.\u201d\n\nParainfluenza viruses are not closely related to flu but belong to another family of viruses called paramyxoviruses.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\nWASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\n", "question": "Does the story commit disease-mongering?", "explanation": "       \n \nThe story fails to note that parainfluenza virus infections do not cause serious disease in the majority of people.\u00a0In doing so, it provides an overly disconcerting  picture of the virus and its potential to cause serious illness. The failure to provide background information in combination  with the initial quote of the lead author, \u201cTherapies for parainfluenza  are urgently needed,\" qualifies as disease-mongering. \n ", "answer": 0}, {"article": "The new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\n''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 0}, {"article": "WEDNESDAY, May 4, 2011 (HealthDay News) -- Among men under 65 with early stage prostate cancer, those who have the prostate gland removed are less likely to die than those who adopt a \"watchful waiting\" approach, according to a new long-term study out of Europe.\nThere was also a benefit in men whose tumors had low-risk characteristics.\nBut much remains to be known about how best to treat different types of prostate cancer.\nThe U.S. National Cancer Institute has more on prostate cancer treatments.\nThe earlier study also found that undergoing a radical prostatectomy lowered the risk of the cancer spreading, as well as the death rate from prostate cancer or any other cause.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story commit disease-mongering?", "explanation": "This column allowed the book-promoting, probiotics-promoting physician-author get away with perpetuating the notion that there is a correct \u2013 or \"regular\" frequency \u2013 of bowel movements to which healthy people should aspire.\u00a0 This myth sells products.\u00a0 And maybe it\u2019s the subject of the next book. ", "answer": 0}, {"article": "TUESDAY, May 25, 2010 (HealthDay News) --Giving certain breast cancer patients estrogen-lowering drugs before surgery enhances their chances of being able to choose a breast-conserving lumpectomy instead of a full mastectomy, new research suggests.\nThe observation was based on a national study launched at 118 hospitals across the United States.\nEstrogen stimulates the growth of ER+ tumors.\nFor more on surgical options for breast cancer, visit the U.S. National Cancer Institute.\nIt focused on postmenopausal women who had been diagnosed with estrogen receptor-positive (ER+) breast cancer that was either at stage II or stage III -- that is, tumors that were around an inch or greater in size and might have spread to the lymph nodes under the arm.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not resort to disease-mongering.", "answer": 1}, {"article": "In its marketing campaign, Cyberonics notes that VNS treatment does not cause the weight gain associated with antidepressants and the confusion and memory loss common after electroconvulsive therapy (ECT), psychiatry's term for shock treatments.\nAt the end of three months, there was no statistically significant difference between the two groups.\nAbout 35,000 epilepsy patients have received the implant.\n\"I am so humbled by this treatment and grateful,\" he said.\n\"This sounds benign, like a pacemaker.\n", "question": "Does the story commit disease-mongering?", "explanation": "No evidence of disease mongering. The story did not exaggerate or misrepresent depression or suicide, ", "answer": 1}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable. There was no disease mongering in this story because the scope of the disease was never explained. As the actual study states, \"Stroke is the third leading cause of death and the leading cause of permanent disability and disability-adjusted loss of independent life-years in Western countries.\" So a better way of diagnosing a stroke could have a huge impact.\u00a0That sort of context should have been in the story.", "answer": 2}, {"article": "Lipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\n\"There is a lot of unmet medical need out there in the treatment of migraine,\" he says.\nAbout 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story indicates that 35 million Americans have migraines and 20-30% of these people have aura-associated symptoms. ", "answer": 1}, {"article": "MONDAY, July 9, 2012 (HealthDay News) -- A daily drink combining several nutrients appears to help people with early Alzheimer's disease improve their memory, a new study suggests.\nFor more about Alzheimer's disease, visit the Alzheimer's Association.\nDuring the study, the brains of those taking the drink shifted from patterns of dementia to more normal ones, the researchers found.\nNearly all patients drank the nutrient cocktail consistently throughout the study, and there were no serious side effects, the researchers reported.\nThe report was published in the July 10 online edition of the Journal of Alzheimer's Disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of Alzheimer\u2019s disease.", "answer": 1}, {"article": "The findings are mixed on substance abuse.\nThe National Institutes of Health is financing more than 50 studies testing mindfulness techniques, up from 3 in 2000, to help relieve stress, soothe addictive cravings, improve attention, lift despair and reduce hot flashes.\nIt was by design a secular version, extracted like a gemstone from the many-layered foundation of Buddhist teaching, which has sprouted a wide variety of sects and spiritual practices and attracted 350 million adherents worldwide.\nThe Agency for Healthcare Research and Quality, which researches health practices, last year published a comprehensive review of meditation studies, including T.M., Zen and mindfulness practice, for a wide variety of physical and mental problems.\nSince mindfulness meditation may have different effects on different mental struggles, the challenge for its proponents will be to specify where it is most effective \u2014 and soon, given how popular the practice is becoming.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering, but attempts to provide balanced information about the growing use of mindfulness meditation in psychotherapy and management of chronic pain and stress-related conditions.", "answer": 1}, {"article": "Amgen has partnered with Novartis AG to co-commercialize Aimovig in the United States, while Amgen has rights to the drug in Japan and Novartis has rights to commercialize in rest of world.\nA decision by the FDA is due by May 17.\nThe drug, a monoclonal antibody, was given monthly by injection at a dose of 140 mg for the trial.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\nHe said previous studies excluded patients who had tried more than two other treatments.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": ".\nIt\u2019s an indescribable feeling.\u201d\n\nIn haploidential transplants, rather than wiping out the patient\u2019s immune system, doctors use just enough drugs to suppress it.\nEverybody now has a donor, and that is a major advance.\u201d\n\nYet doctors and patients may not be aware there are choices other than conventional bone-marrow transplants, Jones said.\nAccording to Be the Match, which operates the national donor program, a patient\u2019s likelihood of finding a donor match on their registry ranges from 66 to 97 percent, depending on ethnic background.\n\u201cWe can find cord-blood donors for 99 percent of patients who cannot find a donor.\u201d\n\nQuinn was hospitalized for 30 days, and she said the recovery was difficult but relatively uneventful.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this piece. In fact, its description of the different cancers that are addressed and its details about the patient experiences are a very nice model for how to be descriptive without trying to exploit readers\u2019 emotions.", "answer": 1}, {"article": "The current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nNonetheless, the odds of survival are about the same for weekend and weekday admission for stroke, the study found.\nA total of 543 weekend stroke sufferers got the drug versus only 229 weekday stroke patients.\nIn fact, that authors note that patients who received tPA were more likely to die in the hospital.\n\u201cAnyone who thinks they are having a stroke should seek care at a hospital immediately.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no evidence of disease-mongering in this story.", "answer": 1}, {"article": "\"There is some limited evidence from my study and others that fish oil may be good for preventing breast cancer, but there is not sufficient evidence to make a public health recommendation right now,\" cautions study researcher Emily White, PhD, an epidemiologist at the Fred Hutchinson Cancer Research Center in Seattle.\nLobular breast cancer forms in the milk glands.\nDuctal breast cancer is the most common type of breast cancer and forms in the milk ducts.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\nResearchers did not have information on the doses of fish oil that were taken by women in the study.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering. ", "answer": 1}, {"article": "But such drugs tend to be extremely expensive.\nDr. John Wagner, the director of pediatric blood and marrow transplantation at the , called the Pennsylvania results \u201cphenomenal\u201d and said they were \u201cwhat we\u2019ve all been working and hoping for but not seeing to this extent.\u201d\n\nA major drug company, , is betting on the Pennsylvania team and has committed $20 million to building a research center on the university\u2019s campus to bring the treatment to market.\nScaling up the procedure should make it even less expensive, he said, but he added, \u201cOur costs do not include any profit margin, facility depreciation costs or other clinical care costs, and other research costs.\u201d\n\nThe research is still in its early stages, and many questions remain.\nWith a pill, you take it, it\u2019s eliminated from your body and you have to take it again.\u201d But T-cells, he said, \u201ccould potentially be given only once, maybe only once or twice or three times.\u201d\n\nThe Pennsylvania researchers said they were surprised to find any big drug company interested in their work, because a new batch of T-cells must be created for each patient \u2014 a far cry from the familiar commercial strategy of developing products like or medicines, in which millions of people take the same drug.\nShe woke up a week later, on May 2, the day she turned 7; the intensive-care staff sang\n\nSince then, the research team has used the same drug, tocilizumab, in several other patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "While certainly a terrible disease, acute lymphoblastic leukemia is\u00a0a treatable cancer. The 5-year survival rate\u00a0(percentage of patients who live\u00a0at least 5 years after their cancer is diagnosed), is more than 85%, according to the American Cancer Society, and many patients who survive that long are considered cured because relapse is rare. This story focused on one of the worst case scenarios, and didn\u2019t provide readers with this larger perspective.\nThe competing Philadelphia Inquirer story at least briefly referenced the 85% estimate.", "answer": 0}, {"article": "In 2008 Sciencewatch (Thomson Reuters http://sciencewatch.com/ana/st/hpv/08julHPVWheler/) ranked her global citation contributions over the past decade, 7th in human papillomavirus contributions and in the top 1% in the field of clinical medicine.\nThey found that the vaccine protected the women against HPV infections during the follow-up period and that the women were protected from many types of HPV across a broad age range.\nIn the US, only about 40 percent of girls and 21 percent of boys receive the three-dose vaccination series.\nHPV vaccines are expected to prevent most of these cancer cases.\nIt treats about 60 percent of adults and virtually all the children in New Mexico diagnosed with cancer \u2014 more than 10,000 people\u2014 from every county in the state in more than 135,000 clinic visits each year.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release gives a fair portrayal of the health implications of HPV without engaging in any disease mongering.", "answer": 1}, {"article": "The U.S. Food and Drug Administration today approved Trulance (plecanatide) for the treatment of Chronic Idiopathic Constipation (CIC) in adult patients.\nThe most common and serious side effects of Trulance was diarrhea.\nIf severe diarrhea occurs, patients should stop taking Trulance and contact their health care provider.\nParticipants were randomly assigned to receive a placebo or Trulance, once daily.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here; CIC is widespread. The release provides context on the condition by citing its prevalence.", "answer": 1}, {"article": "DALLAS - March 29, 2018 - A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern's Simmons Cancer Center announced.\nThe TRK-fusion mutation can be present in many types of cancers, including lung, colon, thyroid, and breast cancer, as well as certain pediatric tumors.\nThe selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nTRK, short for tropomyosin receptor kinase, is a gene that plays a key role in brain and nervous system development and has a limited role in nervous system functions such as regulating pain in later life.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease-mongering. It notes that the NTRK mutations exist in rare pediatric cancers without exaggerating the severity of the underlying disease.", "answer": 1}, {"article": "Tomatoes are particularly high in the powerful antioxidant that acts like a sponge, soaking up rogue molecules called free radicals that if left unchecked can damage cells.\nThe scientists found that those with the highest levels of lycopene were 55% less likely to have a stroke than those with the lowest amounts in their blood.\nIn other words, perhaps better health habits - not necessarily just the lycopene - lead to fewer strokes.\nBut the foods we eat are complex and filled with many nutrients, making it tough to prove what is really providing benefits.\nIf we don't eat enough lycopene-packed foods, experts suspect too many free radicals get left in the body, damaging blood vessels by helping to form fatty deposits.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering of stroke.\u00a0 However, the description of free radicals did sound a little alarming.\u00a0 They are natural byproducts of our biochemical processes.", "answer": 1}, {"article": "Dry eye in the Beaver Dam Offspring Study: prevalence, risk factors, and health-related quality of life.\nJerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\nNational Health and Wellness Survey: The Global Health and Wellness Report - 2014.http://www.kantarhealth.com/docs/ebooks/global-health-and-wellness-report.pdf.\n[1]\n\nAccording to Dilip Shanghvi, Managing Director, Sun Pharma, \"We are happy to see the early onset of action and strong efficacy results for Seciera\u2122.\n\"As a clinician who specializes in diagnosing and treating dry eye, this novel formulation of cyclosporine A would be a unique and welcome addition to our armamentarium to treat these patients\".\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release steps over the line in this category by referring to \u201cdry eye disease.\u201d\u00a0 Dry eyes are a condition that plague some individuals due to aging or changes in hormones; it may be a symptom of other ailments or a side effect of some medications or procedures, such as Lasik surgery. But calling the dry eye condition\u00a0a disease suggests the need for a cure and therefore pushes the idea that a new product might solve that situation. Furthermore, the release itself reinforces that by having one of the product\u2019s company officials discuss the \u201crapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\u201d", "answer": 0}, {"article": "Forty-five minutes later, sweating, he was done.\nHis doctor told him absolutely not, saying, \u201cYou are the kind of guy we will read about who dies during the race of a massive heart attack.\u201d Mr. Del Sontro could still exercise, his cardiologist said, but no more than 45 minutes a day.\nAt dinner one recent evening at their yellow brick townhouse in the Georgetown neighborhood in Washington, his wife, Pura, admitted to worrying, but said, \u201cWe don\u2019t talk about it a lot.\u201d She served Indian takeout \u2014 saffron rice, tandoori chicken, eggplant.\nTo keep the focus on truly rare mutations, the researchers are excluding those that are present in both members of the Del Sontro family and 3 percent or more of the other study participants.\nMr. Del Sontro is all too aware that the cause of his heart disease is a mystery, but he worries that if he fails to eat right and exercise he might make his illness even worse.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story describes this research through the prism of a single family with a strong history of early atherosclerosis, which is a risk factor for clinical events, but not a fait accompli. The story makes no attempt to quantify how common this situation is.\u00a0The story should have made it clearer that most cardiovascular disease occurs in individuals with traditional risk factors, and that addressing these factors is an effective way to reduce risk.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Taking extra vitamin D and calcium doesn\u2019t seem to prevent bone-thinning in older men, according to Australian researchers.\nAt the end of the study, men who exercised had higher bone density than those who had supplemented their diet with 1000 milligrams of calcium and 800 international units (IU) of vitamin D per day.\nThey measured the men\u2019s bone density before and after the study, which took place over 18 months, but they didn\u2019t look at fractures.\nIn animal studies, a lack of vitamin D has been linked to several diseases, such as multiple sclerosis and some types of cancer.\nTo build bone density, weight-bearing exercise is needed, such as running or weight-lifting, according to the NIH.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story cited clear numbers and broke down categories of older women, white men and black men.", "answer": 1}, {"article": "The process of removing plaque sometimes causes fluid to build up in the brain.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\n\"It was surprising, encouraging and thought-provoking to see such a striking reduction of existing plaques,\" Reiman says.\nResults from a small number of patients who received a high dose of the drug, called aducanumab, hint that it may also be able to slow the loss of memory and thinking.\nOne is that the drug appears to ignore benign forms of amyloid protein while attacking the toxic forms thought to damage brain cells.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t disease monger, but it also doesn\u2019t explain what Alzheimer\u2019s is or give any sense as to the impact of the disease. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\u201cAnd when stimulation arrived in a good state, the average was about 15 to 20 percent worse than usual.\u201d\n\nDr. Doris Greenblatt, a psychiatrist who participated in the trial at Emory, said she sought the surgery because her epilepsy had long caused memory problems.\n\u201cIt was a little humiliating, to be honest,\u201d she said of the testing.\nMany of the electrodes sit in or near memory areas, and the wait can take weeks in the hospital.\nShe agreed to the memory testing for the study.\nThis approach \u2014 called direct neural recording, and piggybacking entirely on the clinical placement of the electrodes \u2014 has become the leading edge of research into the biology of human memory.\n", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t\u00a0detect any\u00a0disease-mongering in this story.", "answer": 1}, {"article": "; Eur Uro 2016 \n\niii Loeb et al.\nEvery year, 1.3 million men in the U.S. undergo a prostate biopsy.i Although a biopsy is the only way to diagnose prostate cancer, the procedure is invasive and results in complications in 18 percent of patients, with 3 percent hospitalized for infection within 30 days.ii,iii,iv Common complications from a prostate biopsy may include bleeding, infection, sepsis/bacteremia, urinary symptoms/retention, and sexual dysfunction.\nIRVINE, Calif., Aug. 2, 2018 /PRNewswire/ -- MDxHealth SA (OTC: MDXHF.BR) today announces that a new study validates the cost-effectiveness of the SelectMDx\u00ae for Prostate Cancer test, a non-invasive, urine-based (liquid biopsy) test that helps identify patients at increased risk of aggressive prostate cancer.\nThe test helps to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby improving quality of life and lowering healthcare costs per patient.\nThe primary objective was to characterize changes in health outcomes, measured in quality-adjusted life years, and a secondary objective was evaluating healthcare costs.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It provides helpful context on the numbers of prostate cancer diagnosed each year, as well as the complications associated with testing and followup treatment. Given the relatively high rate of complications stemming from the many prostate biopsies that are conducted each year, this effort to validate a non-invasive diagnostic test could have value.", "answer": 1}, {"article": "The clinical chemistry score worked equally well in men and women.\n\"We have developed a simple lab score that is superior to using cardiac troponin alone for the identification of patients at low and high risk for heart attack or death at emergency department presentation,\" say Dr. Peter Kavsak, McMaster University, Hamilton, Ontario.\n\"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors.\n\"Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department\" is published August 20, 2018.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. When a person lands in the emergency room with apparent heart attack symptoms, physicians struggle to identify those who are truly having a heart attack. The release provides some context on the types of tests used to diagnose heart attacks, and where they are lacking.", "answer": 1}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story commit disease-mongering?", "explanation": "The story did a good job providing background on fecal incontinence and providing NIH estimates of how many have it.", "answer": 1}, {"article": "Even participants who had normal-range blood pressure, triglycerides or cholesterol levels before surgery saw improved measures.\nThe higher a person's insulin levels are, the more likely they are to have or develop insulin resistance, which can increase blood sugar levels and diabetes risk.\nAn estimated 1,600 adolescents undergo metabolic or bariatric surgeries each year, the study notes, but families should only consider such procedures after exhausting other treatment options.\nNearly a third of all children and teens are overweight or obese in the U.S., and an estimated 4 to 7 percent have severe obesity.\n\"It would be considered for the highly obese and those not responding to any behavioral modifications, physical activity or calorie restriction.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. It states that an estimated 4 to 7 percent of teens have severe obesity.", "answer": 1}, {"article": "So what's in blueberries that makes them so good for us?\nLoad up on berries.\nSo, go ahead.\n\"They have effects on blood pressure in animal models,\" says Cassidy.\nEckel says it's not clear.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "This barrier works to protect the brain from toxins.\nStudy funded by Ivy Foundation shows PPF could help treat glioblastomas by sensitizing tumors to chemotherapy and radiation treatments\n\nPHOENIX, Ariz. -- Nov. 12, 2015 -- In a significant breakthrough, the Translational Genomics Research Institute (TGen) has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer.\nIn a study published today in the Journal of NeuroOncology, TGen researchers report that PPF works to limit the spread of glioblastoma multiforme, or GBM -- the most common primary tumor of the brain and central nervous system -- by targeting a protein called TROY.\n\"We showed that PPF decreased glioblastoma cell expression of TROY, inhibited glioma cell invasion, and made brain cancer cells more vulnerable to TMZ and radiation,\" said Dr. Nhan Tran, Associate Professor and head of TGen's Central Nervous System Tumor Research Lab.\n\"GBM is one of the most aggressive of all cancers and it affects people of all ages,\" said Catherine (Bracken) Ivy, founder and president of The Ben & Catherine Ivy Foundation.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release calls glioblastoma multiforme \u201cthe most common primary tumor of the brain and central nervous system,\u201d without noting how rare brain tumors are. The release should have noted that glioblastoma multiforme is diagnosed in about 22,000 people in the United States each year, accounting for barely more than 1 percent of all cancer cases. Glioblastoma multiforme kills about 15,000 people in the U.S. annually, representing about 2-1/2% percent of the total deaths attributed to cancers of all types.\nThis type of tumor is indeed usually life threatening, but this news release misleads readers when it uses the term \u201ccommon\u201d without providing the full picture.", "answer": 0}, {"article": "The rate was 26 percent lower in counties with screening.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nTheir paper is published online in the journal Cancer and will be presented on Friday at a meeting sponsored by the American Society for Clinical Oncology and five other organizations.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n \nThe story does not discuss the prevalence of breast cancer among women in their 40s. That omission would not usually be considered disease mongering, but since surveys indicate most people overestimate the risk of breast cancer among women in their 40s, failing to mention the actual rates leaves those misconceptions intact.\n The story does include comments from experts who raise concerns about overdiagnosis; that is, the number of breast tumors discovered that are not actually life-threatening.", "answer": 1}, {"article": "\"Off-label\" refers to the practice of prescribing medicines to treat conditions not been specifically approved by the FDA.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\nThe results of the study are published online in The Journal of Rheumatology.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story reports a commonly-used estimate of the number of people who are diagnosed as having fibromyalgia. It does not include any statements that could be seen as encouraging the potential use of this drug in a wider population.", "answer": 1}, {"article": "There\u2019s ample reason for caution.\n\u201cIt\u2019s like a rocket that landed on Jupiter, rather than the moon.\u201d Still, Eckel warned it\u2019s too soon to say whether ancetrapib would actually prevent disease over the long run.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\nAccording to a new study, a medication, ancetrapib, appears to simultaneously raise the level of HDL \u2013 sometimes called \u201cgood\u201d cholesterol- and to lower the level of LDL, or \u201cbad\u201d cholesterol.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n\nThe fundamental problem with this story is that it promotes the common misconception that equates elevated cholesterol numbers with heart disease and death. The relationship between cholesterol and health problems is far more complex and murky than most people realize, but this story takes the same short cuts used by advertisements promoting statins to millions of people who don\u2019t actually fit the definition of those shown to benefit from drug treatment.\nThe story points out that the current trial involved people with existing heart disease or at very high risk and that they were all already taking a statin, and the lead sentence also refers to new options for people who are already taking a statin, so it meets this criterion. \nNevertheless, readers are likely to miss the point that the drug has yet to be tested in people who are generally healthy except for having somewhat high cholesterol numbers. This is an important point, because statins are already being prescribed for many people who are at relatively low risk of heart disease and may derive little if any actual health benefit from the drug. The story would have been better if it included stronger caution against a similar premature leap from people with existing disease or very high risk to the far larger number of people with milder cholesterol concerns.", "answer": 0}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of cancer or of side effects of chemotherapy.", "answer": 1}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nThe next step will be to study the effect of longer duration NR supplementation on NAD+ metabolism in healthy adults, but Brenner also has plans to test the effects of NR in people with diseases and health conditions, including elevated cholesterol, obesity and diabetes, and people at risk for chemotherapeutic peripheral neuropathy.\nIn particular, the researchers compared the ability of all three NAD+ precursor vitamins - NR, niacin, and nicotinamide - to boost NAD+ metabolism and stimulate the activity of certain enzymes, which have been linked to longevity and health benefits.\nBut when you can look at a low-abundance metabolite that goes from undetectable to easily detectable, there is a great signal to noise ratio, meaning that NAAD levels could be a useful biomarker for tracking increases in NAD+ in human trials.\"\nThe biggest surprise from his metabolomic analysis was an increase in a metabolite called NAAD, which was multiplied by 45 times, from trace levels to amounts in the micromolar range that were easily detectable.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in outright disease mongering. However, its statement that a natural loss of NAD+ over time \u201cmay play a role in age-related health decline\u201d implies that aging is a condition that needs to be treated.", "answer": 1}, {"article": "Chattoo also offers patients a nutritionist and trainer with the procedure.\nShe told FoxNews.com that the balloon \u201cmakes you feel full all the time to the point where you\u2019re not angry about having to lose things like chocolate and cake.\u201d\n\nBrown said that the balloon acted like a \u201crestart button\u201d and retrained her body to adapt to a new lifestyle of healthy eating and exercise.\nNow, there is a new solution for people with a body mass index (BMI) between 30 and 40 that want to lose weight called the Orbera gastric balloon.\nThe balloon remains in the patient\u2019s stomach for six months and is then removed the same way it was inserted, through the mouth.\n\u201cThe beauty of the procedure is that it is a nonsurgical procedure,\u201d Chattoo said.\n", "question": "Does the story commit disease-mongering?", "explanation": "A story can be guilty of disease mongering if it conflates a risk factor with a disease. This story clearly treats weight loss as the health goal, even singling out cosmetic reasons as a reasonable rationale for using Orbera. What\u2019s more, based on this story, one could be forgiven for thinking that trying to lose weight is a health problem in itself. As the opening sentence notes: \u201cAmerica\u2019s ongoing battle with weight-loss that [sic] has led to fad diets and invasive surgeries like gastric bypass and stomach stapling.\u201d A doctor quoted in the story, who provides Orbera for his clients, says that Orbera may \u201cbe able to prevent young, healthy people from having these chronic diseases like diabetes and hypertension.\u201d That would depend on how much weight the people lost, and how heavy they were to begin with. No one medical intervention is going to prevent chronic diseases associated with obesity \u2014 and it\u2019s not clear from the story whether Orbera would help them lose weight in the first place.", "answer": 0}, {"article": "The research is partially supported by the Claude D. Pepper Older Americans Independence Centers at the University of Florida (1P30AG028740), Wake Forest University (1P30AG21332), Tufts University (1P30AG031679), University of Pittsburgh (P30AG024827), and Yale University (P30AG021342) and the NIH/NCRR CTSA at Stanford University (UL1RR025744).\nTo see benefits at 48 minutes is encouraging.\n58-1950-4-003.\nof Agriculture.\n\"Our goal was to have participants walking up to 150 minutes per week.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "Among 242 patients (137 intervention, 105 control) initially identified as high risk for caries, only a quarter of the patients remained at high risk in the CAMBRA group at 24 months, while just over half (54 percent) of the control group did.\nDental decay was low in both groups.\nis an evidence-based approach to preventing or treating dental caries at its earliest stages.\nDoing so can change the whole picture of caries control.\"\nIf not halted or reversed, this leads to a cavity.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "The European trial, which included 1,713 patients randomly assigned to either stent or endarterectomy, found that stent patients were at much higher risk of stroke, death or heart attack in the first 30 days after surgery, with 7.4 percent suffering one of these adverse events, compared with 4 percent of the surgery group.\nMost of the patients had an artery blockage greater than 70 percent.\nThe death rate in the trial was very low, but risks varied depending on the procedure.\nEach year, almost 800,000 Americans suffer a stroke, and more than 140,000 die.\nYounger patients \u2014 those under 70 \u2014 had better results with stenting, while older patients had better results with surgery, the study found.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "MONDAY, Jan. 28, 2013 (HealthDay News) -- Breast-conserving surgery for early stage breast cancers may result in better survival than mastectomy, according to a new study.\nThis means their cancer depends on estrogen to grow.\nAges ranged from 39 to 80.\n\"They broke it down by year of diagnosis and by age category,\" she said.\n\"At the end of the day, personal preference trumps everything else.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering noted.", "answer": 1}, {"article": "The FDA first approved TMS devices for major depression in 2008, and in 2013 they were approved to treat pain associated with some types of migraine headaches.\nPeople who were taking medication for OCD continued to do so for the trial.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nThe Food and Drug Administration made the announcement on Friday, expanding the use of a technology that has been around for decades.\nThe procedure is noninvasive and doesn't require anesthesia, and the pulses are delivered via an electromagnetic device or coil that is placed or worn on the head.\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "\"The data shows that similar clinical outcomes are had when you look at the traditional open approach versus the endovascular approach but the endovascular approach provides the added benefit of shorter hospital stays and a faster recovery.\"\nWhen they would open me up [the aorta] could just blow.\u201d\n\nThe bulge in the large artery that carries blood away from the heart can be immediately life-threatening if it grows large enough to rupture.\nAccording to the Society for Vascular Surgery, every year, roughly 200,000 Americans are diagnosed with abdominal aortic aneurysms.\n\u201cEach anatomy of the patient is different and that's the problem, that\u2019s why we need stents that are actually specific for the patient,\u201d says Oderich.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story is rife with fear-mongering. The video states that 200,000 patients have abdominal aortic aneurysms and calls it a \u201cdeath sentence\u201d and a \u201cticking time bomb.\u201d The printed version said it is \u201ca hidden, often deadly heart condition with no clear known cause\u201d and \u201ccan be immediately life-threatening if it grows large enough to rupture. The chance of survival when it ruptures is less than 10 percent.\u201d\nThe story doesn\u2019t make it clear how many people with this condition are really at risk of dying. According to the CDC, aortic aneurysms were the primary cause of 9,863 deaths in 2014 and a contributing cause of at least 17,215 deaths in the U.S. in 2009.\nAccording to the Mayo Clinic, \u201cSome aneurysms will never rupture. Many start small and stay small, although many expand over time. Others expand quickly. Predicting how fast an abdominal aortic aneurysm may enlarge is difficult.\u201d\nThe article also doesn\u2019t mention risk factors, which include tobacco use, family history, hypertension, and prolonged alcohol use.\nIt\u2019s also unclear why the story calls abdominal aortic aneurysm a \u201cheart\u201d condition; it\u2019s a vascular condition, meaning a condition affecting the body\u2019s system of arteries and vessels.", "answer": 0}, {"article": "To learn more, visit http://www.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\nNinety-two percent of the 174 reductions performed with the inferior pedicle technique used a Wise pattern incision, which disrupts the lower suspensory ligaments, and 7.5% used a Boston modification of Robertson technique, which preserves the lower suspensory ligaments.\nBy measuring the sternal notch-nipple distance and the nipple-inframammary fold distance ( proxies for upper and lower sensory ligament strength, respectively), the study found a differential rate of stretch - for every 1 cm in upper sensory ligament stretch, the lower sensory ligament length increases by 0.45 cm.\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. The release also includes some context about how often sagging of breast tissue occurs following breast reduction surgery.\nRather than saying aesthetic breast reduction is a \u201ccommon\u201d procedure, we\u2019d like to see a more specific number here. As noted in the Why it Matters section, about 68,000 procedures are done annually, with men electing for the surgery nearly as often as women.", "answer": 1}, {"article": "On the other hand, Vorona says, \"The last thing I want readers to think is that Dr. Vorona thinks we're facing this obesity epidemic because we're sleep deprived.\nMake sure the room temperature is comfortable.\n-- Practice good sleep hygiene.\nThat means turning off all electronics, including the TV, and creating as quiet a sleep space as you can.\n-- Avoid caffeinated coffee, tea and soda.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering about obesity in the story.", "answer": 1}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate either the frequency or the severity of insomnia.", "answer": 1}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\nThe analysis included over 5,700 colorectal cancer cases and 7,100 controls from the United States, Europe, and Asia.\n\"This study adds new information that agencies can use when reviewing evidence for vitamin D guidance and suggests that the concentrations recommended for bone health may be lower than would be optimal for colorectal cancer prevention.\"\nColorectal cancer is the third most common cancer and third leading cause of cancer-related deaths in both men and women in the United States, with about 140,250 new cases and 50,630 deaths expected during 2018.\n\"In the past, substantial differences between assays made it difficult to integrate vitamin D data from different studies,\" explained Regina G. Ziegler, PhD, a National Cancer Institute epidemiologist and co-senior author on the article.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no obvious disease mongering here.\u00a0In fact, numbers of incident cases and deaths in the US expected in 2018 are given for accuracy and to anchor the discussion. Well done.", "answer": 1}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story commit disease-mongering?", "explanation": "The\u00a0statistic on choking is reported in a factual manner\u00a0without any disease mongering:\nNearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\nIt would have been even more helpful if the story had explored whether people who died from choking received the Heimlich maneuver and if so, was it inadequate? That would give us a better sense as to the need for this device. (We realize that\u2019s a lot to ask!)", "answer": 1}, {"article": "The study was funded by the P.J.\nFor example, according to the researchers, those with systolic blood pressures below 140 millimeters of mercury and no calcium had an event rate of 12.7 events per 1,000 person-years, and similar people with systolic blood pressures between 140 and 159 millimeters of mercury had an event rate of 13.6 events per 1,000 person-years.\n\"We can predict that about 15 out of every 100 people with a particular risk score will die of a heart attack, but the equations don't tell us which of those people will be one of the actual 15; they don't give us personalized information,\" says McEvoy.\nAbout 70 million adults in the U.S. have high blood pressure -- a systolic blood pressure over 140 millimeters of mercury -- putting them at increased risk for heart attacks, stroke, heart failure and kidney disease, according to the U.S. Centers for Disease Control and Prevention.\nIn contrast, participants with systolic blood pressure under 140 millimeters of mercury -- below the current cutoff for treatment -- and rated with a low predicted risk of heart disease who had a calcium score over 100 had a high actual event rate of 19.7 events per 1,000 person-years.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release is accurate when it states that nearly one in three adults in the US. has the range of blood pressure it describes as prehypertension. But we wonder why it mentions that 70 million adults in the U.S. have high blood pressure, since the study results do not directly apply to that population.", "answer": 1}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\nFor the study, researchers evaluated 37 children ages 9 to 18 who were obese and at high risk for heart disease and Type 2 diabetes.\nAfter nine days, the researchers found a 33 percent drop in triglycerides, a type of fat tied to heart disease; a 49 percent reduction in a protein called apoC-III that is tied to high triglyceride levels; and large reductions in small, dense LDL cholesterol, a risk factor for heart disease.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\nThough this study is small and short-term, it builds on this group\u2019s previous research implicating added sugars as a contributor to metabolic disorders and heart disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "Calls to reduce sugar in our diets have burgeoned in recent years, and data do seem to suggest that eating less sugar is beneficial.\u00a0 Just how beneficial is still a matter of study.", "answer": 1}, {"article": "Leone-Bay said that cancer studies have been conducted on Afrezza in rats.\nIt will only replace meal-time insulin.\nBecause it's fast-acting, it can't provide the long action of insulin known as basal insulin.\nThe particles then pass through the lungs into the bloodstream and begin acting almost immediately.\nIt's inhaled as a dry powder that dissolves in the lungs.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The article does not engage in disease-mongering.", "answer": 1}, {"article": "Despite popular lore, agency won't allow labels to say drink is good for consumers' hearts\n\nWASHINGTON - There is no credible scientific evidence that drinking green tea reduces the risk of heart disease, federal regulators said last week in rejecting a petition that sought to allow tea labels to make that claim.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\nIto En Ltd., a Japanese company that bills itself as the world's largest green tea company, and its U.S. subsidiary, Ito En (North America) Inc., petitioned the FDA in June, seeking to make the claim that drinking at least five ounces of green tea a day may reduce the risk of heart disease.\nA health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\nThe FDA previously has said that green tea likely does not reduce breast, prostate or any other type of cancer risk.\n", "question": "Does the story commit disease-mongering?", "explanation": "This article reported on the FDA\u2019s rejection of the petition to allow the health claim that green tea affected the risk of heart disease.", "answer": 1}, {"article": "\u201cThis is a very important claim for us to allow to be incorporated into food labels,\u201d said Dr. Scott Gottlieb, the commissioner of the F.D.A.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nThe label warns that evidence is limited.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n", "question": "Does the story commit disease-mongering?", "explanation": "Peanut allergies can result in serious and potentially life-threatening reactions in kids who are exposed. No disease-mongering here.", "answer": 1}, {"article": "The pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nIt employs more than 100 people and has government backing through Innovate UK but also gets private funding through partnerships.\nThe promising early results have given them the confidence to form a wider consortium with the Scottish Islet Transplant Programme, the University of Edinburgh and the Scottish National Blood Transfusion Service.\nIf clinical trials are successful, the technology means tens of thousands more people could live without the need for frequent insulin injections, although it will take a few years until the treatment is available.\nJohn Casey, consultant transplant surgeon at the Royal Infirmary of Edinburgh and lead clinician for the islet transplantation programme in Scotland, said: \u201cIslet transplantation can transform the lives of patients with type 1 diabetes, and in some cases can result in long-term freedom from insulin injections with excellent glucose control.\u201d\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not disease monger; it notes the British and global future prevalence of type 1 diabetes. And it does a good job of distinguishing the disorder from type 2 diabetes.", "answer": 1}, {"article": "\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\nUsing this drug to treat trauma patients is a completely new idea, Levy said.\nIt works by significantly reducing the rate at which blood clots break down, the researchers explained.\nAccording to Roberts, each year about 600,000 people bleed to death worldwide.\nAmong patients receiving TXA, the rate of death from any cause was cut by 10 percent compared to patients receiving placebo, the researchers found.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "In March, the FDA turned down Cephalon's jet-lag application and questioned how good the data supporting it really were.\nWell, the Food and Drug Administration.\nBut today the company said its response fell short.\nCephalon soldiered on, giving FDA more data.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering.", "answer": 1}, {"article": "Moffitt is the No.\nThe HER2 protein is overexpressed in 20-25% of all breast cancer tumors and is associated with aggressive disease and poor prognosis.\nIn order to determine if the HER2-dendritic cell vaccine is safe and effective, the researchers performed a clinical trial in 54 women who have HER2-expressing early-stage breast cancer.\nTheir approach involves creating the vaccine from immune cells called dendritic cells that are harvested from each individual patient to create a personalized vaccine.\nThey report that 13 patients achieved a pCR and patients who had early non-invasive disease called ductal carcinoma in situ (DCIS) achieved a higher rate of pCR than patients who had early-stage invasive disease.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release implies that DCIS is breast cancer, but that\u2019s a controversial assertion. We cover this more in the section on Unjustifiable Language.", "answer": 0}, {"article": "Newswise \u2014 WINSTON-SALEM, N.C. \u2013 Sept. 28, 2016 \u2013 Hot flashes \u2013 the bane of existence for many women during menopause \u2013 can be reduced in frequency by almost half for about 50 percent of women over eight weeks of acupuncture treatment, according to scientists at Wake Forest Baptist Medical Center.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\nOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said.\nHis spouse is the primary shareholder of Chapel Hill Doctors, which is an organization that was subcontracted by Wake Forest School of Medicine as a site for subject recruitment and treatment.\n\u201cWomen bothered by hot flashes and night sweats may want to give acupuncture a try as a relatively low-cost, low-risk treatment,\u201d said Nancy Avis, Ph.D., lead author of the study and professor of Public Health Sciences at Wake Forest School of Medicine, a part of Wake Forest Baptist.\n", "question": "Does the news release commit disease-mongering?", "explanation": "For the most part, disease mongering wasn\u2019t an issue here. Some issues with language are addressed under the \u201cUnjustifiable Language\u201d section (see below).", "answer": 1}, {"article": "The researchers hope to develop an affordable device that people can use at home.\nA small new study published in suggests that one easy way for older adults to get deeper sleep and stronger memories is to listen to a certain soothing sound called \u201cpink noise\u201d\u2014a mix of high and low frequencies that sounds more balanced and natural than its better-known cousin, \u201cwhite noise.\u201d\n\nIt may sound strange, but previous studies have found that playing so-called pink noise during sleep improves the memory of younger adults.\n\u201cThat\u2019s very much tied to what part of the slow wave the stimulus is hitting on.\u201d\n\nThat doesn\u2019t mean there aren\u2019t benefits to other soothing background sounds.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\n\u201cWe wanted to see if it would work in older people, too,\u201d says senior author Dr. Phyllis Zee, professor of neurology at Northwestern University Feinberg School of Medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "Good sleep is important for a number of health outcomes. It\u2019s also pretty easy to make less-than-perfect sleep \u2014\u00a0a certain number of hours of uninterrupted sleep \u2014 sound terrible. This article does not engage in any of that kind of disease mongering.", "answer": 1}, {"article": "The majority of cases are caught at around 66.\nThe next steps should be to understand how this research can be developed into tests that could identify men who might be more likely to develop aggressive cancers, and how this could be rolled out to patients.\u201d\n\nDr. Iain Frame, the director of research at the charity Prostate Cancer UK, highlighted that men with a family history of prostate cancer are two-and-a-half times more likely to be diagnosed with the disease compared to a man with no family history.\nThe new method is being trialed on 300 men in doctors' offices across London, and is due to be expanded to 5,000 next year, according to BBC News.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\nAccording to the American Cancer Society, over 160,600 new cases of prostate cancer are diagnosed each year, and around 29,400 people die of the disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story grabbed our attention in the second paragraph by stating that \u201cone in seven men in the Western world\u201d will be diagnosed with prostate cancer in their lifetime.\nBetter information followed six paragraphs later:\nAccording to the American Cancer Society, over 160,600 new cases of prostate cancer are diagnosed each year, and around 29,400 people die of the disease. The condition is rare in those below the age of 40; older men and African-Americans are most at risk. The majority of cases are caught at around 66.\nThe story could have done without a misleading holiday tie-in: \u201cWith Father\u2019s Day fast approaching, use it as an opportunity to ask your dad, your brother, your uncle, your friends about their risk of prostate cancer. It\u2019s a conversation that could save their life.\u201d", "answer": 1}, {"article": "For most patients the cravings really do disappear.\nIt can force type 2 diabetes into almost instant remission and it appears to reduce the risk of cancer.\nA big reason the operation works is because it seems to suppress appetite.\nSurgeons have been performing bariatric, or weight loss operations since the 1950s, but they're much safer than they used to be.\nDr. Hutcher says the operation itself can take type 2 diabetes - which has ballooned in this country - and throw it into complete remission.\n", "question": "Does the story commit disease-mongering?", "explanation": "The segment does not exaggerate the risks or burdens of obesity or diabetes, which are considerable. ", "answer": 1}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nIn one experiment using stored blood samples, the test was positive for Alzheimer's disease in 38 out of 42 patients who had been independently diagnosed by clinicians as having the disease - a 90 percent accuracy rate.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\nIt is important for us to increase the number of people who realize they are at risk and can still speak out for themselves,\" he said.\nUsing existing laboratory technology, they developed a test that will light up when the 18 molecules are present in a blood sample.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although the story used some dramatic wording, it balanced the drama with hard, objective data on annual mortality rates due to Alzheimers and gave overall prevalence.\u00a0 ", "answer": 1}, {"article": "Without proof of a physical cause, some doctors considered IBS a psychological disorder.\nThe tests, which measure antibodies in the blood, were based on research suggesting that IBS may develop after infection from a bacterial toxin found in food poisoning.\nWhile a positive test result is highly suggestive of IBS, only 44 percent of patients with IBS tested positive, meaning that many people who test negative could in fact still have the condition.\n\"There's always kind of a 'trend of the week' that you had to go and get tested for and rule out, and at the end of the day you don't feel better,\" she said.\nAn estimated 25 million to 45 million Americans suffer from irritable bowel syndrome, or IBS, a gastrointestinal condition that can cause miserable symptoms.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story says IBS affects 25 million to 45 million people in the U.S. While this may be true, the test we\u2019re talking about isn\u2019t a test for IBS in general \u2014 it\u2019s a test for those with the diarrhea predominant version. It\u2019s not clear how many people this amounts to, but according to this study, less than half of the people with IBS meet the criteria for the diarrhea-predominant version. The story exaggerates the potential impact of the test in a way that promotes a commercial interest, so we\u2019ll flag it for disease mongering.", "answer": 0}, {"article": "The study was presented Monday at the annual meeting of the American College of Cardiology in Orlando, Fla.\n\"The triple pill approach is an opportunity to 'leapfrog' over traditional approaches to care and adopt an innovative approach that has been shown to be effective.\"\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\n\"The most urgent need for innovative strategies to control blood pressure is in low- and middle-income countries,\" Webster said.\nThe findings should be considered preliminary because research presented at meetings has not undergone the rigorous scrutiny given to research published in medical journals.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no disease-mongering, and the story provides an FDA link to consumer information that includes U.S. high blood pressure prevalence data.", "answer": 1}, {"article": "And for now, the research is preliminary, so it's too early to know for sure if the treatment is appropriate to be used for any kind of depression.\nStill, the study suggests that brain stimulation \"not only just helps patients who haven't been able to recover from depression, but it seems to be associated with the absence of relapses.\nMost of the patients continued to receive the treatment over two years, although researchers temporarily turned it off in three of them as part of the study before realizing that doing so caused their depression to return.\nThe workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain's rhythms.\nThe St. Jude Medical Neuromodulation company, which has provided consulting fees to Mayberg and some of the other study authors, is currently recruiting patients for a study that could pave the way for its approval as a treatment for depression, Mayberg said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering and makes it clear that it is \u201ctoo early to know for sure if the treatment is appropriate to be used for any kind of depression.\u201d", "answer": 1}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exagerrate the seriousness or prevalence of chronic migraines and is clear to repeatedly mention that chronic, severe\u00a0migraines are the indication in question, not everyday garden-variety headaches.", "answer": 1}, {"article": "That test ruled out a safety problem similar to the one that felled RotaShield, an earlier rotavirus vaccine developed by Wyeth, a drugmaker in Madison, N.J.\nThe recommendation for universal use of the vaccine was approved at a meeting of the Advisory Committee on Immunization Practices, the federal panel that sets vaccination policy in the United States.\nMany people have never heard of rotavirus, but it is one of the most common causes of childhood illness -- many ailments that parents or pediatricians describe as \"stomach flu\" are caused by rotavirus infection.\nThe decision means that pediatricians are likely to recommend three doses of the oral vaccine for nearly every child at age 2 months, 4 months and 6 months, beginning almost immediately.\nThat means many doctors are likely to charge more than $300 retail, putting the Merck product in league with Prevnar, an expensive Wyeth vaccine that has been widely used in the United States for five years.\n", "question": "Does the story commit disease-mongering?", "explanation": "Although the author provides some information on the prevalence and seriousness of rotavirus in the US and abroad, he does not mention that there are multiple strands of rotavirus and the vaccine is not equally effective against all of them. The vaccine is about 75% effective in preventing disease (especially severe diarrhea) and the incidence of emergency room visits and hospitalizations is also reduced. The author does exaggerate the seriousness of rotavirus in the U.S, because although all kids get infected with the virus, few have disease from it and it only accounts for about 40-50 deaths. ", "answer": 0}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in the story. Falls are indeed a serious hazard for older people.\n", "answer": 1}, {"article": "The trial, which was conducted in Sri Lanka, enrolled 700 patients with an average age of 56 and blood pressure of 154/90 mm Hg.\nThis includes examining the acceptability of the Triple Pill approach to patients and their doctors, as well as cost-effectiveness which will be important for governments and other payers to consider.\nWhile the most pressing need, from the perspective of the global burden of disease, is low-and middle-income countries, it's equally relevant in a country like Australia where we're still achieving only 40%-50% control rates for high blood pressure.\"\nThe Triple Pill, consisted of the blood pressure medications telmisartan (20 mg), amlodipine (2.5 mg), and chlorthalidone (12.5 mg).\n\"It's estimated more than a billion people globally suffer from high blood pressure with the vast majority having poorly controlled blood pressure.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease-mongering here and a target blood pressure of <140/90 would be considered appropriate by many medical societies. It provides some context in terms of goals to reduce high blood pressure globally.", "answer": 1}, {"article": "Follow @ACCMediaCenter and #ACC16 for the latest news from the meeting.\nThe study, \"Digital Mammography: Screening for Coronary Artery Disease?,\" will be presented on April 3, 2016, at 9:45 a.m. CT/10:45 a.m. ET/3:45 p.m. UTC at the American College of Cardiology's 65th Annual Scientific Session in Chicago.\nIn an accompanying editorial in JACC: Cardiovascular Imaging, Khurram Nasir, M.D., M.P.H., and John McEvoy, from the Center for Healthcare Advancement and Outcomes at Baptist Health South Florida, said that the report provides impetus to document breast arterial calcification in mammography reports, to improve education of primary care and radiology providers on the link with heart disease, and other actions to establish best practices for incorporating this research into care.\n\"Even by the conservative estimate of 10 percent, approximately 4 million women nationwide undergoing screening mammography will exhibit breast arterial calcification; with 2 to 3 million of them likely to have signs of premature coronary atherosclerotic disease,\" the authors said.\nEarlier research had shown a link between breast arterial calcification and atherosclerotic disease--even heart attack, stroke and other cardiovascular disease events, but researchers said these data provide a more direct relationship between the extent of calcified plaque in the mammary and coronary arteries, as well as a comparison to standard risk evaluation.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The use of fear-mongering language was a weakness of this release. The release calls BAC a \u201cred flag\u201d and says,\u00a0\u201cMany women, especially young women, don\u2019t know the health of their coronary arteries.\u201d\nThat statement presumes that young women should know this information because it can lead to health benefits \u2014 something not established here. It\u2019s not at all clear that BAC is a useful \u201cred flag,\u201d but it does seem pretty certain that this kind of language will cause women to worry about BAC, perhaps unnecessarily.", "answer": 0}, {"article": "Last Wednesday, the F.D.A.\nThe consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\n\nIn June 2014, after another company, Medtronic, did similar studies, its device was approved, too, for high-risk patients.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nand Medicare to devise a plan to restrict the device\u2019s spread to places where doctors had sufficient skill to implant them safely.\n", "question": "Does the story commit disease-mongering?", "explanation": "Aortic stenosis is a serious, sometimes life-threatening condition, but the article hypes the situation:\u00a0 \u201caortic valve disease has risen 35 percent, in large part because more people are living long enough to develop it.\u201d then notes that \u201cmore than 8,000 Americans die from the disease annually.\u201d Eight thousand deaths seems like a lot in isolation, but readers would have benefitted from being told it is still only about 1 percent of all heart disease deaths in the U.S.\nWhat\u2019s more, while these catheter-inserted valves are approved only for the sickest patients, the articles leads readers to the conclusion that all patients with aortic stenosis would be better off being treated with these relatively new devices, without waiting to see what happens in trials involving healthier patients.", "answer": 0}, {"article": "The research was funded by the National Institute for Health Research Imperial Biomedical Research Centre and the Biotechnology and Biological Sciences Research Council\nThe volunteers also had to rate how appealing they found the foods.\nAt the moment, the UK average is 15g.\"\nTo get the same increase from fibre alone, we would need to eat around 60g a day.\nHowever the inulin-propionate ester supplement releases much more propionate in the intestines than inulin alone.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering detected.", "answer": 1}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t see any unwarranted or scary language.", "answer": 1}, {"article": "Newswise \u2014 MAYWOOD, IL \u2013 Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life.\nIn PD surgery, the pleura is removed.\nImproved quality of life was observed in the first month after surgery and was maintained at late follow-up in all patients.\nIt develops in the pleura, the thin layer of tissue surrounding the lungs.\nor a type of tumor cell called non-epithelioid.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the news release.", "answer": 1}, {"article": "If you'd like more information about the ONCOblot\u00ae Test, please visit http://www.\nThe results of this study showed that two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4-10 years prior to clinical diagnosis of malignant mesothelioma, an exciting sign of progress in the cancer detection field.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\n\"Although asbestos-induced mesothelioma is a very specific example of early detection, we are currently pursuing larger-scale clinical trials to investigate the utility of the ENOX2 protein marker to predict the onset of cancers of other tissues of origin as well.\"\nDallas, Texas -February 4, 2016 - MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot\u00ae Test recently completed a retrospective clinical trial focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot\u00ae test detected a molecular marker that is indicative of the presence of mesothelioma, 4-10 years in advance of clinical symptoms appearing.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release emphasizes that \u201cMalignant mesothelioma is an aggressive and almost uniformly fatal tumor caused primarily by exposure to asbestos.\u201d However, it fails to note that not only is the disease rare (fewer than 3,000 cases per year in the United States, compared to more than 1.6 million cases and half a million deaths from all types of cancer), but most people exposed to asbestos never get mesothelioma. By implying that this test might be useful for anyone exposed to asbestos, the release sets the stage for a vast sales market of people, most of whom would never have to deal with mesothelioma, regardless of testing.", "answer": 0}, {"article": "The report documents the experiences of 18 patients in the North Kivu province of the Democratic Republic of Congo who showed symptoms of malaria and were originally treated with the recommended medication: artemisinin-based combination therapy (ACT), which blends artemisinin, a chemical extract from Artemisia annua, with one or more other drugs that attack the malaria parasite in different ways.\nLaboratory tests showed they had no parasites remaining in their blood.\nWatch a video about research at WPI related to this study.\nIn effect, the dried leaves constitute a robust natural combination therapy, one whose benefits far surpass those of ACT and other combination drugs.\nAnd, in an experiment that accelerated the evolution of the malaria parasite by passing it through up to 49 generations of mice, the parasite showed no signs of resistance to DLA.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. The context provided about treatment-resistant malaria was helpful.", "answer": 1}, {"article": "Women who took part in diet, exercise or combination programs were about 20 percent less likely than women in standard-care groups to gain too much weight while pregnant, the researchers report.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\n\u201cIn the next pregnancy, if you don\u2019t get it off, you may go from obese to very obese,\u201d Thornburg said.\nOther benefits may include a lower risk of cesarean delivery, excessive birth weight, and respiratory\n\nproblems in the newborn, \u201cparticularly for high-risk women receiving combined diet and exercise interventions,\u201d add the researchers, led by Benja Muktabhant of Khon Kaen University in Thailand.\n\u201cThis was very reassuring that there wasn\u2019t an increased risk of preterm birth with moderate exercise,\u201d said Thornburg, a high-risk pregnancy expert at the University of Rochester Medical Center in New York.\n", "question": "Does the story commit disease-mongering?", "explanation": "Generally speaking, the story treats excessive weight gain during pregnancy as a disease in itself, rather than as a risk factor for other health problems. Where it does explicitly state that gaining too much weight is linked to \u201can increased risk of complications,\u201d it doesn\u2019t tell readers what those complications might be.", "answer": 0}, {"article": "So, should we be referring to physical therapists, osteopaths or chiropractors from the ER?\"\nThis is especially true if you've been in a car accident, or if you have any neurological symptoms, such as repeatedly dropping things, or if you have pain radiating down your arm.\n\"We found that there are some viable treatment options for neck pain,\" said Gert Bronfort, vice president of research at the Wolfe-Harris Center for Clinical Studies at Northwestern Health Sciences University in Bloomington, Minn.\n\n\"What we don't really know yet is how to individualize these treatments for each particular patient.\nHe also noted that it's important for anyone receiving spinal manipulation to know that there are rare, but serious risks that can occur with neck manipulations.\nMONDAY, Jan. 2, 2012 (HealthDay News) -- Spinal manipulation and home exercise are more effective at relieving neck pain in the long term than medications, according to new research.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story accurately reports that neck pain is common. It also includes cautionary statements about the uncertainty that exists about what sort of treatment works best, thus helping readers keep expectations in line with reality.", "answer": 1}, {"article": "Finzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\n\u201cWe don\u2019t believe it has anything to do with looks,\u201d says researcher Dr. Eric Finzi of Chevy Chase Cosmetic Center.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not engage in disease mongering. It does provide some background on how botox is believed to work on depression and other approved clinical uses for botox. The story would have been better had it given us some idea of how many people are affected by major depressive disorder.", "answer": 1}, {"article": "\"If you know that [atrial fibrillation] eats away your brain at a slow but steady pace and that you can prevent it by staying on treatment, I think most patients would find this a very strong argument for continuing treatment,\" he said.\nAtrial fibrillation also increases the risk for dementia.\n\"In the first year, approximately 15 percent stop taking the drugs, then approximately 10 percent each year.\"\nWhen the researchers focused on people who continued to take the drugs, they found an even larger reduction (48 percent) in the risk for dementia.\nThe researchers found that people taking anticoagulants were 29 percent less likely to develop dementia than were those who were not taking the blood thinners.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no obvious disease mongering here.", "answer": 1}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play here.", "answer": 1}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story commit disease-mongering?", "explanation": "The story did not commit disease mongering.", "answer": 1}, {"article": "\n\u2022 Medimetriks, in collaboration with Otsuka, announces the successful completion of a Phase 2 trial of MM36 (previously known as OPA-15406) in Atopic Dermatitis (AD)\n\u2022 MM36 is a topical phosphodiesterase 4 (PDE4) inhibitor under development for the treatment of AD\n\u2022 Results showed a therapeutic benefit as measured by percentage change in EASI score and improvement in IGA score\n\u2022 MM36 is expected to be the 2nd topical PDE4 inhibitor available in the US and may offer unique benefits for patients suffering from AD\n\nMedimetriks Pharmaceuticals, Inc. today announces the publication of Phase 2 results for MM36 (previously referred to as OPA-15406), a novel topical non-steroidal phosphodiesterase IV (PDE4) inhibitor for the treatment of mild-to-moderate atopic dermatitis.\nIt has been estimated that approximately 18 million people are living with AD in the U.S. and this disease accounts for up to 20% of patient visits to dermatology offices.\nThe majority of affected individuals have resolution of disease during childhood, although 10% to 30% of patients maintain the condition throughout their lives.\nIn particular, MM36 exhibits highly selective inhibitory activity against PDE4 subtype B, which is an enzyme that may play a significant role in inflammation.\nIn pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease-mongering. The release\u00a0mentions a possible link to skin or blood cancer with the use of topical steroids which are in wide use today, but then notes that the studies suggesting the link have not proven the case.", "answer": 1}, {"article": "\u201cI\u2019m thinking, is this the way it\u2019s going to be for the rest of my life?\nIf the patient answers yes to one or both, a questionnaire is recommended to determine if the patient is depressed and the severity.\nThe authors said only about half of heart doctors say they treat depression in their patients \u2014 and not all those diagnosed with depression are treated.\nIf depression is indicated, the patient may need to see a professional qualified in treating depression, the panel said, adding that treatment options include antidepressants, seeing a psychotherapist and exercise.\nI would think, \u2018Is this a heart attack?\u2019\u201d\n\nA couple of months after she got home she called Mended Hearts, a group affiliated with the heart association that provides support to heart patients, and talked to someone who let her know depression was common in heart patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of depression. The story rightly points out that depression is more prevalent in people with heart disease.", "answer": 1}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story commit disease-mongering?", "explanation": "No fear-mongering here.", "answer": 1}, {"article": "The California Walnut Commission (CWC) prohibits discrimination in all programs and activities on the basis of race, color, national origin, age, disability, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or part of an individual's income is derived from any public assistance programs.\n\u2022 Banel HK, Hu FB.\nCWC is an equal opportunity employer and provider.\nJ Nutr.\nThe dose of nuts varied from 5 to 100g/day and most participants followed their typical diet.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "In the first seven months on market, about four in five cardiologists and two in five primary care doctors had prescribed it to more than 250,000 people, Wa\u2019el Hashad, Boehringer\u2019s vice president for cardiovascular marketing, said in an interview last week.\nThe new drugs are not without disadvantages.\nreview panel for atrial fibrillation on Sept. 8.\nreview later this year.\nAs many as 12 million people will have it by 2020 because of an aging population with longer life expectancy.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering.", "answer": 1}, {"article": "With 25 years of specializing in natural phospholipid research, development and production, Lipogen guarantees its customers ingredient systems that are supported by the highest level of scientific data, technical quality and safety to meet the growing demand for natural cognitive health solutions.\nAt the end of the 2-month study, out of 220 women under the age of 40 who consumed the product regularly, 23 women (10.45%) reported that they noticed relief of premenstrual syndromes.\nUp to 80% of women report having some symptoms prior to menstruation.\nPMS is a combination of physical and emotional symptoms linked to the menstrual cycle.\nMore than 200 different symptoms have been associated with PMS, including emotional symptoms such as: stress, anxiety, insomnia, fatigue, mood swings, emotional sensitivity and/or changes in libido.\n", "question": "Does the news release commit disease-mongering?", "explanation": "It is true that PMS can be annoying and disruptive, but many women\u2019s symptoms are not disruptive enough to require any medication interventions. Additionally, lumping PMS it together with PMDD (which is much more severe and intense) is uncalled for and bordering on disease mongering. In addition, the release offered no explanation for how it came up with the claim that \u201cMore than 200 different symptoms have been associated with PMS.\u201d", "answer": 0}, {"article": "These data clearly show the contrary, and demonstrate what can be achieved when we couple good research design with new technology,\" lead author Dr. Jose Montoya, professor of infectious diseases at Stanford, tells Shots.\nWhat the latest research shows, Komaroff tells Shots, is that \"levels of many cytokines do correlate with symptoms: The higher the blood level, the worse the symptoms.\nNow, the Stanford researchers have linked ME/CFS to variations in certain cytokines, immune-signaling proteins, that track with illness severity.\nBut, levels of 17 of the cytokines varied dramatically between the patients with mild versus severe ME/CFS symptoms.\nMiriam E. Tucker is a freelance journalist specializing in medicine and health.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not commit disease-mongering. It would have been helpful to explain that fatigue is a very common symptom and that most patients with fatigue\u2013even prolonged fatigue\u2013won\u2019t be considered as having ME-CFS.", "answer": 1}, {"article": "TUCSON, Ariz., Nov. 10, 2016 /PRNewswire/ -- HSRx Biopharmaceutical, a leading developer of proprietary OTC drugs, announced that an independently conducted clinical study has demonstrated its new product, OsteoRx\u2122, outperformed Osteo Bi-Flex Triple Strength\u00ae in alleviating pain and increasing range of motion in patients suffering from joint pain.\nMeasurements in the level of pain and range of motion in the affected knee were recorded over a 14-day period for each patient.\nAfter 14 days of treatment, average pain reduction was more than twice as large as the competition.\nAfter 14 days of treatment, the average improvement was still nearly twice as large as the competition.\nAt seven days, average pain reduction was more than three times greater than the competition.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Hamilton, ON July 19, 2016 -- The first steps towards developing a vaccine against an insidious sexual transmitted infection (STI) have been accomplished by researchers at McMaster University.\n\"The vaccine would be administered through the nose.\nThe next step is more testing for effectiveness against different strains of Chlamydia and in different formulations.\n22863 \n\nWilsot16@mcmaster.ca\n\"Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,\" said Bulir, who just finished his PhD in medical sciences at McMaster.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the story.", "answer": 1}, {"article": "More About: The Study\n\nNathalie Scheers had looked at parvalbumin before in another context.\nParvalbumin is a cause of fish allergies, so we knew that it passed over to the blood, and that this form of parvalbumin is specific for fish\"\n\nShe joined forces with Pernilla Wittung-Stafshede, and together they took the idea forward.\nWe already knew that they can meet in the gut, the blood, or the brain,\" explains Pernilla Wittung-Stafshede.\nPernilla Wittung-Stafshede stresses the importance of finding ways to combat these neurological conditions in the future:\n\n\"These diseases come with age, and people are living longer and longer.\nParvalbumin effectively 'scavenges' the alpha-synuclein proteins, using them for its own purposes, thus preventing them from forming their own potentially harmful amyloids later on.\n", "question": "Does the news release commit disease-mongering?", "explanation": "While there is no overt disease mongering, there are subtle influences here. \u00a0For example, \u00a0the reader is told of a linkage of amyloid and a host of neurodegenerative diseases including Alzheimer\u2019s and then an author notes:\u00a0\u201cThese diseases come with age, and people are living longer and longer. There\u2019s going to be an explosion of these diseases in the future \u2013 and the scary part is that we currently have no cures. So we need to follow up on anything that looks promising.\u201d The clear take away message being conveyed is these disease are of concern and eating fish is the answer.", "answer": 0}, {"article": "Replacement, by contrast, preserves some range of motion.\n\"All those things I'm able to do for myself now.\"\n\"Our hand is our working instrument,\" said Dr. Evan D. Collins, an orthopedic surgeon with the Methodist Center for Sports Medicine.\n\"If it does fail, revising it may not as difficult as it has been in the past.\"\nFor questions or comments on the Health & Medicine page, contact matthew.schwartz @chron.com.\n", "question": "Does the story commit disease-mongering?", "explanation": "There are no obvious elements of disease mongering. It is clear that wrist replacement surgery is a treatment of \"last resort.\"", "answer": 1}, {"article": "But there's a problem with Plavix, and with a newer, stronger drug in the same class called Effient.\nThat's probably why the 6,732 study patients who got Brilinta were 16% less likely to die, or have a heart attack or stroke, than were the 6,676 patients who got Plavix.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nThe new kid on the block is AstraZeneca's ticagrelor, to be named Brilinta if the experimental drug gets FDA approval.\nThat approval seems likely, given the results of a new clinical trial that compared Plavix to Brilinta in patients with acute coronary syndromes who had stents placed in their arteries to improve blood flow.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story indicated that the drug reported on was needed because \u2018blood clots can be a deadly complication of getting a stent\u2019. \u00a0While this is a true statement, it would be more informative to provide some context about how commonly blood clots occur after a person receives a stent. This information would help readers evaluate the importance of a medicine to prevent this from occurring. Nonetheless, we\u2019ll give the story the benefit of the doubt on this. \n", "answer": 1}, {"article": "heart assocIation Mouth-to-mouth not necessary and seen as deterrent\n\nIn a break from decades-old first aid guidelines, the American Heart Association on Monday endorsed \"hands only\" cardio-pulmonary resuscitation - rapid chest compression without mouth-to-mouth resuscitation - to improve the odds for victims of cardiac arrest.\n\"We think that if we can double the number of bystanders who attempt CPR, we can save tens of thousands of lives every year,\" said Mary Fran Hazinski, a nurse at Vanderbilt University Medical Center and spokeswoman for the American Heart Association.\nThat hesitation is rooted not only in reluctance to lock lips with a stranger, but by anxiety over how to perform conventional CPR, in which the rescuer breathes into the victim twice after every 30 chest compressions.\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nAlthough survival rates for cardiac arrest hover around 10 percent with CPR, Hazinski noted that rates have been pushed as high as 30 percent in cities, such as Seattle, that combine high bystander participation with a strong system of professional emergency medical response.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article explains that a tiny minority of people who need CPR actually receive it. It also reassures readers that untrained bystanders can perform CPR and potentially save lives. The story does not exaggerate the problem of untreated cardiac arrest.", "answer": 1}, {"article": "June 22, 2010 -- Drinking lots of coffee probably isn't entirely good for you, but it does lower your risk of mouth and throat cancer.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nThe protection was seen for oral and pharyngeal cancer, but not for cancer of the larynx.\nDrinking less than five cups of coffee a day had a smaller but statistically significant protective effect: about 4% lower odds of mouth and throat cancer for each cup drunk daily.\nGaleone and colleagues report their findings in the July issue of Cancer Epidemiology, Biomarkers, & Prevention.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable \u2013 there really wasn\u2019t any background given on the types of cancer in question. ", "answer": 2}, {"article": "(Forget to weigh in or track your meals?\nA recent pilot study with Utah-based Intermountain Healthcare that included about 200 people, all of whom were at high risk of Type 2 diabetes, found that 75 percent of the participants completed the Omada program and lost at least 5 percent of their body weight.\nSince last May, he has lost about 50 pounds (52, to be exact, but it fluctuates a bit) and his blood sugar has returned to the normal range.\nIf it were easy, there wouldn't be more than 80 million adults in the U.S. with prediabetes.\nAfter all, pulling off these changes is difficult\n\n\"I'm still on the journey to get to more optimal, health\" says Lonny Northrup, who lives in Utah.\n", "question": "Does the story commit disease-mongering?", "explanation": "The term \u201cprediabetes\u201d is controversial \u2014 it\u2019s a warning sign that your weight and blood sugar are above the normal range, but not yet at the threshold for diabetes itself. Using the phrase \u201cdiagnosed with prediabetes\u201d blurs that line and makes what is essentially a risk factor sound like a condition requiring treatment.", "answer": 0}, {"article": "Such screening is increasingly used in research.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nData from nearly 9,500 people on five continents shows that amyloid can appear 20 to 30 years before symptoms of dementia, that the vast majority of Alzheimer\u2019s patients have amyloid and that the ApoE4 gene, known to increase Alzheimer\u2019s risk, greatly accelerates amyloid accumulation.\n", "question": "Does the story commit disease-mongering?", "explanation": "We saw no indication of fear-mongering. Indeed, there was no mention of the prevalence,\u00a0 incidence or societal burden of Alzheimer\u2019s disease which some readers could find helpful for putting the size of the problem into context. However, we don\u2019t see this as a critical omission in the article.", "answer": 1}, {"article": "All of the babies born by C-section were slightly more likely to use an asthma inhaler at age 5: 10.3 percent of planned C-section babies and 10.19 percent of unscheduled C-section babies wound up using an inhaler, compared with 9.6 percent of vaginally born babies.\nThe remaining 252,917 were vaginal births.\nThere were no significant differences in cancer and irritable bowel disease among any of the types of births.\nNearly 4 percent were born by planned C-section and 17 percent were delivered by emergency surgery.\nIn the United States, nearly one in three babies are born by C-section.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "The U.K.\u2019s new at-home HIV test won\u2019t reach all the undiagnosed or guarantee that the people who test positive wind up receiving the care they need from a doctor, but letting people check their status quickly and accurately is likely to produce cascading positive effects, as HIV-positive people find it easier to seek care for themselves, warn past partners about exposure, and reduce risk for future partners.\nIn the United States, the Affordable Care Act designates HIV testing as a preventive service, meaning that all insurers must cover it without charging a co-pay.\nIn a 2012 study, researchers estimated that in 2008, approximately 20 percent of all HIV-positive people in the United State were undiagnosed.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nIn a small British study of 98 gay and bisexual men who were newly diagnosed as HIV-positive, the use of condoms after the diagnosis doubled relative to the rates of use pre-diagnosis (31 percent to 61 percent of respondents).\n", "question": "Does the story commit disease-mongering?", "explanation": "The story accurately reports that about one-fifth of people with early HIV infections don\u2019t know they carry the virus. However, the story does not explain who testing is recommended for or how frequently.", "answer": 1}, {"article": "More women were still using the intrauterine system after two years than were still taking standard medical treatments -- 64 percent compared to 38 percent.\n\"If women suffer with heavy periods and do not want to get pregnant -- as the levonorgestrel intrauterine system is a contraceptive -- then having the levonorgestrel intrauterine system is a very good first-line treatment option that does not require taking regular, daily oral medications,\" said the study's lead author, Dr. Janesh Gupta, professor of obstetrics and gynecology at the University of Birmingham and Birmingham Women's Hospital in England.\nWEDNESDAY, Jan. 9, 2013 (HealthDay News) -- Women with heavy menstrual bleeding may find some relief using an intrauterine device, or IUD, containing the hormone levonorgestrel, according to new research.\n\"This study really adds to the evidence that shows how useful this intrauterine system is for heavy menstrual bleeding,\" said Dr. Eve Espey, professor of obstetrics and gynecology at the University of New Mexico School of Medicine in Albuquerque.\nWomen in the IUD group reported much greater improvement -- 32.7 points on the symptom scale versus 21.4 points in the standard treatment group.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story states that heavy menstrual bleeding makes up about 20% of all office visits in the US and UK. \u00a0What the story failed to state was the actual prevalence of this condition in the population (which is about 5%).\nBorderline call, but we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "The effect, however, typically lasts only about seven months before the cancer starts to grow again, though some patients benefit for more than two years.\nDoctors are eager to try the two drugs together.\n\u201cIf it weren\u2019t for the trial I wouldn\u2019t be here,\u201d she said.\nVemurafenib is the latest so-called targeted therapy, which inhibits the effects of genetic mutations that spur tumor growth and spread.\nBecause it unleashes the immune system, ipilimumab can have serious side effects.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of melanoma.", "answer": 1}, {"article": "He concluded, \"Given the results of the [Acute Renal Failure Trial Network] study, the renal and intensive care communities must now focus on other strategies to help this population of patients.\nThere was no difference in death rates in both groups, and both also had similar rates of recovering kidney function and other organ failure.\nIn the study, patients who did not need drugs to maintain blood pressure were assigned to either a six-day or three-day dialysis to filter toxins and extra fluid from the blood.\nThroughout the study, patients remained in intensive or less intensive therapy, although as their clinical conditions changed, they could change forms of therapy, Dr. Palevsky said.\nThose patients who needed drugs to increase blood pressure were assigned to two other forms of blood cleaning, both divided into intensive or less intensive groups.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "\u201cThe decreased risk of breast cancer in this group is something we totally didn\u2019t expect when we started the W.H.I.\nNobody knows why estrogen treatment alone appeared to lower breast cancer risk in the study, but one explanation may be that in menopausal women with low levels of natural estrogen, the effects of estrogen drugs induce cell death in existing tumors.\nThe data indicate that for every 10,000 women in their 50s, those using estrogen would experience 12 fewer heart attacks, 13 fewer deaths and 18 fewer adverse events like blood clots or stroke in a given year, compared with those taking a placebo.\nIt is not known whether the benefits of estrogen shown in the Women\u2019s Health Initiative would be replicated using a different type of estrogen.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does a good job of discussing a variety of risks without exaggerating any of them. If anything, they may exaggerate the benefits in the headline.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nTo determine an alternate but effective therapy, the researchers enrolled 100 patients age 45-78 with significant stroke risk and coupled with diligent pulse monitoring -- manually or by using a smartphone - twice a day with \"as needed\" anticoagulants for the treatment of AF.\nPHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n\"This kind of approach to anticoagulation therapy requires an open line of communication between the patient and the care team, and calls for a specific type of patient.\nOral anticoagulation therapy is recommended in patients with infrequent AF and high risk of stroke, however, prolonged use of blood thinners is associated with a higher bleeding risk.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no obvious disease mongering here. Atrial fibrillation is a real and important health issue for which better use of effective drugs is warranted. We\u2019d remind readers that patients who\u2019ve had an ablation (the surgical removal of body tissue) and aren\u2019t in AF may not need anti-coagulation.", "answer": 1}, {"article": "The study included 60 adults with TBI symptoms lasting an average of eight years.\nThese findings provide hope for people who thought, 'This is as good as my recovery is going to get' and for the medical community who have yet to find a way to objectively measure a patient's recovery,\" he said.\nA recent study from the Center for BrainHealth at The University of Texas at Dallas shows that a certain type of instructor-led brain training protocol can stimulate structural changes in the brain and neural connections even years after a traumatic brain injury (TBI).\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\n\"People who showed the greatest change in cortical thickness and connectivity, showed the greatest performance increases in our cognitive tasks.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We found no indication of disease-mongering. The release provides good context on how TBI disrupts the structure of the brain.", "answer": 1}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nDr. Lewy dismissed the idea that harm might lurk in a melatonin-laced brownie.\n\u201cA hangover effect has been reported\u201d with large doses, said Anna Rouse Dulaney, a toxicologist with the Carolinas Poison Center.\n\u201cFor me, it\u2019s not to chill.\n\u201cIt really doesn\u2019t have any documented side effects except for making you sleepy at bedtime, which is good,\u201d he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering in this story.", "answer": 1}, {"article": "CHICAGO (Reuters) - Lightly shocking a person\u2019s brain just before they learned a new task appeared to strengthen memory in a handful of patients with epilepsy, a tantalizing result that could have implications for Alzheimer\u2019s disease, U.S. researchers said on Wednesday.\n\u201cAlthough the current evidence is preliminary, is based on small samples and requires replication, the potential application of deep-brain stimulation in amnestic disorders is enticing,\u201d Black wrote.\nThe current study was done at the University of California at Los Angeles in seven epileptic patients awaiting surgery who had electrodes implanted deep in their brains to help pinpoint the source of their seizures.\nDespite costly efforts, no drug has been found that can keep Alzheimer\u2019s from progressing, and policymakers are growing increasingly worried about the swelling ranks of dementia patients as the population ages.\nPacemaker devices known as deep brain stimulators made by Medtronic and St. Jude Medical are already used to calm muscle tremors in patients with Parkinson\u2019s disease and other movement disorders, and are being tested for a host of other conditions such as treatment-resistant depression.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story mentions the estimated number of people with Alzheimer\u2019s disease in the United States and that their ranks are \u201cswelling,\u201d but it does not exaggerate the prevalence of the disease or the portion of the population that could potentially benefit if this line of research makes progress.", "answer": 1}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story commit disease-mongering?", "explanation": "This story engaged in disease mongering. \u00a0Cirrhosis of the liver is a serious condition and though its incidence appears to be on the rise in seriously obese children, liver disease should not be the top concern for parents of children who are overweight or simply obese. \u00a0The story made it sound as though all children with cirrhosis will require a liver transplant.\nIt presented data that exaggerate the prevalence and severity of the condition in children and provoke fear in the reader. The article says that 2 to 5 percent of kids over age 5 may have NASH, but then says as many\u00a0as 10 percent of children and half of obese children have it. \"It\" being a very mild and early form of the condition,\u00a0that may\u00a0or may not lead to long-term problems. Cirrhosis and the need for liver transplant remain very rare conditions in children. ", "answer": 0}, {"article": "To find out, Sobel, along with Liron Rozenkrantz and their colleagues, presented 18 children with ASD and 18 normally developing children (17 boys and 1 girl in each group) with pleasant and unpleasant odors and measured their sniff responses.\nImagine the way you might smell a rose.\nYou'd take a nice big sniff to breathe in the sweet but subtle floral scent.\nThey also want to find out how early in life such a test might be used.\nSuch early diagnosis would allow for more effective intervention.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "In one of his own studies, Wong found no effect on soy germ isoflavones among women who took the supplements for two years.\nHe generally recommends exercise and an active lifestyle to women who feel bothered by menopause.\n\u201cThere is a major cultural difference in how we deal with menopause symptoms,\u201d he mused.\nBut a U.S. expert wasn\u2019t convinced by the results, which run counter to other published studies.\nThe work was supported by Frutarom Netherlands, which also donated the supplements.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not commit disease mongering.", "answer": 1}, {"article": "Funding came from the National Institutes of Health and the American Heart Association.\nIn the current study, researchers wanted to know if exercise can restore the heart's elasticity in previously sedentary individuals - especially if begun in late middle age.\nAt the end of the two-year study, those who had exercised showed an 18 percent improvement in their maximum oxygen intake during exercise and a more than 25 percent improvement in compliance, or elasticity, of the left ventricular muscle of the heart, Dr. Levine noted.\nHowever, the researchers also found that the heart chamber in competitive masters-level athletes remains large and elastic, and that even four to five days of committed exercise over decades is enough for noncompetitive athletes to reap most of this benefit.\nTo reap the most benefit, the exercise regimen should begin by late middle age (before age 65), when the heart apparently retains some plasticity and ability to remodel itself, according to the findings by researchers at the Institute for Exercise and Environmental Medicine (IEEM), which is a collaboration between UT Southwestern Medical Center and Texas Health Presbyterian Hospital Dallas.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This news release uses the term \u201cheart aging\u201d without explanation. It\u2019s not clear what it means and it sounds vaguely worrisome, but we don\u2019t think it rises to the level of disease mongering.", "answer": 1}, {"article": "Otto tracked 755 patients who died from breast cancer from 1995 to 2003 and another 3,739 control patients matched by age and other measures.\nIt's not clear, for instance, whether the women who died of cancer got less aggressive treatment or refused treatment.\n\"But there is no way to figure out which cancers will be a problem or not,\" she said.\nWomen aged 70 to 75 had the greatest risk reduction, reducing the risk of dying from breast cancer by 84 percent.\nThe risk reduction in younger women, aged 50 to 69, was smaller, at 39 percent, but still considered substantial.\n", "question": "Does the story commit disease-mongering?", "explanation": "A statistical reference to the number of women who are diagnosed and die from breast cancer would be useful, but there is no direct evidence of disease-mongering.\n\u00a0", "answer": 1}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nInfants in the complete treatment group fared best.\nThe study followed the infants from birth to 18 to 22 months of age and measured survival and brain and nervous system outcomes.\nThe infants were grouped according to the mother\u2019s steroid treatment \u2014 no treatment, partial treatment or complete treatment.\nInfants in the partial treatment group fared better than untreated infants.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the news release.", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story commit disease-mongering?", "explanation": "The story quotes a doctor who compares the pain of macromastia to the pain suffered by someone with metastatic cancer of the spine.\nThis is a shamefully sensational exaggeration. It is completely unnecessary to make the point that macromastia is a serious and debilitating condition.\n\u00a0", "answer": 0}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nOAK BROOK, Ill. - An MRI breast imaging technique that requires no contrast agent, combined with sophisticated data analysis, could reduce the number of unnecessary breast biopsies, according to a new study appearing online in the journal Radiology.\n\"Since malignant lesions disrupt the tissue structures at this level, diffusion kurtosis might serve as a relevant marker of changes.\"\nFor the analysis, a software algorithm was developed for lesion characterization, and imaging features were extracted using a kurtosis-based radiomics model.\nIn an independent test set of 127 women, the radiomics analysis reduced false-positive findings by 70 percent, while detecting 60 of 61 malignant lesions, or 98 percent.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering is evident in the news release. Breast cancer is a serious disease, and false positives create a very real level of anxiety in patients.", "answer": 1}, {"article": "Liao said the robotic surgery was the right choice for Holmes, the bypass patient.\nThe number of da Vinci robots has doubled in Minnesota in less than two years, with two at the university and four at the Mayo Clinic in Rochester.\nThe learning curve for cardiac surgeons was too steep, though, and the system\u2019s tools weren\u2019t as useful for heart surgeries as they were for other procedures, said Dr. Goya Raikar, a cardiothoracic surgeon at Regions Hospital in St. Paul.\nUsing the da Vinci, Liao disconnected the mammary artery \u2014 which usually directs blood to the left breast \u2014 and connected it to the heart so normal blood flow could resume.\nThe da Vinci is criticized by health policy experts as the poster child for the medical arms race \u2014 the competitive fever among hospitals to buy new technology whether or not it improves care.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article focuses on an extraordinary application of the daVinci device\u2013in a highly trained athlete whose disease and lifestyle led to a decision to use the machine. This unusual story may create the impression that the robot is a life-saving necessity for hospitals and patients.\u00a0\nNonethless, the story did not exaggerate the condition being treated. \u00a0", "answer": 1}, {"article": "OMT also reduced the in-hospital mortality rates of those with the highest severity of illness.\nThe study analyzed 375 patients ages 50 or older who were randomly assigned to three groups, either receiving OMT, a light touch or conventional care only.\nWhile antibiotic therapy is the current standard of care, the emergence of resistant bacteria is a global threat and provides an incentive to explore adjunct treatments that can improve their efficacy,\" said James Bailey, DO, assistant professor in physical medicine and rehabilitation at Rowan University School of Osteopathic Medicine.\nStudy published in the Journal of the American Osteopathic Association finds OMT plus antibiotics reduces risk of death for the most severely ill patients\n\nCHICAGO--August 29, 2016-- An analysis of multicenter randomized controlled clinical trial found osteopathic manipulative treatment (OMT) for pneumonia reduced length of hospital stay in adults 50 to 74 years old and lowered in-hospital mortality rates for patients 75 and older.\nThe data were analyzed by intention-to-treat analysis of all participants and by per-protocol analysis of participants who finished the study without missing any protocol treatments.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering. Pneumonia in the hospitalized elderly is a serious issue. However, this study also included younger patients and those with less severe pneumonia sick enough to be hospitalized.", "answer": 1}, {"article": "But therapies have been improving steadily.\n``The proof of the pudding is always what happens when you give it to people and look at what the potency of the antiviral effect is,\" said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.\nIn 2003, roughly 1.2 million Americans lived with acquired immune deficiency syndrome, and another estimated 40,000 Americans are newly infected with the human immunodeficiency virus each year, according to the Centers for Disease Control and Prevention.\nThat hints at the opportunity to use bevirimat in potent combination with existing drugs, said Dr. Daniel R. Kuritzkes, director of AIDS research at Brigham and Women's Hospital and an associate professor of medicine at Harvard Medical School.\nThe experimental therapies include drugs that bolster the body's ability to block the doorways that HIV uses to enter cells, that enhance the body's ability to neutralize the virus, and that limit the damage caused by HIV infection.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story provides appropriate prevalence and incidence data on Americans living with HIV. If anything, the story under-reports HIV prevalence worldwide. The story could have questioned: if the therapy is approved, would it be made available to the millions infected with HIV in developing countries? ", "answer": 1}, {"article": "\"Every day.\"\n\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\n\"What I usually have constantly is a dull aching crushing pain like deep in my bones, as if my shin is in a vice or somebody is standing on my foot,\" he told CBS News medical correspondent Dr. Jon LaPook.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\n\"In some way that nobody understands and still seems rather magical, pain might be reduced,\" said Dr. Russell Portenoy.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story opens with an extraordinary anecdote, exaggerating both the severity of chronic pain and the potential of the treatment to help. \nYet it states that up to 1 in 4 Americans suffer from chronic pain, and 1 in 10 have it for over a year. \nThe number of people who suffer the kind of pain as the featured patient is likely much smaller than these figures imply. The segment should have stated this. The true prevalence of chronic pain is unknown.\u00a0 It depends on the definition used and the population surveyed. ", "answer": 0}, {"article": "Leptin, they reasoned, tells the brain how much fat is on the body.\nThey also measured thyroid hormone concentrations in the blood and found that leptin reversed the declines in those levels that occurred with weight loss.\nBut what if the researchers put people - fat and thin - on weight-reducing diets and gave them enough leptin to make their bodies think that they were still fat.\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\nIf people lose weight, they have less leptin.\n", "question": "Does the story commit disease-mongering?", "explanation": "Weight loss is framed as starvation. \nThe study this piece was based on fed the study subjects 800 kcal/day which is more akin to starvation than dieting. It \nmakes the piece less relevant to the dieting process. ", "answer": 0}, {"article": "NEW YORK (Reuters Life!)\nThe study, led by Hung Fu Tseng, a research scientist at Kaiser Permanente in Southern California, compared about 75,000 vaccinated members of the Kaiser Permanente Health plan with about 225,000 similarly aged members who weren\u2019t vaccinated.\nCost is one hurdle, with the vaccine sometimes costing up to $200 for people whose insurance doesn\u2019t cover it.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\nShingles is a viral disease produced by the chicken pox virus, a common childhood disease, and is characterized by pain and a blistering rash along the nerves that have housed the dormant virus.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story accurately describes the population of people eligible to be vaccinated. It notes the vaccine is not recommended for everyone over age 60, but it does not explain why some people are advised not to get this vaccine.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - There may be a seed of truth amidst the many health claims for pomegranate juice, researchers from Israel said Thursday, at least for kidney patients on dialysis.\nThey also made fewer trips to the hospital.\nBy comparison, that number would be nearly 11 in patients not drinking the juice.\n\u201cPomegranate juices \u2014 like most if not all fruit and vegetable juices \u2014 have antioxidant activity.\nAntioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in the story.", "answer": 1}, {"article": "People who don\u2019t get this type of minimally invasive surgery may instead get a more invasive procedure that involves surgeons cutting open the chest to repair a damaged valve.\nThe condition tends to develop with age and can lead to chest pain, shortness of breath, fatigue and heart failure.\nThe analysis focused on people with what\u2019s known as aortic stenosis, which occurs when the large blood vessels leading away from the heart narrow, forcing it to work much harder to pump blood.\nOverall, the current analysis included 2,775 patients from a total of 20 previously published studies on outcomes for this type of surgery.\nThe smaller studies in the analysis ranged in size from 36 to 484 patients, and most of them followed patients for as long as six to 12 months after surgery.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here. However, the story doesn\u2019t give any idea of how common this condition is\u2013which would have been helpful to include.", "answer": 1}, {"article": "Dopamine is a brain chemical that regulates movement and mood.\nThe medications, which include Requip (ropinirole), levodopa, Neurontin (gabapentin) and Lyrica (pregabalin), appear to reduce symptoms of the syndrome in more than 60 percent of patients, researchers report.\n\"Treatments for restless legs syndrome is now frequently advertised direct-to-consumer, and thus while this may enhance awareness it may result in patients seeking treatment for milder or other conditions not well-studied,\" he explained.\nMONDAY, March 4, 2013 (HealthDay News) -- People suffering from restless legs syndrome may find some relief by taking one of several drugs approved to treat the condition, a new review confirms.\n\"Up to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit,\" he noted.\n", "question": "Does the story commit disease-mongering?", "explanation": "The authors warn about the potential for disease-mongering of restless leg syndrome (an issue that others have also called attention to in the past). \u201cTreatments for restless legs syndrome is now frequently advertised direct-to-consumer, and thus while this may enhance awareness it may result in patients seeking treatment for milder or other conditions not well-studied,\u201d he explained.", "answer": 1}, {"article": "This new approach to drug discovery is a promising technology that is rapidly moving in the translational research space , .\nAmong these, the abstract \"Tivanisiran a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials\" (Posterboard number: 925 - B0103) is highlighted, the compound improving the ocular inflammatory parameters, tear quality and a reduction in ocular pain associated with dry eye disease is also underlined1.\nDry eye can be treated with cyclosporin drops or autologous serum, but there is as yet no specific product for chronic treatment of the ocular pain related to dry eye syndrome; oral analgesics or anaesthetics are used in general.\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nThe therapeutic application of targeted siRNAs is booming given the specificity of gene silencing for a particular protein in a given tissue and the lack of side effects.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release crosses the line into disease mongering with its repeat references to \u201cdry eye disease\u201d and \u201cdry eye syndrome\u201d which are not recognized medical conditions. Dry eyes can be caused by numerous things, ranging from side effects of medications to normal aging.", "answer": 0}, {"article": "Genomic Health disclaims any obligation to update these forward-looking statements.\nThe results showed that physician treatment recommendations changed for 31 percent of patients after receiving the DCIS Score result, reducing the number of patients receiving a radiotherapy recommendation by approximately one-third.\n\"Most patients with DCIS are treated with surgery followed by radiation, yet only about 20 percent of them are likely to experience a recurrence or develop an invasive form of the disease,\" said Michael Alvarado, M.D., associate professor of surgery, the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.\nNOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.\nPhysicians in this study rated the DCIS Score as the most important factor in planning treatment compared with pathologic features, patient preference, patient age, comorbidities or consultation with other physicians.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The story did not commit disease mongering. Although it didn\u2019t mention or emphasize the fact that some physicians don\u2019t consider DCIS to be cancer at all, it does call DCIS \u201cindolent\u201d and says that it may be treated too aggressively in some cases.", "answer": 1}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story commit disease-mongering?", "explanation": "Gives estimates of women diagnosed with this type of breast cancer. Perhaps not enough \nemphasis that this is only for post menopausal women with invasive disease \u2014 e.g. last line in story assumes all estrogen \nreceptor/progesterone receptor positive women are eligible.", "answer": 1}, {"article": "Flibanserin is taken nightly at bedtime.\nBut the difference was important to the women, says study researcher Michael L. Krychman, MD, medical director of sexual medicine at Hoag Hospital in Newport Beach, Calif.\n\n\"The absolute number of women who had remission of sexual distress was clinically significant, but equally important to them was how it improved their lives,\" Krychman tells WebMD.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\nWhile HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\n", "question": "Does the story commit disease-mongering?", "explanation": "Except for the headline,\u00a0\" \u2018Female Viagra\u2019 May Treat Low Sexual Desire\",\u00a0this story\u00a0avoids\u00a0disease mongering\u00a0and notes that\u00a0\"hypoactive sexual desire disorder\" in women is a controversial diagnosis.\u00a0 The text clarifies that while the popular press is\u00a0dubbing flibanserin as the \"female Viagra\", it is not similar to Viagra or other drugs to treat erectile dysfunction.\u00a0", "answer": 1}, {"article": "Find more information at www.uab.edu and www.uabmedicine.org.\n\u201cIt is critical for eye care professionals to have a dialogue with patients who report symptoms because dry eye can be a progressive ocular surface disease.\u201d\n\nThe twice-daily eye drop solution of 5 percent lifitegrast ophthalmic solution is the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\nThere is hope for dry eye patients worldwide.\u201d\n\nDiagnosis of dry eye is identified by an eye care professional based on careful evaluation of signs and symptoms, including dryness, discomfort, vision changes and damage to the surface of the eye.\nFocusing her research on all aspects of the eye, Nichols discussed the mechanics of the three layers of the tear film and the importance of each from the cornea outward:\n\u2022 Mucin layer: helps tears adhere to the eye\n\u2022 Aqueous layer or water layer: nourishes and protects the cornea\n\u2022 Lipid or oil layer: lubricates and prevents evaporation and provides smooth refractive surface needed for optimal vision\n\n\u201cWe are unsure which of the 200-plus different lipids and 500-plus unique proteins are most important for protecting and lubricating the eye, and the absence or insufficiency of which results in dry eye,\u201d Nichols said.\nNewswise \u2014 BIRMINGHAM, Ala. \u2013 The Food and Drug Administration recently approved lifitegrast, a new eye drop for treating signs and symptoms of dry eye in adult patients.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Optometrist Kelly Nichols is quoted as saying, \u201cThere is hope for dry eye patients worldwide.\u201d Given that dry eye is not fatal and rarely results in permanent vision loss, that statement might be considered hyperbolic.\nThe news release also states, without attribution, that dry eye affects more than 16 million adults in the United States.\nA search of the National Eye Institute\u2019s website finds no total figure for U.S. adults, but the figures it does offer raise questions about whether the 16 million figure is accurate: \u201cElderly people frequently experience dryness of the eyes, but dry eye can occur at any age. Nearly five million Americans 50 years of age and older are estimated to have dry eye. Of these, more than three million are women and more than one and a half million are men. Tens of millions more have less severe symptoms. Dry eye is more common after menopause. Women who experience menopause prematurely are more likely to have eye surface damage from dry\u00a0eye.\u201d\nThere is a small risk that the release, when encouraging patients to visit the specific eye clinic at UAB, could lead to \u201cindication creep\u201d as more and more people with very mild symptoms go to that clinic for diagnosis and treatment.", "answer": 0}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nInvasive coronary angiography (ICA) is considered the gold standard for determining the percent of stenosis, or narrowing, due to plaque in a coronary artery.\n\"The strategy of direct referral to invasive coronary angiography without noninvasive imaging is obsolete,\" Dr. Kaufmann said.\n\"In patients with multiple lesions or complex coronary anatomy, it is, in many cases, very difficult to correctly identify the culprit lesion,\" he said.\nThey are also looking at what they call \"triple hybrid\" imaging, which combines the CCTA/SPECT hybrid with information on coronary artery shear stress.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering. The release states that \u201cCoronary artery disease is a leading cause of death and disability worldwide,\u201d which is accurate.", "answer": 2}, {"article": "\"A lot of the time, people have quite painful and challenging experiences revisiting the trauma, and [MDMA] can help them do it without being overwhelmed or numbed out,\" he says.\nDon't try this experiment at home.\nAnd when purchased on the street it can be contaminated.\nThe others took a placebo but received the same therapy.\nMDMA is believed to raise levels of the feel-good brain chemical serotonin and the so-called \"bonding hormone,\" oxytocin.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story.", "answer": 1}, {"article": "Scientists have transformed one type of fully developed adult cell directly into another inside a living animal, a startling advance that could lead to cures for a variety of illnesses and sidestep the political and ethical quagmires\n\nThrough a series of painstaking experiments involving mice, the Harvard biologists pinpointed three crucial molecular switches that, when flipped, completely convert a common cell in the pancreas into the more precious insulin-producing ones that diabetics need to survive.\n\"The goal is to create cells that are missing or defective in people.\n\"It introduces a whole new paradigm for treating disease.\"\nIt's very exciting.\"\n\"This is a 'win-win' situation for medicine and ethics.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease mongering.\u00a0 ", "answer": 1}, {"article": "\u201cWhen it recognizes that it\u2019s gone inside the cell, it says OK, now it\u2019s time to disassemble and give off the RNA.\u201d\n\nIn a phase 1 clinical trial in patients with various types of tumors, the team gave doses of the targeted nanoparticles four times over 21 days in a 30-minute intravenous infusion.\nRNA stands for ribonucleic acid \u2014 a chemical messenger that is emerging as a key player in the disease process.\n\u201cIn the particle itself, we\u2019ve built what we call a chemical sensor,\u201d Davis said in a telephone interview.\nBut getting the treatment to the right target in the body has presented a challenge.\nTumor samples taken from three people with melanoma showed the nanoparticles found their way inside tumor cells.\n", "question": "Does the story commit disease-mongering?", "explanation": "Not applicable.\u00a0 No discussion of melanoma in any detail. ", "answer": 2}, {"article": "Although DHEA is included in some dietary supplements, the efficacy and safety of those products have not been established for diagnosing, curing, mitigating, treating or preventing any disease.\nThe most common adverse reactions were vaginal discharge and abnormal Pap smear.\nWomen were randomly assigned to receive Intrarosa or a placebo vaginal insert.\nDuring menopause, levels of estrogen decline in vaginal tissues, which may cause a condition known as VVA, leading to symptoms such as pain during sexual intercourse.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release.", "answer": 1}, {"article": "Medical device makers have been working for years to develop a so-called artificial pancreas to deliver insulin to patients with type 1 diabetes, an autoimmune disease in which the body destroys its own ability to make insulin.\n\u201cThese devices could transform the management of type 1 diabetes, but it is likely to be a gradual process,\u201d Roman Hovorka of Cambridge, who led the research, said in a telephone interview.\nWhen we started, the technology wasn\u2019t very good and the functionality was limited, and it took a number of generations to move to the device that we have now.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\nThe Cambridge study, published in The Lancet medical journal on Friday, used devices and sensors from Smiths Medical, a unit of Smiths Group, Abbott Diabetes Care, a unit of Abbott Laboratories, and Medtronic.\n", "question": "Does the story commit disease-mongering?", "explanation": "The description of type 1 diabetes in this story is a bit sensational. If type 1 diabetes is left untreated, the story states, \"blood vessels and nerves are destroyed, organs fail and patients die.\" \nWhile this is technically true, patients with type 1 diabetes are treated and their experiences with the disease, while often frustrating and\u00a0frightening,\u00a0are not\u00a0well-represented by this overly dramatic one-sentence description. We\u2019ll flag this one for disease-mongering.", "answer": 0}, {"article": "The practical value of the tests depends critically on details like their sensitivity, meaning the proportion of tumors that are detected, and their specificity, meaning how many of the positive results are in fact false alarms.\nProponents of each test note possible weaknesses of the other.\n\u201cExact Sciences has gotten close to that.\n\u201cThe health economics of such a test make no sense,\u201d he said.\nDr.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "But this is where it gets more complicated.\nKenneth Lin, a family physician at Georgetown University who worked on developing the task force\u2019s SERM guidelines, notes that while SERMs may have reduced new cases, they \u201chave not been shown to reduce breast cancer mortality in any study or meta-analysis.\u201d One possible explanation, he says, is that \u201cthese drugs are effective at preventing nonlethal cancers rather than the more serious ones.\u201d\n\nNot used enough?\nThis is an evolving field, and our goal is to better discern who is at high and low risk of breast cancer and develop a greater range of prevention strategies.\u201d\n\nAn individual risk analysis should prompt conversation between doctor and patient about the potential benefits and the risk of the therapy.\n\u201cAt the 1.67 percent high-risk threshold,\u201d Georgetown\u2019s Lin says, \u201cevery woman age 62 and older would be [considered] high-risk.\u201d That might lead to a situation in which millions of women would be encouraged, unnecessarily,to consider this therapy, along with its potential harmful effects.\nAt that point, the panel said, women \u201care likely to have more benefit than harm from using tamoxifen or raloxifene.\u201d\n\nASCO\u2019s lower cutoff worries some experts.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story had a couple of issues that raised concern. The intro paragraph notes that 230,000 women annually receive a \u201cdevastating\u201d diagnosis of breast cancer. But in reality, there is a wide spectrum of disease and many types of breast cancer are very curable (and, in fact, have spurred debate to no longer call them cancer). We wish the story had made that clearer. And by waiting several paragraphs to mention that preventative drugs are meant only for high risk women, the story may prompt many women at low risk to worry about needing chemoprevention.\nOn the other hand, the story does include a related sidebar that has a nice discussion of risk factors. It includes the following reassuring statement: \u201cIt is important to note that having a risk factor, or even a few of them, does not mean a woman will develop cancer. Most women, in fact, do not.\u201d", "answer": 1}, {"article": "When it's functioning properly, BRCA actually helps repair damaged DNA and prevents tumors, but when BRCA1 and BRCA2 go awry, they encourage breast cancers.\nThe drug, talazoparib, works by blocking an enzyme called poly ADP ribose polymerase (PARP), thus preventing cancer cells from killing healthy ones.\nIn the current trial, the women who were randomly selected to receive talazoparib had a higher response rate to treatment than women who received standard chemotherapy: 63 percent versus 27 percent, the researchers found.\nIn addition, several ongoing studies are looking at combinations with PARP inhibitors \"to try to expand who may benefit or lengthen how long they may work,\" Litton said.\nThe trial results are preliminary, as talazoparib has not yet been approved by the U.S. Food and Drug Administration.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. Some discussion of how many women grapple with this stage of breast cancer, along with treatment success rates, would have been useful to include, though.", "answer": 1}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story commit disease-mongering?", "explanation": "We\u2019re going to give the story the benefit of the doubt. There wasn\u2019t any overt disease mongering of the significance of diabetes, obesity and heart disease. The first sentence made an important point \u2013 that the diet \u201chelps improve several risk factors\u201d \u2013 but the emphasis could have been placed more strongly on the fact this impacted RISK\u00a0FACTORS \u2013 not necessarily end-organ endpoints.\u00a0 The point could also have been made that metabolic syndrome itself is not a disease.\u00a0 We could have gone either way on this one.", "answer": 1}, {"article": "LOS ANGELES (Reuters) - Scientists for the first time have used gene therapy to successfully destroy cancer tumors in patients with advanced disease \u2014 a goal that has taken 20 years to achieve.\nIn addition, the long-term viability of the treatment is still unknown.\nWe are going to give you an immune response,\u201d Kalos said.\n\u201cWe are saying forget about stimulating an immune response.\nThe treatment appears safe, but researchers said more study was needed.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease-mongering.", "answer": 1}, {"article": "\"This is the largest clinical study done in the world on conventional electrodes and will have major implications for doctors and their patients who need their long-term hearing restored,\" said the study's lead investigator, George Wanna, MD, Site Chair, Department of Otolaryngology-Head and Neck Surgery at New York Eye and Ear Infirmary of Mount Sinai (NYEE) and Mount Sinai Beth Israel; Chief, Division of Otology-Neurotology and Director of the Center for Hearing and Balance and Ear Institute at Mount Sinai Health System.\nMore specifically, the non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\nThey reported that patients who had the round window approach had a much better chance of keeping their residual hearing in the long term.\n15 nationally in the 2016-2017 \"Best Hospitals\" issue of U.S. News & World Report.\n\"Our results also revealed that using oral steroids also helped in the long term to preserve hearing by preventing inflammation.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "No obvious disease mongering here.", "answer": 1}, {"article": "The academy now takes a neutral stance.\nBut another from the United States gives more weight to findings from Africa that show the procedure, when it's performed on adult men, makes a major difference in preventing such diseases as AIDS.\nFor now, he said, when it comes to circumcision, \"we know it's pretty safe, and we have a lot of evidence for some benefit.\"\nDr. Matthew Golden, an associate professor of medicine at the University of Washington Center for AIDS and STD, said the ideal study would randomly assign thousands of infants to either get circumcised or not get circumcised and then follow them for decades.\nIn general, \"there is still a lot of uncertainty surrounding the risks and benefits of circumcision,\" said Dr. Douglas S. Diekema, a pediatrician at the University of Washington who's familiar with both reviews and serves on a task force working on the academy's recommendations.\n", "question": "Does the story commit disease-mongering?", "explanation": "\nWhile studies have found that circumcised men in Africa have a lower risk of contracting HIV compared to uncircumcised men, this piece points out that these results may not translate to the U.S., as AIDS is much less prevalent here. Furthermore, in Africa, HIV is primarily spread by heterosexual sex, whereas, in the U.S., men who have sex with men make up the majority of newly diagnosed cases, a point that could have been made here.\u00a0\n\n", "answer": 1}, {"article": "\u201cBut if adults believe in echinacea, they\u2019re going to get benefits \u2014 maybe from placebo \u2014 but they\u2019ll get benefits.\u201d\n\nDr. Coleman, who described himself as \u201cnot much of a pill taker,\u201d hedged a bit when asked if he planned to use echinacea himself.\nSome might not have a large enough sample to find a small but statistically significant effect.\nFor example, they did not examine the safety of the herbal remedy, only its effectiveness.\nIn addition, some studies might not use large enough doses of the herb; others might use a species of echinacea that is less effective.\n\u201cI\u2019ll probably consider taking it if I feel a cold coming on,\u201d he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not exaggerate the effects of colds or the value of the treatment. ", "answer": 1}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story commit disease-mongering?", "explanation": "We judge the story unsatisfactory on this criterion for two reasons: ", "answer": 0}, {"article": "BOSTON (Sept. 14, 2016) -- Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time.\nIt offers a promising approach to shortening the duration of therapy in order to achieve a cure.\nDrugs that target the protein are currently being tested in clinical trials for other cancers.\nAlthough second- and third-line targeted therapies can often return the disease to remission, some patients don't benefit from these drugs or develop severe side effects.\nIf successful, the cost savings of such an approach could also be significant.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "We\u00a0don\u2019t\u00a0see\u00a0anything that would scare a reader.", "answer": 1}, {"article": "But are they receiving it?\nThe risk differentials are huge, but this is simply not known by a vast majority of those whose lives are at risk,\u201d adds Sweanor.\nWhen it comes to learning about the differences in risk among certain types of nicotine products, many government websites are actually misleading or under-informing the public, according to two researchers who analyzed the content of numerous health websites.\nThis fear, however, is not based on actual evidence and cannot be used to suppress or otherwise keep the public uninformed of what is clearly known about the lower risks of these products,\u201d adds Kozlowski, PhD, one of the world\u2019s leading researchers on smoking behavior.\nA briefing posted on the site specifically states: \u201cCompared to tobacco products, electronic cigarettes are significantly safer.\u201d\n\nIn their paper, the researchers note that information on comparative risks is common for other products and activities, like over-the-counter medicines and even safety ratings of vehicles.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not take part in disease mongering. The release might have been stronger had it included some figures on the number of people who smoke and how many use smokeless products.", "answer": 1}, {"article": "Still, the failure rate was similar to the failure rate of the IUD when used during the five-year period (which is under 1%).\nThe women were informed of the pregnancy risk associated with using their device longer than recommended, and the researchers called them for followup every 6 months for 36 months or until the women had their device removed.\nAll the women were between the ages of 18 and 45 and their contraceptives were within six months of expiring before they enrolled in the study.\nThe study is still continuing, and it could be quite a long time before any changes to clinical recommendations are considered.\nThe longer use also makes the IUD and implant more convenient for women, since maintenance is reduced.\n", "question": "Does the story commit disease-mongering?", "explanation": "Unintended pregnancy is a real problem, both medically and socially, so the story might have made an even bigger deal out of this.", "answer": 1}, {"article": "\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\nThey were designed for adults, and adults have very different physiological states than adolescents.\nI called him to be sure.\nOf course, having an effective intervention once it is recognized would help.\n\u201cOnly if the discounted benefit outweighs the boosted harm should the treatment be prescribed,\u201d he writes.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "(PHILADELPHIA) -- When patients present with neurologic symptoms such as severe headaches or seizures, the symptoms could suggest anything from infection, cancer, or an autoimmune disease of the brain or spinal cord, leaving physicians scrambling to find the cause in a short amount of time.\nThe diagnostic could prove particularly useful in infants and young children.\nThe differences in diagnosis can mean having mere hours to act or being able to take days or weeks to devise a treatment plan.\n\u201cCytokines are an alarm system in the body,\u201d said Dr. Curtis.\n\u201cInfants and young children have an especially high risk of meningitis and encephalitis and the related, often serious sequelae,\u201d said Dr. Curtis.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We didn\u2019t note any sensational language.", "answer": 1}, {"article": "(CNN) The first large head-to-head comparison of two opioid addiction medications found that, although they were equally effective in getting people off of high levels of opioids, users had a significantly more difficult time starting a regimen of naltrexone, compared with buprenorphine.\n\"They bind to prevent withdrawal, giving some opiate effect,\" he said.\nJust like any other medication, some people are going to feel right with one as opposed to the other.\"\nWithout the opioids, people can go into withdrawal, all contributing to a cycle of dependency.\nBuprenorphine and methadone, which are opioids, work by reducing people's cravings.\n", "question": "Does the story commit disease-mongering?", "explanation": "CDC death estimates from opioid overdose in the United States are included, and the story did not disease monger the problem.", "answer": 1}, {"article": "He is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\nScientists suspect that egg protein may be better at making people feel full longer compared to the protein found in wheat.\nFor people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\nOne large egg has about 70 calories, and it contains about 6 grams of protein, 5 grams of fat, and 186 milligrams of cholesterol.\nIn a small study, it took longer for people who ate eggs for breakfast to show signs of hunger than it did for those who had a bowl of ready-to-eat cereal.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "She also is studying the health effects of teaching the skills to individuals with type 2 diabetes, women with metastatic breast cancer and caregivers of dementia patients.\nThis can lead to increased positive affect in the face of stress \n\n7) Understanding small acts of kindness can have a big impact on positive emotion and practicing a small act of kindness each day \n\n8) Practicing mindfulness with a daily 10-minute breathing exercise, concentrating on the breath\n\nFifteen months after the interventions, 91 percent of the intervention group had a suppressed viral load compared to 76 percent of the control group.\n\"Even in the midst of this stressful experience of testing positive for HIV, coaching people to feel happy, calm and satisfied -- what we call positive affect -- appears to influence important health outcomes,\" said lead author Judith Moskowitz, professor of medical social sciences and director of research at the Osher Center for Integrative Medicine at Northwestern University Feinberg School of Medicine.\nFor the HIV study, which was based in San Francisco, 80 participants (primarily men) were taught a set of eight skills over five weekly sessions to help them experience more positive emotions.\nOr, the reduced viral load may be the result of participants' better adherence to their antiretroviral drug therapy, which generally leads to a suppressed or undetectable viral load, Moskowitz said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering. The release provides a little context about previous research in this area but some background on the numbers of people living with HIV, or the number of new cases diagnosed each year would have been useful to readers.", "answer": 1}, {"article": "But given the 2013 research suggesting \u201ctoxicity of high coffee doses\u201d in some people, he said, \u201cto me the most reasonable approach would be to keep coffee intake to two to three cups most days.\u201d\n\nSecond Take: STAT knows better than to get between coffee lovers and their cup o\u2019 joe, so if you want to take this study as permission to keep beating a path to your Keurig, we\u2019re not going to slow you down.\n.\n.\nOverall, the conclusions have been pro-coffee.\nMore likely, yes, but don\u2019t count on it.\n", "question": "Does the story commit disease-mongering?", "explanation": "None here.", "answer": 1}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nNow that's trickier.\nAnd they consider themselves lucky.\nNo biggie--just zip to your local supermarket and pick up a carton.\nGot raw milk?\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "The combination allowed many women with metastatic hormone-receptor-positive, HER2-negative cancer to delay the start of chemotherapy, which is the traditional treatment option in these patients once hormone drugs have stopped working.\nThe study also aimed to assess whether cancers with particular genetic traits responded less well or better to the combination than others.\nThis trial is an exciting example of one of the most promising approaches to overcoming drug resistance, by combining drugs with different mechanisms of action to block off cancer's escape routes.\nSome 19 per cent in the palbociclib plus fulvestrant group had a decrease in tumour size compared with 9 per cent in the placebo plus fulvestrant group.\nWe hope our results lead to the adoption of this drug combination in breast cancer, where it delays the need to start chemotherapy by an average of nine months.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not commit any disease-mongering related to the specific type of breast cancer considered in the study.", "answer": 1}, {"article": "It's the first study to specifically examine...\nA study published in this month's issue of the Archives of Neurology found that the diet might protect against blood-vessel damage in the brain, reducing the risks of stroke and memory loss.\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story commit disease-mongering?", "explanation": "One might argue that the story inflated the potential role of white matter hyperintensities, but we\u2019ll give the story the benefit of the doubt on this one.", "answer": 1}, {"article": "Miguel A. Mart\u00ednez-Gonz\u00e1lez, M.D., of the University of Navarra in Pamplona and CIBEROBN in Madrid, Spain, and coauthors analyzed the effects of two interventions with the Mediterranean diet (supplemented with extra virgin olive oil [EVOO] or nuts) compared with advice to women to follow a low-fat diet.\nPreventive strategies represent the most sensible approach against cancer.\nBreast cancer is a frequently diagnosed cancer and a leading cause of death in women.\nNevertheless, these results need confirmation by long-term studies with a higher number of incident cases,\" the authors conclude.\nThe women were an average age of 67.7 years old, had an average body mass index of 30.4, most of them had undergone menopause before the age of 55 and less than 3 percent used hormone therapy.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release offers no evidence of disease-mongering.", "answer": 1}, {"article": "Newswise \u2014 SAN FRANCISCO \u2013 A diet rich in vitamin C could cut risk of cataract progression by a third, suggests a study being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.\nThe research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\nThe fluid inside the eye is normally high in vitamin C, which helps prevents oxidation that clouds the lens.\nAbout the American Academy of OphthalmologyThe American Academy of Ophthalmology is the world\u2019s largest membership association of eye physicians and surgeons.\nMore vitamin C in the diet may increase the amount present in the fluid around the lens, providing extra protection.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease mongering.", "answer": 1}, {"article": "The disease is caused when a gene called MLL gets fused to another gene.\n\u201cAlthough this research is only in the lab at the moment, we hope it will move quickly toward clinical trials in patients.\u201d\n\nLeukemia is the most commonly diagnosed cancer in children and accounts for a around a third of all cancers diagnosed in children.\n\u201cIt is important to remember we will need to be successful on a number of additional steps before we can move this from the lab to testing this compound in humans.\u201d\n\nMLL leukemia is thought to account for up to 80 percent of cases of acute leukemia in children below two years old, and up to one in 10 cases in adults.\nKouzarides\u2019s team found that in the disease, the MLL-fusion proteins are targeted to leukemia-causing genes by proteins from the BET family, which recognize certain chemical \u201ctags\u201d on chromatin, the scaffold on which DNA is arranged.\nAccording to Cancer Research UK, eight out of 10 children with leukemia in Britain now survive for five years or more, compared with one in 10 in the late 1960s.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story suggests (as did the news release upon which it was based) that up to 80% of leukemia cases in patients under the age of 2 years involve the MLL fusion protein. Important as this is, it is a bit misleading to the average reader. \nAccording to the National Cancer Institute the variant is present in up to 5% of childhood acute lymphoblastic leukemia cases\nThe decision to focus on the 80% number can be viewed as disease mongering because it has the clear potential to inflate the importance of the findings.", "answer": 0}, {"article": "\"This study contributes to growing evidence that ADHD medication is linked to lower risk for many types of harmful behavior, including substance abuse,\" said Patrick D. Quinn, a postdoctoral researcher in the IU Bloomington College of Arts and Sciences' Department of Psychological and Brain Sciences, who led the study.\n\"The results also highlight the importance of careful diagnosis and compliance with treatment.\"\nLarsson is also affiliated with \u00d6rebro University in Sweden.\nA significantly smaller number used nonstimulant ADHD medication such as Strattera, or atomoxetine.\nOverall, I think people should find these results reassuring.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering in this release.", "answer": 1}, {"article": "The researchers did not observe any side effects.\nHPV causes about 5% of cancers globally.\nThe vaccine consists of three injections in the arm over three months, Kim said.\nEighteen women with high-grade precancerous cervical lesions participated in the phase 1 study.\nThe study was not done as a randomized controlled trial, the gold standard for determining whether a drug works better than chance.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not appear to commit disease mongering.", "answer": 1}, {"article": "Newswise \u2014 CHAPEL HILL, NC \u2013 For patients whose hearing is considered \u201ctoo good\u201d for traditional cochlear implants, but whose hearing loss is too advanced to benefit from hearing aids, there hasn\u2019t been a device to meet their needs.\nThe SYNCHRONY EAS implant best assists people whose hearing loss is referred to as \u201cski-slope\u201d hearing loss, based on the steeply sloping image that appears on an audiogram when a patient has more trouble hearing higher-frequency sounds.\nBut a hearing implant system that just received FDA approval will now meet that previously unmet need and benefit those patients, according to Harold C. Pillsbury, MD, chair of the Department of Otolaryngology/Head and Neck Surgery at the UNC School of Medicine.\n\u201cThe technology is remarkable and so were the results.\u201d\n\nThe implant relies on two auditory technologies \u2013 the SYNCHRONY cochlear implant that stimulates the auditory nerve for high-frequency hearing loss and the EAS audio processor, which has a built-in acoustic amplification for low-frequency hearing loss.\nNinety-two percent of participants reported an improvement in their ability to hear even among background noise, one of the most challenging listening environments for people with hearing loss.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no mongering and to its credit, the release provides concrete statistics on the prevalence of hearing loss. But there is some evidence of \u201cbenefits mongering.\u201d", "answer": 1}, {"article": "LONDON (Reuters) - In an analysis that set off a fierce debate over the health effects of salt, researchers said on Wednesday they had found no evidence that small cuts to salt intake reduce the risk of developing heart disease or dying prematurely.\nThis gave the researchers enough data to be able to start drawing conclusions, they said.\nThe researchers said they suspected the trials conducted so far were not big enough to show any benefits to heart health, and called for large-scale studies to be carried out soon.\n\u201cThe people in the trials we analyzed only reduced their salt intake by a moderate amount, so the effect on blood pressure and heart disease was not large,\u201d he said.\nHigh blood pressure, or hypertension, is a major risk factor for cardiovascular diseases \u2014 the leading causes of death worldwide.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not engage in overt disease mongering.", "answer": 1}, {"article": "\u201cThis is an important finding,\u201d said co-lead researcher Prof David Murray.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\nAbout half of all patients should be suitable for a partial replacement, but an analysis of data routinely collected by the National Joint Registry showed that of 98,147 knee replacements undertaken in 2016, only 9% were partial.\n\u201cThe main strength of this study is that we were able to use real data, from very large numbers of people, about their actual operations, their GP visit, and their own reported quality of life outcomes in a way that is not always possible,\u201d said Dr Rafael Pinedo-Villanueva, the co-lead researcher and NDORMS senior health economist, who is funded by the National Institute of Health Research Oxford Biomedical Research Centre and the Medical Research Council.\nThe NHS, however, needs to get the support of surgeons, many of whom rarely carry out the less invasive procedure.\n", "question": "Does the story commit disease-mongering?", "explanation": "One possible concern here would be that there is an assumption that surgery \u2014 either partial or total replacement \u2014 is a foregone conclusion for patients who have osteoarthritis of the knee. That\u2019s not true \u2014 there are other treatment options available. However, the story doesn\u2019t quite say that. It instead says that osteoarthritis is \u201cthe main reason for [knee replacement] surgery.\u201d Because there are certainly cases of osteoarthritis where replacement, or partial replacement, are indicated \u2014 and it can be inferred that the story is referring only to those cases \u2014 this gets a satisfactory rating.", "answer": 1}, {"article": "Still, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nMalignant cells had spread throughout her body.\nAll patients had inoperable cancers with widespread tumors after conventional treatment.\nThen after several months the tumors began to shrink.\nSerious side effects also became clear.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in this story. ", "answer": 1}, {"article": "And patients may need to continue treatment.\nFor more than 100 years, the Lighthouse has been the leader worldwide in helping people of all ages who are blind or partially sighted overcome the challenges of vision loss.\n\"These symptoms were these wavy lines \u2014 and especially on the periphery of your vision,\" says macular generation patient Daniel Davison.\nThe thought that you could lose your vision is very, very depressing,\" Daniel says.\n\"The short-term course, is excellent so far \u2014 beyond our wildest expectations, says Dr. Lawrence Yannuzzi a leading macular generation specialist.\n", "question": "Does the story commit disease-mongering?", "explanation": "By accurately describing the prevalence and seriousness of AMD, the story avoids disease mongering. However, the story could have been more clear about the difference between the \u201cwet\u201d and \u201cdry\u201d forms of the disease.", "answer": 1}, {"article": "The first CT scan was OK.\nBut over time, periodic scans revealed a small growth in Burton's lungs.\nNearly 175,000 Americans will be diagnosed with lung cancer this year.\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\nA chest X-ray showed nothing suspicious.\n", "question": "Does the story commit disease-mongering?", "explanation": "By accurately describing the prevalence and seriousness of lung cancer, the story avoids disease mongering.", "answer": 1}, {"article": "For the process they used recombinant human collagen, a substance synthesized in the laboratory to mimic human tissue and supplied by the San Francisco biotech firm FibroGen Inc.\n\u201cWith further research, this approach could help restore sight to millions of people who are waiting for a donated human cornea for transplantation.\u201d\n\nThe cornea is a tiny piece of transparent, film-like tissue that covers the surface of our eyes.\nThe researchers found that, eventually, the cells and nerves from nine of the 10 patients regrew completely and packed themselves into the implant, resulting in a kind of \u201cregenerated\u201d cornea that looked and functioned like normal, healthy eye tissue.\n\u201cThis study ... is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\u201d said May Griffith of the Ottawa Hospital Research Institute, who led the study.\nThe scientists, whose work was published Wednesday in the Science Translational Medicine journal, said their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation.\n", "question": "Does the story commit disease-mongering?", "explanation": "Because of the tone of the story and the focus on the \"millions\" who might be saved from blindness and not on the limitations of the study, this story veers into disease mongering. It says, \"Loss of vision due to corneal disease or trauma affects over 10 million people a year, but lack of access to donor tissue limits the number of transplants, particularly in poorer countries. In the United States, an estimated 42,000 corneal grafts a year are performed using tissue from posthumous donors, but there are sometimes problems with rejection and experts say failure rates are significant.\" Both of these statistics needed attribution, especially given that there are conflicting statistics in other coverage of the same study. The statistics do not come from the press release.", "answer": 0}, {"article": "ZURICH (Reuters) - An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.\n\u201cThese data have the potential to allow physicians to address an unmet need in this patient population by using a biomarker-driven treatment to inform their sequencing decisions,\u201d Andre added.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\nLike other companies, Novartis is seeking to personalize treatment for cancer patients by using biomarkers like those showing PIK3CA gene mutations to help guide treatment.\nEven though PIK3CA mutations are the most common genetic change in hormone-receptor positive breast cancer, trials of agents seeking to put a brake on this pathway to tumor growth have largely disappointed including on safety issues.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article provides sufficient information to make clear that this is a treatment for a specific group of women with breast cancer with this\u00a0PIK3CA mutation. More could have been said about what percent of breast cancer patients this may represent, though.", "answer": 1}, {"article": "The blood test that millions of men undergo each year to check for prostate cancer leads to so much unnecessary anxiety, surgery and complications that doctors should stop testing elderly men, and it remains unclear whether the screening is worthwhile for younger men, a federal task force concluded yesterday.\nOthers were highly critical, noting that prostate cancer death rates have plummeted in many countries after they instituted widespread PSA screening.\nEach year, prostate cancer is diagnosed in more than 218,000 U.S. men.\nEven when the test picks up a real cancer, doctors are uncertain what, if anything, men should do about it.\nThe PSA test, which measures a protein in the blood produced by prostate tissue, has significantly increased the number of prostate cancer cases being diagnosed at very early stages.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering. It put the natural history of most prostate cancers into appropriate context. ", "answer": 1}, {"article": "[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\nThe study is the first to show that a point-of-care EVD test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional laboratory-based molecular method used for clinical testing during the recent outbreak in Sierra Leone.\nThe authors caution that given the limitations of the performance of the altona RT-PCR reference test in patients with low levels of the virus in their blood, more research is needed to assess how the new RDT will perform in patients very early in the course of EVD.\nThe RDT detected all confirmed cases of EVD that were positive by RT-PCR in both point-of-care (28/105 patients) and laboratory testing (45/277 patients), with sensitivity of 100% (identifying all patients with EVD as per the benchmark method), and a specificity of 92% (identifying patients who didn't have EVD).\nAlthough the RDT requires refrigeration, this is already available in many health centres in endemic areas, particularly those that store vaccines and other medical products.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "No excessively scary descriptions of Ebola virus infections are anywhere to be found. But because the release didn\u2019t include\u00a0any general information\u00a0about EVD, it has an opposite problem \u2014 a journalist might not grasp the scope and urgency\u00a0of controlling outbreaks, and how intimately a new test might play a role. For example, few understand that there continues to be widespread transmission that is poorly controlled in Guinea in particular. We\u2019ll rate this Satisfactory with reservations.", "answer": 1}, {"article": "TUESDAY, Jan. 31, 2017 (HealthDay News) -- A breath test to detect stomach and esophageal cancers shows promise, researchers say.\nEach year, 1.4 million cases of cancer of the stomach and esophagus (the tube leading from the throat to the stomach) are diagnosed worldwide.\n\"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\nBoth tend to be diagnosed at a late stage and the five-year survival rate for the two cancers is 15 percent, the researchers said.\n\"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here. We were glad to see the story discuss the prevalence of these cancers.", "answer": 1}, {"article": "(Philadelphia, PA) - Reversing memory deficits and impairments in spatial learning is a major goal in the field of dementia research.\nThe study is especially exciting because zileuton is already approved by the Food and Drug Administration for the treatment of asthma.\nWhen the animals were 12 months old, the equivalent of age 60 in humans, they were treated with zileuton, a drug that inhibits leukotriene formation by blocking the 5-lipoxygenase enzyme.\n\"Leukotrienes are in the lungs and the brain, but we now know that in addition to their functional role in asthma, they also have a functional role in dementia,\" Dr. Pratic\u00f2 explained.\nIn addition, levels of phosphorylated and insoluble tau, the form of the protein that is known to directly damage synapses, were 50 percent lower in treated animals.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering here. But nor does the release provide any context on the prevalence of Alzheimer\u2019s.\n\u00a0", "answer": 2}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "Since the focus is on prostate cancer, more information about the natural history of prostate cancer, particularly early prostate cancer should be given. Importantly, there is no mention that early prostate cancer may not even need to be treated and that a man may survive just as long with or without treatment, which would make the distinction between which way to \u201cslice and dice\u201d the prostate less important. Unfortunately, researchers can\u2019t predict which prostate cancers will eventually harm a man or even whether treatment for early prostate cancer is beneficial. ", "answer": 0}, {"article": "(Reuters) - Eli Lilly and Co\u2019s new Jardiance pill slashed deaths by 32 percent in patients with type 2 diabetes at risk of heart attack and stroke, a finding that could make it a mainstay diabetes treatment and triple its use, according to researchers and analysts.\n\u201cThis is the first diabetes therapy to show robust effect in reducing cardiovascular death.\nType 2 diabetes is the most common form of the disease and is linked to obesity.\n\u201cThe big news here is that the drug reduced cardiovascular stuff.\nThere was no significant difference in non-fatal heart attacks or non-fatal strokes.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no evidence of disease mongering in the story.", "answer": 1}, {"article": "UW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nUW team shows progress in search for new antibiotics\n\nCollecting bugs across the globe is paying off for a multidisciplinary research team at the University of Wisconsin-Madison.\nThomas Mackie to lead new joint innovation initiative between UW Health and School of Medicine and Public Health\n\nUW Health has selected Thomas \u201cRock\u201d Mackie to be the inaugural leader of the health system\u2019s innovation initiative, which it is pursuing in partnership with the UW School of Medicine and Public Health.\nThe Wisconsin Partnership Program at the University of Wisconsin School of Medicine and Public Health has awarded $750,000 to 15 community-driven projects to catalyze innovative ideas to improve health equity in Wisconsin.\nOn a beautiful September Sunday, hundreds of bicyclists pedaled the roads of eastern Dane County on The Ride to raise money for cancer research.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release did not exaggerate the impact of Alzheimer\u2019s disease.", "answer": 1}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\nThe researchers found that even former heavy smokers appear to have a reduced incidence of lung cancer if their initial LDCT screening is negative, suggesting that less frequent screening might be warranted.\nThey then compared those patients to other CT-scan recipients whose screenings detected an abnormality to assess any differences in lung cancer incidence and lung cancer-specific deaths.\nThe researchers identified study participants in the CT-scan group whose initial screening was negative.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. This was a balanced news release.", "answer": 1}, {"article": "Calcium recommendations vary according to age.\nThe message here, Senay says, is that calcium supplements are useful for bone health \u2014 but you should only take them if you do so regularly, as directed by a doctor.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nRemember, Senay urged: Most people can achieve the recommended calcium intake by eating three or four servings of dairy products and other foods that contain calcium per day.\nNow, says Senay, a study in the Archives of Internal Medicine shows calcium supplements do reduce the risk of fractures in elderly women, but only among those who take them regularly.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story exaggerates the seriousness of osteoporosis and osteopenia (low bone mass). When we are told that \u201c34 Million Americans have low bone mass,\u201d we have to wonder, how is this defined? What is the seriousness of this condition? We are also told that \u201c1 in 2 women will suffer a fracture in her lifetime.\u201d How many of these fractures are attributable to osteoporosis or osteopenia? While these two statements may be factual, the manner in which they are presented overstates the problem and only serves to alarm the viewer.", "answer": 0}, {"article": "WASHINGTON (Reuters) - The U.S. Food and Drug Administration took a fresh step on Thursday towards setting a maximum nicotine level for tobacco products in a bid to lower tobacco-related deaths across the country, saying it would collect public comment and scientific research over the next three months.\n\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\n\u201cThere is no other single action our country can take that would prevent more young people from smoking or save more lives,\u201d said Matthew L. Myers, president of Campaign for Tobacco-Free Kids.\nMajor tobacco players such as Altria Group and British American Tobacco are grappling with sales declines in the U.S. market and hoping to recoup revenue through novel tobacco and nicotine products such as e-cigarettes.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here. Smoking is the leading cause of preventable deaths, according to the CDC.", "answer": 1}, {"article": "After surgery to remove the bulk of the brain tumor, Badie and his colleagues directly injected the site with the modified immune cells (called chimeric antigen receptor T cells, or CAR T cells) six times, and the remaining part of this tumor stopped growing.\nThe tumors in the first patient remained under control for almost eight months, but the cancer returned after that in new parts of the brain.\nBut after being treated with the immune therapy, his cancer did not grow or recur for nearly eight months.\nThe man did not develop such serious complications, however, and after about four months, these tumors too started to shrink.\nBadie is hoping to take advantage of this information and introduce immune cells with different tumor-targeting proteins.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not disease-monger about glioblastoma, a very deadly form of brain cancer.", "answer": 1}, {"article": "Servan-Schreiber offered more words of wisdom to LaPook -- words he says doctors rarely impart to their patients -- and LaPook discussed with co-anchor Harry Smith on The Early Show Friday why he thinks it is that cancer survivors aren't offered more guidance by the medical establishment:\n\nServan-Schreiber appears in the joint CBS, NBC, ABC special \"Standing Up To Cancer\" Friday night.\n\"There's tremendous evidence that physical exercise helps prevent cancer, and also helps people who already have cancer prevent a recurrence,\" he says.\nIn addition, LaPook spoke with several other cancer patients who told him they're left in the dark, too, about how exercise and eating the right foods might help them in their battles against the disease:\nHe has penned the best-selling book, \"Anti-Cancer: A New Way of Life,\" about his past and on-going battle, and offers suggestions to fellow cancer patients.\nAnd then everybody asks their doctor ... and this is when 99 percent of us get the standard answer, which is, 'Nothing in particular.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of cancer and thereby avoids disease mongering. However, it would have been nice if the story had been more clear about different types of cancer in which there may be more or less evidence of an effect of diet. To lump them all together is a gross oversimplification.", "answer": 1}, {"article": "They all drank caffeine regularly.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\n\u201cThe more caffeine people consumed, the more protected they were against a chronic state of inflammation,\u201d says study author David Furman, consulting associate professor at the Institute for Immunity, Transplantation and Infection at Stanford University.\nIn an upcoming study, Furman and others will soon investigate the immune systems of 1,000 people; he hopes to use that information to develop a reference range of immune-system components to tell people whether their levels are normal, or if they\u2019re at higher risk for developing chronic conditions driven by inflammation.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story says that inflammation \u201cdrives many, if not most, major diseases.\u201d Further, the story states that \u201cdiabetes, hypertension, heart problems, cancer, joint disorders and Alzheimer\u2019s, are all believed to have inflammation in common.\u201d There is some truth here. As a 2014 paper in Nature Reviews Drug Discovery notes, \u201cThe role of inflammation in the pathogenesis of type 2 diabetes and associated complications is now well established.\u201d Similarly, inflammation is associated with some cancers. However, sweeping statements should be supported by solid evidence \u2014 and this one stretches the point. For example, the American Heart Association notes that \u201cAlthough it is not proven that inflammation causes cardiovascular disease, inflammation is common for heart disease and stroke patients and is thought to be a sign or [sic] atherogenic response.\u201d (Note: atherogenic describes something that tends to promote fatty plaque in the arteries.) So, is inflammation a risk factor for heart disease? Many doctors believe so. Does it \u201cdrive\u201d heart disease? That depends on what \u201cdrive\u201d means \u2014 inflammation hasn\u2019t been shown to cause heart disease in itself. Lowering inflammation hasn\u2019t been proven to prevent it. And that\u2019s why vague language is so problematic when writing about health-related research. This is, in part, why the \u201cdisease mongering\u201d category exists \u2014 to ensure that vague writing (not only blatantly incorrect writing) doesn\u2019t lead to increased fears among readers who don\u2019t fully understand the state of the research.", "answer": 0}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. However, it could have been more clear in conveying the number of breast cancer patients who might be candidates for this drug. It states:\n\u201cAbout 250,000 people each year are diagnosed with breast cancer and just over 40,000 die from it, according to the National Cancer Institute. About 20 percent to 25 percent of patients with hereditary [emphasis added by us]\u00a0breast cancers have a BRCA mutation. BRCA-related breast cancer often strikes younger people and is harder to treat than other breast cancers.\u201d\nThe story doesn\u2019t say how many people diagnosed with breast cancer actually have a BRCA mutation. According to ASCO, \u201cUp to 3% of all breast cancers occur in people with inherited changes in genes BRCA1 and BRCA2.\u201d", "answer": 1}, {"article": "For more information, please visit http://www.\nDr. Kwik-Uribe went on to speak about Mars' flavanol research program that has spanned over two decades: \"The amount of research showing the beneficial effects of cocoa flavanol consumption is growing and Mars is proud to be a partner in important research like this that highlights the positive role cocoa flavanols may play in supporting healthy aging.\"\nDr. Giovambattista Desideri, lead author on the paper, said, \"The results of this study are encouraging--they support the idea that diet, and specifically a diet rich in cocoa flavanols, can play an important role in maintaining cognitive health as we age.\"\nThe first study, published in the journal Hypertension in 2012, found cognitive and cardiometabolic benefits of habitual cocoa flavanol consumption in older adults who had been diagnosed with mild cognitive impairment (MCI).\nEnrolling men and women aged 61-85 years with no evidence of cognitive dysfunction, the participants in this controlled, randomized, double-blind study were assigned to one of three flavanol groups, consuming a drink containing either high (993 mg), intermediate (520 mg) or low (48 mg) amounts of cocoa flavanols every day for eight weeks.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release sets the right tone at the beginning and continues throughout describing loss of cognitive function dispassionately. In fact, we\u00a0wish more stories treated aging this way: \u201cIt is normal for cognitive function to slightly deteriorate with age. Memory capacity begins to worsen, along with processing speed and the ability to form long-term memories.\u201d", "answer": 1}, {"article": "But the limit is tricky to impose.\nSher's ethics board said OK.\n\n\"And she went ahead and had a baby at 57 years of age without any problems whatsoever,\" Sher says.\n\"My best friend and I made a pact together that at age 38, if we were both still single, we were going to have a child on our own,\" says Robyn Ross.\n\"There should be guidelines, I think, that are more clearly defined,\" says Dr. Geoffrey Sher, who heads the Sher Institutes for Reproductive Medicine and is based in Las Vegas.\nAnd the uterus doesn't decline like eggs do; in some cases, it can actually be coaxed back into working order.\n", "question": "Does the story commit disease-mongering?", "explanation": "Our medical editor who reviewed this story felt there were elements of disease-mongering in the framing of the story. She wrote:\u00a0\u201cI am not sure that waiting until you are out of the window for a specific biologic function is a disease. The story framing almost makes a disease out of a life choice in this particular example of women who want to risk waiting until they might not be expected to have normal fecundability/fertility and higher risk.\u201d\nIs \u201cNudging Young Women To Think About Fertility\u201d akin to creating a new disease that\u2019s not really a disease?", "answer": 0}, {"article": "\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\nThe researchers say 63% of the women who received depression-specific acupuncture reported a significant reduction in symptoms, compared to 44% of women in the other two groups combined.\nAll of the women received therapy for eight weeks and were interviewed at the four- and eight-week marks by someone who did not know which treatment they were getting.\nAcupuncture might be a useful alternative, they say, because a study of pregnant women shows that the procedure works in reducing depressive symptoms better than other non-pharmacological techniques.\nMany pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story indicates that 14% of pregnant women may suffer from depression; however, the writer might have also noted that 3-5% of pregnant women have actually been diagnosed. ", "answer": 1}, {"article": "The unique ability for CURATE.AI to rapidly identify the drug doses that result in the best possible treatment outcomes allows for actionable, and perpetually optimised personalised medicine,\" explained Professor Dean Ho, Director of the Singapore Institute for Neurotechnology (SINAPSE) at NUS, who led the study.\nReducing the level of prostate specific antigen (PSA) in the patient's blood served as the primary biomarker to determine if the patient was responding to treatment.\nThis advance is expected to dramatically improve response rates for all combination therapies that are being developed for oncology as well as virtually all other diseases.\nComputed tomography (CT) imaging of the cancer lesions monitored the extent of disease progression.\nWe can also expect CURATE.AI to markedly reduce the costs of drug development,\" Prof Ho added.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. Some context on the prevalence of prostate cancer would have been useful.\n\u00a0", "answer": 2}, {"article": "Second induction for VYXEOS-treated patients was 100u/m2 on days 1 and 3 and the control arm was cytarabine 100mg/m2/day by continuous infusion for 5 days and daunorubicin 60mg/m2 on days 1 and 2 (5+2).\nFor a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2014, subsequent reports on Form 10-Q and 8-K, and other filings by the company with the U.S. Securities and Exchange Commission.\nThe hazard ratio (HR) was 0.69 (p=0.005) which represents a 31 percent reduction in the risk of death versus 7+3.\nIn the intent-to-treat population, Grade 3 or higher, hematologic adverse events were similar for overall infections, febrile neutropenia, and bleeding events.\nThe Company estimates that nearly 70 percent of AML patients are over the age of 60, and approximately 75 percent are intermediate or high risk.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This is a serious disease and there was no evidence of disease mongering. We do learn that in patients over 60 with this disease, \u201cthe 5 year survival rate is less than 10%. In high-risk (secondary) AML, overall survival is lower\u2026\u201d", "answer": 1}, {"article": "For Patients and the General Public:", "question": "Does the news release commit disease-mongering?", "explanation": "Aggressive subtypes of breast cancers are common, serious diseases with fewer treatment options and are highly worthy of public attention.", "answer": 1}, {"article": "(CNN) Corey Thomas admitted to his pharmacist that he hated the blood pressure medications a previous doctor had prescribed for him.\nThe men, 35 to 79 years old, had systolic blood pressure of 140 or more.\nShe then helped Thomas find a medication better suited for his body.\n\"No one wanted to do it,\" he said.\n\"They understood that we were there with good intentions.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The study found that, among the women treated with the hormones, there was an increased risk of heart attacks, strokes, blood clots and, most frightening of all to many women, a slightly higher risk of breast cancer among those randomized to take the leading H.R.T.\nAmong these older women, it found no such effect.\n\u201cThe pendulum has swung too far,\u201d she said.\nThere are also lots of products now available and different ways to use them that enhance the safety of hormone replacement.\n\u2014 to counter them.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "A report on the researchers' work was published in the Sept. 2 issue of the New England Journal of Medicine.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nFor the study, a research team led by Dr. Catharina C. Boehme, of the Foundation for Innovative New Diagnostics in Geneva, Switzerland, used the Xpert MTB/RIF test on 1,730 patients suspected of having drug-sensitive or multidrug-resistant pulmonary tuberculosis.\nThe test costs about $63 in Europe, but the company has agreed to provide it for less than half that in poor countries, said John Bishop, Cepheid's chief executive officer, as quoted in a story by the Associated Press.\n\"The test that we developed finally makes it possible to detect TB in a single clinic visit,\" Dr. David Alland, chief of infectious diseases at the UMDNJ-New Jersey Medical School, said in a university news release.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story may be a bit misleading when it states that one third of world\u2019s population is infected with TB.\u00a0This figure includes individuals with latent or inactive TB, which is not the disease diagnosed with the new test.\u00a0However, we don\u2019t feel the\u00a0story overall crossed the line into disease-mongering. \u00a0", "answer": 1}, {"article": "According to Hegde, yoga may curb oxidative stress because it stimulates the parasympathetic nervous system \u2014 the part of the nervous system that basically acts as a brake against the gas pedal of the sympathetic nervous system.\nThe significance of that is not clear.\nIn the real world, yoga classes vary widely.\nIn the U.S., hospitals and local community centers are increasingly offering such classes.\nSome are vigorous work-outs involving complicated poses that would not be appropriate for older adults with chronic health conditions.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease-mongering.", "answer": 1}, {"article": "Investigators conducted a randomized controlled trial in the pediatric Emergency Department at The Mount Sinai Hospital comparing lung ultrasound to chest X-ray in 191 children from birth to 21 years of age.\nFurther research is needed to investigate the impact of lung ultrasound on antibiotic use and stewardship.\nAs more and more handheld ultrasound machines come to market, these results suggest that lung ultrasound has the potential to become the preferred choice for the diagnosis of pneumonia in children.\n\"Ultrasound is portable, cost-saving and safer for children than an X-ray because it does not expose them to radiation,\" says Dr. Tsung.\nFurthermore, the reduction in chest X-rays in the investigational arm resulted in an overall cost savings of $9,200, and length of stay in the Emergency Department was decreased by 26 minutes.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release doesn\u2019t engage in disease-mongering.", "answer": 1}, {"article": "\"Today\u2019s approval marks another step in an important shift toward treating cancers based on their tumor genetics rather than their site of origin in the body,\" said FDA Commissioner Scott Gottlieb, M.D.\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\n\"Accelerated approval\" means that the FDA has fast-tracked the process of getting drugs to patients before the usual clinical trials are completed.\nFor example, immunotherapy drugs can now tag cancer cells so that it's easier for a patient's own immune system to identify and attack them.\nThe search for a cancer cure goes on, but in the meantime, there is hope for more effective treatments.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t explain that this drug is applicable only to a small number of patients\u00a0 \u2014 those who have this rare biomarker and who have seen their tumors progress despite conventional treatment or have no alternative treatments.", "answer": 0}, {"article": "Gulley is director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology, National Cancer Institute.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\n\"In January, it will be four years [for her],\" he tells WebMD.\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\n\"That time frame is not anything to write home about,\" Gulley says.\n", "question": "Does the story commit disease-mongering?", "explanation": "Again, the story deserves high marks for being very specific in the lead and throughout the story. It says, that the vaccine is \u201cfor breast and ovarian cancer that has spread to other parts of the body\u201d in the lead and later details the particular circumstances of the study cohort. It says, \u201cThe patients had already undergone a variety of treatments but the cancer was progressing. Twenty one of the 26 had undergone three or more chemotherapy regimens.\u201d", "answer": 1}, {"article": "As part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\nParticipants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\nThe risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\n\u201cThere\u2019s been a lot of work over the years showing that certain compounds can increase the risk of cancer, but it\u2019s not been shown before that we can reduce the risk with something as simple as aspirin.\u201d\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering.", "answer": 1}, {"article": "The study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\nFive of the participants met the criteria for clinical response and remission.\n\"Further studies are needed to address these questions.\"\n\"The field is in need of new treatment options.\nKetamine has a very different mechanism of action than standard treatments.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "No apparent disease mongering here.", "answer": 1}, {"article": "Decades later, it became popular as a psychedelic club drug.\n\"It became clear to me that the future of psychiatry was going to include ketamine or derivatives of ketamine,\" says David Feifel, a professor of psychiatry at the University of California, San Diego, who began administering the drug to patients in 2010.\nAnd in 2006, a team from the National Institute of Mental Health published a landmark study showing that a single intravenous dose of ketamine produced \"robust and rapid antidepressant effects\" within a couple of hours.\n\"While the science is promising, ketamine is not ready for broad use in the clinic,\" Insel wrote in his blog a few months ago.\nBut the studies of ketamine have produced results so dramatic that some doctors, including Feifel, are bypassing the usual protocols.\n", "question": "Does the story commit disease-mongering?", "explanation": "This ruling is a close call that we\u2019ll ultimately give the benefit of the doubt on. Clearly the gist of the story is that ketamine is something being offered to people with depression so bad that they are thinking about suicide despite having tried all approved treatments. But the key trial highlighted in the story included this strong cautionary note: \u201cAlthough these results are provocative, they may not be generalizable to all populations with depression. The subjects in this study were a refractory subgroup who were relatively late in their course of illness, and as such, their neurobiology and pharmacological responses may be different from those with a less severe or shorter course of illness.\u201d By featuring a man living out in the community (as opposed to a psychiatric facility where the drug was administered in the trial), it\u2019s arguable that this story does just what the researchers warned against.", "answer": 1}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "Scientists had previously observed that cinnamaldehyde, an essential oil that gives cinnamon its flavor, appeared to protect mice against obesity and hyperglycemia.\nTheir findings, which appear in the December issue of the journal Metabolism, indicated that cinnamaldehyde improves metabolic health by acting directly on fat cells, or adipocytes, inducing them to start burning energy through a process called thermogenesis.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\n\"It's only been relatively recently that energy surplus has become a problem,\" Wu said.\nWith the rising obesity epidemic, researchers like Wu have been looking for ways to prompt fat cells to activate thermogenesis, turning those fat-burning processes back on.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering here. Obesity is a problem in the U.S. and around the world in places where food is not scarce. As the news release points our, fat storage is a hedge against starvation, but in economies without starvation, excess fat storage causes obesity and negative impacts on health.", "answer": 1}, {"article": "And studies suggest that fortifying corn masa with folic acid could prevent an additional 40 to 120 cases of neural tube defects among babies born to Hispanic mothers each year.\nThe exact cause of this discrepancy isn't known.\nIt renders the corn more pliable for grinding into masa flour and gives the masa its distinctive aroma and flavor.\nThe catch: Folic acid is only protective if consumed in the earliest weeks of pregnancy.\nAccording to the March of Dimes, about 3,000 pregnancies in the U.S. are affected by neural tube defects each year.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "The researchers previously found that skin cancer survivors and their partners could be trained to spot potentially cancerous moles by doing skin exams.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\n\u201cThere was concern that they might be embarrassed by examining areas of the body that aren\u2019t normally seen close up,\u201d said lead author Dr. June Robinson, of Northwestern University Feinberg School of Medicine in Chicago.\nOverall, the trained group found 51 early melanomas during the study, compared to 18 melanomas found by a comparison group of patients and partners who didn\u2019t receive training.\nThe new study focused on 395 pairs of melanoma survivors who had received training in skin exams in the original study.\n", "question": "Does the story commit disease-mongering?", "explanation": "It\u00a0is well established that early detection of secondary melanomas leads to improved chances of survival.\nThe story could have stressed that it still remains to be fully determined what sorts of follow-up can most efficiently\u00a0lead to early detection of secondary melanomas. Seeing a dermatologist every week might work, but is unlikely to be necessary. Supplementing doctor visits with self or partner skin examinations has evidence of likely benefit in other studies.", "answer": 1}, {"article": "For more information about NIH and its programs, visit http://www.\nAsthmaNet studies are currently being conducted in 14 states.\nThey also did not find any significant differences in safety between the two drugs.\nAll children required daily inhaled treatments to manage their asthma.\nThe study did not detect any worsening of asthma in the children treated with acetaminophen compared with those receiving ibuprofen.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease mongering.", "answer": 1}, {"article": "It is a bold move, but bold moves are what our patients deserve.\"\n\u201cI believe for the first time that we have treatments that are effective enough to make it possible to eradicate multiple myeloma definitively in a substantial proportion of patients, along with having the technology to detect that the disease has been targeted and that treatment can be stopped,\u201d said Luciano Costa, M.D., Ph.D., scientist at the UAB Comprehensive Cancer Center, lead of the Hematologic-Malignancy Working Group, and principal investigator of the MASTER study.\nThe clinical trial Monoclonal Antibody Sequential Therapy for Deep Remission in Multiple Myeloma, also known as MASTER, utilizes next generation sequencing technology to detect minimal residual disease down to a level of one cancer cell in 100,000 \u2014 or 100- to 1,000-fold more sensitive than traditional methods to evaluate response.\nAs it stands, patients with billions of cancer cells in their bodies and patients with true disease eradication will both appear to be in complete remission using current methods to measure disease response to therapy.\nMultiple myeloma is the second most common type of blood cancer in the U.S., impacting more than 25,000 people each year and disproportionatly affecting African-American men.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release cites an accurate number of new multiple myeloma cases (more than 25,000/year), but the lead phrase \u201cMultiple myeloma is the second most common type of blood cancer in the United States\u201d creates an exaggerated impression. The American Cancer Society calls multiple myeloma \u201ca relatively uncommon cancer.\u201d The ACS estimates it accounts for about 2 percent of all cancer cases and deaths.", "answer": 0}, {"article": "Fenfluramine was taken off the market in 1997 after being linked to potentially life-threatening heart valve problems.\nThe drug lorcaserin works on the serotonin receptor -- the same appetite-controlling hormone targeted by the notorious drug fenfluramine, the \"fen\" component of combination medication fen-phen.\nBut lorcaserin is far more selective than the drug fenfluramine and much safer, its manufacturer says, because it specifically targets the serotonin receptor associated with hunger while having no impact on the heart.\nDiet Drug Users Lost Twice as Much Weight The study included about 3,200 obese or overweight adults who were randomly assigned to take 10 milligrams of the diet drug or placebo, twice a day for a year.\nJuly 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\n", "question": "Does the story commit disease-mongering?", "explanation": "This is one of the high points of this story compared to others. Instead of framing the story as \"new hope in the war on obesity,\" it focuses more narrowly on the research. A line about obesity prevalence would have been nice. ", "answer": 1}, {"article": "Most angioplasties not necessary, study finds\n\nNEW ORLEANS \u2014 More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.\nAbout 40 percent had a prior heart attack.\nA tiny balloon is inflated to flatten the clog and a mesh scaffold stent is usually placed.\nHalf of the participants also were assigned to get angioplasty.\nAbout 1.2 million angioplasties are done in the United States each year.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not engage in disease mongering.", "answer": 1}, {"article": "Their findings appear in the Journal of the American Medical Association.\n\u201cThe bad news is that overstating the levels of risk of side effects with these drugs \u2014 which the media have been doing for some time now \u2014 has led people to stop the drugs when they should be taking them,\u201d said Dr. Ethel S. Siris, who heads the Toni Stabile Osteoporosis Center at Columbia University in New York.\nThe findings add to earlier concern over the medicines, called bisphosphonates, whose U.S. labels have been required since October to include a warning about the thighbone fracture risk.\nBut that\u2019s a very rare problem, experts say, which only affects about one in 100,000 people on bisphosphonates.\nApart from atypical fractures, the most serious side effect of the bone drugs is bone death, or osteonecrosis, of the jaw.\n", "question": "Does the story commit disease-mongering?", "explanation": "Good job of avoiding mongering.\nIf anything, the story could have given a line of context regardingwhat a hip fracture truly means as a life-changer for many elderly people. It is common for such a fracture to end independent living and force people into nursing homes for the remainder of their lives. The Centers for Disease Control estimate one in four hip fractures in the elderly results in a year or more in a nursing home.", "answer": 1}, {"article": "William E. Pelham Jr., director of the Center for Children and Families at Florida International University, called neurofeedback \u201ccrackpot charlatanism.\u201d He warned that exaggerated claims for it might lead parents to favor it over proven options like behavioral therapy and medication.\nBrain cells communicate with one another, in part, through a constant storm of electrical impulses.\nTheir patterns show up on an electroencephalogram, or EEG, as brain waves with different frequencies.\nA major attraction of the technique is the hope that it can help patients avoid drugs, which often have side effects.\nNeurofeedback in general is a largely unregulated, with practitioners often devising their own protocols about where on the scalp to place electrodes.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering.", "answer": 1}, {"article": "The signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not exaggerate the prevalence or consequences of Alzheimer\u2019s Disease.", "answer": 1}, {"article": "\u201cToday, marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases,\u201d FDA Commissioner Scott Gottlieb said in a statement, adding that the approval demonstrates \u201cthe continued momentum of this promising new area of medicine.\u201d\n\nA CAR T-cell therapy involves a complicated and customized procedure in which T cells \u2014 sometimes called the foot soldiers of the immune system \u2014 are removed from the patient.\nOnce the modified cells are returned to the patient, their numbers expand exponentially as they become an army of cancer fighters.\nThis type of cancer begins in the immune system and can be fast- or slow-growing, the FDA noted.\nAn independent review committee found that 72 percent of patients treated with a single infusion responded to therapy, including 51 percent who then showed no evidence of remaining cancer.\nKite announced Wednesday that the treatment's brand name will be Yescarta and its price will be $373,000.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering, and did a nice job discussing the prevalence of this type of cancer.", "answer": 1}, {"article": "Researchers found that even though people on the FOLFIRINOX had a longer average survival rate of 11.1 months, versus the gemcitabine group with 6.8 months, the quality of life for patients on FOLFIRINOX was not as good.\nFor most patients, the prognosis is grim.\nFrench investigators from a private company known as BioMed randomly selected 342 patients with pancreatic cancer.\nThe purpose of the study was to record the overall survival rates of each group.\nPart of the group was given gemcitabine, the most favored treatment according to oncologists.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of pancreatic cancer in the story.", "answer": 1}, {"article": "This news release is available in French.\n\"Those numbers reflect the population in general,\" says Bacon, who is also director of the Centre de r\u00e9adaptation Jean-Jacques-Gauthier at Hopital du Sacr\u00e9-Coeur.\nIn a study recently published in BMJ Open Respiratory Research, experts from Concordia University, the H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al and several other institutions* analyzed the exercise habits of 643 participants who had been diagnosed with asthma.\n\"It would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\" he says.\n\"The issue of exercise-induced bronchospasm is real -- but if you use your releaver medication, blue puffer, before you exercise, and then take the time to cool down afterwards, you should be okay,\" he says.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not engage in disease mongering. A little context could have been helpful, however, such as what exactly asthma is, what triggers the condition and how many people suffer from it.\u00a0According to the original research report, asthma remains poorly controlled in the majority of patients: 60 percent of Canadian and 75 percent of European patients report not having their asthma symptoms under control. These patients often use more health care services, perhaps driving up costs for the sector, and also experience greater functional impairment. Asthma is a long-term disease with no cure, and the costs of buying pills and inhalers to control the condition could add up during the lifetime of a patient. Any alternative that could help patients control their asthma and maybe also save money on the side would be newsworthy, since more than 25 million people in the US are known to have asthma \u2013 in which 7\u00a0million are children, according to the National Heart, Lung and Blood Institute.", "answer": 1}, {"article": "\u201cThe mosaic strategy is one way to attempt to deal with the global virus diversity.\u201d\n\nA word of caution, though: We\u2019re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people.\nAn HIV vaccine has long been elusive.\nRecently, researchers even discovered a pill to prevent HIV.\nIn 2000, the UN Security Council convened an unprecedented meeting to address the out-of-control AIDS crisis.\nThe mosaic vaccine was the best tolerated and also capable of generating anti-HIV immune responses in all the people who received the shots.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering here.", "answer": 1}, {"article": "The simple answer is yes!\n\n\u2022 People who have had Type 2 diabetes for up to 10 years can reverse their condition\n\nA new study from Newcastle University has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.\n\"The bottom line is that if a person really wants to get rid of their Type 2 diabetes, they can lose weight, keep it off and return to normal.\nProfessor Roy Taylor said: \"What we have shown is that it is possible to reverse your diabetes, even if you have had the condition for a long time, up to around 10 years.\nIn addition, the team found that even patients who have had Type 2 diabetes for up to 10 years can reverse their condition.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering, but neither does it give us much context about Type 2 diabetes incidence. Because the release included a very important caveat about obesity and diabetes prevalence, we\u2019ll give them the benefit of the doubt. \u201cIndividuals vary in how much weight they can carry without it seeming to affect their metabolism \u2013 don\u2019t forget that 70% of severely obese people do not have diabetes,\u201d according to the release.", "answer": 1}, {"article": "Overweight people could be given help with the discovery that a drug used for sleep disorder could also reduce the impulse for food\n\nOverweight people could be given help with the discovery that a drug used for sleep disorder could also reduce the impulse for food.\n\"The drug improves self-control, which is a key factor in determining obesity, so our hypothesis is that this drug should help in treating the disease.\"\nWhen we eat food that tastes good we get a powerful release of dopamine in the pleasure/reward section of the brain, but food addicts have been found to have a deficiency in a certain type of dopamine so that their sense of reward and pleasure is diminished, thus they have to eat more to reach the same level of pleasure as anybody else.\nThere are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\nThere is mounting evidence to show that there is a substantial number of obese people who are food addicts because they have an inability to control their impulsive actions and this drug has shown it can give them more control, which will help overweight people lose weight and so improve their health.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We rated this category \u201cnot satisfactory\u201d since the headline and text of the release refers to \u201cfood addicts.\u201d There is no medical diagnosis known as food addiction.", "answer": 0}, {"article": "In the latest study, Moss and colleagues explore how much better women did, and why.\nThe original study, published in 2009 in the New England Journal of Medicine, showed patients fared better with a combination cardiac resynchronization therapy and a defibrillator rather than a defibrillator alone.\nOther studies have shown heart attack symptoms are much different in women than in men, something that has been publicized with the American Heart Association\u2019s \u201cGo Red for Women\u201d campaign.\nIn the MADIT-CRT trial, women were more likely to suffer heart failure caused by a viral infection of the heart, whereas in men, the condition is more often caused by blocked heart arteries, Moss said.\nIt is the leading killer of women in the United States, claiming more women each year than men.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story ended with disease mongering about the 42 million American women \u2018living with heart disease\u2019 in a story about heart failure, which, while it may fall under the rubric of heart disease, is only a subset of the vast 42 million. \u00a0The story then went on to share that \u2018It\u2019 is the \u2018leading killer of women\u2019. Why not simply provide heart failure stats, and heart failure stats by gender?", "answer": 0}, {"article": "Alyssa Gold had planned on getting married by age 26 and having kids by age 30 \u2014 but life worked out differently.\nIt\u2019s now being called the \u201cbaby deadline test.\u201d\n\n\u201cThere are some young, healthy women who are living their lives in shape and taking very good care of themselves who might not know that their reserve strength of their ovaries is lower than it should be.\u201d said Dr. Joshua Hurwitz a reproductive endocrinologist and infertility specialist with Reproductive Medical Associates of Connecticut.\n\u201cI was very career-minded and very focused and had relationships throughout my 20s and early 30s, but still wasn't in that forever relationship.\u201d\n\nWomen are born with a finite number of eggs: they start out with roughly one to two million in their ovaries.\nFor years, it\u2019s been a staple in fertility clinics; it\u2019s officially called the Anti-M\u00fcllerian hormone (AMH) test.\n\u201cIf I had waited until I met my husband and we were trying now to have a child it would be a very different story.\u201d\n\n\u201cEven the best AMH level in the world is not a guarantee for someone going forward or even right now but they are good indicators for fertility,\u201d said Hurwitz.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story\u00a0referred to the AMH test as the \u201cbaby deadline test,\u201d implying a woman\u2019s fertility span is\u00a0a disease that must be\u00a0detected and dealt with early, years before she might want to get pregnant. And that the solution is this blood test\u2013which is actually only one indicator of many to assess a woman\u2019s fertility.\u00a0This\u00a0is\u00a0an\u00a0example of disease mongering.", "answer": 0}, {"article": "A third of the projected cancers will occur in people who were ages 35 to 54 when they got their CT, two-thirds will occur in women and 15 percent will arise from scans done in children or teens.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\nThey found radiation dosage varied widely between different types of CT studies, from a median or midpoint of 2 millisieverts for a routine head CT scan to 31 millisieverts for a scan of the abdomen and pelvis, which often involves taking multiple images of the same organ.\nA chest CT scan exposes the patient to more than 100 times the radiation dose of a chest X-ray.\nAmy Berrington de Gonzalez of the National Cancer Institute and colleagues developed a computer model to estimate the impact of so many scans.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story accurately represents the number of cancers that are expected from the radiation doses observed in the study and how many of them could be fatal.", "answer": 1}, {"article": "Dr. Venditti is assistant professor of psychiatry at University of Pittsburgh Medical Center's Western Psychiatric Institute and Clinic.\nThe group that took metformin prevented the onset of type 2 by 18 percent, compared with the control group on a placebo.\nThe study also concluded that participants who underwent positive lifestyle changes delayed type 2 diabetes by about four years, compared with the control group.\nBenefits of intensive lifestyle changes were most pronounced in the elderly, with people 60 or older reducing the rate of developing type 2 diabetes by half.\n\"I feel that it's keeping me healthy,\" said the retired metallurgist.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does nothing to exaggerate the prevalence or severity of type 2 diabetes. ", "answer": 1}, {"article": "That\u2019s what the findings of two new studies published this week suggest.\n\u201cThe walking had to be brisk for men to experience a benefit.\u201d\n\nThe researchers said the effect of brisk walking persisted independent of age, diagnosis, type of treatment and characteristics of disease.\nAnother potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\nIn the first study, published Monday in the journal Cancer Epidemiology, Biomarkers and Prevention, scientists found that men who took a daily dose of acetaminophen (Tylenol) for five years had a 38% lower risk of developing prostate cancer, compared with other men.\nDuring the follow-up, there were 8,092 cases of prostate cancer \u2014 significantly fewer in the group who took acetaminophen daily for five years.\n", "question": "Does the story commit disease-mongering?", "explanation": "We do think there was a subtle element of disease mongering in this story.\nThe facts at the end are all correct \u2013 \u201cProstate cancer is the second leading cause of cancer death in men. According to the National Cancer Institute, about 32,050 men died from prostate cancer in 2010 and 217,000 new cases were diagnosed. More than 2.2 million men in the U.S. are living with prostate cancer.\u201d\nBut there is no context given about prostate cancers not being the same as other cancers \u2013 that many are not killers \u2013 that many men die WITH prostate cancer, not FROM it.\nAnd crediting acetaminophen for a \u201c51% reduced risk of developing an aggressive form of the disease\u201d without every quantifying how relatively few men develop an aggressive form of the disease among the 217,000 new cases diagnosed each year is not helpful.\u00a0 51% of what?", "answer": 0}, {"article": "Such an analysis is months away.\n\u201cThe challenge now shifts from proving the efficacy of the method to developing the proper quality standards, infrastructure and guidelines to bring this needed benefit to those at high risk for the disease \u2014 now,\u201d Ms. Fenton said.\nThere is just tremendous potential.\u201d\n\nBut Dr. Edward F. Patz Jr., professor of radiology at Duke who helped devise the study, said he was far from convinced that a thorough analysis would show that widespread CT screening would prove beneficial in preventing most lung cancer deaths.\nThe study, called the National Lung Screening Trial, was conducted by the American College of Radiology Imaging Network and the cancer institute.\nPatients wishing to get a CT lung screen will most likely have to pay the roughly $300 charge themselves, since few insurers pay for such scans unless an illness is suspected.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n\nThe story reports that this study involved current and former heavy smokers. However, near the end of the story there is a reference to \u201cmore than 80 million current and former smokers in the United States.\u201d It is not clear whether this number is meant to be an estimate of the number of people who smoked as heavily as those included in this trial. (The study enrolled only people who had smoked at least 30 pack-years, which is calculated by multiplying the number of years of smoking and the number of packs smoked per day. For example, 30 years of smoking a pack a day or 15 years of smoking two packs a day would each have 30 pack-years of smoking experience.)", "answer": 1}, {"article": "Schubiner also acknowledged that this general \u201cmodel\u201d for understanding and addressing fibromyalgia pain is controversial.\nThe precise cause of fibromyalgia is unknown \u2014 there are no physical signs, such as inflammation and tissue damage in the painful area \u2014 but some researchers believe the disorder involves problems in how the brain processes pain signals.\nThat is not to say that the pain people with fibromyalgia feel is \u201call in their head,\u201d stressed Dr. Howard Schubiner, of St. John Health/ Providence Hospital and Medical Centers in Southfield, Michigan.\nNEW YORK (Reuters Health) - A form of \u2018mind-body\u2019 therapy that focuses on the role of emotions in physical pain may offer some relief to people with fibromyalgia, a small clinical trial suggests.\nThe study, of 45 women with fibromyalgia, found that those who learned a technique called \u201caffective self-awareness\u201d were more likely to show a significant reduction in their pain over six months.\n", "question": "Does the story commit disease-mongering?", "explanation": "Fibromyalgia is a controversial diagnosis that some experts maintain isn\u2019t a real illness. Nevertheless, the disease is recognized by the FDA, insurers, and the American College of Rheumatology, who estimate that\u00a05 million Americans\u00a0suffer\u00a0from this condition. This prevalence estimate is accurately\u00a0cited in the article.", "answer": 1}, {"article": "All participants slept in the sleep laboratory and were closely monitored with all-night sleep recordings during the treatment period.\n\"Although eight hours of CPAP per night can be difficult to achieve in real-life, our results should provide a strong incentive for anyone with sleep apnea, especially prediabetic individuals, to improve adherence to their treatment for cardio-metabolic risk reduction,\" she said.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\n\"Despite the demonstrated efficacy of lifestyle interventions and the availability of many drug treatments, the economic and public health burden of diabetes remains enormous,\" said Esra Tasali, MD, assistant professor of medicine at the University of Chicago and senior author of the study.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\n", "question": "Does the news release commit disease-mongering?", "explanation": "This release shows no awareness of the debate over the diagnosis of \u201cprediabetes,\u201d unquestioningly labeling it a \u201cdisorder\u201d affecting 57 million people. But if prediabetes signifies that you are \u201cat risk for developing diabetes,\u201d as the release says, wouldn\u2019t it be more appropriate to call prediabetes a \u201crisk factor\u201d rather than a \u201cdisorder\u201d? As this BMJ analysis notes, labeling someone as \u201cprediabetic\u201d carries the potential for harm, so we question any news release that uses the term casually, as this one does.", "answer": 0}, {"article": "\"I think we need to pause and think about whether the extra information [from CT scans] really helps us make a diagnosis,\" Smith-Bindman says.\nThat will require hospitals to feed dose data to a central computer run by the radiology group.\nFor the same body part, the doses varied enormously from one hospital to another and even within the same hospital.\nIn the long run, experts say, newer-generation CT scanners will come equipped to prevent excessive radiation doses.\nInstead of an annual growth rate of 12 percent in CT scans, it's now about 1 percent, lower than the hospital's annual growth in patient load.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story accurately represents the number of cancers that are expected from the radiation doses observed in the study and how many of them could be fatal.", "answer": 1}, {"article": "Boston, MA - Women who eat more high-fiber foods during adolescence and young adulthood--especially lots of fruits and vegetables--may have significantly lower breast cancer risk than those who eat less dietary fiber when young, according to a new large-scale study led by researchers at Harvard T.H.\nThey also completed a questionnaire in 1998 about their diet during high school.\nThe greatest apparent benefit came from fruit and vegetable fiber.\nThe study will be published online February 1, 2016 in Pediatrics.\nAmong all the women, there was a strong inverse association between fiber intake and breast cancer incidence.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t disease monger about breast cancer.", "answer": 1}, {"article": "reconstructions\u201d currently being conducted on injured knees \u201ccould be avoided without adversely affecting outcomes.\u201d\n\nThis possibility should reverberate across playing fields nationwide, where, at the moment, preseason high school, collegiate and adult-league sports practices are under way, with a concomitant surge in A.C.L.\nPart of the reason for A.C.L.\nWhy, then, undergo A.C.L.\n\u201cWe definitely know only parts of the long-term outcome\u201d after different A.C.L.\n(For those fortunate enough not to be personally familiar with A.C.L.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "Wilmington, DE, December 17, 2018 - The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or \"knocking out\" a gene in cancer tumors that helps the tumors develop resistance to the drugs.\n\"We believe that finding ways to use CRISPR to improve existing treatments will lead to some of the first benefits for patients while we tackle the vital ethical issues around the use of CRISPR for edits that can be passed on through DNA.\n\"We think it's best to start with CRISPR therapies that involve relatively conservative uses of this powerful tool,\" Dr. Kmiec said.\nBut he said some patients with non-small-cell lung cancer, the most common form of lung cancer, are resistant to chemotherapy agents used to treat the disease or develop resistance after being exposed to the drugs.\n\"This approach can also hopefully help contain costs and provide a level of safety and reliability that is reassuring for patients and increases the chance that insurance companies will provide coverage.\"\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease-mongering. The release says lung cancer is \u201cthe leading cause of cancer death in the United States.\u201d\nThe news release could have helped readers by explaining how many patients are in a position to possibly benefit \u2014 that is, how many patients have cancer that is resistant to chemotherapy drugs or how many develop resistance after being exposed to the drugs \u2014 as well as whether this would apply to non-small cell or small-cell lung cancer, or both.", "answer": 1}, {"article": "Aggression scores declined to 3.8 from 7.1 in the dextromethorphan-quinidine group and to 5.3 from 7.0 in those who took a placebo.\nThe drug is approved for treating pseudobulbar affect, a neurological disorder that involves involuntary crying, laughing and other emotional displays as its main symptom \u2014 not involuntary movement of the facial muscles.\nDextromethorphan is a cough suppressant commonly found in over-the-counter cough medicines, and quinidine is a drug used to control heart rhythm disorders.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering,\u00a0although the study itself is arguably an attempt to expand the drug\u2019s market from a small number of neurological patients (mostly with amyotrophic lateral sclerosis and multiple sclerosis) with \u201cpseudo-bulbar affect\u201d for which the drug is currently approved, to the much larger market of agitation in Alzheimer\u2019s.", "answer": 1}, {"article": "All said they had taken MDMA for recreational purposes at least twice in their lives.\nIn a study involving a small group of healthy people, investigators found that the drug -- also known as MDMA -- prompted heightened feelings of friendliness, playfulness and love, and induced a lowering of the guard that might have therapeutic uses for improving social interactions.\nTUESDAY, Dec. 21, 2010 (HealthDay News) -- The recreational drug known as ecstasy may have a medicinal role to play in helping people who have trouble connecting to others socially, new research suggests.\nThe study, funded by the U.S. National Institute on Drug Abuse and conducted at the Human Behavioral Pharmacology Laboratory at the University of Chicago, was published in the Dec. 15 issue of Biological Psychiatry.\nThe findings \"suggest that MDMA enhances sociability, but does not necessarily increase empathy,\" noted study author Gillinder Bedi, an assistant professor of clinical psychology at Columbia University and a research scientist at the New York State Psychiatric Institute in New York City.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no discussion of whether problems connecting with others socially is a disease that must be treated. This is a major issue. First, are we talking about social awkwardness or social phobia? There is a real danger of medicalizing a non-medical problem. Second, the study was done in NORMAL VOLUNTEERS. The idea of improving peoples\u2019 ability to connect socially is SPECULATION.", "answer": 0}, {"article": "I thought this is so minimal, it\u2019s stupid.\u201d\n\nAfter a few weeks, she said she began to feel better, and after 12 weeks \u201cthe pain had diminished 90 percent.\u201d She has continued tai chi, lost 50 pounds and can walk three to seven miles a day.\nIt\u2019s defined by what the patient tells you,\u201d he added.\n\u201cThere was no joy to life,\u201d she said.\n\u201cI wouldn\u2019t say it\u2019s a cure.\n\u201cFibromyalgia is so common, and we have such a difficult time treating it effectively.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0There is no disease mongering and the description of the syndrome is the best of the five stories we reviewed. ", "answer": 1}, {"article": "Head and neck cancer was detected in 56% of patients.\n\u201cThe goal is to develop a blood test, such as this one, that can accurately identify cancers in their earliest stages.\u201d\n\nKlein added: \u201cIt is several steps away and more research is needed, but it could be given to healthy adults of a certain age, such as those over 40, to see if they have early signs of cancer.\u201d\n\u201cWe hope this test could save many lives.\u201d\n\nThe study, by a research team that also included scientists from Stanford University, was presented at the annual conference of the American Society of Clinical Oncologists in Chicago.\nThe research scrutinised the cases of more than 1,600 people, 749 of whom were cancer-free at the time of the study, with no diagnosis, and 878 of whom had been newly diagnosed with a disease.\n\u201cThis is potentially the holy grail of cancer research, to find cancers that are currently hard to cure at an earlier stage when they are easier to cure,\u201d said Dr Eric Klein, lead author of the research from Cleveland Clinic\u2019s Taussig Cancer Institute.\n", "question": "Does the story commit disease-mongering?", "explanation": "While it offers overly inflated claims of benefit, there is nothing to suggest that the piece displayed disease mongering about cancer itself. The story would have been stronger, however, if it had noted that catching cancer earlier doesn\u2019t always translate to curing cancer.", "answer": 1}, {"article": "Study participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\nWhile the study found an association between NSAID use and a reduced risk of colorectal cancer, it did not prove a cause-and-effect.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\nExperts say that for studies presented at medical meetings, data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nWomen who reported using these drugs, called NSAIDs, at the beginning of the study and three years later had a roughly 30 percent lower rate of death from colorectal cancer than women who did not take the drugs, or women who took them at only one of these two points in time, according to an American Association for Cancer Research (AACR) news release.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering, but the story did not provide any context or epidemiology on colorectal cancer.", "answer": 1}, {"article": "\"His mood improved.\nThe study also found that the tablets demonstrated significant effectiveness in reducing symptoms of agitation, particularly--but not exclusively--among patients with milder forms of dementia.\nThe researchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\nThis will allow researchers to develop more robust data and expand the scope of the study, including a focus on specific clinical factors that may impact how patients with dementia engage with and respond to apps.\n\"Use of Tablet Devices in the Management of Agitation Among Inpatients with Dementia: An Open Label Study\" was recently published in the online version of The American Journal of Geriatric Psychiatry.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering. But the release didn\u2019t provide us with any context about the size of the population of people with dementia with agitation either. We won\u2019t dock points but will instead rate this Not Applicable.", "answer": 2}, {"article": "(Editing by Pravin Char)\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\n* Scientists say new drug could have fewer side effects\n\nLONDON, Jan 8 (Reuters) - A drug for bipolar disorder that works like lithium - the most common and effective treatment - but without lithium\u2019s side-effects has been identified by British researchers in tests on mice.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in this story. In fact, the story provides this summary of the disease. \u201cBipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer. These high and low phases are often so extreme they interfere with everyday life and work.\u201d", "answer": 1}, {"article": "The five-year \"disease-free\" survival rate was 83.9 percent in those who did not have the more aggressive surgery compared with 82.2 in those who did, the researchers reported.\n\"This is good news.\n\"I think this will be practice-changing,\" he said.\nIt's a substantial number of women,\" Lyman said.\nThey found no significant difference in the patients' chances of surviving five years after their diagnosis.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "\"We believe this may be the most exciting breakthrough in leprosy treatment since multi-drug therapy, the current treatment for leprosy, was launched in the 1980s.\n\"This is a unique example of a vaccine produced by totally synthetic methods.\"\n\"This generation of a vaccine to prevent and possibly treat leprosy is the result of years of research.\nA viable vaccine to prevent and/or treat leprosy is the next step in the effort to bring this disease to an end.\nThe clinical trial is focused on safety, as well as evaluating the immune response to the vaccine.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\u201cWhy would we?\nBut when it comes to science and rigorous studies, he added, \u201ccomparatively, there isn\u2019t a whole lot of evidence out there.\u201d\n\nIn his studies, he found there was no way to predict the effect of a given orthotic.\nThe only indication seems to be that a comfortable orthotic might be better than none at all, at least for the activities of people in the military.\n\u201cBut choosing the right one requires a great deal of care.\u201d\n\nYet Scott D. Cummings, president of the American Academy of Orthotists and Prosthetists, says the trade is only now moving toward becoming a science.\nYour injury is probably linked to these poor-fitting orthotics.\u201d\n\nSo he tried different orthotic styles, different materials, different orthotics labs with every new doctor.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no suggestion of disease mongering. In fact, the article rebutted the need for orthotics in the correction of mechanical/alignment problems and in the management of asymptomatic abnormalities such as flat feet.\n\n \n", "answer": 1}, {"article": "The drug was also granted a priority review.\n\u201cNuplazid represents an important treatment for people with Parkinson\u2019s disease who experience these symptoms.\u201d\n\nAn estimated 50,000 Americans are diagnosed with Parkinson\u2019s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.\nIn clinical trials, the most common side effects reported by participants taking Nuplazid were: swelling, usually of the ankles, legs, and feet due to the accumulation of excessive fluid in the tissue (peripheral edema); nausea; and abnormal state of mind (confused state).\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe hallucinations and delusions experienced with Parkinson\u2019s disease are serious symptoms, and can lead to thinking and emotions that are so impaired that the people experiencing them may not relate to loved ones well or take appropriate care of themselves.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release doesn\u2019t engage in disease mongering. The release reports that\u00a050,000 new cases of PD are diagnosed each year and that hallucinations or delusions are said to occur in as many as 50\u00a0percent of patients with PD at some point during their illness. That\u2019s useful context.", "answer": 1}, {"article": "The other co-authors were from the CDC.\nFailing to screen high-risk adults could lead to delayed treatments to prevent type 2 diabetes or manage the condition for those who already have it, possibly contributing to a worsening of the diabetes epidemic.\nBy following the limited guidelines and only screening patients who are overweight or obese, approximately 30 percent of Asians with prediabetes or type 2 diabetes would be identified.\nIn the study, 50 percent of whites with prediabetes or type 2 diabetes were identified using the limited criteria compared to only 48 percent of African-Americans and only 44 percent of Latinos.\nThat would leave 70 percent of Asians with prediabetes or diabetes undiagnosed until their next screening test, which could occur years later.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Labeling possibly normal, healthy Americans with a unfamiliar term like \u201cdysglycemia\u201d that may entail considerable medical and psychological consequences \u2014 without any firm proof that it will benefit them \u2014 seems like disease-mongering.", "answer": 0}, {"article": "[1] A troponin test measures the level of troponin proteins in the blood.\nDr Shah and colleagues prospectively evaluated the negative predictive value (the probability that patients were not at risk) of heart attack or subsequent death from a heart condition after 30 days for a range of troponin concentrations.\nThe researchers found that a troponin threshold of <5 ng/L at presentation identified around two-thirds (61%) of patients at very low risk of heart attack and may have been eligible for early, safe discharge--with a high negative predictive value of 99.6%.\n\"We have identified a cardiac troponin concentration (less than 5 nanograms per deciliter; <5 ng/L) below which patients are at very low risk of heart attack either during the admission or in the ensuing 30 days.\nInternational guidelines recommend that individuals presenting with chest pain are admitted to hospital for testing for very high levels of troponin (above the 99th percentile)--a sign that a heart attack has occurred.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Anyone who has dialed 911 (or its British equivalent, 999) or worried at home about the meaning of chest pain will understand the need for a rapid, reliable way to rule out an emergent heart attack. No disease mongering here; the accurate diagnosis of heart attack is a serious issue.", "answer": 1}, {"article": "Another sensor, just approved by the F.D.A.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nThe device, made by Medtronic MiniMed, is called the Paradigm Real-Time, a combination insulin pump and continuous glucose sensor.\nIt has to be placed above the hip or the buttocks, which makes reaching it awkward, and then the wire leading from the sensor has to be connected to a transmitter that wirelessly sends the information to the pump.\nThe sensor has a coated tip that measures the electrical conductivity of the interstitial fluid, the juice floating between fat cells right under the skin.\n", "question": "Does the story commit disease-mongering?", "explanation": "The level of monitoring and use of injections as described in this article are beyond what has been tested in randomized controlled trials. ", "answer": 0}, {"article": "(Reuters) - Vanda Pharmaceuticals Inc said its experimental drug for a rare sleep disorder proved effective in a second late-stage trial, and the company now plans to apply for a U.S. approval for the drug in mid-2013.\nWhile the first two are efficacy studies, the remaining two are intended to establish the safety profile of the drug.\nAn orphan drug, if approved, can usually fetch a premium pricing in the market.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nThey have gained nearly 8 percent since December 18.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of the condition known as non-24-hour disorder.", "answer": 1}, {"article": "Before having their drinks, the participants rated their desire to eat on a one-to-10 scale from \u201cnot at all\u201d to \u201cvery much.\u201d Then they drank the liquids and had functional magnetic resonance imaging brain scans while looking at images of food and of neutral objects like buildings or baskets.\n\u201cDon\u2019t stop eating fruit.\n\u201cInsulin is released when we consume glucose,\u201d she said.\nAs they did so, they rated their hunger using the scale.\nThere was no difference in leptin or ghrelin levels between fructose and glucose drinkers.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. However, the story should have mentioned that the predictions of a global pandemic have not been realized. ", "answer": 1}, {"article": "The study, conducted at the University of Texas M.D.\nThey were followed for six to 11 years.\nA serving was a half-cup.\n\"I went into the study expecting to see a difference between the two groups,\" he said.\nBut he also acknowledged the results so far were a surprise.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not engage in disease mongering.", "answer": 1}, {"article": "MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute designated center) Level I Trauma Center, and Institute of Psychiatry.\nHe predicts that the device has the potential to be used widely by emergency personnel but also to appear in other public spaces.\nIt is also not clear how the device would work for patients with cranial implants, as metal interferes with the device's operating radio frequencies.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nThe device's success may be found in its ability to give emergency personnel a clear answer as to whether a patient is experiencing a severe stroke.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease-mongering.", "answer": 1}, {"article": "The official suggested that the baby might be \u201cwhat a baby girl looks like on the outside,\u201d but that \u201cwe\u2019re giving you the results on the inside.\u201d\n\nMs. Lewis, who sued Acu-Gen, said she ultimately received a refund.\nSex-determination tests are part of a new frontier of fetal DNA testing, which can be used to determine paternity and blood type, and is being used to develop early screening tests for genetic diseases or disorders like Down syndrome.\nThe tests are not regulated by the Food and Drug Administration because they are not used for medical purposes, a spokeswoman said, but the agency is investigating the explosion of home genetic tests like these and genome-sequencing kits.\nThe new study found that to be reliable, the sex-determination tests had to be performed after at least seven weeks of gestation.\n\u201cIt\u2019s very important to educate health care providers that pregnant women are buying these tests.\u201d\n\nAnother type of test not studied by the researchers has become popular because it is cheaper and can be done at home.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story balances the potential for danger in giving parents early information about the sex of a fetus and the genuine benefit for some in avoiding more invasive testing when a condition is ruled out by knowing the gender information.", "answer": 1}, {"article": "If media wish to link to the paper once it's published, they can use the following link, which will go live when the embargo lifts: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30179-5/abstract\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nThe rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.\nWhen a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.\nThe NIHR Leicester Respiratory Biomedical Research Unit - a partnership between the University of Leicester and Leicester's Hospitals - focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release verges on disease mongering given some of the exuberant language, particularly from the patient testimonial, but it stops short by noting how many asthma suffers there are in the UK. Asthma is a common and often-serious health problem so giving some context was beneficial.  ", "answer": 1}, {"article": "SUNDAY, Dec. 5, 2010 (HealthDay News) -- Using gene therapy, German researchers report that they managed to \"correct\" a malfunctioning gene responsible for Wiskott-Aldrich syndrome, a rare but devastating childhood disorder that leads to prolonged bleeding from even minor hits or scrapes, and also leaves these children vulnerable to certain cancers and dangerous infections.\nThe study was based on questionnaires returned from more than 12,500 donors, which also showed the donors tended to be in good health and were willing to donate again.\nHowever, one of the 10 kids in the study developed acute T-cell leukemia, apparently as a result of the viral vector that was used to insert the healthy gene.\nThe boy is currently on chemotherapy, the study authors noted.\nA viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t exaggerate the consequences of Wiskott-Aldrich syndrome.", "answer": 1}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story commit disease-mongering?", "explanation": "The story reports that a PSA test result is just the start of a decision-making process, and that many men reasonably choose to have little or no follow-up testing or treatment after a positive PSA result.\n\u00a0", "answer": 1}, {"article": "A government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\nWhen it comes to dosing, experts say sticking to a low-dose baby aspirin is best.\nAccording to the Centers for Disease Control and Prevention, about 610,000 Americans die of heart disease each year, accounting for 1 in 4 deaths.\n\"The benefits of aspirin outweigh the harms for most people in their 50's who are at risk of cardiovascular disease but not at increased risk of bleeding.\nWhile taking low-dose aspirin daily can help prevent heart troubles, doctors note that it also increases the risk of bleeding in the stomach and intestines, and strokes caused by bleeding in the brain.\n", "question": "Does the story commit disease-mongering?", "explanation": "No obvious disease mongering here, as heart disease and colon cancer are substantial burdens on the U.S. population.", "answer": 1}, {"article": "\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d Dr. Philip Greenland, an expert in preventive medicine at Northwestern University and a senior editor of the journal, and Dr. Michael Lauer of the National Heart, Lung and Blood Institute wrote in a commentary.\nIt would be, they report in the Journal of the American Medical Association.\nThey can damage muscle in 5 to 15 percent of patients.\nStatins, which include Lipitor, Mevacor, Crestor and Zocor, are extremely popular.\nPatients and doctors alike complained that the new guidelines were confusing.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story.", "answer": 1}, {"article": "Researchers acknowledge immunotherapy's promise is furthest from realization for bulky solid tumors, perhaps too advanced for the immune system to beat.\nMore are on the way.\nThe challenge was getting the immune system to recognize the enemy.\nBy the mid-90s, textbooks had grown to 1,000 pages.\nAnderson professor of blood and marrow transplantation.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering.", "answer": 1}, {"article": "But researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\nThey were then monitored for 24 hours.\nThe results appear in Nutrition Journal.\nAmong both men and women, the results showed a trend to lower systolic blood pressure six hours after drinking the beet juice.\n\u201cIt\u2019s promising that we can see an effect from a single dose,\u201d says researcher Leah Coles, PhD, a research fellow at the Baker IDI Heart and Diabetes Institute in Melbourne, Australia.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.", "answer": 1}, {"article": "Although the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\nAll of the scanned brains belonged to young, healthy scientists and doctors.\nThere are no laboratory tests to diagnose migraines, depression, bipolar disorder and many other ailments of the brain.\nThanks to this work, we know we have a reliable tool to study these possibilities.\"\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Although it over promises on the applicability of the study results, no disease mongering is evident.", "answer": 1}, {"article": "As for cost, she said that a month's supply of similar ginger supplements typically runs about $10 to $30.\nTUESDAY, Oct. 11, 2011 (HealthDay News) -- A small, preliminary study finds that ginger root supplements seem to reduce inflammation in the intestines -- a potential sign that the pills might reduce the risk of colon cancer.\nResearch has supported its use to treat stomach problems such as nausea and vomiting; the U.S. National Library of Medicine says it's \"likely safe,\" although some people may develop mild side effects.\nHowever, more study needs to be done, and the researchers aren't yet recommending that people head to the supplements' aisle or start gobbling up more ginger at meal times.\n\"We know there are anti-inflammatory drugs like aspirin that appear to have anti-cancer properties.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence given that the kind of inflammation measured in study participants\u2019 intestines is at all related to colon cancer.\nYet the headline reads: \u201cGinger Supplements Might Ease Inflammation Linked to Colon Cancer\u201d\nIs all stomach inflammation so linked?\nReaders may think that inflammation itself is worrisome, when in fact inflammatory markers are always present to varying degrees.", "answer": 0}, {"article": "March 15, 2012 -- A new prescription gel may quickly treat a common precancerous skin condition called actinic keratosis, a new study shows.\nHalf got the new gel and the other half received an inactive placebo.\nThis has long been used as a folk remedy for skin lesions.\nCryotherapy, or freezing the affected skin area, is also used but can sometimes leave a scar.\nBecause the new gel is only used for a few days, any irritation is usually short-lived.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering seen in the story.", "answer": 1}, {"article": "GW Pharmaceuticals funded the clinical trial.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\nIn addition to Dr. Devinsky, the co-authors in this study were: J. Helen Cross, PhD, FRCPCH, Linda Laux, MD, Eric Marsh, MD, Ian Miller, MD, Rima Nabbout, MD, Ingrid E Scheffer, MD, PhD , Elizabeth Thiele, MD, and Stephen Wright, MD on behalf of The Cannabidiol in Dravet Syndrome Study Group.\n\"We still need more research, but this new trial provides more evidence than we have ever had of cannabidiol's effectiveness as a medication for treatment-resistant epilepsy.\"\nThis new, randomized, controlled clinical study eliminated those concerns as participants and their physicians did not know if they were on CBD or placebo, say the study authors.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No evidence of disease mongering here. The release would have been better if it had provided some additional context about Dravet syndrome or on how researchers believe cannabidiol works to reduce seizures.", "answer": 2}, {"article": "Not willing to trust my luck a second time, I got the new vaccine.\nAnother difference is that Zostavax contains a live, weakened virus, making it unsuitable for people with poor immunity, whereas Shingrix contains a nonliving virus particle and may eventually be approved for those with compromised immunity, who are especially susceptible to a severe case of shingles.\nYears ago when I went to bed with what had been a daylong gnawing irritation on one side of my back, I awakened in the middle of the night with the thought, \u201cI have shingles.\u201d First thing in the morning I got a prescription for the antiviral drug acyclovir, which halted progress of the disease.\nAccording to the C.D.C., Shingrix can protect 97 percent of people in their 50s and 60s and 91 percent of those in their 70s and 80s.\nIt also reduces the risk of PHN by 86 percent, and it appears to be longer lasting than Zostavax, which starts to lose its protection after three years.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t acknowledge the possibility of milder cases of shingles, and makes shingles sound very common.\nIt says that by age 85 \u201chalf of adults will have had at least one outbreak of shingles,\u201d but in the study of patients who were older than 70, only 223 people out of more than 6,000 got shingles during a nearly 4-year time span.\nThe study further noted that \u201cthe overall incidence of herpes zoster is 2.0 to 4.6 cases per 1000 person-years but increases with age to 10.0 to 12.8 per 1000 person-years among persons 80 years of age or older.\u201d\u00a0\u00a0\nAnother way to say that? About 1-1.3% of people over 80 develop shingles in a year. While that is a lot of people, that is not nearly as alarming as the prevalence information presented in the Times story.", "answer": 0}, {"article": "The primary goal of our CBT service is to enable patients to receive dental treatment without the need for sedation, by working with each individual patient to set goals according to their priorities.\nFear of dental injections and the dental drill were the most common high scoring items on the MDAS.\nSuicidal thoughts were reported by 12% of patients and four (3%) reported a recent intent to commit suicide.\nSome of the patients referred to us were found to be experiencing additional psychological difficulties, and needed further referral and management.\nIndividuals were referred to support services via the care of their GP and for suicide risk, immediate action was taken based on local service guidelines.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "OTTAWA, ON - August 21, 2017 - Researchers at the Children's Hospital of Eastern Ontario (CHEO) looked at the incidence of and risk factors associated with sedation-related adverse events in pediatric emergency departments as part of a multi-centre observational study published today in JAMA Pediatrics.\nThe overall incidence of adverse events in the study population was 11.7%.\nSignificant interventions in response to an adverse event were rare, occurring in only 1.4% of children.\nThe CHEO Research Institute makes discoveries today for healthier kids tomorrow.\nIt includes children from six emergency departments across Canada, sedated with six different medication combinations.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering; heart disease is clearly a serious concern for women.", "answer": 1}, {"article": "Data from more than 18,000 patients also found that apixaban was safer overall than warfarin, and tended to cause less bleeding in the skull in patients who faced the highest risk of bleeding.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\n\"The benefits of apixaban are preserved, regardless of the risk score used and regardless of the patient risk category,\" study author and cardiologist Dr. Renato Lopes said in a Duke news release.\nThe findings suggest that the current risk scoring systems for tailoring anti-clotting (anticoagulant) treatment to individual patients may be less relevant when using apixaban for patients with atrial fibrillation who have at least one risk factor for stroke, according to the Duke University Medical Center researchers.\n\"With new oral anticoagulants, such as apixaban, we might not need risk scores to guide treatment decisions for stroke prevention in patients with atrial fibrillation.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering in the story. It simply provides a short explanation of the disorder, saying, \u201cAtrial fibrillation affects more than 2.6 million people in the United States. In people with atrial fibrillation, disorganized electrical activity causes ineffective contraction of the upper chambers of the heart. This increases the risk for blood clots that can cause stroke.\u201d", "answer": 1}, {"article": "Politi said a serving of walnuts is about 14 halves, which adds up to 180 calories.\nIt's still important to remember portion control, especially for people on weight loss programs, warned Politi.\nThey're rich in fiber, folic acid, and potassium.\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\n\"Try a serving in a snack bag.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering here. Weight gain with age is fairly common and maintaining cardiovascular health is important.", "answer": 1}, {"article": "\u201cThat\u2019s what\u2019s good about this program.\nThe text messages were most effective at reducing distress at the 2- and 4-month marks, according to the data presented by chief author Kuang-Yi Wen, an assistant professor in the Cancer Prevention and Control program at Fox Chase.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nAt the fourth month mark, \u201cthe gap was huge\u201d between the texting and control groups, she told Reuters Health in a telephone interview.\nCompared to 52 women who only received an American Cancer Society pamphlet on chemotherapy, the 48 women in the texting group reported an overall lower level of distress and a higher quality of life during their therapy.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here. We couldn\u2019t find good data on how common chemotherapy treatments are and how many patients might benefit from better support and clinician communication, but certainly the number is great.", "answer": 1}, {"article": "This study is really a proof of concept.\nThe study authors pointed out that the most common reason American patients are admitted to a hospital is when there is a suspicion of heart failure -- a tough-to-treat condition in which the heart's pumping action grows gradually weaker over time.\n\"Every individual has a breath print that differentiates them from other people, depending on what's going on in their body,\" explained study lead author Dr. Raed Dweik, a staff physician in the department of pulmonary, allergy and critical care medicine with the Respiratory Institute at Cleveland Clinic.\nIn the new study, to gauge how well the noninvasive breath test could identify heart failure, the team collected exhaled breath samples from 41 patients who had been admitted as in-patients to the Cleveland Clinic.\n\"But I would say it would be perhaps more helpful for primary care physicians in an outpatient setting, because that is where it's most challenging to identify heart failure.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no disease mongering of heart failure.\u00a0 But in the way the story addresses early research about this test, it smacks of a subset of disease-mongering.\u00a0 The story cites the study authors\u2019 reference to suspicion of heart failure as the most common reason American patients are admitted to a hospital. But it is far too early to say whether this test might ever be relevant to most, or even any, of those patients. Is it disease mongering to say that most heart failure patients confront diagnostic challenges of the type raised by these researchers? Or are most cases pretty clear \u2013 meaning that most heart failure patients aren\u2019t really threatened by uncertain diagnoses?\u00a0 These are questions that could have been addressed, weren\u2019t, and therefore, the story made the problem seem bigger than it might really be.", "answer": 0}, {"article": "Drowsiness and dizziness are also problems.\n\"You can come in drinking a bottle of scotch a day and get treatment without detox,\" said Dr. Bankole Johnson of the University of Virginia, who led the study, which was conducted at 17 U.S. sites from 2004-2006.\nBy the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\nThe drug works by inhibiting dopamine, the brain's \"feel-good\" neurotransmitters that are involved in all addictions, said Stephen Dewey, a neuroscientist at the Brookhaven National Laboratory.\n\"The size of the treatment effect is larger than in most of the other medications we've seen,\" said Dr. Mark Willenbring of the National Institute on Alcohol Abuse and Alcoholism.\n", "question": "Does the story commit disease-mongering?", "explanation": "While there is no \"disease mongering\" in the sense of exaggerating the scope of\u00a0the problem, there is implication in this report that the drug under study is more widely applicable than the study\u00a0demonstrates.\u00a0 The\u00a0study author was quoted as saying you \"can come in drinking a bottle of scotch\u00a0a day and get treatment without detox.\"\u00a0 In this study, patients who experienced significant withdrawal symptoms with cessation were excluded, as were those who had multiple unsuccessful attempts in the past to stop drinking in inpatient programs.\u00a0 \u00a0", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story commit disease-mongering?", "explanation": "Benefits of calcium and vitamin D supplement were presented as percent reduction in hip fracture rates without the context of how often they occur. The reduction in hip fracture rate reported in the study was 12% (as compared to 29% for those who took the supplements regularly). However the article presented the 21% reduced rate for women over 60 but the story never reported the overall 12% rate. ", "answer": 0}, {"article": "\"The recent 2015 Dietary Guidelines for Americans Committee Report emphasized the importance of eating breakfast for all Americans - and we know that instant oatmeal is a popular and convenient choice,\" comments Marianne O'Shea, PhD, Director of the Quaker Oats Center of Excellence.\nGrams of carbohydrate and total weight of the foods were not significantly different.\nFor more than 130 years, Quaker's brands have served as symbols of quality, great taste and nutrition.\nHolding leadership positions in their respective categories, Quaker\u00ae Oats, Quaker\u00ae Rice Cakes and Quaker Chewy\u00ae Granola Bars are consumer favorites.\nAuthors stated that the processing of the cold cereal might lead to changes in the oat fiber that reduced its ability to enhance satiety.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease-mongering of hunger or obesity.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story commit disease-mongering?", "explanation": "In some ways this story avoided a hysterical tone when discussing a possible bird flu pandemic. But it did include a picture of workers in hazmat suits and if offered the calculation that with the current iteration of vaccine it would be possible to fully immunize a mere 1.25% of the population when a portion of that population has never been vaccinated against the flu. This threw off the otherwise well-maintained balance of the report on this potential public health issue.", "answer": 0}, {"article": "In a previous study, Baker and her colleagues demonstrated that treatment with GHRH provided a short-term boost in memory and concentration for healthy adults.\nIt promotes all kinds of growth in the body and brain, but if you have excess IGF1, it may put you at risk for cancer,\" said Baker, who added that people with Alzheimer's disease tend to have low levels of IGF1.\nPeople with this condition don't yet have Alzheimer's disease, but they do have problems with memory and focus, and they're at higher risk of developing Alzheimer's disease, according to the Alzheimer's Foundation.\n\"IGF1 is a hormone we all have from birth that increases through development until it starts to decline in our early 50s.\nAll of these hormones are believed to play a role in brain health, and decreasing levels of these hormones are suspected to play a role in the development of Alzheimer's disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play here.\nBut, we were a bit troubled by the suggestion that people with mild cognitive impairment, \u201c\u2026don\u2019t yet have Alzheimer\u2019s disease\u2026\u201d\u00a0 While MCI is a precursor, not all people with it go on to develop Alzheimer\u2019s disease.\n\u00a0", "answer": 1}, {"article": "As expected, this process is often inaccurate.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease.\nPULLMAN, Wash. - Washington State University researchers have developed a low-cost, portable laboratory on a phone that works nearly as well as clinical laboratories to detect common viral and bacterial infections.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We will give the release a satisfactory rating on this criterion. However, other than measles, it is not clear that other types of infections used in this study (including mumps, herpes and Lyme disease) are responsible for the type of fast-moving outbreaks that the release says this device could help identify more rapidly.", "answer": 1}, {"article": "WEDNESDAY, May 11, 2011 (HealthDay News) -- It may be possible to assess a man's fertility by checking his \"anogenital distance,\" the gap between his scrotum and anus, a new study suggests.\nOne expert who's done her own research in this area applauded the study.\n\"And second, it suggests that gestational exposures and development may impact adult testicular function.\"\nThey measured the scrotum-anus distance as well as the penis length of 117 infertile and 56 fertile men visiting an andrology clinic.\n\"First, this could represent a noninvasive way to test testicular function and reproductive potential in adult men,\" he said in a Baylor news release.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering in the story.", "answer": 1}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story commit disease-mongering?", "explanation": "While some women may indeed prefer no bleeding to the lighter, shorter \u2018periods\u2019 that are common in those who take traditional birth control pills, no evidence is cited to support this. it would have been interesting to hear from an expert as to whether this new approach is medicalizing a relatively normal bodily function. The suggestion that eliminating monthly menstrual bleeding might improve workplace productivity seems to come close to exaggerating the human consequences of this natural process. ", "answer": 0}, {"article": "\u201cKangaroo mother care is care of preterm infants carried skin-to-skin with the mother.\n\u201cKangaroo mother care may change the behavior of less well-educated mothers by increasing their sensitivity to the needs of their children, thus making them equivalent to mothers in more favorable environments.\u201d\n\nTwenty million babies are born at a low birth weight every year around the globe, the World Health Organization reports.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\nIts key features are: early, continuous and prolonged skin-to-skin contact between the mother and the baby; exclusive breastfeeding (ideally); it is initiated in hospital and can be continued at home; small babies can be discharged early; mothers at home require adequate support and follow-up,\u201d WHO said.\n\u201cIt is a gentle, effective method that avoids the agitation routinely experienced in a busy ward with preterm infants.\u201d\n\nAnd it\u2019s safe, WHO added.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story accurately states that 20 million babies are born at a low birth weight every year, according to the World Health Organization.\nWe did take issue with this speculative quote about the behavior of the babies in the skin-to-skin group, which was featured prominently in all caps in the NBC story:\n\u201cTHEY EXHIBITED LESS ANTISOCIAL BEHAVIOR, WHICH MIGHT BE ASSOCIATED WITH SEPARATION FROM THE MOTHER AT BIRTH.\u201d\nThis borders on fear-mongering. For all mothers\u2013but especially moms who have premature babies and/or complicated births\u2013having a newborn is very stressful. The looming threat that antisocial behavior is a risk the mother is specifically responsible for in these fragile days and hours may compound the\u00a0stress.", "answer": 1}, {"article": "SpermCheck Fertility is designed to help couples determine more quickly whether male infertility might be a problem for them, said Ray Lopez, CEO of SpermCheck, based in Charlottesville, Va.\n\"It may provide (an opportunity for) both physicians and couples to take a closer look at ways for men to step up to the plate and optimize their reproductive potential,\" said Dr. Robert Brannigan, urologist at Northwestern University Feinberg School of Medicine.\nWhen a couple is struggling to conceive, it's the woman who is usually the first \u2014 and often the only one \u2014 to be poked, prodded and analyzed, experts say.\nAlthough it's not a comprehensive evaluation and could give some consumers a false sense of security, the test does provide a starting point while drawing attention to male infertility as a legitimate health concern.\nBy detecting that protein, the test indicates whether or not a semen sample contains 20 million sperm per milliliter.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story. Instead, the story provides some statistics about fertility. We wished they had been sourced beyond one \u201cexpert in male fertility.\u201d The story says, \u201cApproximately 15 percent of U.S. couples of reproductive age who are trying to conceive face infertility issues, said Brannigan, an expert in male fertility.\u00a0Male infertility contributes to 50 percent of those cases, he said. Male infertility alone is the cause 30 percent of the time; a combination of male and female factors account for the other 20 percent.\u201d", "answer": 1}, {"article": "The experimental treatment, a decades-old generic vaccine for tuberculosis called bacillus Calmette-Gu\u00e9rin (BCG), seems to alter both cellular metabolism and the immune system, said Dr. Denise Faustman of Massachusetts General Hospital, senior author of the study published Thursday in npj Vaccines.\nAccording to studies in mice, it has two effects.\nThe U.S. market for insulin meters and insulin pumps is $20 billion.\nIt is testing multiple BCG doses in 150 patients with longstanding type 1 diabetes.\n\u201cThis cheap, old vaccine is lowering blood sugar to levels never achieved before,\u201d she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease-mongering in the story.", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nWith each subsequent generation, the number of repeats tends to rise.\nThe gene for fragile X was discovered in 1991.\nThe two got to talking and decided to collaborate.\nIn anyone with 200 or more repeats, the body shuts off the gene.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story does not resort to disease-mongering.", "answer": 1}, {"article": "\"It's meaningless, and it could very easily introduce real confusion.\"\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\n\"There is at least a significant chance this test will could falsely reassure some women and alarm others,\" said Eric Winer, a breast cancer expert at Harvard Medical School and a spokesman for the American Society of Clinical Oncology.\n\"There is concern about the validity of many genetic tests that are being offered,\" said Joan Scott, deputy director of the Center for Genetics and Public Policy at Johns Hopkins University.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story lists the annual incidence of new breast cancers and mortality rate.\u00a0 The story is tempered in reporting about a new genetic test which may or may not be another option for women looking to assess their risk. The story mentions that knowing individual risk may inform a woman\u2019s decision whether to increase surveillance and/or take chemoprevention medication, such as tamoxifen.\u00a0 ", "answer": 1}, {"article": "That is the process that he says is reversed by resveratrol and, he hopes, by the more powerful sirtuin-activator drugs that his company is developing, though many years of clinical trials will still be needed to demonstrate whether they work and are safe to use.\nHe found that their muscle fibers had been remodeled by the drug into the type more prevalent in trained human athletes.\nDr. Auwerx attributes this change in large part to the significantly increased number of mitochondria he detected in the muscle cells of treated mice.\nAnd higher doses may not be as safe as the lower doses found now in foods and \u201cnutraceuticals\u201d like the extract capsules.\nIncreased energy production by mitochondria generates potentially dangerous reactive chemicals that are known to damage cells.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story portrays aging as a disease that could be treated with a pill.\u00a0 ", "answer": 0}, {"article": "Peer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\nDr. Ashley Brenton, Associate Director of R&D for Proove states, \"This validation study builds on the peer-reviewed evidence supporting Proove Opioid Risk\u00ae and its components as an optimal model to predict opioid abuse risk.\"\nThis study evaluated 186 patients, comparing 94 Medicaid patients at an addiction treatment facility with confirmed cases of opioid abuse, and 92 healthy patients with no history of opioid use.\nFurthermore, the sensitivity of the \"moderate risk\" cut-off score was 98%, while the specificity of the \"high risk\" score was 100%.\nAbout Proove\u00ae Biosciences: Proove\u00ae Biosciences is the leader in precision medicine for the condition that lies at the nexus of health \u2013 pain.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Opioid use disorder is a very serious public health issue, and there is evidence that many of those who become addicted to opioids first use them as legitimate prescribed medicines. Thus, the news release is not guilty of disease mongering.", "answer": 1}, {"article": "In a separate analysis published in the same issue of JAMA Cardiology, researchers used data from the PARADIGM-HF trial to model the health consequences and cost-effectiveness of Entresto over a 30-year time period.3 They compared Entresto to the ACE-inhibitor enalapril and found Entresto was associated with more than a year longer average survival time, and that it was cost-effective compared to enalapril when these medications were used with other standard of care therapies.3 For every 1,000 patients treated with Entresto vs. enalapril, potentially 59.7 HF hospital admissions could be averted per each year alive in the model.3 In addition, Entresto increased life expectancy at an incremental cost-effectiveness ratio consistent with other high-value widely accepted cardiovascular interventions such as implantable cardioverter defibrillators (ICDs) and cholesterol-lowering statins before they became generic.3\n\nAbout Heart Failure\n\nHeart failure is a debilitating and life-threatening condition, which impacts nearly 6 million Americans and is the leading cause of hospitalization among Americans over the age of 65.4,8 About half of people with heart failure have heart failure with reduced ejection fraction (HFrEF).5 Reduced ejection fraction means the heart does not contract with enough force, so less blood is pumped out.9 Heart failure presents a major and growing health-economic burden that currently exceeds $30 billion in the United States, which accounts for both direct and indirect costs.10\n\nAbout Entresto\n\nEntresto is a twice-a-day medicine that reduces the strain on the failing heart.\nYou should not place undue reliance on these statements.\nPatients should either take Entresto or breastfeed.\nCirculation.\nCirculation.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "A breakthrough in helping the body to produce more insulin could make tedious injections of the hormone history.\nJohn Anderson, president of medicine and science for the American Diabetes Association, says \u201cIt\u2019s very promising and opens up new avenues of research, but we are a long way from replacing insulin, or a cure, or even knowing how this [hormone] will work in human tissue.\u201d\n\nThose concerns aren\u2019t lost on Melton, who also recognizes that more research is needed to confirm that betatrophin may benefit patients.\nIn theory, if the same results occur in people, it\u2019s possible that those on the verge of developing diabetes might never progress to develop the disease, since the high blood sugar levels that can cause damage to tissues and lead the body to become less responsive to insulin could be avoided.\nStudy Says Heart Benefits Outweigh Diabetes Risk\n\nIt\u2019s an exciting breakthrough in diabetes research, which for many years was focused on finding ways to externally supplement the body\u2019s waning insulin levels.\nMORE: Half of Diabetes Cases Are Undiagnosed\n\nNow, researchers working with mice at the Harvard Stem Cell Institute report in the journal Cell that they have discovered a hormone, betatrophin, that can prompt the body to generate more insulin-producing beta cells and, if the work is confirmed, the hormone could potentially do away with the need for regular insulin shots.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story\u2019s emphasis on doing away with\u00a0\u201ctedious [insulin] injections\u201d is questionable, as most type 2 diabetes patients don\u2019t require insulin. But since we\u2019ve already addressed this problem elsewhere, we won\u2019t dock any points here.", "answer": 1}, {"article": "(Reuters) - Bayer Healthcare said on Wednesday the U.S. Food and Drug Administration approved using transvaginal ultrasound as an alternate test to confirm if the company\u2019s Essure permanent birth control device has been placed properly.\nThe training will start in September, the same month the FDA will hold a public panel meeting to discuss the safety and effectiveness of Essure.\nEssure is a small metal coil inserted into woman\u2019s fallopian tubes.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\nIn a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article doesn\u2019t engage in disease mongering. It describes the test as an approved alternative to HSG to determine proper placement.", "answer": 1}, {"article": "During the 48 weeks, there were no statistically significant differences between groups:\n\u2022 The number of asthma exacerbations per child averaged 0.81 in the acetaminophen group versus 0.87 in the ibuprofen group.\nMedication adherence was closely monitored.\n\"There was no difference that would cause me to be alarmed,\" she says.\n\"Our findings should alleviate the concerns for safety that were based on observational data.\"\nAt least two episodes occurred in 21 and 24 percent, respectively.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this news release.", "answer": 1}, {"article": "That finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection.\nThe American Cancer Society has more on lymphoma.\nPeople whose physical activity was greater than normal before diagnosis were less likely to have died from lymphoma, or from any other cause, than were those who'd been less active, the study found.\nPeople who'd boosted their physical activity level after being diagnosed with lymphoma also were less likely to have died in that three-year span than were those who hadn't increased their activity level.\nResearch presented at meetings should be considered preliminary because it has not been subjected to the rigorous scrutiny given to research published in medical journals.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Not the smells of their colognes or perfumes, not of the laundry detergents they use \u2014 the smells of them?\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nThe breath of diabetics sometimes smells of rotten apples, experts report; the skin of typhoid patients, like baking bread.\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no obvious disease mongering here and the diseases that the odor sensing technology will look for include some serious forms of cancer (ovarian, lung or colon), However, the story would have been stronger if it had mentioned that early detection doesn\u2019t always guarantee better outcomes\u2013sometimes all it does it ensure a longer period of treatment with the same outcome.", "answer": 1}, {"article": "The frequency of screening mammograms -- and the appropriate age to begin them -- has been debated since the U.S. Preventive Services Task Force in 2009 recommended that women routinely get screening mammograms every other year starting at age 50.\n\"Hopefully, there will be less anxiety about getting a recall.\"\nInformation about the women and their mammograms came from the Breast Cancer Surveillance Consortium, funded by the National Cancer Institute.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\nThey found a small but not significant increase in the chance that women diagnosed with breast cancer had a more advanced case if they underwent screening every other year instead of every year.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering.", "answer": 1}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering.\u00a0 To the contrary, it shoots down some of the estimates of the size of the problem:\n\u201cRichard Pollack, an entomology instructor and insect expert at the Harvard School of Public Health, estimates that only about 200,000 elementary-school students actually get head lice each year, rather than the six to 12 million children from the CDC\u2019s 1997 estimates. In an email, a CDC spokeswoman said its figures were based on sales of head-lice treatments, noting a report by the American Academy of Pediatrics published last year that said the totals were most likely an overestimation.\u201d", "answer": 1}, {"article": "SUNDAY, Aug. 28, 2011 (HealthDay News) -- An experimental drug, apixaban (Eliquis), appears better than the old standby warfarin in preventing strokes in people with the abnormal heart rhythm called atrial fibrillation, a new study finds.\nThe issue of cost remains a factor, however.\nThe new trial comes on the heels of another study on apixaban that was stopped early due to safety concerns.\n\"This represents a very important therapeutic advance in the care of patients with atrial fibrillation.\"\nAnother similar drug, Pradaxa (dabigatran), has been on the market for about a year and many patients with atrial fibrillation have been switched or started on it, he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "With the memory of Memorial Day cheeseburgers and bratwursts still lingering, many of us may be relieved to hear that a new study suggests that a meaty, high-fat, Atkins-style diet can do more than contribute to rapid weight loss.\nThe results, though, come with several caveats.\nThe sessions lasted for at least 30 minutes three times a week.\nThe researchers then waited for each person to lose 10 pounds.\nThe full study will monitor the volunteers for six months and include additional measures of cardiovascular health after both diets.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story commit disease-mongering?", "explanation": "Repeat heart attacks are relatively common, making continued, at-home treatment of heart attack victims important.", "answer": 1}, {"article": "Epclusa carries a warning for patients and health care providers that serious slowing of the heart rate (symptomatic bradycardia) and cases requiring pacemaker intervention have been reported when amiodarone is used with sofosbuvir in combination with another HCV direct-acting antiviral.\nThe most common side effects of Epclusa include headache and fatigue.\nKnowing the genotype helps inform treatment recommendations and the duration of treatment.\nCo-administration of amiodarone with Epclusa is not recommended.\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering.", "answer": 1}, {"article": "Loading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\nThe good news is that your initial levels are not your fate.\nThe diet was followed by six weeks of eating normally.\nA recent study published in adds to the growing evidence that fiber might be a critical gut-nourishing nutrient.\nThe authors of the new study wanted to look at what changes in diet do to one particular gut microbe species: a strain that\u2019s been associated with leanness and better glucose tolerance in mice.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does a good job of distinguishing between risk factors and actual health problems. No disease mongering here.", "answer": 1}, {"article": "Breast cancer treatments that have shown the best results for for disease free survival include chemotherapy, hormonal therapy, or both.\nFor younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility.\nEarly menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nWhile many women choose to preserve the option of having children by storing eggs before cancer treatment, the process can be costly and difficult.\nWhile most breast cancer is diagnosed at later ages, about 6% of women learn that they're ill before age 40 - when they are still of childbearing age.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story is free of disease-mongering and clearly states the importance of the issue for a specific population,\u00a0 younger breast cancer patients.\n", "answer": 1}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\nAlso, the longer patients used statin drugs, the greater their reduction in risk for colorectal cancer.\n\u201cThis effect was largely consistent across study design with both case control and cohort studies showing a strong correlation,\u201d he says in a news release.\nThe analysis shows there was a 12% reduction of colorectal cancer risk among statin users.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering in this story. ", "answer": 1}, {"article": "This was not statistically different.\nThe study suggests most patients can have just aspirin without increasing the risk for venous thromboembolism, but doctors need to consider factors such as a patient's history of clots, obesity and ability to mobilize after surgery when determining the best measure for clot prevention, Hallstrom adds.\nThe critical care specialists who make up the American College of Chest Physicians favor heparin to reduce the risk of blood clots, while the American Academy of Orthopaedic Surgeons guidelines state that no one drug is better than another for preventing clots.\n\"Aspirin alone may provide similar protection compared to anticoagulation treatments,\" says Brian R. Hallstrom, M.D., an orthopaedic surgeon and associate chair for quality and safety at the University of Michigan Department of Orthopaedic Surgery.\nAlthough warfarin costs a few dollars for a 30-day supply, its cost approaches that of the other anticoagulants when doctor visits for monitoring are factored in, Hallstrom says.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not push knee replacement or clot-preventing drugs, though it does somewhat overstate the number of total knee replacements. The release cites a figure of \u201cnearly 1 million Americans\u201d each year, while other sources estimate the rate is closer to 700,000 per year.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story commit disease-mongering?", "explanation": "Does not provide a natural history of heart failure; article mentions an estimate for the number of Americans that have heart failure (5 million) and the number who will be hospitalized for decompensation appear reasonable. But the tyranny of the anecdote comes into play with the patient testimonials used (\u201cI actually could breathe again\u201d and \u201cIt gave me my life back.\u201d). How were these patients selected? Were there any negative experiences? ", "answer": 0}, {"article": "Indiana University researchers have found that magnesium intake may be beneficial in preventing pancreatic cancer.\nThe overall occurrence of pancreatic cancer has not significantly changed since 2002, but the mortality rate has increased annually from 2002 to 2011, according to the National Cancer Institute.\nBut few studies have explored the direct association of magnesium with pancreatic cancer; of those that did, their findings were inconclusive, said Daniel Dibaba, a Ph.D. student at the School of Public Health-Bloomington, who led the IU study.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\n\"Pancreatic cancer is really unique and different from other cancers,\" said study co-author Ka He, chair of the Department of Epidemiology and Biostatistics at the IU School of Public Health-Bloomington.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release calls pancreatic cancer \u201cthe fourth leading cause of cancer-related death in both men and women in the United States.\u201d \u00a0But this statement should have been accompanied by some statistics that demonstrate the relative rarity of the disease. \u00a0According to the National Cancer Institute, the lifetime risk of developing pancreatic cancer is approximately 1.5 percent.", "answer": 0}, {"article": "The epidemiologic study, led by Carol O'Neil of the Louisiana State University Agricultural Center, used a nationally representative analytic sample to examine the association of fresh pear consumption with nutrient intake, nutrient adequacy, diet quality, and cardiovascular risk factors in adults.\nThey are sodium-free, cholesterol-free, fat-free and contain 190 mg of potassium.\n\"The association between pears and lower body weight is very exciting,\" said Dr. Carol O'Neil.\nThe USDA Dietary Guidelines for Americans state that people who eat more fruit as part of an overall healthy diet are likely to reduce their risk of some chronic diseases, although little is published on the health outcomes associated with individual fruits, including pears.\nPears are an excellent source of fiber (24% DV) and a good source of vitamin C (10% DV) for only 100 calories per medium sized pear.\n", "question": "Does the news release commit disease-mongering?", "explanation": "It\u2019s not \u201cmongering\u201d to acknowledge the obesity epidemic in the United States so we give this a Satisfactory.", "answer": 1}, {"article": "Washington, DC - September 18, 2018 - An international team of researchers has successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells, which had been transplanted into mice.\nMice that got the ZIKV-LAV injected as well saw a significant delay in tumor development.\nThe ZIKV-LAV has a small deletion from the viral genome that prevents it from replicating itself efficiently.\nMice that got the injection of the GSCs only rapidly developed tumors.\nThe American Society for Microbiology is the largest single life science society, composed of more than 30,000 scientists and health professionals.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in this release. Incurable cancer is clearly a serious concern.", "answer": 1}, {"article": "UnitedHealthcare's medical policy for TMS says it is unproven for treating depression.\n\"Most people are not scared of it,\" she said.\nWest is a Medicare provider.\n\"But I've been working on that.\"\n\"It sounds sort of creepy and weird when you think about it, but for the most part, it is safer in general than taking a medicine.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here", "answer": 1}, {"article": "\"CMS made the right decision,\" said John Petrini, a Santa Barbara, Calif., gastroenterologist who heads the American Society for Gastrointestinal Endoscopy.\n\"They got it completely wrong,\" he said.\n\"Some people will die from that decision, completely unnecessarily,\" because they won't get a standard colonoscopy.\nMedicare's decision has sparked a furious lobbying campaign.\nRowe planned to be at his desk an hour or so later.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of colon cancer.", "answer": 1}, {"article": "As part of the research for the World Journal of Surgery study, 108 patients with early-stage breast cancer were prospectively implanted with the marker during \"reconstructive lumpectomy,\" a method of oncoplastic surgery to remove the cancer while reconstructing the remaining breast to improve cosmetic outcomes.\nIt is the first and only device that identifies in a reliable way the 3-D region where the tumor was removed.\nThe article also noted that there was a shift during the three-year course of the study toward increasing use of hypo-fractionated radiation methods.\nThe average age of women in the study was 63 years.\nThe device is available in a range of sizes to accommodate a variety of clinical situations.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release didn\u2019t engage in disease mongering.", "answer": 1}, {"article": "Whether it is encouraging people to eat right or to exercise, they said, the hardest part is not getting them to start doing the right things but getting them to keep doing the right things.\nThe results, being published today in the Journal of the American Medical Association, are heartening, but Willis and Marsiske cautioned that the biggest challenge lies ahead, in getting people to apply the findings to their lives.\n\"If you think you have come to a time in your life when new learning is impossible and there are no benefits of continuing mental activity, the study shows that for a large number of people that this is not true,\" added Marsiske, a clinical and health psychologist at the University of Florida at Gainesville.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\nAlthough it did not examine the effects of mental exercise on people who had begun to show signs of Alzheimer's or other brain disorders, previous studies have pointed toward the conclusion that anyone can benefit.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story said, \"Experts said the federally funded study is a call to action for anyone who has ever worried about developing Alzheimer's, dementia and similar disorders.\" But the research reported on was not about prevention of actual diseases, only about preservation of some mental acuity.\u00a0 Age-related decline in cognitive capacity is not the same as development of age-related disease.\nIn addition \u2013 the article included reference to inability to drive at night, which is something of great concern but is not relevant to the study described.", "answer": 0}, {"article": "In a new clinical trial, scientists show that a daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over a period of just 12 weeks is enough to yield a moderate but significant improvement in the score of elderly Alzheimer's patients on the Mini-Mental State Examination (MMSE) scale, a standard measure of cognitive impairment.\nWalter Lukiw, Professor of Neurology, Neuroscience and Ophthalmology and Bollinger Professor of Alzheimer's disease at Louisiana State University, who reviewed the study but was not involved in the research, said: \"This early study is interesting and important because it provides evidence for gastrointestinal (GI) tract microbiome components playing a role in neurological function, and indicates that probiotics can in principle improve human cognition.\nBut scientists have long hypothesized that probiotics might also boost cognition, as there is continuous two-way communication between the intestinal microflora, the gastrointestinal tract, and the brain through the nervous system, the immune system, and hormones (along the so-called \"microbiota-gut-brain axis\").\n\"These findings indicate that change in the metabolic adjustments might be a mechanism by which probiotics affect Alzheimer's and possibly other neurological disorders,\" says Salami.\nAt the beginning and the end of the 12-week experimental period, the scientists took blood samples for biochemical analyses and tested the cognitive function of the subjects with the MMSE questionnaire, which includes tasks like giving the current date, counting backwards from 100 by sevens, naming objects, repeating a phrase, and copying a picture.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release essentially does the opposite of disease mongering. It does not describe what Alzheimer\u2019s disease is or who may be at risk. While this information would be helpful for readers, it is also prudent that they did not overreach on who may be affected by the disease.", "answer": 2}, {"article": "Some small pilot studies have indicated that the newer class of antidepressants known as selective serotonin and serotonin norepinephrine reupdate inhibitors (SSRIs and SNRIs) might be effective.\nIn the new study, Ellen Freeman of the University of Pennsylvania School of Medicine in Philadelphia and colleagues gave 205 women who were either starting to go through menopause who had already gone through menopause either Lexapro or a placebo for eight weeks.\nBut hormone use plummeted after the federal government's massive Women's Health Initiative shocked women and doctors by concluding the risks of the medication outweighed its benefits.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The\u00a0story didn\u2019t\u00a0state that the study discussed here was restricted to women with moderate to severe symptoms, as the competing WebMD coverage did.\u00a0\u00a0Also, the story\u00a0would have been more informative if it had reported the proportion of menopausal women who have moderate to severe symptoms. By our\u00a0read, a reader could misconstrue the study to mean that\u00a0all menopausal women with hot flashes are appropriate candidates for treatment.", "answer": 0}, {"article": "\u201cThe big question is, how can we make sure that everybody responds?\u201d\n\nThe Duke team compared their 61 volunteers to similar past patients who did not get the treatment.\nAll but one of those previous patients died after an average of 11 months.\nThese patients have a \u201cdismal\u201d prognosis, the Duke team wrote in the New England Journal of Medicine.\nThe patient who had the hemorrhage suffered aphasia but was still alive more nearly five years later.\nThey infused various doses into the tumors of the 61 glioma patients.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t exaggerate the prevalence of this disease.", "answer": 1}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story commit disease-mongering?", "explanation": "The story contains no obvious elements of disease-mongering. ", "answer": 1}, {"article": "\"Nicotine replacement therapies ... do not show any long-term effect on quitting even when combined with counseling,\" says researcher Gregory Connolly, DMD, director of the Center for Global Tobacco Control and professor of public health at the Harvard School of Public Health.\n\"Long term, our study would not say it would prevent relapse.\"\n\"In the short term, what it is designed for is treatment of withdrawal,\" he says.\nInstead, he suggests understanding its use.\nIt gives a more ''real world'' picture, he tells WebMD.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering.", "answer": 1}, {"article": "Researchers recommend large-scale clinical trials to confirm that nighttime fasting results in favorable changes to biomarkers of glycemic control and breast cancer risk.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\nIt may have a big impact on public health without requiring complicated counting of calories or nutrients.\u201d\n\nWomen who fasted for longer periods of time overnight had significantly better control over blood glucose concentrations.\nThe data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.\nNewswise \u2014 A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report University of California, San Diego School of Medicine researchers in the journal Cancer Epidemiology, Biomarkers & Prevention.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no overt disease-mongering in the news release. \u00a0But there is\u00a0an element of it in the researcher\u2019s quote:\u00a0\u201cThis is a simple dietary change that we believe most women can understand and adopt.\u201d \u00a0This implies a suggestion then, that most women should consider fasting longer at night to\u00a0reduce risk. That smacks of disease-mongering.\u00a0", "answer": 0}, {"article": "The Kelly study appears in the Oct. 5 online issue of the Journal of Epidemiology and Community Health.\nMothers were first asked about their alcohol use when the kids were 9 months old.\nMore than 11,500 children and their mothers were included in the study.\nThe children were last given a battery of behavioral and cognitive tests when they were 5 years of age.\nSo our recommendation is not to consume any alcohol at all,\" Pressman tells WebMD.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not engage in disease-mongering.", "answer": 1}, {"article": "Testing cholesterol in toddlers and babies?\nAn expert panel in the United States recommends this test for children between the ages of 9 and 11, but many aren\u2019t tested now unless they are obese or have other heart risk factors such as diabetes or high blood pressure.\nThe study authors in England estimated that if cholesterol testing costs $7 and gene testing costs $300, it would cost $2,900 for every person identified as having the disorder.\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\nFor every 1,000 people screened in the study, four children and four parents were identified as being at risk for early heart disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story included numbers on how prevalent this condition is, and the increased risk of heart disease that it carries, though it would have been stronger if it had given specifics on what the baseline risk is versus the 10-fold increase.", "answer": 1}, {"article": "Researchers say breast cancer survivors often experience side effects from cancer treatments that can persist months or years after completion of treatment.\nFor example, because many treatments designed to prevent breast cancer recurrence inhibit the body's production or use of estrogen, the hormone that can fuel breast cancer growth, breast cancer patients often experience hot flashes and night sweats, among other side effects.\nThe lead author on the study, Sarah Oppeneer Nomura, PhD, of Georgetown Lombardi, said that while further research is needed in larger study populations and with more detailed dietary data, this project addresses an important gap in research on the possible role of lifestyle factors, such as dietary habits, in relation to side effects of treatments.\n\"Understanding the role of life style factors is important because diet can serve as a modifiable target for possibly reducing symptoms among breast cancer survivors.\"\nIn the study, published in Breast Cancer Research and Treatment, higher intake of cruciferous vegetables and soy foods were associated with fewer reports of menopausal symptoms.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No mongering. But more detail on the number of women who experience menopausal symptoms as side effects from cancer treatments beyond saying they \u201coften\u201d do would help put the problem in context.", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story commit disease-mongering?", "explanation": "While this article does not frame pre-hypertension as a disease per se, it does suggest its \u2018treatment\u2019 will prevent development of hypertension. But the story doesn\u2019t give any context for the percentage of people with pre-hypertension who actually go on to develop hypertension. The drug may prevent pre-hypertension from turning into hypertension, but the story does not tell us if this early treatment reduces hard clinical outcomes (stroke, heart attack, peripheral vascular disease and mortality). ", "answer": 0}, {"article": "In the study in Nature, investigators show that HIF-2 inhibition was able to control metastatic kidney cancer even after 7 lines of prior therapy.\nHe Zhang, and Jenny Chang.\n\"This is a completely new treatment for kidney cancer.\nSimmons Cancer Center includes 13 major cancer care programs.\nSee video.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No obvious disease mongering.", "answer": 1}, {"article": "\"LaVonne has had Alzheimer's disease longer than anybody I know, and that sounds negative, but it's really a positive thing because it shows that we're doing something right,\" Moore said.\nOn a broader level, he noted, this study highlights an important point: \"Alzheimer's disease is more than just amnesia.\"\nMore than 5 million Americans have Alzheimer's -- a number that could rise to 16 million by 2050, according to the Alzheimer's Association.\nBut it's far too early to know whether it has value for people with Alzheimer's, Scharre stressed.\nBut they declined at a slower rate, compared to 96 similar patients whose information was taken from an Alzheimer's research database.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story states: \u201cMore than 5 million Americans have Alzheimer\u2019s \u2014 a number that could rise to 16 million by 2050, according to the Alzheimer\u2019s Association.\u201d", "answer": 1}, {"article": "SUNDAY, Sept. 19, 2010 (HealthDay News) -- For asthma patients whose condition is not controlled with standard inhaled steroids, the addition of Spiriva -- a medication already approved for lung disease -- appears to improve breathing, a new study finds.\n\"My hope is that in three to five years we will have the drug approved for asthma,\" he said.\nThe researchers found that Spiriva plus an inhaled steroid was more effective than giving a double dose of steroids in improving breathing and controlling asthma for these tough-to-treat patients.\nPatients stayed on each regiment for 14 weeks.\nThat's important, Peters said, because there have been some safety concerns raised about long-acting beta agonists.\n", "question": "Does the story commit disease-mongering?", "explanation": "The headline itself specifies \u201csome asthmatics,\u201d and the first sentence goes further in identifying the population affected by this research. So no disease-mongering here. ", "answer": 1}, {"article": "Bardwell hasn't worked since November because his condition, inherited, makes breathing so difficult.\nThe method, commonly used to treat pain, activates nerves that Methodist Hospital doctors think will improve the heart's ability to pump effectively, lowering blood pressure, reducing the amount of irregular heartbeats and stopping stress hormones from overreacting and causing cardiac damage.\nNew pathway to the heart\n\nElectrical stimulation of the spinal column may ease cardiac problems without drugs\n\nIn a possible new way to treat heart failure, Houston surgeons implanted a device and wire in a Pearland man Monday that will electrically stimulate portions of his spinal cord.\nThe hope is that such stimulation will modulate nervous system responses, such as toning down the release of hormones that typically occur at times of stress and increasing the flow of blood.\n\"The most I feel is a tingle like when your hand is going to sleep on you.\n", "question": "Does the story commit disease-mongering?", "explanation": "The patient profiled in the story is clearly in the most advanced stage of heart failure and may have\u00a0a dire outlook, but there are many effective and life prolonging therapies for earlier stages and not all patients reach his stage.\u00a0In addition, it is misleading to suggest that most\u00a0patients end up on 7 drugs that are ineffective;\u00a0there are many lifestyle, dietary, and drug treatments that are known to be effective for heart failure. This patient anecdote \u2013 coupled with phrases such as \"prognosis is grave\" and \"usually ultimately fatal\" \u2013 may mislead readers. ", "answer": 0}, {"article": "But, lead author Dr. Giacomo Koch said, \u201cWhat we found is that the improvement was more marked in those patients that were more impaired.\u201d\n\nKoch, from the Santa Lucia Foundation in Rome, told Reuters Health he thinks those patients with more severe problems would likely see a benefit outside of just test results.\n\u201cThey\u2019re less likely to become completely independent.\u201d\n\nMost of those patients can improve with therapy and exercises, she said, but the process is often slow, and keeping people in the hospital during it is costly.\nIt\u2019s also not clear if the treatment might help most neglect patients, or if the findings only apply to certain groups, she told Reuters Health.\nShe said that because of that, the new findings are \u201cpromising,\u201d but added that brain stimulation is still an experimental technique, and not ready to be used as part of normal stroke rehabilitation.\nFor the study, Italian researchers randomly assigned 20 patients with neglect to get real or fake magnetic stimulation in ten sessions over two weeks, in addition to their conventional rehab program.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story notes that about half of the 800,000 people who suffer a stroke each year experience\u00a0symptoms similar to those of patients in this study. This gives readers a good frame of reference for judging the impact the treatment might have. ", "answer": 1}, {"article": "WEDNESDAY, Sept. 8, 2010 (HealthDay News) -- Statins, lauded for their ability to lower cholesterol and prevent heart attacks and strokes, may also reduce the risk of developing rheumatoid arthritis, Israeli researchers report.\nThe researchers looked for connections between statin use and the development of both rheumatoid arthritis and osteoarthritis, a degenerative joint disease that is unlikely to be affected by statins, the researchers noted.\nFor example, compared with patients who took statins less than 20 percent of the time, patients who took statins for 40 percent to 59 percent of the time had a 23 percent lower risk of developing rheumatoid arthritis, he said.\n\"We found that statin users who purchased their medication persistently were less likely to develop rheumatoid arthritis over a long follow-up period,\" said lead researcher Gabriel Chodick, from Maccabi Healthcare Services in Tel Aviv.\n\"Although the study does not have immediate clinical implications, our findings may suggest that patients who were prescribed statins and take it persistently may benefit from the many effects of statins, which go far beyond cholesterol reduction, including the reduction of rheumatoid arthritis risk,\" Chodick said.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe story does not resort to disease-mongering, but neither does it provide any information to the reader about the prevalence of the disorder or its impact on quality of life. The story would have been improved with a bit of background information about RA and its societal impact, The American College of Rheumatology estimates the prevalence of RA between 2 and 10.7 per 1,000 adults. While relatively uncommon, RA can be a devastating chronic illness. It would have been helpful to provide\u00a0information on prevalence.", "answer": 1}, {"article": "That's why I was so interested in a report last week in the Journal of the American...\nWe've heard a lot about the health benefits of tea, especially green tea.\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nThere's a growing body of research to suggest that both are probably good for you.\nCoffee or tea?\n", "question": "Does the story commit disease-mongering?", "explanation": "Cancer and cardiovascular disease (two major causes of death in the U.S.) are not hyped. ", "answer": 1}, {"article": "Participants who slept for six hours each night did only slightly better -- they were 4.2 times more likely to develop a cold than the seven-hour-a-night folks.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\nThe actigraphy measured sleep in a much more accurate way than information researchers get from self-reports, he says.\n\"Sleep is part of our own nature's defense against illness,\" says Dr. M. Safwan Badr, former president of the American Academy of Sleep Medicine and chief of the division of pulmonary, critical care and sleep medicine at Wayne State University School of Medicine in Detroit.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story makes no mention of the incidence or severity of the common cold. So in that respect, we can\u2019t really give credit here for avoiding disease-mongering. We\u2019ll rule in Not Applicable.", "answer": 2}, {"article": "\u2022 Even among patients with hypertension, a longer median overall survival was observed among users of NSBBs compared with nonusers (90 months versus 38.2 months).\nfrom Washington University School of Medicine.\nThey target a receptor protein in heart muscle that causes the heart to beat harder and faster when activated by stress hormones,\" Sood said.\nAll these factors were associated with decreased survival, yet those who received beta-blockers had either equivalent or improved overall survival.\nWith further research, they may also prove beneficial in conjunction with other treatment regimens and across other cancer types.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\"There are 150,000 new cases of colon cancer each year in the United States, treated at an estimated cost of $14 billion,\" noted Dr. David A. Ahlquist, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn.\n\n\"The dream is to eradicate colon cancer altogether and the most realistic approach to getting there is screening,\" he said.\nCologuard is not yet available for sale.\n\"We learned there are still some bugs and we can make the test even better,\" he said.\n\"These findings are interesting,\" he said.\nThen we will know if this is a big step forward,\" he said.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The study started in August 2010.\nComplications from shingles can include PHN, (the most common complication), scarring, vision complications, secondary infection and nerve palsies3,4.PHN is often defined as a localized pain of significant intensity persisting at least 90 days after the appearance of the acute shingles rash4.\nIf approved, this candidate vaccine could be an important tool for the prevention of shingles and the pain associated with it, which would significantly impact the health and quality of life of so many people.\"\nAnyone who has been infected with VZV is at risk of developing shingles, with age and altered immune system being recognised as the main risk factors3,4.\nThe candidate vaccine was shown to be 89% (95% confidence interval: 68-97%) efficacious in preventing PHN in people aged 70 years and older and 91% efficacious (95% confidence interval: 75-98%) in people aged 50 years and over1.\n", "question": "Does the news release commit disease-mongering?", "explanation": "Shingles is a common problem, and it can be severe. The news release avoids overstating either the frequency of shingles\u2019 occurrence or the severity of its symptoms.", "answer": 1}, {"article": "Obstructive sleep apnea occurs when the soft tissues of the mouth and airway, especially the tongue, block air flow into the lungs.\n\u201cAnd then the doctors looked piece by piece, and realized that what I have is sleep apnea.\u201d\n\nTurner\u2019s nightly interrupted breathing increased her chances of heart attack or stroke by three to four times, according to Dr. Robson Capasso, associate professor of Otolaryngology Head and Neck Surgery at Stanford University.\nI thought since I'm older so that's what it is.\u201d\n\nIt wasn\u2019t until a mother-daughter vacation that Turner\u2019s daughter noticed something interesting when her mother slept.\n\u201cI was exhausted all the time, from the time I woke to the time I went to bed,\u201d says Turner.\n\u201cIt was 41 times per hour that I would stop breathing,\u201d says Turner.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no overt disease mongering here. But we\u2019d\u00a0like to know where the\u00a0\u201c90% are undiagnosed\u201d figure comes from since this could contribute to disease mongering.", "answer": 1}, {"article": "Oct. 6, 2010 -- An extended-release version of the seizure and pain drug gabapentin may be one step closer to becoming the first approved nonhormonal treatment for menopause -related hot flashes .\n\u201cEstrogen and estrogen-progestin drugs are about 95% effective for treating hot flashes,\u201d he tells WebMD.\nResearchers presented findings from two studies of Serada at the NAMS meeting.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\nUtian is now an independent consultant and was a co-author of one of the studies.\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "First, he asks patients for whom statins are recommended according to the current guidelines if they would want to avoid taking the drugs if they turn out to have a calcium score of zero and an actual risk of less than 5 percent.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\nBut if that person has a calcium score of zero, the actual risk turned out to be 4 percent, below the 7.5 percent threshold for recommending a statin according to the guidelines and below the 5 percent risk for considering a statin.\nThe study subjects were nearly 4,000 men and women ages 45 to 84 and included blacks, whites, Hispanics and Asians who were recruited in 2000 through 2002.\nBut the amount of calcium in arteries can give a good idea of the presence or extent of coronary artery disease.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story reports that proponents are suggesting this sort of scan only for people who need more information to make a decision about statin treatment. It also includes skeptics who doubt the value of the test for most people.\u00a0The tone is calm, not shrill. We saw no evidence of disease mongering.", "answer": 1}, {"article": "Clinical trials are needed to investigate whether these beverages do indeed help prevent diabetes, the researchers say.\nThe fact that the effects were seen with decaf as well as coffee and tea suggest that if the effects are real, they aren\u2019t just due to caffeine, but may be related to other substances found in these beverages, the researchers say, for example magnesium, lignans (estrogen-like chemicals found in plants), or chlorogenic acids, which are antioxidants that slow the release of sugar into the blood after a meal.\nIt\u2019s also not possible to say from the current evidence that heavy coffee drinkers (and tea and decaf drinkers) don\u2019t have other characteristics that might protect them against developing diabetes, they add, such as eating a healthier diet.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nIn the years since then, they add, the amount of research on coffee and diabetes risk \u201chas more than doubled,\u201d while other studies have suggested that tea and decaf coffee may also be preventive.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0The story did not engage in overt disease mongering. In contrast with the WebMD story, it provided a source when it stated, \"Type 2 diabetes, which is often tied to obesity, affects about 8 percent of the U.S. population, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\" ", "answer": 1}, {"article": "Sharif said the excellent short-term outcomes and 100 percent cure rate of HCV in organ recipients should prompt transplant centers to rethink use of HCV-infected kidneys.\nIn a study of 20 uninfected patients, researchers found that transplanting infected kidneys and then treating recipients for HCV resulted in a 100 percent cure rate.\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\n\"Because of the opioid crisis, there are many people who die from a drug overdose and have HCV and want to donate their organs.\"\n\"And we found that these kidney transplants were working as well as kidney transplants from uninfected patients,\" Reese said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story said of the \u201croughly a half-million patients in the United States who were on dialysis for late-stage kidney disease in 2016, only 19,000 received kidney transplants.\u201d", "answer": 1}, {"article": "\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe laparoscope is a slender tube that allows the surgeon to see inside the body.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\nMost minimally invasive prostate operations are robot assisted.\nLaparoscopic operations for prostate cancer, a minimally invasive surgery that is in rising demand, result in fewer immediate complications and quicker recovery than the more common open procedure, a new study reports.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does nothing to exaggerate the complications of prostatectomy or the success of the procedures studied.\u00a0 \n\u00a0", "answer": 1}, {"article": "Each patient completed standardized behavioral rating scales and participated in a semi-structured interview answering five open-ended questions to stimulate conversation, such as \"Do you have hope?\"\nThe study is published in the journal Suicide and Life-Threatening Behavior, a leading journal for suicide research.\n\"These computational approaches provide novel opportunities to apply technological innovations in suicide care and prevention, and it surely is needed,\" says Dr. Pestian.\nThose enrolled included patients who were suicidal, were diagnosed as mentally ill and not suicidal, or neither - serving as a control group.\nThe scientists also noticed that the control patients tended to laugh more during interviews, sigh less, and express less anger, less emotional pain and more hope.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We\u00a0didn\u2019t\u00a0see any problematic descriptions of suicide here, which is of special concern given the evidence for contagion.", "answer": 1}, {"article": "When it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\nPeople with a lot of social jet lag also tend to get fewer hours of sleep, which exacerbates these same health problems.\nFor one, teens need more sleep than adults: about eight or nine hours a night, compared with about the six or seven their parents require.\nTeens tend to be night owls, and forcing them to be early birds can mess with their health\n\nTeens tend to go to sleep a bit later and wake up a bit later than the average adult \u2014 something called a \u201cdelayed\u201d sleep phase.\nBeing tired in the morning can be a dangerous distraction while on the road.\n", "question": "Does the story commit disease-mongering?", "explanation": "Sleep deprivation, while not a disease per se, makes it hard to function and may have long-term impacts, as well.", "answer": 1}, {"article": "\u201cAnd Amgen\u2019s not a company that likes to price gouge.\u201d\n\nSchmidt said Imlygic\u2019s market potential as a standalone drug is \u201cvery, very modest.\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\nAnd as the first tumor-killing virus to receive the FDA\u2019s blessing, Imlygic could accelerate the development of other viral therapies.\n\u201cBut short of that, this might be like diabetes, where we can control it and people live normal lives.\u201d\n\nImlygic is based on a form of the herpes simplex virus that commonly causes cold sores.\nIt\u2019s being developed in combination with other immunotherapies, where we think there\u2019s a little more of a commercial opportunity, but we still need to see more data.\u201d\n\nImlygic is approved for skin tumors that are inoperable in patients whose cancer has returned following surgery.\n", "question": "Does the story commit disease-mongering?", "explanation": "Metastatic melanoma is a serious disease that is difficult to treat successfully.\u00a0 The story heralds this use of a genetically modified herpes simplex virus as important, and we think that is an appropriate judgment.", "answer": 1}, {"article": "\u201cHowever,\u201d she added, \u201cunlike a pill, which always has the same ingredients, acupuncture, like psychotherapy, varies from one provider to the other.\u201d\n\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n\nIt\u2019s estimated that 3 to 5 percent of pregnant women are diagnosed with depression, Manber and her colleagues note in their report.\nAnother 49 women received control acupuncture and 49 received massage.\nFourteen women who received depression-specific acupuncture reported pain during the needling, as did seven in the control-acupuncture group.\nAfter eight weeks, patients in the depression-specific acupuncture group had a higher rate of response to treatment.\nAcupuncture has been used for more than 2,000 years in Chinese medicine to treat a wide variety of ailments.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story included data indicating that 3-5% of pregnant women are diagnosed with depression.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "The story describes how many people are on waiting lists for kidney transplants.", "answer": 1}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering here.", "answer": 1}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cNow, patients can undergo a minimally invasive procedure to fix complex problems of the aorta without having open surgery.\u201d\n\nThe Valiant Navion\u2122 thoracic stent graft system is delivered from a groin blood vessel into the aorta, is positioned above the affected aneurysm, and is deployed under x-ray guidance.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\nThough aneurysms can happen anywhere in the body, they most commonly happen in the brain, or in the main vessels that lead to the heart, legs and arms.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no obvious disease mongering and we learn that \u201caneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\u201d \u00a0What we don\u2019t get is how common or uncommon such ruptures are, and this would have been a very good educational point to make in this news release.", "answer": 0}, {"article": "MONDAY, Oct. 31, 2011 (HealthDay News) -- Doctors who listen to Mozart while performing colonoscopies may spot more precancerous growths, researchers suggest.\nThis was up from a baseline detection rate of 21 percent before the study began.\nWhen spotted early, potentially dangerous polyps can be removed during colonoscopies, preventing the development of disease.\n\"Adenoma detection rate is linked to a reduction in colorectal cancer incidence, so it is an important quality indicator for colonoscopy,\" said O'Shea.\n\"Anything we can do to get those rates up has the potential to save lives.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story provided some brief information on invasive colorectal cancer, based on the information in the news release.", "answer": 1}, {"article": "She tried decongestants, antihistamines and steroid nasal sprays.\n\"And if we can use those as novel targets for, let's say, nasal sprays or medications, we may be able to treat people like Judy without surgery,\" Metson says.\nBut when she overcame her squeamishness and finally had the operation, she found it wasn't nearly as bad as she thought it would be.\nBut they can't stop the inflammation some people are prone to, and that inflammation can cause new obstructions.\nTo avoid poking through to the brain or into the orbit of an eye, there's a device around the patient's head with a guidance system that tells Metson, in three dimensions, exactly where his sharp instruments are on a CT scan of Butler's head.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in this story. The story makes it clear that the surgery being described is a last-ditch approach for people with intractable problems.", "answer": 1}, {"article": "\"Gardasil has the potential to meet an unmet medical need as the first vaccine to prevent cervical cancer,\" Merck's Dr. Patrick Brill-Edwards told the Vaccine and Related Biological Products advisory committee.\nHPV is the most common sexually transmitted disease.\nAlso, the drug does not protect against infection from the many other virus strains not included in the vaccine.\nSeveral speakers said the vaccine should not replace screening.\nThe drug protects against the two types of human papillomavirus (HPV) believed responsible for about 70 percent of cervical cancer cases.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to engage in disease mongering.", "answer": 1}, {"article": "Visit redrazz.org for more information, and follow us on our social media channels:\nThese findings provide a basis for formulating hypotheses for conducting additional studies, particularly in human trials.\nSeven individual anthocyanins were identified in the samples.\nThis may reflect differences in varieties, origins, processing methods among other influential factors.\nThirty-four samples - both domestic and imported - were reviewed.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was no disease mongering.\u00a0", "answer": 1}, {"article": "WEDNESDAY, July 13, 2011 (HealthDay News) -- For men who have prostate cancer that's considered \"intermediate risk,\" radiation plus four months of hormone therapy appears to improve survival, a new study finds.\nThe hormone therapy is known as androgen deprivation therapy.\nYou need to give long-term androgen deprivation therapy in addition to radiation to have the best results,\" Jones said.\nIt could be four months, six months or longer.\"\nHe noted that the radiation treatments in use today differ from those given in 1994 when the trial began.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story did not engage in overt disease mongering.", "answer": 1}, {"article": "WEDNESDAY, Aug. 17, 2011 (HealthDay News) -- People who have narrowed carotid arteries in the neck and show no symptoms may be at risk for stroke and not know it, but a simple ultrasound test can identify the problem, a new study suggests.\nThe patients who are at high risk are candidates for surgery, he said.\nThe problem is identifying the patients at the highest risk for stroke, he said.\nThe report was published in the Aug. 17 online edition of Neurology.\nEach participant had an ultrasound to see if there were signs that a stroke might occur.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease mongering.", "answer": 1}, {"article": "Contributing authors Dr. Farid Saad is a full time employee of Bayer Pharma.\nTo date, there are limited studies comparing the effects of long-term TTh in hypogonadal men who were treated or remained untreated with T.\n\nResearchers at Boston University Schools of Medicine (BUSM) and Public Health (BUSPH), along with researchers in Germany, established a registry to assess long-term effectiveness and safety of T in men.\n(Boston)--Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.\nWe believe that the protective effect of T on the CV system provides clinicians with the opportunity to utilize this approach for secondary prevention for hypogonadal men with a history of CV events,\" explained corresponding author Abdulmaged M. Traish, PhD, professor of biochemistry and urology at BUSM.\nIn the absence of large, prospective, placebo-controlled clinical trials of longer duration, substantial evidence regarding the safety and risk of testosterone therapy (TTh) with regard to cardiovascular outcomes can only be gleaned from observational studies.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We credit the release for not referring to the manufactured disease label \u201clow T\u201d that others have ascribed to the natural decline in testosterone levels as men age.\nGiven the controversies over the necessity for testosterone replacement, the study results beg the question of why these men were on testosterone replacement in the first place \u2014 and whether it was successfully addressing the symptoms for which it was prescribed. If not disease mongering, then this is product mongering.", "answer": 0}, {"article": "\u201cSo in our study we wanted to expand that and look at all-cause mortality and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d\n\nFor the study, the researchers analyzed data on from 2004 to 2012 on 70,000 women who participated in the Nurses\u2019 Health Study, a long-running research project tracking women\u2019s health via surveys every two years.\nHaving an optimistic outlook on life may do more than just boost your mood.\nThe study, published in the American Journal of Epidemiology, found that women who were optimistic had a significantly lower risk of dying from several major diseases, including cancer, heart disease, stroke, and respiratory disease, compared to other women whose outlook on life was less positive.\nWhile the study is observational and cannot prove a cause-and-effect relationship between optimism and a longer life, the researchers have some theories for what might be behind the connection.\nThey suggested a number of steps people can take to improve their level of optimism.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s\u00a0no sign of dramatic or charged language here.", "answer": 1}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story commit disease-mongering?", "explanation": "There is no disease mongering in the story, and it makes it clear what type of patient was being studied: \u201cThe patients studied had heart disease in two or three of the vessels that provide blood to the heart. They were stable, and thus didn\u2019t need a procedure urgently. Currently, such patients could be candidates for either approach.\u201d", "answer": 1}, {"article": "Instead, the chief usefulness of the \"ALVAC-AIDSVAX\" vaccine is likely to be what it can teach virologists about what is happening in the immune system when a person is even somewhat protected from HIV.\nThe vaccine is not licensed or being produced in large amounts.\nThat the vaccine is at least nominally a success comes as a surprise.\nAn experiment in Thailand involving more than 16,000 men and women has demonstrated for the first time a small but measurable protective effect of an AIDS vaccine.\n\"I just think it's too early really,\" said one, who spoke on the condition of anonymity for that reason.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering in this story. ", "answer": 1}, {"article": "All were enrolled in the CHARGE study (CHildhood Autism Risks from Genetics and Environment) from 2003 to 2009.\nThe researchers collected blood from all family members to evaluate their genetic makeup.\nIt may be that the vitamins contribute to high levels of folate.\nThe risk rose if the mothers or the children had a high-risk gene form.\nThe research needs to be duplicated, Hertz-Picciotto tells WebMD.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease-mongering in this story. Autism incidence was clearly stated and there were no dramatic anecdotes.", "answer": 1}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story commit disease-mongering?", "explanation": "By accurately describing the prevalence of Alzheimer\u2019s, the story avoids disease mongering.", "answer": 1}, {"article": "In the meantime, she cautions Alzheimer\u2019s patients not to rush out and try to take insulin.\nThose who received placebos got worse.\nThe lower dose seemed more effective than the higher one.\nAgain, the hormone seemed to help.\nFrom there the hormone travels along the path of nerves into the brain.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease-mongering.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A small U.S. study suggests daily hormone injections may boost mental agility in older people with and without mild cognitive problems.\nIt dwindles naturally with aging, which has been linked to declines in memory and executive function.\nAn expert who wasn\u2019t involved in the research echoed the cautions.\nIt\u2019s possible health problems could show up down the road, and the mental boost may be short-lived.\nIt\u2019s unclear how the test differences will translate into real life, said Baker.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play here.", "answer": 1}, {"article": "Besides M.D.\nIn the last decade, hopeful of finding a better test, ovarian cancer researchers have invested much time in the investigation of other biomarkers and technologies.\nMore than half of the women in the study came from Houston.\nBut she added that an ongoing study in the United Kingdom involving 200,000 women should more definitively determine the test's value.\nAnd if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not hype the seriousness or prevalence of ovarian cancer. It is a devastating diagnosis.", "answer": 1}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness of blood clots. However, the story may mislead women into thinking they are more common than they are by describing them as \"one of the most common health risks associated with hormones.\" No sense of absolute risk is given in the general population of women or among women taking hormone therapy. Blood clots are still very rare with hormones, occuring in fewer than 25 women per 10,000. Nonetheless, we'll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "The CoolSculpting procedure is not a treatment for obesity.\n\"A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73 percent of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.\"\nThese factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS\u00ae, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017.\nCoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one treatment.1\n\n\"Allergan is committed to advancing innovation for CoolSculpting\u00ae to meet the needs of patients seeking non-invasive aesthetic treatments,\" said David Nicholson, Chief Research and Development Officer at Allergan.\nDUBLIN, Dec. 12, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting\u00ae treatment is the first and only non-surgical fat reduction technology to be FDA-cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release suggests that a 2017 consumer survey \u201c\u2026revealed that 73 percent of patients are bothered by excess fat under the chin.\u201d \u00a0Really?\u00a0\u00a0Are these survey participants bothered enough that they want the \u201cexcess fat\u201d removed? \u00a0And if so, what is wrong with the rest of us who are not eager to do so?\u00a0 This statistic suggests that the vast majority of the population are candidates for treatment with this device \u2014 and that\u2019s simply not the case.\u00a0 We\u2019re rating this Not Satisfactory for disease-mongering.", "answer": 0}, {"article": "\u2022 If you have any question or request regarding interview opportunities, please contact:\n\u2022 For full details of a session, have a look at the Scientific Programme & Planner: http://spo.\nIts mission is to reduce the burden of cardiovascular disease in Europe.\nDifferent activities have been associated with different MET intensity.\nRelation between physical activity and morbi-mortality of elderly people: the Proof cohort study.\nA systematic review and meta-analysis.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease mongering.", "answer": 1}, {"article": "Article reference: R.M.\n\"The results are compelling and strongly argue for a change in practice,\" says Vincenzo Berghella, M.D., the Director of Maternal Fetal Medicine and Professor in the Department of Obstetrics and Gynecology at the Sidney Kimmel Medical College at Thomas Jefferson University.\nOf those, about half (or 593 women) received IV fluids at a rate of 250 milliliters per hour, and the other half (622 women) received fluids at the lower rate of 125 milliliters per hour.\nWith a university and hospital that date back to 1824, today Jefferson is comprised of six colleges, nine hospitals, 34 outpatient and urgent care locations, and a multitude of physician practices throughout the region, serving more than 100,000 inpatients, 373,000 emergency patients and 2.2 million outpatients annually.\nBy pooling the data of several studies, Thomas Jefferson University researchers showed that a higher rate of IV fluids not only decreased c-section rates, but also shortened the overall length of labor by one hour, as well as shortened the pushing phase.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It notes that cesarean surgery remains ubiquitous despite ongoing attempts by obstetrics organizations to reduce its incidence and, as a result, its accompanying risks. That\u2019s important context.", "answer": 1}, {"article": "The results are interesting but need to be duplicated in larger, more ethnically diverse populations, said Dr. Laura Svetkey, director of Duke University's Hypertension Center.\nAverage blood pressure at the start was about 147 over 86.\nIt was funded by University Hospital in Cologne.\n\"I would be as happy as the next person if I got to eat more chocolate,\" she said.\nFor most people, \"the lower your blood pressure, the better you are.\n", "question": "Does the story commit disease-mongering?", "explanation": "No overt disease-mongering.", "answer": 1}, {"article": "Watch Chief Medical Correspondent Dr. Sanjay Gupta's CNN Special Report \"Weed 4: Pot vs.\n\"There is a great deal of movement in the Northeast, with New Hampshire and New Jersey being well-positioned to legalize adult use,\" Moore said.\nThe researchers found that states that allow the use of cannabis for medical purposes had 2.21 million fewer daily doses of opioids prescribed per year under Medicare Part D, compared with those states without medical cannabis laws.\nThe details of the medical cannabis laws were found to have a significant impact on opioid prescription patterns, the researchers found.\nBut unlike opioids, marijuana has little addiction potential, and virtually no deaths from marijuana overdose have been reported in the United States, according to Bradford.\n", "question": "Does the story commit disease-mongering?", "explanation": "It is widely acknowledged that the country is in the midst of an opioid epidemic. In 2016, there were more than 63,600 drug overdose deaths in the United States.", "answer": 1}, {"article": "This was the first time a portable device was used for these tests.\n\"While the portable device clearly distinguished people with schizophrenia from those without a psychiatric diagnosis, it's too soon to call this a diagnostic tool,\" said lead author Docia Demmin, a graduate assistant in UBHC's Division of Schizophrenia Research and a doctoral student in Rutgers Department of Psychology.\nAlthough we know quite a bit about it, it's still not that well understood,\" said Steven Silverstein, professor of psychiatry at Rutgers Robert Wood Johnson Medical School and director of research at Rutgers University Behavioral Health Care (UBHC), who designed the study.\n\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\nIn the study, published in the May 2018 issue of the Journal of Abnormal Psychology, researchers used RETeval, a hand-held device developed to record electrical activity from the retina, to replicate and extend prior studies showing that people with schizophrenia had abnormal electrical activity in the retina.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here. But the release doesn\u2019t provide much context about the disease other than a quote from the lead researcher: \u201cSchizophrenia is a devastating disorder, probably the most disabling disorder long term. Although we know quite a bit about it, it\u2019s still not that well understood.\u201d\nThe prevalence of schizophrenia and related psychotic disorders in the U.S. is estimated at 0.25 percent to 0.64 percent of the US population.", "answer": 2}, {"article": "Chronic rhinosinusitis (CRS) affects a sizable minority -- 14 percent to 16 percent -- of U.S. residents.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\nFollowing the surgery, about 76 percent of patients had \"clinically significant\" improvement in quality of life, as measured by various validated scales.\nThe U.S. National Institute of Allergy and Infectious Diseases has more on sinusitis.\n\"Some people with stage 1 and 2 diseases may even get cured.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story provides data showing how many people in the U.S. have been diagnosed with chronic rhinosinusitis.\u00a0\u00a0\u00a0", "answer": 1}, {"article": "Newswise \u2014 TORONTO, June 20, 2017 \u2013 In a Canadian first, a medical team has implanted a wireless device inside a heart failure patient, permitting clinicians to monitor the patient\u2019s cardiovascular status \u2013 virtually and in real-time \u2013 and proactively adjust treatment to prevent costly, potentially unnecessary hospitalization.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\n\u201cNever before have we had the ability to obtain a patient\u2019s accurate lung pressure data while they are outside the hospital,\u201d said Meredith Linghorne, nurse practitioner, Peter Munk Cardiac Centre.\nThe CardioMEMS\u2122 HF System is designed to monitor heart failure patients whose condition is serious but who are not so ill that the technology cannot improve their outcome.\nThis technology is a way to directly measure how much fluid is in a patient, allowing us to intervene before they develop symptoms of congestion, before they end up in hospital.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering in the news release per se, but the lead scientist refers to heart failure as an epidemic, which could give the wrong impression. However, this is addressed in the unjustifiable language section. We also wish the news release could have given us the sources for its heart failure numbers, as they vary widely across agencies.\nWe give the news release the benefit of the doubt and a Satisfactory rating.", "answer": 1}, {"article": "\"And with the one oral option we have today, there has been a lot of concern over a possible risk for immune suppression and also an increased risk for cancer,\" added Zamvil, who was not a part of the current study team.\nThe incidence of liver enzyme elevation was higher in patients treated with laquinimod, according to Comi, but he added that the elevations were temporary, reversible and did not lead to any signs of liver problems.\nThe findings concern the experimental drug laquinimod, and stem from work with over 1,100 MS patients at 139 medical facilities in 24 countries.\nBut there's a lot of excitement about this new option and these results, because even though the injectables are safe and effective in terms of convenience and patient compliance, oral drugs are much better than shots.\"\nIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. In fact, we would have preferred a little more information about the disease and the different drugs used to treat various aspects of the disease.", "answer": 1}, {"article": "U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\nPatients came for treatment from every state and 180 countries.\nBlood pressure is typically recorded as two numbers.\nBefore age 50, an elevated diastolic blood pressure is associated with increased cardiovascular disease risk.\nAt the beginning and end of each diet period, participants spent three days undergoing metabolic testing in a clinical research setting.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The current treatment for chronic HCV -- intravenously administered peg-interferon and ribavirin -- cures about half of people with genotype 1 who take it.\nThe research is so early that the drug hasn't been named.\nIt is known as BMS-790052.\n\"What we are developing, and a lot of other companies too, are small molecule antiviral agents that specifically target the virus.\"\nBut many patients find they cannot tolerate months of treatment with interferon, which can cause anemia and severe flu-like symptoms.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story does not exaggerate the prevalence or severity of hepatitis C.", "answer": 1}, {"article": "The drug is not approved for children \u2013 except a rare few with premature puberty \u2013 because it can impair bone development crucial to growth, said Dr. Gary Berkovitz, chief of pediatric endocrinology at the University of Miami medical school.\nTeresa Badillo was at the meeting.\nLupron therapy grew from the mercury camp.\nGeier could not be reached for comment despite several attempts by phone.\nAutistic children are prone to seizures.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering in this story. ", "answer": 1}, {"article": "With this new approach, SD-101 is the match that starts the fire.\"\nIn UCLA-led study, new treatment is more effective in people receiving immunotherapy for the first time\n\nA UCLA-led study has found that a treatment that uses a bacteria-like agent in combination with an immunotherapy drug could help some people with advanced melanoma, an aggressive form of skin cancer, live longer.\n\"We are really starting to understand the science of how immunotherapies work in patients,\" said Ribas, who is also the director of the Parker Institute for Cancer Immunotherapy Center at UCLA.\nThe results of the study suggest that the combination of pembrolizumab and SD-101 could provide an alternative treatment for people with melanoma whose tumors have not responded or would be unlikely to respond to other therapies.\nThe research showed that using the immunotherapy drug pembrolizumab and the experimental agent SD-101, a sequence of nucleic acids that mimics a bacterial infection, altered the microenvironment around the tumor in a way that enabled the immune system to more effectively attack the cancer.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There is no disease mongering. Some statistics on how many people are diagnosed with metastatic melanoma every year would have been useful to include.", "answer": 1}, {"article": "Editor's note: To obtain a copy of the Cancer Prevention Research paper, \"Effect of vitamin D3 supplementation in combination with weight loss on inflammatory biomarkers in postmenopausal women: a randomized controlled trial,\" or to arrange an interview with corresponding author Catherine Duggan, please contact: Kristen Woodward in Fred Hutch media relations, kwoodwar@fredhutch.org or 206-667-5095.\nChronic inflammation is known to contribute to the development and progression of several diseases, including some cancers.\n\"It is thought that this state of chronic inflammation is pro-tumorigenic, that is, it encourages the growth of cancer cells,\" she said.\nWhile IL-6 has normal functions in the body, elevated levels are associated with an increased risk of developing certain cancers and diabetes and may be implicated as a cause of depression, Duggan said.\nHalf of the study participants were randomly selected to receive 2,000 IU of vitamin D daily for the duration of the year-long trial, and the other half received an identical-appearing placebo, or dummy vitamin.\n", "question": "Does the news release commit disease-mongering?", "explanation": "It\u2019s hard to argue that overweight, vitamin deficiency, chronic inflammation and cancer are not real threats, so no mongering\u00a0apparent here.", "answer": 1}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story commit disease-mongering?", "explanation": "We had a healthy debate within our review team as to whether the story should be flagged here. The story says that brain metastases affect \u201can estimated 400,000 to 600,000 patients annually in the U.S. alone.\u201d It\u2019s not clear where this number comes from. According to the NCI, \u201cit has been estimated that 98,000 to 170,000 new cases [of brain metastases] are diagnosed in the United States each year.\u201d These numbers fall well below the \u201c400,000 to 600,000\u201d cited in the story.\nThat being said, the story is likely referring to the number of living people in the U.S. who have been diagnosed with brain metastases at some point, which could easily amount to 400,000 to 600,000. But the wording is not clear on that point, and we think many readers will assume the story is talking about new cases each year. We\u2019ll give the benefit of the doubt as we usually do in these cases, but we wish that the story had given a citation for these numbers and clarified that the numbers were for prevalent disease (anyone living with the condition), not new cases. Brain cancer is sufficiently scary without throwing around large, unsourced numbers.", "answer": 1}, {"article": "Bianchi said one study had estimated the blood test costs about 255 pounds in the UK (about $413), all included.\nThat leaves some room for error, which could be important if parents are making medical decisions based on the results \u2014 such as whether or not to get an invasive procedure to look for genetic disorders.\nThey found parents could trust the test 98.8 percent of the time when it said they\u2019d have a boy, and 94.8 percent of the time when it indicated a girl.\n\u201cRemember, gender is not a disease.\u201d\n\nThe test looks for small pieces of the male sex chromosome in the mother\u2019s blood, which would mean she is carrying a baby boy.\nSome European hospitals already rely on the method, called cell-free fetal DNA, although it\u2019s not available from doctors in the U.S.\n\n\u201cWhat they are finding in England is that many women are not going on to have the invasive tests,\u201d Bianchi told Reuters Health.\n", "question": "Does the story commit disease-mongering?", "explanation": "Reuters clearly discusses the alternatives for determining fetal sex, including chorionic villi and amniotic fluid sampling, and ultrasound. They don\u2019t exaggerate the benefits or problems with gender testing.", "answer": 1}, {"article": "[Seriously, why does anyone under 18 still have access to a tanning bed?]\nThe FDA warned, however, that the treatment also has the potential to kill other types of cells, such as skin cells, if injected improperly.\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\nAccording to a survey last year by the American Society for Dermatologic Surgery, nearly 70 percent of respondents listed \"excess fat under the chin/neck\" as a key concern about their appearance.\nKeith Leonard, chief executive of Kythera, the California-based firm that developed Kybella, said at a conference last month that he believes the new treatment \"can drive a very large market and leave very satisfied patients.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "Providing comments such as: \u201cAccording to a survey last year by the American Society for Dermatologic Surgery, nearly 70 percent of respondents listed \u2018excess fat under the chin/neck\u2019 as a key concern about their appearance\u201d\u00a0 suggests that this is indeed an issue for a majority of Americans. The story could have provided more detail about where this number came from \u2014 how was the survey conducted and in whom? \u2014 but since it provides a link to a report on the findings, readers can theoretically find out more if they want to. So we\u2019ll rate this Satisfactory.\nAs noted above, we\u2019d prefer it if the story had mentioned the concern \u2014 underscored by the FDA in its announcement \u2014 that the drug could be prescribed to melt fat elsewhere in the body, which may not be safe.", "answer": 1}, {"article": "After a systematic review of medical research on the subject, experts reported that adding an aromatase inhibitor -- a drug that reduces the amount of estrogen produced in the body -- has clearly been shown to reduce the number of tumor recurrences in postmenopausal women compared with the standard drug tamoxifen, which works by blocking the action of estrogen on cancer tumors that are estrogen-receptor positive.\n\"Are [aromatase inhibitors] better than tamoxifen?\nThe drugs can also cause side effects that need to be taken into account when prescribing.\n\"Aromatase inhibitors are clearly associated with osteoporosis and with bone and joint [conditions].\nBut the [financial] costs are much more expensive.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "Statins may protect against fatal prostate cancer through their known cholesterol-lowering effects, said Dr. Stephen Freedland, who studies prostate cancer at the Duke University Medical Center in Durham, but wasn\u2019t involved in the new study.\nBut it\u2019s also possible that statins don\u2019t prevent certain cancers at all, Freedland said, and it\u2019s something else about men who take statins \u2014 for example, if they also change their diet and start exercising \u2014 that explains their lower risk of fatal cancer.\nBut, Marcella added, \u201cI would not tell a person if they don\u2019t have a risk of heart disease, (if) they don\u2019t have hypertension...to take a statin just to prevent lethal prostate cancer.\u201d\n\nThe evidence that\u2019s effective, he said, just isn\u2019t there yet.\nTo prove that statins protect against aggressive cancer would require a large study in which cancer-free men, or those with early-stage disease, are randomly assigned to take statins or not and then tracked for years to see how many of them die from cancer.\nWhen they accounted for whether or not men were overweight and their other health problems and medications, it turned out that those with fatal cancers were 63 percent less likely to have ever taken a statin, according to findings published in Cancer.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.\u00a0 Ends with \u201cResearchers agreed that until there\u2019s clearer evidence for benefit, men with healthy hearts shouldn\u2019t seek out statin prescriptions for the purpose of lowering their prostate cancer risks.\u201d", "answer": 1}, {"article": "Some experts said they hope the findings will encourage more doctors to consider treating elderly men.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\nThe study of more than 44,000 American men ages 65 to 80 found that those who chose to aggressively treat their prostate cancer with surgery or radiation were about 30 percent less likely to die than those who waited, indicating that treatment offered a clear advantage.\nThe findings prompted debate among specialists, who said the results could have potentially far-reaching implications because they address one of the central quandaries about prostate cancer and because the disease is so common.\nSome doctors fear the cancer is being over-treated, particularly in older men, subjecting them to therapies that leave many impotent and incontinent when their cancer would never bother them if left untreated.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does provide some context about early prostate cancer, including numbers of men who are diagnosed with or die from the condition, as well as the fact that many prostate cancers are slow-growing and may never cause harm before a man dies of something else.\u00a0\u00a0 ", "answer": 1}, {"article": "(CNN) -- Taking dietary supplements containing essential fatty acids can help reduce the symptoms of premenstrual syndrome, according to the results of study by researchers at a Brazilian university.\nOther treatments studied for PMS include vitamin B6, ascorbic acid and niacin.\nEssential fatty acids are substances that are not produced by the human body and are only available from diet.\nThe study cites research dating back to 1983 examining such a possible link.\nAccording to the study, women who took the supplements for six months saw a bigger benefit than those who took them for three months.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate symptoms of PMS.", "answer": 1}, {"article": "MONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests.\nVisit the National Multiple Sclerosis Society for more on MS.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\nMost people are diagnosed between the ages of 20 and 50, although individuals as young as 2 and as old as 75 have developed the disease, the society says.\nIn effect, those patients gambled with a treatment that could be fatal for a disease that isn't, said Dr. Michael Racke, a professor in the department of neurology at Ohio State University.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering. The story addresses MS, its prevalence and its symptoms.", "answer": 1}, {"article": "Animal models had skin injuries infected with Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii, three different types of bacteria that commonly infect wounds and develop biofilms that are treatment resistant.\nWorking with a mechanical and aerospace engineering team led by Shaurya Prakash, PhD and Vish Subramaniam, PhD, the scientists have optimized the bandage\u2019s design and the amount of electrical current delivered.\nThe immune system cannot penetrate the biofilm, and antibiotics can\u2019t get in either \u2013 causing constant inflammation and low-level infection that can further dampen the healing process.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\nEarly results, which were presented at the Wound Healing Society\u2019s Annual Meeting in April 2016 indicate that infected wounds covered by the experimental bioelectric dressing healed better and more quickly than those covered with a plain dressing that is commonly used in the care of wounds today.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in disease mongering. It also puts chronic wounds in context by stating how many Americans may be affected.", "answer": 1}, {"article": "Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others: the ability of HETIOZ\u00ae to provide significant benefit in the treatment of the symptoms of jet lag disorder; Vanda's ability to obtain marketing approval for the use of HETLIOZ\u00ae in the treatment of jet lag disorder; and other factors that are described in the \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2017, which is on file with the SEC and available on the SEC's website at www.sec.gov.\nThe results of that study were published in The Lancet in 2009.1 The observation that HETLIOZ\u00ae is effective in treating the symptoms caused by an abrupt advance of the circadian cycle of a magnitude of 5 or 8 hours suggests that HETLIOZ\u00ae will be an effective therapeutic tool in the treatment of individuals that experience symptoms of jet lag.\nIt is also reported that 8% (approximately 1.6 million) travel in Business or First class.2\n\n\"We are extremely pleased with the outcome of this study which establishes the utility of HETLIOZ\u00ae in the treatment of jet lag disorder as HETLIOZ\u00ae was shown to overcome a significant circadian challenge of an 8 hour phase advance.\nThe risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ\u00ae is increased by approximately 2-fold compared with younger patients.\nThe risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ\u00ae is increased by approximately 2-fold compared with younger patients.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There was some mongering here. Although jet lag is clearly common among long distance flyers, the idea that it is a \u201ccircadian disorder\u201d in need of extravagant drug treatment is troubling. Late shift workers, and some military personnel, along with some percentage of business travelers clearly have a chronic problem that could qualify as medically in need of serious therapy. But it\u2019s likely a substantial percentage of them already cope with the symptoms. First class and business class flyers able to sleep better across time zones, for example, are likely over-represented among frequent business travelers.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cThese encouraging results support the development of a large, randomized trial to directly compare HDIT/HCT to standard of care for this often-debilitating disease.\u201d\n\nMS symptoms vary widely and may include motor and speech difficulties, weakness, fatigue and chronic pain.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital.\nThe trial, called HALT-MS, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN).\nThe most common form of MS is relapsing-remitting MS, which is characterized by periods of mild or no symptoms interspersed with symptom flare-ups or relapses.\n", "question": "Does the news release commit disease-mongering?", "explanation": "There\u2019s no disease mongering. And the release provides useful context about multiple sclerosis when it states: \n\u201cMS symptoms vary widely and may include motor and speech difficulties, weakness, fatigue and chronic pain. The most common form of MS is relapsing-remitting MS, which is characterized by periods of mild or no symptoms interspersed with symptom flare-ups or relapses. Over years, the disease can worsen and shift to a progressive form.\u201d\nThe release doesn\u2019t exaggerate the symptoms, but it does give some sense of the impact this disease may have for some people.", "answer": 1}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story commit disease-mongering?", "explanation": "The story provides an appropriate description of how the body either does not produce or cannot use insulin in type 2 diabetes.\u00a0 The story also describes that being overweight and weight gain\u00a0are significant issues for most people with type 2 diabetes.\u00a0 The story could have been improved by providing some additional background information to let readers know how serious this condition is (e.g. how many people have this, what sorts of complications can arise, etc.).\u00a0 ", "answer": 1}, {"article": "\"In the absence of treatment alternatives, reverse total shoulder arthroplasty [RTSA] is a justifiable treatment for patients with a massive, irreparable rotator cuff tear before the age of 60,\" according to the report by Christian Gerber, MD, of the University of Zurich and colleagues.\nThe new study focused on long-term outcomes of RTSA in patients under age 60.\nCompared to their preoperative status, most patients had substantial long-term improvement after RTSA.\nWith refinements in technique and components in more recent years, the procedure has been used in younger, more active patients.\nThe improvement was similar for patients with and without prior shoulder surgery.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not commit disease mongering.", "answer": 1}, {"article": "\"We estimated that 47 percent of lethal prostate cancer cases would be prevented in the United States if men over 60 had five or more of these healthy habits,\" said Kenfield, assistant professor in the Department of Urology at UCSF Medical Center, and formerly of the Department of Medicine at Harvard Medical School in Boston, where the study was initiated.\nReducing intake of processed meats would cut the risk by 12 percent, they reported.\nChan School of Public Health, and Brigham and Women's Hospital.\nCases were confirmed through medical records and pathology reports, and cause of death was determined by death certificate and medical record, and secondarily by next of kin.\nFor dietary factors alone, men with three points, versus those with zero points, had a 46 percent decreased chance of developing lethal prostate cancer in the health professionals' group.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Griffiths says his team's new study grew out of a decade of research at Johns Hopkins on the effects of psilocybin in healthy volunteers, which found that psilocybin can consistently produce positive changes in mood, behavior and spirituality when administered to carefully screened and prepared participants.\nBlood pressure and mood were monitored throughout the sessions.\nHalf of the participants were female with an average age of 56.\nEighty-three percent reported increases in well-being or life satisfaction.\nMedicines and Healthcare Products Regulatory Authority.\n", "question": "Does the news release commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "The UroLift System provides an alternative to tissue removing surgery for the treatment of an enlarged prostate.\n\"The UroLift System has an excellent safety profile and provides men suffering from an enlarged prostate a beneficial first-line treatment alternative to drug therapy or more invasive surgery.\nThe UroLift System's permanent implants, delivered during a minimally-invasive procedure, act like window curtain tie-backs to hold the lobes of an enlarged prostate open.\n\"We are committed to providing patients with the highest quality, most effective options to address their urology needs,\" said Matthias Hofer, MD , urologist at Northwestern Memorial Hospital.\nThe most common adverse events reported during the study included pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate, and the inability to control urine because of an urgent need to urinate.\n", "question": "Does the news release commit disease-mongering?", "explanation": "While the release doesn\u2019t disease-monger, it could have been more informative \u2014 for example by accurately describing how severe/bothersome the symptoms were for patients treated with this device.", "answer": 1}, {"article": "The back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\nIn a statement, Drank inventor Peter Bianchi says \"the safety of Drank's consumers remains a top priority\" and the company is working to modify the product's packaging and marketing \"to reflect its classification as a dietary supplement.\"\n\"The issue is this: Some of them probably have some biologic effect, but they haven't been as well studied as you'd like,\" Scharf says.\nHowever, a study published in January in the Journal of the American Geriatrics Society found that a pre-bedtime cocktail of magnesium, zinc and a five-milligram dose of melatonin significantly improved sleep among a group of 43 elderly Italian insomniacs.\nIn January 2010, the FDA sent a warning letter to the Innovative Beverage Group, which makes the relaxation beverage Drank, saying the melatonin it uses is an \"unapproved food additive\" and not \"generally recognized as safe.\"\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not exaggerate the impact of\u00a0disordered sleep. In fact, some comment on the high prevalence of insomnia and its potential to create distress and potentially contribute to other health problems would have been appropriate.", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\n \nThe story points out that the drug has been tested only in patients with advanced disease who have tried other treatments. However, the story expands the definition of who stands to benefit by raising hopes that future studies will show effectiveness in patients with less advanced disease, even though such trials have yet to begin. Furthermore, extending these new treatments to earlier-stage disease is  problematic given the known risks for already overtreating many of these  patients.  The final quote that sequentially using the various new  medications could further extend life is troubling because there is no  evidence for this strategy\u2013which could also be very expensive. That quote could have been challenged. \n The statement that prostate cancer is second only to lung cancer as a killer of men creates a troubling comparison that obscures that fact that while most lung cancer patients die of their disease within a couple of years of diagnosis, most men diagnosed with prostate cancer ultimately die of something else after many years of life.", "answer": 0}, {"article": "That\u2019s called secondary prevention.\nIt is important to keep in mind that other therapies, such as statins, have also been proven to decrease the risk of cardiovascular events.\nWe know that taking aspirin will prevent a first heart attack and a first stroke, but we also know that aspirin can cause serious bleeding, mainly in the gastrointestinal system and, more rarely, in the brain.\nIf there was a foolproof way to identify individuals at high risk for a future heart attack or stroke, as well as those at high risk for developing complications, we would know who should be taking aspirin for primary prevention and who should not.\nIt is important to note that this draft recommendation applies to people who are not at increased risk for bleeding, have at least a 10-year life expectancy, and are willing to take low-dose aspirin daily.\n", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease mongering here, as cardiovascular disease is the top cause of death in the U.S. for both women and men.", "answer": 1}, {"article": "About 15% of people with MCI develop full-blown Alzheimer's disease each year.\nAlzheimer's disease is the most common type of dementia.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\nCoffee was the main, or only source, of caffeine among people in the study.\nPeople whose memory loss did not progress all had blood caffeine levels higher than this level, the study shows.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of Alzheimer\u2019s disease.", "answer": 1}, {"article": "This study received funding from the Divers Alert Network and U.S.\n\"During immersion in water, particularly cold water, susceptible people have an exaggerated degree of the normal redistribution of blood from the extremities to the chest area, causing increased pressure in the blood vessels of the lungs and leakage of fluid into the lungs,\" said Richard Moon, M.D., an anesthesiologist and medical director of the Duke Center for Hyperbaric Medicine & Environmental Physiology.\n\"It appears that the drug, which dilates the blood vessels, could be creating more capacity in the blood vessels in the arms and legs, reducing the tendency for blood to redistribute to the thorax, and therefore reducing the high pressure in the pulmonary vessels.\"\nThe drug -- best known as Viagra\u2122 -- is normally used for treatment of male impotence, but also for pulmonary arterial hypertension.\nIt dilates blood vessels, giving it the potential to ease an abrupt cold water-induced constriction of blood vessels in the arms and legs that can lead to blood pooling in the heart and lungs.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release offers no information about the incidence of this condition among swimmers and divers and, because this condition is rare, it could unnecessarily raise some alarms. And while it makes clear that the symptoms of swimming-induced pulmonary edema \u201coften\u201d disappear over the course of 24 hours in the subset of swimmers and divers who have\u00a0the condition, it also notes that the problem\u00a0can be fatal, again without providing any incidence data. The reader will likely be more concerned than she or he should be.", "answer": 0}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story commit disease-mongering?", "explanation": "The story does an excellent job of\u00a0detailing the effects of uncontrolled diabetes, and the risks of the surgery, in a clear, factual manner. ", "answer": 1}, {"article": "The method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\nIt is increasing acknowledged that these sleep disturbances may accelerate memory loss in Alzheimer\u2019s disease.\n\u201cThe analysis showed us consistently that glymphatic transport was most efficient in the lateral position when compared to the supine or prone positions,\u201d said Dr. Benveniste.\n\u201cIt is interesting that the lateral sleep position is already the most popular in human and most animals \u2013 even in the wild \u2013 and it appears that we have adapted the lateral sleep position to most efficiently clear our brain of the metabolic waste products that built up while we are awake,\u201d says Dr. Nedergaard.\nTheir colleagues at the University of Rochester, including Lulu Xie, Rashid Deane and Maiken Nedergaard, PhD, used fluorescence microscopy and radioactive tracers to validate the MRI data and to assess the influence of body posture on the clearance of amyloid from the brains.\n", "question": "Does the news release commit disease-mongering?", "explanation": "We saw no evidence of disease mongering.\u00a0The release is careful to talk about efficiency in clearing brain waste and doesn\u2019t suggest that a non-prone position could be harmful.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - New findings add to confusion over whether taking aspirin, ibuprofen or related painkillers reduces the risk of developing melanoma.\n\u201cI think it\u2019s just too early\u201d to say NSAIDs offer any protection, she said.\nAnimal experiments have suggested that the class of painkillers known as nonsteroidal anti-inflammatory drugs (NSAIDs) could play a role in preventing melanoma, but a large 2008 study failed to find any evidence to support this possibility.\nSpecifically, more than 40 percent of people who were cancer-free said they\u2019d been taking NSAIDs at least once per week for more than 5 years, versus only 28 percent of those who developed melanoma.\nNSAIDs - which include aspirin, naproxen (marketed as Aleve), and ibuprofen (Advil) \u2014 have side effects, she noted, such as stomach bleeding.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease-mongering of melanoma in the story.", "answer": 1}, {"article": "One innovative aspect of the study was the measurement of bone texture of the lumbar spine using trabecular bone score (TBS) - the first use of this technique in adolescent athletes.\n\"We now need to consider how to counteract the lack of bone growth stimulus caused by cycling and swimming, possibly by encouraging swimmers and cyclists to add weight-bearing exercise in their training.\"\n\"This raises a question about whether swimming and cycling are good for bone development,\" Dr Gracia Marco said.\n\"We already knew exercise was key for bone growth, but here we clarify what type of exercise.\nDespite the many health benefits of cycling and swimming, the study found little difference in bone development between cyclists, swimmers and the control group.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release notes that poor bone growth before age 30 can increase an individual\u2019s risk of fractures and osteoporosis later in life, but it does not engage in disease mongering.", "answer": 1}, {"article": "Mr. McCourry came home from war unable to escape scenes of an explosion that nearly killed him, and haunted by the memory of two young girls he accidentally killed in a fire fight.\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\nIn follow-up psychotherapy, patients process emotions and insights brought up during the MDMA session.\nI relived the parts of me I had lost.\nHe was contemplating suicide when he tried MDMA.\n", "question": "Does the story commit disease-mongering?", "explanation": "None. PTSD is fairly common and moderate to severe cases often prove difficult to treat.", "answer": 1}, {"article": "The study looked only at those IBS patients with the non-constipation form, he tells WebMD.\nJan. 5, 2011 -- A two-week course of the antibiotic rifaximin (Xifaxan) helps to relieve the symptoms of irritable bowel syndrome (IBS), and the relief lasts up to 10 weeks after stopping the medication, according to new research.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\nThe drug is approved by the FDA only for traveler's diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in disease-mongering and presented the information about the disease in a straightforward way. \u201cThe study looked only at those IBS patients with the non-constipation form, he tells WebMD. For those with this type of IBS, symptoms can include abdominal pain, bloating, and changes in bowel function such as diarrhea.\u00a0IBS is considered a functional gastrointestinal disorder without a known physiologic cause, with the symptoms recurring and often worsened by stress. Existing treatment options \u2014 diet and lifestyle modification, psychological therapy, and other drugs \u2014 do not help all people with the condition.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "Starting the story with reference to food as being ones 'torture' does have an air of disease mongering.\u00a0 But the story actually doesn't address the incidence of obesity in this country nor the rise in weight related health conditions, so we can rule it neither satisfactory nor unsatisfactory on disease-mongering.\u00a0 ", "answer": 2}, {"article": "The key to making the therapy work?\nThey usually die within five years of diagnosis.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nThey become unable to eat without a feeding tube, to see, hear or think.\nOne of medicine\u2019s greatest villains: HIV.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "Aug. 12, 2012 -- Daily aspirin use, long recommended for people at high risk of heart attack, may also reduce the risk of dying from cancer, according to new research.\nHe found an association, not cause and effect.\nThe new analysis is published in the Journal of the National Cancer Institute.\nHe describes that reduction as modest.\nMany other strategies will also reduce the risk of cancer, he says.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play.", "answer": 1}, {"article": "These initial findings are interesting, but, as with all areas of mental health, there is still more research to be done.\u201d\n\nMental health problems, including depression, are estimated to cost \u00a3105bn a year in England.\nOne in six Britons will suffer depression at some point in their life.\n\u201cThis study provides a clinically suitable approach for personalising antidepressants therapy.\nCurrently it is impossible to establish who should or should not be given antidepressants, or combinations of them.\nResearchers focused on two independent clinical groups of depressed patients on two biological markers that measure inflammation of the blood, as heightened levels are associated with poor response to antidepressants.\n", "question": "Does the story commit disease-mongering?", "explanation": "There\u2019s no sign of disease mongering.", "answer": 1}, {"article": "A new study by researchers at Wake Forest University suggests combining weight training with a low-calorie diet preserves much needed lean muscle mass that can be lost through aerobic workouts.\nPartial support also comes from grants by the National Institute on Aging.\nLoss of lean mass could have important consequences given the high risk of physical disability among the growing population of older adults.\nPut another way, the percentage of weight loss coming from muscle mass was 20% in the weight loss plus walking group, 16% in the weight loss alone group, and 10% in the weight loss plus weight training group.\nThe participants were randomly assigned to one of three groups: a weight-loss-only group, who followed a calorie-restricted diet with no exercise regimen; a weight loss plus cardio (i.e., walking) group; and a weight loss plus weight-training group.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release did not engage in disease mongering.", "answer": 1}, {"article": "Panel Says Aspirin Lowers Heart Attack Risk For Some\n\nMillions of Americans take baby aspirin every day to prevent a heart attack or stroke.\n\"With all the good therapies, better blood pressure control, better cholesterol control, all the things we do in modern medicine,\" he says, \"over the last couple of decades, we've had nearly a 50 percent reduction in the rate of cardiovascular disease.\"\nIf people don't have a significantly increased risk of having a heart attack or stroke over the next decade, Nissen says, they may be \"causing more harm than benefit.\"\nConcerns have been raised about whether aspirin is really effective enough, when so many other medicines are available to help control heart disease risk.\nSeveral groups including the American Heart Association offer online calculators to help people figure out their risk, which, along with discussion with a health care provider, can help determine whether daily aspirin might be useful.\n", "question": "Does the story commit disease-mongering?", "explanation": "To its credit, the story offers a narrative\u00a0that is the antithesis of disease-mongering.\u00a0 Its primary goal is to inform the public that a task force of experts is recommending less use of a common, over-the-counter medicine. \u00a0The daily use of aspirin, for most reasonably healthy Americans, appears to be a \u201cwash\u201d; that is, both its benefits and harms will be negligible for most of us.\u00a0 That last point is mentioned but could have been explained \u00a0a bit more thoroughly.", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\n\"More research is needed to advance this concept to the point that it can be made widely available to men as a method of contraception,\" Festin said.\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\nThe research was co-sponsored and funded by UNDP/UNFPA/UNICEF/WHO/World Bank Special Program of Research, Development, and Research Training in Human Reproduction in Geneva, Switzerland, and CONRAD (using funding from the Bill & Melinda Gates Foundation and the U.S. Agency for International Development).\nWashington, DC -- Men can take birth control shots to prevent pregnancy in their female partners, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release does not appear to be disease-mongering. It states that better birth control options are needed for men, citing data from the Guttmacher Institute that 40 percent of pregnancies worldwide in 2012 were unintended. Of course, expanding contraceptive use would not eliminate all unintended pregnancies.", "answer": 1}, {"article": "The power of data science, analytics and machine learning\n\nThe study leverages a unique statistical method and software platform originally developed by Dr. Marsh at UD and commercialized by GenPro to measure methylation patterns in DNA (a cell's genetic code) using next generation sequencing (NGS) data.\nThe researchers identified a strong set of methylation markers, or patterns, that indicate differences in the genome between children with spastic CP and those without it.\nThe approach uses sophisticated machine learning techniques and algorithms to sort through hundreds of gigabytes of NGS data looking for these distinct DNA methylation patterns.\nIn a second study, using samples from children aged 2-5 years, the researchers were able to validate their results and predict with 73 percent accuracy whether the blood samples came from children who had CP.\nEstablished as The Nemours Foundation through the legacy and philanthropy of Alfred I. duPont, Nemours provides pediatric clinical care, research, education, advocacy, and prevention programs to families in the communities it serves.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. It provides some context about the disease, including its prevalence.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story commit disease-mongering?", "explanation": "There is no evidence of disease mongering. The story accurately notes that only 20-25% of women would be eligible to take lapatinib, as they have the more aggressive form of breast cancer. ", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Considering having a surgeon remove your cancerous prostate using a robot?\nIt may be necessary, however, for surgeons to do 80 or more procedures to ensure that they do not leave cancerous tissue behind.\nBut a US study on nearly 9,000 men published in October 2009 found that while open and minimally invasive surgery were equally good for getting rid of prostate cancer, the risk of incontinence and impotence was higher with the minimally invasive approach.\nLaparoscopic surgery, in which a surgeon performs the operation through small incisions, usually with the help of a surgical robot, has been touted as carrying a lower risk of incontinence and impotence than the standard \u201copen\u201d form of the surgery.\nThere was also a lack of data on how well patients functioned after surgery, and how patients with high-risk prostate cancer fared long-term.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering. It might have been useful to note that not all prostate cancers result in morbidity or mortality meaning that not all prostate need active treatment.", "answer": 1}, {"article": "On average, the score on a scale for ranking gastrointestinal symptoms dropped 82 percent from the beginning to the end of treatment, while average developmental age increased by 1.4 years, according to the release.\nChildren without autism were used as a control for the study, the news release reported.\nThe children ranged from 7 to 16 years old.\nThe study, which was published in the journal Microbiome, included 18 children with autism and moderate to severe gastrointestinal problems.\nA questionnaire was used to assess social skills, irritability, hyperactivity and communication.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story didn\u2019t have any information on what autism is, nor how many people it affects in the U.S.", "answer": 0}, {"article": "Ideally, the order goes the other way around: We test the idea, and then we implement.\u201d\n\nThese states have the fattest pets \u2014 and they might surprise you\n\nLong before they conquered the Internet, cats took over the world\n\nA kitten nursery saves tiny lives in a city aiming to become \u2018no kill\u2019\n\nBear breaks into house, plays the piano but not very well\n\u201cKids are already participating in this on a huge scale.\nA therapy-animal trend grips the United States.\n\u201cThe literature does show it\u2019s not bad.\nThere\u2019s something intuitive about the good feelings animals give us.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "This study was presented at a medical conference.\nBut if the findings are confirmed, \"patients who are taking aspirin for other reasons may see an added benefit,\" says study head Kevin Choe, MD, a radiation oncologist at the University of Texas Southwestern Medical School in Dallas.\nThe study involved 5,275 men with localized cancer whose disease had not spread beyond the prostate gland; 1,982 of the men were taking anticlotting medications: aspirin, Lovenox, Plavix, and/or warfarin.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nThe risk that cancer spread was also reduced by anticlotting medications, from 7% to 3%.\n", "question": "Does the story commit disease-mongering?", "explanation": "\n\n\nThe body of story is clear about who these results are relevant to. It points out that the study involved the records of men who had been diagnosed with prostate cancer that had not spread. However, the headline and lead imply that aspirin could lower the risk of prostate cancer death for all men, not just those diagnosed with localized tumors of a type likely to spread.\n", "answer": 1}, {"article": "More trials need to be done of this unique treatment, she added.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\n\"Of note is the reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\nMONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does highlight the fact that this trial included only people who have problems when they take statin drugs. Most readers should get the point that the point of the trial was to address those specific statin side effect problems, not the more general questions about heart disease risk that matter to the average patient.", "answer": 1}, {"article": "The panel withheld a recommendation about tuna, second only to shrimp in popularity in the United States.\nOver time, large fish sharks and swordfish accumulate high levels of mercury.\nPlants, plankton and tiny fish that have absorbed small amounts of mercury are eaten by larger fish.\nFor more fitness, food and wellness news, \u201clike\u201d our Facebook page.\n\u201cThe benefit of having (omega-3 fatty acids) in your diet really exceeds the likely risk of contamination.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering here.", "answer": 1}, {"article": "\"Our findings show that ocrelizumab rapidly suppresses inflammatory activity,\" noted the study authors, led by Dr. Ludwig Kappos from the University Hospital, Basel, Switzerland, in a journal news release.\nWhat's more, to date the treatment appears to be safe.\nAfter 24 weeks, some of the doses were adjusted.\nThe number of active lesions had dropped 89 percent more among the 600-mg group compared with those getting a placebo.\nIt's not better or worse.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering of MS.", "answer": 1}, {"article": "You know, they go to rehab and there\u2019s not much more [more] they can recover usually.\u201d\n\nFor the study, Steinberg and his team recruited 18 patients who had suffered their first and only stroke six months to three years prior to the trial.\nSome of the patients bound to wheelchairs were even able to walk again.\nStroke.\nAbout 800,000 people in the United States suffer from a stroke each year.\nPatients recover from strokes over the first six months, and then there\u2019s very little recovery [after that].\n", "question": "Does the story commit disease-mongering?", "explanation": "No mongering here.", "answer": 1}, {"article": "What to do?\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\nThe researchers looked at whether or not women were getting a dual-energy X-ray absorptiometry (DXA) test, which measures bone mineral density.\nMeanwhile, it was common among women at low fracture risk, such as younger women without osteoporosis risk factors,\" Amarnath said in a journal news release.\nMONDAY, May 25, 2015 (HealthDay News) -- Too few women at high risk for osteoporosis are being tested for the bone-depleting condition, while too many women at low-risk are being screened, a new study suggests.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not overstate the prevalence or impact of osteoporosis. In fact, it makes no mention at all of how many people it affects or its cost.", "answer": 1}, {"article": "AOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids\n\u201cPhysicians should counsel those with first time injuries on these benefits moving forward.\u201d\n\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is a global leader in orthopaedic sports medicine education, research, communication and fellowship, and includes national and international sports medicine leaders.\nAfter treatment with an arthroscopic bankart repair, the postoperative dislocation rate in the first-time injury group was 29%, compared to 62% in those who did not have surgery after their initial injury.\nThe Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\nOf this group, 68 patients had experienced their first dislocation, while 53 had recurrent dislocations after being initially treated non-operatively.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The news release doesn\u2019t engage in disease mongering. Nor does it say how many people are affected by shoulder instability or even what \u201cshoulder instability\u201d is, how it\u2019s caused, or what its impact is. Any or all of these would have provided useful context.", "answer": 2}, {"article": "\"The next questions are, 'how do we increase the number of patients who respond?'\nWe have a real opportunity to change clinical practice for patients when other therapies have failed,\" said principal investigator Padmanee Sharma, MD, PhD, professor, Departments of Genitourinary Medical Oncology and Immunology and scientific director of the Immunotherapy Platform, part of MD Anderson's Moon Shots Program.\nThe study included 821 patients with advanced RCC across 151 sites in 24 countries in North America, Europe, Australia, South America and Asia.\nEach year, there are 338,000 new cases of RCC diagnosed worldwide; it is the most common type of kidney cancer among adults and approximately 30% of patients present with metastatic disease at diagnosis, according to the scientific literature.\nBased on the CheckMate-025 findings, earlier this month (September 16) the FDA granted Breakthrough Therapy Designation to nivolumab for the potential indication of metastatic RCC.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release appropriately notes the number of cases of RCC diagnosed worldwide and the frequency on metastatic disease on presentation. We\u00a0would have preferred it if the prevalence of the disease had been described as a rate (per 100,000), so we could appreciate how rare it is.", "answer": 1}, {"article": "TRENTON, N.J. (AP) - GlaxoSmithKline PLC on Wednesday applied for approval in the U.S. and Europe to sell an existing breast-cancer drug as a first-line treatment.\nApproval as an initial treatment likely would boost that sharply.\nIt targets cancer cells more than healthy ones, Roychowdhury said.\nAbout two-thirds of breast cancers are hormone sensitive.\nThe British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs.\n", "question": "Does the story commit disease-mongering?", "explanation": "The study didn\u2019t exaggerate the condition of advanced breast cancer.", "answer": 1}, {"article": "In this study, the average age was about 59 years old - six years younger than the age at which the U.S. Preventive Services Task Force, a government-backed panel, recommends all women begin being screened for osteoporosis.\nThe idea, say the researchers, is doctors can use patients\u2019 CT scans that are ordered for another reason - such as looking for tumors - to also check for signs of osteoporosis.\nThe researchers then found that their ability to accurately diagnose those same patients with osteoporosis from a CT scan depended on what threshold for bone density they used.\nThe researchers, who published their findings in the Annals of Internal Medicine on Monday, compared patients\u2019 CT scans to their dual-energy X-ray absorptiometry (DXA), which is traditionally used to diagnose osteoporosis.\nAt the lower threshold, the researchers found 9 percent of those diagnosed with osteoporosis were misdiagnosed.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no disease mongering of osteoporosis.\u00a0 In fact, quite the opposite, as the story explained the risk of overdiagnosis or \u201cincidentaloporosis.\u201d", "answer": 1}, {"article": "Zyban, a repackaging of the antidepressant Wellbutrin, was approved by the F.D.A.\nThe multishot sequences being tested are designed to extend the antibody response for many months, although eventually the body will stop producing the anti-nicotine antibodies, he said.\nAlthough smoking rates in the United States have declined in recent decades, tens of millions of adults continue to smoke, and the habit causes more than 440,000 deaths a year, according to the Centers for Disease Control and Prevention.\nIf the vaccine helps smokers quit, Dr. Reus said, a central question will be whether booster shots could help prevent relapse.\nBecause the compound is too big to cross the blood-brain barrier, the vaccine is expected to diminish or eliminate the pleasure associated with puffing a cigarette.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story provides smoking mortality rates from the Center for Disease Control. Intention to quit survey results are also mentioned, but we are not told the source of these or the 20 percent success rate. ", "answer": 1}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story commit disease-mongering?", "explanation": "The story provided a clear explanation about the nature of the people in the study it reported on \u2013 elderly patients who had already fractured their hip.\u00a0 Although not including an age range for defining the term \u2018elderly\u2019 it did mention the average age of the study participants.\nThe story did not engage in overt disease mongering.", "answer": 1}, {"article": "The hospital staff reacted immediately and gave her a shot of epinephrine.\nDoctors and patients both know exactly how much you're getting, he said, \"and that's important because if you're reactive to, say, a 50th of a peanut, you don't want to have a mistake where you're suddenly getting a 10th of peanut.\"\nIf this ends up being the first approved treatment, if it is covered by insurance and if details of whom it works for best were all worked out and the risks and benefits were clear, \"that would be so amazing, because we haven't really had anything like that before,\" he said.\n\"It's not everything we would hope for, but it's still fantastic to be able to raise someone's threshold from a teeny tiny amount of peanut to a couple of peanuts or more,\" said Sicherer, who believes that other allergy products will be developed in time: \"I can tell my patients that this might be the right thing for them, but if not, we're looking at things that might be easier and better down the road.\"\nThe risk paid off: Two-thirds of the kids in the study were able to eat the equivalent of two peanuts without any symptoms after following the months-long experimental treatment regimen, the researchers found.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story appropriately characterizes peanut allergy as a \u201cpotentially life-threatening\u201d condition, with peanut ingestion. It also says peanut and tree nut allergies affect \u201can estimated\u00a03 million Americans\u00a0or more,\u201d although it\u2019s not clear what number of those would benefit from this treatment. ", "answer": 1}, {"article": "Researchers reintroduced the drug to 32 patients who were initially treated as part of a study of 634 patients.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nCHICAGO (Reuters) - An experimental cancer drug showed early promise at helping patients with advanced melanoma that had spread to the brain, according to a summary of data from a mid-stage study.\nEight of the 32 got ipilimumab alone, 23 got ipilimumab plus a vaccine called gp100, and one got the vaccine alone.\nIpilimumab is a monoclonal antibody, an engineered human immune system protein that boosts the body\u2019s immune response by interfering with another immune compound called CTLA-4, which acts as a sort of brake on immune system cells.\n", "question": "Does the story commit disease-mongering?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThere is a mismatch in this story between the specific experimental intervention and the background on the extent of the disease. The trial highlighted in the lead included only patients with melanoma that had spread to the brain\u2026 but then the story quotes total incidence and death statistics for all cases of melanoma\u2026 certainly a far larger number.\u00a0 We\u2019ll give the story the benefit of the doubt but wish this distinction had been made clear. ", "answer": 1}, {"article": "\"For high-risk people, those with heart disease or [who] have had a stroke who are taking a standard dose of a statin, further reduction in LDL cholesterol will give them extra benefit,\" said Dr. Colin Baigent of the Clinical Trial Service Unit and Epidemiological Studies Unit at University of Oxford in the United Kingdom, who was involved in both studies.\nThe researchers noted that the higher dose of Zocor (simvastatin) did result in a risk of a muscle disease 10 times higher than that associated with the lower dose.\nThis benefit was seen even among those whose cholesterol levels were already low, researchers say.\nTwo died within a few weeks of developing the disorder, with one cause of death mentioning the muscle disorder as a contributing factor.\n(All statins carry the risk of myopathy, but lower dosages are associated with a reduced risk.)\n", "question": "Does the story commit disease-mongering?", "explanation": "The story did not engage in overt disease mongering.", "answer": 1}, {"article": "Rose Cooper, a microbiologist and honey expert at the University of Wales Institute at Cardiff, remains cautiously optimistic that the increased use of honey dressings will help better information to emerge.\nThe level of UMF can vary, and each batch of manuka is ranked according to its UMF value: The higher the concentration, the darker, thicker and more expensive the manuka is.\n\"Honey is not a panacea,\" she said in a telephone interview, but it has been used by British doctors for several years, and with its growing use elsewhere in the world, \"health-care professionals will be more likely to consider honey in treating wounds, and so more data will accumulate.\"\nAlthough Molan says he has no direct financial interests in honey, the honey research unit was set up with support from New Zealand's Honey Industry Trust, and his work has resulted in his university's signing a multimillion-dollar contract last year with New Zealand health-care products company Comvita.\nThe company, which has been developing manuka products since 2005, buys medical-grade honey from Comvita, which receives unprocessed honey from beekeepers in New Zealand.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not appear to exaggerate the seriousness or prevalence of wounds, though it is not always clear\u00a0what is the \"disease\" in question.", "answer": 1}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story commit disease-mongering?", "explanation": "The story is clear that this study is relevant to people who have Type 2 diabetes.", "answer": 1}, {"article": "Jan. 13, 2010 (Coronado, Calif.) -- A blood test under study to help diagnose lung cancer looks promising, researchers reported Tuesday at a cancer meeting in California.\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\nWhen that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not exaggerate the burden of lung cancer, accurately citing ACS statistics and the enormous importance of the disease. It also does not overstate the problem of false positives.", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story commit disease-mongering?", "explanation": "", "answer": 1}, {"article": "Sadly, disappointment is part of it, according to Pharr, who typically hears the frustration of people who go through a study that worked for another person but not for them.\n\"We put them into the spinal cord, and they came from a human spinal cord.\n\"My father was actually 69 when he was diagnosed.\n\"It may have had a different effect on someone else,\" she said.\nNeither his primary care physician nor his neurologist could identify the cause of his deterioration.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. In fact, it explains that ALS is rare.", "answer": 1}, {"article": "Ingber says some scientists are interested in using the chips to conduct research that would be unethical if performed on people, such as studying the effects of gamma radiation on the human body.\nThe sophisticated architecture of these organs-on-chips\u2014which are about the size of a thumb drive\u2014has also earned the Wyss Institute recognition in the art world with a Design of the Year award from the Design Museum and placement in the Museum of Modern Art\u2019s permanent collection.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nIt takes up to 15 years and $5 billion for a new drug to make it through testing and earn approval from the U.S. Food and Drug Administration (FDA).\nWhen air entered the lung cell channel, the channel filled with fluid and then blood clots\u2014exactly what happens in the lungs of patients who develop this life-threatening condition.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story addresses a new technology that can potentially improve the testing of new therapeutics. This is an important topic and it is presented in a reasonable way, without resorting to disease-mongering.", "answer": 1}, {"article": "\u201cYou are looking at a therapy that can avert, we hope, complications and be as effective,\u201d he said.\nIn recent years, the safety of defibrillator wires has come in particular focus because a model made by Medtronic has been prone to fracturing.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\nThe device will not be suitable for a significant number of heart patients, particularly those who require units that also include a pacemaker, which regulates a heart that is beating too fast or too slowly.\nBefore the device can be sold here, Cameron Health will have to submit more extensive human trial data to the F.D.A.. Dr. Bardy said a larger study of the device has just begun in this country and overseas and that it will most likely take a year or more to assemble data from it for the agency\u2019s review.\n", "question": "Does the story commit disease-mongering?", "explanation": "\nThe story points out that the new device is intended for use in a subset of patients who are already considered candidates for conventional implantable defibrillators.", "answer": 1}, {"article": "\"My basic message is that, overall, there may be some slight risks associated with the medication, but in balancing risks and benefits for most women, I would suggest they stay on their medication,\" she said.\nBOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\nResearchers at Brigham and Women's Hospital in Boston looked at 3.8 million pregnant women nationwide and found that those taking popular antidepressants, called SSRIs, did not appear to be at significantly increased risk of having a baby with pulmonary hypertension.\n", "question": "Does the story commit disease-mongering?", "explanation": "We didn\u2019t see any distracting statements or portrayals in this story that exaggerate PPHN, its nature, or its prevalence. And that could have been easy to do, since stories about dying children can be particularly harrowing. If anything, this is an anti-scaremongering story, and quotes from experts\u00a0go a long way\u00a0in tempering worries.", "answer": 1}, {"article": "He was not involved with the research.\nNew stretch marks were also softer and smoother in 54 women who used the cream for three months, says Zoe Draelos, MD, a consulting professor of dermatology at Duke University Medical Center in Durham, N.C. \"The stretch marks did not go away,\" she tells WebMD.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nMarch 11, 2010 (Miami Beach, Fla.) -- A moisturizing cream whose active ingredient is extract of onion can help take the redness out of new stretch marks.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\n", "question": "Does the story commit disease-mongering?", "explanation": "The entire concept behind this story is a subtle form of disease-mongering. Stretch marks are a ubiquitous\u00a0part of the human experience, and the notion that we need to \"treat\" them is a medicalization of a normal state. \nThe story does earn credit for pointing out that stretch marks \"are not harmful to your health,\" but it wanders into unsatisfactory territory when it\u00a0characterizes\u00a0stretch marks as\u00a0\"a problem that currently has no cure.\" Stretch marks are not a disease, but this description makes them sound like one.", "answer": 0}, {"article": "The findings don't confirm that the ancient Chinese discipline relieves hot flashes, and only 14 men participated in the study, which was conducted by researchers at New York Methodist Hospital and Weill Cornell Medical College of Cornell University.\nHormone therapy designed to reduce levels of testosterone in the body is one of the standard treatments for prostate cancer.\nAcupuncture, a popular form of alternative medicine, involves inserting ultra-thin needles into the skin.\nIn the study, researchers followed 14 men who were taking hormone therapy for prostate cancer and suffered from hot flashes.\n\"Usually it's mild and self-limiting and improves with time.\n", "question": "Does the story commit disease-mongering?", "explanation": "NO disease mongering of the problem of post-prostate cancer treatment hot flashes.", "answer": 1}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release commit disease-mongering?", "explanation": "The news release doesn\u2019t promote disease mongering. It didn\u2019t oversell the disease\u2019s impact but it perhaps missed an opportunity to inform readers about the disease\u2019s characteristics and rates of stroke in the sickle cell population.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story commit disease-mongering?", "explanation": "The assertion that \u201cWomen who drink cola\u00e2\u20ac\u00a6. May be putting themselves at risk for osteoporosis\u201d is more than a little over blown. First the data only show an association between a dietary parameter (cola consumption) and an intermediary measure (bone mineral density) rather than for the disease (osteoporosis) itself. Bone density is an imperfect predictor of osteoporosis. Secondly, the study reported a dose response between bone mineral density and cola consumption and only found statistically significant lower bone mineral density for those women drinking more than 3 servings of cola per week. The story made it sound as though any cola intake put a woman\u2019s bones at risk.", "answer": 0}, {"article": "The 7 percent figure works out to about 18 pounds for someone who weighs 250.\nOrlistat was approved as a weight loss and weight maintenance drug by the FDA in 1999 to treat obese and overweight people -- those with a body mass index of 30 or higher -- and overweight people (with BMI of 27 or higher) who already have weight-related health problems including diabetes, heart disease or high blood pressure.\nWhile the Food and Drug Administration (FDA) still must approve the switch, the agency often follows the advice of its experts.\nMore than 100 studies involving some 30,000 patients have been conducted with Orlistat, according to GlaxoSmithKline (GSK) Consumer Healthcare, the maker of Orlistat, which has petitioned the FDA to permit OTC sales of the drug.\nAnd many consumers may be put off by the drug's significant gastrointestinal side effects, including flatulence, diarrhea and anal leakage.\n", "question": "Does the story commit disease-mongering?", "explanation": "Brief mention of \nmedical benefits that can be gained from the amount of weight loss attained with the use of xenical (e.g. lower BP, improved \ncholesterol levels, reduced risk of diabetes).", "answer": 1}, {"article": "University of Pennsylvania researchers Rebecca Ashare and Heath Schmidt saw potential for a permanent cessation solution in a class of FDA-approved medications used to improve cognitive impairments from Alzheimer's disease.\nThe findings sparked the CIRNA clinical trial, which has to date studied 33 smokers ages 18 to 60.\nOur goal is to target different populations of smokers who may be more likely to experience these cognitive deficits.\"\nPeople who were interested in quitting smoking signed on for 23 days.\n\"That week-long period is a proxy for longer-term cessation.\n", "question": "Does the news release commit disease-mongering?", "explanation": "It would be difficult to overstate the harms of cigarette smoking. The release does not engage in fear mongering.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - A less common form of obesity surgery may spur more weight loss than its far more popular cousin, gastric bypass \u2014 but at the price of greater long-term risks, researchers reported Tuesday.\nThe surgeon removes part of the stomach, and the remaining \u201csleeve\u201d-like stomach is attached to the final section of the small intestine; that puts even greater limits on the body\u2019s absorption of calories and nutrients.\nIn a 2008 study, it accounted for just 1 percent of weight-loss, or bariatric, surgeries done in the U.S., and 5 percent in Europe.\nThe study involved 850 U.S. veterans who underwent some form of weight-loss surgery, at an average age of about 50, and more than 41,000 vets who had only non-surgical care.\nIn general, experts say that surgery could be an option for anyone with a BMI of 40 or higher; that translates, roughly, to a man who is at least 100 pounds overweight or a woman who is 80 pounds overweight.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story does a good job of probing territory that is under-explored in most media accounts about obesity treatment. It poses the questions of long-term quality of life and life expectancy post treatment. Could obesity itself be less life-threatening than some of the radical treatments aimed at treating it?", "answer": 1}, {"article": "\u201cThis is a patient population that\u2019s at risk for thrombotic [clotting] issues.\u201d\n\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nThere are currently no treatments for Prader-Willi syndrome, the most common genetic cause of life-threatening obesity.\nSome analysts have suggested the FDA might approve the drug, despite the adverse events, if Zafgen can prove its benefits outweigh its risks to some patients.\nBut he conceded that Zafgen, which had once hoped to begin selling its drug candidate, Beloranib, as early as 2016, will have to conduct at least one additional study before it can apply for FDA approval.\nIt can dominate the lives of patients and their families, leading to excessive overeating, choking, and stomach rupture, along with slowed metabolism and psychiatric disorders.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article provides an accurate profile of the Prader-WIlli syndrome emphasizing its life-threatening consequences but also conceding that it is a rare disease affecting roughly 6,000 to 8,000 Americans.", "answer": 1}, {"article": "Contact Professor Ole G. Mouritsen, head of Centre for Biomembrane Physics (MEMPHYS) at University of Southern Denmark, head of center Taste For Life, President of the Danish Academy of Gastronomy.\nIt can even enhance the flavor of the food, they argue.\n\u2022 Some species may contain large amounts of iodine.\nMany seaweed species have a variety of health benefits.\nAnother effect was that they consumed 16.4% less energy in the 24 hour period after eating the seaweed enriched bread.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not engage in any disease mongering.", "answer": 1}, {"article": "Research involving 800 patients ultimately led to the approval of Zecuity.\nIt's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\nIn general, though, \"the more options that are available to migraine headache patients, the better,\" Waltman said.\n\"I've had some patients where the nausea and vomiting was so bad they couldn't even swallow a pill,\" said Nancy Waltman, a nurse practitioner with the University of Nebraska Medical Center College of Nursing, Lincoln Division.\nMONDAY, Jan. 21 (HealthDay News) -- A skin patch for the treatment of migraines, and the intense waves of nausea that often accompany these debilitating headaches, has been approved by the U.S. Food and Drug Administration.\n", "question": "Does the story commit disease-mongering?", "explanation": "Two thoughts give us pause as we think about this criterion.\nThe story didn\u2019t explore or reference the claim, made by an expert source, that \u201cMigraine patients tend to be underdiagnosed and undertreated and inappropriately treated.\u201d While this pinged on our disease-mongering radar, the available epidemiologic evidence does appear to support this contention. But the story didn\u2019t reference that evidence.\nThe other, broader question is how often migraine suffers need alternatives to pills. How often is the nausea so bad that the intranasal, injection or patch methods would even be needed? We also can\u2019t be sure \u2013 even if migraines are undertreated or inappropriately treated \u2013\u00a0 whether the patch would do anything to change this. The story mentions that some people have nausea and vomiting so bad that they can\u2019t take a pill, but knowing how many migraine sufferers there are and how many fit that description is the question.\nTo fail to explore these questions is on the borderline of cheerleading for a new delivery method (the patch) for an old drug (sumatriptan) without reporting on sufficient evidence (data) for true need in comparison with what\u2019s already available.", "answer": 0}, {"article": "The medical approach to treating tonsil infections has evolved over recent decades.\n\"The decision about whether those children should have tonsillectomy for that temporary benefit is really tied to what those children need or what they're suffering with,\" Chinnadurai said.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\n\"Though a tonsillectomy is low-risk, it is not risk-free, and those risks need to be weighed against the benefits for each individual child,\" Chinnadurai said.\nThe researchers decided to review whether the throat infection guidelines are too stringent, ruling out patients who potentially could benefit but don't meet the high threshold of recurring infections, Chinnadurai said.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story doesn\u2019t engage in disease mongering and, as noted above, provides very thorough context on how many tonsillectomies are performed on children each year.\nThe article might waver toward \u201ctreatment-mongering,\u201d however, with its emphasis on why the current guidelines might be relaxed.", "answer": 1}, {"article": "You should go through six to eight weeks of conservative management.\u2019 \u201d\n\nAt the Partners Healthcare System in Boston, spine experts have the same struggle to convince patients that an M.R.I.\n\u201cWe are trying to fix things that shouldn\u2019t be fixed.\u201d\n\nAs a rheumatologist, Dr. Felson saw patient after patient with knee pain, many of whom had already had scans.\nDr. Gazelle went to see his primary-care doctor but, he said, \u201cI didn\u2019t get an M.R.I.\u201d That decision, he added, \u201cwas the right thing to do.\u201d\n\nAbout three months later, he had recovered on his own.\n\u201cIf you\u2019re going to look at a spine, you need to know what that spine might look like in a normal patient,\u201d said Dr. Michael Modic, chairman of the Neurological Institute at the Cleveland Clinic.\n\u201cI will cope on my own with this knee.\u201d\n\nIn fact, Mrs. Weinstein was also lucky because her problem was with her knee.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease mongering. A strength of this story is that it puts common complaints (knee or back pain) and common abnormal findings (meniscal tear for the knee and disk degeneration for the back) into a larger more complete picture. However, the story inaccurately describes the meniscus as \"a ligament that stabilizes the knee\". In reality, the meniscus is a cartillage-like pad that cushions the knee joint . [Note: the NYT later corrected this error]", "answer": 1}, {"article": "Well, why not?\nA cautionary note:The damning evidence against vitamin A, which has long been used as a skin-cancer treatment, came from experiments done on mice, which have a far higher susceptibility to skin cancers than humans.\nIf you're squeamish about vitamin A, there are a number of alternatives.\nMost are still of the opinion that sunscreens with an SPF of up to 50, and containing avobenzone and oxybenzone, efficiently protect the skin from both UVA and UVB ultraviolet rays.\nWhen you're stuck outside for long periods, re-apply at least every couple of hours.\n", "question": "Does the story commit disease-mongering?", "explanation": "The article does not hype or monger skin cancer or skin aging from sun rays.", "answer": 1}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story commit disease-mongering?", "explanation": "The 2017-2018 flu season was the worst the US had experienced in nearly a decade. The flu impacted the entire country, and was responsible for 172 pediatric deaths. The news article did not use these or any other flu-related statistics to increase fear about the flu and, in turn, the need for this medication.", "answer": 1}, {"article": "Three years later, researchers continue to detect the presence of the cloned cells they infused into the patient, 61-year-old high school history teacher Gardiner Vinnedge of North Bend, Wash.\n\nFor six years, Vinnedge endured painful rounds of chemotherapy, only to have his melanoma return.\n\"My back, my legs were just covered with a hot red rash,\" Vinnedge said.\nYee's team tried to do this more precisely.\nThe last step was to infuse the resulting army of cancer-fighting clones back into the patient.\nIn six of the 11 patients in the trial, the melanoma stopped progressing for 12 to 19 weeks.\n", "question": "Does the story commit disease-mongering?", "explanation": "No disease mongering at play here.", "answer": 1}, {"article": "The American Academy of Periodontology has more on gum disease.\n\"These were patients with severe periodontal disease but who were otherwise systemically healthy,\" said study senior author Dr. Laurie K. McCauley, chair of the department of periodontic and oral medicine at the University of Michigan in Ann Arbor.\nAfter eight weeks of treatment with Forteo, though, the pain went away and the osteonecrosis resolved, reported the authors, from Austin Health in Melbourne, Australia.\nIt is much rarer in people who take a lower-dose bisphosphonate (such as Actonel, Boniva or Fosamax) for osteoporosis.\nBesides being linked to chronic, severe gum disease, this type of bone loss has also been connected in rare cases to the use of bisphosphonates, a different class of osteoporosis drugs.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not engage in disease-mongering. While raising the connection between bisphosphonates and bone loss in the jaw, the article is careful to add qualifiers like \u201cheavy use\u201d and several mentions of \u201crare.\u201d It states that the incidence is increasing in patients receiving bisphosphonates for osteoporosis, but it\u2019s much rarer than the 5% incidence in patients receiving bisphosphonates during cancer treatment. The story also distinguishes between low-dose and high-dose brands of bisphosphonates.", "answer": 1}, {"article": "The rest of the men used a placebo spray.\nJune 2, 2010 (San Francisco) -- A quick spray of a new drug may help men who suffer from premature ejaculation last nearly six times longer, new research suggests.\n\"Yet I think a substantial number of [men with premature ejaculation] would use it,\" he tells WebMD, alternatives being unproven products with names like \"Stay Erect\" and \"Play Longer.\"\nAt the meeting, Sharlip presented the pooled results of two pivotal studies of PSD502 involving 530 men with premature ejaculation.\nNonetheless, doctors like Irwin Goldstein, MD, director of San Diego Sexual Medicine at Alvarado Hospital in San Diego, tell WebMD they're excited because this is the first time a drug is being rigorously tested for men with really serious premature ejaculation problems.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story includes the important caveat \u2013 \"Not all men with premature ejaculation suffer to the same degree as the men in the study\" \u2013 although did they really need to use the term \"suffer\"???\nIt did not question the oft-cited statistic that \"Up to 30% of men suffer some degree of premature ejaculation\" as the Wall Street Journal did, but we\u2019ll give it a satisfactory grade on this nonetheless because of the caveat above.\u00a0", "answer": 1}, {"article": "TEL AVIV (Reuters) - Israel-based Neuronix, which has developed a non-invasive medical device to help to treat Alzheimer\u2019s disease, expects the system to be approved by the U.S. Food & Drug Administration in late 2014.\nIn Israel, a few dozen patients are being treated with the device.\n\u201cThe application in Alzheimer\u2019s disease and in combination with cognitive training is novel,\u201d Pascual-Leono said in a phone interview from Boston.\nAbout 20 percent of patients experience a mild headache but there are no long-term negative effects, he said.\nThe U.S. trials are expected to run till the end of 2013.\n", "question": "Does the story commit disease-mongering?", "explanation": "There was no overt disease-mongering of Alzheimer\u2019s disease in the story.", "answer": 1}, {"article": "Officials at St. Andrew's Episcopal School in Potomac gently suggested that the high school sophomore get a mental health screening.\nThe idea of a psychiatric evaluation sent chills down the spine of Caroline's mother, Mathy Milling Downing, who believed that her younger daughter, Candace, had committed suicide because of an adverse reaction linked to a psychiatric drug -- the antidepressant Zoloft.\nDowning's family offers a powerful case study into the pros and cons of new guidelines recommending widespread screening of adolescents for mental disorders: Last month, the U.S. Preventive Services Task Force, a federal group that makes public health recommendations, said that all adolescents between ages 12 and 18 should be screened for major depression.\nIn March, the Institute of Medicine, which advises Congress on scientific matters, told policymakers that early screening was key to reducing the financial and medical burden of mental disorders in the United States.\nBy contrast, she said, the multiple screenings that Caroline received carefully evaluated the child as an individual and homed in on the kind of therapy that was best for her.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story mentions that mental health problems are a major health issue in adolescents. The article reports rates of positive tests from the Teen Screen project and these numbers are high.\u00a0 The story could have been strengthened if it discussed that diagnostic certainty for depression in childrenis a bit less than for adults and that the screeners are not as accurate.", "answer": 1}, {"article": "The study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nIt's been shown to be useful in treating a wide range of diseases from breast cancer to Parkinson's.\nThe National Institutes of Health has also jumped on board and is funding a variety of studies on tai chi for chronic disease.\nPatients got an instructional video tape, and were encouraged to practice at home at least 3 times a week.\nThe tai chi group also reported an improvement in mood.\n", "question": "Does the story commit disease-mongering?", "explanation": "This story didn\u2019t exaggerate the consequences of heart failure or otherwise engage in disease mongering.", "answer": 1}, {"article": "\"In Europe, we have been reluctant to recommend that all men get PSA testing as we have felt that there has been a lack of knowledge,\" agreed lead researcher Dr. Jonas Hugosson, a professor of urology at the University of Gothenburg.\n\"When we see patients with low-risk disease we don't treat them, we observe them,\" he said.\nThe men were between 50 and 65 at the start of the study.\n\"So it is more or less the standard to care in America to get a PSA done.\"\nPersonally, I would recommend my friends check their PSA,\" Hugosson added.\n", "question": "Does the story commit disease-mongering?", "explanation": "\u00a0There was no overt disease-mongering. ", "answer": 1}, {"article": "MORE: Concussion Expert: Over 90% of NFL Players Have Brain Disease\n\nIn all people, regardless of the type of injury they had, the levels of the proteins, called GFAP and UCH-L1, rose within the first hour after the injuries.\nEven at that point, the study shows, GFAP levels might be higher than normal and therefore might indicate TBI and need for further tests.\nAnd because the expose patients to radiation, doctors are often reluctant to use them on every patient, especially young children, who come to the emergency room with a head injury.\nAll of the people had their blood drawn 19 times, starting at within four hours of their injury and up to 7 days later.\nGFAP, which is specific to cells known as astrocytes that form a matrix for nerves in the central nervous system (which includes the brain and spinal cord), peak at 20 hours after the injury and then decline steadily but are still detectable seven days later.\n", "question": "Does the story commit disease-mongering?", "explanation": "No obvious disease mongering in this story. Concussions and traumatic brain injury are a serious public health issue.", "answer": 1}, {"article": "\u201cThe No.\n\u201cIt would be incorporated into these dreams where I was tied up, like in the movie \u2018Alien.\u2019 It was more difficult to sleep with that thing on than to just get through the night with the apnea.\u201d\n\nMr. Bleck got rid of the machine after he discovered Provent.\n\u201cAll sleep apnea is not created equal.\u201d\n\nSome people, for example, breathe through the mouth at night, not the nostrils.\nFor decades, the standard treatment has been \u201ccontinuous positive airway pressure.\u201d A mask worn at night pushes air into the nasal passages, enabling easier breathing.\n\u201cI tried it for six months, and I don\u2019t think I had one full night of sleep the whole time.\u201d\n\n\u201cI\u2019m just so happy that I found it,\u201d she said.\n", "question": "Does the story commit disease-mongering?", "explanation": "There seems to have been some disease mongering in the first sentence. Most estimates of sleep apnea in the published literature puts the condition at somewhere between 15 million and 18 million. We could find no reference in PubMed to 28 million Americans suffering from the disorder. This would mean that nearly 1 out every 10 people have sleep apnea. The story also uses marketing language, calling the Provent patch, a \u201cnew weapon in the battle against sleep apnea,\u201d and saying that \u201cmany patients who struggled with C.P.A.P. call it a godsend.\u201d", "answer": 0}, {"article": "Dr Weaver said: \"As the outcomes of heart disease is worse in diabetic versus non-diabetic patients, there is a need to identify additional treatment options.\nThe drug is not regularly given to patients with Type 1 diabetes.\nIt is estimated around 400,000 people in the UK have the condition.\nThis follows previous laboratory work at Newcastle University which explored the mechanism behind metformin.\nParticipants were advised to adjust their insulin to keep blood glucose levels safe.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release does not appear to commit disease mongering.", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nResults of the fecal analysis demonstrated that, after five weeks, dTMS-treated subjects had greatly increased quantities of several beneficial bacterial species with anti-inflammatory properties, such as are found in healthy people.\nIn their study, funded by the Italian Ministry of Health, the investigators recruited three men and 11 women, ages 22 to 65, with obesity as shown by a body mass index (BMI) of 30 to 45 kg/m2.\nCurrently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\n\"These changes suggest a beneficial effect of dTMS on both weight loss and change in microbiota composition,\" Luzi said.\n", "question": "Does the news release commit disease-mongering?", "explanation": "The release doesn\u2019t engage in disease mongering. Obesity is an increasing problem on both the individual and population-level scales. The release provides some context about why new obesity treatments are needed, as well as the possible role gut microbes might play in weight management.", "answer": 1}, {"article": "University of Miami cardiologists last week reported success in a small, preliminary human clinical trial of a new stem cell therapy they hope some day will routinely mend human hearts and reduce the need for lifelong medication, even for transplants.\n\u201cThat's the Holy Grail, the quest the whole field has been pursuing for close to a decade, and this is evidence we're on the right track,\u201d said Dr. Joshua Hare, director of the University of Miami Medical School's Interdisciplinary Stem Cell Institute.\nThe study shed new light on a question of prime interest to cardiologists: whether the injected stem cells actually transformed themselves into heart muscle, or improved heart function in some other way.\nMax Eaton, the 68-year-old direct-buy franchise owner who was patient No.1 in the eight-person trial, said Wednesday he's thankful he was part of the trial, adding that he had just completed a 2.8-mile, 41-minute walk around his neighborhood in Lauderdale-by-the-Sea, Fla.\n\n\u201cI feel very grateful,\u201d he said.\n\u201cAlmost certainly, I would be deceased or in much worse shape had I not had the opportunity to be in this program.\u201d\n\nHare stressed that the current trial is only a small, run-up phase of extensive testing that will take up to five years and involve dozens of hospitals and hundreds of patients before winning U.S. Food and Drug Administration approval for routine use.\n", "question": "Does the story commit disease-mongering?", "explanation": "The story does not exaggerate the seriousness or prevalence of cardiomyopathy; however, it does include a quote from a study participant that makes an unsubstantiated claim regarding the treatment: \u201cAlmost certainly, I would be deceased or in much worse shape had I not had the opportunity to be in this program.\u201d\n", "answer": 0}, {"article": "According to the Associated Press, lorcaserin will be reviewed by an FDA panel in September, and Contrave will be reviewed in December.\nThe third new drug is Orexigen Therapeutic's Contrave, which is a combination of the antidepressant Wellbutrin and the addiction drug naltrexone.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\nAlso, it does not have the same problems as the previous weight-loss drugs, Fen-Phen (Phentermine), Acomplia (rimonabant) or Meridia (sibutramine), which had been associated with heart problems, he said.\nThe report is published in the July 15 issue of the New England Journal of Medicine, and was sponsored by Arena Pharmaceuticals, of San Diego, Calif., which used its own doctors as part of the study group.\n", "question": "Does the story commit disease-mongering?", "explanation": "The second sentence begins, \"A potential player in fighting the obesity epidemic.\" That is the sole reference to the problem of obesity, and, although it contributes to the framing of\u00a0obesity as a disease that needs medication versus a risk factor for disease that can be altered with lifestyle changes, it doesn\u2019t quite register as disease mongering. So we judge this\u00a0 to be satisfactory. ", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story commit disease-mongering?", "explanation": "This story labels common breathing patterns as \u201cdysfunctional\u201d and suggests they represent a condition in need of treatment. \u201cScreen apnea\u201d is not a generally recognized condition. While sitting for long periods (in front of a computer screen or TV or steering wheel, etc.) is associated with health risks, the role of breathing patterns is not clearly understood. The story should not have presented claims of a link between computer use, breathing patterns, and health effects without noting the lack of evidence to support such claims. Indeed, almost all of the scientific publications supporting the premise of the Spire device (polyvagal theory) have been authored by a single researcher who is an advisor to the company.", "answer": 0}]